PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11527419-5	2001	The stimulatory effect of R(+)-methanandamide on COX-2 expression was mimicked by the structurally unrelated cannabinoid Delta(9)-tetrahydrocannabinol.	Dronabinol	121-150	prostaglandin-endoperoxide synthase 2	Homo sapiens	49-54
11528220-0	2001	Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat.	Dronabinol	116-145	corticotropin releasing hormone	Rattus norvegicus	32-63
11528220-0	2001	Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat.	Dronabinol	116-145	proopiomelanocortin	Rattus norvegicus	68-87
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	20-49	corticotropin releasing hormone	Rattus norvegicus	75-106
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	20-49	corticotropin releasing hormone	Rattus norvegicus	108-111
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	20-49	proopiomelanocortin	Rattus norvegicus	117-136
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	20-49	proopiomelanocortin	Rattus norvegicus	138-142
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	51-63	corticotropin releasing hormone	Rattus norvegicus	75-106
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	51-63	corticotropin releasing hormone	Rattus norvegicus	108-111
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	51-63	proopiomelanocortin	Rattus norvegicus	117-136
11528220-1	2001	Chronic exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increases corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the rat hypothalamus.	Dronabinol	51-63	proopiomelanocortin	Rattus norvegicus	138-142
11528220-7	2001	Administration of Delta(9)-THC to intact male rats increased CRH gene expression.	Dronabinol	18-30	corticotropin releasing hormone	Rattus norvegicus	61-64
11528220-10	2001	Delta(9)-THC treatment similarly increases POMC gene expression of intact, orchidectomized and DHT-replaced males.	Dronabinol	0-12	proopiomelanocortin	Rattus norvegicus	43-47
11528220-12	2001	Delta(9)-THC administration increased CRH gene expression to the same extent in castrated and estradiol-replaced rats.	Dronabinol	0-12	corticotropin releasing hormone	Rattus norvegicus	38-41
11528220-13	2001	On the other hand, POMC gene expression was increased by ovariectomy, and Delta(9)-THC administration did only increase POMC transcript levels in the estradiol-replaced group.	Dronabinol	83-86	proopiomelanocortin	Rattus norvegicus	120-124
11528220-14	2001	These data show that gonadal steroids differentially regulate the effects of Delta(9)-THC on both CRH and POMC gene expression in the hypothalamus of male and female rats, suggesting gender differences in the reaction to cannabinoids.	Dronabinol	77-89	corticotropin releasing hormone	Rattus norvegicus	98-101
11528220-14	2001	These data show that gonadal steroids differentially regulate the effects of Delta(9)-THC on both CRH and POMC gene expression in the hypothalamus of male and female rats, suggesting gender differences in the reaction to cannabinoids.	Dronabinol	77-89	proopiomelanocortin	Rattus norvegicus	106-110
11470906-3	2001	To date, these neural signaling pathways have been shown to comprise a cannabinoid receptor (CB(1)) that binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous CB(1) ligand anandamide.	Dronabinol	148-168	cannabinoid receptor 1 (brain)	Mus musculus	93-98
11470906-3	2001	To date, these neural signaling pathways have been shown to comprise a cannabinoid receptor (CB(1)) that binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous CB(1) ligand anandamide.	Dronabinol	170-173	cannabinoid receptor 1 (brain)	Mus musculus	93-98
11408034-7	2001	antagonized the actions of the CB1 receptor agonist Delta9-tetrahydrocannabinol, but not of livanil, anandamide or capsaicin.	Dronabinol	52-79	cannabinoid receptor 1	Rattus norvegicus	31-34
11331425-3	2001	We report that, in rat and mouse hippocampal slices, anandamide and 2-arachidonoylglycerol, synthetic cannabinoids, and delta(9)-tetrahydrocannabinol activated p38 mitogen-activated protein kinases (MAPK), but not c-Jun N-terminal kinase (JNK).	Dronabinol	120-149	mitogen-activated protein kinase 14	Mus musculus	160-163
11331425-3	2001	We report that, in rat and mouse hippocampal slices, anandamide and 2-arachidonoylglycerol, synthetic cannabinoids, and delta(9)-tetrahydrocannabinol activated p38 mitogen-activated protein kinases (MAPK), but not c-Jun N-terminal kinase (JNK).	Dronabinol	120-149	mitogen-activated protein kinase 8	Mus musculus	214-237
11331425-3	2001	We report that, in rat and mouse hippocampal slices, anandamide and 2-arachidonoylglycerol, synthetic cannabinoids, and delta(9)-tetrahydrocannabinol activated p38 mitogen-activated protein kinases (MAPK), but not c-Jun N-terminal kinase (JNK).	Dronabinol	120-149	mitogen-activated protein kinase 8	Mus musculus	239-242
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	222-225	neutral sphingomyelinase activation associated factor	Homo sapiens	31-34
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	222-225	neutral sphingomyelinase activation associated factor	Homo sapiens	181-184
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	222-225	neutral sphingomyelinase activation associated factor	Homo sapiens	181-184
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	323-326	neutral sphingomyelinase activation associated factor	Homo sapiens	31-34
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	323-326	neutral sphingomyelinase activation associated factor	Homo sapiens	181-184
11306675-6	2001	A role for the adaptor protein FAN in CB(1) receptor-coupled sphingomyelin breakdown is supported by two observations: 1) coimmunoprecipitation experiments show that the binding of FAN to the CB(1) receptor is enhanced by THC and prevented by SR141716; 2) cells expressing a dominant-negative form of FAN are refractory to THC-induced sphingomyelin breakdown.	Dronabinol	323-326	neutral sphingomyelinase activation associated factor	Homo sapiens	181-184
11296091-1	2001	BACKGROUND: SR141716, a recently developed CB1 cannabinoid receptor antagonist, blocks acute effects of Delta-9-tetrahydrocannabinol (THC) and other CB1 cannabinoid agonists in vitro and in animals.	Dronabinol	104-132	cannabinoid receptor 1	Homo sapiens	43-46
11296091-1	2001	BACKGROUND: SR141716, a recently developed CB1 cannabinoid receptor antagonist, blocks acute effects of Delta-9-tetrahydrocannabinol (THC) and other CB1 cannabinoid agonists in vitro and in animals.	Dronabinol	134-137	cannabinoid receptor 1	Homo sapiens	43-46
11448725-2	2001	Delta(9)-THC binds to and activates two known cannabinoid receptors found in mammalian tissue, CB1 and CB2.	Dronabinol	0-12	cannabinoid receptor 1	Homo sapiens	95-98
11448725-2	2001	Delta(9)-THC binds to and activates two known cannabinoid receptors found in mammalian tissue, CB1 and CB2.	Dronabinol	0-12	cannabinoid receptor 2	Homo sapiens	103-106
11316486-2	2001	The major psychoactive ingredient of cannabis is Delta(9)-tetrahydrocannabinol, which exerts effects in the brain by binding to a G-protein-coupled receptor known as the CB1 cannabinoid receptor.	Dronabinol	49-78	cannabinoid receptor 1	Homo sapiens	170-173
11245634-0	2001	Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol.	Dronabinol	93-123	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	63-69
11245634-5	2001	Here we show that Delta(9)-THC acts through the aryl hydrocarbon receptor complex to activate transcription of CYP1A1.	Dronabinol	18-30	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	111-117
11245634-6	2001	A 2-microg/ml concentration of Delta(9)-THC produced an average 2.5-fold induction of CYP1A1 mRNA, whereas a 10- microg/ml concentration of Delta(9)-THC produced a 4.3-fold induction.	Dronabinol	31-43	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	86-92
11245634-8	2001	At the same time, Delta(9)-THC competitively inhibited the CYP1A1 enzyme, reducing its ability to metabolize other substrates.	Dronabinol	18-30	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	59-65
11245634-9	2001	Spiking tobacco tar with Delta(9)-THC resulted in a dose-dependent decrease in the ability to generate CYP1A1 enzyme activity as measured by the ethoxyresorufin-o-deethylase (EROD) assay.	Dronabinol	25-37	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	103-109
11168391-0	2001	delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells.	Dronabinol	0-29	nerve growth factor	Homo sapiens	40-59
11168391-6	2001	We show that addition of Delta(9)-tetrahydrocannabinol to PC-3 cells stimulated nerve growth factor production in a dose-dependent and time-dependent manner.	Dronabinol	25-54	nerve growth factor	Homo sapiens	80-99
11168391-10	2001	These results indicate that Delta(9)-tetrahydrocannabinol stimulation of nerve growth factor production in these cells was mediated by the cannabinoid CB1 receptor.	Dronabinol	28-57	nerve growth factor	Homo sapiens	73-92
11168391-10	2001	These results indicate that Delta(9)-tetrahydrocannabinol stimulation of nerve growth factor production in these cells was mediated by the cannabinoid CB1 receptor.	Dronabinol	28-57	cannabinoid receptor 1	Homo sapiens	151-154
11168391-11	2001	The implication of Raf-1 activation in the mode of action of Delta(9)-tetrahydrocannabinol is also suggested.	Dronabinol	61-90	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	19-24
11168564-3	2001	These Delta(9)-THC-induced effects are known to be mediated through the brain-type cannabinoid receptor 1 (CB1).	Dronabinol	15-18	cannabinoid receptor 1 (brain)	Mus musculus	107-110
11168564-5	2001	We found that an intraperitoneal injection of 10 mg/kg Delta(9)-THC led to the same increase in the hot plate latencies in both genotypes, suggesting that Delta(9)-THC-mediated antinociception does not involve nNOS.	Dronabinol	64-67	nitric oxide synthase 1, neuronal	Mus musculus	210-214
11168564-6	2001	In contrast, a significant Delta(9)-THC-induced decrease of body temperature and locomotor activity was only observed in WT, but not in nNOS-KO mice.	Dronabinol	27-39	nitric oxide synthase 1, neuronal	Mus musculus	136-140
11267636-11	2001	On the other hand, they had the following ID(50) potency order against the ESR: CP 55,940 > HU-210 > WIN 55,212-2 > Delta(9)-THC > Delta(8)-THC.	Dronabinol	134-137	esterase 5 regulator	Mus musculus	75-78
11158625-0	2001	Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats.	Dronabinol	61-89	progesterone receptor	Rattus norvegicus	0-21
11158625-5	2001	Progesterone- and THC-facilitated sexual behavior was inhibited in animals treated with antisense oligonucleotides to PR or to D(1)R. Antagonists to cannabinoid receptor-1 subtype (CB(1)), but not to cannabinoid receptor-2 subtype (CB(2)) inhibited progesterone- and dopamine-facilitated sexual receptivity in female rats.	Dronabinol	18-21	cannabinoid receptor 1	Rattus norvegicus	149-171
11158625-5	2001	Progesterone- and THC-facilitated sexual behavior was inhibited in animals treated with antisense oligonucleotides to PR or to D(1)R. Antagonists to cannabinoid receptor-1 subtype (CB(1)), but not to cannabinoid receptor-2 subtype (CB(2)) inhibited progesterone- and dopamine-facilitated sexual receptivity in female rats.	Dronabinol	18-21	cannabinoid receptor 2	Rattus norvegicus	200-222
11166698-1	2001	Tetrahydrocannabinol (THC) is the principle psychoactive ingredient of marijuana and produces various psychoactive effects through the brain cannabinoid (CB1) receptor.	Dronabinol	0-20	cannabinoid receptor 1	Rattus norvegicus	154-157
11166698-1	2001	Tetrahydrocannabinol (THC) is the principle psychoactive ingredient of marijuana and produces various psychoactive effects through the brain cannabinoid (CB1) receptor.	Dronabinol	22-25	cannabinoid receptor 1	Rattus norvegicus	154-157
11329626-6	2001	Delta(9)-THC and IMMA also inhibit LPS-induced PGE(2) production and COX-2 induction, while AEA and 2-AG have no effects.	Dronabinol	0-12	cytochrome c oxidase subunit 2	Cannabis sativa	69-74
11038155-6	2000	When the substrates were incubated with the CYP3A4-expressed microsomes under oxygen-18 gas phase, atmospheric oxygen was incorporated into 35% of 7-oxo-Delta(8)-THC formed from 7alpha-OH-Delta(8)-THC, but only 12% of 7-oxo-Delta(8)-THC formed from 7beta-OH-Delta(8)-THC.	Dronabinol	160-165	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
11020293-1	2000	The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series.	Dronabinol	46-50	cannabinoid receptor 1	Homo sapiens	84-87
11020293-9	2000	Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced.	Dronabinol	146-149	cannabinoid receptor 1	Homo sapiens	158-161
11204352-2	2000	A principal active ingredient of cannabis, delta-9-tetrahydrocannabinol, acts in the brain on a specific receptor, termed the cannabinoid receptor 1 (CNR1).	Dronabinol	43-71	cannabinoid receptor 1	Homo sapiens	126-148
11204352-2	2000	A principal active ingredient of cannabis, delta-9-tetrahydrocannabinol, acts in the brain on a specific receptor, termed the cannabinoid receptor 1 (CNR1).	Dronabinol	43-71	cannabinoid receptor 1	Homo sapiens	150-154
11041539-15	2000	Alternatively, the delta9-THC-induced excitation of dopaminergic neurons seems to be mediated by CB1 cannabinoid receptors, while neither mu-opioid receptors nor substantia nigra pars reticulata neurons are involved.	Dronabinol	19-29	cannabinoid receptor 1	Rattus norvegicus	97-100
10903956-6	2000	Conversely, Delta(9)-tetrahydrocannabinol-induced memory impairment and inhibition of hippocampal extracellular acetylcholine concentration were potentiated by the subcutaneous administration of the D(2) dopamine receptor agonist (-)-quinpirole (25 and 500 microg kg(-1)).	Dronabinol	12-41	dopamine receptor D2	Rattus norvegicus	199-221
10861074-0	2000	Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.	Dronabinol	0-28	cannabinoid receptor 2 (macrophage)	Mus musculus	62-65
10861074-5	2000	The immune inhibitory cytokines, IL-10 and TGF-beta, were augmented, while IFN-gamma was down-regulated at both the tumor site and in the spleens of THC-treated mice.	Dronabinol	149-152	interferon gamma	Mus musculus	75-84
10861074-6	2000	Administration of either anti-IL-10- or anti-TGF-beta-neutralizing Abs prevented the THC-induced enhancement in tumor growth.	Dronabinol	85-88	interleukin 10	Mus musculus	30-35
10861074-6	2000	Administration of either anti-IL-10- or anti-TGF-beta-neutralizing Abs prevented the THC-induced enhancement in tumor growth.	Dronabinol	85-88	transforming growth factor, beta 1	Mus musculus	45-53
10861074-10	2000	In vivo administration of a specific antagonist of the CB2 cannabinoid receptor also blocked the effects of THC.	Dronabinol	108-111	cannabinoid receptor 2 (macrophage)	Mus musculus	55-58
10861074-11	2000	Our findings suggest the THC promotes tumor growth by inhibiting antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.	Dronabinol	25-28	cannabinoid receptor 2 (macrophage)	Mus musculus	89-92
10842224-1	2000	The CB(1)-type cannabinoid receptor mediates physiologic effects of Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of the drug marijuana.	Dronabinol	68-97	cannabinoid receptor 1	Rattus norvegicus	4-9
10843702-0	2000	Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.	Dronabinol	0-28	interferon gamma	Mus musculus	69-78
10843702-3	2000	BALB/c mice showed significant increases in serum IL-12 and IFN-gamma within hours of infection; however, the levels of these Th1-promoting cytokines as well as resistance to a challenge infection were suppressed by THC (8 mg/kg) injected 18 h before priming.	Dronabinol	216-219	interferon gamma	Mus musculus	60-69
10843702-4	2000	The Th2-promoting cytokine, IL-4, was increased within hours of a Legionella infection and was further increased by THC treatment.	Dronabinol	116-119	interleukin 4	Mus musculus	28-32
10802025-0	2000	Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.	Dronabinol	48-51	cannabinoid receptor 1 (brain)	Mus musculus	11-16
10802025-5	2000	These results strongly suggest the involvement of CB(1) receptor in the expression of Delta(9)-THC-induced motor impairment.	Dronabinol	95-98	cannabinoid receptor 1 (brain)	Mus musculus	50-55
10802025-6	2000	The intracerebellar microinfusion of adenosine A(1)-selective agonist, N(6)-cyclohexyladenosine (CHA) (4 ng/100 nl) significantly enhanced Delta(9)-THC-induced motor impairment, suggesting a cerebellar A(1) adenosinergic modulation of motor impairment.	Dronabinol	148-151	POC1 centriolar protein A	Mus musculus	97-100
10802025-13	2000	Conversely, the results in the present study also suggested co-modulation by cerebellar adenosine A(1) and CB(1) receptors of ethanol-induced motor impairment, thereby indicating a possible common signal transduction pathway in the expression of motor impairment produced by Delta(9)-THC as well as ethanol.	Dronabinol	275-287	cannabinoid receptor 1 (brain)	Mus musculus	107-112
10708885-0	2000	Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages.	Dronabinol	0-29	cathepsin D	Homo sapiens	61-72
10708885-1	2000	Delta(9)-tetrahydrocannabinol (THC) causes an antigen-dependent defect in the ability of macrophages to activate helper T cells, and this drug-induced impairment is mediated through the peripheral CB2 receptor.	Dronabinol	0-29	cannabinoid receptor 2	Homo sapiens	197-200
10708885-1	2000	Delta(9)-tetrahydrocannabinol (THC) causes an antigen-dependent defect in the ability of macrophages to activate helper T cells, and this drug-induced impairment is mediated through the peripheral CB2 receptor.	Dronabinol	31-34	cannabinoid receptor 2	Homo sapiens	197-200
10708885-3	2000	A THC-exposed macrophage hybridoma inefficiently stimulated interleukin-2 secretion by a helper T cell hybridoma in response to native lysozyme and its reduced form, suggesting that disulfide bond reduction was unaffected.	Dronabinol	2-5	interleukin 2	Homo sapiens	60-73
10708885-6	2000	The proteolytic activity of two thiol cathepsins was unaltered, but aspartyl cathepsin D activity was significantly increased in THC-exposed macrophages.	Dronabinol	129-132	cathepsin D	Homo sapiens	77-88
10837859-6	2000	Conversely, the hypothermic effect of Delta(9)-tetrahydrocannabinol was potentiated by the D(2) dopamine receptor agonists (-)-quinpirole (0.025 and 0.500 mg/kg, SC) and (+)-bromocriptine (0.5 and 1 mg/kg, IP).	Dronabinol	38-67	dopamine receptor D2	Rattus norvegicus	91-113
10760375-0	2000	Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.	Dronabinol	8-36	cathelicidin antimicrobial peptide	Rattus norvegicus	57-61
10760375-0	2000	Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.	Dronabinol	8-36	cathelicidin antimicrobial peptide	Rattus norvegicus	73-77
10760375-2	2000	Chronic exposure to Delta(9)-THC caused a significant reduction in CB1 receptor binding in all brain areas that contain this receptor.	Dronabinol	20-32	cannabinoid receptor 1	Rattus norvegicus	67-70
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	100-129	protein tyrosine kinase 2 beta	Homo sapiens	204-220
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	100-129	AKT serine/threonine kinase 1	Homo sapiens	221-224
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	100-129	AKT serine/threonine kinase 1	Homo sapiens	226-229
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	131-134	protein tyrosine kinase 2 beta	Homo sapiens	204-220
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	131-134	AKT serine/threonine kinase 1	Homo sapiens	221-224
10749665-3	2000	Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).	Dronabinol	131-134	AKT serine/threonine kinase 1	Homo sapiens	226-229
10727732-0	2000	Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences.	Dronabinol	9-38	proenkephalin	Rattus norvegicus	57-70
10727732-1	2000	Perinatal Delta(9)-tetrahydrocannabinol (Delta(9)-THC) exposure in rats resulted in enhanced morphine self-administration behavior, naloxone-precipitated withdrawal signs or changes in pain sensitivity, which have been related to changes in micro-opioid receptor binding and/or proenkephalin mRNA levels in several brain regions.	Dronabinol	10-39	proenkephalin	Rattus norvegicus	278-291
10727732-1	2000	Perinatal Delta(9)-tetrahydrocannabinol (Delta(9)-THC) exposure in rats resulted in enhanced morphine self-administration behavior, naloxone-precipitated withdrawal signs or changes in pain sensitivity, which have been related to changes in micro-opioid receptor binding and/or proenkephalin mRNA levels in several brain regions.	Dronabinol	41-53	proenkephalin	Rattus norvegicus	278-291
10727732-5	2000	Prenatal Delta(9)-THC exposure altered proenkephalin mRNA levels in most of the brain areas studied at different fetal ages, but the effects were different between sexes.	Dronabinol	9-21	proenkephalin	Rattus norvegicus	39-52
10727732-6	2000	Thus, proenkephalin mRNA levels increased in females, but decreased in males that had been prenatally exposed to Delta(9)-THC.	Dronabinol	113-125	proenkephalin	Rattus norvegicus	6-19
10727732-9	2000	In summary, prenatal Delta(9)-THC exposure produced a sex-dependent effect in proenkephalin mRNA levels in several brain structures of rat fetuses.	Dronabinol	30-33	proenkephalin	Rattus norvegicus	78-91
10787386-6	2000	AnNH has been shown to bind specifically to the cannabinoid receptor (CB(1)) and mimic many of the pharmacological and behavioural effects of THC including tolerance development.	Dronabinol	142-145	cannabinoid receptor 1 (brain)	Mus musculus	70-75
10810367-4	2000	Some cannabinoid derivatives such as cannabinol, cannabispirol and cannabidiol increased drug accumulation, while cannabidiolic acid, delta-9-THC and tetrahydro-cannabidiolic acid reduced drug accumulation of the human mdr1-gene transfected mouse lymphoma cells.	Dronabinol	134-145	ATP binding cassette subfamily B member 1	Homo sapiens	219-223
10700234-2	2000	Here, we show that intratumoral administration of Delta9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2.	Dronabinol	50-77	recombination activating gene 2	Mus musculus	224-255
10700552-1	2000	The incubation of cultured fetal mesencephalic neurons with Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increased the activity of tyrosine hydroxylase (TH) and this increase was reversed by SR141716A, a specific antagonist for cannabinoid CB(1) receptors.	Dronabinol	60-89	tyrosine hydroxylase	Homo sapiens	131-151
10700552-1	2000	The incubation of cultured fetal mesencephalic neurons with Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increased the activity of tyrosine hydroxylase (TH) and this increase was reversed by SR141716A, a specific antagonist for cannabinoid CB(1) receptors.	Dronabinol	91-103	tyrosine hydroxylase	Homo sapiens	131-151
10650181-4	2000	The parallel measurement of interferon gamma and interleukin 2 levels revealed that Delta(9)-tetrahydrocannabinol significantly reduced (about 70%) the former cytokine without affecting the latter.	Dronabinol	84-113	interferon gamma	Mus musculus	28-62
10650181-5	2000	Cannabinoid CB(1) and CB(2) receptor antagonists completely reversed the interferon gamma reduction induced by Delta(9)-tetrahydrocannabinol.	Dronabinol	111-140	interferon gamma	Mus musculus	73-89
10965147-5	2000	On the contrary, TH expression was maintained stable in the SN pars compacta of Delta(9)-THC-exposed females from PD21.	Dronabinol	89-92	tyrosine hydroxylase	Rattus norvegicus	17-19
10965147-6	2000	These differences in neuronal development caused by prenatal Delta(9)-THC exposure were associated with significant differences in GFAP expression by astroglial cells in both sexes.	Dronabinol	61-73	glial fibrillary acidic protein	Rattus norvegicus	131-135
10965147-7	2000	On PD21, GFAP immunoreactivity decreased in the SN in Delta(9)-THC-exposed male rats.	Dronabinol	63-66	glial fibrillary acidic protein	Rattus norvegicus	9-13
10965147-8	2000	Although GFAP expression increased in Delta(9)-THC-exposed males with age, it did not reach control levels by PD70.	Dronabinol	47-50	glial fibrillary acidic protein	Rattus norvegicus	9-13
10965147-9	2000	On the contrary, significantly increased GFAP expression in the Delta(9)-THC-exposed females on PD21 was observed, compared to their controls and also to Delta(9)-THC-exposed male rats; however, the GFAP expression shown by Delta(9)-THC-exposed females stabilized from PD21.	Dronabinol	73-76	glial fibrillary acidic protein	Rattus norvegicus	41-45
10965147-9	2000	On the contrary, significantly increased GFAP expression in the Delta(9)-THC-exposed females on PD21 was observed, compared to their controls and also to Delta(9)-THC-exposed male rats; however, the GFAP expression shown by Delta(9)-THC-exposed females stabilized from PD21.	Dronabinol	73-76	glial fibrillary acidic protein	Rattus norvegicus	199-203
10965147-9	2000	On the contrary, significantly increased GFAP expression in the Delta(9)-THC-exposed females on PD21 was observed, compared to their controls and also to Delta(9)-THC-exposed male rats; however, the GFAP expression shown by Delta(9)-THC-exposed females stabilized from PD21.	Dronabinol	163-166	glial fibrillary acidic protein	Rattus norvegicus	41-45
10965147-9	2000	On the contrary, significantly increased GFAP expression in the Delta(9)-THC-exposed females on PD21 was observed, compared to their controls and also to Delta(9)-THC-exposed male rats; however, the GFAP expression shown by Delta(9)-THC-exposed females stabilized from PD21.	Dronabinol	163-166	glial fibrillary acidic protein	Rattus norvegicus	41-45
10807034-1	2000	CB1 and CB2 cannabinoid receptors can be activated by several different classes of agonists, including cannabinoids such as delta9-tetrahydrocannabinol and 9-nor-9beta-hydroxyhexahydrocannabinol, and eicosanoids such as arachidonylethanolamide.	Dronabinol	124-151	cannabinoid receptor 1	Homo sapiens	0-3
10807034-1	2000	CB1 and CB2 cannabinoid receptors can be activated by several different classes of agonists, including cannabinoids such as delta9-tetrahydrocannabinol and 9-nor-9beta-hydroxyhexahydrocannabinol, and eicosanoids such as arachidonylethanolamide.	Dronabinol	124-151	cannabinoid receptor 2	Homo sapiens	8-11
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	80-109	interleukin 1 alpha	Rattus norvegicus	190-199
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	80-109	interleukin 1 beta	Rattus norvegicus	201-209
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	80-109	interleukin 6	Rattus norvegicus	211-215
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	80-109	tumor necrosis factor	Rattus norvegicus	221-230
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	111-114	interleukin 1 alpha	Rattus norvegicus	190-199
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	111-114	interleukin 1 beta	Rattus norvegicus	201-209
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	111-114	interleukin 6	Rattus norvegicus	211-215
10594923-2	2000	Exposure of neonatal rat cortical microglial cells to the exogenous cannabinoid delta(9)-tetrahydrocannabinol (THC) resulted in reduced amounts of lipopolysaccharide (LPS)-induced mRNAs for IL-1alpha, IL-1beta, IL-6, and TNF-alpha.	Dronabinol	111-114	tumor necrosis factor	Rattus norvegicus	221-230
10594923-3	2000	Of these cytokine mRNAs, the response of that for IL-6 was exquisitely sensitive to THC.	Dronabinol	84-87	interleukin 6	Rattus norvegicus	50-54
10588688-5	1999	HU-308 shows no activity in mice in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB(1).	Dronabinol	116-136	cannabinoid receptor 1 (brain)	Mus musculus	180-185
10588688-5	1999	HU-308 shows no activity in mice in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB(1).	Dronabinol	138-141	cannabinoid receptor 1 (brain)	Mus musculus	180-185
10612710-6	1999	The CB1 antagonist, SR141716A, differentially blocks Delta(9)-THC versus AEA.	Dronabinol	53-65	cannabinoid receptor 1	Homo sapiens	4-7
10575284-2	1999	In the last decade it was established that Delta9-THC acts through specific receptors - CB1 and CB2 - and mimics the physiological activity of endogenous cannabinoids of two types, the best known representatives being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG).	Dronabinol	43-53	cannabinoid receptor 1	Homo sapiens	88-91
10575284-2	1999	In the last decade it was established that Delta9-THC acts through specific receptors - CB1 and CB2 - and mimics the physiological activity of endogenous cannabinoids of two types, the best known representatives being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG).	Dronabinol	43-53	cannabinoid receptor 2	Homo sapiens	96-99
10546994-3	1999	In the present study the possible direct effect of the cannabinoid receptor agonist delta9-Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures.	Dronabinol	84-111	prolactin	Rattus norvegicus	121-130
10546994-3	1999	In the present study the possible direct effect of the cannabinoid receptor agonist delta9-Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures.	Dronabinol	113-116	prolactin	Rattus norvegicus	121-130
10546994-4	1999	THC (0.1 and 1 microM) increased cAMP levels, and induced PRL release (1 and 10 mu).	Dronabinol	0-3	prolactin	Rattus norvegicus	58-61
10546994-6	1999	However, THC did prevent VIP-dependent increases in prolactin secretion.	Dronabinol	9-12	vasoactive intestinal peptide	Rattus norvegicus	25-28
10546994-6	1999	However, THC did prevent VIP-dependent increases in prolactin secretion.	Dronabinol	9-12	prolactin	Rattus norvegicus	52-61
10546994-7	1999	These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP.	Dronabinol	28-31	prolactin	Rattus norvegicus	109-112
10546994-7	1999	These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP.	Dronabinol	28-31	prolactin	Rattus norvegicus	178-181
10546994-7	1999	These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP.	Dronabinol	28-31	vasoactive intestinal peptide	Rattus norvegicus	195-198
10780256-10	1999	In summary, CB1-receptor agonists such as delta 9-THC and WIN 55,212-2 were more disruptive to the rate and accuracy of learning in old-world monkeys than the CB1-receptor antagonist SR141716A or cannabidiol.	Dronabinol	42-53	cannabinoid receptor 1	Macaca mulatta	12-15
10521585-0	1999	Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine).	Dronabinol	55-84	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	165-170
10521585-6	1999	THC (delta(9)-tetrahydrocannabinol), 25 mg/kg, induced c-fos mRNA again in the lateral septum and furthermore in large parts of the striatum including the nucleus accumbens.	Dronabinol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-60
10521585-6	1999	THC (delta(9)-tetrahydrocannabinol), 25 mg/kg, induced c-fos mRNA again in the lateral septum and furthermore in large parts of the striatum including the nucleus accumbens.	Dronabinol	5-34	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-60
10395487-1	1999	We have recently reported that racemic 5,11-cis-diethyl-5,6,11, 12-tetrahydrochrysene-2,8-diol (THC, rac-2b) acts as an agonist on estrogen receptor alpha (ERalpha) and as a complete antagonist on estrogen receptor beta (ERbeta) (Sun et al.	Dronabinol	96-99	estrogen receptor 1	Homo sapiens	131-154
10395487-1	1999	We have recently reported that racemic 5,11-cis-diethyl-5,6,11, 12-tetrahydrochrysene-2,8-diol (THC, rac-2b) acts as an agonist on estrogen receptor alpha (ERalpha) and as a complete antagonist on estrogen receptor beta (ERbeta) (Sun et al.	Dronabinol	96-99	estrogen receptor 1	Homo sapiens	156-163
10395487-1	1999	We have recently reported that racemic 5,11-cis-diethyl-5,6,11, 12-tetrahydrochrysene-2,8-diol (THC, rac-2b) acts as an agonist on estrogen receptor alpha (ERalpha) and as a complete antagonist on estrogen receptor beta (ERbeta) (Sun et al.	Dronabinol	96-99	estrogen receptor 2	Homo sapiens	197-219
10395487-1	1999	We have recently reported that racemic 5,11-cis-diethyl-5,6,11, 12-tetrahydrochrysene-2,8-diol (THC, rac-2b) acts as an agonist on estrogen receptor alpha (ERalpha) and as a complete antagonist on estrogen receptor beta (ERbeta) (Sun et al.	Dronabinol	96-99	estrogen receptor 2	Homo sapiens	221-227
10395487-10	1999	This study illustrates that the antagonist character in THC ligands for ERbeta depends in a progressive way on the size and geometric disposition of substituent groups and suggests that the induction of an antagonist conformation in ERbeta can be achieved with these ligands with less steric perturbation than in ERalpha.	Dronabinol	56-59	estrogen receptor 2	Homo sapiens	72-78
10395487-10	1999	This study illustrates that the antagonist character in THC ligands for ERbeta depends in a progressive way on the size and geometric disposition of substituent groups and suggests that the induction of an antagonist conformation in ERbeta can be achieved with these ligands with less steric perturbation than in ERalpha.	Dronabinol	56-59	estrogen receptor 2	Homo sapiens	233-239
10395487-10	1999	This study illustrates that the antagonist character in THC ligands for ERbeta depends in a progressive way on the size and geometric disposition of substituent groups and suggests that the induction of an antagonist conformation in ERbeta can be achieved with these ligands with less steric perturbation than in ERalpha.	Dronabinol	56-59	estrogen receptor 1	Homo sapiens	313-320
10362691-1	1999	The CB1 subtype of the cannabinoid receptor is present on neurons in the brain and mediates the perceptual effects of Delta9-tetrahydrocannabinol and other cannabinoids.	Dronabinol	118-145	cannabinoid receptor 1	Homo sapiens	4-7
10402157-5	1999	In the CA2 layer of the Ammon"s horn, there was an increase in mRNA levels of delta9-THC-exposed animals, although this was statistically significant only in males.	Dronabinol	85-88	carbonic anhydrase 2	Rattus norvegicus	7-10
10336560-9	1999	In contrast, the CB2-selective antagonist SR144528 completely blocked THC"s suppression of the T cell response, implicating the participation of the CB2 receptor.	Dronabinol	70-73	cannabinoid receptor 2	Homo sapiens	17-20
10336560-9	1999	In contrast, the CB2-selective antagonist SR144528 completely blocked THC"s suppression of the T cell response, implicating the participation of the CB2 receptor.	Dronabinol	70-73	cannabinoid receptor 2	Homo sapiens	149-152
10349037-3	1999	This P50 sensory gating report is part of a larger neurophysiological and neurocognitive investigation of chronic THC exposure using rigorously screened medically and psychiatrically normal individuals without concurrent use of non-THC substances.	Dronabinol	114-117	nuclear factor kappa B subunit 1	Homo sapiens	5-8
10349037-3	1999	This P50 sensory gating report is part of a larger neurophysiological and neurocognitive investigation of chronic THC exposure using rigorously screened medically and psychiatrically normal individuals without concurrent use of non-THC substances.	Dronabinol	232-235	nuclear factor kappa B subunit 1	Homo sapiens	5-8
10349037-9	1999	CONCLUSIONS: Reduced P50 suppression in the sensory gating paradigm may be a possible neurophysiological CNS sequela of long-term cumulative exposure to THC.	Dronabinol	153-156	nuclear factor kappa B subunit 1	Homo sapiens	21-24
10318961-6	1999	Delta9-THC-induced ring-catalepsy, hypomobility, and hypothermia were completely absent in CB1 mutant mice.	Dronabinol	0-10	cannabinoid receptor 1 (brain)	Mus musculus	91-94
10357256-0	1999	Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	85-88
10357256-9	1999	Both gastric motor and cardiovascular effects of peripherally administered delta9-THC seem to be mediated through cannabinoid CB1 receptors.	Dronabinol	75-85	cannabinoid receptor 1	Rattus norvegicus	126-129
10101241-0	1999	Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.	Dronabinol	59-86	proenkephalin	Homo sapiens	90-103
10101241-0	1999	Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.	Dronabinol	59-86	cannabinoid receptor 1	Homo sapiens	187-190
10101241-1	1999	The purpose of the present study was to examine the time-related effects of repeated administration of Delta9-tetrahydrocannabinol during 1, 3, 7 and 14 days on cannabinoid and mu-opioid receptor agonist-stimulated [35S]GTPgammaS binding, and CB1 cannabinoid receptor and proenkephalin gene expression in the caudate-putamen.	Dronabinol	103-130	cannabinoid receptor 1	Homo sapiens	243-246
10101241-1	1999	The purpose of the present study was to examine the time-related effects of repeated administration of Delta9-tetrahydrocannabinol during 1, 3, 7 and 14 days on cannabinoid and mu-opioid receptor agonist-stimulated [35S]GTPgammaS binding, and CB1 cannabinoid receptor and proenkephalin gene expression in the caudate-putamen.	Dronabinol	103-130	proenkephalin	Homo sapiens	272-285
10101241-7	1999	Taken together, the results of the present study indicate that, in the caudate-putamen, repeated administration with Delta9-tetrahydrocannabinol produces a time-related increase in proenkephalin gene expression and mu-opioid receptor activation of G-proteins, and a time-related decrease in CB1 cannabinoid receptor gene expression and reduction in CB1 cannabinoid receptor activation of G-proteins.	Dronabinol	124-144	proenkephalin	Homo sapiens	181-194
10101241-7	1999	Taken together, the results of the present study indicate that, in the caudate-putamen, repeated administration with Delta9-tetrahydrocannabinol produces a time-related increase in proenkephalin gene expression and mu-opioid receptor activation of G-proteins, and a time-related decrease in CB1 cannabinoid receptor gene expression and reduction in CB1 cannabinoid receptor activation of G-proteins.	Dronabinol	124-144	cannabinoid receptor 1	Homo sapiens	291-294
10101241-7	1999	Taken together, the results of the present study indicate that, in the caudate-putamen, repeated administration with Delta9-tetrahydrocannabinol produces a time-related increase in proenkephalin gene expression and mu-opioid receptor activation of G-proteins, and a time-related decrease in CB1 cannabinoid receptor gene expression and reduction in CB1 cannabinoid receptor activation of G-proteins.	Dronabinol	124-144	cannabinoid receptor 1	Homo sapiens	349-352
10098887-2	1999	Delta9-Tetrahydrocannabinol (THC), the major active component of marijuana, produced a malonyl-CoA-independent stimulation of carnitine palmitoyltransferase I (CPT-I) and ketogenesis from [14C]palmitate.	Dronabinol	0-27	carnitine palmitoyltransferase 1B	Rattus norvegicus	126-158
10098887-2	1999	Delta9-Tetrahydrocannabinol (THC), the major active component of marijuana, produced a malonyl-CoA-independent stimulation of carnitine palmitoyltransferase I (CPT-I) and ketogenesis from [14C]palmitate.	Dronabinol	0-27	carnitine palmitoyltransferase 1B	Rattus norvegicus	160-165
10098887-2	1999	Delta9-Tetrahydrocannabinol (THC), the major active component of marijuana, produced a malonyl-CoA-independent stimulation of carnitine palmitoyltransferase I (CPT-I) and ketogenesis from [14C]palmitate.	Dronabinol	29-32	carnitine palmitoyltransferase 1B	Rattus norvegicus	126-158
10098887-2	1999	Delta9-Tetrahydrocannabinol (THC), the major active component of marijuana, produced a malonyl-CoA-independent stimulation of carnitine palmitoyltransferase I (CPT-I) and ketogenesis from [14C]palmitate.	Dronabinol	29-32	carnitine palmitoyltransferase 1B	Rattus norvegicus	160-165
10098887-3	1999	The THC-induced stimulation of ketogenesis was mimicked by the synthetic cannabinoid HU-210 and was prevented by pertussis toxin and the CB1 cannabinoid receptor antagonist SR141716.	Dronabinol	4-7	cannabinoid receptor 1	Rattus norvegicus	137-140
10098887-6	1999	THC produced a CB1 receptor-dependent stimulation of sphingomyelin breakdown that was concomitant to an elevation of intracellular ceramide levels.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	15-18
10219981-0	1999	Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat.	Dronabinol	27-54	proopiomelanocortin	Rattus norvegicus	125-144
10219981-0	1999	Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat.	Dronabinol	27-54	corticotropin releasing hormone	Rattus norvegicus	149-179
10219981-1	1999	The purpose of the present study was to explore the time related effects of repeated administration of delta9-tetrahydrocannabinol on opioid and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat.	Dronabinol	103-130	corticotropin releasing hormone	Rattus norvegicus	145-175
9927308-3	1999	A tetrahydrochrysene (THC) has a 4-fold preferential binding affinity for ER beta; it is an agonist on ER alpha, but a complete antagonist on ER beta.	Dronabinol	22-25	estrogen receptor 2	Homo sapiens	74-81
9927308-3	1999	A tetrahydrochrysene (THC) has a 4-fold preferential binding affinity for ER beta; it is an agonist on ER alpha, but a complete antagonist on ER beta.	Dronabinol	22-25	estrogen receptor 1	Homo sapiens	103-111
9927308-3	1999	A tetrahydrochrysene (THC) has a 4-fold preferential binding affinity for ER beta; it is an agonist on ER alpha, but a complete antagonist on ER beta.	Dronabinol	22-25	estrogen receptor 2	Homo sapiens	142-149
9927308-6	1999	This difference in binding affinity accounts for the full ER beta antagonist activity of the THC racemate (a 1:1 mixture of R,R-THC and S,S-THC).	Dronabinol	93-96	estrogen receptor 2	Homo sapiens	58-65
9988095-8	1999	Since (-)-delta9-tetrahydrocannabinol is a cannabinoid CB1 receptor agonist, densely present in limbic and basal ganglia circuits, and since amphetamine enhances monoaminergic inputs (i.e., dopamine, serotonin) in these brain areas, the present data support the hypothesis of a role for the cannabinoid CB1 receptor as a regulatory mechanism of monoaminergic neuron-mediated psychomotor activation.	Dronabinol	6-37	cannabinoid receptor 1	Rattus norvegicus	55-58
9918839-4	1999	We find that THC 18, which has a side chain with a pi-bonded SP2 conformation, binds differently to the tubulin isoforms, while THC 5 with a slightly different side chain does not.	Dronabinol	13-16	Sp2 transcription factor	Bos taurus	61-64
9882692-6	1999	Delta9-THC (100 nM) inhibition of spiking was reversed by 300 nM N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (SR 141716), indicating that the inhibition was mediated by CB1 cannabinoid receptors.	Dronabinol	0-10	cannabinoid receptor 1	Rattus norvegicus	213-216
11400780-2	1999	Most clinically ascertained cases are caused by thc point mutation K329E in MCAD gene.	Dronabinol	48-51	acyl-CoA dehydrogenase medium chain	Homo sapiens	76-80
9916880-3	1998	After 7 days of treatment, when mice were tolerant to delta9-THC-induced analgesia, these functional parameters were strongly inhibited and there was a persistent reduction in IL-2 and IFNgamma.	Dronabinol	61-64	interleukin 2	Mus musculus	176-180
9916880-3	1998	After 7 days of treatment, when mice were tolerant to delta9-THC-induced analgesia, these functional parameters were strongly inhibited and there was a persistent reduction in IL-2 and IFNgamma.	Dronabinol	61-64	interferon gamma	Mus musculus	185-193
9974175-1	1998	The effects of the primary psychoactive constituent of marijuana, delta 9-tetrahydrocannabinol, are mediated by cannabinoid receptors, CB1 and CB2.	Dronabinol	66-94	cannabinoid receptor 1	Homo sapiens	135-138
9813289-0	1998	Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions.	Dronabinol	33-43	cannabinoid receptor 1	Rattus norvegicus	83-86
9813289-1	1998	The time course of changes across 21 days of continuous exposure to Delta9-tetrahydrocannabinol (Delta9-THC) was assessed for the level of cannabinoid receptor (CB1) mRNA expression in three different rat brain regions: cerebellum, hippocampus and corpus striatum.	Dronabinol	68-95	cannabinoid receptor 1	Rattus norvegicus	161-164
9813289-6	1998	CB1 message expression in all three brain areas returned to vehicle control levels by day 21 of Delta9-THC treatment, a time at which behavioral tolerance has been previously reported.	Dronabinol	103-106	cannabinoid receptor 1	Rattus norvegicus	0-3
9813289-10	1998	Comparisons suggests that CB1 message may be regulated by different effector systems in each of the three areas during chronic Delta9-THC exposure.	Dronabinol	134-137	cannabinoid receptor 1	Rattus norvegicus	26-29
9825732-4	1998	Thus, the acute administration of (-)-delta9-tetrahydrocannnabinol (delta9-THC) produced, as expected, a marked decrease in plasma PRL and LH levels, with no changes in follicle-stimulating hormone (FSH) levels.	Dronabinol	68-78	prolactin	Rattus norvegicus	131-134
9825732-6	1998	The co-administration of delta9-THC and SR141716, a specific antagonist for CB1 receptors, attenuated both PRL and LH decrease and GABA increase, thus asserting the involvement of the activation of CB1 receptors in these effects.	Dronabinol	25-35	cannabinoid receptor 1	Rattus norvegicus	76-79
9825732-6	1998	The co-administration of delta9-THC and SR141716, a specific antagonist for CB1 receptors, attenuated both PRL and LH decrease and GABA increase, thus asserting the involvement of the activation of CB1 receptors in these effects.	Dronabinol	25-35	prolactin	Rattus norvegicus	107-110
9825732-6	1998	The co-administration of delta9-THC and SR141716, a specific antagonist for CB1 receptors, attenuated both PRL and LH decrease and GABA increase, thus asserting the involvement of the activation of CB1 receptors in these effects.	Dronabinol	25-35	cannabinoid receptor 1	Rattus norvegicus	198-201
9795237-5	1998	The possible involvement of the CB2 receptor in THC-mediated AA release and ANA synthesis is addressed using the antagonist SR144528.	Dronabinol	48-51	cannabinoid receptor 2 (macrophage)	Mus musculus	32-35
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	41-45
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	C-C motif chemokine ligand 3	Homo sapiens	47-57
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	C-C motif chemokine ligand 4	Homo sapiens	59-68
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	C-C motif chemokine ligand 5	Homo sapiens	74-80
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	tumor necrosis factor	Homo sapiens	124-133
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	colony stimulating factor 2	Homo sapiens	135-141
9858061-4	1998	THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells.	Dronabinol	0-3	interferon gamma	Homo sapiens	146-155
9804618-3	1998	These effects of THC were mimicked by the synthetic cannabinoid HU-210, and prevented by forskolin, pertussis toxin, and the CB1 receptor antagonist SR 141716.	Dronabinol	17-20	cannabinoid receptor 1	Rattus norvegicus	125-128
9804618-5	1998	THC stimulated p42/p44 mitogen-activated protein kinase (MAPK) activity, Raf-1 phosphorylation, and Raf-1 translocation to the particulate cell fraction.	Dronabinol	0-3	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	73-78
9804618-5	1998	THC stimulated p42/p44 mitogen-activated protein kinase (MAPK) activity, Raf-1 phosphorylation, and Raf-1 translocation to the particulate cell fraction.	Dronabinol	0-3	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	100-105
9862397-0	1998	The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.	Dronabinol	95-122	cannabinoid receptor 1	Rattus norvegicus	16-19
9862397-2	1998	The purpose of the present investigation was to determine if the cannabinoid CB1 receptor antagonist SR141716A could attenuate THC- or anandamide-induced memory impairment, and to assess the effects on memory of SR141716A alone.	Dronabinol	127-130	cannabinoid receptor 1	Rattus norvegicus	77-80
9795096-5	1998	Delta9-THC effects were antagonized by the cannabinoid CB1 antagonist SR141716A at the i.p.	Dronabinol	0-10	cannabinoid receptor 1	Rattus norvegicus	55-58
9757010-10	1998	On the contrary, delta9-THC-exposed females exhibited higher density of these receptors than their respective oil-exposed controls in the prefrontal cortex, the hippocampus (CA3 area), the amygdala (posteromedial cortical nucleus), the ventral tegmental area and the periaqueductal grey matter, whereas the binding was lower than control females only in the lateral amygdala.	Dronabinol	17-27	carbonic anhydrase 3	Rattus norvegicus	174-177
9761594-2	1998	In the present study, we have examined whether this loss in the responsiveness to amphetamine might be due to changes at the level of dopamine transporter (DAT), the main molecular site for the action of amphetamine, following the perinatal exposure to delta9-THC.	Dronabinol	253-263	solute carrier family 6 member 3	Rattus norvegicus	134-154
9761594-2	1998	In the present study, we have examined whether this loss in the responsiveness to amphetamine might be due to changes at the level of dopamine transporter (DAT), the main molecular site for the action of amphetamine, following the perinatal exposure to delta9-THC.	Dronabinol	253-263	solute carrier family 6 member 3	Rattus norvegicus	156-159
9761594-6	1998	Both adult male and female rats that had been perinatally exposed to delta9-THC exhibited similar mRNA levels to controls for both DAT and TH in the substantia nigra as well as in the ventral tegmental area.	Dronabinol	69-79	solute carrier family 6 member 3	Rattus norvegicus	131-134
9748483-0	1998	A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain.	Dronabinol	16-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
9748483-4	1998	delta 9-THC and anandamide caused equally high levels of c-fos expression in the paraventricular nucleus of the hypothalamus and the lateral septum.	Dronabinol	0-11	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	57-62
9748483-6	1998	Only delta 9-THC caused significant increases in c-fos expression in the nucleus accumbens and caudate-putamen.	Dronabinol	5-16	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	49-54
9723953-6	1998	administration of 0.5 to 5 mg kg(-1) delta9-THC; maximum decreases being 0.8+/-0.2 degrees C to 2.9+/-0.3 degrees C. This hypothermic response was attenuated by the cannabinoid CB1 receptor antagonist SR 141716.	Dronabinol	37-47	cannabinoid receptor 1	Rattus norvegicus	177-180
9778102-2	1998	The costimulatory activity of a THC-exposed macrophage hybridoma was investigated by its ability to elicit interleukin-2 secretion by a helper T cell hybridoma activated with immobilized monoclonal anti-CD3 antibody.	Dronabinol	32-35	interleukin 2	Homo sapiens	107-120
9694974-0	1998	Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1.	Dronabinol	0-27	B cell leukemia/lymphoma 2	Mus musculus	93-98
9694974-0	1998	Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1.	Dronabinol	0-27	caspase 1	Mus musculus	103-112
9694974-7	1998	In addition, THC treatment of splenocytes resulted in a decrease of Bcl-2 mRNA and protein as measured by Northern and Western blotting, respectively, and the drug induced apoptosis was blocked by the caspase inhibitor, Ac-Tyr-Val-Ala-L-aspartic acid aldehyde.	Dronabinol	13-16	B cell leukemia/lymphoma 2	Mus musculus	68-73
9694974-7	1998	In addition, THC treatment of splenocytes resulted in a decrease of Bcl-2 mRNA and protein as measured by Northern and Western blotting, respectively, and the drug induced apoptosis was blocked by the caspase inhibitor, Ac-Tyr-Val-Ala-L-aspartic acid aldehyde.	Dronabinol	13-16	caspase 1	Mus musculus	201-208
9694974-8	1998	These data suggest that THC treatment of cultured immune cells induces apoptosis through the regulation of Bcl-2 and caspase activity.	Dronabinol	24-27	B cell leukemia/lymphoma 2	Mus musculus	107-112
9694974-8	1998	These data suggest that THC treatment of cultured immune cells induces apoptosis through the regulation of Bcl-2 and caspase activity.	Dronabinol	24-27	caspase 1	Mus musculus	117-124
9666136-1	1998	It is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as well as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes of cannabinoid receptors, CB1 and CB2, which have recently been characterized.	Dronabinol	144-171	cannabinoid receptor 1	Rattus norvegicus	234-237
9666136-1	1998	It is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as well as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes of cannabinoid receptors, CB1 and CB2, which have recently been characterized.	Dronabinol	144-171	cannabinoid receptor 2	Rattus norvegicus	242-245
9618400-1	1998	Early molecular modeling studies with Delta9-tetrahydrocannabinol (Delta9-THC) reported that three discrete regions which interact with brain cannabinoid (CB1) receptors corresponded to the C-9 position of the cyclohexene ring, the phenolic hydroxyl and the carbon side chain at the C3 position.	Dronabinol	38-65	cannabinoid receptor 1	Rattus norvegicus	155-158
9618400-1	1998	Early molecular modeling studies with Delta9-tetrahydrocannabinol (Delta9-THC) reported that three discrete regions which interact with brain cannabinoid (CB1) receptors corresponded to the C-9 position of the cyclohexene ring, the phenolic hydroxyl and the carbon side chain at the C3 position.	Dronabinol	67-77	cannabinoid receptor 1	Rattus norvegicus	155-158
9618417-0	1998	CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.	Dronabinol	67-94	cannabinoid receptor 1 (brain)	Mus musculus	0-3
9632241-11	1998	Finally, the ability of the CB1 receptor antagonist SR141716A to antagonize the enhancement of morphine by THC indicates that THC was acting through a cannabinoid receptor mechanism.	Dronabinol	107-110	cannabinoid receptor 1 (brain)	Mus musculus	28-31
9632241-11	1998	Finally, the ability of the CB1 receptor antagonist SR141716A to antagonize the enhancement of morphine by THC indicates that THC was acting through a cannabinoid receptor mechanism.	Dronabinol	126-129	cannabinoid receptor 1 (brain)	Mus musculus	28-31
9751146-0	1998	Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.	Dronabinol	0-27	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	56-60
9751146-0	1998	Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.	Dronabinol	0-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	86-89
9751146-2	1998	Using electrophoretic mobility-shift assay and one-dimensional Western blot, we here report that delta9-THC increases Activator protein-1 (AP-1) DNA-binding and Fos-related antigen activity in discrete areas of the rat brain.	Dronabinol	97-107	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	139-143
9751146-2	1998	Using electrophoretic mobility-shift assay and one-dimensional Western blot, we here report that delta9-THC increases Activator protein-1 (AP-1) DNA-binding and Fos-related antigen activity in discrete areas of the rat brain.	Dronabinol	97-107	rabaptin, RAB GTPase binding effector protein 2	Rattus norvegicus	161-180
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	93-97
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	229-234
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	FosB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	236-240
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	FOS like 1, AP-1 transcription factor subunit	Rattus norvegicus	242-247
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	rabaptin, RAB GTPase binding effector protein 2	Rattus norvegicus	249-268
9751146-3	1998	One hour after the intraperitoneal administration of delta9-THC at a dose of 10 or 15 mg/kg, AP-1 DNA-binding activity in the nucleus accumbens increased by 33 and 49%, respectively, while Western blot showed an increase in both c-Fos, FosB, Fra-1 (Fos-related antigen) and Fra-2.	Dronabinol	53-63	FosB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	274-279
9751146-6	1998	The effect of delta9-THC on the AP-1 DNA binding and the Fos-related antigens in the nucleus accumbens was blocked by the specific cannabinoid antagonist SR141716 A (3 mg/kg i.p.).	Dronabinol	14-24	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	32-36
9751146-6	1998	The effect of delta9-THC on the AP-1 DNA binding and the Fos-related antigens in the nucleus accumbens was blocked by the specific cannabinoid antagonist SR141716 A (3 mg/kg i.p.).	Dronabinol	14-24	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	57-60
9751146-8	1998	The results indicate that delta9-THC activates gene coding for AP-1 DNA-binding proteins by acting on cannabinoid receptors, and induces a different transcriptional program on the early-immediate gene of the Fos family, in different areas in the rat brain, suggesting that this mechanism might be involved in the central actions of cannabinoids.	Dronabinol	26-36	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	63-67
9751146-8	1998	The results indicate that delta9-THC activates gene coding for AP-1 DNA-binding proteins by acting on cannabinoid receptors, and induces a different transcriptional program on the early-immediate gene of the Fos family, in different areas in the rat brain, suggesting that this mechanism might be involved in the central actions of cannabinoids.	Dronabinol	26-36	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	208-211
9630001-4	1998	Four cannabimimetic agents were assessed in this study: (R)-methanandamide (AM 356), a hydrolytically stable analog of arachidonylethanolamide, an endogenous ligand for the CB1 receptor; CP-55,940, a potent non-classical synthetic ligand; (-)-delta8-tetrahydrocannabinol (delta8-THC), an isomer of the naturally occurring delta9-THC; and WIN 55,212-2, a synthetic aminoalkylindole.	Dronabinol	322-332	cannabinoid receptor 1	Rattus norvegicus	173-176
9645967-5	1998	Subchronic administration of THC or AM356 increased PENK mRNA levels in the ventromedial nucleus of the hypothalamus, (82%) and (39%), in the periaqueductal grey matter, (97%) and (49%), and mammillary nucleus, (43%) and (9%), respectively.	Dronabinol	29-32	proenkephalin	Rattus norvegicus	52-56
10065936-7	1998	The delta-9-tetrahydrocannabinol-induced increase in circling was blocked by the central cannabinoid receptor CB1 antagonist SR 141716.	Dronabinol	4-32	cannabinoid receptor 1	Rattus norvegicus	110-113
9666273-1	1998	Delta-9-tetrahydrocannabinol (THC) has been shown to decrease Th1 responses (cell mediated immunity) while increasing Th2 responses (humoral immunity), both in vitro and in vivo.	Dronabinol	0-28	negative elongation factor complex member C/D, Th1l	Mus musculus	62-65
9666273-1	1998	Delta-9-tetrahydrocannabinol (THC) has been shown to decrease Th1 responses (cell mediated immunity) while increasing Th2 responses (humoral immunity), both in vitro and in vivo.	Dronabinol	0-28	heart and neural crest derivatives expressed 2	Mus musculus	118-121
9666273-1	1998	Delta-9-tetrahydrocannabinol (THC) has been shown to decrease Th1 responses (cell mediated immunity) while increasing Th2 responses (humoral immunity), both in vitro and in vivo.	Dronabinol	30-33	negative elongation factor complex member C/D, Th1l	Mus musculus	62-65
9666273-1	1998	Delta-9-tetrahydrocannabinol (THC) has been shown to decrease Th1 responses (cell mediated immunity) while increasing Th2 responses (humoral immunity), both in vitro and in vivo.	Dronabinol	30-33	heart and neural crest derivatives expressed 2	Mus musculus	118-121
9666273-2	1998	The addition of THC to murine splenocytes stimulated for 72 hrs with pokeweed mitogen (PWM) increased the detection of IL-4 and IL-10, cytokines associated with Th2 responses, and decreased IFN-gamma, IL-15 and IL-12, cytokines associated with Th1 responses.	Dronabinol	16-19	interleukin 4	Mus musculus	119-123
9666273-2	1998	The addition of THC to murine splenocytes stimulated for 72 hrs with pokeweed mitogen (PWM) increased the detection of IL-4 and IL-10, cytokines associated with Th2 responses, and decreased IFN-gamma, IL-15 and IL-12, cytokines associated with Th1 responses.	Dronabinol	16-19	heart and neural crest derivatives expressed 2	Mus musculus	161-164
9666273-2	1998	The addition of THC to murine splenocytes stimulated for 72 hrs with pokeweed mitogen (PWM) increased the detection of IL-4 and IL-10, cytokines associated with Th2 responses, and decreased IFN-gamma, IL-15 and IL-12, cytokines associated with Th1 responses.	Dronabinol	16-19	interleukin 15	Mus musculus	201-206
9666273-2	1998	The addition of THC to murine splenocytes stimulated for 72 hrs with pokeweed mitogen (PWM) increased the detection of IL-4 and IL-10, cytokines associated with Th2 responses, and decreased IFN-gamma, IL-15 and IL-12, cytokines associated with Th1 responses.	Dronabinol	16-19	negative elongation factor complex member C/D, Th1l	Mus musculus	244-247
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	interleukin 15	Mus musculus	40-45
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	interleukin 6	Mus musculus	50-54
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	interleukin 1 alpha	Mus musculus	69-79
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	interleukin 1 beta	Mus musculus	81-90
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	tumor necrosis factor	Mus musculus	96-105
9666273-10	1998	Thus, the effects of THC on macrophages reflects the basic observation that THC decreases Th1 responses and increases Th2 responses.	Dronabinol	21-24	negative elongation factor complex member C/D, Th1l	Mus musculus	90-93
9666273-10	1998	Thus, the effects of THC on macrophages reflects the basic observation that THC decreases Th1 responses and increases Th2 responses.	Dronabinol	21-24	heart and neural crest derivatives expressed 2	Mus musculus	118-121
9666273-10	1998	Thus, the effects of THC on macrophages reflects the basic observation that THC decreases Th1 responses and increases Th2 responses.	Dronabinol	76-79	negative elongation factor complex member C/D, Th1l	Mus musculus	90-93
9666273-10	1998	Thus, the effects of THC on macrophages reflects the basic observation that THC decreases Th1 responses and increases Th2 responses.	Dronabinol	76-79	heart and neural crest derivatives expressed 2	Mus musculus	118-121
9666273-11	1998	The data obtained adds to the understanding of the THC-induced Th1/Th2 shift, but the mechanisms still must be determined.	Dronabinol	51-54	negative elongation factor complex member C/D, Th1l	Mus musculus	63-66
9666273-11	1998	The data obtained adds to the understanding of the THC-induced Th1/Th2 shift, but the mechanisms still must be determined.	Dronabinol	51-54	heart and neural crest derivatives expressed 2	Mus musculus	67-70
9666274-1	1998	Splenocyte cultures from BALB/c mice were treated with THC and mitogen and shown to produce less Th1 cytokine, IFN gamma, and more Th2 cytokines, IL-4 and IL-10.	Dronabinol	55-58	negative elongation factor complex member C/D, Th1l	Mus musculus	97-100
9666274-1	1998	Splenocyte cultures from BALB/c mice were treated with THC and mitogen and shown to produce less Th1 cytokine, IFN gamma, and more Th2 cytokines, IL-4 and IL-10.	Dronabinol	55-58	interferon gamma	Mus musculus	111-120
9666274-1	1998	Splenocyte cultures from BALB/c mice were treated with THC and mitogen and shown to produce less Th1 cytokine, IFN gamma, and more Th2 cytokines, IL-4 and IL-10.	Dronabinol	55-58	heart and neural crest derivatives expressed 2	Mus musculus	131-134
9666274-1	1998	Splenocyte cultures from BALB/c mice were treated with THC and mitogen and shown to produce less Th1 cytokine, IFN gamma, and more Th2 cytokines, IL-4 and IL-10.	Dronabinol	55-58	interleukin 4	Mus musculus	146-150
9666274-1	1998	Splenocyte cultures from BALB/c mice were treated with THC and mitogen and shown to produce less Th1 cytokine, IFN gamma, and more Th2 cytokines, IL-4 and IL-10.	Dronabinol	55-58	interleukin 10	Mus musculus	155-160
9422383-1	1998	The human cannabinoid receptor associated with the CNS (CB1) binds delta9-tetrahydrocannabinol, the psychoactive component of marijuana, and other cannabimimetic compounds.	Dronabinol	67-94	cannabinoid receptor 1	Homo sapiens	56-59
9422389-1	1998	The major active ingredient of marijuana, (-)-delta9-tetrahydrocannabinol, exerts its psychoactive effects via binding to cannabinoid CB1 receptors, which are widely distributed in the brain.	Dronabinol	42-73	cannabinoid receptor 1	Homo sapiens	134-137
9718090-2	1998	WIN 55,212-2 and delta9-THC induced a concentration-dependent decrease in TNF-alpha level in the bronchoalveolar lavage fluid (BALF) (maximum inhibition 52.7% and 36.9% for intranasal doses of 750 nmol x kg(-1) and 2.65 mmol x kg(-1), respectively).	Dronabinol	17-27	tumor necrosis factor	Mus musculus	74-83
9734704-0	1998	Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats.	Dronabinol	10-37	proenkephalin	Rattus norvegicus	55-68
9734704-5	1998	The results showed a marked reduction in proenkephalin mRNA levels in the caudate-putamen of delta9-THC-exposed females as compared to oil-exposed females, whereas no changes were observed between delta9-THC- and oil-exposed males.	Dronabinol	93-103	proenkephalin	Rattus norvegicus	41-54
9734704-7	1998	In summary, perinatal exposure to delta9-THC exposure decreased proenkephalin gene expression in the caudate-putamen of adult rats, although this effect exhibited a marked sexual dimorphism since it was only seen in females.	Dronabinol	34-44	proenkephalin	Rattus norvegicus	64-77
9392783-5	1997	The most interesting observation was that both adult males and females, when perinatally exposed to delta(9)-THC, showed a more marked AMPH-induced decrease in the production of L-3,4-dihydroxyphenylacetic acid (DOPAC), the main intraneuronal metabolite of dopamine (DA), although this did not affect the prolactin (PRL) release.	Dronabinol	100-112	prolactin	Rattus norvegicus	316-319
9392783-10	1997	The perinatal exposure to delta(9)-THC also modified the degree of increase in plasma PRL levels induced by both compounds, with opposite responses as a function of sex.	Dronabinol	26-38	prolactin	Rattus norvegicus	86-89
9392783-13	1997	These silent changes could be revealed after the administration of drugs such as: (i) AMPH, whose effect producing a decreased DOPAC accumulation was more marked in delta(9)-THC-exposed males and females; and (ii) SKF 38393 and sulpiride, whose stimulatory effects on PRL secretion were of different magnitude in delta(9)-THC-exposed animals, with an evident sexual dimorphism in the response.	Dronabinol	174-177	prolactin	Rattus norvegicus	268-271
9258987-9	1997	Decreases in regional cerebral blood flow following THC were seen in such areas as the CA1 region of the hippocampus, frontal and medial prefrontal cortex, the nucleus accumbens, and the claustrum.	Dronabinol	52-55	carbonic anhydrase 1	Rattus norvegicus	87-90
9272839-0	1997	Desensitization of Fos protein induction in rat striatum and nucleus accumbens following repeated administration of delta9-tetrahydrocannabinol.	Dronabinol	116-143	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	19-22
9272839-1	1997	The purpose of the present study was to clarify the effect of repeated administration of delta9-tetrahydrocannabinol (THC) on Fos protein induction in the rat brain.	Dronabinol	89-116	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	126-129
9272839-1	1997	The purpose of the present study was to clarify the effect of repeated administration of delta9-tetrahydrocannabinol (THC) on Fos protein induction in the rat brain.	Dronabinol	118-121	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	126-129
9272839-3	1997	attenuated the effect of THC (10 mg/kg) to induce the expression of Fos protein in rat striatum and nucleus accumbens.	Dronabinol	25-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	68-71
9272839-4	1997	This desensitization of Fos protein induction might explain the rapid development of behavioral tolerance to repeated administration of THC.	Dronabinol	136-139	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	24-27
9253958-7	1997	TNF-alpha, interleukin-6 and interleukin-8 synthesis was maximally inhibited by 3 nM delta9-tetrahydrocannabinol but stimulated by 3 microM delta9-tetrahydrocannabinol, as was interleukin-8 and interferon-gamma synthesis.	Dronabinol	85-112	tumor necrosis factor	Homo sapiens	0-9
9253958-7	1997	TNF-alpha, interleukin-6 and interleukin-8 synthesis was maximally inhibited by 3 nM delta9-tetrahydrocannabinol but stimulated by 3 microM delta9-tetrahydrocannabinol, as was interleukin-8 and interferon-gamma synthesis.	Dronabinol	85-112	interleukin 6	Homo sapiens	11-24
9253958-7	1997	TNF-alpha, interleukin-6 and interleukin-8 synthesis was maximally inhibited by 3 nM delta9-tetrahydrocannabinol but stimulated by 3 microM delta9-tetrahydrocannabinol, as was interleukin-8 and interferon-gamma synthesis.	Dronabinol	85-112	C-X-C motif chemokine ligand 8	Homo sapiens	29-42
9253958-7	1997	TNF-alpha, interleukin-6 and interleukin-8 synthesis was maximally inhibited by 3 nM delta9-tetrahydrocannabinol but stimulated by 3 microM delta9-tetrahydrocannabinol, as was interleukin-8 and interferon-gamma synthesis.	Dronabinol	140-167	tumor necrosis factor	Homo sapiens	0-9
9253958-7	1997	TNF-alpha, interleukin-6 and interleukin-8 synthesis was maximally inhibited by 3 nM delta9-tetrahydrocannabinol but stimulated by 3 microM delta9-tetrahydrocannabinol, as was interleukin-8 and interferon-gamma synthesis.	Dronabinol	140-167	C-X-C motif chemokine ligand 8	Homo sapiens	29-42
9253958-8	1997	The level of interleukin-4, interleukin-10 and p75 TNF-alpha soluble receptors was diminished by 3 microM delta9-tetrahydrocannabinol.	Dronabinol	106-133	interleukin 4	Homo sapiens	13-26
9253958-8	1997	The level of interleukin-4, interleukin-10 and p75 TNF-alpha soluble receptors was diminished by 3 microM delta9-tetrahydrocannabinol.	Dronabinol	106-133	interleukin 10	Homo sapiens	28-42
9253958-8	1997	The level of interleukin-4, interleukin-10 and p75 TNF-alpha soluble receptors was diminished by 3 microM delta9-tetrahydrocannabinol.	Dronabinol	106-133	TNF receptor superfamily member 1B	Homo sapiens	47-50
9253958-8	1997	The level of interleukin-4, interleukin-10 and p75 TNF-alpha soluble receptors was diminished by 3 microM delta9-tetrahydrocannabinol.	Dronabinol	106-133	tumor necrosis factor	Homo sapiens	51-60
9256167-1	1997	Several reports have demonstrated that (-)-delta9-tetrahydrocannabinol (delta9-THC) and arachidonylethanolamide [anandamide (AEA)] were able to inhibit prolactin (PRL) secretion from the anterior pituitary gland in male rodents, whereas ovarian phase-dependent effects were seen in females.	Dronabinol	39-70	prolactin	Rattus norvegicus	152-161
9256167-1	1997	Several reports have demonstrated that (-)-delta9-tetrahydrocannabinol (delta9-THC) and arachidonylethanolamide [anandamide (AEA)] were able to inhibit prolactin (PRL) secretion from the anterior pituitary gland in male rodents, whereas ovarian phase-dependent effects were seen in females.	Dronabinol	39-70	prolactin	Rattus norvegicus	163-166
9256167-1	1997	Several reports have demonstrated that (-)-delta9-tetrahydrocannabinol (delta9-THC) and arachidonylethanolamide [anandamide (AEA)] were able to inhibit prolactin (PRL) secretion from the anterior pituitary gland in male rodents, whereas ovarian phase-dependent effects were seen in females.	Dronabinol	72-82	prolactin	Rattus norvegicus	152-161
9256167-1	1997	Several reports have demonstrated that (-)-delta9-tetrahydrocannabinol (delta9-THC) and arachidonylethanolamide [anandamide (AEA)] were able to inhibit prolactin (PRL) secretion from the anterior pituitary gland in male rodents, whereas ovarian phase-dependent effects were seen in females.	Dronabinol	72-82	prolactin	Rattus norvegicus	163-166
9256167-9	1997	Interestingly, the time course of the effect of delta9-THC resembled that of AEA and AM356 only during the later part of the response, because delta9-THC produced a marked increase in plasma PRL levels at 20 min, no changes at 40 min and a decrease from 60 min up to 180 min.	Dronabinol	48-58	prolactin	Rattus norvegicus	191-194
9256167-9	1997	Interestingly, the time course of the effect of delta9-THC resembled that of AEA and AM356 only during the later part of the response, because delta9-THC produced a marked increase in plasma PRL levels at 20 min, no changes at 40 min and a decrease from 60 min up to 180 min.	Dronabinol	143-153	prolactin	Rattus norvegicus	191-194
9256167-12	1997	The activation of these receptors by delta9-THC seems to be involved in the inhibitory phase of the effect of this cannabinoid on PRL release, but not in the early stimulation; when these receptors were blocked with a specific antagonist, SR141716, the stimulation by delta9-THC was still observed, but the late inhibition was abolished.	Dronabinol	37-47	prolactin	Rattus norvegicus	130-133
9256167-14	1997	delta9-THC also produced a marked inhibition of LH secretion, but its effects on PRL were biphasic with an early stimulation not mediated by the activation of cannabinoid receptors, followed by a late and cannabinoid receptor-mediated inhibition.	Dronabinol	0-10	prolactin	Rattus norvegicus	81-84
9191083-12	1997	In summary, CB1 receptor binding decreases after chronic delta9-THC exposure in most of the brain regions studied, although this was not accompanied by parallel decreases in CB receptor mRNA levels.	Dronabinol	57-67	cannabinoid receptor 1	Rattus norvegicus	12-15
9208407-7	1997	Furthermore, pretreatment with the CRH receptor antagonist, alpha-helical CRH (100 micrograms/5 microliters, icv), 30 min before THC administration, attenuated the ability of a high THC dose (1.0 mg/kg) to inhibit LH release in ovariectomized rats.	Dronabinol	129-132	corticotropin releasing hormone	Rattus norvegicus	35-38
9208407-7	1997	Furthermore, pretreatment with the CRH receptor antagonist, alpha-helical CRH (100 micrograms/5 microliters, icv), 30 min before THC administration, attenuated the ability of a high THC dose (1.0 mg/kg) to inhibit LH release in ovariectomized rats.	Dronabinol	129-132	corticotropin releasing hormone	Rattus norvegicus	74-77
9208407-7	1997	Furthermore, pretreatment with the CRH receptor antagonist, alpha-helical CRH (100 micrograms/5 microliters, icv), 30 min before THC administration, attenuated the ability of a high THC dose (1.0 mg/kg) to inhibit LH release in ovariectomized rats.	Dronabinol	182-185	corticotropin releasing hormone	Rattus norvegicus	35-38
9208407-7	1997	Furthermore, pretreatment with the CRH receptor antagonist, alpha-helical CRH (100 micrograms/5 microliters, icv), 30 min before THC administration, attenuated the ability of a high THC dose (1.0 mg/kg) to inhibit LH release in ovariectomized rats.	Dronabinol	182-185	corticotropin releasing hormone	Rattus norvegicus	74-77
9208407-8	1997	Together, these results demonstrate that THC has significant effects on LH and ACTH secretion in ovariectomized rats and suggest that THC-induced CRH activation, but not corticosterone release, plays a role in the suppression of LH release by cannabinoids.	Dronabinol	41-44	corticotropin releasing hormone	Rattus norvegicus	146-149
9208407-8	1997	Together, these results demonstrate that THC has significant effects on LH and ACTH secretion in ovariectomized rats and suggest that THC-induced CRH activation, but not corticosterone release, plays a role in the suppression of LH release by cannabinoids.	Dronabinol	134-137	corticotropin releasing hormone	Rattus norvegicus	146-149
9175591-0	1997	delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	95-98
9175591-8	1997	These data provide the first evidence that delta9-THC-induced changes in mesolimbic dopamine neuronal activity are mediated by the CB1 cannabinoid receptor, but a causal link for the involvement of opioid systems could not be established.	Dronabinol	43-53	cannabinoid receptor 1	Rattus norvegicus	131-134
9152379-5	1997	Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha-neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of delta 9-THC but not CP55,940.	Dronabinol	237-248	prodynorphin	Mus musculus	38-54
9152379-5	1997	Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha-neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of delta 9-THC but not CP55,940.	Dronabinol	237-248	prodynorphin	Mus musculus	57-72
9152379-5	1997	Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha-neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of delta 9-THC but not CP55,940.	Dronabinol	237-248	prodynorphin	Mus musculus	77-95
9164547-7	1997	These findings indicate that the antinociceptive and cataleptic effects of delta 9-THC and CP 55,940 are mediated through CB1 cannabinoid receptors.	Dronabinol	75-86	cannabinoid receptor 1	Rattus norvegicus	122-125
9128838-0	1997	delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus.	Dronabinol	0-28	proopiomelanocortin	Rattus norvegicus	39-58
9128838-2	1997	The aim of this study was to examine the effects of delta 9-tetrahydrocannabinol on proopiomelanocortin (POMC) gene expression in the arcuate nucleus of the hypothalamus and anterior lobe of the pituitary.	Dronabinol	52-80	proopiomelanocortin	Rattus norvegicus	84-103
9128838-2	1997	The aim of this study was to examine the effects of delta 9-tetrahydrocannabinol on proopiomelanocortin (POMC) gene expression in the arcuate nucleus of the hypothalamus and anterior lobe of the pituitary.	Dronabinol	52-80	proopiomelanocortin	Rattus norvegicus	105-109
9128838-5	1997	These data indicate that delta 9-tetrahydrocannabinol stimulates opioid gene expression and regulates distinctively POMC in the hypothalamus and the anterior lobe of the pituitary in the rat.	Dronabinol	25-53	proopiomelanocortin	Rattus norvegicus	116-120
9188039-0	1997	delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.	Dronabinol	0-28	tyrosine hydroxylase	Rattus norvegicus	51-71
9188039-1	1997	The exposure of pregnant rats to delta 9-tetrahydrocannabinol (delta 9-THC), the main psychoactive constituent of Cannabis sativa, during gestation and lactation, affects the gene expression and the activity of tyrosine hydroxylase (TH) in the brain of their offspring, measured at fetal and early postnatal ages, when the expression of this enzyme plays an important role in neural development.	Dronabinol	33-61	tyrosine hydroxylase	Rattus norvegicus	211-231
9188039-1	1997	The exposure of pregnant rats to delta 9-tetrahydrocannabinol (delta 9-THC), the main psychoactive constituent of Cannabis sativa, during gestation and lactation, affects the gene expression and the activity of tyrosine hydroxylase (TH) in the brain of their offspring, measured at fetal and early postnatal ages, when the expression of this enzyme plays an important role in neural development.	Dronabinol	63-74	tyrosine hydroxylase	Rattus norvegicus	211-231
9188039-3	1997	Thus, TH activity increased approximately twofold in cells obtained from naive fetuses when exposed for 24 h to medium containing delta 9-THC.	Dronabinol	130-141	tyrosine hydroxylase	Rattus norvegicus	6-8
9188039-4	1997	In addition, TH activity was also approx twofold higher in cells obtained from fetuses exposed daily to delta 9-THC from d 5 of gestation than in cells obtained from control fetuses, when both were exposed to basal media.	Dronabinol	104-115	tyrosine hydroxylase	Rattus norvegicus	13-15
9188039-5	1997	This effect of delta 9-THC on TH activity seems to be produced via the activation to cannabinoid receptors, in particular the CB1 subtype, which would presumably be located in these cells.	Dronabinol	15-26	cannabinoid receptor 1	Rattus norvegicus	126-129
9188039-6	1997	This is because the exposure to medium containing both delta 9-THC and SR141716A, a specific antagonist for CB1 receptors, abolished the effect observed with delta 9-THC alone.	Dronabinol	55-66	cannabinoid receptor 1	Rattus norvegicus	108-111
9188039-6	1997	This is because the exposure to medium containing both delta 9-THC and SR141716A, a specific antagonist for CB1 receptors, abolished the effect observed with delta 9-THC alone.	Dronabinol	158-169	cannabinoid receptor 1	Rattus norvegicus	108-111
9115639-0	1997	Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor.	Dronabinol	50-77	interleukin 2 receptor subunit alpha	Homo sapiens	13-41
9115639-0	1997	Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor.	Dronabinol	50-77	cannabinoid receptor 1	Homo sapiens	119-122
9115639-1	1997	Previously, we reported that the cannabinoid delta9-tetrahydrocannabinol (THC) increased the expression of interleukin-2 (IL-2) receptor (R) alpha and beta proteins and mRNAs in NKB61A2 cells, but decreased the level of the gamma-chain message.	Dronabinol	45-72	interleukin 2	Homo sapiens	107-120
9115639-1	1997	Previously, we reported that the cannabinoid delta9-tetrahydrocannabinol (THC) increased the expression of interleukin-2 (IL-2) receptor (R) alpha and beta proteins and mRNAs in NKB61A2 cells, but decreased the level of the gamma-chain message.	Dronabinol	74-77	interleukin 2	Homo sapiens	107-120
9115639-7	1997	To link the increased nuclear factor activity with the THC-induced increase in IL-2R alpha message, antisense oligodeoxynucleotides were used to inhibit expression of the RelA component of NF-kappaB.	Dronabinol	55-58	interleukin 2 receptor subunit alpha	Homo sapiens	79-90
9115639-7	1997	To link the increased nuclear factor activity with the THC-induced increase in IL-2R alpha message, antisense oligodeoxynucleotides were used to inhibit expression of the RelA component of NF-kappaB.	Dronabinol	55-58	RELA proto-oncogene, NF-kB subunit	Homo sapiens	171-175
9115639-10	1997	These results suggest that THC treatment of NKB61A2 cells increases IL-2R alpha gene transcription by increasing the nuclear level of NF-kappaB through a mechanism involving cannabinoid receptor type 1 expression.	Dronabinol	27-30	tachykinin precursor 3	Homo sapiens	44-47
9115639-10	1997	These results suggest that THC treatment of NKB61A2 cells increases IL-2R alpha gene transcription by increasing the nuclear level of NF-kappaB through a mechanism involving cannabinoid receptor type 1 expression.	Dronabinol	27-30	interleukin 2 receptor subunit alpha	Homo sapiens	68-79
9046384-14	1997	In contrast, all clinical indicators of pancreatitis improved in the DDI patients who utilized Marinol/marijuana, including amylase (-34%), lipase (-30.8%), ALT (-21.4%), and AST (-20.1%).	Dronabinol	95-102	solute carrier family 17 member 5	Homo sapiens	175-178
9070350-7	1997	Competition binding in intact mouse splenocytes demonstrated that nonradiolabeled cannabinoids CP-55940, Win-55212-2, CP-56667, delta 9-THC, and cannabinol all competed for receptor binding with 3H-CP-55940, a high-affinity nondiscriminating CB1 and CB2 receptor ligand.	Dronabinol	128-139	cannabinoid receptor 1 (brain)	Mus musculus	242-245
9070350-7	1997	Competition binding in intact mouse splenocytes demonstrated that nonradiolabeled cannabinoids CP-55940, Win-55212-2, CP-56667, delta 9-THC, and cannabinol all competed for receptor binding with 3H-CP-55940, a high-affinity nondiscriminating CB1 and CB2 receptor ligand.	Dronabinol	128-139	cannabinoid receptor 2 (macrophage)	Mus musculus	250-253
9013047-2	1997	Our previous pilot studies suggested that auditory P300 latencies and amplitudes, auditory P50 and somatosensory P30 amplitudes and brainstem auditory evoked potential latencies were altered in THC users.	Dronabinol	194-197	E1A binding protein p300	Homo sapiens	51-55
9013047-4	1997	When age effects were controlled, THC related alterations of brain stem and both auditory and visual P300 responses could not be seen.	Dronabinol	34-37	E1A binding protein p300	Homo sapiens	101-105
9126878-4	1997	Treatment of N18 mouse neuroblastoma cells with the CB1 antisense probe, at two concentrations, resulted in a dramatic decrease of THC stimulated arachidonate release while treatment with antisense CB2 was less effective.	Dronabinol	131-134	cannabinoid receptor 1 (brain)	Mus musculus	52-55
9126878-7	1997	The CB1 antagonist, SR141716A, was effective in reducing the THC elevated levels of free arachidonate in these cells in agreement with the antisense data.	Dronabinol	61-64	cannabinoid receptor 1	Homo sapiens	4-7
9126878-8	1997	In the macrophage line, RAW 264.7, we found that while the sense, the random and the CB1 antisense oligonucleotides were ineffective, the CB2 antisense probe gave significant reductions of the THC induced response.	Dronabinol	193-196	cannabinoid receptor 2	Homo sapiens	138-141
9244374-0	1997	delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat.	Dronabinol	0-28	proenkephalin	Rattus norvegicus	56-69
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	39-67	prodynorphin	Rattus norvegicus	104-108
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	39-67	proenkephalin	Rattus norvegicus	114-127
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	39-67	proenkephalin	Rattus norvegicus	129-133
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	69-72	prodynorphin	Rattus norvegicus	104-108
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	69-72	proenkephalin	Rattus norvegicus	114-127
9244374-2	1997	The effect of five days treatment with delta-9-tetrahydrocannabinol (THC) was examined on prodynorphin (PDYN) and proenkephalin (PENK) gene expression in the spinal cord of male rats.	Dronabinol	69-72	proenkephalin	Rattus norvegicus	129-133
9012363-14	1997	However, the mRNA level for IL-6 was markedly increased following treatment of the infected animals with THC, suggesting the possible involvement of this pro-inflammatory cytokine in increased mortality.	Dronabinol	105-108	interleukin 6	Mus musculus	28-32
8894609-6	1996	Furthermore, most delta 9-tetrahydrocannabinol-sensitive neurons in the nucleus tractus solitarii showed opposite responses to delta 9-tetrahydrocannabinol and the 5-HT3 receptor agonist 1-phenylbiguanide, and might therefore be involved in the nausea-reducing effects of cannabinoids.	Dronabinol	18-46	5-hydroxytryptamine receptor 3A	Rattus norvegicus	164-178
8765472-1	1996	delta 9-Tetrahydrocannabinol (THC) inhibited nitric oxide (NO) production by mouse peritoneal macrophages activated by bacterial endotoxin lipopolysaccharide (LPS) and interferon-gamma (IFN)-gamma).	Dronabinol	0-28	interferon gamma	Mus musculus	168-196
8765472-1	1996	delta 9-Tetrahydrocannabinol (THC) inhibited nitric oxide (NO) production by mouse peritoneal macrophages activated by bacterial endotoxin lipopolysaccharide (LPS) and interferon-gamma (IFN)-gamma).	Dronabinol	30-33	interferon gamma	Mus musculus	168-196
8765472-3	1996	Inhibition was greatest if THC was added 1-4 hr before induction of nitric oxide synthase (NOS) by LPS and IFN-gamma, and declined with time after addition of the inducing agents.	Dronabinol	27-30	nitric oxide synthase 1, neuronal	Mus musculus	68-89
8765472-3	1996	Inhibition was greatest if THC was added 1-4 hr before induction of nitric oxide synthase (NOS) by LPS and IFN-gamma, and declined with time after addition of the inducing agents.	Dronabinol	27-30	interferon gamma	Mus musculus	107-116
8700141-0	1996	Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.	Dronabinol	66-94	nitric oxide synthase 2, inducible	Mus musculus	15-46
8700141-3	1996	In the current study, we show that delta 9-THC produces a marked inhibition of inducible nitric oxide synthase (iNOS) transcription and nitric oxide production by the macrophage line RAW 264.7 in response to lipopolysaccharide (LPS).	Dronabinol	35-46	nitric oxide synthase 2, inducible	Mus musculus	79-110
8700141-3	1996	In the current study, we show that delta 9-THC produces a marked inhibition of inducible nitric oxide synthase (iNOS) transcription and nitric oxide production by the macrophage line RAW 264.7 in response to lipopolysaccharide (LPS).	Dronabinol	35-46	nitric oxide synthase 2, inducible	Mus musculus	112-116
8700141-7	1996	We demonstrate that delta 9-THC inhibits the activation and binding of NF-kappa B/Rel proteins to their cognate DNA site, kappa B, in response to LPS stimulation.	Dronabinol	20-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-81
8700141-12	1996	This activation of iNOS is attenuated by delta 9-THC through the inhibition of cAMP signaling.	Dronabinol	41-52	nitric oxide synthase 2, inducible	Mus musculus	19-23
8667192-2	1996	The ability of THC-exposed macrophages to provide costimulatory signals to helper T cell hybridomas was investigated by induction of interleukin-2 secretion by T cells in response to immobilized monoclonal anti-CD3 antibody.	Dronabinol	15-18	interleukin 2	Homo sapiens	133-146
8662742-5	1996	Treatment of EL4.IL-2 cells with either cannabinol or Delta9-THC disrupted the adenylate cyclase signaling cascade by inhibiting forskolin-stimulated cAMP accumulation which consequently led to a decrease in protein kinase A activity and the binding of transcription factors to a CRE consensus sequence.	Dronabinol	54-64	interleukin 2	Mus musculus	17-21
8662742-6	1996	Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta9-THC.	Dronabinol	213-223	interleukin 2	Mus musculus	83-96
8662742-6	1996	Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta9-THC.	Dronabinol	213-223	interleukin 2	Mus musculus	98-102
8662742-6	1996	Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta9-THC.	Dronabinol	213-223	interleukin 2	Mus musculus	153-157
8807671-9	1996	The production of the cytokine interleukin-2 by T helper cells was markedly suppressed in both tolerant and abstinent mice, whereas the production of interleukin-4 was significantly suppressed only in THC-abstinent mice.	Dronabinol	201-204	interleukin 4	Mus musculus	150-163
8773449-9	1996	The effect of delta 9-tetrahydrocannabinol was also blocked by administration of dynorphin A-(1-8) antiserum in the same test.	Dronabinol	14-42	prodynorphin	Mus musculus	81-97
8651947-0	1996	Delta-9-tetrahydrocannabinol: an inhibitor of STAT1 alpha protein tyrosine phosphorylation.	Dronabinol	0-28	signal transducer and activator of transcription 1	Mus musculus	46-51
8651947-3	1996	The tyrosine phosphorylation of STAT1 alpha was found highly sensitive to treatment by delta-9 tetrahydrocannabinol (THC), a major marijuana component.	Dronabinol	87-115	signal transducer and activator of transcription 1	Mus musculus	32-37
8651947-3	1996	The tyrosine phosphorylation of STAT1 alpha was found highly sensitive to treatment by delta-9 tetrahydrocannabinol (THC), a major marijuana component.	Dronabinol	117-120	signal transducer and activator of transcription 1	Mus musculus	32-37
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	23-26	signal transducer and activator of transcription 1	Mus musculus	62-67
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	23-26	interferon gamma	Mus musculus	85-94
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	23-26	interferon gamma	Mus musculus	215-224
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	104-107	signal transducer and activator of transcription 1	Mus musculus	62-67
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	104-107	interferon gamma	Mus musculus	85-94
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	104-107	signal transducer and activator of transcription 1	Mus musculus	62-67
8651947-5	1996	Although inhibition by THC of the tyrosine phosphorylation of STAT1 alpha induced by IFN-gamma was in a THC concentration-related manner, the tyrosine phosphorylation of other proteins induced by lipopolysaccharide/IFN-gamma treatment of macrophages appeared insensitive to THC treatment.	Dronabinol	104-107	interferon gamma	Mus musculus	85-94
8651947-6	1996	Our data suggest that blockade by THC of tyrosine phosphorylation of STAT1 alpha may be an important mechanism involved in the broad immunosuppressive effects of THC.	Dronabinol	34-37	signal transducer and activator of transcription 1	Mus musculus	69-74
8651947-6	1996	Our data suggest that blockade by THC of tyrosine phosphorylation of STAT1 alpha may be an important mechanism involved in the broad immunosuppressive effects of THC.	Dronabinol	162-165	signal transducer and activator of transcription 1	Mus musculus	69-74
8963664-0	1996	Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain.	Dronabinol	34-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-88
8963664-1	1996	We examined whether administration of delta 9-tetrahydrocannabinol (THC) induces the expression of Fos protein or not in the rat brain.	Dronabinol	38-66	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	99-102
8963664-1	1996	We examined whether administration of delta 9-tetrahydrocannabinol (THC) induces the expression of Fos protein or not in the rat brain.	Dronabinol	68-71	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	99-102
8963664-2	1996	A single administration of 3.2 and 10 mg/kg THC produced a dose-dependent and significant increase in Fos-immunoreactive cells in the striatum, particularly in its dorsomedial portions.	Dronabinol	44-47	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	102-105
8963664-3	1996	The peak increase was reached 2 h after THC treatment and was absent at 8 h. Fos induction was also observed in the nucleus accumbens after administration of 10 mg/kg THC.	Dronabinol	40-43	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	77-80
8963664-3	1996	The peak increase was reached 2 h after THC treatment and was absent at 8 h. Fos induction was also observed in the nucleus accumbens after administration of 10 mg/kg THC.	Dronabinol	167-170	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	77-80
8963664-5	1996	SCH-23390, a selective dopamine D1 receptor antagonist, at 0.32 mg/kg produced a significant block of the effects of THC on Fos expression in the striatum and the nucleus accumbens.	Dronabinol	117-120	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	124-127
8963664-7	1996	These findings indicate that THC induces the expression of Fos protein and that this expression is mediated at least by dopamine D1 receptors.	Dronabinol	29-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	59-62
8732433-0	1996	Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages.	Dronabinol	0-28	tumor necrosis factor	Mus musculus	40-67
8732433-2	1996	The present studies have examined the mechanism of THC"s effects on tumor necrosis factor alpha (TNF-alpha), a major macrophage-produced cytokine and an important mediator involved in cytokine networks and in host defense mechanisms.	Dronabinol	51-54	tumor necrosis factor	Mus musculus	68-95
8732433-2	1996	The present studies have examined the mechanism of THC"s effects on tumor necrosis factor alpha (TNF-alpha), a major macrophage-produced cytokine and an important mediator involved in cytokine networks and in host defense mechanisms.	Dronabinol	51-54	tumor necrosis factor	Mus musculus	97-106
8732433-3	1996	Exposure of macrophages to medium containing THC has resulted in low levels of soluble TNF-alpha protein and reduced TNF-alpha bioactivity in the culture supernatant.	Dronabinol	45-48	tumor necrosis factor	Mus musculus	87-96
8732433-3	1996	Exposure of macrophages to medium containing THC has resulted in low levels of soluble TNF-alpha protein and reduced TNF-alpha bioactivity in the culture supernatant.	Dronabinol	45-48	tumor necrosis factor	Mus musculus	117-126
8732433-5	1996	The higher the THC concentration in the medium during TNF-alpha induction, the greater the amount of intracellular TNF-alpha precursors that accumulated in the activated macrophages and the less mature TNF-alpha was released from the cells.	Dronabinol	15-18	tumor necrosis factor	Mus musculus	54-63
8732433-5	1996	The higher the THC concentration in the medium during TNF-alpha induction, the greater the amount of intracellular TNF-alpha precursors that accumulated in the activated macrophages and the less mature TNF-alpha was released from the cells.	Dronabinol	15-18	tumor necrosis factor	Mus musculus	115-124
8732433-5	1996	The higher the THC concentration in the medium during TNF-alpha induction, the greater the amount of intracellular TNF-alpha precursors that accumulated in the activated macrophages and the less mature TNF-alpha was released from the cells.	Dronabinol	15-18	tumor necrosis factor	Mus musculus	115-124
8732433-6	1996	Data suggest that TNF-alpha production by macrophages was altered greatly by exposure to THC at the levels of TNF-alpha precursor maturation and secretion.	Dronabinol	89-92	tumor necrosis factor	Mus musculus	18-27
8732433-6	1996	Data suggest that TNF-alpha production by macrophages was altered greatly by exposure to THC at the levels of TNF-alpha precursor maturation and secretion.	Dronabinol	89-92	tumor necrosis factor	Mus musculus	110-119
8968950-0	1996	Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain.	Dronabinol	33-61	tyrosine hydroxylase	Rattus norvegicus	110-130
8968950-1	1996	The exposure of pregnant rats to delta 9-tetrahydrocannabinol (delta 9-THC), the main psychoactive constituent of Cannabis sativa, during the perinatal period affects the gene expression and the activity of tyrosine hydroxylase (TH) in the brains of their offspring at peripubertal and adult ages.	Dronabinol	33-61	tyrosine hydroxylase	Rattus norvegicus	207-227
8968950-1	1996	The exposure of pregnant rats to delta 9-tetrahydrocannabinol (delta 9-THC), the main psychoactive constituent of Cannabis sativa, during the perinatal period affects the gene expression and the activity of tyrosine hydroxylase (TH) in the brains of their offspring at peripubertal and adult ages.	Dronabinol	63-74	tyrosine hydroxylase	Rattus norvegicus	207-227
8968950-9	1996	However, a marked sexual dimorphism in the response of TH gene to cannabinoid exposure appeared from GD18 and was particularly evident at GD21, when TH-mRNA amounts increased in developing female brains, but decreased in developing male brains exposed to delta 9-THC, effects that were mostly prolonged to early postnatal ages.	Dronabinol	255-266	tyrosine hydroxylase	Rattus norvegicus	55-57
8614278-1	1996	Recent evidence has demonstrated that arachidonylethanolamide ("anandamide", AEA), the major endogenous ligand of CB1 receptors, inhibits motor behavior in rats, as does (-)delta 9-tetrahydrocannabinol (THC), the prototypical tricyclic cannabinoid derived from Cannabis sativa preparations.	Dronabinol	173-201	cannabinoid receptor 1	Rattus norvegicus	114-117
8614278-1	1996	Recent evidence has demonstrated that arachidonylethanolamide ("anandamide", AEA), the major endogenous ligand of CB1 receptors, inhibits motor behavior in rats, as does (-)delta 9-tetrahydrocannabinol (THC), the prototypical tricyclic cannabinoid derived from Cannabis sativa preparations.	Dronabinol	203-206	cannabinoid receptor 1	Rattus norvegicus	114-117
8938728-3	1996	Delta 9-THC also inhibited Kv1.2 channels with comparable potency (IC50, 2.4 muM), as did several N-acyl-ethanolamides with cannabinoid receptor binding activity.	Dronabinol	0-11	potassium voltage-gated channel subfamily A member 2	Homo sapiens	27-32
8938728-3	1996	Delta 9-THC also inhibited Kv1.2 channels with comparable potency (IC50, 2.4 muM), as did several N-acyl-ethanolamides with cannabinoid receptor binding activity.	Dronabinol	0-11	latexin	Homo sapiens	77-80
8788864-2	1995	The objective of this study was to determine the extent to which the cannabinoid (CB1) receptor is involved in the observed behavioral changes following delta 9-THC administration.	Dronabinol	153-164	cannabinoid receptor 1 (brain)	Mus musculus	82-85
8788864-7	1995	It is suggested that the diverse neurobehavioral alterations induced by delta 9-THC may not be mediated solely by the CB1 receptors in the brain and that the CB1 genes may not be uniform in the mouse strains.	Dronabinol	72-83	cannabinoid receptor 1 (brain)	Mus musculus	118-121
21153215-5	1995	Hormone analyses revealed that prolactin levels were significantly lower in the THC-vs vehicle-exposed male (THC: 5.2+-0.4vs vehicle: 8.4+-0.6 ng/ml) and female offspring (THC: 5.7+-0.3vs vehicle: 12.2+-1.8 ng/ml).	Dronabinol	80-83	prolactin	Rattus norvegicus	31-40
21153215-5	1995	Hormone analyses revealed that prolactin levels were significantly lower in the THC-vs vehicle-exposed male (THC: 5.2+-0.4vs vehicle: 8.4+-0.6 ng/ml) and female offspring (THC: 5.7+-0.3vs vehicle: 12.2+-1.8 ng/ml).	Dronabinol	109-112	prolactin	Rattus norvegicus	31-40
21153215-5	1995	Hormone analyses revealed that prolactin levels were significantly lower in the THC-vs vehicle-exposed male (THC: 5.2+-0.4vs vehicle: 8.4+-0.6 ng/ml) and female offspring (THC: 5.7+-0.3vs vehicle: 12.2+-1.8 ng/ml).	Dronabinol	109-112	prolactin	Rattus norvegicus	31-40
8964654-5	1995	IL-1, IL-4, and IL-6 modified cell proliferation in general, and their effects had some age-related differences, but these actions were independent of THC.	Dronabinol	151-154	interleukin 1 complex	Mus musculus	0-4
8964654-5	1995	IL-1, IL-4, and IL-6 modified cell proliferation in general, and their effects had some age-related differences, but these actions were independent of THC.	Dronabinol	151-154	interleukin 6	Mus musculus	16-20
8964654-6	1995	In contrast, the THC-induced enhancement appeared to be related in part to IL-2 levels in the adult cell cultures such that when IL-2 was removed, not only did up-regulation not occur, but THC was, in fact, suppressive.	Dronabinol	17-20	interleukin 2	Mus musculus	75-79
8964654-6	1995	In contrast, the THC-induced enhancement appeared to be related in part to IL-2 levels in the adult cell cultures such that when IL-2 was removed, not only did up-regulation not occur, but THC was, in fact, suppressive.	Dronabinol	17-20	interleukin 2	Mus musculus	129-133
8964654-7	1995	Addition of IL-2 or supernatants from adult cells did lead to a modified THC-induced up-regulation of proliferation in cells from adult or 2-week-old mice.	Dronabinol	73-76	interleukin 2	Mus musculus	12-16
8964654-10	1995	These results demonstrate a difference in immune response to THC related to the age of the mice which correlates at least in part to IL-2 levels in 2-week-old and young adult mice.	Dronabinol	61-64	interleukin 2	Mus musculus	133-137
8560429-5	1995	Comparison of TAT and THC (thrombin-hirudin complex) generated until the onset of platelet aggregation on a molar basis showed that much more thrombin was inactivated in the presence of rH than in plasma containing UH.	Dronabinol	22-25	coagulation factor II, thrombin	Homo sapiens	27-35
8560429-5	1995	Comparison of TAT and THC (thrombin-hirudin complex) generated until the onset of platelet aggregation on a molar basis showed that much more thrombin was inactivated in the presence of rH than in plasma containing UH.	Dronabinol	22-25	coagulation factor II, thrombin	Homo sapiens	142-150
7565624-3	1995	In competitive binding experiments, (-)-delta 9-tetrahydrocannabinol and CP 55,940 were equipotent at the CB1 and CB2 receptors, but WIN 55212-2 and cannabinol bound with higher affinity to the CB2 than the CB1 receptor.	Dronabinol	36-68	cannabinoid receptor 1	Homo sapiens	106-109
7565624-3	1995	In competitive binding experiments, (-)-delta 9-tetrahydrocannabinol and CP 55,940 were equipotent at the CB1 and CB2 receptors, but WIN 55212-2 and cannabinol bound with higher affinity to the CB2 than the CB1 receptor.	Dronabinol	36-68	cannabinoid receptor 2	Homo sapiens	114-117
7636714-0	1995	delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.	Dronabinol	0-28	interleukin 2	Homo sapiens	69-72
7636714-0	1995	delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.	Dronabinol	30-33	interleukin 2	Homo sapiens	69-72
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	45-73	interleukin 2	Homo sapiens	91-104
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	45-73	interleukin 2	Homo sapiens	106-109
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	45-73	interleukin 2	Homo sapiens	246-249
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	75-78	interleukin 2	Homo sapiens	91-104
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	75-78	interleukin 2	Homo sapiens	106-109
7636714-1	1995	Previously, we reported that the cannabinoid delta 9-tetrahydrocannabinol (THC) suppressed interleukin 2 (IL2)-induced proliferation of a cloned, natural killer-like cell line (NKB61A2) and decreased the number of high- and intermediate-affinity IL2 binding sites.	Dronabinol	75-78	interleukin 2	Homo sapiens	246-249
7636714-2	1995	However, the surface expression of interleukin 2 receptor alpha (IL2R alpha) chain, as measured by flow cytometry, was increased rather than decreased by THC treatment.	Dronabinol	154-157	interleukin 2 receptor subunit alpha	Homo sapiens	35-63
7636714-2	1995	However, the surface expression of interleukin 2 receptor alpha (IL2R alpha) chain, as measured by flow cytometry, was increased rather than decreased by THC treatment.	Dronabinol	154-157	interleukin 2 receptor subunit alpha	Homo sapiens	65-75
7636714-4	1995	Because the IL2 receptor complex is composed of alpha, beta and gamma chains, we examined the effect of THC treatment on the expression of these chains.	Dronabinol	104-107	interleukin 2	Homo sapiens	12-15
7636714-5	1995	In a result consistent with our previous findings, we observed that treatment of NKB61A2 cells with THC increased the cellular immunoprecipitable IL2R alpha protein (p55) and mRNA.	Dronabinol	100-103	tachykinin precursor 3	Homo sapiens	81-84
7636714-5	1995	In a result consistent with our previous findings, we observed that treatment of NKB61A2 cells with THC increased the cellular immunoprecipitable IL2R alpha protein (p55) and mRNA.	Dronabinol	100-103	interleukin 2 receptor subunit alpha	Homo sapiens	146-156
7636714-5	1995	In a result consistent with our previous findings, we observed that treatment of NKB61A2 cells with THC increased the cellular immunoprecipitable IL2R alpha protein (p55) and mRNA.	Dronabinol	100-103	interleukin 2 receptor subunit alpha	Homo sapiens	166-169
7636714-7	1995	The mRNA stability assay showed that THC increased the stability of IL2 beta mRNA, and nuclear run-on experiments suggested that the increase in subunit production was not due to a drug effect on gene transcription.	Dronabinol	37-40	interleukin 2	Homo sapiens	68-71
7636714-8	1995	The IL2R gamma chain was also affected by THC treatment in that Northern blotting studies showed a drug-induced decrease in the cellular level of gamma chain mRNA.	Dronabinol	42-45	interleukin 2 receptor subunit alpha	Homo sapiens	4-8
7636714-9	1995	In addition, THC treatment decreased the 125I-labeled IL2 internalization under high-affinity binding conditions.	Dronabinol	13-16	interleukin 2	Homo sapiens	54-57
7791094-2	1995	The ability of macrophages exposed to THC to process and present soluble protein antigens was investigated by the stimulation of antigen-specific helper T cell hybridomas to secrete interleukin-2.	Dronabinol	38-41	interleukin 15	Gallus gallus	182-195
7791094-4	1995	In contrast, THC exposure did not alter the capacity of the macrophage hybridoma to process chicken ovalbumin and augmented their presenting cell function for a pigeon cytochrome c response.	Dronabinol	13-16	cytochrome c, somatic	Gallus gallus	168-180
7791094-6	1995	The level of T cell activation with peptides of lysozyme and cytochrome c, which do not require processing, was inhibited only at the highest concentrations of THC, suggesting that THC mainly affects antigen processing.	Dronabinol	160-163	cytochrome c, somatic	Gallus gallus	61-73
7791094-6	1995	The level of T cell activation with peptides of lysozyme and cytochrome c, which do not require processing, was inhibited only at the highest concentrations of THC, suggesting that THC mainly affects antigen processing.	Dronabinol	181-184	cytochrome c, somatic	Gallus gallus	61-73
7791094-7	1995	Peritoneal macrophages exposed to THC during an antigen pulse and fixed with paraformaldehyde showed similar effects on the subsequent T cell responses to lysozyme and cytochrome c in the absence of THC, arguing against a possible influence of THC on the T cells.	Dronabinol	34-37	cytochrome c, somatic	Gallus gallus	168-180
7753807-6	1995	The gene encoding lactoferrin is an estrogen-responsive gene in the mouse uterus that was rapidly and transiently up-regulated by THC, but not by CBD, in ovariectomized mice in the absence of ovarian steroids.	Dronabinol	130-133	lactotransferrin	Mus musculus	18-29
7753807-7	1995	This effect, unlike that of 17 beta-estradiol (E2), was not influenced by a pure antiestrogen, ICI 182780, suggesting that the THC-induced uterine lactoferrin gene expression does not involve estrogen receptors.	Dronabinol	127-130	lactotransferrin	Mus musculus	147-158
7540878-1	1995	The purpose of this pilot study was to determine the effect of recombinant hirudin (r-hirudin) on coagulopathy and the relationship between concentrations of thrombin-antithrombin III (ATIII) complex (TAT) and thrombin-hirudin complex (THC) in patients with disseminated intravascular coagulation (DIC).	Dronabinol	236-239	serpin family C member 1	Homo sapiens	158-183
7540878-1	1995	The purpose of this pilot study was to determine the effect of recombinant hirudin (r-hirudin) on coagulopathy and the relationship between concentrations of thrombin-antithrombin III (ATIII) complex (TAT) and thrombin-hirudin complex (THC) in patients with disseminated intravascular coagulation (DIC).	Dronabinol	236-239	serpin family C member 1	Homo sapiens	185-190
7540878-1	1995	The purpose of this pilot study was to determine the effect of recombinant hirudin (r-hirudin) on coagulopathy and the relationship between concentrations of thrombin-antithrombin III (ATIII) complex (TAT) and thrombin-hirudin complex (THC) in patients with disseminated intravascular coagulation (DIC).	Dronabinol	236-239	coagulation factor II, thrombin	Homo sapiens	158-166
7740051-0	1995	IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice.	Dronabinol	33-61	interleukin 1 beta	Mus musculus	0-9
7740051-0	1995	IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice.	Dronabinol	33-61	tumor necrosis factor	Mus musculus	14-23
7740051-2	1995	Recombinant IL-1 beta (400 ng/mouse, IV) and TNF alpha (500 ng/mouse, IV) were effective in potentiating the cataleptic effect of low-dose THC (10 micrograms/mouse, IV).	Dronabinol	139-142	interleukin 1 beta	Mus musculus	12-21
7740051-2	1995	Recombinant IL-1 beta (400 ng/mouse, IV) and TNF alpha (500 ng/mouse, IV) were effective in potentiating the cataleptic effect of low-dose THC (10 micrograms/mouse, IV).	Dronabinol	139-142	tumor necrosis factor	Mus musculus	45-54
7740051-4	1995	Anti-IL-1 beta and anti-TNF alpha antibodies were effective in attenuating high-dose (75 micrograms/mouse) THC-induced catalepsy.	Dronabinol	107-110	interleukin 1 beta	Mus musculus	5-14
7740051-4	1995	Anti-IL-1 beta and anti-TNF alpha antibodies were effective in attenuating high-dose (75 micrograms/mouse) THC-induced catalepsy.	Dronabinol	107-110	tumor necrosis factor	Mus musculus	24-33
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	69-97	prolactin	Rattus norvegicus	173-182
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	69-97	prolactin	Rattus norvegicus	184-187
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	69-97	gonadotropin releasing hormone receptor	Rattus norvegicus	193-207
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	69-97	gonadotropin releasing hormone receptor	Rattus norvegicus	209-211
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	99-102	prolactin	Rattus norvegicus	173-182
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	99-102	prolactin	Rattus norvegicus	184-187
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	99-102	gonadotropin releasing hormone receptor	Rattus norvegicus	193-207
7776832-1	1995	It has been shown that the main psychoactive component of marihuana, delta 9-tetrahydrocannabinol (THC) has mainly inhibitory effects on pituitary luteinizing hormone (LH), prolactin (PRL) and growth hormone (GH) and has no or little effect on follicle stimulating hormone (FSH) secretion.	Dronabinol	99-102	gonadotropin releasing hormone receptor	Rattus norvegicus	209-211
7776832-9	1995	Serum GH was increased after THC administration and significantly decreased after ANA.	Dronabinol	29-32	gonadotropin releasing hormone receptor	Rattus norvegicus	6-8
7776833-11	1995	These results indicate that Anandamide and THC exert a similar inhibition of killing of TNF-sensitive target cells.	Dronabinol	43-46	tumor necrosis factor	Mus musculus	88-91
7776842-2	1995	We published a pilot study in which psychiatric patient THC users had significantly prolonged auditory P300 latencies and reduced amplitudes as contrasted with non-users.	Dronabinol	56-59	E1A binding protein p300	Homo sapiens	103-107
7776842-6	1995	However, when age differences between THC users and controls were removed, all significant P300 amplitude differences were removed as well.	Dronabinol	38-41	E1A binding protein p300	Homo sapiens	91-95
7776846-9	1995	THC-exposed females exhibited higher levels of both corticotropin releasing factor (CRF-41) in the medial basal hypothalamus (MBH) and plasma corticosterone, whereas THC-exposed males showed the lower levels of both endocrine parameters.	Dronabinol	0-3	corticotropin releasing hormone	Rattus norvegicus	52-82
7776847-0	1995	The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development.	Dronabinol	25-53	tyrosine hydroxylase	Rattus norvegicus	102-122
7776847-1	1995	We have previously reported that the exposure of pregnant female rats to delta 9-tetrahydrocannabinol (THC) during the perinatal period affected the gene expression and the activity of tyrosine hydroxylase (TH) in the brain of their male offspring.	Dronabinol	73-101	tyrosine hydroxylase	Rattus norvegicus	185-205
7776847-1	1995	We have previously reported that the exposure of pregnant female rats to delta 9-tetrahydrocannabinol (THC) during the perinatal period affected the gene expression and the activity of tyrosine hydroxylase (TH) in the brain of their male offspring.	Dronabinol	73-101	tyrosine hydroxylase	Rattus norvegicus	103-105
7776847-1	1995	We have previously reported that the exposure of pregnant female rats to delta 9-tetrahydrocannabinol (THC) during the perinatal period affected the gene expression and the activity of tyrosine hydroxylase (TH) in the brain of their male offspring.	Dronabinol	103-106	tyrosine hydroxylase	Rattus norvegicus	185-205
7776847-8	1995	Thus, the amounts of TH-mRNA at this age were higher (2-fold) in THC-exposed fetuses than in controls.	Dronabinol	65-68	tyrosine hydroxylase	Rattus norvegicus	21-23
7701042-3	1994	Perinatal exposure to THC increased both rearing and locomotor activities in males and females at immature preweanling ages (P-15 and P-20).	Dronabinol	22-25	cyclin-dependent kinase inhibitor 2B	Rattus norvegicus	125-129
7701042-3	1994	Perinatal exposure to THC increased both rearing and locomotor activities in males and females at immature preweanling ages (P-15 and P-20).	Dronabinol	22-25	heat shock protein family B (small) member 6	Rattus norvegicus	134-138
7945419-10	1994	Treatment of cells with interleukin-1 alpha, an agent known to elevate PLA2 levels, caused an increase in the THC response, supporting a role for this enzyme in the release reaction.	Dronabinol	110-113	interleukin 1 alpha	Mus musculus	24-43
7945419-10	1994	Treatment of cells with interleukin-1 alpha, an agent known to elevate PLA2 levels, caused an increase in the THC response, supporting a role for this enzyme in the release reaction.	Dronabinol	110-113	phospholipase A2, group IB, pancreas	Mus musculus	71-75
7945419-11	1994	Direct evidence, by immunoblotting, for the activation and phosphorylation of PLA2 by THC was also obtained.	Dronabinol	86-89	phospholipase A2, group IB, pancreas	Mus musculus	78-82
8063421-0	1994	Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection.	Dronabinol	80-108	negative elongation factor complex member C/D, Th1l	Mus musculus	49-52
8063421-3	1994	In this report, delta 9-tetrahydrocannabinol (THC), the major psychoactive cannabinoid of marijuana and an immunomodulator, suppressed development of secondary immunity to L. pneumophila, which correlated with a reduction in Th1 activity.	Dronabinol	16-44	negative elongation factor complex member C/D, Th1l	Mus musculus	225-228
8063421-3	1994	In this report, delta 9-tetrahydrocannabinol (THC), the major psychoactive cannabinoid of marijuana and an immunomodulator, suppressed development of secondary immunity to L. pneumophila, which correlated with a reduction in Th1 activity.	Dronabinol	46-49	negative elongation factor complex member C/D, Th1l	Mus musculus	225-228
8063421-6	1994	The level of anti-L. pneumophila antibodies in serum increased in both THC-treated and control mice; however, in the THC group IgG1 antibodies which are stimulated by Th2 cells were elevated while Th1-regulated, IgG2a antibodies were depressed.	Dronabinol	117-120	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	127-131
8063421-6	1994	The level of anti-L. pneumophila antibodies in serum increased in both THC-treated and control mice; however, in the THC group IgG1 antibodies which are stimulated by Th2 cells were elevated while Th1-regulated, IgG2a antibodies were depressed.	Dronabinol	117-120	heart and neural crest derivatives expressed 2	Mus musculus	167-170
8063421-6	1994	The level of anti-L. pneumophila antibodies in serum increased in both THC-treated and control mice; however, in the THC group IgG1 antibodies which are stimulated by Th2 cells were elevated while Th1-regulated, IgG2a antibodies were depressed.	Dronabinol	117-120	immunoglobulin heavy variable V1-9	Mus musculus	212-217
8063421-8	1994	Normal mouse splenocytes treated in vitro with THC and pokeweed mitogen showed suppressed production of gamma interferon, a cytokine associated with Th1 cells, but increased production of interleukin 4, a cytokine produced by Th2 cells.	Dronabinol	47-50	negative elongation factor complex member C/D, Th1l	Mus musculus	149-152
8063421-8	1994	Normal mouse splenocytes treated in vitro with THC and pokeweed mitogen showed suppressed production of gamma interferon, a cytokine associated with Th1 cells, but increased production of interleukin 4, a cytokine produced by Th2 cells.	Dronabinol	47-50	heart and neural crest derivatives expressed 2	Mus musculus	226-229
8063421-9	1994	Splenocytes from THC-treated mice, stimulated in vitro with either pokeweed mitogen or anti-CD3 antibodies, also produced less gamma interferon, indicating less Th1 activity in these mice.	Dronabinol	17-20	negative elongation factor complex member C/D, Th1l	Mus musculus	161-164
8063421-10	1994	These results suggest that THC decreases the development of anti-L. pneumophila immunity by causing a change in the balance of Th1 and Th2 activities.	Dronabinol	27-30	negative elongation factor complex member C/D, Th1l	Mus musculus	127-130
8063421-10	1994	These results suggest that THC decreases the development of anti-L. pneumophila immunity by causing a change in the balance of Th1 and Th2 activities.	Dronabinol	27-30	heart and neural crest derivatives expressed 2	Mus musculus	135-138
7932187-2	1994	Because delta 9-tetrahydrocannabinol (THC) treatment also has been reported to affect these physiological responses, we tested the drug effect on IL1 production and secretion.	Dronabinol	8-36	interleukin 1 complex	Mus musculus	146-149
7932187-2	1994	Because delta 9-tetrahydrocannabinol (THC) treatment also has been reported to affect these physiological responses, we tested the drug effect on IL1 production and secretion.	Dronabinol	38-41	interleukin 1 complex	Mus musculus	146-149
7932187-3	1994	Addition of THC to endotoxin (ETX)-treated murine, resident peritoneal macrophage cultures increased, in a dose-dependent manner, supernatant IL1 activity over ETX only treatment.	Dronabinol	12-15	interleukin 1 complex	Mus musculus	142-145
7932187-8	1994	These results showed THC treatment had no effect on the level of ETX-induced intracellular promature IL1 alpha and IL1 beta proteins; however, a THC-induced increase and prolongation of release of promature IL1 alpha and mature IL1 beta were observed.	Dronabinol	145-148	interleukin 1 alpha	Mus musculus	207-216
7932187-8	1994	These results showed THC treatment had no effect on the level of ETX-induced intracellular promature IL1 alpha and IL1 beta proteins; however, a THC-induced increase and prolongation of release of promature IL1 alpha and mature IL1 beta were observed.	Dronabinol	145-148	interleukin 1 beta	Mus musculus	228-236
7932187-10	1994	These results suggest THC augments the ETX-induced processing of IL1 beta and release of IL1 alpha rather than increasing the cellular production of IL1 protein.	Dronabinol	22-25	interleukin 1 beta	Mus musculus	65-73
7932187-10	1994	These results suggest THC augments the ETX-induced processing of IL1 beta and release of IL1 alpha rather than increasing the cellular production of IL1 protein.	Dronabinol	22-25	interleukin 1 alpha	Mus musculus	89-98
7932187-10	1994	These results suggest THC augments the ETX-induced processing of IL1 beta and release of IL1 alpha rather than increasing the cellular production of IL1 protein.	Dronabinol	22-25	interleukin 1 complex	Mus musculus	65-68
7855789-3	1994	THC was determined by means of ELISA using specific antibodies to thrombin and rH.	Dronabinol	0-3	coagulation factor II, thrombin	Homo sapiens	66-74
7970205-0	1994	delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain.	Dronabinol	0-28	myotrophin	Rattus norvegicus	62-75
7970205-0	1994	delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain.	Dronabinol	0-28	pleiotrophin	Rattus norvegicus	76-88
7970205-4	1994	We found, 30 min after a single injection of THC, a significant increase of PTN mRNA concentrations in the cingulate cortex (38%), fronto-parietal cortex (31%) and caudate-putamen (27%).	Dronabinol	45-48	pleiotrophin	Rattus norvegicus	76-79
7523319-0	1994	Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes.	Dronabinol	0-28	interleukin 2	Homo sapiens	67-80
7523319-1	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, has been shown to suppress a variety of interleukin-2-(IL-2)-dependent cellular functions in both murine and human lymphocytes.	Dronabinol	0-28	interleukin 2	Mus musculus	123-136
7523319-1	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, has been shown to suppress a variety of interleukin-2-(IL-2)-dependent cellular functions in both murine and human lymphocytes.	Dronabinol	0-28	interleukin 2	Homo sapiens	138-142
7523319-1	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, has been shown to suppress a variety of interleukin-2-(IL-2)-dependent cellular functions in both murine and human lymphocytes.	Dronabinol	30-33	interleukin 2	Mus musculus	123-136
7523319-1	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, has been shown to suppress a variety of interleukin-2-(IL-2)-dependent cellular functions in both murine and human lymphocytes.	Dronabinol	30-33	interleukin 2	Homo sapiens	138-142
7523319-3	1994	Interleukin-2-induced thymidine uptake and uridine uptake were suppressed in a dose related manner when cells were co-incubated for 48 h with 100 U rhIL-2/ml and 1-10 micrograms THC/ml.	Dronabinol	178-181	interleukin 2	Homo sapiens	0-13
7523319-4	1994	Interleukin-2-induced protein synthesis was also suppressed in a dose related manner over this THC concentration range, with the hPBL being more susceptible to the suppressive effect of THC than the CTLL-2 cells.	Dronabinol	95-98	interleukin 2	Mus musculus	0-13
7523319-4	1994	Interleukin-2-induced protein synthesis was also suppressed in a dose related manner over this THC concentration range, with the hPBL being more susceptible to the suppressive effect of THC than the CTLL-2 cells.	Dronabinol	186-189	interleukin 2	Mus musculus	0-13
7523319-6	1994	Human natural killer cell activity is only affected at the highest concentration tested (10 micrograms THC/ml) while lymphokine-(IL-2)-activated natural killer cell activity is affected throughout the range of 1-10 micrograms THC/ml.	Dronabinol	226-229	interleukin 2	Homo sapiens	129-133
7523319-7	1994	Together these results suggest that THC interferes with the IL-2:IL-2 receptor signaling cascade at one or possibly many points causing a decrease in IL-2-induced metabolic activity and cytolytic function.	Dronabinol	36-39	interleukin 2	Homo sapiens	60-64
7523319-7	1994	Together these results suggest that THC interferes with the IL-2:IL-2 receptor signaling cascade at one or possibly many points causing a decrease in IL-2-induced metabolic activity and cytolytic function.	Dronabinol	36-39	interleukin 2	Homo sapiens	65-69
7523319-7	1994	Together these results suggest that THC interferes with the IL-2:IL-2 receptor signaling cascade at one or possibly many points causing a decrease in IL-2-induced metabolic activity and cytolytic function.	Dronabinol	36-39	interleukin 2	Homo sapiens	65-69
8031318-2	1994	Macrophages pretreated for 3 hr with 1 microgram delta-9-tetrahydrocannabinol (THC)/mL had decreased tyrosine phosphorylation of p77 and p82 after incubation with LPS for 30 min.	Dronabinol	49-77	A kinase (PRKA) anchor protein 4	Mus musculus	137-140
8031318-2	1994	Macrophages pretreated for 3 hr with 1 microgram delta-9-tetrahydrocannabinol (THC)/mL had decreased tyrosine phosphorylation of p77 and p82 after incubation with LPS for 30 min.	Dronabinol	79-82	A kinase (PRKA) anchor protein 4	Mus musculus	137-140
8031318-3	1994	Simultaneous treatment of macrophages with THC (10 micrograms/mL) plus LPS for 30 min had a similar effect on p77 and p82 tyrosine phosphorylation.	Dronabinol	43-46	A kinase (PRKA) anchor protein 4	Mus musculus	118-121
8031318-4	1994	When the THC pretreatment protocol was combined with the simultaneous treatment protocol, 0.5 and 5 micrograms THC/mL, respectively, completely blocked LPS-induced p77 and p82 tyrosine phosphorylation.	Dronabinol	9-12	A kinase (PRKA) anchor protein 4	Mus musculus	172-175
8031318-4	1994	When the THC pretreatment protocol was combined with the simultaneous treatment protocol, 0.5 and 5 micrograms THC/mL, respectively, completely blocked LPS-induced p77 and p82 tyrosine phosphorylation.	Dronabinol	111-114	A kinase (PRKA) anchor protein 4	Mus musculus	172-175
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	30-33	aminoacyl tRNA synthetase complex-interacting multifunctional protein 1	Mus musculus	108-111
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	30-33	erythrocyte membrane protein band 4.1	Mus musculus	169-172
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	30-33	nucleoporin 43	Mus musculus	177-180
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	91-94	aminoacyl tRNA synthetase complex-interacting multifunctional protein 1	Mus musculus	108-111
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	91-94	erythrocyte membrane protein band 4.1	Mus musculus	169-172
8031318-6	1994	Pretreatment with 1 microgram THC/mL followed by simultaneous treatment with 10 micrograms THC/mL induced a p43 protein that showed tyrosine phosphorylation in place of p41 and p42.	Dronabinol	91-94	nucleoporin 43	Mus musculus	177-180
8031318-9	1994	Three cellular proteins (p65, p70, and p72) seemed most susceptible to inhibition by THC.	Dronabinol	85-88	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	25-28
8031318-9	1994	Three cellular proteins (p65, p70, and p72) seemed most susceptible to inhibition by THC.	Dronabinol	85-88	E74 like ETS transcription factor 1	Mus musculus	30-33
8031318-9	1994	Three cellular proteins (p65, p70, and p72) seemed most susceptible to inhibition by THC.	Dronabinol	85-88	DEAD box helicase 17	Mus musculus	39-42
8031318-10	1994	The data suggest that suppression of tyrosine phosphorylation by THC in macrophages may be one of the mechanisms associated with inhibition of cell function, including the suppression of tumor necrosis factor-alpha release from macrophages.	Dronabinol	65-68	tumor necrosis factor	Mus musculus	187-214
7970141-2	1994	The enhancing effect of CPP on THC-induced catalepsy was dose-dependently blocked by a muscarinic receptor antagonist, scopolamine, and by dopamine D1 and D2 receptor agonists such as apomorphine, SKF 38393 and quinpirole.	Dronabinol	31-34	dopamine receptor D2	Mus musculus	155-166
7919180-5	1994	Twenty minutes after a single THC injection, significant increases in concentration of the mRNAs for C-FOS, C-JUN and ZIF-268 were observed in the cingulate cortex (75, 45 and 37%) and for C-FOS and ZIF-268 in the fronto-parietal cortex (60 and 64%) and caudate-putamen (81 and 32%) while JUN-D mRNA levels were not changed.	Dronabinol	30-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	101-106
7919180-5	1994	Twenty minutes after a single THC injection, significant increases in concentration of the mRNAs for C-FOS, C-JUN and ZIF-268 were observed in the cingulate cortex (75, 45 and 37%) and for C-FOS and ZIF-268 in the fronto-parietal cortex (60 and 64%) and caudate-putamen (81 and 32%) while JUN-D mRNA levels were not changed.	Dronabinol	30-33	early growth response 1	Rattus norvegicus	118-125
7919180-5	1994	Twenty minutes after a single THC injection, significant increases in concentration of the mRNAs for C-FOS, C-JUN and ZIF-268 were observed in the cingulate cortex (75, 45 and 37%) and for C-FOS and ZIF-268 in the fronto-parietal cortex (60 and 64%) and caudate-putamen (81 and 32%) while JUN-D mRNA levels were not changed.	Dronabinol	30-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	189-194
7919180-5	1994	Twenty minutes after a single THC injection, significant increases in concentration of the mRNAs for C-FOS, C-JUN and ZIF-268 were observed in the cingulate cortex (75, 45 and 37%) and for C-FOS and ZIF-268 in the fronto-parietal cortex (60 and 64%) and caudate-putamen (81 and 32%) while JUN-D mRNA levels were not changed.	Dronabinol	30-33	early growth response 1	Rattus norvegicus	199-206
7919180-5	1994	Twenty minutes after a single THC injection, significant increases in concentration of the mRNAs for C-FOS, C-JUN and ZIF-268 were observed in the cingulate cortex (75, 45 and 37%) and for C-FOS and ZIF-268 in the fronto-parietal cortex (60 and 64%) and caudate-putamen (81 and 32%) while JUN-D mRNA levels were not changed.	Dronabinol	30-33	JunD proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	289-294
7515821-0	1994	delta-9-Tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen.	Dronabinol	0-28	proenkephalin	Rattus norvegicus	55-65
7515821-2	1994	We now report for the first time, by quantitative in situ hybridization, that a 3-week treatment with THC significantly increases in the adult rat caudate-putamen the messenger RNAs levels for substance P and enkephalin.	Dronabinol	102-105	proenkephalin	Rattus norvegicus	209-219
8118892-5	1994	We find that these low levels of THC inhibit tumor necrosis factor-alpha (TNF) induction from LGL by C. albicans and are dependent upon THC dose (0.005-5.0 micrograms/ml) and length of exposure (0.05-3.0 hr).	Dronabinol	33-36	tumor necrosis factor	Homo sapiens	74-77
8118892-6	1994	Northern blot analysis indicates that the downregulation of TNF production from LGL by THC resides at the mRNA level.	Dronabinol	87-90	tumor necrosis factor	Homo sapiens	60-63
8164509-0	1994	delta 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines.	Dronabinol	0-28	interleukin 1 beta	Homo sapiens	45-49
8164509-0	1994	delta 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines.	Dronabinol	30-33	interleukin 1 beta	Homo sapiens	45-49
8164509-1	1994	We have previously observed that delta 9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, increased supernatant interleukin-1 (IL-1) bioactivity in cultures of mouse resident peritoneal macrophages stimulated with lipopolysaccharide (LPS).	Dronabinol	33-61	interleukin 1 beta	Homo sapiens	153-157
8164509-1	1994	We have previously observed that delta 9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, increased supernatant interleukin-1 (IL-1) bioactivity in cultures of mouse resident peritoneal macrophages stimulated with lipopolysaccharide (LPS).	Dronabinol	63-66	interleukin 1 beta	Homo sapiens	153-157
8164509-3	1994	The results showed that THC increased the levels of supernatant IL-1 bioactivity of two human monocytic cell lines, but only if the cells were differentiated with phorbol myristate acetate.	Dronabinol	24-27	interleukin 1 beta	Homo sapiens	64-68
8164509-4	1994	Undifferentiated cells displayed decreased IL-1 bioactivity in response to THC.	Dronabinol	75-78	interleukin 1 beta	Homo sapiens	43-47
8164509-5	1994	However, under conditions in which THC augmented supernatant IL-1 bioactivity from THP-1 cells, ELISA studies showed that the levels of IL-1 alpha and IL-1 beta were unchanged and decreased, respectively.	Dronabinol	35-38	interleukin 1 beta	Homo sapiens	61-65
8164509-5	1994	However, under conditions in which THC augmented supernatant IL-1 bioactivity from THP-1 cells, ELISA studies showed that the levels of IL-1 alpha and IL-1 beta were unchanged and decreased, respectively.	Dronabinol	35-38	interleukin 1 alpha	Homo sapiens	136-146
8164509-5	1994	However, under conditions in which THC augmented supernatant IL-1 bioactivity from THP-1 cells, ELISA studies showed that the levels of IL-1 alpha and IL-1 beta were unchanged and decreased, respectively.	Dronabinol	35-38	interleukin 1 beta	Homo sapiens	151-160
8164509-6	1994	Furthermore, supernatant interleukin-6 (IL-6) levels were decreased, but tumor necrosis factor (TNF-alpha) levels were increased by THC treatment.	Dronabinol	132-135	tumor necrosis factor	Homo sapiens	73-94
8164509-6	1994	Furthermore, supernatant interleukin-6 (IL-6) levels were decreased, but tumor necrosis factor (TNF-alpha) levels were increased by THC treatment.	Dronabinol	132-135	tumor necrosis factor	Homo sapiens	96-105
8164509-7	1994	These results show that THC treatment modulates cytokine production and/or release by mouse and human macrophages and the drug effects on IL-1-like bioactivity in the supernatants of the human THP-1 cells are due to increased levels of other cytokines, such as TNF-alpha, rather than IL-1 itself.	Dronabinol	24-27	interleukin 1 beta	Homo sapiens	138-142
8164509-7	1994	These results show that THC treatment modulates cytokine production and/or release by mouse and human macrophages and the drug effects on IL-1-like bioactivity in the supernatants of the human THP-1 cells are due to increased levels of other cytokines, such as TNF-alpha, rather than IL-1 itself.	Dronabinol	24-27	tumor necrosis factor	Homo sapiens	261-270
8164509-7	1994	These results show that THC treatment modulates cytokine production and/or release by mouse and human macrophages and the drug effects on IL-1-like bioactivity in the supernatants of the human THP-1 cells are due to increased levels of other cytokines, such as TNF-alpha, rather than IL-1 itself.	Dronabinol	24-27	interleukin 1 beta	Homo sapiens	284-288
8196497-5	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, was shown to inhibit inducible protein expression in response to the priming agents Concanavalin A (Con A) supernatant and IFN gamma.	Dronabinol	0-28	interferon gamma	Mus musculus	206-215
8196497-5	1994	Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, was shown to inhibit inducible protein expression in response to the priming agents Concanavalin A (Con A) supernatant and IFN gamma.	Dronabinol	30-33	interferon gamma	Mus musculus	206-215
8196497-6	1994	THC also suppressed protein expression in response to LPS.	Dronabinol	0-3	toll-like receptor 4	Mus musculus	54-57
8196497-12	1994	THC also altered the expression of tumor necrosis factor alpha (TNF alpha) elicited by RAW264.7 cells in response to LPS.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	35-62
8196497-12	1994	THC also altered the expression of tumor necrosis factor alpha (TNF alpha) elicited by RAW264.7 cells in response to LPS.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	64-73
8196497-12	1994	THC also altered the expression of tumor necrosis factor alpha (TNF alpha) elicited by RAW264.7 cells in response to LPS.	Dronabinol	0-3	toll-like receptor 4	Mus musculus	117-120
8263818-0	1993	Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events.	Dronabinol	0-28	tumor necrosis factor	Mus musculus	43-70
8263818-2	1993	The purpose of this study was to determine whether delta 9-THC inhibited this function by affecting tumor necrosis factor-alpha (TNF-alpha).	Dronabinol	51-62	tumor necrosis factor	Mus musculus	100-127
8263818-2	1993	The purpose of this study was to determine whether delta 9-THC inhibited this function by affecting tumor necrosis factor-alpha (TNF-alpha).	Dronabinol	51-62	tumor necrosis factor	Mus musculus	129-138
8263818-8	1993	These results indicate that delta 9-THC suppresses soluble macrophage tumoricidal activity, at least in part, by decreasing the intracellular conversion of presecretory TNF-alpha to its 17-kD secretory form.	Dronabinol	28-39	tumor necrosis factor	Mus musculus	169-178
7504099-6	1993	The THC-induced mortality resembled cytokine-mediated shock in both kinetics and symptoms; therefore, sera from drug-treated animals were measured for the acute-phase cytokines tumor necrosis factor (TNF) and interleukin 6 (IL6).	Dronabinol	4-7	interleukin 6	Mus musculus	224-227
7902959-7	1993	By contrast, plasma PRL levels increased when THC was administered on the afternoon of estrus, in parallel with a significant reduction in the number of D2 receptors in the anterior pituitary gland and no effects on TIDA activity.	Dronabinol	46-49	prolactin	Homo sapiens	20-23
8390853-0	1993	Effects of 9-ene-tetrahydrocannabinol on expression of beta-type transforming growth factors, insulin-like growth factor-I and c-myc genes in the mouse uterus.	Dronabinol	11-37	insulin-like growth factor 1	Mus musculus	94-122
8390853-7	1993	In contrast, E2 treatment induced a rapid, but transient, increase in IGF-I and c-myc mRNAs, and THC antagonized the rapid c-myc mRNA response and altered the timing of the IGF-I mRNA response.	Dronabinol	97-100	insulin-like growth factor 1	Mus musculus	173-178
8396073-10	1993	Cells were pre-treated with pertussis toxin to inhibit Gi activity; this blocked the THC-induced suppression of cAMP production.	Dronabinol	85-88	hydroxycarboxylic acid receptor 3	Homo sapiens	55-57
8396073-11	1993	These results suggest that THC can exert its effects on second messenger systems at the lymphocyte membrane level, and that a pertussis toxin-sensitive Gi protein may be involved.	Dronabinol	27-30	hydroxycarboxylic acid receptor 3	Homo sapiens	152-154
8389330-0	1993	Increase in cytoplasmic free calcium in murine splenocytes following stimulation with anti-CD3 antibody in the presence of delta-9-tetrahydrocannabinol.	Dronabinol	123-151	CD3 antigen, epsilon polypeptide	Mus musculus	91-94
8389330-2	1993	In contrast, when these cells were stimulated with anti-CD3 antibody in combination with THC, lower doses of THC stimulated proliferation of the splenocytes.	Dronabinol	109-112	CD3 antigen, epsilon polypeptide	Mus musculus	56-59
8387622-4	1993	THC inhibited LPCAT and lysophosphatidylethanolamine:acyl-CoA acyltransferase (LPEAT) by 40-50%, but had no effect or only slightly increased the activities of the other acyltransferases when assayed with oleoyl-CoA as the acyl donor.	Dronabinol	0-3	lysophosphatidylcholine acyltransferase 1	Homo sapiens	14-19
8387622-4	1993	THC inhibited LPCAT and lysophosphatidylethanolamine:acyl-CoA acyltransferase (LPEAT) by 40-50%, but had no effect or only slightly increased the activities of the other acyltransferases when assayed with oleoyl-CoA as the acyl donor.	Dronabinol	0-3	membrane bound O-acyltransferase domain containing 2	Homo sapiens	24-77
8387622-4	1993	THC inhibited LPCAT and lysophosphatidylethanolamine:acyl-CoA acyltransferase (LPEAT) by 40-50%, but had no effect or only slightly increased the activities of the other acyltransferases when assayed with oleoyl-CoA as the acyl donor.	Dronabinol	0-3	membrane bound O-acyltransferase domain containing 2	Homo sapiens	79-84
8389726-2	1993	Further, it is observed that delta-9-THC both at low (1.6 x 10(-6) M and 6.4 x 10(-6) M) and high (13.33 x 10(-6) M) concentrations inhibits the binding of theophylline to BSA; whereas theophylline (11.0 x 10(-6) M-550.0 x 10(-6) M) promotes the binding of delta-9-THC to BSA.	Dronabinol	29-40	albumin	Homo sapiens	172-175
8389726-2	1993	Further, it is observed that delta-9-THC both at low (1.6 x 10(-6) M and 6.4 x 10(-6) M) and high (13.33 x 10(-6) M) concentrations inhibits the binding of theophylline to BSA; whereas theophylline (11.0 x 10(-6) M-550.0 x 10(-6) M) promotes the binding of delta-9-THC to BSA.	Dronabinol	29-40	albumin	Homo sapiens	272-275
8389726-3	1993	Kinetic analysis (using Scatchard plots) shows that delta-9-THC (1.6-13.33 x 10(-6) M) reduces the high affinity binding constant (K1) and the number of low affinity binding sites (n2) of theophylline to BSA; while its low affinity binding constant (K2) increased without affecting the number of high affinity binding sites (n1) under identical conditions.	Dronabinol	52-63	albumin	Homo sapiens	204-207
8389726-4	1993	Further, it is observed that at lower concentrations (1.6-6.4 x 10(-6) M) delta-9-THC exerts greater effect on the binding parameters of theophylline-BSA interactions as compared to the effect observed with its high concentration (13.33 x 10(-6) M).	Dronabinol	74-85	albumin	Homo sapiens	150-153
8389726-6	1993	on the other hand, increases the affinity of the binding of delta-9-THC to BSA without changing the number of its binding sites.	Dronabinol	60-71	albumin	Homo sapiens	75-78
8389726-7	1993	These suggest that (a) delta-9-THC and theophylline bind at different sites of BSA molecules and (b) the two drugs interfere with each other in their individual binding with the molecular orientation of the BSA molecule.	Dronabinol	23-34	albumin	Homo sapiens	79-82
8389726-7	1993	These suggest that (a) delta-9-THC and theophylline bind at different sites of BSA molecules and (b) the two drugs interfere with each other in their individual binding with the molecular orientation of the BSA molecule.	Dronabinol	23-34	albumin	Homo sapiens	207-210
8380215-0	1993	Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages.	Dronabinol	22-50	interleukin 2	Mus musculus	54-58
8380215-9	1993	The THC modulating activity is directly related to its effect on both IL-2 activity and generation of Tac positive cells in spleen and lymph node cells of both adult and young mice.	Dronabinol	4-7	interleukin 2	Mus musculus	70-74
8231631-6	1993	Co-incubation of 0.1 microM epinephrine with 0.8 or 3.1 microgram/ml THC significantly stimulated lactate secretion when compared to epinephrine or THC alone, while only the high THC dose increased transferrin secretion.	Dronabinol	69-72	transferrin	Rattus norvegicus	198-209
8231631-7	1993	Moreover, co-incubation of FSH (1 micrograms/ml) with THC (0.8 or 3.1 micrograms/ml), significantly stimulated both lactate and transferrin production by immature rat Sertoli cells.	Dronabinol	54-57	transferrin	Rattus norvegicus	128-139
1445887-8	1992	When they are incubated with protein solutions containing ER (approximately 10(-9) M), the emission from the donor-acceptor THCs bound specifically to ER is in the 500-570-nm range, whereas fluorescence from non-receptor-bound fluorophores is in the 425-460-nm range.	Dronabinol	124-128	estrogen receptor 1	Homo sapiens	58-60
1445887-8	1992	When they are incubated with protein solutions containing ER (approximately 10(-9) M), the emission from the donor-acceptor THCs bound specifically to ER is in the 500-570-nm range, whereas fluorescence from non-receptor-bound fluorophores is in the 425-460-nm range.	Dronabinol	124-128	estrogen receptor 1	Homo sapiens	151-153
1334476-0	1992	Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages.	Dronabinol	14-42	tumor necrosis factor	Mus musculus	46-67
1334476-1	1992	Suppression by delta-9-tetrahydrocannabinol (THC) of tumor necrosis factor (TNF) production by macrophages has not been reported previously.	Dronabinol	15-43	tumor necrosis factor	Mus musculus	53-74
1334476-1	1992	Suppression by delta-9-tetrahydrocannabinol (THC) of tumor necrosis factor (TNF) production by macrophages has not been reported previously.	Dronabinol	15-43	tumor necrosis factor	Mus musculus	76-79
1334476-1	1992	Suppression by delta-9-tetrahydrocannabinol (THC) of tumor necrosis factor (TNF) production by macrophages has not been reported previously.	Dronabinol	45-48	tumor necrosis factor	Mus musculus	53-74
1334476-1	1992	Suppression by delta-9-tetrahydrocannabinol (THC) of tumor necrosis factor (TNF) production by macrophages has not been reported previously.	Dronabinol	45-48	tumor necrosis factor	Mus musculus	76-79
1334476-2	1992	The present study evaluated the effect in vitro of THC on soluble TNF-alpha production by cultured murine peritoneal macrophages.	Dronabinol	51-54	tumor necrosis factor	Mus musculus	66-75
1334476-4	1992	Macrophages pretreated with THC at 0.1, 0.5, or 1.0 micrograms/ml in protein-free medium for 3 h at 37 degrees C, prior to TNF induction, also showed a decreased ability to produce TNF-alpha in a dose-dependent manner.	Dronabinol	28-31	tumor necrosis factor	Mus musculus	123-126
1334476-4	1992	Macrophages pretreated with THC at 0.1, 0.5, or 1.0 micrograms/ml in protein-free medium for 3 h at 37 degrees C, prior to TNF induction, also showed a decreased ability to produce TNF-alpha in a dose-dependent manner.	Dronabinol	28-31	tumor necrosis factor	Mus musculus	181-190
1334476-5	1992	Increasing the protein concentration from 0.5 to 5% BSA in the medium which was used to induce TNF prevented the inhibitory activity of THC.	Dronabinol	136-139	tumor necrosis factor	Mus musculus	95-98
1334476-6	1992	Human peripheral blood adherent cells treated with THC-containing medium produced less TNF-alpha than controls that were not exposed to THC.	Dronabinol	51-54	tumor necrosis factor	Homo sapiens	87-96
1334476-7	1992	Thus, our data provide evidence that THC can inhibit TNF production by mouse and human macrophages.	Dronabinol	37-40	tumor necrosis factor	Mus musculus	53-56
1329110-0	1992	Modulation of interleukin 2 activity by delta 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody.	Dronabinol	40-68	interleukin 2	Homo sapiens	14-27
1329110-0	1992	Modulation of interleukin 2 activity by delta 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody.	Dronabinol	40-68	CD3 antigen, epsilon polypeptide	Mus musculus	136-139
1329110-2	1992	THC was found to suppress mitogen-induced proliferation, but to enhance anti-CD3-antibody-induced proliferation.	Dronabinol	0-3	CD3 antigen, epsilon polypeptide	Mus musculus	77-80
1329110-3	1992	These results reflected THC-induced suppression of Ly2 cells following concanavalin A or phytohemagglutinin stimulation and THC-induced enhancement of Ly2 cells following CD3 stimulation.	Dronabinol	124-127	CD3 antigen, epsilon polypeptide	Mus musculus	171-174
1329110-4	1992	The combination of THC and concanavalin A or phytohemagglutinin resulted in suppressed IL-2 activity, whereas the combination of THC and anti-CD3 antibody resulted in enhanced IL-2 activity.	Dronabinol	19-22	interleukin 2	Homo sapiens	87-91
1329110-4	1992	The combination of THC and concanavalin A or phytohemagglutinin resulted in suppressed IL-2 activity, whereas the combination of THC and anti-CD3 antibody resulted in enhanced IL-2 activity.	Dronabinol	129-132	interleukin 2	Homo sapiens	176-180
1329110-6	1992	These results suggest that the dysregulation in immune responses following THC treatment, either suppression or enhancement, may relate to the effects of THC on IL-2 production.	Dronabinol	75-78	interleukin 2	Homo sapiens	161-165
1329110-6	1992	These results suggest that the dysregulation in immune responses following THC treatment, either suppression or enhancement, may relate to the effects of THC on IL-2 production.	Dronabinol	154-157	interleukin 2	Homo sapiens	161-165
1319584-3	1992	Flow cytometry was used to determine whether delta 9-THC altered T cytotoxic (Lyt-2+) and T helper (L3T4+) lymphocyte numbers or cell ratios.	Dronabinol	45-56	CD8 antigen, alpha chain	Mus musculus	78-83
1321451-6	1992	THC treatment produced a dose-related decline in plasma prolactin (PRL) levels.	Dronabinol	0-3	prolactin	Rattus norvegicus	67-70
1321451-7	1992	Furthermore, both the basal and DA-inhibited in vitro release of PRL were reduced in animals exposed to THC in a dose-dependent manner.	Dronabinol	104-107	prolactin	Rattus norvegicus	65-68
1321451-8	1992	This inhibitory effect of THC on PRL release was accompanied by a decreased DOPAC/DA ratio in medial basal hypothalamus that, in turn, may be a result of the fall in PRL levels rather than a direct action of the drug.	Dronabinol	26-29	prolactin	Rattus norvegicus	33-36
1321451-8	1992	This inhibitory effect of THC on PRL release was accompanied by a decreased DOPAC/DA ratio in medial basal hypothalamus that, in turn, may be a result of the fall in PRL levels rather than a direct action of the drug.	Dronabinol	26-29	prolactin	Rattus norvegicus	166-169
1321451-10	1992	Our results suggest that the reduction of PRL release following THC exposure, both in vivo and in vitro, might be elicited by a direct action of THC on the pituitary.	Dronabinol	64-67	prolactin	Rattus norvegicus	42-45
1321451-10	1992	Our results suggest that the reduction of PRL release following THC exposure, both in vivo and in vitro, might be elicited by a direct action of THC on the pituitary.	Dronabinol	145-148	prolactin	Rattus norvegicus	42-45
1347001-0	1992	Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats.	Dronabinol	66-94	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
1325494-4	1992	In contrast, spleen cells stimulated with anti-CD3 antibody and treated with low doses of THC displayed an enhanced proliferation whereas the response in lymph nodes did not change.	Dronabinol	90-93	CD3 antigen, epsilon polypeptide	Mus musculus	47-50
1313519-0	1992	Effect of acute intravenous administration of delta-9-tetrahydrocannabinol on the episodic secretion of immunoassayable growth hormone in the rat.	Dronabinol	46-74	gonadotropin releasing hormone receptor	Rattus norvegicus	120-134
1313519-7	1992	Although further investigation is needed to define clearly the physiological mechanisms involved in this response, these data indicate that THC can inhibit the hypothalamic-pituitary control of normal episodic growth hormone secretion in the rat.	Dronabinol	140-143	gonadotropin releasing hormone receptor	Rattus norvegicus	210-224
1806943-6	1991	The results from HHC were very similar to those from THC, namely hydroxylation at C-11 in most species, and the production of high concentrations of 8 alpha-hydroxy-HHC in the mouse and 8 beta-hydroxy-HHC in the hamster.	Dronabinol	53-56	polymerase (RNA) III (DNA directed) polypeptide K	Mus musculus	82-86
1649242-2	1991	We report here that the interleukin-2 (IL-2)-dependent murine cell line, NKB61A2, which we recently found to express both NK and NC functions, can be modulated selectively by 9 delta-tetrahydrocannabinol (THC).	Dronabinol	205-208	interleukin 2	Mus musculus	24-37
1649242-2	1991	We report here that the interleukin-2 (IL-2)-dependent murine cell line, NKB61A2, which we recently found to express both NK and NC functions, can be modulated selectively by 9 delta-tetrahydrocannabinol (THC).	Dronabinol	205-208	interleukin 2	Mus musculus	39-43
1667651-3	1991	Concentrations of THC and CBD, comparable to plasma levels found after smoking marijuana (10-100 ng/ml), increased the concentration of measurable IFN (139 and 68%), while high concentrations of both cannabinoids (5-20 micrograms/ml) completely blocked synthesis and/or release of this cytokine.	Dronabinol	18-21	interferon gamma	Homo sapiens	147-150
1846934-4	1991	It was found that: 1) indomethacin pre-treatment decreased the elevation of prostaglandins induced by THC; 2) indomethacin significantly attenuated the subjective "high" and the heart rate accelerating effects of THC, although the magnitude of this effect was modest; 3) indomethacin abolished the profound effect of THC on time estimation and production; and 4) indomethacin pretreatment did not affect the decremental effects of THC on word recall.	Dronabinol	213-216	ankyrin repeat domain containing 26	Homo sapiens	102-108
1846934-4	1991	It was found that: 1) indomethacin pre-treatment decreased the elevation of prostaglandins induced by THC; 2) indomethacin significantly attenuated the subjective "high" and the heart rate accelerating effects of THC, although the magnitude of this effect was modest; 3) indomethacin abolished the profound effect of THC on time estimation and production; and 4) indomethacin pretreatment did not affect the decremental effects of THC on word recall.	Dronabinol	213-216	ankyrin repeat domain containing 26	Homo sapiens	102-108
1979873-1	1990	Previous in vivo studies have shown that delta 9-tetrahydrocannabinol (THC), the principal active ingredient in marijuana, can suppress both luteinizing hormone (LH) and growth hormone (GH) secretion after its injection into the third ventricle of conscious male rats.	Dronabinol	41-69	gonadotropin releasing hormone receptor	Rattus norvegicus	170-184
1979873-1	1990	Previous in vivo studies have shown that delta 9-tetrahydrocannabinol (THC), the principal active ingredient in marijuana, can suppress both luteinizing hormone (LH) and growth hormone (GH) secretion after its injection into the third ventricle of conscious male rats.	Dronabinol	71-74	gonadotropin releasing hormone receptor	Rattus norvegicus	170-184
1979873-4	1990	Although THC (10 nM) did not alter basal release of LH-releasing hormone (LHRH) from MEs in vitro, it completely blocked the stimulatory action of dopamine or norepinephrine on LHRH release.	Dronabinol	9-12	gonadotropin releasing hormone 1	Rattus norvegicus	177-181
1979873-9	1990	The results indicate that the suppressive effect of THC on LH release is mediated by a blockade of LHRH release, whereas the suppressive effect of the compound on growth hormone release is mediated, at least in part, by a stimulation of somatostatin release.	Dronabinol	52-55	gonadotropin releasing hormone 1	Rattus norvegicus	99-103
1981541-0	1990	Cytochrome P-450 isozymes in metabolic activation of delta 9-tetrahydrocannabinol by rat liver microsomes.	Dronabinol	53-81	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
1981541-1	1990	delta 9-Tetrahydrocannabinol (THC) was incubated with a reconstituted system consisting of dilauroylphosphatidylcholine, NADPH-cytochrome c reductase, cytochrome b5, and cytochrome P-450 (P-450) isozyme UT-2, UT-4, or UT-5, which was purified from liver microsomes of adult male rats.	Dronabinol	0-28	cytochrome b5 type A	Rattus norvegicus	151-164
1981541-1	1990	delta 9-Tetrahydrocannabinol (THC) was incubated with a reconstituted system consisting of dilauroylphosphatidylcholine, NADPH-cytochrome c reductase, cytochrome b5, and cytochrome P-450 (P-450) isozyme UT-2, UT-4, or UT-5, which was purified from liver microsomes of adult male rats.	Dronabinol	0-28	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	170-186
1981541-1	1990	delta 9-Tetrahydrocannabinol (THC) was incubated with a reconstituted system consisting of dilauroylphosphatidylcholine, NADPH-cytochrome c reductase, cytochrome b5, and cytochrome P-450 (P-450) isozyme UT-2, UT-4, or UT-5, which was purified from liver microsomes of adult male rats.	Dronabinol	30-33	cytochrome b5 type A	Rattus norvegicus	151-164
1981541-1	1990	delta 9-Tetrahydrocannabinol (THC) was incubated with a reconstituted system consisting of dilauroylphosphatidylcholine, NADPH-cytochrome c reductase, cytochrome b5, and cytochrome P-450 (P-450) isozyme UT-2, UT-4, or UT-5, which was purified from liver microsomes of adult male rats.	Dronabinol	30-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	170-186
1700926-6	1990	Furthermore, the THC-treated animals had significantly elevated beta-endorphin and methionine-enkephalin levels in almost all the brain areas sampled for the study.	Dronabinol	17-20	proenkephalin	Rattus norvegicus	94-104
1700926-7	1990	In addition, the neonatally THC-treated rats exhibited significantly higher levels of substance P (SP) and significantly lower levels of gonadotropin releasing hormone (GnRH) in the anterior hypothalamus-preoptic area.	Dronabinol	28-31	gonadotropin releasing hormone 1	Rattus norvegicus	137-167
1700926-7	1990	In addition, the neonatally THC-treated rats exhibited significantly higher levels of substance P (SP) and significantly lower levels of gonadotropin releasing hormone (GnRH) in the anterior hypothalamus-preoptic area.	Dronabinol	28-31	gonadotropin releasing hormone 1	Rattus norvegicus	169-173
2164090-7	1990	Serum PRL, which increased with age, was suppressed after 1 day of THC treatment at 27 or 30 days of age, but only the former was associated with delayed puberty.	Dronabinol	67-70	prolactin	Rattus norvegicus	6-9
2175259-2	1990	PtK2 cells were more sensitive to THC treatment than RAE cells.	Dronabinol	34-37	focal adhesion kinase 1	Oryctolagus cuniculus	0-4
2175259-3	1990	Exposure of PtK2 cells to 10 microM THC for 2 h disrupted the microfilament network.	Dronabinol	36-39	focal adhesion kinase 1	Oryctolagus cuniculus	12-16
2175259-4	1990	After treatment with 20 microM THC for 2 h there was a loss of cell-to-cell contact between PtK2 cells, and at 30 microM THC, the cells started to detach from the substratum.	Dronabinol	31-34	focal adhesion kinase 1	Oryctolagus cuniculus	92-96
1966044-0	1990	The effects of pH and temperature on the in vitro bindings of delta-9-tetrahydrocannabinol and other cannabinoids to bovine serum albumin.	Dronabinol	62-90	albumin	Homo sapiens	124-137
1966044-3	1990	The authors are interested in the pH and temperature effects of the binding of delta-9-tetrahydrocannabinol to albumin.	Dronabinol	79-107	albumin	Homo sapiens	111-118
2154651-0	1990	Tetrahydrocannabinol inhibits adenyl cyclase in human leukemia cells.	Dronabinol	0-20	adenylate cyclase 1	Homo sapiens	30-44
126214-1	1975	Delta1-tetrahydrocannabinol was found to be a potent inhibitor of some membrane-bound enzymes, such as Mg-ATPase, Na-K-ATPase and acetylcholinesterase.	Dronabinol	0-27	acetylcholinesterase (Cartwright blood group)	Homo sapiens	130-150
33802282-0	2021	THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.	Dronabinol	0-3	G protein-coupled receptor 55	Homo sapiens	83-88
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	0-22	cannabinoid receptor 1	Homo sapiens	173-176
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	0-22	cannabinoid receptor 2	Homo sapiens	181-184
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	0-22	G protein-coupled receptor 18	Homo sapiens	218-223
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	0-22	G protein-coupled receptor 55	Homo sapiens	227-232
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	24-27	cannabinoid receptor 1	Homo sapiens	173-176
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	24-27	cannabinoid receptor 2	Homo sapiens	181-184
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	24-27	G protein-coupled receptor 18	Homo sapiens	218-223
33802282-2	2021	9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best-characterized components of Cannabis sativa plants with modulating effects on cannabinoid receptors 1 and 2 (CB1 and CB2) and on orphan receptors such as GPR18 or GPR55.	Dronabinol	24-27	G protein-coupled receptor 55	Homo sapiens	227-232
33802282-3	2021	Previous studies have demonstrated anti-tumorigenic effects of THC and CBD in several tumor entities including GBM, mostly mediated via CB1 or CB2.	Dronabinol	63-66	cannabinoid receptor 1	Homo sapiens	136-139
33802282-3	2021	Previous studies have demonstrated anti-tumorigenic effects of THC and CBD in several tumor entities including GBM, mostly mediated via CB1 or CB2.	Dronabinol	63-66	cannabinoid receptor 2	Homo sapiens	143-146
33802282-4	2021	In this study, we investigated the non-CB1/CB2 effects of THC on the cell cycle of GBM cells isolated from human tumor samples.	Dronabinol	58-61	cannabinoid receptor 2	Homo sapiens	43-46
33802282-9	2021	All examined cells expressed the receptors, but only in presence of the GPR55 antagonist CID was the THC effect diminished.	Dronabinol	101-104	G protein-coupled receptor 55	Homo sapiens	72-77
33802282-10	2021	Stimulation with the GPR55 agonist lysophosphatidylinositol (LPI) revealed similar effects as obtained for THC.	Dronabinol	107-110	G protein-coupled receptor 55	Homo sapiens	21-26
32244040-0	2020	MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Delta9-tetrahydrocannabinol and cannabidiol in human macrophages.	Dronabinol	94-121	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
32244040-0	2020	MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Delta9-tetrahydrocannabinol and cannabidiol in human macrophages.	Dronabinol	94-121	toll like receptor 3	Homo sapiens	48-52
32244040-0	2020	MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Delta9-tetrahydrocannabinol and cannabidiol in human macrophages.	Dronabinol	94-121	toll like receptor 4	Homo sapiens	57-61
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	toll like receptor 3	Homo sapiens	40-44
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	interferon regulatory factor 3	Homo sapiens	55-59
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	88-94
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	IFN1@	Homo sapiens	95-103
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	NFKB inhibitor alpha	Homo sapiens	164-177
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	tumor necrosis factor	Homo sapiens	194-203
32244040-7	2020	THC and CBD (both at 10 muM) attenuated TLR3/4-induced IRF3 activation and induction of CXCL10/IFN-beta, while both phytocannabinoids failed to impact TLR4-induced IkappaB-alpha degradation and TNF-alpha/CXCL8 expression.	Dronabinol	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	204-209
32244040-8	2020	The role of CB1, CB2 and PPARgamma receptors in mediating the effect of THC and CBD on MyD88-independent signalling was investigated.	Dronabinol	72-75	cannabinoid receptor 1	Homo sapiens	12-15
32244040-8	2020	The role of CB1, CB2 and PPARgamma receptors in mediating the effect of THC and CBD on MyD88-independent signalling was investigated.	Dronabinol	72-75	peroxisome proliferator activated receptor gamma	Homo sapiens	25-34
32244040-8	2020	The role of CB1, CB2 and PPARgamma receptors in mediating the effect of THC and CBD on MyD88-independent signalling was investigated.	Dronabinol	72-75	MYD88 innate immune signal transduction adaptor	Homo sapiens	87-92
32244040-9	2020	TLRs are attractive therapeutic targets given their role in inflammation and initiation of adaptive immunity, and data herein indicate that both CBD and THC preferentially modulate TLR3 and TLR4 signalling via MyD88-independent mechanisms in macrophages.	Dronabinol	153-156	toll like receptor 3	Homo sapiens	181-185
32244040-9	2020	TLRs are attractive therapeutic targets given their role in inflammation and initiation of adaptive immunity, and data herein indicate that both CBD and THC preferentially modulate TLR3 and TLR4 signalling via MyD88-independent mechanisms in macrophages.	Dronabinol	153-156	toll like receptor 4	Homo sapiens	190-194
32244040-9	2020	TLRs are attractive therapeutic targets given their role in inflammation and initiation of adaptive immunity, and data herein indicate that both CBD and THC preferentially modulate TLR3 and TLR4 signalling via MyD88-independent mechanisms in macrophages.	Dronabinol	153-156	MYD88 innate immune signal transduction adaptor	Homo sapiens	210-215
15234473-2	2004	Previously, we showed that a standardized cannabis extract (SCE), isolated Delta9-tetrahydrocannabinol (Delta9-THC), and even Delta9-THC-free SCE inhibited muscarinic agonist-induced epileptiform bursting in rat olfactory cortical brain slices, acting via CB1 receptors.	Dronabinol	126-136	cannabinoid receptor 1	Rattus norvegicus	256-259
15234473-3	2004	The present work demonstrates that although Delta9-THC (1 microM) significantly depressed evoked depolarizing postsynaptic potentials (PSPs) in rat olfactory cortex neurones, both SCE and Delta9-THC-free SCE significantly potentiated evoked PSPs (all results were fully reversed by the CB1 receptor antagonist SR141716A, 1 microM); interestingly, the potentiation by Delta9-THC-free SCE was greater than that produced by SCE.	Dronabinol	44-54	cannabinoid receptor 1	Rattus norvegicus	286-289
15234473-3	2004	The present work demonstrates that although Delta9-THC (1 microM) significantly depressed evoked depolarizing postsynaptic potentials (PSPs) in rat olfactory cortex neurones, both SCE and Delta9-THC-free SCE significantly potentiated evoked PSPs (all results were fully reversed by the CB1 receptor antagonist SR141716A, 1 microM); interestingly, the potentiation by Delta9-THC-free SCE was greater than that produced by SCE.	Dronabinol	188-198	cannabinoid receptor 1	Rattus norvegicus	286-289
15234473-3	2004	The present work demonstrates that although Delta9-THC (1 microM) significantly depressed evoked depolarizing postsynaptic potentials (PSPs) in rat olfactory cortex neurones, both SCE and Delta9-THC-free SCE significantly potentiated evoked PSPs (all results were fully reversed by the CB1 receptor antagonist SR141716A, 1 microM); interestingly, the potentiation by Delta9-THC-free SCE was greater than that produced by SCE.	Dronabinol	188-198	cannabinoid receptor 1	Rattus norvegicus	286-289
7675800-2	1995	The purpose of this study was to determine whether THC inhibited macrophage cytolytic function by targeting selectively tumor necrosis factor (TNF)-dependent pathways versus L-arginine-dependent reactive nitrogen intermediates.	Dronabinol	51-54	tumor necrosis factor	Mus musculus	120-141
7675800-2	1995	The purpose of this study was to determine whether THC inhibited macrophage cytolytic function by targeting selectively tumor necrosis factor (TNF)-dependent pathways versus L-arginine-dependent reactive nitrogen intermediates.	Dronabinol	51-54	tumor necrosis factor	Mus musculus	143-146
7675800-6	1995	THC inhibited TNF-dependent killing by macrophages subjected to either multistep or direct activation.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	14-17
7675800-7	1995	Decreased amounts of TNF-alpha were detected in medium of macrophage cultures treated with THC.	Dronabinol	91-94	tumor necrosis factor	Mus musculus	21-30
7675800-11	1995	Inhibition of macrophage tumoricidal activity against TNF-sensitive L929 cells was effected by both isomers of THC analogs.	Dronabinol	111-114	tumor necrosis factor	Mus musculus	54-57
34860284-0	2022	Anxiety and cognitive-related effects of Delta 9-tetrahydrocannabinol (THC) are differentially mediated through distinct GSK-3 vs. Akt-mTOR pathways in the nucleus accumbens of male rats.	Dronabinol	41-69	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
34860284-0	2022	Anxiety and cognitive-related effects of Delta 9-tetrahydrocannabinol (THC) are differentially mediated through distinct GSK-3 vs. Akt-mTOR pathways in the nucleus accumbens of male rats.	Dronabinol	41-69	mechanistic target of rapamycin kinase	Rattus norvegicus	135-139
34860284-0	2022	Anxiety and cognitive-related effects of Delta 9-tetrahydrocannabinol (THC) are differentially mediated through distinct GSK-3 vs. Akt-mTOR pathways in the nucleus accumbens of male rats.	Dronabinol	71-74	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
34860284-0	2022	Anxiety and cognitive-related effects of Delta 9-tetrahydrocannabinol (THC) are differentially mediated through distinct GSK-3 vs. Akt-mTOR pathways in the nucleus accumbens of male rats.	Dronabinol	71-74	mechanistic target of rapamycin kinase	Rattus norvegicus	135-139
34860284-7	2022	RESULTS: We report that THC in the posterior NASh causes distortions in emotional salience attribution, impaired sensory filtering and memory retention and heightened anxiety, through a glycogen-synthase-kinase-3 (GSK-3)-beta-catenin dependent signalling pathway.	Dronabinol	24-27	catenin beta 1	Rattus norvegicus	221-233
34860284-8	2022	In contrast, THC in the anterior NASh produces anxiolytic effects via modulation of protein kinase B (Akt) phosphorylation states.	Dronabinol	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	102-105
34954656-9	2022	In human primary gingival epithelial cells, miR-125a-5p post-transcriptionally downregulated DUOX1 and THC inhibited IDO1 protein expression through a cannabinoid receptor-2 mediated mechanism.	Dronabinol	103-106	indoleamine 2,3-dioxygenase 1	Homo sapiens	117-121
34954656-9	2022	In human primary gingival epithelial cells, miR-125a-5p post-transcriptionally downregulated DUOX1 and THC inhibited IDO1 protein expression through a cannabinoid receptor-2 mediated mechanism.	Dronabinol	103-106	cannabinoid receptor 2	Homo sapiens	151-173
34774731-5	2022	The THC in the blood cockle hemolymph declined from pre-spawning (1.2 x 108 cell mL-1) to post-spawning (0.9 x 108 cell mL-1), possibly due to the spawning stress and the massive infiltration of hemocytes in the gonad to phagocytose and resorb the residual gametes during the post-spawning period.	Dronabinol	4-7	L1 cell adhesion molecule	Mus musculus	81-85
34774731-5	2022	The THC in the blood cockle hemolymph declined from pre-spawning (1.2 x 108 cell mL-1) to post-spawning (0.9 x 108 cell mL-1), possibly due to the spawning stress and the massive infiltration of hemocytes in the gonad to phagocytose and resorb the residual gametes during the post-spawning period.	Dronabinol	4-7	L1 cell adhesion molecule	Mus musculus	120-124
34625464-3	2022	Although cannabinoid 1 (CB1) receptor agonists, including Delta9-tetrahydrocannabinol (THC), ameliorate opioid withdrawal in both clinical and pre-clinical studies of opioid dependence, this strategy elicits cannabimimetic side effects as well as tolerance and dependence following repeated administration.	Dronabinol	58-85	cannabinoid receptor 1 (brain)	Mus musculus	24-27
34625464-3	2022	Although cannabinoid 1 (CB1) receptor agonists, including Delta9-tetrahydrocannabinol (THC), ameliorate opioid withdrawal in both clinical and pre-clinical studies of opioid dependence, this strategy elicits cannabimimetic side effects as well as tolerance and dependence following repeated administration.	Dronabinol	87-90	cannabinoid receptor 1 (brain)	Mus musculus	24-27
34922011-12	2022	Applying THC protected corneal nerve morphology, thus maintained corneal sensitivity and reduced CD4+ T-cell infiltration.	Dronabinol	9-12	CD4 antigen	Mus musculus	97-100
34493601-6	2021	Strong inhibition of UGT1A9 was also demonstrated by THC and CBN, with IC50,u values of 0.45 {plus minus} 0.12 microM and 0.51 {plus minus} 0.063 microM, respectively.	Dronabinol	53-56	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	21-27
34493601-7	2021	Strong inhibition of UGT2B7 was also observed for THC and CBN; no or weak inhibition was observed with cannabinoid metabolites.	Dronabinol	50-53	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	21-27
34493602-7	2021	THC and CBD showed mixed-type inhibition for CYP2C19 and CYP1A2, respectively.	Dronabinol	0-3	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	45-52
34493602-7	2021	THC and CBD showed mixed-type inhibition for CYP2C19 and CYP1A2, respectively.	Dronabinol	0-3	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Dronabinol	47-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	110-113
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Dronabinol	47-50	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	290-296
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Dronabinol	47-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	298-304
34493602-8	2021	These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.	Dronabinol	47-50	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	309-315
34758399-0	2021	Similarities and differences upon binditng of naturally occurring Delta9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors.	Dronabinol	66-93	cannabinoid receptor 1	Homo sapiens	121-124
34758399-0	2021	Similarities and differences upon binditng of naturally occurring Delta9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors.	Dronabinol	66-93	cannabinoid receptor 2	Homo sapiens	129-132
34747647-11	2021	Delta9-THC-treated mice, compared with vehicle-treated animals, exhibited significant upregulation of G-CSF as well as BDNF and GDNF in the cerebral cortex, striatum, and HP.	Dronabinol	0-10	colony stimulating factor 3 (granulocyte)	Mus musculus	102-107
34747647-11	2021	Delta9-THC-treated mice, compared with vehicle-treated animals, exhibited significant upregulation of G-CSF as well as BDNF and GDNF in the cerebral cortex, striatum, and HP.	Dronabinol	0-10	brain derived neurotrophic factor	Mus musculus	119-123
34747647-11	2021	Delta9-THC-treated mice, compared with vehicle-treated animals, exhibited significant upregulation of G-CSF as well as BDNF and GDNF in the cerebral cortex, striatum, and HP.	Dronabinol	0-10	glial cell line derived neurotrophic factor	Mus musculus	128-132
34523142-5	2021	In the dorsal CA1 subfield, there was an increase in the number of PV interneurons in both the EtOH and EtOH + THC groups, but only a possible decrease with THC alone.	Dronabinol	111-114	carbonic anhydrase 1	Rattus norvegicus	14-17
34523142-7	2021	There was also an increase in cell layer volume between the EtOH + THC group and control group in the DG, and an increase from the control and THC group to the EtOH group in the CA1 region.	Dronabinol	143-146	carbonic anhydrase 1	Rattus norvegicus	178-181
34523142-8	2021	CONCLUSIONS: Prenatal alcohol and prenatal THC exposure differentially affect parvalbumin interneuron numbers in the hippocampus, indicating that both individual and combined exposure can impact the balance of excitation and inhibition in a structure critically involved in learning and memory processes.	Dronabinol	43-46	parvalbumin	Rattus norvegicus	78-89
34638139-0	2021	Activity of THC, CBD, and CBN on Human ACE2 and SARS-CoV1/2 Main Protease to Understand Antiviral Defense Mechanism.	Dronabinol	12-15	angiotensin converting enzyme 2	Homo sapiens	39-43
34638139-2	2021	This study aims to determine the mechanism of action of THC, CBD, and CBN by selecting two essential targets that directly affect the coronavirus infections as viral main proteases and human angiotensin-converting enzyme2.	Dronabinol	56-59	angiotensin converting enzyme 2	Homo sapiens	191-221
34610637-4	2021	We report that the psychoactive cannabinoid Delta9-tetrahydrocannabinol (THC) induces two hallmark HH loss-of-function phenotypes (HPE and ventral neural tube patterning defects) in Cdon mutant mice, which have a subthreshold deficit in HH signaling.	Dronabinol	44-71	cell adhesion molecule-related/down-regulated by oncogenes	Mus musculus	182-186
34610637-4	2021	We report that the psychoactive cannabinoid Delta9-tetrahydrocannabinol (THC) induces two hallmark HH loss-of-function phenotypes (HPE and ventral neural tube patterning defects) in Cdon mutant mice, which have a subthreshold deficit in HH signaling.	Dronabinol	73-76	cell adhesion molecule-related/down-regulated by oncogenes	Mus musculus	182-186
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily B member 1	Homo sapiens	103-117
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily B member 1	Homo sapiens	124-129
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	135-167
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	169-173
34326138-0	2021	Tetrahydrocannabinol and Its Major Metabolites are Not (or are poor) Substrates or Inhibitors of Human P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	Dronabinol	0-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	174-179
34326138-7	2021	The efflux ratio of THC-COOH in MDCKII-BCRP cells was 1.6, which was significantly decreased to 1.0 by the BCRP inhibitor Ko143.	Dronabinol	20-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-111
34326138-9	2021	THC-COOH also significantly inhibited BCRP-mediated transport of lucifer yellow, a BCRP substrate; however, THC-COOH was neither a substrate nor an inhibitor of P-gp.	Dronabinol	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	38-42
34326138-9	2021	THC-COOH also significantly inhibited BCRP-mediated transport of lucifer yellow, a BCRP substrate; however, THC-COOH was neither a substrate nor an inhibitor of P-gp.	Dronabinol	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	83-87
34326138-11	2021	THC-COOH is a weak substrate and inhibitor of BCRP, but not of P-gp.	Dronabinol	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-50
34708636-10	2021	Besides, THC enhanced mRNA or protein expression levels of clathrin and RAB5B, and decreased NMDAR1 (P < 0.05).	Dronabinol	9-12	RAB5B, member RAS oncogene family	Rattus norvegicus	72-77
34708636-10	2021	Besides, THC enhanced mRNA or protein expression levels of clathrin and RAB5B, and decreased NMDAR1 (P < 0.05).	Dronabinol	9-12	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	93-99
34255372-6	2021	In females with elevated estrogen states (proestrus/estrus stage), acute THC altered the opioid system so that it resembled that seen in vehicle-injected females with low estrogen states (diestrus) and males: 1) mossy fiber LEnk levels in CA2/3a decreased; 2) phosphorylated-DOR levels in CA2/3a pyramidal cells increased; and 3) phosphorylated-MOR levels increased in most CA3b laminae.	Dronabinol	73-76	carbonic anhydrase 2	Rattus norvegicus	239-245
34255372-6	2021	In females with elevated estrogen states (proestrus/estrus stage), acute THC altered the opioid system so that it resembled that seen in vehicle-injected females with low estrogen states (diestrus) and males: 1) mossy fiber LEnk levels in CA2/3a decreased; 2) phosphorylated-DOR levels in CA2/3a pyramidal cells increased; and 3) phosphorylated-MOR levels increased in most CA3b laminae.	Dronabinol	73-76	carbonic anhydrase 2	Rattus norvegicus	289-295
34255372-8	2021	In both sexes, acute THC redistributed DORs to the near plasma membrane of CA3 pyramidal cell dendrites, however, the dendritic region varied with sex.	Dronabinol	21-24	carbonic anhydrase 3	Rattus norvegicus	75-78
34255372-9	2021	Additionally, acute THC also resulted in a sex-specific redistribution of DORs within CA3 pyramidal cell dendrites which could differentially promote synaptic plasticity and/or opioid-associated learning processes in both females and males.	Dronabinol	20-23	carbonic anhydrase 3	Rattus norvegicus	86-89
34895699-9	2021	Normalizing Kmt2a in the NAc rescued the motivational phenotype of prenatally THC-exposed animals.	Dronabinol	78-81	lysine methyltransferase 2A	Homo sapiens	12-17
34573260-0	2021	Epigenetic Mediation of AKT1 rs1130233"s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing.	Dronabinol	51-79	AKT serine/threonine kinase 1	Homo sapiens	24-28
34573260-2	2021	Additionally, THC effects have been shown to be modulated by genotype, including the single nucleotide polymorphism (SNP) rs1130233 at the protein kinase AKT1 gene, a key component of the dopamine signalling cascade.	Dronabinol	14-17	AKT serine/threonine kinase 1	Homo sapiens	154-158
34573260-3	2021	As such, it is likely that epigenetic methylation around this SNP may affect AKT gene expression, which may in turn impact on the acute effects of THC on brain function.	Dronabinol	147-150	AKT serine/threonine kinase 1	Homo sapiens	77-80
34573260-8	2021	Number of A alleles at the AKT1 rs1130233 SNP, and percentage methylation at the CpG11-12 site, were independently associated with a greater effect of THC on activation in a network of brain regions including left and right parahippocampal gyri, respectively.	Dronabinol	151-154	AKT serine/threonine kinase 1	Homo sapiens	27-31
34573260-9	2021	AKT1 rs1130233 moderation of the THC effect on left parahippocampal activation persisted after covarying for methylation percentage, and was partially mediated in sections of the left parahippocampal gyrus/hippocampus by methylation percentage.	Dronabinol	33-36	AKT serine/threonine kinase 1	Homo sapiens	0-4
34603022-0	2021	Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble Delta9-THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism.	Dronabinol	68-78	cannabinoid receptor 1 (brain)	Mus musculus	125-128
34500787-2	2021	In addition to their other pharmacological targets, both THC and CBD are competitive inhibitors of the equilibrative nucleoside transporter-1 (ENT-1), a primary inactivation mechanism for adenosine, and thereby increase adenosine signaling.	Dronabinol	57-60	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	103-141
34500787-2	2021	In addition to their other pharmacological targets, both THC and CBD are competitive inhibitors of the equilibrative nucleoside transporter-1 (ENT-1), a primary inactivation mechanism for adenosine, and thereby increase adenosine signaling.	Dronabinol	57-60	solute carrier family 29 (nucleoside transporters), member 1	Mus musculus	143-148
34500787-3	2021	The goal of this study was to examine the role of adenosine A2A receptor activation in the effects of intraperitoneally administered THC alone and in combination with CBD or PECS-101, a 4"-fluorinated derivative of CBD, in the cannabinoid tetrad, elevated plus maze (EPM) and marble bury assays.	Dronabinol	133-136	adenosine A2a receptor	Mus musculus	50-72
34146926-6	2021	Delta9-THC and Delta8-THC also suppressed the migration/invasion by inhibiting epithelial-mesenchymal transition markers, such as E-cadherin, in addition to decreasing reactive oxygen species (ROS) production and increasing glutathione (GSH) and the expression of mtMP.	Dronabinol	0-10	cadherin 1	Homo sapiens	130-140
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	cyclin D1	Homo sapiens	45-54
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	tumor protein p53	Homo sapiens	56-59
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	61-65
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	DNA damage regulated autophagy modulator 1	Homo sapiens	82-86
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	H3 histone pseudogene 16	Homo sapiens	113-116
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	7-10	H2A.X variant histone	Homo sapiens	121-125
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	cyclin D1	Homo sapiens	45-54
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	tumor protein p53	Homo sapiens	56-59
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	61-65
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	DNA damage regulated autophagy modulator 1	Homo sapiens	82-86
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	H3 histone pseudogene 16	Homo sapiens	113-116
34146926-7	2021	Delta9-THC and Delta8-THC also downregulated cyclin D1, p53, NOXA, PUMAalpha, and DRAM expressions but increased p21 and H2AX expression.	Dronabinol	22-25	H2A.X variant histone	Homo sapiens	121-125
34405459-2	2021	The aim of this study was to compare the protracted effects of adolescent versus late-adolescent chronic exposure to THC on short-term memory and plasticity, and to examine whether rapamycin, a blocker of the mammalian target of rapamycin (mTOR) pathway, can restore THC-induced deficits in memory and plasticity.	Dronabinol	267-270	mechanistic target of rapamycin kinase	Homo sapiens	209-238
34405459-2	2021	The aim of this study was to compare the protracted effects of adolescent versus late-adolescent chronic exposure to THC on short-term memory and plasticity, and to examine whether rapamycin, a blocker of the mammalian target of rapamycin (mTOR) pathway, can restore THC-induced deficits in memory and plasticity.	Dronabinol	267-270	mechanistic target of rapamycin kinase	Homo sapiens	240-244
34451896-1	2021	GPR18 is an orphan GPCR that is activated by the cannabinoid tetrahydrocannabinol (THC).	Dronabinol	61-81	G protein-coupled receptor 18	Homo sapiens	0-5
34451896-1	2021	GPR18 is an orphan GPCR that is activated by the cannabinoid tetrahydrocannabinol (THC).	Dronabinol	83-86	G protein-coupled receptor 18	Homo sapiens	0-5
34344922-8	2021	Since THC-induced repetitive behavior remained in co-administrations with cannabinoid receptor 1 inverse agonist AM251, the phenotype may be cannabinoid receptor 1-independent.	Dronabinol	6-9	cannabinoid receptor 1	Danio rerio	141-163
34344922-9	2021	Conversely, the inverse cannabinoid receptor 2 agonist AM630 significantly reduced THC-induced behavioral stereotypy, indicating cannabinoid receptor 2 as a possible mediator.	Dronabinol	83-86	cannabinoid receptor 2	Danio rerio	24-46
34344922-9	2021	Conversely, the inverse cannabinoid receptor 2 agonist AM630 significantly reduced THC-induced behavioral stereotypy, indicating cannabinoid receptor 2 as a possible mediator.	Dronabinol	83-86	cannabinoid receptor 2	Danio rerio	129-151
34367237-1	2021	Cannabinoid receptor 1 activation by the major psychoactive component in cannabis, Delta9-tetrahydrocannabinol (THC), produces motor impairments, hypothermia, and analgesia upon acute exposure.	Dronabinol	83-110	cannabinoid receptor 1 (brain)	Mus musculus	0-22
34367237-1	2021	Cannabinoid receptor 1 activation by the major psychoactive component in cannabis, Delta9-tetrahydrocannabinol (THC), produces motor impairments, hypothermia, and analgesia upon acute exposure.	Dronabinol	112-115	cannabinoid receptor 1 (brain)	Mus musculus	0-22
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	NADH:ubiquinone oxidoreductase core subunit S2	Mus musculus	58-64
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	sterol carrier protein 2, liver	Mus musculus	66-70
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	72-79
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	83-89
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	phosphodiesterase 4D, cAMP specific	Mus musculus	91-96
34367237-9	2021	We identified genomic loci and candidate genes, including Ndufs2, Scp2, Rps6kb1 or P70S6K, Pde4d, and Pten, that may control variation in THC initial sensitivity.	Dronabinol	138-141	phosphatase and tensin homolog	Mus musculus	102-106
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	Dronabinol	155-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-120
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	Dronabinol	155-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
34299119-10	2021	Interestingly, decreases in miR-203a-3p and miR-29a/b/c, both implicated in dyslipidemia, were also observed in these Delta9-THC-exposed offspring.	Dronabinol	125-128	microRNA 29a	Rattus norvegicus	44-55
34243602-3	2021	In vivo, THC administration rescued learning and memory, and reduced Abeta burden in the hippocampus of APP/PS1 mice.	Dronabinol	9-12	presenilin 1	Mus musculus	108-111
34243602-4	2021	By proteomic analysis of the hippocampus of mice, 157 differentially expressed proteins were identified in APP/PS1 mice treated with THC (comparing with APP/PS1 mice), which also suggested that the effects of THC on the cell cycle and apoptosis were mostly related to the "Ras signaling pathway", etc.	Dronabinol	133-136	presenilin 1	Mus musculus	111-114
34243602-4	2021	By proteomic analysis of the hippocampus of mice, 157 differentially expressed proteins were identified in APP/PS1 mice treated with THC (comparing with APP/PS1 mice), which also suggested that the effects of THC on the cell cycle and apoptosis were mostly related to the "Ras signaling pathway", etc.	Dronabinol	209-212	presenilin 1	Mus musculus	111-114
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	presenilin 1	Mus musculus	7-10
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	growth factor receptor bound protein 2-associated protein 2	Mus musculus	173-177
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	179-184
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	caspase 3	Mus musculus	186-195
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	tumor necrosis factor	Mus musculus	200-209
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	transforming growth factor, beta 1	Mus musculus	228-237
34243602-5	2021	In APP/PS1 mice, the down-regulation of Gab2 and K-Ras, and the up-regulation of caspase-3, TGF-beta1 and TNF-alpha were observed; THC attenuated the abnormal expression of Gab2, K-Ras, caspase-3 and TNF-alpha, and up-regulated TGF-beta1 and Bag1 expression.	Dronabinol	131-134	BCL2-associated athanogene 1	Mus musculus	242-246
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	growth factor receptor bound protein 2-associated protein 2	Mus musculus	52-56
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	58-63
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	transforming growth factor, beta 1	Mus musculus	68-77
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	caspase 3	Mus musculus	105-114
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	poly (ADP-ribose) polymerase family, member 1	Mus musculus	116-121
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	poly (ADP-ribose) polymerase family, member 1	Mus musculus	131-136
34243602-6	2021	In BV-2 cells, Abeta induced the down-regulation of Gab2, K-Ras and TGF-beta1, and the overexpression of caspase-3, PARP1, cleaved-PARP1 and TNF-alpha, which were restored by THC.	Dronabinol	175-178	tumor necrosis factor	Mus musculus	141-150
34243602-7	2021	Moreover, THC up-regulated Bag1 expression in Abeta-treated BV-2 cells.	Dronabinol	10-13	BCL2-associated athanogene 1	Mus musculus	27-31
34243602-8	2021	The decreased transcriptional expression of Ccnd2 and Cdkn1a were also observed in Abeta-treated BV-2 cells, and THC alleviated the down-regulation of Ccnd2.	Dronabinol	113-116	cyclin D2	Mus musculus	44-49
34243602-8	2021	The decreased transcriptional expression of Ccnd2 and Cdkn1a were also observed in Abeta-treated BV-2 cells, and THC alleviated the down-regulation of Ccnd2.	Dronabinol	113-116	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	54-60
34243602-8	2021	The decreased transcriptional expression of Ccnd2 and Cdkn1a were also observed in Abeta-treated BV-2 cells, and THC alleviated the down-regulation of Ccnd2.	Dronabinol	113-116	cyclin D2	Mus musculus	151-156
34243602-9	2021	For the first time, we identified that the action of THC in preventing AD was associated with inhibition of cell cycle arrest and apoptosis of microglia via the Ras/ERK signaling pathway, shedding new light on the role of THC in alleviating the progression of AD.	Dronabinol	53-56	mitogen-activated protein kinase 1	Mus musculus	165-168
34182795-0	2021	Perinatal CBD or THC Exposure Results in Lasting Resistance to Fluoxetine in the Forced Swim Test: Reversal by Fatty Acid Amide Hydrolase Inhibition.	Dronabinol	17-20	fatty acid amide hydrolase	Mus musculus	122-137
34182795-16	2021	The restoration of fluoxetine responsiveness in THC or CBD PCE adults by inhibition of FAAH suggests that PCE causes a lasting reduction of the ECS and that enhancement of anandamide signaling represents a potential treatment for behavioral deficits following PCE.	Dronabinol	48-51	fatty acid amide hydrolase	Mus musculus	87-91
34939063-10	2021	Results: Delta-9-THC reduced OT and VP plasma levels (p < 0.0001, p = 0.0141; respectively), cocaine reduced plasma OT (p = 0.0023), while MA reduced plasma VP levels (p = 0.0001), all versus control.	Dronabinol	9-20	arginine vasopressin	Rattus norvegicus	36-38
34250019-3	2021	Our previous work found that male mice expressing a desensitization resistant form (S426A/S430A) of the type 1 cannabinoid receptor (CB1R) show delayed tolerance and increased sensitivity to the antinociceptive effects of delta-9-tetrahydrocannabinol ( 9-THC).	Dronabinol	222-250	cannabinoid receptor 1 (brain)	Mus musculus	133-137
34250019-3	2021	Our previous work found that male mice expressing a desensitization resistant form (S426A/S430A) of the type 1 cannabinoid receptor (CB1R) show delayed tolerance and increased sensitivity to the antinociceptive effects of delta-9-tetrahydrocannabinol ( 9-THC).	Dronabinol	253-258	cannabinoid receptor 1 (brain)	Mus musculus	133-137
34250019-9	2021	The anti-allodynic effects of  9-THC were blocked following pretreatment with the CB1R antagonist, rimonabant, and partially blocked following pretreatment with the CB2R inverse agonist, SR144528.	Dronabinol	31-36	cannabinoid receptor 1 (brain)	Mus musculus	82-86
34165606-2	2022	Male mice expressing a desensitization-resistant form (S426A/S430A) of the type-1 cannabinoid receptor (CB1R) show delayed tolerance to delta-9-tetrahydrocannabinol ( 9-THC) but not CP55,940.	Dronabinol	136-164	cannabinoid receptor 1 (brain)	Mus musculus	104-108
34165606-2	2022	Male mice expressing a desensitization-resistant form (S426A/S430A) of the type-1 cannabinoid receptor (CB1R) show delayed tolerance to delta-9-tetrahydrocannabinol ( 9-THC) but not CP55,940.	Dronabinol	167-172	cannabinoid receptor 1 (brain)	Mus musculus	104-108
34165606-10	2022	CONCLUSIONS: Our results suggest that disruption of the GRK/betaarrestin2 pathway of desensitization alters tolerance to Delta9-THC but not CP55,940 in male but not female mice.	Dronabinol	121-131	G protein-coupled receptor kinase 4	Mus musculus	56-59
34165606-10	2022	CONCLUSIONS: Our results suggest that disruption of the GRK/betaarrestin2 pathway of desensitization alters tolerance to Delta9-THC but not CP55,940 in male but not female mice.	Dronabinol	121-131	arrestin, beta 2	Mus musculus	60-73
34719637-8	2021	In contrast, some EDCs, such as Delta9-tetrahydrocannabinol and bisphenol AF, can exhibit anti-estrogenic effects through up-regulation of ERbeta expression without affecting the ERalpha expression levels.	Dronabinol	32-59	estrogen receptor 1	Homo sapiens	139-145
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	14-17	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	103-109
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	14-17	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	129-132
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-139
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	14-17	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	145-151
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	95-98	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	103-109
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	95-98	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	129-132
35370140-3	2022	To populate a THC/11-OH-THC PBPK model, we previously characterized the depletion clearance of THC (by CYP2C9) and 11-OH-THC (by UGT, CYP3A, and CYP2C9) in adult human liver microsomes.	Dronabinol	95-98	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	145-151
35370140-10	2022	Significance Statement This is the first characterization and quantification of THC and 11-OH-THC depletion clearance by CYP and UGT enzymes in extrahepatic human tissues: intestine, fetal liver, lung, and placenta.	Dronabinol	80-83	peptidylprolyl isomerase G	Homo sapiens	121-124
35370140-10	2022	Significance Statement This is the first characterization and quantification of THC and 11-OH-THC depletion clearance by CYP and UGT enzymes in extrahepatic human tissues: intestine, fetal liver, lung, and placenta.	Dronabinol	80-83	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	129-132
35588954-0	2022	Delta-9-tetrahydrocannabinol increases vascular endothelial growth factor (VEGF) secretion through a cyclooxygenase-dependent mechanism in rat granulosa cells.	Dronabinol	0-28	vascular endothelial growth factor A	Rattus norvegicus	39-73
35588954-0	2022	Delta-9-tetrahydrocannabinol increases vascular endothelial growth factor (VEGF) secretion through a cyclooxygenase-dependent mechanism in rat granulosa cells.	Dronabinol	0-28	vascular endothelial growth factor A	Rattus norvegicus	75-79
35588954-2	2022	The aim of this study was to assess the effect of THC on the expression and secretion of the angiogenic factor vascular endothelial growth factor (VEGF) in the ovary, and to determine if these effects were mediated by prostaglandins.	Dronabinol	50-53	vascular endothelial growth factor A	Rattus norvegicus	111-145
35588954-2	2022	The aim of this study was to assess the effect of THC on the expression and secretion of the angiogenic factor vascular endothelial growth factor (VEGF) in the ovary, and to determine if these effects were mediated by prostaglandins.	Dronabinol	50-53	vascular endothelial growth factor A	Rattus norvegicus	147-151
35588954-6	2022	THC-exposed SIGCs had a significant increase in VEGF and PGE2 secretion, along with an increase in proliferation and cell survival when challenged with an apoptosis-inducing factor.	Dronabinol	0-3	vascular endothelial growth factor A	Rattus norvegicus	48-52
35588954-7	2022	Pre-treatment with COX inhibitors reversed the THC-induced increase in both PGE2 and VEGF secretion.	Dronabinol	47-50	vascular endothelial growth factor A	Rattus norvegicus	85-89
35489334-2	2022	Delta9-tetrahydrocannabinol (Delta9-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	116-119
35489334-2	2022	Delta9-tetrahydrocannabinol (Delta9-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD.	Dronabinol	29-39	cannabinoid receptor 1 (brain)	Mus musculus	116-119
35625855-7	2022	In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM).	Dronabinol	9-12	C-X-C motif chemokine ligand 8	Homo sapiens	133-137
35625855-7	2022	In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM).	Dronabinol	9-12	transient receptor potential cation channel subfamily A member 1	Homo sapiens	83-88
35625855-7	2022	In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM).	Dronabinol	9-12	C-X-C motif chemokine ligand 8	Homo sapiens	118-131
35625855-7	2022	In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM).	Dronabinol	9-12	matrix metallopeptidase 3	Homo sapiens	143-167
35625855-7	2022	In RASF, THC (>=5 microM) increased intracellular calcium levels/PoPo3 uptake in a TRPA1-dependent manner and reduced interleukin-8 (IL-8) and matrix metalloprotease 3 (MMP-3) production at high concentrations (25 microM).	Dronabinol	9-12	matrix metallopeptidase 3	Homo sapiens	169-174
35625855-9	2022	In PBMC alone, THC decreased interleukin-10 (IL-10) production and increased immunoglobulin G (IgG).	Dronabinol	15-18	interleukin 10	Homo sapiens	29-43
35625855-9	2022	In PBMC alone, THC decreased interleukin-10 (IL-10) production and increased immunoglobulin G (IgG).	Dronabinol	15-18	interleukin 10	Homo sapiens	45-50
35625855-10	2022	In PBMC/RASF co-culture, THC decreased TNF production when cells were stimulated with interferon-gamma (IFN-gamma) or CpG.	Dronabinol	25-28	tumor necrosis factor	Homo sapiens	39-42
35625855-10	2022	In PBMC/RASF co-culture, THC decreased TNF production when cells were stimulated with interferon-gamma (IFN-gamma) or CpG.	Dronabinol	25-28	interferon gamma	Homo sapiens	86-102
35625855-10	2022	In PBMC/RASF co-culture, THC decreased TNF production when cells were stimulated with interferon-gamma (IFN-gamma) or CpG.	Dronabinol	25-28	interferon gamma	Homo sapiens	104-113
35524041-0	2022	Inhibition of human androgen receptor by delta 9-tetrahydro-cannabinol and cannabidiol related to reproductive dysfunction: A computational study.	Dronabinol	41-70	androgen receptor	Homo sapiens	20-37
35524041-2	2022	Hence this study was aimed to ascertain the impact of tetrahydrocannabinol (THC) and cannabidiol (CBD) binding affinity on human androgen receptor (AR) via computational molecular dynamic simulation.	Dronabinol	54-74	androgen receptor	Homo sapiens	129-146
35524041-2	2022	Hence this study was aimed to ascertain the impact of tetrahydrocannabinol (THC) and cannabidiol (CBD) binding affinity on human androgen receptor (AR) via computational molecular dynamic simulation.	Dronabinol	54-74	androgen receptor	Homo sapiens	148-150
35524041-2	2022	Hence this study was aimed to ascertain the impact of tetrahydrocannabinol (THC) and cannabidiol (CBD) binding affinity on human androgen receptor (AR) via computational molecular dynamic simulation.	Dronabinol	76-79	androgen receptor	Homo sapiens	129-146
35524041-2	2022	Hence this study was aimed to ascertain the impact of tetrahydrocannabinol (THC) and cannabidiol (CBD) binding affinity on human androgen receptor (AR) via computational molecular dynamic simulation.	Dronabinol	76-79	androgen receptor	Homo sapiens	148-150
35524041-8	2022	Despite the diversity within the chemical space, both CBD and THC poses bond flexibility required to bind avidly to AR with the docking scores comparable to R18.	Dronabinol	62-65	androgen receptor	Homo sapiens	116-118
35524041-12	2022	This study hypothesized that CBD and THC binds complimentarily to the pocket AR, indicating a likely inhibition of reproductive function and prostate cancer progression.	Dronabinol	37-40	androgen receptor	Homo sapiens	77-79
35512806-4	2022	Oral MPH undergoes extensive pre-systemic metabolism by carboxylesterase 1 (CES1), a hepatic enzyme which can be inhibited by two prominent cannabinoids,  9-tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	155-177	carboxylesterase 1	Homo sapiens	56-74
35512806-4	2022	Oral MPH undergoes extensive pre-systemic metabolism by carboxylesterase 1 (CES1), a hepatic enzyme which can be inhibited by two prominent cannabinoids,  9-tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	155-177	carboxylesterase 1	Homo sapiens	76-80
35512806-4	2022	Oral MPH undergoes extensive pre-systemic metabolism by carboxylesterase 1 (CES1), a hepatic enzyme which can be inhibited by two prominent cannabinoids,  9-tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	179-182	carboxylesterase 1	Homo sapiens	56-74
35512806-4	2022	Oral MPH undergoes extensive pre-systemic metabolism by carboxylesterase 1 (CES1), a hepatic enzyme which can be inhibited by two prominent cannabinoids,  9-tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	179-182	carboxylesterase 1	Homo sapiens	76-80
35201352-9	2022	Although low CB1 affinity/potency of M7 precluded in vivo studies, both M2 and THC produce locomotor suppression and CB1-mediated dose-dependent hypothermia and analgesia in mice.	Dronabinol	79-82	cannabinoid receptor 1 (brain)	Mus musculus	117-120
35563697-8	2022	Our results revealed that CBD and, for the first time, THC significantly inhibited NLRP3 inflammasome activation following LPS + ATP stimulation, leading to a reduction in the levels of IL-1beta in THP-1 macrophages and HBECs.	Dronabinol	55-58	NLR family pyrin domain containing 3	Homo sapiens	83-88
35563697-8	2022	Our results revealed that CBD and, for the first time, THC significantly inhibited NLRP3 inflammasome activation following LPS + ATP stimulation, leading to a reduction in the levels of IL-1beta in THP-1 macrophages and HBECs.	Dronabinol	55-58	interleukin 1 alpha	Homo sapiens	186-194
35563697-8	2022	Our results revealed that CBD and, for the first time, THC significantly inhibited NLRP3 inflammasome activation following LPS + ATP stimulation, leading to a reduction in the levels of IL-1beta in THP-1 macrophages and HBECs.	Dronabinol	55-58	GLI family zinc finger 2	Homo sapiens	198-203
35563697-10	2022	Our multiplex ELISA data revealed that CBD and THC significantly diminished the levels of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) after LPS treatment in THP-1 macrophages and HBECs.	Dronabinol	47-50	interleukin 6	Homo sapiens	90-94
35563697-10	2022	Our multiplex ELISA data revealed that CBD and THC significantly diminished the levels of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) after LPS treatment in THP-1 macrophages and HBECs.	Dronabinol	47-50	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
35563697-10	2022	Our multiplex ELISA data revealed that CBD and THC significantly diminished the levels of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) after LPS treatment in THP-1 macrophages and HBECs.	Dronabinol	47-50	tumor necrosis factor	Homo sapiens	106-133
35563697-10	2022	Our multiplex ELISA data revealed that CBD and THC significantly diminished the levels of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) after LPS treatment in THP-1 macrophages and HBECs.	Dronabinol	47-50	tumor necrosis factor	Homo sapiens	135-144
35563697-10	2022	Our multiplex ELISA data revealed that CBD and THC significantly diminished the levels of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) after LPS treatment in THP-1 macrophages and HBECs.	Dronabinol	47-50	GLI family zinc finger 2	Homo sapiens	169-174
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	85-88	signal transducer and activator of transcription 3	Homo sapiens	36-41
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	85-88	GLI family zinc finger 2	Homo sapiens	92-97
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	85-88	tyrosine kinase 2	Homo sapiens	184-201
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	85-88	tyrosine kinase 2	Homo sapiens	203-207
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	220-223	signal transducer and activator of transcription 3	Homo sapiens	36-41
35563697-11	2022	In addition, the phosphorylation of STAT3 was significantly downregulated by CBD and THC in THP-1 macrophages and HBECs, which was in turn attributed to the reduced phosphorylation of tyrosine kinase-2 (TYK2) by CBD and THC after LPS stimulation in these cells.	Dronabinol	220-223	tyrosine kinase 2	Homo sapiens	184-201
35563697-12	2022	Overall, CBD and THC were found to be effective in alleviating the LPS-induced cytokine storm in human macrophages and primary HBECs, at least via modulation of NLRP3 inflammasome and STAT3 signaling pathways.	Dronabinol	17-20	NLR family pyrin domain containing 3	Homo sapiens	161-166
35563697-12	2022	Overall, CBD and THC were found to be effective in alleviating the LPS-induced cytokine storm in human macrophages and primary HBECs, at least via modulation of NLRP3 inflammasome and STAT3 signaling pathways.	Dronabinol	17-20	signal transducer and activator of transcription 3	Homo sapiens	184-189
35457070-0	2022	The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC.	Dronabinol	88-91	presenilin 1	Mus musculus	31-34
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	124-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	124-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	154-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	154-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	164-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	223-238
35115300-1	2022	We previously reported the unbound reversible (IC50,u) and time-dependent (KI,u) inhibition potencies of cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and THC metabolites (11-OH THC, 11-COOH THC) against the major cytochrome P450 (CYP) enzymes (1A2, 2C9, 2C19, 2D6, 3A).	Dronabinol	164-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
35115300-3	2022	The IC50,u of CBD, 7-OH CBD, THC, and 11-OH THC against CYP2B6 was 0.05, 0.34, 0.40, and 0.38 microM, respectively and against CYP2C8 was 0.28, 1.02, 0.67, and 4.37 microM, respectively.	Dronabinol	29-32	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-62
35115300-3	2022	The IC50,u of CBD, 7-OH CBD, THC, and 11-OH THC against CYP2B6 was 0.05, 0.34, 0.40, and 0.38 microM, respectively and against CYP2C8 was 0.28, 1.02, 0.67, and 4.37 microM, respectively.	Dronabinol	44-47	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-62
35115300-3	2022	The IC50,u of CBD, 7-OH CBD, THC, and 11-OH THC against CYP2B6 was 0.05, 0.34, 0.40, and 0.38 microM, respectively and against CYP2C8 was 0.28, 1.02, 0.67, and 4.37 microM, respectively.	Dronabinol	44-47	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	127-133
35115300-8	2022	Oral (130 mg) or inhaled (75 mg) THC was predicted to precipitate interactions with drugs predominately metabolized by CYP2C9 (diclofenac, 6.6 or 2.3, respectively) >3A (midazolam, 1.8) >1A2 (theophylline, 1.4).	Dronabinol	33-36	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	119-125
35115300-10	2022	Significance Statement This study, combined with our previous findings, provides for the first time a comprehensive analysis of the potential for cannabidiol, delta-9-tetrahydrocannabinol, and their metabolites to inhibit cytochrome P450 enzymes in a reversible or time-dependent manner.	Dronabinol	159-187	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	222-237
35468673-14	2022	The administration of Delta9-THC effectively increased the production of CERK to the level of aerobic control (p = 0.028, N = 6-9).	Dronabinol	22-32	ceramide kinase	Rattus norvegicus	73-77
35227761-5	2022	In this study, we examine two mechanistic hypotheses for the origin of partial agonism in cannabinoid receptors and predict the mechanistic basis of partial agonism exhibited by Delta9-Tetrahydrocannabinol (THC) against CB1.	Dronabinol	178-205	cannabinoid receptor 1	Homo sapiens	220-223
35227761-5	2022	In this study, we examine two mechanistic hypotheses for the origin of partial agonism in cannabinoid receptors and predict the mechanistic basis of partial agonism exhibited by Delta9-Tetrahydrocannabinol (THC) against CB1.	Dronabinol	207-210	cannabinoid receptor 1	Homo sapiens	220-223
35227761-7	2022	We used extensive molecular dynamics simulations and Markov state modeling to capture the THC binding in both antagonist and agonist binding poses in the CB1 receptor.	Dronabinol	90-93	cannabinoid receptor 1	Homo sapiens	154-157
35145212-7	2022	Moreover, the stress-CS inhibited THC + CBD-CS induced reinstatement.	Dronabinol	34-37	citrate synthase	Rattus norvegicus	21-23
35145212-7	2022	Moreover, the stress-CS inhibited THC + CBD-CS induced reinstatement.	Dronabinol	34-37	citrate synthase	Rattus norvegicus	44-46
35145212-11	2022	Transient spine head expansion in nucleus accumbens core is necessary for cue-induced drug seeking, and THC + CBD self-administration prevented the increase in head diameter by stress-CS in control rats.	Dronabinol	104-107	citrate synthase	Rattus norvegicus	184-186
35145212-12	2022	These data show THC + CBD self-administration altered the salience of environmental cues, causing neutral cues to promote active behavior (drug seeking and burying) and stress-CS to switch from active to passive behavior (inhibiting drug seeking and immobilization).	Dronabinol	16-19	citrate synthase	Rattus norvegicus	176-178
35418857-12	2022	Using a functional assay in cells for CB1 receptors, the major target of cannabinoids, we found that this CaSE contains Delta9-THC which activates CB1 receptors.	Dronabinol	120-130	cannabinoid receptor 1	Homo sapiens	147-150
35319274-5	2022	Outcomes: The lowest CBD (2.5 mg):THC (0.035 mg/kg) ratio (1:1) resulted in maximal attenuation of both THC-induced psychotomimetic effects (Positive and Negative Syndrome Scale (PANSS) positive: Anova Type Statistic (ATS)=7.83, pcorrected=0.015) and neural noise (ATS=8.83, pcorrected=0.009).	Dronabinol	104-107	opsin 1, medium wave sensitive	Homo sapiens	21-24
35319274-7	2022	Interpretation: These novel results demonstrate that CBD attenuates specific THC-induced subjective and objective effects relevant to psychosis in a dose/ratio-dependent manner.	Dronabinol	77-80	opsin 1, medium wave sensitive	Homo sapiens	53-56
35335126-0	2022	Botanically-Derived Delta9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis.	Dronabinol	20-47	toll like receptor 3	Homo sapiens	101-127
35335126-3	2022	Recent data from our laboratory reported that the plant-derived cannabinoids, Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD), regulate viral and bacterial inflammatory signalling pathways controlled by TLR3 and TLR4 in macrophages.	Dronabinol	78-105	toll like receptor 3	Homo sapiens	211-215
35335126-3	2022	Recent data from our laboratory reported that the plant-derived cannabinoids, Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD), regulate viral and bacterial inflammatory signalling pathways controlled by TLR3 and TLR4 in macrophages.	Dronabinol	78-105	toll like receptor 4	Homo sapiens	220-224
35335126-3	2022	Recent data from our laboratory reported that the plant-derived cannabinoids, Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD), regulate viral and bacterial inflammatory signalling pathways controlled by TLR3 and TLR4 in macrophages.	Dronabinol	107-110	toll like receptor 3	Homo sapiens	211-215
35335126-3	2022	Recent data from our laboratory reported that the plant-derived cannabinoids, Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD), regulate viral and bacterial inflammatory signalling pathways controlled by TLR3 and TLR4 in macrophages.	Dronabinol	107-110	toll like receptor 4	Homo sapiens	220-224
35335126-4	2022	The aim of this study was to assess the impact of THC and CBD, when delivered in isolation and in combination (1:1), on TLR3- and TLR4-dependent signalling in peripheral blood mononuclear cells (PBMCs) from people with MS (pwMS; n = 21) and healthy controls (HCs; n = 26).	Dronabinol	50-53	toll like receptor 3	Homo sapiens	120-124
35335126-4	2022	The aim of this study was to assess the impact of THC and CBD, when delivered in isolation and in combination (1:1), on TLR3- and TLR4-dependent signalling in peripheral blood mononuclear cells (PBMCs) from people with MS (pwMS; n = 21) and healthy controls (HCs; n = 26).	Dronabinol	50-53	toll like receptor 4	Homo sapiens	130-134
35335126-7	2022	THC and CBD (delivered in 1:1 combination at 10 muM) attenuated TLR3-induced CXCL10 and IFN-beta protein expression in PBMCs from pwMS and HCs, and this effect was not seen consistently when THC and CBD were delivered alone.	Dronabinol	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	77-83
35335126-7	2022	THC and CBD (delivered in 1:1 combination at 10 muM) attenuated TLR3-induced CXCL10 and IFN-beta protein expression in PBMCs from pwMS and HCs, and this effect was not seen consistently when THC and CBD were delivered alone.	Dronabinol	0-3	IFN1@	Homo sapiens	88-96
35335126-7	2022	THC and CBD (delivered in 1:1 combination at 10 muM) attenuated TLR3-induced CXCL10 and IFN-beta protein expression in PBMCs from pwMS and HCs, and this effect was not seen consistently when THC and CBD were delivered alone.	Dronabinol	191-194	C-X-C motif chemokine ligand 10	Homo sapiens	77-83
35335126-7	2022	THC and CBD (delivered in 1:1 combination at 10 muM) attenuated TLR3-induced CXCL10 and IFN-beta protein expression in PBMCs from pwMS and HCs, and this effect was not seen consistently when THC and CBD were delivered alone.	Dronabinol	191-194	IFN1@	Homo sapiens	88-96
35335126-11	2022	Given their role in inflammation, TLRs are clinical targets, and data herein identify CBD and THC as TLR3 and TLR4 modulating drugs in primary immune cells in vitro.	Dronabinol	94-97	toll like receptor 3	Homo sapiens	101-105
35335126-11	2022	Given their role in inflammation, TLRs are clinical targets, and data herein identify CBD and THC as TLR3 and TLR4 modulating drugs in primary immune cells in vitro.	Dronabinol	94-97	toll like receptor 4	Homo sapiens	110-114
35151230-3	2022	Thus, chronic exposure to Delta9-THC during adolescence may alter the expression and/or distribution of M2Rs in PL-PFC neurons receiving CB1R terminals.	Dronabinol	26-36	cannabinoid receptor 1 (brain)	Mus musculus	137-141
35151230-7	2022	Adolescent Delta9-THC significantly increased plasmalemmal M2R-immunogold density exclusively in large dendrites receiving input from CB1R-labeled terminals.	Dronabinol	11-21	cannabinoid receptor 1 (brain)	Mus musculus	134-138
35127309-6	2022	This effect may be due to THC partially exerting its anti-proliferative effects through the estrogen receptor (ER), present in the MCF-7 cell line.	Dronabinol	26-29	estrogen receptor 1	Homo sapiens	92-109
35127309-6	2022	This effect may be due to THC partially exerting its anti-proliferative effects through the estrogen receptor (ER), present in the MCF-7 cell line.	Dronabinol	26-29	estrogen receptor 1	Homo sapiens	111-113
35202235-7	2022	In particular, the expression of PSD95 was reduced following incubation for 72 h with THC and was increased following incubation with CBD.	Dronabinol	86-89	discs large MAGUK scaffold protein 4	Rattus norvegicus	33-38
35202235-8	2022	THC for 72 h caused disorganisation of CA1 stratum pyramidalis (SP) and complex morphological modifications in a significant number of pyramidal neurons and in astrocytes.	Dronabinol	0-3	carbonic anhydrase 1	Rattus norvegicus	39-42
35053451-10	2022	These THC were characterized by high PD-L1 and stemness markers (SOX2, NANOG, miR-302) as compared with non-fused (CD11b-EPCAM+) cancer cells.	Dronabinol	6-9	CD274 molecule	Homo sapiens	37-42
35053451-10	2022	These THC were characterized by high PD-L1 and stemness markers (SOX2, NANOG, miR-302) as compared with non-fused (CD11b-EPCAM+) cancer cells.	Dronabinol	6-9	SRY-box transcription factor 2	Homo sapiens	65-69
35053451-10	2022	These THC were characterized by high PD-L1 and stemness markers (SOX2, NANOG, miR-302) as compared with non-fused (CD11b-EPCAM+) cancer cells.	Dronabinol	6-9	Nanog homeobox	Homo sapiens	71-76
35053451-10	2022	These THC were characterized by high PD-L1 and stemness markers (SOX2, NANOG, miR-302) as compared with non-fused (CD11b-EPCAM+) cancer cells.	Dronabinol	6-9	epithelial cell adhesion molecule	Homo sapiens	121-126
2684401-2	1989	Two-dimensional gel analysis of components immunoprecipitated with MAb 362.50 or anti-gp 105-2 antibodies from detergent extracts of cells surface labeled with 125I showed that cell-CAM 105 from three different THC exhibited a more basic pI than its counterpart from normal rat hepatocytes.	Dronabinol	211-214	CEA cell adhesion molecule 1	Rattus norvegicus	177-189
2684401-5	1989	Immunofluorescence analysis of normal rat tissues indicated that cell-CAM 105 was also present in the brush border of the small intestine and a subset of tubules in the kidney, raising the possibility that THC cells were expressing an isoform normally found in nonhepatic tissues.	Dronabinol	206-209	CEA cell adhesion molecule 1	Rattus norvegicus	65-77
2684401-8	1989	Immunoprecipitation analysis of PHC induced by ethionine or diethylnitrosamine and choline-deficient diet showed that one of four PHC was expressing an altered form of cell-CAM 105 with the more basic pI characteristic of the THC form of this molecule.	Dronabinol	226-229	CEA cell adhesion molecule 1	Rattus norvegicus	168-180
2819719-5	1989	Based on these results, it was concluded that there were significant differences in the glycosylation of ARH and THC cell-CAM 105.	Dronabinol	113-116	CEA cell adhesion molecule 1	Rattus norvegicus	117-129
2478620-10	1989	Four distinct TCR V beta genes (V beta 2, V beta 4, V beta 6, and V beta 8) were found to be used in our panel of 16 apamin-specific THC.	Dronabinol	133-136	T cell receptor alpha variable 6-3	Mus musculus	14-17
2540743-3	1989	Hepatic expression of the c-k-ras protooncogene was 3-fold higher in THC exposed animals.	Dronabinol	69-72	KRAS proto-oncogene, GTPase	Rattus norvegicus	26-33
2540100-0	1989	Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2.	Dronabinol	27-55	interleukin 2	Homo sapiens	110-123
2540100-7	1989	Addition of 1-100 U IL-2, either during pretreatment with THC or during overnight incubation, precluded or promoted the reversal of the inhibition of NK cell cytotoxicity.	Dronabinol	58-61	interleukin 2	Homo sapiens	20-24
2540100-8	1989	We conclude that the regulatory mechanism(s) involved in depression of NK cell cytotoxicity by THC is significantly influenced by IL-2.	Dronabinol	95-98	interleukin 2	Homo sapiens	130-134
2852360-1	1988	The effect of naturally occurring cannabinoids, delta 9-tetrahydrocannabinol (THC), cannabinol (CBN) and cannabidiol (CBD), on the brain receptors for thyrotropin releasing hormone (TRH) was investigated.	Dronabinol	48-76	thyrotropin releasing hormone	Rattus norvegicus	151-180
2840598-0	1988	Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat.	Dronabinol	23-51	prolactin	Rattus norvegicus	78-87
2840598-0	1988	Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat.	Dronabinol	23-51	gonadotropin releasing hormone receptor	Rattus norvegicus	92-106
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	22-50	prolactin	Rattus norvegicus	83-92
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	22-50	prolactin	Rattus norvegicus	94-97
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	22-50	gonadotropin releasing hormone receptor	Rattus norvegicus	103-117
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	52-55	prolactin	Rattus norvegicus	83-92
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	52-55	prolactin	Rattus norvegicus	94-97
2840598-1	1988	The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments.	Dronabinol	52-55	gonadotropin releasing hormone receptor	Rattus norvegicus	103-117
2449494-2	1988	We evaluated the processing requirement of this compact peptide by accessory cells for presentation to apamin-reactive T hybridoma cells (THC) by analyzing the IL-2 responses of 16 THC from apamin-primed BALB/c or C57BL/6 mice, to various forms of either native or chemically synthesized apamin analogs.	Dronabinol	138-141	interleukin 2	Mus musculus	160-164
2844686-0	1988	Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity.	Dronabinol	15-43	interleukin 2	Mus musculus	47-60
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	44-72	interleukin 2	Homo sapiens	162-175
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	44-72	interleukin 2	Homo sapiens	177-181
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	44-72	interleukin 2	Homo sapiens	278-282
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	74-77	interleukin 2	Homo sapiens	162-175
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	74-77	interleukin 2	Homo sapiens	177-181
2844686-1	1988	The major psychoactive marijuana component, delta-9-tetrahydrocannabinol (THC), suppressed proliferation of murine spleen cells stimulated with recombinant human interleukin 2 (IL-2) and also suppressed the appearance of the lymphokine-activated killer (LAK) cell phenomenon in IL-2-treated spleen cell preparations.	Dronabinol	74-77	interleukin 2	Homo sapiens	278-282
2844686-3	1988	In addition, spleen cells previously stimulated in culture with IL-2 and then incubated with THC for 4 h prior to target cell addition, displayed suppressed cytolytic activity against both YAC-1 and EL-4 tumor targets.	Dronabinol	93-96	interleukin 2	Mus musculus	64-68
2844686-3	1988	In addition, spleen cells previously stimulated in culture with IL-2 and then incubated with THC for 4 h prior to target cell addition, displayed suppressed cytolytic activity against both YAC-1 and EL-4 tumor targets.	Dronabinol	93-96	ADP-ribosyltransferase 1	Mus musculus	189-194
2844686-3	1988	In addition, spleen cells previously stimulated in culture with IL-2 and then incubated with THC for 4 h prior to target cell addition, displayed suppressed cytolytic activity against both YAC-1 and EL-4 tumor targets.	Dronabinol	93-96	epilepsy 4	Mus musculus	199-203
2844686-5	1988	These results suggest that THC can suppress several important functions of IL-2 including clonal expansion of lymphocytes, expansion of killer cell populations and stimulation of killer cell cytotoxic activity.	Dronabinol	27-30	interleukin 2	Mus musculus	75-79
2838862-1	1988	The effect of alpha-fluoromethylhistidine (alpha-FMH), a specific inhibitor of histidine decarboxylase, on the potentiation of thiopental-induced sleep by delta 9-tetrahydrocannabinol (THC), which inhibits the histamine turnover in the brain, was examined in mice and rats.	Dronabinol	155-183	histidine decarboxylase	Mus musculus	79-102
2825925-4	1987	Electron micrographs revealed a striking ultrastructural appearance and statistically significant decreases in mean volume of neurons and their nuclei sampled from the hippocampal CA3 region of rats treated with the highest doses of THC.	Dronabinol	233-236	carbonic anhydrase 3	Rattus norvegicus	180-183
2825925-6	1987	Golgi impregnation studies of additional groups of rats treated with 10 or 20 mg/kg/day THC and sacrificed 2 months after their last treatment with THC revealed a reduction in the dendritic length of CA3 pyramidal neurons, despite normal appearing ultrastructure and no changes in synaptic density.	Dronabinol	88-91	carbonic anhydrase 3	Rattus norvegicus	200-203
2830949-1	1987	The duration of long-term potentiation (LTP) of the CA1 evoked field potential in rat hippocampal slices was significantly modulated by pre-treatment of slices with delta-9-tetrahydrocannabinol (THC) added to the incubation media.	Dronabinol	165-193	carbonic anhydrase 1	Rattus norvegicus	52-55
2830949-1	1987	The duration of long-term potentiation (LTP) of the CA1 evoked field potential in rat hippocampal slices was significantly modulated by pre-treatment of slices with delta-9-tetrahydrocannabinol (THC) added to the incubation media.	Dronabinol	195-198	carbonic anhydrase 1	Rattus norvegicus	52-55
3451955-4	1987	In addition, when the animals were treated with THC during the latter half of a 5 weeks CCl4-treatment period, THC had a marked therapeutic effect on CCl4-induced chronic liver injury in rats by an improvement of the decreased body weight gain, suppression of the elevated serum enzyme activities (glutamic pyruvic transaminase, glutamic oxaloacetic transaminase and alkaline phosphatase) and increases in the decreased serum total protein and glucose contents.	Dronabinol	48-51	C-C motif chemokine ligand 4	Rattus norvegicus	88-92
3451955-4	1987	In addition, when the animals were treated with THC during the latter half of a 5 weeks CCl4-treatment period, THC had a marked therapeutic effect on CCl4-induced chronic liver injury in rats by an improvement of the decreased body weight gain, suppression of the elevated serum enzyme activities (glutamic pyruvic transaminase, glutamic oxaloacetic transaminase and alkaline phosphatase) and increases in the decreased serum total protein and glucose contents.	Dronabinol	48-51	C-C motif chemokine ligand 4	Rattus norvegicus	150-154
3451955-4	1987	In addition, when the animals were treated with THC during the latter half of a 5 weeks CCl4-treatment period, THC had a marked therapeutic effect on CCl4-induced chronic liver injury in rats by an improvement of the decreased body weight gain, suppression of the elevated serum enzyme activities (glutamic pyruvic transaminase, glutamic oxaloacetic transaminase and alkaline phosphatase) and increases in the decreased serum total protein and glucose contents.	Dronabinol	111-114	C-C motif chemokine ligand 4	Rattus norvegicus	88-92
3451955-4	1987	In addition, when the animals were treated with THC during the latter half of a 5 weeks CCl4-treatment period, THC had a marked therapeutic effect on CCl4-induced chronic liver injury in rats by an improvement of the decreased body weight gain, suppression of the elevated serum enzyme activities (glutamic pyruvic transaminase, glutamic oxaloacetic transaminase and alkaline phosphatase) and increases in the decreased serum total protein and glucose contents.	Dronabinol	111-114	C-C motif chemokine ligand 4	Rattus norvegicus	150-154
3451955-6	1987	These results suggested that THC stimulates protein synthesis in the liver and has a therapeutic effect on chronic liver injury induced by CCl4.	Dronabinol	29-32	C-C motif chemokine ligand 4	Rattus norvegicus	139-143
2827048-6	1987	The results indicate that THC alters pituitary LH release by inhibiting the release of LHRH which then increases in the MBH by continued synthesis or transport from rostral areas.	Dronabinol	26-29	gonadotropin releasing hormone 1	Rattus norvegicus	87-91
3446768-3	1987	THC suppressed the elevation of plasma transaminase activities and hepatic lipid contents induced by CCl4 in rats when the animals were treated with THC for 4 consecutive days simultaneously with CCl4 administration.	Dronabinol	0-3	C-C motif chemokine ligand 4	Rattus norvegicus	101-105
3446768-3	1987	THC suppressed the elevation of plasma transaminase activities and hepatic lipid contents induced by CCl4 in rats when the animals were treated with THC for 4 consecutive days simultaneously with CCl4 administration.	Dronabinol	0-3	C-C motif chemokine ligand 4	Rattus norvegicus	196-200
3446768-3	1987	THC suppressed the elevation of plasma transaminase activities and hepatic lipid contents induced by CCl4 in rats when the animals were treated with THC for 4 consecutive days simultaneously with CCl4 administration.	Dronabinol	149-152	C-C motif chemokine ligand 4	Rattus norvegicus	101-105
3446768-4	1987	THC also suppressed the elevation of hepatic lipid contents induced by the 4 d-treatment of rats with CCl4 when administered for 4 consecutive days from the next day after treatment with CCl4.	Dronabinol	0-3	C-C motif chemokine ligand 4	Rattus norvegicus	102-106
3446768-4	1987	THC also suppressed the elevation of hepatic lipid contents induced by the 4 d-treatment of rats with CCl4 when administered for 4 consecutive days from the next day after treatment with CCl4.	Dronabinol	0-3	C-C motif chemokine ligand 4	Rattus norvegicus	187-191
3446768-9	1987	These results suggested that THC protected rats against liver injuries induced by CCl4, B.B., GALN and ANIT and had a protective effect on the microsomal membrane against lipid peroxide in vitro.	Dronabinol	29-32	C-C motif chemokine ligand 4	Rattus norvegicus	82-86
2824983-3	1987	Incubation of cerebral cortex slices for 1 hr with concentrations of THC over the range of 0.8-16 microM significantly inhibited the formation of both PGE and PGF by up to 50% of control levels.	Dronabinol	69-72	placental growth factor	Homo sapiens	159-162
2824983-4	1987	Incubation of cortical slices with delta 8-THC, a psychoactive THC congener, resulted in similar dose-dependent inhibitions in both PGE and PGF levels.	Dronabinol	43-46	placental growth factor	Homo sapiens	140-143
2824983-10	1987	In the cerebral cortex, 0.8 microM THC abolished the ACh-induced increase in PGE levels and inhibited the rise in PGF by 70%.	Dronabinol	35-38	placental growth factor	Homo sapiens	114-117
2820552-4	1987	Awake rats exhibited a similar response to THC, however, the CA1 response was less sensitive to THC and there was no change in the maximal response as there was in the anesthetized rat.	Dronabinol	96-99	carbonic anhydrase 1	Rattus norvegicus	61-64
3038580-0	1987	Acute delta 9-tetrahydrocannabinol exposure alters Ca2+ ATPase activity in neuroendocrine and gonadal tissues in mice.	Dronabinol	6-34	carbonic anhydrase 2	Mus musculus	51-62
3038580-1	1987	Acute administration of delta 9-tetrahydrocannabinol (THC) (50 mg/kg) at puberty (35-40 days) significantly (P less than 0.05) reduced Ca2+ ATPase activity in hypothalamic plasma membranes but increased, although not significantly, enzyme activity in hypothalamic tissue obtained from adult mice.	Dronabinol	24-52	dynein, axonemal, heavy chain 8	Mus musculus	140-146
3038580-1	1987	Acute administration of delta 9-tetrahydrocannabinol (THC) (50 mg/kg) at puberty (35-40 days) significantly (P less than 0.05) reduced Ca2+ ATPase activity in hypothalamic plasma membranes but increased, although not significantly, enzyme activity in hypothalamic tissue obtained from adult mice.	Dronabinol	54-57	dynein, axonemal, heavy chain 8	Mus musculus	140-146
3038580-2	1987	In contrast, testicular Ca2+ ATPase activity was increased in pubertal THC-treated males, and significantly reduced in adults.	Dronabinol	71-74	carbonic anhydrase 2	Mus musculus	24-35
3038580-3	1987	Pituitary Ca2+ ATPase activity exhibited a dose-related decrease after acute THC administration at 0.5, 5 or 50 mg/kg, but there were no differential effects of age.	Dronabinol	77-80	dynein, axonemal, heavy chain 8	Mus musculus	15-21
3038580-4	1987	Pituitary plasma membranes obtained from THC-treated males did not respond to in vitro exposure to luteinizing hormone releasing hormone (LHRH, 10(-7) M) with the marked reduction (approximately 40%) in Ca2+ ATPase activity observed in pituitaries from oil-treated controls.	Dronabinol	41-44	carbonic anhydrase 2	Mus musculus	203-214
3038580-5	1987	In addition, effects of THC appear specific for Ca2+ ATPase activity, since Mg2+ ATPase and Na+/K+ ATPase activities were not affected.	Dronabinol	24-27	carbonic anhydrase 2	Mus musculus	48-59
3038580-5	1987	In addition, effects of THC appear specific for Ca2+ ATPase activity, since Mg2+ ATPase and Na+/K+ ATPase activities were not affected.	Dronabinol	24-27	dynein, axonemal, heavy chain 8	Mus musculus	53-59
3038580-6	1987	These findings indicate that acute in vivo administration of THC influences Ca2+ membrane transport, in particular Ca2+ ATPase activity.	Dronabinol	61-64	carbonic anhydrase 2	Mus musculus	115-126
3038580-8	1987	Furthermore, THC exposure modulates pituitary sensitivity to LHRH receptor-mediated effects on Ca2+ ATPase activity.	Dronabinol	13-16	gonadotropin releasing hormone 1	Mus musculus	61-65
3038580-8	1987	Furthermore, THC exposure modulates pituitary sensitivity to LHRH receptor-mediated effects on Ca2+ ATPase activity.	Dronabinol	13-16	carbonic anhydrase 2	Mus musculus	95-106
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	231-234	gonadotropin releasing hormone 1	Mus musculus	17-54
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	231-234	gonadotropin releasing hormone 1	Mus musculus	56-60
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	231-234	gonadotropin releasing hormone 1	Mus musculus	350-354
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	231-234	gonadotropin releasing hormone 1	Mus musculus	350-354
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	265-268	gonadotropin releasing hormone 1	Mus musculus	17-54
3033703-2	1987	The secretion of luteinizing hormone-releasing hormone (LHRH) under basal conditions, and in the presence of norepinephrine (NE; 60 microM), was significantly enhanced in median eminence fragments obtained 1 hr post-treatment with THC (50 mg/kg), while addition of THC (250 ng/ml) to the incubation media enhanced clonidine, as well as NE-stimulated LHRH release, but did not affect basal LHRH release.	Dronabinol	265-268	gonadotropin releasing hormone 1	Mus musculus	56-60
3033703-3	1987	In vitro exposure to THC also enhanced LHRH-stimulated LH release by pituitaries, but did not affect basal secretion rates.	Dronabinol	21-24	gonadotropin releasing hormone 1	Mus musculus	39-43
3033703-4	1987	In vivo THC exposure tended to enhance pituitary responsiveness to LHRH, although this effect was not statistically significant.	Dronabinol	8-11	gonadotropin releasing hormone 1	Mus musculus	67-71
3803591-2	1987	Cannabinoids delta 1-tetrahydrocannabinol, cannabinol, cannabidiol and cannabigerol have been shown to affect directly the activity of phospholipase A2 in a cell-free assay.	Dronabinol	13-41	phospholipase A2 group IB	Homo sapiens	135-151
3018216-0	1986	Tolerance to the luteinizing hormone and prolactin suppressive effects of delta-9-tetrahydrocannabinol develops during chronic prepubertal treatment of female rats.	Dronabinol	74-102	prolactin	Rattus norvegicus	41-50
3018216-2	1986	to block luteinizing hormone (LH) and prolactin (PRL) surges acutely at first proestrus in animals that were treated repetitively with THC before puberty.	Dronabinol	135-138	prolactin	Rattus norvegicus	38-47
3024047-2	1986	Delta-1-tetra-hydrocannabinol (delta 1-THC) and several of its metabolites induced a dose-dependent (0.32-16 microM) stimulation of phospholipase A2 (PLA2) activity resulting in the increased release of free arachidonic acid from exogenous [1-14C]phosphatidylcholine (PC).	Dronabinol	31-42	phospholipase A2, group V	Mus musculus	150-154
3024047-3	1986	The potencies of the cannabinoids in modulating PLA2 activity were approximately of the order: 7-OH-delta 1-THC greater than delta 1-THC greater than 7-oxo-delta 1-THC greater than delta 1-THC-7-oic acid = 6 alpha OH-delta 1-THC much greater than 6 beta-OH-delta 1-THC.	Dronabinol	100-111	phospholipase A2, group V	Mus musculus	48-52
3018361-6	1986	Deuterium-labeled THC (THC-d3) was used as internal standard (IS) and was added to the samples immediately prior to extraction.	Dronabinol	18-21	WASP actin nucleation promoting factor	Homo sapiens	23-29
3013206-8	1986	In homogenized islet preparations, THC inhibited acyl-CoA acyltransferase, while it stimulated phospholipase A2 activity.	Dronabinol	35-38	phospholipase A2 group IB	Rattus norvegicus	95-111
2871232-0	1986	Delta-9-tetrahydrocannabinol stimulates ABP secretion from rat Sertoli cells in vitro.	Dronabinol	0-28	amine oxidase, copper containing 1	Rattus norvegicus	40-43
2871232-2	1986	THC significantly increased ABP secretion by 1.5- to 2.1-fold but did not consistently enhance the stimulation of ABP induced by FSH, testosterone or dibutyryl cyclic AMP.	Dronabinol	0-3	amine oxidase, copper containing 1	Rattus norvegicus	28-31
2871232-4	1986	The minimal concentration of THC that stimulated ABP was 10 ng/ml; maximal stimulation was observed with 100-200 ng/ml.	Dronabinol	29-32	amine oxidase, copper containing 1	Rattus norvegicus	49-52
2871232-6	1986	This observation that THC affects ABP secretion specifically is the first report of any differential effect of a drug on Sertoli cell secretion.	Dronabinol	22-25	amine oxidase, copper containing 1	Rattus norvegicus	34-37
3012058-1	1986	The effects of cannabidiol (CBD) and delta 9-tetrahydrocannabinol (delta 9-THC) on the synthesis and degradation of hepatic microsomal cytochrome P-450 were studied in mice.	Dronabinol	37-65	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	135-151
3012058-1	1986	The effects of cannabidiol (CBD) and delta 9-tetrahydrocannabinol (delta 9-THC) on the synthesis and degradation of hepatic microsomal cytochrome P-450 were studied in mice.	Dronabinol	67-78	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	135-151
2432439-8	1986	In the THC-treated animals, the met-enkephalin and beta-end LI levels were lower in the AHPOA and higher in the MBH.	Dronabinol	7-10	proenkephalin	Rattus norvegicus	36-46
2432439-9	1986	The LHRH levels of THC-treated rats were significantly lower in the MBH.	Dronabinol	19-22	gonadotropin releasing hormone 1	Rattus norvegicus	4-8
3025759-0	1986	Reversal of the delta-9-tetrahydrocannabinol inhibitory effect on prolactin secretion by rostral deafferentation of the medial basal hypothalamus.	Dronabinol	16-44	prolactin	Rattus norvegicus	66-75
3025759-1	1986	The effect of rostral deafferentation of the medial basal hypothalamus (MBH) on delta-9-tetrahydrocannabinol (THC)-induced changes in serum prolactin (PRL) concentrations was investigated in female rats having retrochiasmatic frontal cuts that transected the rostral hypothalamus.	Dronabinol	80-108	prolactin	Rattus norvegicus	140-149
3025759-1	1986	The effect of rostral deafferentation of the medial basal hypothalamus (MBH) on delta-9-tetrahydrocannabinol (THC)-induced changes in serum prolactin (PRL) concentrations was investigated in female rats having retrochiasmatic frontal cuts that transected the rostral hypothalamus.	Dronabinol	80-108	prolactin	Rattus norvegicus	151-154
3025759-1	1986	The effect of rostral deafferentation of the medial basal hypothalamus (MBH) on delta-9-tetrahydrocannabinol (THC)-induced changes in serum prolactin (PRL) concentrations was investigated in female rats having retrochiasmatic frontal cuts that transected the rostral hypothalamus.	Dronabinol	110-113	prolactin	Rattus norvegicus	140-149
3025759-7	1986	When administered to ovariectomized animals without brain lesions, THC suppressed serum PRL concentrations from the average treatment level within 30 min (p less than 0.05), and PRL levels remained suppressed for the remainder of the posttreatment sampling period.	Dronabinol	67-70	prolactin	Rattus norvegicus	88-91
3025759-9	1986	Animals with retrochiasmatic plane cuts that did not transect the rostral hypothalamus similarly displayed PRL suppression in response to THC administration (p less than 0.05).	Dronabinol	138-141	prolactin	Rattus norvegicus	107-110
2995745-7	1985	In the presence of human chorionic gonadotropin (hCG; 12.5 mIU/ml), a lower dose of THC (25 ng/ml), stimulated T production at 0.25 to 1 mM Ca++, but had no effect as Ca++ reached 2.5 mM.	Dronabinol	84-87	hypertrichosis 2 (generalised, congenital)	Homo sapiens	49-52
2995745-9	1985	In contrast, in the presence of hCG, a higher THC dose (25 micrograms/ml), suppressed T accumulation at 0.127, and from 1.0 to 12.7, but had no effect at 0.25 mM, or in the absence of Ca++.	Dronabinol	46-49	hypertrichosis 2 (generalised, congenital)	Homo sapiens	32-35
2995745-10	1985	In the presence of hCG, the high 25 micrograms/ml dose of THC stimulated T production, in the absence of additional Mg++, and at 0.01 mM Mg++, but THC had no effect at 0.1 mM Mg++, but inhibited T production at 1.1 mM Mg++.	Dronabinol	58-61	hypertrichosis 2 (generalised, congenital)	Homo sapiens	19-22
2995745-11	1985	In the presence of hCG, 25 micrograms THC/ml produced a consistent suppression of T production across glucose concentrations examined.	Dronabinol	38-41	hypertrichosis 2 (generalised, congenital)	Homo sapiens	19-22
2995745-13	1985	Differential requirements for these divalent cations by the gonadotropins may explain the interactive effects of THC with LH, hCG or FSH.	Dronabinol	113-116	hypertrichosis 2 (generalised, congenital)	Homo sapiens	126-129
3914916-2	1985	Evidence on the mode of tetrahydrocannabinol action on the central nervous system indicates that acetylcholine turnover in the hippocampus through a GABA-ergic mechanism is of major importance, though the role of the dopaminergic or serotoninergic mechanism and involvement of prostaglandins and c-AMP is not ruled out.	Dronabinol	24-44	cathelicidin antimicrobial peptide	Homo sapiens	296-301
2989518-10	1985	Selected substitutions at C-10 also resulted in analogues that were partially effective in blocking delta 9-THC antinociceptive activity.	Dronabinol	100-111	gene rich cluster, C10 gene	Mus musculus	26-30
6328543-6	1984	The effects of delta 9-THC on the ability of thyrotropin releasing hormone (TRH) to increase serum TSH and T3 were determined.	Dronabinol	15-26	thyrotropin releasing hormone	Rattus norvegicus	45-74
6092266-0	1984	Fluorescence probe, 1-anilino-8-naphthalene sulphonate, as a tool to study interaction of delta 9-tetrahydrocannabinol with bovine serum albumin.	Dronabinol	90-118	albumin	Homo sapiens	131-144
6090910-11	1984	It can be concluded with reasonable confidence that THC alters the secretion of the pituitary reproductive hormones, and that of ACTH as well, through actions in the brain.	Dronabinol	52-55	proopiomelanocortin	Homo sapiens	129-133
6100504-1	1984	The rat experimental model has been utilized to demonstrate pronounced suppressive effects of THC on the secretion of both LH and PRL, a point of considerable interest since the tonic secretions of these two hormones are regulated in opposite fashions, that of LH requiring active stimulation, and that of PRL, continued inhibition.	Dronabinol	94-97	prolactin	Rattus norvegicus	130-133
6100504-1	1984	The rat experimental model has been utilized to demonstrate pronounced suppressive effects of THC on the secretion of both LH and PRL, a point of considerable interest since the tonic secretions of these two hormones are regulated in opposite fashions, that of LH requiring active stimulation, and that of PRL, continued inhibition.	Dronabinol	94-97	prolactin	Rattus norvegicus	306-309
6100504-3	1984	The most direct explanation for this broad inhibitory capability of THC would be direct inhibitory action on the pituitary cells secreting LH and PRL.	Dronabinol	68-71	prolactin	Rattus norvegicus	146-149
6320227-5	1984	Prenatal THC exposure altered the negative feedback effects of exogenous gonadal steroids in castrated adults, with lower plasma T and FSH levels after 20 micrograms T than in castrated controls.	Dronabinol	9-12	follicle stimulating hormone beta	Mus musculus	135-138
6098037-6	1984	Chronic delta 9-THC treatment resulted in an increase in POA and MBH methioine-enkephalin and beta-end LI as well as an increase in plasma beta-end LI.	Dronabinol	8-19	proenkephalin	Rattus norvegicus	79-89
6140904-3	1983	This report describes the effect of three active marijuana components: delta-9-tetrahydrocannabinol (THC), cannabidiol (CD) and cannabinol (CN) on various human Sertoli cell markers: transferrin, protein secretion and gamma glutamyl transpeptidase activity utilizing cultured human Sertoli cells.	Dronabinol	101-104	transferrin	Homo sapiens	183-194
6139760-5	1983	Hypothalamic LHRH levels were significantly elevated 4 h after THC administration as compared to the vehicle-injected controls, but pituitary response to exogenous LHRH was not affected.	Dronabinol	63-66	gonadotropin releasing hormone 1	Rattus norvegicus	13-17
6139760-6	1983	These data suggest that THC inhibits the steroid-induced positive feedback release of LH by reducing NE metabolism and the release of hypothalamic LHRH.	Dronabinol	24-27	gonadotropin releasing hormone 1	Rattus norvegicus	147-151
6309462-3	1983	delta 9-THC is converted by microsomal hydroxylation to 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), which is both a key intermediate for further metabolism to 11-nor-delta 9-THC-9-carboxylic acid (11-nor-acid) by liver alcohol-dehydrogenase enzymes and a potent psychoactive metabolite.	Dronabinol	0-11	aldo-keto reductase family 1 member A1	Homo sapiens	219-240
6311573-5	1983	The prostaglandin synthetase inhibitors acetyl salicylic acid and indomethacin and the phospholipase A2 inhibitor quinacrine all abolished the increase in adenylate cyclase activity produced by delta 9-THC, suggesting the involvement of prostaglandins in this cannabinoid action.	Dronabinol	194-205	phospholipase A2, group IB, pancreas	Mus musculus	87-103
6305469-1	1983	The effects of (-) trans-delta 9-tetrahydrocannabinol (THC) and its metabolite cannabidiol (CBD) were investigated on evoked responses in the CA1 and dentate gyrus regions of the guinea pig transverse hippocampal slice.	Dronabinol	55-58	carbonic anhydrase 1	Cavia porcellus	142-145
6295828-5	1983	This decrease was reversed by the administration of human chorionic gonadotropin (hCG) at 6 hours after THC administration.	Dronabinol	104-107	chorionic gonadotropin subunit beta 5	Homo sapiens	82-85
6298838-5	1983	Administration of THC significantly reduced levels of gonadotropins, PRL and GH in intact males.	Dronabinol	18-21	growth hormone	Mus musculus	77-79
6312620-0	1983	Effect of an acute dose of delta 9-THC on hypothalamic luteinizing hormone releasing hormone and met-enkephalin content and serum levels of testosterone and corticosterone in rats.	Dronabinol	27-38	proenkephalin	Rattus norvegicus	101-111
6312620-2	1983	In delta 9-THC treated ovariectomized rats, the mediobasal hypothalamic (MBH) LHRH and methionine-enkephalin (met-enk) contents were high compared to either vehicle or naloxone groups.	Dronabinol	3-14	gonadotropin releasing hormone 1	Rattus norvegicus	78-82
6312620-2	1983	In delta 9-THC treated ovariectomized rats, the mediobasal hypothalamic (MBH) LHRH and methionine-enkephalin (met-enk) contents were high compared to either vehicle or naloxone groups.	Dronabinol	3-14	proenkephalin	Rattus norvegicus	98-108
6312620-2	1983	In delta 9-THC treated ovariectomized rats, the mediobasal hypothalamic (MBH) LHRH and methionine-enkephalin (met-enk) contents were high compared to either vehicle or naloxone groups.	Dronabinol	3-14	proenkephalin	Rattus norvegicus	98-101
6312620-4	1983	This suggests that LHRH release from the MBH, which is normally accelerated by ovariectomy, is blocked by delta 9-THC and this inhibitory effect of delta 9-THC on LHRH release is reversed by naloxone, suggesting an involvement of endogenous opiate system.	Dronabinol	106-117	gonadotropin releasing hormone 1	Rattus norvegicus	19-23
6312620-4	1983	This suggests that LHRH release from the MBH, which is normally accelerated by ovariectomy, is blocked by delta 9-THC and this inhibitory effect of delta 9-THC on LHRH release is reversed by naloxone, suggesting an involvement of endogenous opiate system.	Dronabinol	148-159	gonadotropin releasing hormone 1	Rattus norvegicus	19-23
6312620-4	1983	This suggests that LHRH release from the MBH, which is normally accelerated by ovariectomy, is blocked by delta 9-THC and this inhibitory effect of delta 9-THC on LHRH release is reversed by naloxone, suggesting an involvement of endogenous opiate system.	Dronabinol	148-159	gonadotropin releasing hormone 1	Rattus norvegicus	163-167
6312620-6	1983	The delta 9-THC decreased immunoassayable LHRH in anterior hypothalamus preoptic area (AHPOA) and MBH in a dose-related manner.	Dronabinol	4-15	gonadotropin releasing hormone 1	Rattus norvegicus	42-46
6312620-9	1983	The results of this study suggest that delta 9-THC may decrease biosynthesis and/or release of LHRH by partly interacting with the endogenous opiate system.	Dronabinol	39-50	gonadotropin releasing hormone 1	Rattus norvegicus	95-99
6322367-0	1983	Naloxone blocks the effects of delta 9-tetrahydrocannabinol on serum luteinizing hormone and prolactin in rats.	Dronabinol	31-59	prolactin	Rattus norvegicus	93-102
6322367-6	1983	Naloxone enhanced the EBP-induced hypersecretion of LH by 2-fold while delta 9-THC completely blocked the EBP-induced secretion of LH.	Dronabinol	71-82	EBP, cholestenol delta-isomerase	Rattus norvegicus	106-109
6322367-7	1983	delta 9-THC slightly diminished the stimulatory effect of Nal on LH secretion and caused a 2-fold increase in serum Prl concentrations, while Nal did not influence the serum PRL levels in these EBP rats.	Dronabinol	0-11	prolactin	Rattus norvegicus	116-119
6322367-8	1983	However, Nal did block the stimulatory effects of delta 9-THC on Prl secretion.	Dronabinol	50-61	prolactin	Rattus norvegicus	65-68
6322367-9	1983	delta 9-THC caused a significant increase in MBH content of LHRH, an effect which was prevented by Nal.	Dronabinol	0-11	gonadotropin releasing hormone 1	Rattus norvegicus	60-64
6284318-2	1982	Using a wide range of doses (1 pM-10 nM), it was found that mid-range concentrations of estradiol (100 pM) and THC (10 pM) tended to increase field potentials in CA1 of rodents.	Dronabinol	111-114	carbonic anhydrase 1	Homo sapiens	162-165
6279040-5	1982	Delta-9-tetrahydrocannabinol may inhibit the release of luteinizing hormone releasing hormone (LHRH).	Dronabinol	0-28	gonadotropin releasing hormone 1	Rattus norvegicus	56-93
6279250-0	1982	Changes in hippocampal CA1 population spikes following administration of delta-9-THC.	Dronabinol	73-84	carbonic anhydrase 1	Rattus norvegicus	23-26
6279250-1	1982	The effects of delta-9-tetrahydrocannabinol (delta-9-THC) on monosynaptic population responses in hippocampal CA1 pyramidal cells were examined in acute rats for several doses and at several post injection time periods.	Dronabinol	15-43	carbonic anhydrase 1	Rattus norvegicus	110-113
6279250-1	1982	The effects of delta-9-tetrahydrocannabinol (delta-9-THC) on monosynaptic population responses in hippocampal CA1 pyramidal cells were examined in acute rats for several doses and at several post injection time periods.	Dronabinol	45-56	carbonic anhydrase 1	Rattus norvegicus	110-113
6280729-3	1982	The study indicates that delta 9-THC reduces the activities of the enzymes, beta-glucuronidase, alpha-glucosidase acid phosphatase and fructose-6-phosphatase in a dose related manner in the testis, prostate as well as in the epididymis.	Dronabinol	25-36	glucuronidase beta	Homo sapiens	76-94
6284475-0	1982	Effects of (-)-trans- delta 9-tetrahydrocannabinol on serum prolactin in the pseudopregnant rat.	Dronabinol	11-50	prolactin	Rattus norvegicus	60-69
6284475-1	1982	Groups of pseudopregnant rats were injected intravenously with (-)-trans- delta 9-tetrahydrocannabinol (THC) to determine its effects on serum prolactin (PRL) and the maintenance of pseudopregnancy.	Dronabinol	63-102	prolactin	Rattus norvegicus	143-152
6284475-1	1982	Groups of pseudopregnant rats were injected intravenously with (-)-trans- delta 9-tetrahydrocannabinol (THC) to determine its effects on serum prolactin (PRL) and the maintenance of pseudopregnancy.	Dronabinol	63-102	prolactin	Rattus norvegicus	154-157
6284475-2	1982	A single injection of 4 mg THC/kg BW at 2400 h on the first day of leukocytic vaginal smears of pseudopregnancy (D-1) delayed the ensuing nocturnal PRL surge for approximately one hour.	Dronabinol	27-30	prolactin	Rattus norvegicus	148-151
6284475-3	1982	When THC (1.0 mg/kg BW) was administered hourly from 2400 h on D-1 through 1700 h on D-2, the nocturnal surge was blocked and serum PRL levels were suppressed until 0600 h on D-2, but not thereafter.	Dronabinol	5-8	prolactin	Rattus norvegicus	132-135
6284475-5	1982	These results indicate that the nocturnal surge secretion of PRL during early pseudopregnancy in the rat is sensitive to THC suppression, but that this suppression is not adequate to influence the duration of pseudopregnancy.	Dronabinol	121-124	prolactin	Rattus norvegicus	61-64
6274514-0	1981	O-and C-D-glucosyluronic acid derivatives of delta 1-tetrahydrocannabinol: synthesis and differential behavior to beta-glucuronidase.	Dronabinol	45-73	glucuronidase beta	Homo sapiens	114-132
6273940-6	1981	This THC effect was slightly increased by physostigmine, a cholinesterase inhibitor, relatively unaffected by scopolamine, a muscarinic antagonist, and almost completely blocked by ethopropazine, an anticholinergic antiparkinson drug.	Dronabinol	5-8	butyrylcholinesterase	Rattus norvegicus	59-73
6266813-0	1981	Delta 9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect.	Dronabinol	0-28	prolactin	Rattus norvegicus	44-53
6271817-4	1981	THC will be made available to hospital pharmacies which are: (1) an NCI recognized Cancer Center (P-30 grant supported), (2) an NCI designated New Drug Study Group, (3) a member of the Council of Teaching Hospitals.	Dronabinol	0-3	centromere protein V	Homo sapiens	98-102
6271829-3	1981	The release reaction could be antagonized by phospholipase A2 inhibitors such as quinacrine and quinine, suggesting that THC can stimulate the activity of this enzyme.	Dronabinol	121-124	phospholipase A2 group IB	Homo sapiens	45-61
6271847-1	1981	We studied the effect of THC upon the pharmacokinetics of cyclophosphamide (CTX) and doxorubicin (ADR).	Dronabinol	25-28	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	76-79
6273937-4	1981	Exposure to a much lower dose of THC (0.5 mg/kg) did augment the LRF-induced increases in plasma T levels suggesting a possible synergism between gonadotropins and THC on androgen production.	Dronabinol	33-36	CREB3 regulatory factor	Mus musculus	65-68
6273937-4	1981	Exposure to a much lower dose of THC (0.5 mg/kg) did augment the LRF-induced increases in plasma T levels suggesting a possible synergism between gonadotropins and THC on androgen production.	Dronabinol	164-167	CREB3 regulatory factor	Mus musculus	65-68
6258926-1	1980	The influence of thyrotropin releasing hormone (TRH) and its postulated metabolite histidyl-proline diketopiperazine (HPD) on sedation and analgesia produced by delta 9-tetrahydrocannabinol (THC) was investigated in mice.	Dronabinol	161-189	thyrotropin releasing hormone	Mus musculus	48-51
6258926-6	1980	Pretreatment with TRH or HPD also antagonized the THC-induced analgesia.	Dronabinol	50-53	thyrotropin releasing hormone	Mus musculus	18-21
6258926-9	1980	These studies indicate that TRH and HPD can antagonize THC-induced sedation and analgesia and that HPD may be an active metabolite of TRH.	Dronabinol	55-58	thyrotropin releasing hormone	Mus musculus	28-31
6258926-11	1980	Finally THC induced analgesia does not seem to involve opiate receptors and their involvement in the mechanism by which TRH or HPD antagonize THC-induced analgesia is unlikely.	Dronabinol	142-145	thyrotropin releasing hormone	Mus musculus	120-123
7420350-3	1980	(b) Two groups of THC-type cannabinoids which differ only in that the chemical groupings in one of them at C-1, C-2 are situated at C-1, C-6 in the other (but retain their stereochemistry) have almost equivalent psychotropic activity.	Dronabinol	18-21	complement C2	Macaca mulatta	112-115
7420350-3	1980	(b) Two groups of THC-type cannabinoids which differ only in that the chemical groupings in one of them at C-1, C-2 are situated at C-1, C-6 in the other (but retain their stereochemistry) have almost equivalent psychotropic activity.	Dronabinol	18-21	complement C6	Macaca mulatta	132-140
6249575-1	1980	Marihuana and its constitutents delta 9-tetrahydrocannabinol (delta 9-THC) and cannabinol (CBN) were tested for their ability to interact with the androgen receptor in rat prostate cytosol.	Dronabinol	32-60	androgen receptor	Rattus norvegicus	147-164
6249575-1	1980	Marihuana and its constitutents delta 9-tetrahydrocannabinol (delta 9-THC) and cannabinol (CBN) were tested for their ability to interact with the androgen receptor in rat prostate cytosol.	Dronabinol	62-73	androgen receptor	Rattus norvegicus	147-164
6249575-2	1980	Smoked marihuana condensate, delta 9-THC, and CBN inhibit specific binding of dihydrotestosterone (DHT) to the androgen receptor with a dissociatin constant of the inhibitors (Li) of 2.1-5.8 X 10(-7)M. in addition, other metabolites of delta 9-THC were also androgen antagonists.	Dronabinol	29-40	androgen receptor	Rattus norvegicus	111-128
6249575-2	1980	Smoked marihuana condensate, delta 9-THC, and CBN inhibit specific binding of dihydrotestosterone (DHT) to the androgen receptor with a dissociatin constant of the inhibitors (Li) of 2.1-5.8 X 10(-7)M. in addition, other metabolites of delta 9-THC were also androgen antagonists.	Dronabinol	236-247	androgen receptor	Rattus norvegicus	111-128
6251493-1	1980	delta 9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) caused a marked stimulation of phospholipase A2 when incubated with intact human platelets that were prelabeled with [14C] arachidonate.	Dronabinol	0-28	phospholipase A2 group IB	Homo sapiens	88-104
6251493-1	1980	delta 9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) caused a marked stimulation of phospholipase A2 when incubated with intact human platelets that were prelabeled with [14C] arachidonate.	Dronabinol	30-33	phospholipase A2 group IB	Homo sapiens	88-104
6251493-7	1980	The multiple effects of THC and CBD on phospholipase A2 and arachidonate metabolism may mediate some of the pharmacological actions of these compounds, such as their anticonvulsant, anti-inflammatory, and hypotensive properties.	Dronabinol	24-27	phospholipase A2 group IB	Homo sapiens	39-55
6243536-1	1980	Adult mice were actively immunized with delta 9-tetrahydrocannabinol-bovine serum albumin (delta 9-THC-BSA) conjugate.	Dronabinol	40-68	albumin	Mus musculus	76-106
6247150-0	1980	The nature of the inhibition of cholesterol esterase by delta 1-tetrahydrocannabinol.	Dronabinol	56-84	carboxyl ester lipase	Homo sapiens	32-52
115723-0	1979	Acute decreases in serum prolactin concentrations caused by delta 9-tetrahydrocannabinol in nonhuman primates.	Dronabinol	60-88	prolactin	Macaca mulatta	25-34
115723-1	1979	The acute effects of single injections of delta 9-tetrahydrocannabinol (THC) on serum prolactin (PRL) concentrations were studied in oophorectomized female and intact adult male rhesus monkeys.	Dronabinol	42-70	prolactin	Macaca mulatta	86-95
115723-1	1979	The acute effects of single injections of delta 9-tetrahydrocannabinol (THC) on serum prolactin (PRL) concentrations were studied in oophorectomized female and intact adult male rhesus monkeys.	Dronabinol	42-70	prolactin	Macaca mulatta	97-100
115723-1	1979	The acute effects of single injections of delta 9-tetrahydrocannabinol (THC) on serum prolactin (PRL) concentrations were studied in oophorectomized female and intact adult male rhesus monkeys.	Dronabinol	72-75	prolactin	Macaca mulatta	86-95
115723-1	1979	The acute effects of single injections of delta 9-tetrahydrocannabinol (THC) on serum prolactin (PRL) concentrations were studied in oophorectomized female and intact adult male rhesus monkeys.	Dronabinol	72-75	prolactin	Macaca mulatta	97-100
115723-3	1979	THC markedly suppresses serum PRL concentrations in animals of both sexes.	Dronabinol	0-3	prolactin	Macaca mulatta	30-33
115723-5	1979	These results suggest that the serum prolactin-lowering effect of THC occurs principally at a suprapituitary level.	Dronabinol	66-69	prolactin	Macaca mulatta	37-46
116333-1	1979	Delta 9-THC and 11-OH-delta 9-THC appear to in vivo affect the metabolism of both Type I and Type II substrates involving cytochrome P-450 as well as to affect the metabolism of a substrate requiring cytochrome P-448.	Dronabinol	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
747459-0	1978	The inhibitory effect induced by delta9-tetrahydrocannabinol on the contractions of the isolated rat vas deferens.	Dronabinol	33-60	arginine vasopressin	Rattus norvegicus	101-104
699971-4	1978	Prolactin rose to a peak level in plasma earlier in lactation in the control mice than in the delta1-THC-treated mice.	Dronabinol	101-104	prolactin	Mus musculus	0-9
699971-5	1978	This delayed rise in plasma prolactin due to delta1-THC may account for the depression of mammary gland growth and development by the drug and for the delay in the appearance of high activities of lipoprotein lipase until later in lactation.	Dronabinol	45-55	prolactin	Mus musculus	28-37
744093-1	1978	(-) delta-9-Tetrahydrocannabinol (THC) was previously shown to suppress serum PRL levels (SPL) in rats.	Dronabinol	4-32	prolactin	Rattus norvegicus	78-81
744093-1	1978	(-) delta-9-Tetrahydrocannabinol (THC) was previously shown to suppress serum PRL levels (SPL) in rats.	Dronabinol	34-37	prolactin	Rattus norvegicus	78-81
744093-2	1978	In the present study, various pathways by which THC suppresses PRL secretion were investigated.	Dronabinol	48-51	prolactin	Rattus norvegicus	63-66
744093-5	1978	These results suggest on involvement of a serotonergic pathway in the suppressive effect of THC on PRL secretion.	Dronabinol	92-95	prolactin	Rattus norvegicus	99-102
744093-8	1978	It seems that THC also enhances the dopaminergic activity in the pathway that controls PRL secretion.	Dronabinol	14-17	prolactin	Rattus norvegicus	87-90
693562-2	1978	One possible mechanism by which delta9-THC could have its effect is by affecting acetylcholinesterase (AChE) and there is evidence that has suggested that this may be an important mechanism.	Dronabinol	32-42	acetylcholinesterase (Cartwright blood group)	Homo sapiens	81-101
693562-2	1978	One possible mechanism by which delta9-THC could have its effect is by affecting acetylcholinesterase (AChE) and there is evidence that has suggested that this may be an important mechanism.	Dronabinol	32-42	acetylcholinesterase (Cartwright blood group)	Homo sapiens	103-107
637098-3	1978	Thc serum insulin level increased first and reached a peak at 10 minutes, before the rise in plasma glucose, which reached a maximum at 30 minutes, suggesting that beta 2-receptor stimulation affects insulin secretion directly and not via a rise in the glucose level.	Dronabinol	0-3	insulin	Homo sapiens	10-17
637098-3	1978	Thc serum insulin level increased first and reached a peak at 10 minutes, before the rise in plasma glucose, which reached a maximum at 30 minutes, suggesting that beta 2-receptor stimulation affects insulin secretion directly and not via a rise in the glucose level.	Dronabinol	0-3	insulin	Homo sapiens	200-207
252923-3	1978	These effects are probably attributable to complex reciprocal action between the active constituents of the resin, particularly THC, and the metabolisms of the cerebral monoamines and c-AMP.	Dronabinol	128-131	cathelicidin antimicrobial peptide	Rattus norvegicus	184-189
637625-1	1978	Rats pretreated daily with delta9-tetrahydrocannabinol (delta9-THC, 8 mg/kg) during 14 days showed tolerance to THC-induced hypothermia and depression of CAR acquisition in a shuttle-box.	Dronabinol	27-54	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	154-157
637625-1	1978	Rats pretreated daily with delta9-tetrahydrocannabinol (delta9-THC, 8 mg/kg) during 14 days showed tolerance to THC-induced hypothermia and depression of CAR acquisition in a shuttle-box.	Dronabinol	56-66	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	154-157
637625-1	1978	Rats pretreated daily with delta9-tetrahydrocannabinol (delta9-THC, 8 mg/kg) during 14 days showed tolerance to THC-induced hypothermia and depression of CAR acquisition in a shuttle-box.	Dronabinol	63-66	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	154-157
752632-1	1978	To study effects of delta-9-tetrahydrocannabinol (THC) on the regulation of prolactin (PRL) release, a chronic cannula was placed in the right atrium of postpartum lactating rats.	Dronabinol	50-53	prolactin	Rattus norvegicus	87-90
752632-6	1978	Relative to vehicle-injected controls, both doses of THC significantly reduced plasma PRL levels and disrupted all components of maternal behavior.	Dronabinol	53-56	prolactin	Rattus norvegicus	86-89
752632-7	1978	These findings indicate that THC inhibits suckling-induced PRL release in the postpartum rat.	Dronabinol	29-32	prolactin	Rattus norvegicus	59-62
22740-1	1978	The biphasic degradation of delta9-tetrahydrocannabinol (I), as monitored by flame-ionization GLC, produced delta8-tetrahydrocannabinol (II), cannabidiol (X), 9-hydroxyhexahydrocannabinol (VI), 9,10-dihydro-9-hydroxyisocannabidiol (VI), and and 6,12-dihydro-6-hydroxycannabidiol (VIII) in acidic solutions.	Dronabinol	28-55	cytochrome c oxidase subunit 8A	Homo sapiens	280-284
201449-1	1977	ACTH, cholera toxin, cyclic AMP but not pregnenolone-induced steroidogenesis in Y-1 functional mouse adrenal tumor cells was significantly inhibited by delta-9-tetrahydrocannabinol, cannabidiol, and cannabinol.	Dronabinol	152-180	pro-opiomelanocortin-alpha	Mus musculus	0-4
890504-0	1977	delta9-tetrahydrocannabinol and the hippocampus: effects on CA1 field potentials in rats.	Dronabinol	0-27	carbonic anhydrase 1	Rattus norvegicus	60-63
890504-1	1977	The effects of delta9-tetrahydrocannabinol (THC) on ortho- and antidromically elicited CA1 field potentials were observed in locally anesthetized rats and in anesthetized with urethane.	Dronabinol	15-42	carbonic anhydrase 1	Rattus norvegicus	87-90
890504-1	1977	The effects of delta9-tetrahydrocannabinol (THC) on ortho- and antidromically elicited CA1 field potentials were observed in locally anesthetized rats and in anesthetized with urethane.	Dronabinol	44-47	carbonic anhydrase 1	Rattus norvegicus	87-90
17525-3	1977	Acute administration of THC or CBD, 10 mg/kg, evoked no detectable changes in cytochrome P-450 levels, but a significant decrease in those of cytochrome b5.	Dronabinol	24-27	cytochrome b5 type A	Rattus norvegicus	142-155
17525-4	1977	Chronic administration of THC or CBD, 2 mg/kg, decreased levels of cytochrome P-450, whereas cytochrome b5 levels appeared normal.	Dronabinol	26-29	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-83
558623-2	1977	A corresponding reduction in potency was seen for the impairing effect of delta9-THC on performance of a conditioned avoidance response (CAR).	Dronabinol	74-84	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	137-140
558623-6	1977	When tested 2 hr after oral administration, delta9-THC caused significantly greater impairment of CAR performance in fed than fasted rats, whereas the opposite was found after 8 hr.	Dronabinol	44-54	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	98-101
331132-1	1977	Administration of delta1-tetrahydrocannabinol (delta1-THC), the principal psychoactive ingredient of cannabis, to proestrous rats (2 mg/rat, i.p., between 12.00 and 16.00 h) suppressed the proestrous rise in the plasma levels of LH, FSH and prolactin (Prl) and caused a 24 h delay in ovulation.	Dronabinol	18-45	prolactin	Rattus norvegicus	241-250
331132-1	1977	Administration of delta1-tetrahydrocannabinol (delta1-THC), the principal psychoactive ingredient of cannabis, to proestrous rats (2 mg/rat, i.p., between 12.00 and 16.00 h) suppressed the proestrous rise in the plasma levels of LH, FSH and prolactin (Prl) and caused a 24 h delay in ovulation.	Dronabinol	47-57	prolactin	Rattus norvegicus	241-250
954827-2	1976	administration of delta9-THC (2.5 mg/kg) To anesthetized dogs resulted in a decrease in heart rate, pulmonary blood flow (PBF), and a significant increase in pulmonary artery pressure (PAP) and total pulmonary vascular resistance (PVR).	Dronabinol	18-28	PVR cell adhesion molecule	Canis lupus familiaris	231-234
954827-3	1976	The increase in PVR to delta9-THC was significantly reduced by cardiac pacing, and was virtually abolished either by bilateral vagotomy or by pretreatment with hexamethonium.	Dronabinol	23-33	PVR cell adhesion molecule	Canis lupus familiaris	16-19
954827-4	1976	The data indicated the delta9-THC induced elevation of PVR was mediated via reflexogenic mechanisms involving afferent vagi and efferent autonomic pathways.	Dronabinol	23-33	PVR cell adhesion molecule	Canis lupus familiaris	55-58
1084269-1	1976	Acute intraperitoneal administration of delta-9-THC (at doses of 10 mg/kg and 50 mg/kg) to adult male albino rats showed characteristic stimulating effect on adrenocortical tissues with marked depletion of ascorbic acid, cholesterol containing neutral lipids and significant increase in the delta5-3 beta -hydroxysteroid dehydrogenase and glucose-6-phosphate dehydrogenase activities in the zona fasciculata and zona reticularis regions.	Dronabinol	40-51	glucose-6-phosphate dehydrogenase	Rattus norvegicus	339-372
1084269-3	1976	Chronic intraperitoneal administration of delta-9-THC (at doses of 10 mg/kg per day for 15 days) produced marked accumulation of cholesterol containing neutral lipids, with increase in ascorbic acid and delta5-3 beta-hydroxysteroid dehydrogenase and glucose 6-phosphate dehydrogenase activities in the fasciculata-reticularis regions.	Dronabinol	42-53	glucose-6-phosphate dehydrogenase	Rattus norvegicus	250-283
1270583-0	1976	Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man.	Dronabinol	104-132	growth hormone 1	Homo sapiens	14-28
1270583-2	1976	A diminished maximal serum human growth hormone (GH) increase followed the prolonged THC ingestion.	Dronabinol	85-88	growth hormone 1	Homo sapiens	49-51
1270583-3	1976	The mean maximal GH response was: 52.6 ng/ml +/- 8.7 (+/-SE) before THC and 18.8 ng/ml +/- 6.7 (+/-SE) during THC, P less than 0.01; corresponding cortisol responses were 20.1 mug/dl +/- 3.0 before THC and 10.0 mug/dl +/- 1.1 during THC, P less than 0.05.	Dronabinol	68-71	growth hormone 1	Homo sapiens	17-19
1270583-3	1976	The mean maximal GH response was: 52.6 ng/ml +/- 8.7 (+/-SE) before THC and 18.8 ng/ml +/- 6.7 (+/-SE) during THC, P less than 0.01; corresponding cortisol responses were 20.1 mug/dl +/- 3.0 before THC and 10.0 mug/dl +/- 1.1 during THC, P less than 0.05.	Dronabinol	110-113	growth hormone 1	Homo sapiens	17-19
1270583-3	1976	The mean maximal GH response was: 52.6 ng/ml +/- 8.7 (+/-SE) before THC and 18.8 ng/ml +/- 6.7 (+/-SE) during THC, P less than 0.01; corresponding cortisol responses were 20.1 mug/dl +/- 3.0 before THC and 10.0 mug/dl +/- 1.1 during THC, P less than 0.05.	Dronabinol	110-113	growth hormone 1	Homo sapiens	17-19
1270583-3	1976	The mean maximal GH response was: 52.6 ng/ml +/- 8.7 (+/-SE) before THC and 18.8 ng/ml +/- 6.7 (+/-SE) during THC, P less than 0.01; corresponding cortisol responses were 20.1 mug/dl +/- 3.0 before THC and 10.0 mug/dl +/- 1.1 during THC, P less than 0.05.	Dronabinol	110-113	growth hormone 1	Homo sapiens	17-19
126628-3	1975	Acute delta9-THC treatment reduced the total catecholamine content (including noradrenaline) of the gland, was accompanied by increased ATP-ase, AChE, BChE activities and increased calcium distribution in the gland.	Dronabinol	6-16	butyrylcholinesterase	Rattus norvegicus	151-155
1237419-0	1975	Effect of acute delta9-tetrahydrocannabinol treatment on serum luteinizing hormone and prolactin levels in adult female rats.	Dronabinol	16-43	prolactin	Rattus norvegicus	87-96
1091392-1	1975	To investigate the hypothesis that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of marihuana, acts by interfering with cholinergic brain mechanisms, 0.75 to 1.25 mg of physostigmine, a centrally active cholinergic drug, was given intravenously to 5 normal volunteers who had ingested 20 to 40 mg of THC 2 hours earlier.	Dronabinol	35-63	ankyrin repeat domain containing 26	Homo sapiens	324-329
1091392-1	1975	To investigate the hypothesis that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of marihuana, acts by interfering with cholinergic brain mechanisms, 0.75 to 1.25 mg of physostigmine, a centrally active cholinergic drug, was given intravenously to 5 normal volunteers who had ingested 20 to 40 mg of THC 2 hours earlier.	Dronabinol	65-68	ankyrin repeat domain containing 26	Homo sapiens	324-329
4443705-0	1974	Increase of serum prolactin in male rats by (minus)-trans-delta9-tetrahydrocannabinol.	Dronabinol	51-85	prolactin	Rattus norvegicus	18-27
4140529-0	1974	Suppression of prolactin secretion by acute administration of delta9-THC in rats.	Dronabinol	62-72	prolactin	Rattus norvegicus	15-24
4451818-0	1974	The effect of delta1-tetrahydrocannabinol on the release of (3H-(-)-noradrenaline from the isolated vas deferens of the rat.	Dronabinol	14-41	arginine vasopressin	Rattus norvegicus	100-103
4793331-6	1973	An injection of 1 mg/kg Delta(9)-THC intravenously into rats 3 h after an intraperitoneal injection of reserpine accentuated the reserpine hypothermia as well as the reduction of 5-HT but not of NA in the brain.5.	Dronabinol	24-36	POU class 6 homeobox 1	Rattus norvegicus	205-212
4350929-1	1973	Serum dopamine beta-hydroxylase activity, a useful biochemical index of peripheral sympathetic nervous activity, was measured in rats treated with Delta(9)-tetrahydrocannabinol or ethanol or both substances.	Dronabinol	147-176	dopamine beta-hydroxylase	Rattus norvegicus	6-31
33861997-0	2021	Cocaine-Induced Fos Expression in the Rat Brain: Modulation by Prior Delta9-Tetrahydrocannabinol Exposure During Adolescence and Sex-Specific Effects.	Dronabinol	69-96	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	16-19
32815089-2	2021	This study aimed to investigate the apoptotic effects of THC via mechanisms related to p53 and AKT signaling pathways on Sertoli cells and seminiferous germinal cells, as well as the possible protective role of selenium pretreatment in both in vitro and in vivo models.	Dronabinol	57-60	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	87-90
32815089-2	2021	This study aimed to investigate the apoptotic effects of THC via mechanisms related to p53 and AKT signaling pathways on Sertoli cells and seminiferous germinal cells, as well as the possible protective role of selenium pretreatment in both in vitro and in vivo models.	Dronabinol	57-60	AKT serine/threonine kinase 1	Rattus norvegicus	95-98
32815089-8	2021	The results of the in vitro study revealed that THC significantly decreases the cell viability (p < 0.001) and expression of the p-AKt protein (p < 0.05) and increases Sertoli cells" apoptosis (p < 0.001) and p53 protein expression (p < 0.001).	Dronabinol	48-51	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	209-212
33368252-0	2021	Acute Delta9-tetrahydrocannabinol prompts rapid changes in cannabinoid CB1 receptor immunolabeling and subcellular structure in CA1 hippocampus of young adult male mice.	Dronabinol	6-33	cannabinoid receptor 1 (brain)	Mus musculus	71-74
33368252-2	2021	Here we use electron microscopy and a highly sensitive pre-embedding immunogold method to examine CB1 receptors in the hippocampus cornu ammonis subfield 1 (CA1) 30 min after male mice were exposed to a single THC injection (5 mg/kg).	Dronabinol	210-213	cannabinoid receptor 1 (brain)	Mus musculus	98-101
33368252-3	2021	The findings show that acute exposure to THC can significantly decrease the percentage of CB1 receptor immunopositive terminals making symmetric synapses, mitochondria and astrocytes.	Dronabinol	41-44	cannabinoid receptor 1 (brain)	Mus musculus	90-93
33368252-8	2021	Altogether, these results indicate that even a single THC exposure can have a significant impact on CB1 receptor expression, and can alter CA1 ultrastructure, within 30 min of drug exposure.	Dronabinol	54-57	cannabinoid receptor 1 (brain)	Mus musculus	100-103
33725642-0	2021	Destabilization of the Alzheimer"s amyloid-beta protofibrils by THC: A molecular dynamics simulation study.	Dronabinol	64-67	amyloid beta precursor protein	Homo sapiens	35-47
33725642-5	2021	In our present study, by employing all atom molecular dynamics simulations, we have investigated the mechanism of the interaction of the THC molecules with the amyloid-beta protofibrils.	Dronabinol	137-140	amyloid beta precursor protein	Homo sapiens	160-172
33722705-5	2021	Considering this, our work aims to clarify the molecular mechanisms underlying the anti-cancer properties of the endocannabinoid anandamide (AEA) and of the phytocannabinoids, cannabidiol (CBD) and Delta9-tetrahydrocannabinol (THC), in estrogen receptor-positive (ER+) breast cancer cells that overexpress aromatase (MCF-7aro).	Dronabinol	198-225	estrogen receptor 1	Homo sapiens	236-253
33722705-5	2021	Considering this, our work aims to clarify the molecular mechanisms underlying the anti-cancer properties of the endocannabinoid anandamide (AEA) and of the phytocannabinoids, cannabidiol (CBD) and Delta9-tetrahydrocannabinol (THC), in estrogen receptor-positive (ER+) breast cancer cells that overexpress aromatase (MCF-7aro).	Dronabinol	198-225	epiregulin	Homo sapiens	264-266
34007062-7	2022	The nuclear translocation of STAT1 played important roles in Delta9-THC-induced angiogenesis and tumor progression.	Dronabinol	61-71	signal transducer and activator of transcription 1	Homo sapiens	29-34
34007062-8	2022	Pharmacological treatment with STAT1 antagonist or abrogation of STAT1 with CRISPR/Cas9-based strategy rescued those effects of Delta9-THC in CRC.	Dronabinol	128-138	signal transducer and activator of transcription 1	Homo sapiens	31-36
34007062-8	2022	Pharmacological treatment with STAT1 antagonist or abrogation of STAT1 with CRISPR/Cas9-based strategy rescued those effects of Delta9-THC in CRC.	Dronabinol	128-138	signal transducer and activator of transcription 1	Homo sapiens	65-70
33970442-7	2021	THC indirectly decreases gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus.	Dronabinol	0-3	gonadotropin releasing hormone 1	Homo sapiens	25-55
33970442-7	2021	THC indirectly decreases gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus.	Dronabinol	0-3	gonadotropin releasing hormone 1	Homo sapiens	57-61
33965396-9	2021	Systemic Delta9-THC also prompted impulsive cocaine seeking in a Go/NoGo cocaine self-administration task and this was blocked by intra-LHb AM251.	Dronabinol	9-19	reticulon 4	Homo sapiens	68-72
33021007-3	2021	As did acute cocaine, amphetamine, or Delta9 -tetrahydrocannabinol (THC) pretreatments, an acute 1-h wheel-running session increased the AMPAR/NMDAR ratio in VTA dopaminergic neurones.	Dronabinol	38-66	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	143-148
33021007-3	2021	As did acute cocaine, amphetamine, or Delta9 -tetrahydrocannabinol (THC) pretreatments, an acute 1-h wheel-running session increased the AMPAR/NMDAR ratio in VTA dopaminergic neurones.	Dronabinol	68-71	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	143-148
34026562-0	2021	Possible roles of AMPK and macropinocytosis in the defense responses against Delta9-THC toxicity on HL-1 cardiomyocytes.	Dronabinol	77-87	asialoglycoprotein receptor 1	Mus musculus	100-104
34026562-5	2021	Transcriptome analysis showed upregulation of the genes involved in the unfolded protein response (UPR), including Bip, CHOP, ATF4 and ATF6, in cells treated with Delta9-THC.	Dronabinol	163-173	heat shock protein 5	Mus musculus	115-118
34026562-5	2021	Transcriptome analysis showed upregulation of the genes involved in the unfolded protein response (UPR), including Bip, CHOP, ATF4 and ATF6, in cells treated with Delta9-THC.	Dronabinol	163-173	DNA-damage inducible transcript 3	Mus musculus	120-124
34026562-5	2021	Transcriptome analysis showed upregulation of the genes involved in the unfolded protein response (UPR), including Bip, CHOP, ATF4 and ATF6, in cells treated with Delta9-THC.	Dronabinol	163-173	activating transcription factor 4	Mus musculus	126-130
34026562-5	2021	Transcriptome analysis showed upregulation of the genes involved in the unfolded protein response (UPR), including Bip, CHOP, ATF4 and ATF6, in cells treated with Delta9-THC.	Dronabinol	163-173	activating transcription factor 6	Mus musculus	135-139
34026562-6	2021	Immunoblot analysis showed caspase3 activation, indicating apoptosis caused by ER stress in Delta9-THC-treated cells.	Dronabinol	99-102	caspase 3	Mus musculus	27-35
34026562-10	2021	Collectively, these results indicate that the activation of AMPK is necessary for the survival of HL-1 cells against Delta9-THC toxicity.	Dronabinol	124-127	asialoglycoprotein receptor 1	Mus musculus	98-102
33892503-6	2021	THC exposure caused increased mortality and deformities (pericardial and yolk sac edemas, reduction in length) in cnr1-/- and cnr2-/- fish compared to cnr+/+ suggesting Cnr receptors are involved in protective pathways.	Dronabinol	0-3	cannabinoid receptor 1	Danio rerio	114-118
33892503-6	2021	THC exposure caused increased mortality and deformities (pericardial and yolk sac edemas, reduction in length) in cnr1-/- and cnr2-/- fish compared to cnr+/+ suggesting Cnr receptors are involved in protective pathways.	Dronabinol	0-3	cannabinoid receptor 2	Danio rerio	126-130
33879850-7	2021	Moreover, these Delta9-THC-exposed offsprings exhibited increased expression of collagen I and III, decreased matrix metallopeptidase-2 expression, and increased inactivation of glycogen synthase kinase-3beta, all associated with cardiac remodelling.	Dronabinol	16-26	matrix metallopeptidase 2	Rattus norvegicus	110-135
33879850-7	2021	Moreover, these Delta9-THC-exposed offsprings exhibited increased expression of collagen I and III, decreased matrix metallopeptidase-2 expression, and increased inactivation of glycogen synthase kinase-3beta, all associated with cardiac remodelling.	Dronabinol	16-26	glycogen synthase kinase 3 beta	Rattus norvegicus	178-208
33477086-12	2021	The VIP plots of all models demonstrated that the THC and CBD distinctive band regions bared the highest importance for predicting the content of the molecules of interest in the respected PLS models.	Dronabinol	50-53	vasoactive intestinal peptide	Homo sapiens	4-7
33477086-14	2021	Taking into account the presented results, ATR-MIR should be considered as a promising PAT tool for THC and CBD content estimation, in terms of critical material and quality parameters for Cannabis flowers and extracts.	Dronabinol	100-103	ATR serine/threonine kinase	Homo sapiens	43-46
33865124-5	2021	The total estimated ship emissions for SO2, NOX, PM10, PM2.5, THC and CO in 2018 were 1.453 x 104 t, 2.861 x 104 t, 2.04 x 103 t, 1.82 x 103 t, 1.13 x 103 t, and 2.21 x 103 t, respectively.	Dronabinol	62-65	inositol polyphosphate-5-phosphatase D	Homo sapiens	20-24
32927465-35	2021	: In females (a-c; g-i), THC dose-dependently induced Fos immunoreactivity in several structures, as indicated by *symbol under bars that significantly differ from vehicle in that structure.	Dronabinol	25-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	54-57
32927465-44	2021	Effects of THC doses on global network connectivity (THC-induced change in overall regional Fos cross-correlation) are shown in females (c) and males (d).	Dronabinol	11-14	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	92-95
32927465-44	2021	Effects of THC doses on global network connectivity (THC-induced change in overall regional Fos cross-correlation) are shown in females (c) and males (d).	Dronabinol	53-56	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	92-95
33582152-0	2021	Reelin deficiency contributes to long-term behavioral abnormalities induced by chronic adolescent exposure to Delta9-tetrahydrocannabinol in mice.	Dronabinol	110-137	reelin	Mus musculus	0-6
33582152-8	2021	Overall, these findings show that Reelin deficiency influences behavioral abnormalities caused by heavy consumption of THC during adolescence and suggest that elucidating Reelin signaling will improve our understanding of neurobiological mechanisms underlying behavioral traits relevant to the development of psychiatric conditions.	Dronabinol	119-122	reelin	Mus musculus	34-40
33561772-7	2021	The LOI ranged from 0.3 to 1426.7 ng mL-1 for most analytes which was within expected concentration range for authentic samples with THC-COOH (>1722.0 ng mL-1) and morphine (1426.7 ng mL-1) as notable exceptions.	Dronabinol	133-136	L1 cell adhesion molecule	Mus musculus	37-41
33723716-1	2021	The present research has reported that cannabinoid receptor 1 (CB1) agonist, delta-(9)-tetrahydrocannabinol (THC) modulates synaptogenesis during overexcitation.	Dronabinol	77-107	cannabinoid receptor 1	Homo sapiens	39-61
33723716-1	2021	The present research has reported that cannabinoid receptor 1 (CB1) agonist, delta-(9)-tetrahydrocannabinol (THC) modulates synaptogenesis during overexcitation.	Dronabinol	77-107	cannabinoid receptor 1	Homo sapiens	63-66
33723716-1	2021	The present research has reported that cannabinoid receptor 1 (CB1) agonist, delta-(9)-tetrahydrocannabinol (THC) modulates synaptogenesis during overexcitation.	Dronabinol	109-112	cannabinoid receptor 1	Homo sapiens	39-61
33723716-1	2021	The present research has reported that cannabinoid receptor 1 (CB1) agonist, delta-(9)-tetrahydrocannabinol (THC) modulates synaptogenesis during overexcitation.	Dronabinol	109-112	cannabinoid receptor 1	Homo sapiens	63-66
33723716-3	2021	Low concentration of THC (10 nM) increased synaptophysin expression and neurite length, while high concentration of THC (1 microM) induced neurotoxicity.	Dronabinol	21-24	synaptophysin	Homo sapiens	43-56
33723716-9	2021	This suggests that CB1 receptors play a role in neurite growth and the low concentration of THC protects neurons during overexcitation, whereas the high concentration of THC enhances the neurotoxicity.	Dronabinol	170-173	cannabinoid receptor 1	Homo sapiens	19-22
33737216-4	2021	This period of insight began in the mid-1990s when it was discovered that phytocannabinoids (e.g., delta-9-tetrahydrocannabinol) act on G-protein coupled receptors (i.e., CB1/CB2) in the brain to produce their psychoactive effects.	Dronabinol	99-127	cannabinoid receptor 1	Homo sapiens	171-174
33737216-4	2021	This period of insight began in the mid-1990s when it was discovered that phytocannabinoids (e.g., delta-9-tetrahydrocannabinol) act on G-protein coupled receptors (i.e., CB1/CB2) in the brain to produce their psychoactive effects.	Dronabinol	99-127	cannabinoid receptor 2	Homo sapiens	175-178
33027805-6	2021	Therapeutic targeting of the CB2R with the agonists, tetrahydrocannabinol (THC) and JWH-133, revealed that only THC mitigated lethal T cell-mediated acute GVHD.	Dronabinol	53-73	cannabinoid receptor 2 (macrophage)	Mus musculus	29-33
33027805-8	2021	In vitro, both THC and JWH-133 induced arrestin recruitment and ERK phosphorylation via CB2R, but THC had no effect on CB2R-mediated inhibition of adenylyl cyclase.	Dronabinol	15-18	mitogen-activated protein kinase 1	Mus musculus	64-67
33027805-8	2021	In vitro, both THC and JWH-133 induced arrestin recruitment and ERK phosphorylation via CB2R, but THC had no effect on CB2R-mediated inhibition of adenylyl cyclase.	Dronabinol	15-18	cannabinoid receptor 2 (macrophage)	Mus musculus	88-92
32810571-8	2021	Further, 11-OH-THC was more potent in THC drug discrimination (7- to 9-fold) in C57Bl/6 J mice, with THC-like discriminative stimulus effects being CB1-, but not CB2-, mediated.	Dronabinol	15-18	cannabinoid receptor 1 (brain)	Mus musculus	148-151
32956517-6	2021	Mechanistically, THC-induced-myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists.	Dronabinol	17-20	cannabinoid receptor 1	Homo sapiens	57-60
32956517-6	2021	Mechanistically, THC-induced-myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists.	Dronabinol	17-20	cannabinoid receptor 2	Homo sapiens	65-68
32956517-6	2021	Mechanistically, THC-induced-myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists.	Dronabinol	127-130	cannabinoid receptor 1	Homo sapiens	57-60
32956517-6	2021	Mechanistically, THC-induced-myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists.	Dronabinol	127-130	cannabinoid receptor 2	Homo sapiens	65-68
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Dronabinol	14-17	CREB regulated transcription coactivator 1	Mus musculus	147-153
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Dronabinol	14-17	CREB regulated transcription coactivator 1	Mus musculus	177-183
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Dronabinol	225-228	CREB regulated transcription coactivator 1	Mus musculus	147-153
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Dronabinol	225-228	CREB regulated transcription coactivator 1	Mus musculus	177-183
32116130-4	2021	Studies showed that cannabinoid (CB), specifically delta-9-tetrahydrocannabinol (Del9THC), can increase the expression of ERbeta and inhibits BC cell proliferation.	Dronabinol	51-79	estrogen receptor 1	Homo sapiens	122-128
32116130-4	2021	Studies showed that cannabinoid (CB), specifically delta-9-tetrahydrocannabinol (Del9THC), can increase the expression of ERbeta and inhibits BC cell proliferation.	Dronabinol	81-88	estrogen receptor 1	Homo sapiens	122-128
33352148-3	2021	The aim of this study was to investigate the effect of THC on human dental pulp cell (HDPC) viability and biomineralization, as well as the molecular mechanism of THC-induced odonto/osteogenic differentiation of HDPCs.	Dronabinol	55-58	decapping mRNA 2	Homo sapiens	86-90
33352148-7	2021	The molecular mechanism of THC on HDPCs was investigated by examining the MAPK signaling pathway via blocking CB1 or CB2 receptors.	Dronabinol	27-30	cannabinoid receptor 1	Homo sapiens	110-113
33352148-7	2021	The molecular mechanism of THC on HDPCs was investigated by examining the MAPK signaling pathway via blocking CB1 or CB2 receptors.	Dronabinol	27-30	cannabinoid receptor 2	Homo sapiens	117-120
33352148-10	2021	At low dose (<5 muM), THC considerably increased HDPC cell division.	Dronabinol	22-25	decapping mRNA 2	Homo sapiens	49-53
33352148-11	2021	HDPC proliferation reduced with higher THC concentrations (>5 muM).	Dronabinol	39-42	decapping mRNA 2	Homo sapiens	0-4
33352148-16	2021	THC induced HDPCs odonto/osteogenic differentiation through activation of MAPK mediated by CB1 and CB2 receptors.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	91-94
33352148-16	2021	THC induced HDPCs odonto/osteogenic differentiation through activation of MAPK mediated by CB1 and CB2 receptors.	Dronabinol	0-3	cannabinoid receptor 2	Homo sapiens	99-102
33998887-0	2021	Recovery from Traumatic Brain Injury Following Treatment with Delta9-Tetrahydrocannabinol Is Associated with Increased Expression of Granulocyte-Colony Stimulating Factor and Other Neurotrophic Factors.	Dronabinol	62-89	colony stimulating factor 3 (granulocyte)	Mus musculus	133-170
33998887-3	2021	Conversely, Delta9-tetrahydrocannabinol (Delta9THC) treatment of normal mice has been shown to increase blood levels of G-CSF in the periphery.	Dronabinol	12-39	colony stimulating factor 3 (granulocyte)	Mus musculus	120-125
33998887-3	2021	Conversely, Delta9-tetrahydrocannabinol (Delta9THC) treatment of normal mice has been shown to increase blood levels of G-CSF in the periphery.	Dronabinol	41-50	colony stimulating factor 3 (granulocyte)	Mus musculus	120-125
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	Dronabinol	51-60	colony stimulating factor 3 (granulocyte)	Mus musculus	145-150
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	Dronabinol	51-60	brain derived neurotrophic factor	Mus musculus	152-156
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	Dronabinol	51-60	glial cell line derived neurotrophic factor	Mus musculus	162-166
33596644-0	2021	The TRPV2 channel mediates Ca2+ influx and the Delta9-THC-dependent decrease in osmotic fragility in red blood cells.	Dronabinol	54-57	transient receptor potential cation channel subfamily V member 2	Homo sapiens	4-9
33597628-7	2021	We also observed increased expression of cellular stress markers, HSP70 and HSP60, following exposure to THC.	Dronabinol	105-108	heat shock protein family A (Hsp70) member 4	Homo sapiens	66-71
33597628-7	2021	We also observed increased expression of cellular stress markers, HSP70 and HSP60, following exposure to THC.	Dronabinol	105-108	heat shock protein family D (Hsp60) member 1	Homo sapiens	76-81
33334652-8	2021	Unexpectedly, Delta9-THC produced a dose-dependent decrease in extracellular DA in WT mice, that was potentiated in CB1-KO mice.	Dronabinol	14-24	cannabinoid receptor 1 (brain)	Mus musculus	116-119
33334652-9	2021	However, in CB2-KO mice Delta9-THC produced a dose-dependent increase in extracellular DA, suggesting that activation of the CB2R inhibits DA release in the NAc.	Dronabinol	31-34	cannabinoid receptor 2 (macrophage)	Mus musculus	12-15
33334652-9	2021	However, in CB2-KO mice Delta9-THC produced a dose-dependent increase in extracellular DA, suggesting that activation of the CB2R inhibits DA release in the NAc.	Dronabinol	31-34	cannabinoid receptor 2 (macrophage)	Mus musculus	125-129
33334652-12	2021	Both CB1 and CB2 receptor mechanisms were shown to underlie Delta9-THC-induced hypolocomotion.	Dronabinol	67-70	cannabinoid receptor 1	Rattus norvegicus	5-8
33268546-7	2021	In addition, pre-treatment with L-theanine blocked THC-induced downregulation of local GSK-3 and Akt signaling pathways directly in the PFC, two biomarkers previously associated with cannabis-related psychiatric risk and sub-cortical DAergic dysregulation.	Dronabinol	51-54	AKT serine/threonine kinase 1	Rattus norvegicus	97-100
33174869-13	2021	An experimental detection limit of 2 ng mL-1 for THC with a linear detection range of 2-15 ng mL-1 was achieved.	Dronabinol	49-52	L1 cell adhesion molecule	Mus musculus	40-44
33174869-13	2021	An experimental detection limit of 2 ng mL-1 for THC with a linear detection range of 2-15 ng mL-1 was achieved.	Dronabinol	49-52	L1 cell adhesion molecule	Mus musculus	94-98
33998881-6	2022	Results: THCA and THC inhibited the peak current amplitude CaV3.1 with pEC50s of 6.0+-0.7 and 5.6+-0.4, respectively.	Dronabinol	9-12	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	59-65
33998881-7	2022	THC (1 muM) or THC produced a significant negative shift in half activation and inactivation of CaV3.1, and both drugs prolonged CaV3.1 deactivation kinetics.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	96-102
33998881-7	2022	THC (1 muM) or THC produced a significant negative shift in half activation and inactivation of CaV3.1, and both drugs prolonged CaV3.1 deactivation kinetics.	Dronabinol	15-18	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	96-102
33998881-8	2022	THCA (10 muM) inhibited CaV3.2 by 53%+-4%, and both THCA and THC produced a substantial negative shift in the voltage for half inactivation and modest negative shift in half activation of CaV3.2.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 H	Homo sapiens	24-30
33998881-8	2022	THCA (10 muM) inhibited CaV3.2 by 53%+-4%, and both THCA and THC produced a substantial negative shift in the voltage for half inactivation and modest negative shift in half activation of CaV3.2.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 H	Homo sapiens	188-194
33998881-9	2022	THC prolonged the deactivation time of CaV3.2, while THCA did not.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 H	Homo sapiens	39-45
33998881-10	2022	THCA inhibited the peak current of CaV3.3 by 43%+-2% (10 muM) but did not notably affect CaV3.3 channel activation or inactivation; however, THC caused significant hyperpolarizing shift in CaV3.3 steady-state inactivation.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 I	Homo sapiens	35-41
32623021-10	2021	Moreover, THC induced robust phosphorylation of ERK1/2 that was prevented by CBD, while CBD decreased phosphorylation of p70S6K, independently of THC.	Dronabinol	10-13	mitogen activated protein kinase 3	Rattus norvegicus	48-54
32623021-11	2021	These results suggest that intra-PFC infusion of THC promotes panic-like behaviour associated with increased ERK1/2 phosphorylation.	Dronabinol	49-52	mitogen activated protein kinase 3	Rattus norvegicus	109-115
33407988-5	2021	Ovaries from Delta9-THC-exposed offspring had reduced blood vessel density in association with decreased expression of the pro-angiogenic factor VEGF and its receptor VEGFR-2, as well as an increase in the anti-angiogenic factor thrombospondin 1 (TSP-1).	Dronabinol	20-23	vascular endothelial growth factor A	Rattus norvegicus	145-149
33407988-5	2021	Ovaries from Delta9-THC-exposed offspring had reduced blood vessel density in association with decreased expression of the pro-angiogenic factor VEGF and its receptor VEGFR-2, as well as an increase in the anti-angiogenic factor thrombospondin 1 (TSP-1).	Dronabinol	20-23	kinase insert domain receptor	Rattus norvegicus	167-174
33407988-5	2021	Ovaries from Delta9-THC-exposed offspring had reduced blood vessel density in association with decreased expression of the pro-angiogenic factor VEGF and its receptor VEGFR-2, as well as an increase in the anti-angiogenic factor thrombospondin 1 (TSP-1).	Dronabinol	20-23	thrombospondin 1	Rattus norvegicus	247-252
32867595-2	2021	Inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which are the enzymes responsible for the inactivation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, respectively, may exert therapeutic effects without inducing the adverse side effects associated with direct cannabinoid CB1 receptor stimulation by THC.	Dronabinol	358-361	fatty acid amide hydrolase	Homo sapiens	14-40
32867595-2	2021	Inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which are the enzymes responsible for the inactivation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, respectively, may exert therapeutic effects without inducing the adverse side effects associated with direct cannabinoid CB1 receptor stimulation by THC.	Dronabinol	358-361	fatty acid amide hydrolase	Homo sapiens	42-46
32867595-2	2021	Inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which are the enzymes responsible for the inactivation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, respectively, may exert therapeutic effects without inducing the adverse side effects associated with direct cannabinoid CB1 receptor stimulation by THC.	Dronabinol	358-361	monoglyceride lipase	Homo sapiens	52-75
32867595-2	2021	Inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), which are the enzymes responsible for the inactivation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol, respectively, may exert therapeutic effects without inducing the adverse side effects associated with direct cannabinoid CB1 receptor stimulation by THC.	Dronabinol	358-361	monoglyceride lipase	Homo sapiens	77-81
33332002-6	2021	THC acts as a partial agonist at cannabinoid 1/2 receptors (CB1/2).	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	60-65
33723124-3	2021	Advances in technology and scientific findings led to the discovery of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis, that further led to the discovery of endogenous cannabinoids system consisting of G-protein-coupled receptors - cannabinoid receptor 1 and cannabinoid receptor 2 along with their ligands, mainly anandamide and 2-arachidonoylglycerol.	Dronabinol	71-99	cannabinoid receptor 1	Homo sapiens	266-288
33723124-3	2021	Advances in technology and scientific findings led to the discovery of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis, that further led to the discovery of endogenous cannabinoids system consisting of G-protein-coupled receptors - cannabinoid receptor 1 and cannabinoid receptor 2 along with their ligands, mainly anandamide and 2-arachidonoylglycerol.	Dronabinol	71-99	cannabinoid receptor 2	Homo sapiens	293-315
33723124-3	2021	Advances in technology and scientific findings led to the discovery of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis, that further led to the discovery of endogenous cannabinoids system consisting of G-protein-coupled receptors - cannabinoid receptor 1 and cannabinoid receptor 2 along with their ligands, mainly anandamide and 2-arachidonoylglycerol.	Dronabinol	101-104	cannabinoid receptor 1	Homo sapiens	266-288
33723124-3	2021	Advances in technology and scientific findings led to the discovery of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis, that further led to the discovery of endogenous cannabinoids system consisting of G-protein-coupled receptors - cannabinoid receptor 1 and cannabinoid receptor 2 along with their ligands, mainly anandamide and 2-arachidonoylglycerol.	Dronabinol	101-104	cannabinoid receptor 2	Homo sapiens	293-315
32599581-8	2021	In patients with preliminary use of tetrahydrocannabinol (THC) the NRXN1 promoter turned out to be methylated almost two times higher than in non-consumer patients.	Dronabinol	36-56	neurexin 1	Homo sapiens	67-72
32599581-8	2021	In patients with preliminary use of tetrahydrocannabinol (THC) the NRXN1 promoter turned out to be methylated almost two times higher than in non-consumer patients.	Dronabinol	58-61	neurexin 1	Homo sapiens	67-72
32599581-13	2021	With consumption of THC, mean methylation rates were increased: in the case of MAPT compared with controls, and in NRXN1 even significantly beyond that.	Dronabinol	20-23	microtubule associated protein tau	Homo sapiens	79-83
32599581-13	2021	With consumption of THC, mean methylation rates were increased: in the case of MAPT compared with controls, and in NRXN1 even significantly beyond that.	Dronabinol	20-23	neurexin 1	Homo sapiens	115-120
33111197-10	2021	Adolescent THC-exposed rats exhibited reductions in CB1, GABA, and glutamate receptor protein, primarily in the prefrontal cortex, dorsal hippocampus, and ventral tegmental area.	Dronabinol	11-14	cannabinoid receptor 1	Rattus norvegicus	52-55
33998876-0	2022	Cannabidiol Interferes with Establishment of Delta9-Tetrahydrocannabinol-Induced Nausea Through a 5-HT1A Mechanism.	Dronabinol	45-72	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-104
33998876-12	2022	The attenuation of THC-induced conditioned gaping by CBD was mediated by its action on 5-HT1A receptors, similar to that of LiCl-induced nausea.	Dronabinol	19-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	87-93
33331878-9	2021	THC acted on both immune cells via CB2 and on enterocytes to attenuate colitis.	Dronabinol	0-3	cannabinoid receptor 2 (macrophage)	Mus musculus	35-38
33376801-9	2020	Cinnamaldehyde (CA), Delta9-THC, and 2-arachidonoylglycerol (2-AG) activated TRPA1 receptors with high efficacy and similar potency (EC50s of ~10 muM).	Dronabinol	21-31	transient receptor potential cation channel subfamily A member 1	Homo sapiens	77-82
33141759-4	2020	We find that THC indiscriminately affects pyramidal cells and both cannabinoid receptor 1 (CB1R)+ and CB1R- interneurons by P16.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	67-89
33141759-4	2020	We find that THC indiscriminately affects pyramidal cells and both cannabinoid receptor 1 (CB1R)+ and CB1R- interneurons by P16.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	91-95
33141759-4	2020	We find that THC indiscriminately affects pyramidal cells and both cannabinoid receptor 1 (CB1R)+ and CB1R- interneurons by P16.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	102-106
32981464-7	2020	The combination of various genetic strategies in vivo supports the idea that CNR1 molecules located on neurons belonging to the direct (striatonigral) pathway are required for the autophagy- and motor-impairing activity of THC.	Dronabinol	223-226	cannabinoid receptor 1 (brain)	Mus musculus	77-81
32829065-11	2020	Indeed, THC increases the expression of the hydrolyzing enzymes alpha beta hydrolase domain -6 (ABHD6) and -12 (ABHD12), that we firstly describe in human placental tissues.	Dronabinol	8-11	abhydrolase domain containing 6, acylglycerol lipase	Homo sapiens	96-101
32829065-11	2020	Indeed, THC increases the expression of the hydrolyzing enzymes alpha beta hydrolase domain -6 (ABHD6) and -12 (ABHD12), that we firstly describe in human placental tissues.	Dronabinol	8-11	abhydrolase domain containing 12, lysophospholipase	Homo sapiens	112-118
32706449-3	2020	The assay had linearity between 1-100 ng mL-1 for THC-COOH and 0.5 to 50 ng mL-1 for the other tested cannabinoids.	Dronabinol	50-53	L1 cell adhesion molecule	Mus musculus	41-45
32409991-12	2020	The immune modulating activity of THC is largely mediated through cannabinoid receptors (CB) 1 and 2, with CB1 also responsible for the psychotropic properties of cannabis.	Dronabinol	34-37	cannabinoid receptor 1	Homo sapiens	66-100
33635755-3	2020	THC and CBD bind with cannabinoid receptors (CB1 and CB2), which are present in the brain and many organs.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	45-48
33635755-3	2020	THC and CBD bind with cannabinoid receptors (CB1 and CB2), which are present in the brain and many organs.	Dronabinol	0-3	cannabinoid receptor 2	Homo sapiens	53-56
32860777-0	2020	Differential glutamatergic and GABAergic contributions to the tetrad effects of Delta9-tetrahydrocannabinol revealed by cell-type-specific reconstitution of the CB1 receptor.	Dronabinol	80-107	cannabinoid receptor 1 (brain)	Mus musculus	161-164
32860777-4	2020	Conditional CB1 receptor knock-out mice were previously used to identify CB1 receptor subpopulations that are "necessary" for the tetrad effects of a high dose of THC: hypothermia, hypolocomotion, catalepsy and analgesia.	Dronabinol	163-166	cannabinoid receptor 1 (brain)	Mus musculus	12-15
32860777-4	2020	Conditional CB1 receptor knock-out mice were previously used to identify CB1 receptor subpopulations that are "necessary" for the tetrad effects of a high dose of THC: hypothermia, hypolocomotion, catalepsy and analgesia.	Dronabinol	163-166	cannabinoid receptor 1 (brain)	Mus musculus	73-76
32860777-6	2020	Glutamatergic CB1 receptor was not only necessary but also sufficient for THC-induced hypothermia and hypolocomotion.	Dronabinol	74-77	cannabinoid receptor 1 (brain)	Mus musculus	14-17
32860777-9	2020	In animals with CB1 receptors exclusively in forebrain GABAergic neurons, THC stimulated rather than reduced locomotion.	Dronabinol	74-77	cannabinoid receptor 1 (brain)	Mus musculus	16-19
33998869-5	2021	Results: Using whole body plethysmography, the nonselective CB1R and CB2R agonist (Delta9-tetrahydrocannabinol) and the CB1R synthetic cannabinoid, AM356, induced respiratory depression, whereas the well-published selective CB2 agonist, JWH 133, and the novel CB2 agonist (AM2301) did not.	Dronabinol	83-110	cannabinoid receptor 1 (brain)	Mus musculus	60-64
33998869-5	2021	Results: Using whole body plethysmography, the nonselective CB1R and CB2R agonist (Delta9-tetrahydrocannabinol) and the CB1R synthetic cannabinoid, AM356, induced respiratory depression, whereas the well-published selective CB2 agonist, JWH 133, and the novel CB2 agonist (AM2301) did not.	Dronabinol	83-110	cannabinoid receptor 2 (macrophage)	Mus musculus	69-73
33998869-5	2021	Results: Using whole body plethysmography, the nonselective CB1R and CB2R agonist (Delta9-tetrahydrocannabinol) and the CB1R synthetic cannabinoid, AM356, induced respiratory depression, whereas the well-published selective CB2 agonist, JWH 133, and the novel CB2 agonist (AM2301) did not.	Dronabinol	83-110	cannabinoid receptor 2 (macrophage)	Mus musculus	69-72
32754917-12	2020	Transcriptome array showed that THC up-regulated several genes like lysozyme-1&2, beta-defensin-2, claudin, zonula-1, occludin-1, Mucin2 and Muc5b while downregulating beta-defensin-1.	Dronabinol	32-35	defensin beta 2	Mus musculus	82-97
32754917-12	2020	Transcriptome array showed that THC up-regulated several genes like lysozyme-1&2, beta-defensin-2, claudin, zonula-1, occludin-1, Mucin2 and Muc5b while downregulating beta-defensin-1.	Dronabinol	32-35	mucin 2	Mus musculus	130-136
32754917-12	2020	Transcriptome array showed that THC up-regulated several genes like lysozyme-1&2, beta-defensin-2, claudin, zonula-1, occludin-1, Mucin2 and Muc5b while downregulating beta-defensin-1.	Dronabinol	32-35	mucin 5, subtype B, tracheobronchial	Mus musculus	141-146
32754917-12	2020	Transcriptome array showed that THC up-regulated several genes like lysozyme-1&2, beta-defensin-2, claudin, zonula-1, occludin-1, Mucin2 and Muc5b while downregulating beta-defensin-1.	Dronabinol	32-35	defensin beta 1	Mus musculus	168-183
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	82-85	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	126-132
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	82-85	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	82-85	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	93-96	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	126-132
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	93-96	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
32712703-8	2020	In addition, this study showed significantly higher values in the ratio of Delta9-THC/Delta9-THC-COOH for the carriers of the CYP2C9 variants CYP2C9*2 and CYP2C9*3 compared with the carriers of the corresponding wild-type alleles.	Dronabinol	93-96	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
32898566-8	2020	These data highlight the microtubule dynamicity as a molecular target for Delta9-THC, which affects memory dysfunction.	Dronabinol	74-84	amyloid beta precursor protein	Rattus norvegicus	7-8
32898566-9	2020	However, Delta9-THC can be inhibited the AChE activity and provide an improved therapeutics for neurodegenerative diseases.	Dronabinol	9-19	acetylcholinesterase	Rattus norvegicus	41-45
33126623-6	2020	Furthermore, CBD and/or THC reduced the expression of PD-L1 by either PC or PSC cells.	Dronabinol	24-27	CD274 antigen	Mus musculus	54-59
33126623-7	2020	Knockout of p-21 activated kinase 1 (PAK1, activated by KRas) in PC and PSC cells and, in mice, dramatically decreased or blocked these inhibitory effects of CBD and/or THC.	Dronabinol	169-172	p21 (RAC1) activated kinase 1	Mus musculus	12-35
33126623-7	2020	Knockout of p-21 activated kinase 1 (PAK1, activated by KRas) in PC and PSC cells and, in mice, dramatically decreased or blocked these inhibitory effects of CBD and/or THC.	Dronabinol	169-172	p21 (RAC1) activated kinase 1	Mus musculus	37-41
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	37-40	p21 (RAC1) activated kinase 1	Mus musculus	87-110
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	37-40	p21 (RAC1) activated kinase 1	Mus musculus	112-116
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	37-40	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	174-178
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	37-40	p21 (RAC1) activated kinase 1	Mus musculus	210-214
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	161-164	p21 (RAC1) activated kinase 1	Mus musculus	87-110
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	161-164	p21 (RAC1) activated kinase 1	Mus musculus	112-116
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	161-164	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	174-178
33126623-8	2020	These results indicated that CBD and THC exerted their inhibitions on PC and PSC via a p-21 activated kinase 1 (PAK1)-dependent pathway, suggesting that CBD and THC suppress Kras activated pathway by targeting PAK1.	Dronabinol	161-164	p21 (RAC1) activated kinase 1	Mus musculus	210-214
33126623-9	2020	The inhibition by CBD and THC of PD-L1 expression will enhance the immune checkpoint blockade of PC.	Dronabinol	26-29	CD274 antigen	Mus musculus	33-38
33064815-6	2021	RESULTS: In THC, relative to the Q1 concentration, the risks of gouts were higher in participants exposed to the Q2 to Q4 concentrations (aHR, 1.10 with 95% CI, 1.01-1.19 in the Q2 concentration of THC; aHR, 4.20 with 95% CI, 3.93-4.49 in the Q3 concentration of THC; aHR, 5.65 with 95% CI, 5.29-6.04 in the Q4 concentration of THC).	Dronabinol	12-15	aryl hydrocarbon receptor	Homo sapiens	138-141
33103246-10	2020	Despite significant mean differences in total cannabinoid content, CBDAS genotypes blindly predicted the THC:CBD ratio among clinical cultivars, and the same was true for industrial grain cultivars when plants exhibited >0.5% total cannabinoid content.	Dronabinol	105-108	cannabidiolic acid synthase	Cannabis sativa	67-72
33103246-11	2020	CONCLUSIONS: Our results extend the generality of the inheritance model for THC:CBD to diverse C. sativa accessions and demonstrate that CBDAS genotyping can predict the ratio in a variety of practical applications.	Dronabinol	76-79	cannabidiolic acid synthase	Cannabis sativa	137-142
32587099-9	2020	A combined (reversible inhibition and TDI) mechanistic static model populated with these data predicted a moderate to strong pharmacokinetic interaction risk between orally administered CBD and drugs extensively metabolized by CYP1A2/2C9/2C19/2D6/3A and between orally administered THC and drugs extensively metabolized by CYP1A2/2C9/3A.	Dronabinol	282-285	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	227-233
33998860-12	2020	Tweed Argyle also inhibited ABCB11 transporter function with an IC50 value of 11.9 muM for CBD and 7.7 muM for Delta9-THC.	Dronabinol	118-121	ATP binding cassette subfamily B member 11	Homo sapiens	28-34
33998858-10	2022	The Delta9-THCA/Delta9-THC mixture, however, increased spontaneous seizure severity and increased mortality of Scn1a+/- mice.	Dronabinol	11-14	sodium channel, voltage-gated, type I, alpha	Mus musculus	111-116
32923660-16	2020	As these traits directly result from THC activation of the cannabinoid receptor 1, gene variants between B6 and D2 in cannabinoid signaling pathways are likely to mediate strain differences in response to THC.	Dronabinol	37-40	cannabinoid receptor 1 (brain)	Mus musculus	59-81
32923660-16	2020	As these traits directly result from THC activation of the cannabinoid receptor 1, gene variants between B6 and D2 in cannabinoid signaling pathways are likely to mediate strain differences in response to THC.	Dronabinol	205-208	cannabinoid receptor 1 (brain)	Mus musculus	59-81
32510591-1	2020	BACKGROUND AND PURPOSE: Delta9 -THCA-A, the precursor of Delta9 -THC, is a non-psychotropic phytocannabinoid that shows PPARgamma agonistic activity.	Dronabinol	24-35	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
32608111-12	2020	CONCLUSION AND IMPLICATIONS: Low doses of Delta9 -THC are anticonvulsant against hyperthermia-induced seizures in Scn1a+/ mice, effects that are enhanced by a sub-anticonvulsant dose of CBD.	Dronabinol	42-53	sodium channel, voltage-gated, type I, alpha	Mus musculus	114-119
32553926-6	2020	KEY FINDINGS: Upon the treatment of aged pancreatic islets cells with cannabidiol and tetrahydrocannabinol, the expression of p53, p38, p21 and the activity of beta-galactosidase were reduced.	Dronabinol	86-106	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	126-129
32553926-6	2020	KEY FINDINGS: Upon the treatment of aged pancreatic islets cells with cannabidiol and tetrahydrocannabinol, the expression of p53, p38, p21 and the activity of beta-galactosidase were reduced.	Dronabinol	86-106	mitogen activated protein kinase 14	Rattus norvegicus	131-134
32553926-6	2020	KEY FINDINGS: Upon the treatment of aged pancreatic islets cells with cannabidiol and tetrahydrocannabinol, the expression of p53, p38, p21 and the activity of beta-galactosidase were reduced.	Dronabinol	86-106	KRAS proto-oncogene, GTPase	Rattus norvegicus	136-139
32872332-12	2020	THC caused the downregulation of miR-185, which correlated with an increase in the pro-apoptotic gene targets.	Dronabinol	0-3	microRNA 185	Homo sapiens	33-40
32942172-3	2020	Here we show that delta-9-tetrahydrocannabinol (THC) attenuates colitis-associated colon cancer and colitis induced by anti-CD40.	Dronabinol	18-46	CD40 molecule	Homo sapiens	124-128
32942172-3	2020	Here we show that delta-9-tetrahydrocannabinol (THC) attenuates colitis-associated colon cancer and colitis induced by anti-CD40.	Dronabinol	48-51	CD40 molecule	Homo sapiens	124-128
32942172-4	2020	Working through cannabinoid receptor 2 (CB2), THC increases CD103 expression on DCs and macrophages and upregulates TGF-beta1 to increase T regulatory cells (Tregs).	Dronabinol	46-49	cannabinoid receptor 2	Homo sapiens	16-38
32942172-4	2020	Working through cannabinoid receptor 2 (CB2), THC increases CD103 expression on DCs and macrophages and upregulates TGF-beta1 to increase T regulatory cells (Tregs).	Dronabinol	46-49	cannabinoid receptor 2	Homo sapiens	40-43
32942172-4	2020	Working through cannabinoid receptor 2 (CB2), THC increases CD103 expression on DCs and macrophages and upregulates TGF-beta1 to increase T regulatory cells (Tregs).	Dronabinol	46-49	integrin subunit alpha E	Homo sapiens	60-65
32942172-4	2020	Working through cannabinoid receptor 2 (CB2), THC increases CD103 expression on DCs and macrophages and upregulates TGF-beta1 to increase T regulatory cells (Tregs).	Dronabinol	46-49	transforming growth factor beta 1	Homo sapiens	116-125
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	0-3	interferon gamma	Homo sapiens	51-59
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	0-3	tumor necrosis factor	Homo sapiens	64-72
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	0-3	CD40 molecule	Homo sapiens	88-92
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	134-137	cannabinoid receptor 2	Homo sapiens	98-101
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	134-137	amyloid P component, serum	Homo sapiens	126-130
32942172-5	2020	THC-induced Tregs are necessary to remedy systemic IFNgamma and TNFalpha caused by anti-CD40, but CB2-mediated suppression of APCs by THC quenches pathogenic release of IL-22 and IL-17A in the colon.	Dronabinol	134-137	interleukin 22	Homo sapiens	169-174
32942172-6	2020	By examining tissues from multiple sites, we confirmed that THC affects DCs, especially in mucosal barrier sites in the colon and lungs, to reduce DC CD86.	Dronabinol	60-63	CD86 molecule	Homo sapiens	150-154
32942172-7	2020	Using models of colitis and systemic inflammation we show that THC, through CB2, is a potent suppressor of aberrant immune responses by provoking coordination between APCs and Tregs.	Dronabinol	63-66	cannabinoid receptor 2	Homo sapiens	76-79
32942172-7	2020	Using models of colitis and systemic inflammation we show that THC, through CB2, is a potent suppressor of aberrant immune responses by provoking coordination between APCs and Tregs.	Dronabinol	63-66	amyloid P component, serum	Homo sapiens	167-171
32690657-5	2020	In contrast, anti-inflammatory cannabinoids such as cannabidiol or delta-9-tetrahydrocannabinol decreased the expression of AW112010 in T cells.	Dronabinol	67-95	expressed sequence AW112010	Mus musculus	124-132
32852544-8	2020	Activation of CB1 receptors by THC or the cannabinoid agonist CP55940 reduces tearing in male mice.	Dronabinol	31-34	cannabinoid receptor 1 (brain)	Mus musculus	14-17
32330591-8	2020	Exposure of these cells to tetrahydrocannabinol (THC) or cannabidiol (CBD) reduced the immunological response of the P2X7 receptor, which was dependent on the identified genetic variant.	Dronabinol	27-47	purinergic receptor P2X 7	Homo sapiens	117-130
32330591-8	2020	Exposure of these cells to tetrahydrocannabinol (THC) or cannabidiol (CBD) reduced the immunological response of the P2X7 receptor, which was dependent on the identified genetic variant.	Dronabinol	49-52	purinergic receptor P2X 7	Homo sapiens	117-130
32266676-6	2020	P-glycoprotein was included in the brain compartment to characterize an efflux of THC from the brain.	Dronabinol	82-85	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
32504994-8	2020	Furthermore, THC restored the reduction of NAD-dependent protein deacetylase sirtuin-1 (SIRT1) in the lungs of experimental COPD mice.	Dronabinol	13-16	sirtuin 1	Mus musculus	43-86
32504994-8	2020	Furthermore, THC restored the reduction of NAD-dependent protein deacetylase sirtuin-1 (SIRT1) in the lungs of experimental COPD mice.	Dronabinol	13-16	sirtuin 1	Mus musculus	88-93
32752303-6	2020	The activities of glutathione reductase and glutathione peroxidase were significantly increased in cells exposed to THC and significantly decreased in those treated with CBD.	Dronabinol	116-119	glutathione-disulfide reductase	Homo sapiens	18-39
32752303-9	2020	The Annexin V-Propidium Iodide assay showed a significantly increased percentage of cells apoptotic after CB83 exposition and necrotic cells after CBD and THC exposition.	Dronabinol	155-158	annexin A5	Homo sapiens	4-13
32704063-0	2020	Epigenetic alterations in cytochrome P450 oxidoreductase (Por) in sperm of rats exposed to tetrahydrocannabinol (THC).	Dronabinol	91-111	cytochrome p450 oxidoreductase	Rattus norvegicus	26-56
32704063-0	2020	Epigenetic alterations in cytochrome P450 oxidoreductase (Por) in sperm of rats exposed to tetrahydrocannabinol (THC).	Dronabinol	91-111	cytochrome p450 oxidoreductase	Rattus norvegicus	58-61
32704063-0	2020	Epigenetic alterations in cytochrome P450 oxidoreductase (Por) in sperm of rats exposed to tetrahydrocannabinol (THC).	Dronabinol	113-116	cytochrome p450 oxidoreductase	Rattus norvegicus	26-56
32704063-0	2020	Epigenetic alterations in cytochrome P450 oxidoreductase (Por) in sperm of rats exposed to tetrahydrocannabinol (THC).	Dronabinol	113-116	cytochrome p450 oxidoreductase	Rattus norvegicus	58-61
32704063-10	2020	Significant hypermethylation was confirmed (p < 0.05) following oral THC administration for cytochrome P450 oxidoreductase (Por), involved in toxin processing and disorders of sexual development.	Dronabinol	69-72	cytochrome p450 oxidoreductase	Rattus norvegicus	92-122
32704063-10	2020	Significant hypermethylation was confirmed (p < 0.05) following oral THC administration for cytochrome P450 oxidoreductase (Por), involved in toxin processing and disorders of sexual development.	Dronabinol	69-72	cytochrome p450 oxidoreductase	Rattus norvegicus	124-127
32733202-2	2020	Synthetic cannabinoids (SCs) are synthetic analogs of Delta9-tetrahydrocannabinol (Delta9-THC), the psychotropic compound of cannabis, acting as agonists of eCB receptor CB1.	Dronabinol	54-81	cannabinoid receptor 1	Homo sapiens	170-173
32733202-2	2020	Synthetic cannabinoids (SCs) are synthetic analogs of Delta9-tetrahydrocannabinol (Delta9-THC), the psychotropic compound of cannabis, acting as agonists of eCB receptor CB1.	Dronabinol	83-93	cannabinoid receptor 1	Homo sapiens	170-173
32616535-1	2020	A 19-year-old man vaping with tetrahydrocannabinol presented with dyspnoea and right pneumothorax.	Dronabinol	30-50	immunoglobulin kappa variable 2-28	Homo sapiens	0-4
31626712-4	2020	In adult males, adolescent low-dose Delta9 -THC exposure led to increased spontaneous locomotor activity, impaired behavioral motor habituation, and defective short-term spatial memory, paralleled with decreased BDNF protein levels in the prefrontal cortex.	Dronabinol	44-47	brain-derived neurotrophic factor	Rattus norvegicus	212-216
31626712-5	2020	In this brain area, serotonergic activity was increased, as depicted by the increased serotonin turnover rate, while the opposite effect was observed in the hippocampus, a region where SERT levels were enhanced by Delta9 -THC, compared with vehicle.	Dronabinol	222-225	solute carrier family 6 member 4	Rattus norvegicus	185-189
31626712-6	2020	In adult females, adolescent Delta9 -THC treatment led to decreased spontaneous vertical activity and impaired short-term spatial memory, accompanied by increased BDNF protein levels in the prefrontal cortex.	Dronabinol	37-40	brain-derived neurotrophic factor	Rattus norvegicus	163-167
32345621-8	2020	Moreover, the brain of adolescent mice contained higher mRNA levels of the multi-drug transporter Abcg2, which may extrude Delta9-THC from the brain, and of claudin-5, a protein that contributes to blood-brain barrier integrity.	Dronabinol	130-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
32353393-7	2020	RESULTS: Locomotor activity and c-Fos IR changes induced by THC challenge were altered by nicotine pre-exposure and modified by age and sex.	Dronabinol	60-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	32-37
32353393-10	2020	THC increased c-Fos IR in the caudate, nucleus accumbens, stria terminalis, septum, amygdala, hypothalamus, and thalamus.	Dronabinol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	14-19
33998853-15	2022	Myc proto-oncogene was identified as associated with THC-COOH levels in both molecular insight and potential marker analyses.	Dronabinol	53-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
33062188-1	2020	GPR18 is a rhodopsin-like orphan G-protein-coupled receptor (GPCR) that is activated by the natural cannabinoid (CB) Delta9-tetrahydrocannabinol (THC).	Dronabinol	117-144	G protein-coupled receptor 18	Homo sapiens	0-5
33062188-1	2020	GPR18 is a rhodopsin-like orphan G-protein-coupled receptor (GPCR) that is activated by the natural cannabinoid (CB) Delta9-tetrahydrocannabinol (THC).	Dronabinol	117-144	rhodopsin	Homo sapiens	11-20
33062188-1	2020	GPR18 is a rhodopsin-like orphan G-protein-coupled receptor (GPCR) that is activated by the natural cannabinoid (CB) Delta9-tetrahydrocannabinol (THC).	Dronabinol	146-149	G protein-coupled receptor 18	Homo sapiens	0-5
33062188-1	2020	GPR18 is a rhodopsin-like orphan G-protein-coupled receptor (GPCR) that is activated by the natural cannabinoid (CB) Delta9-tetrahydrocannabinol (THC).	Dronabinol	146-149	rhodopsin	Homo sapiens	11-20
33062188-5	2020	PSB-KD107 (5) and PSB-KD477 (16) displayed significantly higher potency and efficacy than THC, determined in a GPR18-dependent beta-arrestin recruitment assay, and were found to be selective versus the CB-sensitive receptors CB1, CB2, and GPR55.	Dronabinol	90-93	G protein-coupled receptor 18	Homo sapiens	111-116
32612530-4	2020	In the current study, we investigated the effect of THC treatment on SEB-induced ARDS in mice.	Dronabinol	52-55	seborrheic dermatitis	Mus musculus	69-72
32612530-6	2020	THC treatment significantly suppressed the inflammatory cytokines, IFN-gamma and TNF-alpha.	Dronabinol	0-3	interferon gamma	Mus musculus	67-76
32612530-6	2020	THC treatment significantly suppressed the inflammatory cytokines, IFN-gamma and TNF-alpha.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	81-90
32612530-7	2020	Additionally, THC elevated the induction of regulatory T cells (Tregs) and their associated cytokines, IL-10 and TGF-beta.	Dronabinol	14-17	interleukin 10	Mus musculus	103-108
32612530-7	2020	Additionally, THC elevated the induction of regulatory T cells (Tregs) and their associated cytokines, IL-10 and TGF-beta.	Dronabinol	14-17	transforming growth factor alpha	Mus musculus	113-121
32612530-9	2020	THC acted through CB2 receptor as pharmacological inhibitor of CB2 receptors blocked the anti-inflammatory effects.	Dronabinol	0-3	cannabinoid receptor 2 (macrophage)	Mus musculus	18-21
32612530-11	2020	Specifically, THC caused downregulation of let7a-5p which targeted SOCS1 and downregulation of miR-34-5p which caused increased expression of FoxP3, NOS1, and CSF1R.	Dronabinol	14-17	suppressor of cytokine signaling 1	Mus musculus	67-72
32612530-11	2020	Specifically, THC caused downregulation of let7a-5p which targeted SOCS1 and downregulation of miR-34-5p which caused increased expression of FoxP3, NOS1, and CSF1R.	Dronabinol	14-17	forkhead box P3	Mus musculus	142-147
32612530-11	2020	Specifically, THC caused downregulation of let7a-5p which targeted SOCS1 and downregulation of miR-34-5p which caused increased expression of FoxP3, NOS1, and CSF1R.	Dronabinol	14-17	nitric oxide synthase 1, neuronal	Mus musculus	149-153
32612530-11	2020	Specifically, THC caused downregulation of let7a-5p which targeted SOCS1 and downregulation of miR-34-5p which caused increased expression of FoxP3, NOS1, and CSF1R.	Dronabinol	14-17	colony stimulating factor 1 receptor	Mus musculus	159-164
32612530-12	2020	Together, these data suggested that THC-mediated alterations in miR expression in the lungs may play a critical role in the induction of immunosuppressive Tregs and MDSCs as well as suppression of cytokine storm leading to attenuation of SEB-mediated lung injury.	Dronabinol	36-39	microRNA 615	Mus musculus	64-67
32612530-12	2020	Together, these data suggested that THC-mediated alterations in miR expression in the lungs may play a critical role in the induction of immunosuppressive Tregs and MDSCs as well as suppression of cytokine storm leading to attenuation of SEB-mediated lung injury.	Dronabinol	36-39	seborrheic dermatitis	Mus musculus	238-241
32923132-5	2020	Then, the presence of THCs in bloodstream and samples from primary and metastatic lesions were detected by FACS and immunofluorescence protocols, and their correlations with TNM stages established.	Dronabinol	22-26	teneurin transmembrane protein 1	Homo sapiens	174-177
32923132-10	2020	THCs levels in circulation correlate with TNM classification.	Dronabinol	0-4	teneurin transmembrane protein 1	Homo sapiens	42-45
32385136-4	2020	Administration of Delta9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice.	Dronabinol	18-28	interleukin 10	Mus musculus	76-81
32385136-4	2020	Administration of Delta9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice.	Dronabinol	18-28	interleukin 6	Mus musculus	105-109
32385136-4	2020	Administration of Delta9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice.	Dronabinol	18-28	chemokine (C-C motif) ligand 2	Mus musculus	114-119
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	cannabinoid receptor 1 (brain)	Mus musculus	83-110
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	cannabinoid receptor 1 (brain)	Mus musculus	112-116
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	319-324
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	G protein-coupled receptor 18	Mus musculus	326-331
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	G protein-coupled receptor 55	Mus musculus	333-338
32385136-5	2020	The anti-inflammatory effects of Delta9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.	Dronabinol	33-43	G-protein coupled receptor 119	Mus musculus	344-350
32385136-7	2020	Finally, using IL-10-GFP reporter mice, we showed that blood monocytic myeloid-derived suppressive cells mediate the Delta9-THC-induced early rise in circulating IL-10.	Dronabinol	117-127	interleukin 10	Mus musculus	15-20
32385136-7	2020	Finally, using IL-10-GFP reporter mice, we showed that blood monocytic myeloid-derived suppressive cells mediate the Delta9-THC-induced early rise in circulating IL-10.	Dronabinol	117-127	interleukin 10	Mus musculus	162-167
32385136-8	2020	These results indicate that Delta9-THC potently induces IL-10, while reducing proinflammatory cytokines, chemokines, and related organ injury in endotoxemic mice via the activation of CB1R.	Dronabinol	28-38	interleukin 10	Mus musculus	56-61
32385136-8	2020	These results indicate that Delta9-THC potently induces IL-10, while reducing proinflammatory cytokines, chemokines, and related organ injury in endotoxemic mice via the activation of CB1R.	Dronabinol	28-38	cannabinoid receptor 1 (brain)	Mus musculus	184-188
32497151-10	2020	Administration of cannabinoids, particularly the 1:1 combination of THC, elicited a sustained mechanical anti-hypersensitive effect in males with persistent peripheral NP, which corresponded to beneficial changes in myelinated Abeta mechanoreceptive fibers.	Dronabinol	68-71	amyloid beta precursor protein	Rattus norvegicus	227-232
32147492-4	2020	This study aims to look at the effect of different concentrations of THC and CBD separately and in combination on the release of oxygen from erythrocytes by measuring the p50 of the oxygen haemoglobin dissociation curve.	Dronabinol	69-72	nuclear factor kappa B subunit 1	Homo sapiens	171-174
32147492-7	2020	The results indicate that there is a decrease in P50 with increasing concentrations of both THC and CBD separately and in combination.	Dronabinol	92-95	nuclear factor kappa B subunit 1	Homo sapiens	49-52
32147492-8	2020	The decrease in P50 was significant (p < .05) at all concentrations of THC and CBD.	Dronabinol	71-74	nuclear factor kappa B subunit 1	Homo sapiens	16-19
32227279-6	2020	Treatment with the lowest dose of THC significantly reduced wet weight, the incidence of kyphosis, and the expression of several senescence and inflammatory markers (p16ink4ab, tnfalpha, il-1beta, il-6, pparalpha and ppargamma) in the liver, but not at higher doses indicating a biphasic or hormetic effect.	Dronabinol	34-37	tumor necrosis factor a (TNF superfamily, member 2)	Danio rerio	166-185
32227279-6	2020	Treatment with the lowest dose of THC significantly reduced wet weight, the incidence of kyphosis, and the expression of several senescence and inflammatory markers (p16ink4ab, tnfalpha, il-1beta, il-6, pparalpha and ppargamma) in the liver, but not at higher doses indicating a biphasic or hormetic effect.	Dronabinol	34-37	interleukin 6 (interferon, beta 2)	Danio rerio	197-201
32227279-6	2020	Treatment with the lowest dose of THC significantly reduced wet weight, the incidence of kyphosis, and the expression of several senescence and inflammatory markers (p16ink4ab, tnfalpha, il-1beta, il-6, pparalpha and ppargamma) in the liver, but not at higher doses indicating a biphasic or hormetic effect.	Dronabinol	34-37	peroxisome proliferator-activated receptor alpha b	Danio rerio	203-212
32338122-0	2020	In utero Delta9-tetrahydrocannabinol exposure confers vulnerability towards cognitive impairments and alcohol drinking in the adolescent offspring: Is there a role for neuropeptide Y?	Dronabinol	9-36	neuropeptide Y	Rattus norvegicus	168-182
32338122-6	2020	RESULTS: In utero THC-exposed adolescent rats showed: (a) increased locomotor activity; (b) no alteration in neutral declarative memory; (c) impaired aversive limbic memory; (d) decreased NPY-positive neurons in limbic regions; (e) region-specific variations in Homer-1, 1b/c and 2 immunoreactivity; (f) decreased instrumental learning and increased alcohol drinking, relapse and conflict behaviour in the operant chamber.	Dronabinol	18-21	neuropeptide Y	Rattus norvegicus	188-191
32338122-6	2020	RESULTS: In utero THC-exposed adolescent rats showed: (a) increased locomotor activity; (b) no alteration in neutral declarative memory; (c) impaired aversive limbic memory; (d) decreased NPY-positive neurons in limbic regions; (e) region-specific variations in Homer-1, 1b/c and 2 immunoreactivity; (f) decreased instrumental learning and increased alcohol drinking, relapse and conflict behaviour in the operant chamber.	Dronabinol	18-21	homer scaffold protein 1	Rattus norvegicus	262-281
32351768-2	2020	We report a case involving a 16-year-old female who presented with fever, nonproductive cough, and shortness of breath after vaping e-cig/tetrahydrocannabinol dab pen.	Dronabinol	138-158	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	163-166
32330839-5	2020	Group I with (CBD/THC > 1) had a clear advantage in terms of the damage to the D1, RbCL and Lhc1 protein holo-complex.	Dronabinol	18-21	ribulose 1,5-bisphosphate carboxylase/oxygenase large subunit	Cannabis sativa	83-87
32488050-6	2020	Both THC and DHM reduced the density of parvalbumin expressing cells surrounded by perineuronal nets and, when combined, they disrupted the ratio between the density of puncta expressing excitatory and inhibitory markers.	Dronabinol	5-8	parvalbumin	Mus musculus	40-51
32433545-5	2020	As the primary endocannabinoid receptor in the brain, CB1 is the main molecular target of the endocannabinoid ligand, as well as tetrahydrocannabinol (THC), the principal psychoactive ingredient of cannabis.	Dronabinol	129-149	cannabinoid receptor 1	Homo sapiens	54-57
32433545-5	2020	As the primary endocannabinoid receptor in the brain, CB1 is the main molecular target of the endocannabinoid ligand, as well as tetrahydrocannabinol (THC), the principal psychoactive ingredient of cannabis.	Dronabinol	151-154	cannabinoid receptor 1	Homo sapiens	54-57
32433545-14	2020	THC or ethanol are each significantly associated with dysregulated expression of CNR1 in the PFC of patients with affective disorder, and the expression of CNR1 is significantly upregulated in the PFC of schizophrenia patients who completed suicide.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	81-85
32329240-2	2020	In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of  9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood.	Dronabinol	206-228	mechanistic target of rapamycin kinase	Mus musculus	79-83
32329240-2	2020	In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of  9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood.	Dronabinol	206-228	mechanistic target of rapamycin kinase	Mus musculus	299-303
32329240-2	2020	In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of  9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood.	Dronabinol	230-233	mechanistic target of rapamycin kinase	Mus musculus	79-83
32329240-2	2020	In line with previous findings that revealed a role of 5-HT6 receptor-operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of  9-tetrahydrocannabinol (THC) to mice during adolescence induces a long-lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long-term depression, as well as cognitive deficits in adulthood.	Dronabinol	230-233	mechanistic target of rapamycin kinase	Mus musculus	299-303
32329240-5	2020	Collectively, these findings suggest a role of 5-HT6 receptor-operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5-HT6 receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent cannabis abusers.	Dronabinol	142-145	mechanistic target of rapamycin kinase	Mus musculus	71-75
31013550-7	2020	Results indicated that CNR1 rs1049353 GG carriers showed increased state satiety after THC/THC + CBD administration in comparison with placebo and reduced the salience of appetitive cues after THC in comparison with CBD administration; A carriers did not vary on either of these measures indicative of a vulnerability to CUD.	Dronabinol	87-90	cannabinoid receptor 1	Homo sapiens	23-27
31013550-7	2020	Results indicated that CNR1 rs1049353 GG carriers showed increased state satiety after THC/THC + CBD administration in comparison with placebo and reduced the salience of appetitive cues after THC in comparison with CBD administration; A carriers did not vary on either of these measures indicative of a vulnerability to CUD.	Dronabinol	91-94	cannabinoid receptor 1	Homo sapiens	23-27
31013550-7	2020	Results indicated that CNR1 rs1049353 GG carriers showed increased state satiety after THC/THC + CBD administration in comparison with placebo and reduced the salience of appetitive cues after THC in comparison with CBD administration; A carriers did not vary on either of these measures indicative of a vulnerability to CUD.	Dronabinol	91-94	cannabinoid receptor 1	Homo sapiens	23-27
31013550-9	2020	FAAH rs324420 A carriers showed greater bias to appetitive cues after THC, in comparison with CC carriers.	Dronabinol	70-73	fatty acid amide hydrolase	Homo sapiens	0-4
31013550-10	2020	FAAH CC carriers showed reduced bias after THC in comparison with CBD.	Dronabinol	43-46	fatty acid amide hydrolase	Homo sapiens	0-4
32365486-4	2020	In the present study, we constructed a homology model of the human GPR18 based on an ensemble of three GPCR crystal structures to investigate the binding modes of the agonist THC and the recently reported antagonists which feature an imidazothiazinone core to which a (substituted) phenyl ring is connected via a lipophilic linker.	Dronabinol	175-178	G protein-coupled receptor 18	Homo sapiens	67-72
32365486-9	2020	The agonist THC is presumed to bind differently to GPR18 than to the distantly related CB receptors.	Dronabinol	12-15	G protein-coupled receptor 18	Homo sapiens	51-56
32954298-10	2020	Delta9-Tetrahydrocannabinol administration following injury also showed beneficial effects on the expression of Cnr1, Comt and Vegf-2R in the hippocampus, nucleus accumbens and prefrontal cortex.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	112-116
32954298-10	2020	Delta9-Tetrahydrocannabinol administration following injury also showed beneficial effects on the expression of Cnr1, Comt and Vegf-2R in the hippocampus, nucleus accumbens and prefrontal cortex.	Dronabinol	0-27	catechol-O-methyltransferase	Rattus norvegicus	118-122
31543247-2	2020	Cannabis potency is determined by the concentration of Delta9-tetrahydrocannabinol (Delta9-THC), a psychoactive constituent that activates cannabinoid CB1 and CB2 receptors.	Dronabinol	55-82	cannabinoid receptor 1	Homo sapiens	151-154
31543247-2	2020	Cannabis potency is determined by the concentration of Delta9-tetrahydrocannabinol (Delta9-THC), a psychoactive constituent that activates cannabinoid CB1 and CB2 receptors.	Dronabinol	55-82	cannabinoid receptor 2	Homo sapiens	159-162
31543247-2	2020	Cannabis potency is determined by the concentration of Delta9-tetrahydrocannabinol (Delta9-THC), a psychoactive constituent that activates cannabinoid CB1 and CB2 receptors.	Dronabinol	84-94	cannabinoid receptor 1	Homo sapiens	151-154
31543247-2	2020	Cannabis potency is determined by the concentration of Delta9-tetrahydrocannabinol (Delta9-THC), a psychoactive constituent that activates cannabinoid CB1 and CB2 receptors.	Dronabinol	84-94	cannabinoid receptor 2	Homo sapiens	159-162
31877572-6	2020	Unexpectedly, genetic deletion of CB2Rs also abolished analgesia and catalepsy produced by Delta9 -THC or WIN55212-2, but not by XLR11.	Dronabinol	99-102	cannabinoid receptor 2 (macrophage)	Mus musculus	34-37
31877572-8	2020	CB2-KO mice displayed a reduction in intra-ventricle Delta9 -THC-induced analgesia and catalepsy.	Dronabinol	61-64	cannabinoid receptor 2 (macrophage)	Mus musculus	0-3
31877572-9	2020	In contrast to CB1Rs and CB2Rs, genetic deletion of GPR55s caused enhanced responses to Delta9 -THC or WIN55212-2.	Dronabinol	96-99	G protein-coupled receptor 55	Mus musculus	52-57
32272438-10	2020	We provide evidence that dronabinol induces transcription of OGT via epigenetic hypomethylation of the transcription start site (TSS).	Dronabinol	25-35	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	61-64
32272438-11	2020	A lentiviral OGT-knock out approach proves the central role of OGT exerting antileukemic efficacy via a dual-mechanism of action: High concentrations of dronabinol result in induction of apoptosis, whereas lower concentrations drive cellular maturation.	Dronabinol	153-163	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	13-16
32272438-11	2020	A lentiviral OGT-knock out approach proves the central role of OGT exerting antileukemic efficacy via a dual-mechanism of action: High concentrations of dronabinol result in induction of apoptosis, whereas lower concentrations drive cellular maturation.	Dronabinol	153-163	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	63-66
31982904-2	2020	Specifically, THC affects the development of pyramidal neurons and GABAergic interneurons via cannabinoid CB1 receptors (CB1R).	Dronabinol	14-17	cannabinoid receptor 1 (brain)	Mus musculus	106-109
31982904-2	2020	Specifically, THC affects the development of pyramidal neurons and GABAergic interneurons via cannabinoid CB1 receptors (CB1R).	Dronabinol	14-17	cannabinoid receptor 1 (brain)	Mus musculus	121-125
31982904-8	2020	This THC-induced CCK-interneuron reduction was not evident in mice lacking CB1R selectively in GABAergic interneurons, thus pointing to a cell-autonomous THC action.	Dronabinol	5-8	cholecystokinin	Mus musculus	17-20
31982904-8	2020	This THC-induced CCK-interneuron reduction was not evident in mice lacking CB1R selectively in GABAergic interneurons, thus pointing to a cell-autonomous THC action.	Dronabinol	154-157	cholecystokinin	Mus musculus	17-20
32077955-5	2020	Delta9-Tetrahydrocannabinol produced a dose-dependent deficit in hemicholinium-3 binding, an index of presynaptic ACh activity, superimposed on regionally selective increases in choline acetyltransferase activity, a biomarker for numbers of ACh terminals.	Dronabinol	0-27	choline O-acetyltransferase	Rattus norvegicus	178-203
32070103-5	2020	Under on-chip exposure to the psychoactive cannabinoid, delta-9-tetrahydrocannabinol (THC), cerebral organoids exhibited reduced neuronal maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaired neurite outgrowth.	Dronabinol	56-84	cannabinoid receptor 1	Homo sapiens	168-200
32070103-5	2020	Under on-chip exposure to the psychoactive cannabinoid, delta-9-tetrahydrocannabinol (THC), cerebral organoids exhibited reduced neuronal maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaired neurite outgrowth.	Dronabinol	86-89	cannabinoid receptor 1	Homo sapiens	168-200
32256440-7	2020	Nabiximols (a combination of THC and CBD oromucosal spray) interact with both CB1 and CB2 receptors.	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	78-81
32256440-7	2020	Nabiximols (a combination of THC and CBD oromucosal spray) interact with both CB1 and CB2 receptors.	Dronabinol	29-32	cannabinoid receptor 2	Homo sapiens	86-89
32163506-8	2020	Last, THC activated the Akt/GSK3beta pathway dose-dependently in both control and PCP-treated animals.	Dronabinol	6-9	AKT serine/threonine kinase 1	Rattus norvegicus	24-27
32163506-8	2020	Last, THC activated the Akt/GSK3beta pathway dose-dependently in both control and PCP-treated animals.	Dronabinol	6-9	glycogen synthase kinase 3 alpha	Rattus norvegicus	28-36
31917333-0	2020	Delta9-tetrahydrocannabinol and 2-AG decreases neurite outgrowth and differentially affects ERK1/2 and Akt signaling in hiPSC-derived cortical neurons.	Dronabinol	0-27	mitogen-activated protein kinase 3	Homo sapiens	92-98
31917333-0	2020	Delta9-tetrahydrocannabinol and 2-AG decreases neurite outgrowth and differentially affects ERK1/2 and Akt signaling in hiPSC-derived cortical neurons.	Dronabinol	0-27	AKT serine/threonine kinase 1	Homo sapiens	103-106
31917333-7	2020	Interestingly, acute exposure to both 2AG and Delta9-THC inhibited phosphorylation of serine/threonine kinase extracellular signal-regulated protein kinases (ERK1/2), whereas Delta9-THC also reduced phosphorylation of Akt (aka PKB).	Dronabinol	53-56	mitogen-activated protein kinase 3	Homo sapiens	158-164
31917333-7	2020	Interestingly, acute exposure to both 2AG and Delta9-THC inhibited phosphorylation of serine/threonine kinase extracellular signal-regulated protein kinases (ERK1/2), whereas Delta9-THC also reduced phosphorylation of Akt (aka PKB).	Dronabinol	53-56	AKT serine/threonine kinase 1	Homo sapiens	218-221
31917333-7	2020	Interestingly, acute exposure to both 2AG and Delta9-THC inhibited phosphorylation of serine/threonine kinase extracellular signal-regulated protein kinases (ERK1/2), whereas Delta9-THC also reduced phosphorylation of Akt (aka PKB).	Dronabinol	53-56	AKT serine/threonine kinase 1	Homo sapiens	227-230
31917333-8	2020	Moreover, the CB1R inverse agonist SR 141716A attenuated the decrease in neurite outgrowth and ERK1/2 phosphorylation induced by 2AG and Delta9-THC.	Dronabinol	137-147	cannabinoid receptor 1	Homo sapiens	14-18
31917333-8	2020	Moreover, the CB1R inverse agonist SR 141716A attenuated the decrease in neurite outgrowth and ERK1/2 phosphorylation induced by 2AG and Delta9-THC.	Dronabinol	137-147	mitogen-activated protein kinase 3	Homo sapiens	95-101
31758947-4	2020	In the current study, we found that pretreatment with the JNK inhibitor SP600125 (3 mg/kg) attenuates tolerance to the antinociceptive in the formalin test and to the anti-allodynic effects of Delta9-THC (6 mg/kg) in cisplatin-evoked neuropathic pain using wild-type mice.	Dronabinol	193-203	mitogen-activated protein kinase 8	Mus musculus	58-61
31758947-7	2020	These results demonstrate that inhibition of JNK signaling pathways delay tolerance to Delta9-THC, but not to CP55,940 or WIN55,212-2, demonstrating that the mechanisms of cannabinoid tolerance are agonist-specific.	Dronabinol	87-97	mitogen-activated protein kinase 8	Mus musculus	45-48
32106399-7	2020	In preclinical studies, CB1 and CB2 agonists (i.e., anandamide, THC) have been shown to inhibit the proliferation of ER positive BC cell lines.	Dronabinol	64-67	cannabinoid receptor 1	Homo sapiens	24-27
32106399-7	2020	In preclinical studies, CB1 and CB2 agonists (i.e., anandamide, THC) have been shown to inhibit the proliferation of ER positive BC cell lines.	Dronabinol	64-67	cannabinoid receptor 2	Homo sapiens	32-35
31986271-8	2020	For both CBD and Delta9-THC, in-tube SPME/UHPLC-MS/MS presented linear range from 10 to 300 ng mL-1, precision with coefficient of variation (CV) values ranging from 0.2% to 19.1% (LLOQ), and accuracy with relative standard deviation (RSD) values spanning from -9.3% to 19.6% (LLOQ).	Dronabinol	17-27	L1 cell adhesion molecule	Mus musculus	95-99
32049991-3	2020	This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	123-143	cannabinoid receptor 1	Homo sapiens	91-94
32049991-3	2020	This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydrocannabinol (THC) and cannabidiol (CBD).	Dronabinol	123-143	cannabinoid receptor 2	Homo sapiens	99-102
32049991-14	2020	THC and CBD alone or in combination restored the epithelial phenotype, as evidenced by increased expression of CDH1 and reduced expression of CDH2 and VIM, as well as by fluorescence analysis of cellular cytoskeleton.	Dronabinol	0-3	cadherin 1	Homo sapiens	111-115
32049991-14	2020	THC and CBD alone or in combination restored the epithelial phenotype, as evidenced by increased expression of CDH1 and reduced expression of CDH2 and VIM, as well as by fluorescence analysis of cellular cytoskeleton.	Dronabinol	0-3	cadherin 2	Homo sapiens	142-146
32049991-14	2020	THC and CBD alone or in combination restored the epithelial phenotype, as evidenced by increased expression of CDH1 and reduced expression of CDH2 and VIM, as well as by fluorescence analysis of cellular cytoskeleton.	Dronabinol	0-3	vimentin	Homo sapiens	151-154
32049991-17	2020	THC and CBD inhibited the proliferation and expression of EGFR in the lung cancer cells studied.	Dronabinol	0-3	epidermal growth factor receptor	Homo sapiens	58-62
32050487-2	2020	SCBs are more dangerous than Delta9-Tetrahydrocannabinol as a consequence of their stronger affinities for the CB1 and CB2 receptors, which may result in longer duration of distinct effects, greater potency, and toxicity.	Dronabinol	29-56	cannabinoid receptor 1	Homo sapiens	111-114
32050487-2	2020	SCBs are more dangerous than Delta9-Tetrahydrocannabinol as a consequence of their stronger affinities for the CB1 and CB2 receptors, which may result in longer duration of distinct effects, greater potency, and toxicity.	Dronabinol	29-56	cannabinoid receptor 2	Homo sapiens	119-122
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	interleukin 6	Mus musculus	276-279
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	DNA-damage inducible transcript 3	Mus musculus	281-285
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	X-box binding protein 1	Mus musculus	287-291
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	heme oxygenase 1	Mus musculus	293-297
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	heme oxygenase 2	Mus musculus	321-325
31837780-10	2020	Compared with HC goats, THC goats had lower ruminal epithelium activity of the enzymes myeloperoxidase and matrix metalloproteinase (MMP) 2 and 9.	Dronabinol	24-27	myeloperoxidase	Capra hircus	87-102
31837780-10	2020	Compared with HC goats, THC goats had lower ruminal epithelium activity of the enzymes myeloperoxidase and matrix metalloproteinase (MMP) 2 and 9.	Dronabinol	24-27	matrix metalloproteinase-9	Capra hircus	107-145
31837780-11	2020	In contrast to HC, THC had downregulated mRNA expression of nuclear factor-kappaB (NFKB), TLR4, IL1B, MMP2, and MMP9 in ruminal epithelium.	Dronabinol	19-22	toll-like receptor 4	Capra hircus	90-94
31837780-11	2020	In contrast to HC, THC had downregulated mRNA expression of nuclear factor-kappaB (NFKB), TLR4, IL1B, MMP2, and MMP9 in ruminal epithelium.	Dronabinol	19-22	interleukin-1 beta	Capra hircus	96-100
31837780-11	2020	In contrast to HC, THC had downregulated mRNA expression of nuclear factor-kappaB (NFKB), TLR4, IL1B, MMP2, and MMP9 in ruminal epithelium.	Dronabinol	19-22	72 kDa type IV collagenase	Capra hircus	102-106
31837780-11	2020	In contrast to HC, THC had downregulated mRNA expression of nuclear factor-kappaB (NFKB), TLR4, IL1B, MMP2, and MMP9 in ruminal epithelium.	Dronabinol	19-22	matrix metalloproteinase-9	Capra hircus	112-116
31730886-12	2020	For UR-144, this effect was reversed by the CB1 antagonist AM281, for JWH-018 and THC this effect was mediated by both cannabinoid receptors CB1 and CB2 while for JWH-122 it was cannabinoid receptor-independent.	Dronabinol	82-85	cannabinoid receptor 1	Homo sapiens	44-47
31730886-12	2020	For UR-144, this effect was reversed by the CB1 antagonist AM281, for JWH-018 and THC this effect was mediated by both cannabinoid receptors CB1 and CB2 while for JWH-122 it was cannabinoid receptor-independent.	Dronabinol	82-85	cannabinoid receptor 1	Homo sapiens	141-144
31730886-12	2020	For UR-144, this effect was reversed by the CB1 antagonist AM281, for JWH-018 and THC this effect was mediated by both cannabinoid receptors CB1 and CB2 while for JWH-122 it was cannabinoid receptor-independent.	Dronabinol	82-85	cannabinoid receptor 2	Homo sapiens	149-152
31891265-0	2020	Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal Cannabis sativa Variety: Delta9-Tetrahydrocannabutol, the Butyl Homologue of Delta9-Tetrahydrocannabinol.	Dronabinol	162-189	cannabinoid receptor 1	Homo sapiens	55-58
31891265-4	2020	The butyl homologue of Delta9-THC, Delta9-THCB, showed an affinity for the human CB1 (Ki = 15 nM) and CB2 receptors (Ki = 51 nM) comparable to that of (-)-trans-Delta9-THC.	Dronabinol	23-33	cannabinoid receptor 1	Homo sapiens	81-84
31891265-4	2020	The butyl homologue of Delta9-THC, Delta9-THCB, showed an affinity for the human CB1 (Ki = 15 nM) and CB2 receptors (Ki = 51 nM) comparable to that of (-)-trans-Delta9-THC.	Dronabinol	23-33	cannabinoid receptor 2	Homo sapiens	102-105
31891265-5	2020	Docking studies suggested the key bonds responsible for THC-like binding affinity for the CB1 receptor.	Dronabinol	56-59	cannabinoid receptor 1	Homo sapiens	90-93
31972514-6	2020	Furthermore, THC increased D1-D2-linked calcium signaling markers (pCaMKIIalpha, pThr75-DARPP-32, BDNF/pTrkB) and inhibited cyclic AMP signaling (pThr34-DARPP-32, pERK1/2, pS845-GluA1, pGSK3).	Dronabinol	13-16	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	88-96
31972514-6	2020	Furthermore, THC increased D1-D2-linked calcium signaling markers (pCaMKIIalpha, pThr75-DARPP-32, BDNF/pTrkB) and inhibited cyclic AMP signaling (pThr34-DARPP-32, pERK1/2, pS845-GluA1, pGSK3).	Dronabinol	13-16	brain derived neurotrophic factor	Homo sapiens	98-102
31972514-6	2020	Furthermore, THC increased D1-D2-linked calcium signaling markers (pCaMKIIalpha, pThr75-DARPP-32, BDNF/pTrkB) and inhibited cyclic AMP signaling (pThr34-DARPP-32, pERK1/2, pS845-GluA1, pGSK3).	Dronabinol	13-16	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	153-161
31972514-6	2020	Furthermore, THC increased D1-D2-linked calcium signaling markers (pCaMKIIalpha, pThr75-DARPP-32, BDNF/pTrkB) and inhibited cyclic AMP signaling (pThr34-DARPP-32, pERK1/2, pS845-GluA1, pGSK3).	Dronabinol	13-16	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	178-183
31953475-10	2020	E19.5 placentas from Delta9-THC-exposed pregnancies exhibited a phenotype characterized by increased labyrinth area, reduced Epcam expression (marker of labyrinth trophoblast progenitors), altered maternal blood space, decreased fetal capillary area and an increased recruitment of pericytes with greater collagen deposition, when compared to vehicle controls.	Dronabinol	21-31	epithelial cell adhesion molecule	Rattus norvegicus	125-130
31953475-11	2020	Further, at E19.5 labyrinth trophoblast had reduced glucose transporter 1 (GLUT1) and glucocorticoid receptor (GR) expression in response to Delta9-THC exposure.	Dronabinol	141-151	solute carrier family 2 member 1	Rattus norvegicus	52-73
31953475-11	2020	Further, at E19.5 labyrinth trophoblast had reduced glucose transporter 1 (GLUT1) and glucocorticoid receptor (GR) expression in response to Delta9-THC exposure.	Dronabinol	141-151	solute carrier family 2 member 1	Rattus norvegicus	75-80
31953475-11	2020	Further, at E19.5 labyrinth trophoblast had reduced glucose transporter 1 (GLUT1) and glucocorticoid receptor (GR) expression in response to Delta9-THC exposure.	Dronabinol	141-151	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	86-109
31953475-11	2020	Further, at E19.5 labyrinth trophoblast had reduced glucose transporter 1 (GLUT1) and glucocorticoid receptor (GR) expression in response to Delta9-THC exposure.	Dronabinol	141-151	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	111-113
31953475-13	2020	These findings implicate GLUT1 as a Delta9-THC target and provide a potential mechanism for the fetal growth restriction observed in women who use cannabis during pregnancy.	Dronabinol	43-46	solute carrier family 2 member 1	Homo sapiens	25-30
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	43-70	cannabinoid receptor 1	Danio rerio	168-172
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	43-70	cannabinoid receptor 2	Danio rerio	177-181
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	72-82	cannabinoid receptor 1	Danio rerio	168-172
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	72-82	cannabinoid receptor 2	Danio rerio	177-181
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	79-82	cannabinoid receptor 1	Danio rerio	168-172
31947970-2	2020	The psychoactive ingredient in cannabis is Delta9-Tetrahydrocannabinol (Delta9-THC, hereafter referred to as THC), which is an agonist at the endocannabinoid receptors CB1R and CB2R.	Dronabinol	79-82	cannabinoid receptor 2	Danio rerio	177-181
30378732-4	2020	To assess the role of different nAChR subtypes in THC withdrawal, we used transgenic mouse, preclinical pharmacological, and human genetic correlation approaches.	Dronabinol	50-53	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	32-37
30378732-5	2020	Our findings show that selective alpha3beta4* nAChR antagonist, AuIB, and alpha3beta4* nAChR partial agonist, AT-1001, dose-dependently attenuated somatic withdrawal signs in THC-dependent mice that were challenged with the cannabinoid-1 receptor antagonist rimonabant.	Dronabinol	175-178	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	46-51
30378732-5	2020	Our findings show that selective alpha3beta4* nAChR antagonist, AuIB, and alpha3beta4* nAChR partial agonist, AT-1001, dose-dependently attenuated somatic withdrawal signs in THC-dependent mice that were challenged with the cannabinoid-1 receptor antagonist rimonabant.	Dronabinol	175-178	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	87-92
30378732-6	2020	Additionally, THC-dependent alpha5 and alpha6 nAChR knockout (KO) mice displayed decreased rimonabant precipitated somatic withdrawal signs compared with their wild-type counterparts.	Dronabinol	14-17	cholinergic receptor, nicotinic, alpha polypeptide 6	Mus musculus	39-51
30378732-10	2020	Overall, these findings suggest that alpha3beta4* and alpha6beta4* nAChR subtypes represent viable targets for the development of medications to counteract THC dependence.	Dronabinol	156-159	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	67-72
31451081-6	2020	Adult male rats exposed to delta-9-tetrahydrocannabinol (THC) showed differential DNA methylation at Dlgap2 in sperm (p &lt; 0.03), as did the nucleus accumbens of rats whose fathers were exposed to THC prior to conception (p &lt; 0.05).	Dronabinol	27-55	DLG associated protein 2	Rattus norvegicus	101-107
31451081-6	2020	Adult male rats exposed to delta-9-tetrahydrocannabinol (THC) showed differential DNA methylation at Dlgap2 in sperm (p &lt; 0.03), as did the nucleus accumbens of rats whose fathers were exposed to THC prior to conception (p &lt; 0.05).	Dronabinol	57-60	DLG associated protein 2	Rattus norvegicus	101-107
32236882-4	2020	CB1 receptors mediate the cannabimimetic effects of THC and are highly expressed on presynaptic neurons in the nervous system, where they modulate neurotransmitter release.	Dronabinol	52-55	cannabinoid receptor 1	Homo sapiens	0-3
32564014-4	2020	THC significantly suppressed LPS-induced interleukin-1beta production and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression and significantly decreased LPS-induced nuclear factor-kappaB activation by attenuating p65 phosphorylation and inhibitor of kappa B degradation.	Dronabinol	0-3	interleukin 1 beta	Homo sapiens	41-58
32564014-4	2020	THC significantly suppressed LPS-induced interleukin-1beta production and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression and significantly decreased LPS-induced nuclear factor-kappaB activation by attenuating p65 phosphorylation and inhibitor of kappa B degradation.	Dronabinol	0-3	intercellular adhesion molecule 1	Homo sapiens	74-107
32564014-4	2020	THC significantly suppressed LPS-induced interleukin-1beta production and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression and significantly decreased LPS-induced nuclear factor-kappaB activation by attenuating p65 phosphorylation and inhibitor of kappa B degradation.	Dronabinol	0-3	vascular cell adhesion molecule 1	Homo sapiens	112-145
32564014-4	2020	THC significantly suppressed LPS-induced interleukin-1beta production and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression and significantly decreased LPS-induced nuclear factor-kappaB activation by attenuating p65 phosphorylation and inhibitor of kappa B degradation.	Dronabinol	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	245-248
32564014-6	2020	THC resulted in increased expression of SIRT1 in LPS-challenged HUVECs.	Dronabinol	0-3	sirtuin 1	Homo sapiens	40-45
32564014-7	2020	Among the downstream molecular targets of SIRT1, the level of LPS-induced acetylated p53 was significantly decreased by THC treatment, whereas no noticeable change was observed in the levels of forkhead box O3 and peroxisome proliferator activated receptor gamma coactivator 1 alpha.	Dronabinol	120-123	sirtuin 1	Homo sapiens	42-47
32564014-7	2020	Among the downstream molecular targets of SIRT1, the level of LPS-induced acetylated p53 was significantly decreased by THC treatment, whereas no noticeable change was observed in the levels of forkhead box O3 and peroxisome proliferator activated receptor gamma coactivator 1 alpha.	Dronabinol	120-123	tumor protein p53	Homo sapiens	85-88
32564014-8	2020	In conclusion, the results clearly demonstrate that THC possesses anti-inflammatory properties by increasing SIRT1 expression and subsequent suppression of p53 activation in LPS-challenged HUVECs.	Dronabinol	52-55	sirtuin 1	Homo sapiens	109-114
32564014-8	2020	In conclusion, the results clearly demonstrate that THC possesses anti-inflammatory properties by increasing SIRT1 expression and subsequent suppression of p53 activation in LPS-challenged HUVECs.	Dronabinol	52-55	tumor protein p53	Homo sapiens	156-159
31323660-0	2020	Chronic adolescent exposure to  9-tetrahydrocannabinol decreases NMDA current and extrasynaptic plasmalemmal density of NMDA GluN1 subunits in the prelimbic cortex of adult male mice.	Dronabinol	32-54	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	125-130
31323660-3	2020	Thus, chronic occupancy of CB1Rs by  9-THC during adolescence may competitively decrease the functional expression and activity of NMDA receptors in the mature PL-PFC.	Dronabinol	37-42	cannabinoid receptor 1 (brain)	Mus musculus	27-30
31323660-6	2020	Electron microscopic immunolabeling in the PL-PFC of adult mice that had received Delta9-THC only during adolescence showed a significant (1) decrease in the extrasynaptic plasmalemmal density of obligatory GluN1-NMDA subunits in dendrites of all sizes and (2) a shift from cytoplasmic to plasmalemmal distribution of GluN1 in large dendrites receiving mainly inhibitory-type synapses from CB1R-labeled terminals.	Dronabinol	82-92	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	207-212
31323660-6	2020	Electron microscopic immunolabeling in the PL-PFC of adult mice that had received Delta9-THC only during adolescence showed a significant (1) decrease in the extrasynaptic plasmalemmal density of obligatory GluN1-NMDA subunits in dendrites of all sizes and (2) a shift from cytoplasmic to plasmalemmal distribution of GluN1 in large dendrites receiving mainly inhibitory-type synapses from CB1R-labeled terminals.	Dronabinol	82-92	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	318-323
31323660-6	2020	Electron microscopic immunolabeling in the PL-PFC of adult mice that had received Delta9-THC only during adolescence showed a significant (1) decrease in the extrasynaptic plasmalemmal density of obligatory GluN1-NMDA subunits in dendrites of all sizes and (2) a shift from cytoplasmic to plasmalemmal distribution of GluN1 in large dendrites receiving mainly inhibitory-type synapses from CB1R-labeled terminals.	Dronabinol	82-92	cannabinoid receptor 1 (brain)	Mus musculus	390-394
32009043-3	2020	THC, but not CBD, has been shown to produce abnormal behavior in animals; these effects are caused, at least in part, by binding to cannabinoid receptor type 1 (CB1) in the brain.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	161-164
32009044-8	2020	The rank order of cytotoxicological potency was synthetic cannabinoids>Delta9-THC and related to the agonistic activities of the CB1 receptor.	Dronabinol	71-81	cannabinoid receptor 1 (brain)	Mus musculus	129-132
31856143-1	2019	BACKGROUND This study aimed to prepare doxorubicin- and tetrahydrocurcumin-loaded and transferrin-modified PEG-PLGA nanoparticles (Tf-NPs-DOX-THC) for enhanced and synergistic chemoradiotherapy.	Dronabinol	138-145	transferrin	Mus musculus	86-97
31672337-15	2019	Pharmaceutical THC (with or without CBD) did not significantly affect any other primary outcomes for the mental disorders examined but did increase the number of people who had adverse events (OR 1 99 [95% CI 1 20 to 3 29]; ten studies; n=1495) and withdrawals due to adverse events (2 78 [1 59 to 4 86]; 11 studies; n=1621) compared with placebo across all mental disorders examined.	Dronabinol	15-18	olfactory receptor family 7 subfamily E member 16 pseudogene	Homo sapiens	193-200
31465975-9	2019	In this article, we tried to discuss our hypothesis regarding the possible role of CBD and Delta9-THC, as a potent neuroprotective and anti-inflammatory agents, in inhibition or treatment of METH-induced neurodegeneration, neuro-inflammation and mitochondrial dysfunction through its effects on TLR4/NF-kappaB signaling pathway.	Dronabinol	91-101	toll like receptor 4	Homo sapiens	295-299
31467080-6	2019	We have previously reported that tetrahydrocannabinol-mediated cognitive impairment arises from homo- or hetero-oligomerization between the GPCRs cannabinoid receptor type 1 (CB1R) and 5-hydroxytryptamine 2A (5-HT2AR) receptors.	Dronabinol	33-53	cannabinoid receptor 1	Homo sapiens	175-179
31690747-2	2019	The CBs, Delta9-THC, cannabidiol, HU-210, and CP 55,940 caused alcohol-like effects on craniofacial and brain development, phenocopying Shh mutations.	Dronabinol	9-19	sonic hedgehog	Mus musculus	136-139
31356922-4	2019	THC + CBD treatment attenuated EAE and caused significant decrease in inflammatory cytokines such as IL-17 and IFN-gamma while promoting the induction of anti-inflammatory cytokines such as IL-10 and TGF-beta.	Dronabinol	0-3	interleukin 17A	Mus musculus	101-106
31356922-4	2019	THC + CBD treatment attenuated EAE and caused significant decrease in inflammatory cytokines such as IL-17 and IFN-gamma while promoting the induction of anti-inflammatory cytokines such as IL-10 and TGF-beta.	Dronabinol	0-3	interferon gamma	Mus musculus	111-120
31356922-4	2019	THC + CBD treatment attenuated EAE and caused significant decrease in inflammatory cytokines such as IL-17 and IFN-gamma while promoting the induction of anti-inflammatory cytokines such as IL-10 and TGF-beta.	Dronabinol	0-3	interleukin 10	Mus musculus	190-195
31356922-4	2019	THC + CBD treatment attenuated EAE and caused significant decrease in inflammatory cytokines such as IL-17 and IFN-gamma while promoting the induction of anti-inflammatory cytokines such as IL-10 and TGF-beta.	Dronabinol	0-3	transforming growth factor alpha	Mus musculus	200-208
31165913-14	2019	CONCLUSIONS: The acute administration of THC, partial CB1R agonist, significantly impaired non-spatial memory in humans, monkeys, and non-human primates but not rodents.	Dronabinol	41-44	cannabinoid receptor 1	Homo sapiens	54-58
31187152-0	2019	Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans.	Dronabinol	173-201	catechol-O-methyltransferase	Homo sapiens	118-147
31187152-1	2019	RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain.	Dronabinol	131-159	catechol-O-methyltransferase	Homo sapiens	15-44
31187152-1	2019	RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain.	Dronabinol	131-159	catechol-O-methyltransferase	Homo sapiens	46-50
31187152-1	2019	RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain.	Dronabinol	161-164	catechol-O-methyltransferase	Homo sapiens	15-44
31187152-1	2019	RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain.	Dronabinol	161-164	catechol-O-methyltransferase	Homo sapiens	46-50
31187152-2	2019	OBJECTIVE: This study was designed to evaluate the effect of (1) a functional polymorphism and (2) acute pharmacological inhibition of COMT on the acute response to THC in humans.	Dronabinol	165-168	catechol-O-methyltransferase	Homo sapiens	135-139
31187152-10	2019	CONCLUSIONS: The interaction between COMT rs4680 polymorphisms and tolcapone on the cognitive, but not on the psychotomimetic and overall subjective effects of THC, suggests that modulation of dopaminergic signaling may selectively influence specific cannabinoid effects in healthy individuals.	Dronabinol	160-163	catechol-O-methyltransferase	Homo sapiens	37-41
31570536-0	2019	Cannabidiol Counteracts the Psychotropic Side-Effects of Delta-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.	Dronabinol	57-85	mitogen activated protein kinase 3	Rattus norvegicus	146-152
31570536-7	2019	We demonstrate that THC induces cognitive and affective abnormalities resembling neuropsychiatric symptoms directly in the hippocampus, while dysregulating dopamine activity states and amplifying oscillatory frequencies in the ventral tegmental area via modulation of the extracellular signal-regulated kinase (ERK) signaling pathway.	Dronabinol	20-23	Eph receptor B1	Rattus norvegicus	311-314
31570536-8	2019	In contrast, CBD coadministration blocked THC-induced ERK phosphorylation, and prevented THC-induced behavioral and neural abnormalities.	Dronabinol	42-45	Eph receptor B1	Rattus norvegicus	54-57
31636565-5	2019	Here, we report that a single THC dose on PND 10 decreased transcript levels of tropomyosin receptor kinase b (Trkb) 24 h after exposure in both the frontal and parietal cortex, and in the hippocampus in mice.	Dronabinol	30-33	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	80-109
31636565-5	2019	Here, we report that a single THC dose on PND 10 decreased transcript levels of tropomyosin receptor kinase b (Trkb) 24 h after exposure in both the frontal and parietal cortex, and in the hippocampus in mice.	Dronabinol	30-33	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	111-115
31636565-6	2019	An increase in the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) ratio were also found in both the parietal cortex and hippocampus following neonatal exposure to THC.	Dronabinol	211-214	nuclear factor, erythroid derived 2, like 2	Mus musculus	19-62
31636565-6	2019	An increase in the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) ratio were also found in both the parietal cortex and hippocampus following neonatal exposure to THC.	Dronabinol	211-214	nuclear factor, erythroid derived 2, like 2	Mus musculus	64-68
31636565-6	2019	An increase in the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) ratio were also found in both the parietal cortex and hippocampus following neonatal exposure to THC.	Dronabinol	211-214	kelch-like ECH-associated protein 1	Mus musculus	70-105
31636565-6	2019	An increase in the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) ratio were also found in both the parietal cortex and hippocampus following neonatal exposure to THC.	Dronabinol	211-214	kelch-like ECH-associated protein 1	Mus musculus	107-112
31636565-7	2019	In addition, THC exposure increased transcript levels of cannabinoid receptor type 1 (Cb1r) in the parietal cortex and increased the apoptosis regulator BAX in the frontal cortex.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	57-84
31636565-7	2019	In addition, THC exposure increased transcript levels of cannabinoid receptor type 1 (Cb1r) in the parietal cortex and increased the apoptosis regulator BAX in the frontal cortex.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	86-90
31636565-7	2019	In addition, THC exposure increased transcript levels of cannabinoid receptor type 1 (Cb1r) in the parietal cortex and increased the apoptosis regulator BAX in the frontal cortex.	Dronabinol	13-16	BCL2-associated X protein	Mus musculus	133-156
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	142-145	neurotrophic receptor tyrosine kinase 2	Homo sapiens	222-226
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	142-145	neurotrophic receptor tyrosine kinase 2	Homo sapiens	368-372
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	142-145	brain derived neurotrophic factor	Homo sapiens	512-545
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	142-145	brain derived neurotrophic factor	Homo sapiens	547-551
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	142-145	neurotrophic receptor tyrosine kinase 2	Homo sapiens	553-557
31636565-8	2019	This study is important for mainly 3 reasons: 1) we are starting to get information on the developmental neurotoxic AOP of PND 10 exposure to THC, where we suggest that transcriptional changes of the neurotrophic receptor Trkb are central, 2) our PND 10 exposure model provides information relevant to human exposure and 3) since PND 10 exposure to AAP also decreased Trkb transcript levels, we suggest THC and AAP may share key events in their respective AOP through endocannabinoid-mediated alterations of the brain-derived neurotrophic factor (BDNF)-TRKB signaling pathway.	Dronabinol	403-406	neurotrophic receptor tyrosine kinase 2	Homo sapiens	222-226
31328790-1	2019	BACKGROUND AND PURPOSE: Delta9 -tetrahydrocannabinol (THC) acts via cannabinoid CB1 receptors to increase feeding.	Dronabinol	24-52	cannabinoid receptor 1	Rattus norvegicus	80-83
31328790-1	2019	BACKGROUND AND PURPOSE: Delta9 -tetrahydrocannabinol (THC) acts via cannabinoid CB1 receptors to increase feeding.	Dronabinol	54-57	cannabinoid receptor 1	Rattus norvegicus	80-83
31114948-2	2019	Cytochrome P450 (CYP) 2C9, the primary enzyme responsible for THC metabolism, has two single nucleotide polymorphisms-Arg144Cys (*2) and Ile359Leu (*3).	Dronabinol	62-65	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-25
31114948-6	2019	We therefore sought to characterize the pharmacokinetics of THC and its major metabolites 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in healthy volunteers with known CYP2C9 status by non-compartmental analysis (NCA), compartmental modeling (CM) and minimal physiologically based pharmacokinetic (mPBPK) modeling.	Dronabinol	60-63	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	233-239
31114948-11	2019	THC hepatic clearance is dependent on the CYP2C9 genetic variant in the population.	Dronabinol	0-3	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	42-48
31114948-15	2019	THC-COOH is glucuronidated and renally cleared; subjects homozygous for CYP2C9*3 have reduced exposure to this metabolite as a result of the polymorphism reducing THC production, the hepatic diffusional barrier impeding egress from the hepatocyte, and increased renal clearance.	Dronabinol	0-3	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-78
31114948-15	2019	THC-COOH is glucuronidated and renally cleared; subjects homozygous for CYP2C9*3 have reduced exposure to this metabolite as a result of the polymorphism reducing THC production, the hepatic diffusional barrier impeding egress from the hepatocyte, and increased renal clearance.	Dronabinol	163-166	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-78
31114948-16	2019	CONCLUSION: It has recently been reported that the terminal metabolite THC-COOH is active, implying the exposure difference in individuals homozygous for CYP2C9*3 may become therapeutically relevant.	Dronabinol	71-74	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	154-160
31383729-0	2019	Delta9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture.	Dronabinol	0-27	C-C motif chemokine ligand 2	Homo sapiens	81-115
31383729-0	2019	Delta9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture.	Dronabinol	0-27	interleukin 6	Homo sapiens	120-133
31383729-0	2019	Delta9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture.	Dronabinol	0-27	toll like receptor 7	Homo sapiens	139-159
31383729-8	2019	THC treatment of the TLR7-stimulated coculture suppressed monocyte secretion of IL-1beta, resulting in decreased astrocyte production of MCP-1 and IL-6.	Dronabinol	0-3	toll like receptor 7	Homo sapiens	21-25
31383729-8	2019	THC treatment of the TLR7-stimulated coculture suppressed monocyte secretion of IL-1beta, resulting in decreased astrocyte production of MCP-1 and IL-6.	Dronabinol	0-3	interleukin 1 beta	Homo sapiens	80-88
31383729-8	2019	THC treatment of the TLR7-stimulated coculture suppressed monocyte secretion of IL-1beta, resulting in decreased astrocyte production of MCP-1 and IL-6.	Dronabinol	0-3	C-C motif chemokine ligand 2	Homo sapiens	137-142
31383729-8	2019	THC treatment of the TLR7-stimulated coculture suppressed monocyte secretion of IL-1beta, resulting in decreased astrocyte production of MCP-1 and IL-6.	Dronabinol	0-3	interleukin 6	Homo sapiens	147-151
31383729-9	2019	Furthermore, THC displayed direct inhibition of monocytes, as TLR7-stimulated monocyte monocultures treated with THC also showed suppressed IL-1beta production.	Dronabinol	13-16	interleukin 1 beta	Homo sapiens	140-148
31383729-9	2019	Furthermore, THC displayed direct inhibition of monocytes, as TLR7-stimulated monocyte monocultures treated with THC also showed suppressed IL-1beta production.	Dronabinol	113-116	toll like receptor 7	Homo sapiens	62-66
31383729-9	2019	Furthermore, THC displayed direct inhibition of monocytes, as TLR7-stimulated monocyte monocultures treated with THC also showed suppressed IL-1beta production.	Dronabinol	113-116	interleukin 1 beta	Homo sapiens	140-148
31383729-10	2019	The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2.	Dronabinol	129-132	cannabinoid receptor 2	Homo sapiens	4-26
31383729-10	2019	The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2.	Dronabinol	129-132	cannabinoid receptor 2	Homo sapiens	28-31
31383729-10	2019	The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2.	Dronabinol	129-132	cannabinoid receptor 2	Homo sapiens	156-159
31383729-11	2019	THC also suppressed key elements of the IL-1beta production pathway, including IL1B mRNA levels and caspase-1 activity.	Dronabinol	0-3	interleukin 1 beta	Homo sapiens	40-48
31383729-11	2019	THC also suppressed key elements of the IL-1beta production pathway, including IL1B mRNA levels and caspase-1 activity.	Dronabinol	0-3	interleukin 1 beta	Homo sapiens	79-83
31383729-12	2019	Collectively, this study demonstrates that the anti-inflammatory properties of THC suppress TLR7-induced monocyte secretion of IL-1beta through CB2, which results in decreased astrocyte secretion of MCP-1 and IL-6.	Dronabinol	79-82	toll like receptor 7	Homo sapiens	92-96
31383729-12	2019	Collectively, this study demonstrates that the anti-inflammatory properties of THC suppress TLR7-induced monocyte secretion of IL-1beta through CB2, which results in decreased astrocyte secretion of MCP-1 and IL-6.	Dronabinol	79-82	interleukin 1 beta	Homo sapiens	127-135
31383729-12	2019	Collectively, this study demonstrates that the anti-inflammatory properties of THC suppress TLR7-induced monocyte secretion of IL-1beta through CB2, which results in decreased astrocyte secretion of MCP-1 and IL-6.	Dronabinol	79-82	cannabinoid receptor 2	Homo sapiens	144-147
31383729-12	2019	Collectively, this study demonstrates that the anti-inflammatory properties of THC suppress TLR7-induced monocyte secretion of IL-1beta through CB2, which results in decreased astrocyte secretion of MCP-1 and IL-6.	Dronabinol	79-82	C-C motif chemokine ligand 2	Homo sapiens	199-204
31383729-12	2019	Collectively, this study demonstrates that the anti-inflammatory properties of THC suppress TLR7-induced monocyte secretion of IL-1beta through CB2, which results in decreased astrocyte secretion of MCP-1 and IL-6.	Dronabinol	79-82	interleukin 6	Homo sapiens	209-213
31559333-2	2019	Cannabinoids such as Delta9-tetrahydrocannabinol (Delta9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling.	Dronabinol	21-48	cannabinoid receptor 1 (brain)	Mus musculus	104-107
31559333-2	2019	Cannabinoids such as Delta9-tetrahydrocannabinol (Delta9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling.	Dronabinol	21-48	cannabinoid receptor 2 (macrophage)	Mus musculus	137-140
31559333-2	2019	Cannabinoids such as Delta9-tetrahydrocannabinol (Delta9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling.	Dronabinol	50-60	cannabinoid receptor 1 (brain)	Mus musculus	104-107
31559333-2	2019	Cannabinoids such as Delta9-tetrahydrocannabinol (Delta9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling.	Dronabinol	50-60	cannabinoid receptor 2 (macrophage)	Mus musculus	137-140
31158514-1	2019	Described during the late 1980s and 1990s, cannabinoid receptors (CB1R and CB2R) are G-protein-coupled receptors (GPCRs) activated by endogenous ligands and cannabinoid drug compounds, such as Delta9-THC.	Dronabinol	193-203	cannabinoid receptor 1	Homo sapiens	66-70
31081965-0	2019	The effects of delta-9-tetrahydrocannabinol on Kruppel-like factor-4 expression, redox homeostasis, and inflammation in the kidney of diabetic rat.	Dronabinol	15-43	Kruppel like factor 4	Rattus norvegicus	47-68
31081965-9	2019	Furthermore, mRNA expression of Kruppel-like factor-4, secreted immunopositive cell number changes of interleukin-6, nuclear factor kappabeta (NF-kappabeta), and peroxisome proliferator-activated receptor-gamma and tumor necrosis factor alpha (TNF-alpha) levels were analyzed for the immunomodulatory activity of THC.	Dronabinol	313-316	Kruppel like factor 4	Rattus norvegicus	32-53
31081965-9	2019	Furthermore, mRNA expression of Kruppel-like factor-4, secreted immunopositive cell number changes of interleukin-6, nuclear factor kappabeta (NF-kappabeta), and peroxisome proliferator-activated receptor-gamma and tumor necrosis factor alpha (TNF-alpha) levels were analyzed for the immunomodulatory activity of THC.	Dronabinol	313-316	interleukin 6	Rattus norvegicus	102-141
31081965-9	2019	Furthermore, mRNA expression of Kruppel-like factor-4, secreted immunopositive cell number changes of interleukin-6, nuclear factor kappabeta (NF-kappabeta), and peroxisome proliferator-activated receptor-gamma and tumor necrosis factor alpha (TNF-alpha) levels were analyzed for the immunomodulatory activity of THC.	Dronabinol	313-316	tumor necrosis factor	Rattus norvegicus	215-242
31081965-9	2019	Furthermore, mRNA expression of Kruppel-like factor-4, secreted immunopositive cell number changes of interleukin-6, nuclear factor kappabeta (NF-kappabeta), and peroxisome proliferator-activated receptor-gamma and tumor necrosis factor alpha (TNF-alpha) levels were analyzed for the immunomodulatory activity of THC.	Dronabinol	313-316	tumor necrosis factor	Rattus norvegicus	244-253
31433338-6	2019	FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).	Dronabinol	253-256	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	141-147
31433338-6	2019	FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).	Dronabinol	253-256	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	149-155
31433338-6	2019	FINDINGS: After comparing the in vitro inhibition parameters to physiologically achievable cannabinoid concentrations, it was concluded that CYP2C9, CYP1A1/2, and CYP1B1 are likely to be inhibited by all 3 major cannabinoids Delta-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).	Dronabinol	253-256	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	163-169
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Dronabinol	66-69	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Dronabinol	66-69	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	21-28
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Dronabinol	66-69	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Dronabinol	66-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
31433338-11	2019	Carboxylesterase 1 (CES1) is potentially inhibited by THC and CBD.	Dronabinol	54-57	carboxylesterase 1	Homo sapiens	0-18
31433338-11	2019	Carboxylesterase 1 (CES1) is potentially inhibited by THC and CBD.	Dronabinol	54-57	carboxylesterase 1	Homo sapiens	20-24
31044291-4	2019	METHODS: Adolescent rats of both sexes were exposed to either cannabis smoke from postnatal days (P) 29-49 or ascending doses of THC from P35-45.	Dronabinol	129-132	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	138-141
31497013-5	2019	These effects were mediated through CB1 and CB2 receptors inasmuch as, THC+CBD failed to ameliorate EAE in mice deficient in CB1 and CB2.	Dronabinol	71-74	cannabinoid receptor 2 (macrophage)	Mus musculus	44-47
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 17A	Mus musculus	122-127
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	140-149
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 1 beta	Mus musculus	151-159
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 6	Mus musculus	161-165
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	T-box 21	Mus musculus	171-176
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	forkhead box P3	Mus musculus	232-237
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	signal transducer and activator of transcription 5B	Mus musculus	239-245
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 4	Mus musculus	247-251
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 10	Mus musculus	253-258
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	transforming growth factor, beta 1	Mus musculus	264-272
31497013-8	2019	miRNA microarray analysis of brain-derived CD4+ T cells revealed that THC+CBD treatment significantly down-regulated miR-21a-5p, miR-31-5p, miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p while upregulating miR-706-5p and miR-7116.	Dronabinol	70-73	microRNA 31	Mus musculus	129-135
31497013-8	2019	miRNA microarray analysis of brain-derived CD4+ T cells revealed that THC+CBD treatment significantly down-regulated miR-21a-5p, miR-31-5p, miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p while upregulating miR-706-5p and miR-7116.	Dronabinol	70-73	microRNA 27b	Mus musculus	193-200
31497013-8	2019	miRNA microarray analysis of brain-derived CD4+ T cells revealed that THC+CBD treatment significantly down-regulated miR-21a-5p, miR-31-5p, miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p while upregulating miR-706-5p and miR-7116.	Dronabinol	70-73	microRNA 7065	Mus musculus	223-233
31075393-1	2019	The primary psychoactive compound in cannabis, Delta9-tetrahydrocannabinol (THC), binds to cannabinoid receptors (CB1) present in high concentrations in the prefrontal cortex (PFC).	Dronabinol	47-74	cannabinoid receptor 1	Homo sapiens	114-117
31075393-1	2019	The primary psychoactive compound in cannabis, Delta9-tetrahydrocannabinol (THC), binds to cannabinoid receptors (CB1) present in high concentrations in the prefrontal cortex (PFC).	Dronabinol	76-79	cannabinoid receptor 1	Homo sapiens	114-117
31417379-1	2019	Background: Delta9-Tetrahydrocannabinol (THC, a CB1 receptor agonist) and Cannabidiol (CBD, a non-competitive antagonist of endogenous CB1 and CB2 ligands) are two primary components of Cannabis species, and may modulate fear learning in mammals.	Dronabinol	41-44	cannabinoid receptor 1	Rattus norvegicus	48-51
30737573-9	2019	THC increased ROS levels and activated the NRF2-NMRAL2P-NQO1 expressions.	Dronabinol	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	43-47
30737573-9	2019	THC increased ROS levels and activated the NRF2-NMRAL2P-NQO1 expressions.	Dronabinol	0-3	NmrA like redox sensor 2, pseudogene	Homo sapiens	48-60
30737573-10	2019	Inhibition of NQO1 in ESCC cells by shRNA or NQO1 inhibitor resulted in an increased sensitivity of cells to THC, whereas overexpression of NQO1 antagonized it.	Dronabinol	109-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	14-18
30737573-10	2019	Inhibition of NQO1 in ESCC cells by shRNA or NQO1 inhibitor resulted in an increased sensitivity of cells to THC, whereas overexpression of NQO1 antagonized it.	Dronabinol	109-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-49
30737573-10	2019	Inhibition of NQO1 in ESCC cells by shRNA or NQO1 inhibitor resulted in an increased sensitivity of cells to THC, whereas overexpression of NQO1 antagonized it.	Dronabinol	109-112	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-49
30737573-11	2019	Notably, NQO1 inhibitor significantly enhanced the antitumor effects of THC in ESCC PDX tumors.	Dronabinol	72-75	NAD(P)H quinone dehydrogenase 1	Homo sapiens	9-13
30610611-0	2019	Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Delta9-Tetrahydrocannabinol-Induced Cognitive Impairment.	Dronabinol	89-116	cannabinoid receptor 1	Homo sapiens	26-29
30610611-4	2019	Here, by combining in vivo and complementary molecular techniques, we demonstrate for the first time that CBD blunts the Delta9-THC-induced cognitive impairment in an adenosine A2A receptor (A2AR)-dependent manner.	Dronabinol	121-131	adenosine A2a receptor	Homo sapiens	167-189
30610611-4	2019	Here, by combining in vivo and complementary molecular techniques, we demonstrate for the first time that CBD blunts the Delta9-THC-induced cognitive impairment in an adenosine A2A receptor (A2AR)-dependent manner.	Dronabinol	121-131	adenosine A2a receptor	Homo sapiens	191-195
31054322-3	2019	BeWo human trophoblast cells treated with Delta9-THC (3-30 muM) led to a dose-dependent increase in all ER stress markers and CHOP; these effects could be blocked with CB1R/CB2R antagonists.	Dronabinol	42-52	DNA damage inducible transcript 3	Homo sapiens	126-130
31054322-3	2019	BeWo human trophoblast cells treated with Delta9-THC (3-30 muM) led to a dose-dependent increase in all ER stress markers and CHOP; these effects could be blocked with CB1R/CB2R antagonists.	Dronabinol	42-52	cannabinoid receptor 1	Homo sapiens	168-172
31054322-4	2019	Moreover, expression of ER stress-sensitive genes ERRgamma, VEGFA, and FLT-1 were increased by Delta9-THC, and abrogated with the ER stress inhibitor TUDCA.	Dronabinol	95-105	estrogen related receptor gamma	Homo sapiens	50-58
31054322-4	2019	Moreover, expression of ER stress-sensitive genes ERRgamma, VEGFA, and FLT-1 were increased by Delta9-THC, and abrogated with the ER stress inhibitor TUDCA.	Dronabinol	95-105	vascular endothelial growth factor A	Homo sapiens	60-65
31054322-4	2019	Moreover, expression of ER stress-sensitive genes ERRgamma, VEGFA, and FLT-1 were increased by Delta9-THC, and abrogated with the ER stress inhibitor TUDCA.	Dronabinol	95-105	fms related receptor tyrosine kinase 1	Homo sapiens	71-76
30910385-8	2019	The THC derivatization assay was validated and achieved a limit of quantitation (LOQ) of 0.50 pg/ml using either of the two regio-isomers of the azo-derivative of THC (THC-DRV).	Dronabinol	4-7	WASP actin nucleation promoting factor	Homo sapiens	168-175
30910385-8	2019	The THC derivatization assay was validated and achieved a limit of quantitation (LOQ) of 0.50 pg/ml using either of the two regio-isomers of the azo-derivative of THC (THC-DRV).	Dronabinol	163-166	WASP actin nucleation promoting factor	Homo sapiens	168-175
30951717-1	2019	Cannabinoid CB1 and CB2 receptors are activated by Delta9-tetrahydrocannabinol, a psychoactive component of marijuana.	Dronabinol	51-78	cannabinoid receptor 2	Homo sapiens	20-23
31048453-7	2019	CYP2C9 pathway was the major pathway for depletion of THC (fm = 0.91, Km,u = 3 nM) and formation of 11-OH-THC.	Dronabinol	54-57	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
31048453-8	2019	The remaining THC depletion pathway was attributed to CYP2D6.	Dronabinol	14-17	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
31013455-10	2019	CONCLUSIONS: THC disrupts the DMN, and the PCC is a key brain region involved in the subjective experience of THC intoxication.	Dronabinol	110-113	crystallin gamma D	Homo sapiens	43-46
30965351-4	2019	Remarkably, THC consumption by adolescent male rats and not female rats led to impaired Pavlovian reward-predictive cue behaviors in adulthood consistent with a male-specific loss of CB1R-expressing vGlut-1 synaptic terminals in the ventral tegmental area (VTA).	Dronabinol	12-15	solute carrier family 17 member 7	Rattus norvegicus	199-206
31095906-1	2019	Cannabinoid receptor 1 (CB1) mediates the functional responses of Delta9-tetrahydrocannabinol.	Dronabinol	66-93	cannabinoid receptor 1	Homo sapiens	0-22
31095906-1	2019	Cannabinoid receptor 1 (CB1) mediates the functional responses of Delta9-tetrahydrocannabinol.	Dronabinol	66-93	cannabinoid receptor 1	Homo sapiens	24-27
30219209-0	2019	Adolescent Delta9-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-kappaB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood.	Dronabinol	11-38	prostaglandin-endoperoxide synthase 2	Mus musculus	127-143
30219209-2	2019	The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Delta9-tetrahydrocannabinol (Delta9-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1.	Dronabinol	156-183	cannabinoid receptor 1 (brain)	Mus musculus	250-272
30219209-2	2019	The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Delta9-tetrahydrocannabinol (Delta9-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1.	Dronabinol	185-195	cannabinoid receptor 1 (brain)	Mus musculus	250-272
30219209-3	2019	As both neurons and glial cells express cannabinoid receptor 1, genetic vulnerability could influence Delta9-THC-induced signaling in a cell type-specific manner.	Dronabinol	102-112	cannabinoid receptor 1 (brain)	Mus musculus	40-62
30219209-6	2019	Similar deficits in recognition memory were observed following knockdown of endogenous Disc1 in hippocampal astrocytes in mice treated with Delta9-THC during adolescence.	Dronabinol	140-150	disrupted in schizophrenia 1	Mus musculus	87-92
30219209-7	2019	At the molecular level, DN-DISC1 and Delta9-THC synergistically activated the nuclear factor-kappaB-cyclooxygenase-2 pathway in astrocytes and decreased immunoreactivity of parvalbumin-positive presynaptic inhibitory boutons around pyramidal neurons of the hippocampal CA3 area.	Dronabinol	37-47	prostaglandin-endoperoxide synthase 2	Mus musculus	100-116
30219209-7	2019	At the molecular level, DN-DISC1 and Delta9-THC synergistically activated the nuclear factor-kappaB-cyclooxygenase-2 pathway in astrocytes and decreased immunoreactivity of parvalbumin-positive presynaptic inhibitory boutons around pyramidal neurons of the hippocampal CA3 area.	Dronabinol	37-47	carbonic anhydrase 3	Mus musculus	269-272
30219209-8	2019	The cognitive abnormalities were prevented in DN-DISC1 mice exposed to Delta9-THC by simultaneous adolescent treatment with the cyclooxygenase-2 inhibitor, NS398.	Dronabinol	71-81	disrupted in schizophrenia 1	Mus musculus	49-54
30219209-8	2019	The cognitive abnormalities were prevented in DN-DISC1 mice exposed to Delta9-THC by simultaneous adolescent treatment with the cyclooxygenase-2 inhibitor, NS398.	Dronabinol	71-81	prostaglandin-endoperoxide synthase 2	Mus musculus	128-144
31029878-10	2019	Hypolocomotion induced by edible THC was attenuated by SR141716A, indicating mediation by CB1 receptor activation.	Dronabinol	33-36	cannabinoid receptor 1 (brain)	Mus musculus	90-93
30975584-0	2019	Acute effects of  9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype.	Dronabinol	18-40	catechol-O-methyltransferase	Homo sapiens	103-107
30975584-0	2019	Acute effects of  9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype.	Dronabinol	42-45	catechol-O-methyltransferase	Homo sapiens	103-107
30975584-4	2019	Here we investigated the acute effects of  9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, on resting state brain neurophysiology, and their modulation by catechol-methyl-transferase (COMT) Val158Met genotype.	Dronabinol	43-65	catechol-O-methyltransferase	Homo sapiens	213-217
30975584-11	2019	Resting state perfusion was modulated by COMT genotype, indicated by a significant interaction effect between drug and genotype on perfusion in the executive network, with increased perfusion after THC in Val/Met heterozygotes only.	Dronabinol	198-201	catechol-O-methyltransferase	Homo sapiens	41-45
31112855-8	2019	These results were maintained after controlling prolactin levels for sex, age, THC consumption, baseline TSH, and PSS.	Dronabinol	79-82	prolactin	Homo sapiens	48-57
31178692-11	2019	Finally, we validated higher expression of CNR1 in B6 striatum and demonstrated greater sensitivity of this strain to the locomotor inhibiting effects of the CNR1 agonist, Delta9-tetrahydrocannabinol (THC).	Dronabinol	172-199	cannabinoid receptor 1 (brain)	Mus musculus	43-47
31178692-11	2019	Finally, we validated higher expression of CNR1 in B6 striatum and demonstrated greater sensitivity of this strain to the locomotor inhibiting effects of the CNR1 agonist, Delta9-tetrahydrocannabinol (THC).	Dronabinol	172-199	cannabinoid receptor 1 (brain)	Mus musculus	158-162
31178692-11	2019	Finally, we validated higher expression of CNR1 in B6 striatum and demonstrated greater sensitivity of this strain to the locomotor inhibiting effects of the CNR1 agonist, Delta9-tetrahydrocannabinol (THC).	Dronabinol	201-204	cannabinoid receptor 1 (brain)	Mus musculus	43-47
31110286-0	2019	FABP1 controls hepatic transport and biotransformation of Delta9-THC.	Dronabinol	65-68	fatty acid binding protein 1, liver	Mus musculus	0-5
31110286-5	2019	Using X-ray crystallography, molecular modeling, and in vitro binding approaches we demonstrate that FABP1 accommodates one molecule of THC within its ligand binding pocket.	Dronabinol	136-139	fatty acid binding protein 1, liver	Mus musculus	101-106
31110286-6	2019	Consistent with its role as a THC carrier, biotransformation of THC was reduced in primary hepatocytes obtained from FABP1-knockout (FABP1-KO) mice.	Dronabinol	30-33	fatty acid binding protein 1, liver	Mus musculus	117-122
31110286-6	2019	Consistent with its role as a THC carrier, biotransformation of THC was reduced in primary hepatocytes obtained from FABP1-knockout (FABP1-KO) mice.	Dronabinol	30-33	fatty acid binding protein 1, liver	Mus musculus	133-138
31110286-6	2019	Consistent with its role as a THC carrier, biotransformation of THC was reduced in primary hepatocytes obtained from FABP1-knockout (FABP1-KO) mice.	Dronabinol	64-67	fatty acid binding protein 1, liver	Mus musculus	117-122
31110286-6	2019	Consistent with its role as a THC carrier, biotransformation of THC was reduced in primary hepatocytes obtained from FABP1-knockout (FABP1-KO) mice.	Dronabinol	64-67	fatty acid binding protein 1, liver	Mus musculus	133-138
31110286-7	2019	Compared to their wild-type littermates, administration of THC to male and female FABP1-KO mice potentiated the physiological and behavioral effects of THC.	Dronabinol	59-62	fatty acid binding protein 1, liver	Mus musculus	82-87
31110286-7	2019	Compared to their wild-type littermates, administration of THC to male and female FABP1-KO mice potentiated the physiological and behavioral effects of THC.	Dronabinol	152-155	fatty acid binding protein 1, liver	Mus musculus	82-87
31110286-8	2019	The stark pharmacodynamic differences were confirmed upon pharmacokinetic analyses which revealed that FABP1-KO mice exhibit reduced rates of THC biotransformation.	Dronabinol	142-145	fatty acid binding protein 1, liver	Mus musculus	103-108
31110286-10	2019	Since commonly used medications bind to FABP1 with comparable affinities to THC, our results further suggest that FABP1 could serve a previously unrecognized site of drug-drug interactions.	Dronabinol	76-79	fatty acid binding protein 1, liver	Mus musculus	114-119
30742938-0	2019	Delta9-Tetrahydrocannabinol elicited 22-kHz ultrasonic vocalization changes after air puff stimulus through CB1 receptor in adult rats.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	108-111
30742938-1	2019	Delta9-Tetrahydrocannabinol (THC) is known to have various pharmacological effects mediated through activation of cannabinoid CB1 and CB2 receptors in rodents.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	126-129
30742938-1	2019	Delta9-Tetrahydrocannabinol (THC) is known to have various pharmacological effects mediated through activation of cannabinoid CB1 and CB2 receptors in rodents.	Dronabinol	0-27	cannabinoid receptor 2	Rattus norvegicus	134-137
30742938-1	2019	Delta9-Tetrahydrocannabinol (THC) is known to have various pharmacological effects mediated through activation of cannabinoid CB1 and CB2 receptors in rodents.	Dronabinol	29-32	cannabinoid receptor 1	Rattus norvegicus	126-129
30742938-1	2019	Delta9-Tetrahydrocannabinol (THC) is known to have various pharmacological effects mediated through activation of cannabinoid CB1 and CB2 receptors in rodents.	Dronabinol	29-32	cannabinoid receptor 2	Rattus norvegicus	134-137
30742938-10	2019	These results suggest that THC induced changes in sensitivity to aversive air puff stimuli through CB1 receptors, and as a result increased emission of 22-kHz USVs in rats.	Dronabinol	27-30	cannabinoid receptor 1	Rattus norvegicus	99-102
30767215-4	2019	KEY RESULTS: Two mixed CB1 / CB2 receptor agonists, Delta9 -tetrahydrocannabinol (Delta9 -THC) and WIN55,212-2, produced biphasic effects-mild enhancement of brain-stimulation reward (BSR) at low doses but inhibition at higher doses.	Dronabinol	52-80	cannabinoid receptor 1	Rattus norvegicus	23-26
30767215-4	2019	KEY RESULTS: Two mixed CB1 / CB2 receptor agonists, Delta9 -tetrahydrocannabinol (Delta9 -THC) and WIN55,212-2, produced biphasic effects-mild enhancement of brain-stimulation reward (BSR) at low doses but inhibition at higher doses.	Dronabinol	52-80	cannabinoid receptor 2	Rattus norvegicus	29-32
30767215-4	2019	KEY RESULTS: Two mixed CB1 / CB2 receptor agonists, Delta9 -tetrahydrocannabinol (Delta9 -THC) and WIN55,212-2, produced biphasic effects-mild enhancement of brain-stimulation reward (BSR) at low doses but inhibition at higher doses.	Dronabinol	82-93	cannabinoid receptor 1	Rattus norvegicus	23-26
30767215-4	2019	KEY RESULTS: Two mixed CB1 / CB2 receptor agonists, Delta9 -tetrahydrocannabinol (Delta9 -THC) and WIN55,212-2, produced biphasic effects-mild enhancement of brain-stimulation reward (BSR) at low doses but inhibition at higher doses.	Dronabinol	82-93	cannabinoid receptor 2	Rattus norvegicus	29-32
30833288-6	2019	The inhibition of CES1 by THC, CBD, and CBN was reversible and appears to proceed through a mixed competitive-noncompetitive mechanism.	Dronabinol	26-29	carboxylesterase 1	Homo sapiens	18-22
30833288-9	2019	Compared with the potential unbound plasma concentrations attainable clinically, the K i values suggest a potential for clinically significant inhibition of CES1 by THC and CBD.	Dronabinol	165-168	carboxylesterase 1	Homo sapiens	157-161
30903985-8	2019	RESULTS: After adjusting for demographic and HIV-related covariates, THC-positive patients had significantly higher CD4+ and CD8+ counts than their THC-negative counterparts.	Dronabinol	69-72	CD4 molecule	Homo sapiens	116-119
30903985-8	2019	RESULTS: After adjusting for demographic and HIV-related covariates, THC-positive patients had significantly higher CD4+ and CD8+ counts than their THC-negative counterparts.	Dronabinol	69-72	CD8a molecule	Homo sapiens	125-128
30833484-6	2019	We found that unbiased CB1R agonists Delta9-THC and JWH-018 produced similar tolerance to these effects, but lesser tolerance was observed with PNR-4-20 for hypothermic and cataleptic effects.	Dronabinol	37-47	cannabinoid receptor 1 (brain)	Mus musculus	23-27
30151725-10	2019	In vitro, THC elicited glutamate release from cortical astrocytes (on which we demonstrated co-localization of the CB1Rs and alpha7nAChR mRNAs), and this effect was prevented by KYNA and rimonabant.	Dronabinol	10-13	cannabinoid receptor 1	Rattus norvegicus	115-118
31114576-4	2019	Compared to VEH/SIV rhesus macaques, 10 miRNAs were significantly upregulated in THC/SIV rhesus macaques, among which miR-204 was confirmed to directly target MMP8, an extracellular matrix-degrading collagenase that was significantly downregulated in THC/SIV rhesus macaques.	Dronabinol	81-84	microRNA 204	Macaca mulatta	118-125
31114576-4	2019	Compared to VEH/SIV rhesus macaques, 10 miRNAs were significantly upregulated in THC/SIV rhesus macaques, among which miR-204 was confirmed to directly target MMP8, an extracellular matrix-degrading collagenase that was significantly downregulated in THC/SIV rhesus macaques.	Dronabinol	81-84	matrix metallopeptidase 8	Macaca mulatta	159-163
31114576-4	2019	Compared to VEH/SIV rhesus macaques, 10 miRNAs were significantly upregulated in THC/SIV rhesus macaques, among which miR-204 was confirmed to directly target MMP8, an extracellular matrix-degrading collagenase that was significantly downregulated in THC/SIV rhesus macaques.	Dronabinol	251-254	microRNA 204	Macaca mulatta	118-125
31114576-4	2019	Compared to VEH/SIV rhesus macaques, 10 miRNAs were significantly upregulated in THC/SIV rhesus macaques, among which miR-204 was confirmed to directly target MMP8, an extracellular matrix-degrading collagenase that was significantly downregulated in THC/SIV rhesus macaques.	Dronabinol	251-254	matrix metallopeptidase 8	Macaca mulatta	159-163
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	occludin	Macaca mulatta	86-94
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	claudin 3	Macaca mulatta	96-105
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	mucin 13, cell surface associated	Macaca mulatta	126-131
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	KRT8	Macaca mulatta	133-142
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	prominin 1	Macaca mulatta	164-169
31114576-6	2019	Further, THC/SIV rhesus macaques showed higher expression of tight junction proteins (occludin, claudin-3), anti-inflammatory MUC13, keratin-8 (stress protection), PROM1 (epithelial proliferation), and anti-HIV CCL5.	Dronabinol	9-12	C-C motif chemokine 5	Macaca mulatta	211-215
31114576-8	2019	Furthermore, using flow cytometry, we showed that Delta9-THC suppressed intestinal T cell proliferation/activation (Ki67/HLA-DR) and PD-1 expression and increased the percentages of anti-inflammatory CD163+ macrophages.	Dronabinol	50-60	synuclein alpha	Homo sapiens	133-137
31114576-8	2019	Furthermore, using flow cytometry, we showed that Delta9-THC suppressed intestinal T cell proliferation/activation (Ki67/HLA-DR) and PD-1 expression and increased the percentages of anti-inflammatory CD163+ macrophages.	Dronabinol	50-60	CD163 molecule	Homo sapiens	200-205
31114576-9	2019	Finally, while Delta9-THC did not affect the levels of CD4+ T cells, it significantly reduced absolute CD8+ T cell numbers in peripheral blood at 14 and 150 days post-SIV infection.	Dronabinol	15-25	CD8a molecule	Homo sapiens	103-106
31068789-0	2019	Oleoylethanolamide Modulates BDNF-ERK Signaling and Neurogenesis in the Hippocampi of Rats Exposed to Delta9-THC and Ethanol Binge Drinking During Adolescence.	Dronabinol	102-112	brain-derived neurotrophic factor	Rattus norvegicus	29-33
31068789-8	2019	OEA restored ethanol/THC-related decreases in both short-term spatial memory (spontaneous alternation by Y-maze) and circulating levels of BDNF, reduced cell proliferation (Mki67 and IdU+ cells) and maturation (Dcx, Calb1), and improved cell survival (Casp3 and BrdU+ cells) in the dorsal hippocampus.	Dronabinol	21-24	brain-derived neurotrophic factor	Rattus norvegicus	139-143
31068789-8	2019	OEA restored ethanol/THC-related decreases in both short-term spatial memory (spontaneous alternation by Y-maze) and circulating levels of BDNF, reduced cell proliferation (Mki67 and IdU+ cells) and maturation (Dcx, Calb1), and improved cell survival (Casp3 and BrdU+ cells) in the dorsal hippocampus.	Dronabinol	21-24	doublecortin	Rattus norvegicus	211-214
31068789-8	2019	OEA restored ethanol/THC-related decreases in both short-term spatial memory (spontaneous alternation by Y-maze) and circulating levels of BDNF, reduced cell proliferation (Mki67 and IdU+ cells) and maturation (Dcx, Calb1), and improved cell survival (Casp3 and BrdU+ cells) in the dorsal hippocampus.	Dronabinol	21-24	calbindin 1	Rattus norvegicus	216-221
31068789-8	2019	OEA restored ethanol/THC-related decreases in both short-term spatial memory (spontaneous alternation by Y-maze) and circulating levels of BDNF, reduced cell proliferation (Mki67 and IdU+ cells) and maturation (Dcx, Calb1), and improved cell survival (Casp3 and BrdU+ cells) in the dorsal hippocampus.	Dronabinol	21-24	caspase 3	Rattus norvegicus	252-257
31068789-9	2019	Interestingly, OEA alone or combined with THC also decreased the mRNA levels of neurotrophic factors (Bdnf, Ntf3) and the NT3 receptor TrkC, but increased the BDNF receptor TrkB in the hippocampus of ethanol-exposed rats.	Dronabinol	42-45	brain-derived neurotrophic factor	Rattus norvegicus	102-106
31068789-9	2019	Interestingly, OEA alone or combined with THC also decreased the mRNA levels of neurotrophic factors (Bdnf, Ntf3) and the NT3 receptor TrkC, but increased the BDNF receptor TrkB in the hippocampus of ethanol-exposed rats.	Dronabinol	42-45	neurotrophin 3	Rattus norvegicus	108-112
31068789-9	2019	Interestingly, OEA alone or combined with THC also decreased the mRNA levels of neurotrophic factors (Bdnf, Ntf3) and the NT3 receptor TrkC, but increased the BDNF receptor TrkB in the hippocampus of ethanol-exposed rats.	Dronabinol	42-45	neurotrophin 3	Rattus norvegicus	122-125
31068789-9	2019	Interestingly, OEA alone or combined with THC also decreased the mRNA levels of neurotrophic factors (Bdnf, Ntf3) and the NT3 receptor TrkC, but increased the BDNF receptor TrkB in the hippocampus of ethanol-exposed rats.	Dronabinol	42-45	brain-derived neurotrophic factor	Rattus norvegicus	159-163
31068789-9	2019	Interestingly, OEA alone or combined with THC also decreased the mRNA levels of neurotrophic factors (Bdnf, Ntf3) and the NT3 receptor TrkC, but increased the BDNF receptor TrkB in the hippocampus of ethanol-exposed rats.	Dronabinol	42-45	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	173-177
31068789-11	2019	These results suggest a regulatory role of OEA in short-term spatial memory and hippocampal neurogenesis through BDNF/AKT/ERK1 signaling in response to acute THC in an alcoholic context during adolescence.	Dronabinol	158-161	brain-derived neurotrophic factor	Rattus norvegicus	113-117
31068789-11	2019	These results suggest a regulatory role of OEA in short-term spatial memory and hippocampal neurogenesis through BDNF/AKT/ERK1 signaling in response to acute THC in an alcoholic context during adolescence.	Dronabinol	158-161	AKT serine/threonine kinase 1	Rattus norvegicus	118-121
31068789-11	2019	These results suggest a regulatory role of OEA in short-term spatial memory and hippocampal neurogenesis through BDNF/AKT/ERK1 signaling in response to acute THC in an alcoholic context during adolescence.	Dronabinol	158-161	mitogen activated protein kinase 3	Rattus norvegicus	122-126
31010235-0	2019	DNA Damaging Effects, Oxidative Stress Responses and Cholinesterase Activity in Blood and Brain of Wistar Rats Exposed to Delta9-Tetrahydrocannabinol.	Dronabinol	122-149	butyrylcholinesterase	Rattus norvegicus	53-67
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	28-31	cannabinoid receptor 1	Homo sapiens	53-75
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	28-31	cannabinoid receptor 1	Homo sapiens	77-80
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	160-163	cannabinoid receptor 1	Homo sapiens	191-194
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	160-163	cannabinoid receptor 2	Homo sapiens	199-202
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	160-163	cannabinoid receptor 1	Homo sapiens	191-194
30807757-4	2019	The psychotropic effects of THC are mediated through cannabinoid receptor 1 (CB1) expressed in the central nervous system while the immunomodulatory effects of THC result from THC binding to CB1 and CB2 on immune cells.	Dronabinol	160-163	cannabinoid receptor 2	Homo sapiens	199-202
30807757-8	2019	Further, the phosphorylation of IRF7, TBK1, NFkappaB, and IKKgamma, key events in pDC activation, were suppressed by THC, JWH-133, and JWH-015.	Dronabinol	117-120	interferon regulatory factor 7	Homo sapiens	32-36
30807757-8	2019	Further, the phosphorylation of IRF7, TBK1, NFkappaB, and IKKgamma, key events in pDC activation, were suppressed by THC, JWH-133, and JWH-015.	Dronabinol	117-120	TANK binding kinase 1	Homo sapiens	38-42
30807757-8	2019	Further, the phosphorylation of IRF7, TBK1, NFkappaB, and IKKgamma, key events in pDC activation, were suppressed by THC, JWH-133, and JWH-015.	Dronabinol	117-120	nuclear factor kappa B subunit 1	Homo sapiens	44-52
30807757-8	2019	Further, the phosphorylation of IRF7, TBK1, NFkappaB, and IKKgamma, key events in pDC activation, were suppressed by THC, JWH-133, and JWH-015.	Dronabinol	117-120	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	58-66
30987191-5	2019	THC is a partial agonist for CB1-R and CB2-R; CBD is an inverse agonist for both.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	29-34
30987191-5	2019	THC is a partial agonist for CB1-R and CB2-R; CBD is an inverse agonist for both.	Dronabinol	0-3	cannabinoid receptor 2	Homo sapiens	39-42
30949710-12	2019	THC also increased plasma motilin (P = 0.0021) and decreased octanoylated ghrelin (P = 0.023) concentrations before milkshake consumption (i.e., in both oral intake and intragastric infusion test sessions), whereas glucagon-like peptide 1 responses to milkshake intake were attenuated by THC during both oral (P = 0.0002) and intragastric (P = 0.0055) administration.	Dronabinol	0-3	glucagon	Homo sapiens	215-238
30629988-3	2019	Mice expressing a mutant form of CB1, in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Delta9-tetrahydrocannabinol (Delta9-THC).	Dronabinol	231-258	cannabinoid receptor 1 (brain)	Mus musculus	33-36
30629988-3	2019	Mice expressing a mutant form of CB1, in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Delta9-tetrahydrocannabinol (Delta9-THC).	Dronabinol	260-270	cannabinoid receptor 1 (brain)	Mus musculus	33-36
30460515-9	2019	Pretreatment with 1 mg/kg Delta9-THC or 0.01 mg/kg AM2389 shifted the 8-OH-DPAT dose-effect function for LLR to the left and isobolographic analysis of the data indicates CB1 and 5-HT1A interactions can be supraadditive.	Dronabinol	26-36	cannabinoid receptor 1	Rattus norvegicus	171-174
30460515-9	2019	Pretreatment with 1 mg/kg Delta9-THC or 0.01 mg/kg AM2389 shifted the 8-OH-DPAT dose-effect function for LLR to the left and isobolographic analysis of the data indicates CB1 and 5-HT1A interactions can be supraadditive.	Dronabinol	26-36	5-hydroxytryptamine receptor 1A	Rattus norvegicus	179-185
30659320-5	2019	We demonstrate that THC (10-40 microM) impairs placental endocannabinoid system by disrupting the endocannabinoid anandamide (AEA) levels and the expression of AEA synthetic and degrading enzymes N-arachidonoylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), respectively.	Dronabinol	20-23	N-acyl phosphatidylethanolamine phospholipase D	Homo sapiens	196-259
30659320-5	2019	We demonstrate that THC (10-40 microM) impairs placental endocannabinoid system by disrupting the endocannabinoid anandamide (AEA) levels and the expression of AEA synthetic and degrading enzymes N-arachidonoylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), respectively.	Dronabinol	20-23	N-acyl phosphatidylethanolamine phospholipase D	Homo sapiens	261-269
30659320-5	2019	We demonstrate that THC (10-40 microM) impairs placental endocannabinoid system by disrupting the endocannabinoid anandamide (AEA) levels and the expression of AEA synthetic and degrading enzymes N-arachidonoylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), respectively.	Dronabinol	20-23	fatty acid amide hydrolase	Homo sapiens	275-301
30659320-5	2019	We demonstrate that THC (10-40 microM) impairs placental endocannabinoid system by disrupting the endocannabinoid anandamide (AEA) levels and the expression of AEA synthetic and degrading enzymes N-arachidonoylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH), respectively.	Dronabinol	20-23	fatty acid amide hydrolase	Homo sapiens	303-307
30427077-12	2019	Caspase-3 and NF-kappabeta immunopositive cell numbers increased in fructose + THC rats compared with fructose group.	Dronabinol	79-82	caspase 3	Rattus norvegicus	0-9
30427077-13	2019	The number of IL-6 immunopositive cell decreased in fructose + THC group compared with fructose group.	Dronabinol	63-66	interleukin 6	Rattus norvegicus	14-18
30538288-9	2019	Interestingly, the effects of PFC THC vs. CBD were found to be mediated through dissociable CB1 vs. 5-HT1A-dependent receptor signaling mechanisms, directly in the PFC.	Dronabinol	34-37	cannabinoid receptor 1	Rattus norvegicus	92-95
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	16-43	Cbl proto-oncogene	Homo sapiens	279-284
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
30733293-5	2019	The cannabinoid Delta9-tetrahydrocannabinol (THC) disrupts HER2-CB2R complexes by selectively binding to CB2R, which leads to (i) the inactivation of HER2 through disruption of HER2-HER2 homodimers, and (ii) the subsequent degradation of HER2 by the proteasome via the E3 ligase c-CBL.	Dronabinol	45-48	Cbl proto-oncogene	Homo sapiens	279-284
30553767-0	2019	Delta9-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPARalpha induction: A possible evidence for the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha in MDA-MB-231 cells.	Dronabinol	0-27	fatty acid 2-hydroxylase	Homo sapiens	40-64
30553767-0	2019	Delta9-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPARalpha induction: A possible evidence for the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha in MDA-MB-231 cells.	Dronabinol	0-27	fatty acid 2-hydroxylase	Homo sapiens	66-70
30553767-0	2019	Delta9-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPARalpha induction: A possible evidence for the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha in MDA-MB-231 cells.	Dronabinol	0-27	peroxisome proliferator activated receptor alpha	Homo sapiens	76-85
30553767-0	2019	Delta9-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPARalpha induction: A possible evidence for the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha in MDA-MB-231 cells.	Dronabinol	0-27	peroxisome proliferator activated receptor delta	Homo sapiens	141-149
30553767-0	2019	Delta9-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPARalpha induction: A possible evidence for the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha in MDA-MB-231 cells.	Dronabinol	0-27	peroxisome proliferator activated receptor alpha	Homo sapiens	179-188
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	33-60	fatty acid 2-hydroxylase	Homo sapiens	170-194
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	33-60	fatty acid 2-hydroxylase	Homo sapiens	196-200
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	33-60	peroxisome proliferator activated receptor alpha	Homo sapiens	222-231
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	62-72	fatty acid 2-hydroxylase	Homo sapiens	170-194
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	62-72	fatty acid 2-hydroxylase	Homo sapiens	196-200
30553767-4	2019	We have previously reported that Delta9-tetrahydrocannabinol (Delta9-THC), a major cannabinoid component of the drug-type cannabis plant, can stimulate the expression of fatty acid 2-hydroxylase (FA2H) via upregulation of PPARalpha expression in human breast cancer MDA-MB-231 cells.	Dronabinol	62-72	peroxisome proliferator activated receptor alpha	Homo sapiens	222-231
30553767-5	2019	Although the possibility of an inhibitory interaction between PPARalpha and PPARbeta/delta has not been demonstrated in MDA-MB-231 cells, we reasoned if this interaction were to exist, Delta9-THC should make PPARalpha free to achieve FA2H induction.	Dronabinol	185-195	peroxisome proliferator activated receptor alpha	Homo sapiens	208-217
30553767-5	2019	Although the possibility of an inhibitory interaction between PPARalpha and PPARbeta/delta has not been demonstrated in MDA-MB-231 cells, we reasoned if this interaction were to exist, Delta9-THC should make PPARalpha free to achieve FA2H induction.	Dronabinol	185-195	fatty acid 2-hydroxylase	Homo sapiens	234-238
30553767-6	2019	Here, we show that a PPARbeta/delta-mediated suppression of PPARalpha function, but not of PPARgamma, exists in MDA-MB-231 cells and Delta9-THC causes FA2H induction via mechanisms underlying the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha, in addition to the upregulation of PPARalpha.	Dronabinol	133-143	peroxisome proliferator activated receptor delta	Homo sapiens	21-29
30553767-6	2019	Here, we show that a PPARbeta/delta-mediated suppression of PPARalpha function, but not of PPARgamma, exists in MDA-MB-231 cells and Delta9-THC causes FA2H induction via mechanisms underlying the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha, in addition to the upregulation of PPARalpha.	Dronabinol	133-143	fatty acid 2-hydroxylase	Homo sapiens	151-155
30553767-6	2019	Here, we show that a PPARbeta/delta-mediated suppression of PPARalpha function, but not of PPARgamma, exists in MDA-MB-231 cells and Delta9-THC causes FA2H induction via mechanisms underlying the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha, in addition to the upregulation of PPARalpha.	Dronabinol	133-143	peroxisome proliferator activated receptor delta	Homo sapiens	212-220
30553767-6	2019	Here, we show that a PPARbeta/delta-mediated suppression of PPARalpha function, but not of PPARgamma, exists in MDA-MB-231 cells and Delta9-THC causes FA2H induction via mechanisms underlying the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha, in addition to the upregulation of PPARalpha.	Dronabinol	133-143	peroxisome proliferator activated receptor alpha	Homo sapiens	250-259
30553767-6	2019	Here, we show that a PPARbeta/delta-mediated suppression of PPARalpha function, but not of PPARgamma, exists in MDA-MB-231 cells and Delta9-THC causes FA2H induction via mechanisms underlying the cancellation of PPARbeta/delta-mediated inhibition of PPARalpha, in addition to the upregulation of PPARalpha.	Dronabinol	133-143	peroxisome proliferator activated receptor alpha	Homo sapiens	250-259
30573162-5	2019	RESULTS: Cox regression showed an increased risk of progression from cannabis initiation to cannabis use disorder symptom onset by 1.41 times (p &lt; .001) for each unit increase in national average delta-9-tetrahydrocannabinol as compared to those not endorsing CUD symptom onset, adjusting for sex, regular use, and cohort effects.	Dronabinol	199-227	cytochrome c oxidase subunit 8A	Homo sapiens	9-12
30597181-0	2019	CB1 positive allosteric modulation attenuates Delta9-THC withdrawal and NSAID-induced gastric inflammation.	Dronabinol	53-56	cannabinoid receptor 1 (brain)	Mus musculus	0-3
30597181-3	2019	For example, ZCZ011 blocks neuropathic pain, absent the catalepsy, sedation, and hypothermia caused by CB1 orthosteric modulators, including Delta9-tetrahydrocannabinol (THC).	Dronabinol	141-168	cannabinoid receptor 1 (brain)	Mus musculus	103-106
30597181-3	2019	For example, ZCZ011 blocks neuropathic pain, absent the catalepsy, sedation, and hypothermia caused by CB1 orthosteric modulators, including Delta9-tetrahydrocannabinol (THC).	Dronabinol	170-173	cannabinoid receptor 1 (brain)	Mus musculus	103-106
30594692-5	2019	However, during key developmental stages (14, 24, 48, 72, and 96 h post fertilization) THC and CBD caused differential expression of c-fos, brain-derived neurotrophic factor (bdnf), and deleted-in-azoospermia like (dazl), while in F1 larvae only CBD differentially expressed dazl.	Dronabinol	87-90	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	133-138
30594692-5	2019	However, during key developmental stages (14, 24, 48, 72, and 96 h post fertilization) THC and CBD caused differential expression of c-fos, brain-derived neurotrophic factor (bdnf), and deleted-in-azoospermia like (dazl), while in F1 larvae only CBD differentially expressed dazl.	Dronabinol	87-90	brain-derived neurotrophic factor	Danio rerio	140-173
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily V member 2	Homo sapiens	131-136
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily V member 3	Homo sapiens	159-164
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily V member 4	Homo sapiens	166-171
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily A member 1	Homo sapiens	173-178
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily M member 8	Homo sapiens	184-189
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	14-41	transient receptor potential cation channel subfamily V member 1	Homo sapiens	237-242
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily V member 2	Homo sapiens	131-136
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily V member 3	Homo sapiens	159-164
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily V member 4	Homo sapiens	166-171
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily A member 1	Homo sapiens	173-178
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily M member 8	Homo sapiens	184-189
30697147-11	2018	Additionally, Delta9-tetrahydrocannabinol (Delta9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Delta9-THC is not reported to modulate TRPV1.	Dronabinol	43-53	transient receptor potential cation channel subfamily V member 1	Homo sapiens	237-242
30326170-1	2019	Delta-9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9.	Dronabinol	0-28	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	122-128
30326170-1	2019	Delta-9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9.	Dronabinol	30-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	122-128
30326170-6	2019	The in vitro study indicated that THC inhibits the CYP2C9-mediated metabolism of warfarin.	Dronabinol	34-37	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	51-57
31436397-7	2019	RESULTS: This study confirms that the incubation of oocytes with THC during IVM accelerated some events of that process like the phosphorylation pattern of ERK and AKT and was able to increase the blastocyst rate in response to IVF.	Dronabinol	65-68	mitogen-activated protein kinase 1	Homo sapiens	156-159
31436397-7	2019	RESULTS: This study confirms that the incubation of oocytes with THC during IVM accelerated some events of that process like the phosphorylation pattern of ERK and AKT and was able to increase the blastocyst rate in response to IVF.	Dronabinol	65-68	AKT serine/threonine kinase 1	Homo sapiens	164-167
30391834-8	2019	Repeated treatment with THC resulted in pronounced CB1 receptor desensitization and downregulation in both sexes in all brain regions with a greater magnitude of change in females.	Dronabinol	24-27	cannabinoid receptor 1	Rattus norvegicus	51-54
30391834-9	2019	CONCLUSIONS: These results suggest that sex differences in the density and G-protein coupling of brain CB1 receptors may play a limited role in sex differences in acute THC effects not mediated by the hippocampus.	Dronabinol	169-172	cannabinoid receptor 1	Rattus norvegicus	103-106
30636988-0	2019	9-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB1 receptor.	Dronabinol	0-22	cannabinoid receptor 1 (brain)	Mus musculus	113-116
30766656-6	2019	The binding affinities of the test substances to CB1 were determined to be (from highest to lowest) 9.52 x 10-13 M (JWH-210), 6.54 x 10-12 M (JWH-250), 1.56 x 10-11 M (Delta9-tetrahydrocannabinol), 2.75 x 10-11 M (RCS-4), and 6.80 x10-11 M (JWH-015) using the non-isotopic method.	Dronabinol	168-195	cannabinoid receptor 1	Homo sapiens	49-52
30671538-4	2018	Cannabis, or THC, also stimulates CB1R and increases caloric intake during acute exposures.	Dronabinol	13-16	cannabinoid receptor 1	Homo sapiens	34-38
30278899-4	2018	The addition of the mutant p53 gene causes the disassembly of the THC probes with the release of the Fc-tagged sequence and the folding of the MB-labeled sequence into a hairpin structure, causing the change in the current response ratio of MB to Fc for monitoring the mutant p53 gene.	Dronabinol	66-69	tumor protein p53	Homo sapiens	27-30
30278899-4	2018	The addition of the mutant p53 gene causes the disassembly of the THC probes with the release of the Fc-tagged sequence and the folding of the MB-labeled sequence into a hairpin structure, causing the change in the current response ratio of MB to Fc for monitoring the mutant p53 gene.	Dronabinol	66-69	tumor protein p53	Homo sapiens	276-279
30278899-6	2018	With the significant signal amplification and the advantageous specificity of the THC probes, sub-femtomolar detection limit and a highly enhanced SNP discrimination factor for the mutant p53 gene can be obtained.	Dronabinol	82-85	tumor protein p53	Homo sapiens	188-191
30550613-3	2018	THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	68-71
30550613-3	2018	THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly.	Dronabinol	0-3	cannabinoid receptor 2 (macrophage)	Mus musculus	73-76
30550613-3	2018	THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly.	Dronabinol	0-3	G protein-coupled receptor 18	Mus musculus	78-83
30550613-3	2018	THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly.	Dronabinol	0-3	G-protein coupled receptor 119	Mus musculus	85-91
30550613-3	2018	THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly.	Dronabinol	0-3	G protein-coupled receptor 55	Mus musculus	93-98
30550613-12	2018	Conclusions: We conclude that THC lowers IOP by activating two receptors-CB1 and GPR18-but in a sex-dependent manner.	Dronabinol	30-33	cannabinoid receptor 1 (brain)	Mus musculus	73-76
30550613-12	2018	Conclusions: We conclude that THC lowers IOP by activating two receptors-CB1 and GPR18-but in a sex-dependent manner.	Dronabinol	30-33	G protein-coupled receptor 18	Mus musculus	81-86
29875475-8	2018	Treating an Htr2b-/- knockout mouse with THC resulted in increased aggressive behavior, whereas wild-type mice following THC administration showed decreased aggression in the resident-intruder paradigm, demonstrating that HTR2B variation moderates the effects of cannabis on aggression.	Dronabinol	41-44	5-hydroxytryptamine (serotonin) receptor 2B	Mus musculus	12-17
29940172-10	2018	While pure THC acted by activating cannabinoid CB2 receptors and generating reactive oxygen species, the BDP modulated different targets and mechanisms of action.	Dronabinol	11-14	cannabinoid receptor 2	Homo sapiens	47-50
30134192-2	2018	Its principal psychoactive component, Delta9-tetrahydrocannabinol (THC), affects multiple brain functions, including cognitive performance, by modulating cannabinoid type-1 (CB1) receptors.	Dronabinol	38-65	cannabinoid receptor 1 (brain)	Mus musculus	174-177
30134192-2	2018	Its principal psychoactive component, Delta9-tetrahydrocannabinol (THC), affects multiple brain functions, including cognitive performance, by modulating cannabinoid type-1 (CB1) receptors.	Dronabinol	67-70	cannabinoid receptor 1 (brain)	Mus musculus	174-177
30194918-5	2018	From the huge amount of generated data, we would like to highlight that the two psychotropic molecules (Delta9-tetrahydrocannabinol/THC and CP-55940) showed similar bias in CB1R and that the bias of THC was particularly relevant toward MAPK pathway.	Dronabinol	104-131	cannabinoid receptor 1	Homo sapiens	173-177
30194918-5	2018	From the huge amount of generated data, we would like to highlight that the two psychotropic molecules (Delta9-tetrahydrocannabinol/THC and CP-55940) showed similar bias in CB1R and that the bias of THC was particularly relevant toward MAPK pathway.	Dronabinol	104-131	mitogen-activated protein kinase 3	Homo sapiens	236-240
30194918-5	2018	From the huge amount of generated data, we would like to highlight that the two psychotropic molecules (Delta9-tetrahydrocannabinol/THC and CP-55940) showed similar bias in CB1R and that the bias of THC was particularly relevant toward MAPK pathway.	Dronabinol	132-135	cannabinoid receptor 1	Homo sapiens	173-177
30194918-5	2018	From the huge amount of generated data, we would like to highlight that the two psychotropic molecules (Delta9-tetrahydrocannabinol/THC and CP-55940) showed similar bias in CB1R and that the bias of THC was particularly relevant toward MAPK pathway.	Dronabinol	132-135	mitogen-activated protein kinase 3	Homo sapiens	236-240
30173052-3	2018	THC efficiently decreased the mRNA expression of interleukin-8 (IL-8) in LPS-stimulated A549 airway epithelial cells.	Dronabinol	0-3	chemokine (C-X-C motif) ligand 15	Mus musculus	49-62
30173052-3	2018	THC efficiently decreased the mRNA expression of interleukin-8 (IL-8) in LPS-stimulated A549 airway epithelial cells.	Dronabinol	0-3	chemokine (C-X-C motif) ligand 15	Mus musculus	64-68
30173052-4	2018	THC induced heme oxygenase-1 (HO-1) expression in A549 cells.	Dronabinol	0-3	heme oxygenase 1	Mus musculus	12-28
30173052-4	2018	THC induced heme oxygenase-1 (HO-1) expression in A549 cells.	Dronabinol	0-3	heme oxygenase 1	Mus musculus	30-34
30173052-6	2018	In LPS-induced ALI in mice, THC significantly suppressed neutrophil influx and monocyte chemoattractant protein-1 (MCP-1) production in the bronchoalveolar lavage fluid (BALF).	Dronabinol	28-31	chemokine (C-C motif) ligand 2	Mus musculus	79-113
30173052-6	2018	In LPS-induced ALI in mice, THC significantly suppressed neutrophil influx and monocyte chemoattractant protein-1 (MCP-1) production in the bronchoalveolar lavage fluid (BALF).	Dronabinol	28-31	chemokine (C-C motif) ligand 2	Mus musculus	115-120
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	elastase, neutrophil expressed	Mus musculus	34-53
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	elastase, neutrophil expressed	Mus musculus	55-57
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	60-87
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	89-98
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	interleukin 6	Mus musculus	104-117
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	interleukin 6	Mus musculus	119-123
30173052-8	2018	In addition, THC inhibited the expressions of inducible nitric oxide synthase (iNOS) and the activation of nuclear factor-kappa B (NF-kappaB) in the lung.	Dronabinol	13-16	nitric oxide synthase 2, inducible	Mus musculus	46-77
30173052-8	2018	In addition, THC inhibited the expressions of inducible nitric oxide synthase (iNOS) and the activation of nuclear factor-kappa B (NF-kappaB) in the lung.	Dronabinol	13-16	nitric oxide synthase 2, inducible	Mus musculus	79-83
30173052-8	2018	In addition, THC inhibited the expressions of inducible nitric oxide synthase (iNOS) and the activation of nuclear factor-kappa B (NF-kappaB) in the lung.	Dronabinol	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-129
30173052-8	2018	In addition, THC inhibited the expressions of inducible nitric oxide synthase (iNOS) and the activation of nuclear factor-kappa B (NF-kappaB) in the lung.	Dronabinol	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
30173052-9	2018	These protective effects of THC were accompanied with HO-1 induction and AMPK activation.	Dronabinol	28-31	heme oxygenase 1	Mus musculus	54-58
29982505-3	2018	We recently reported that most depressive-like behaviors triggered by adolescent Delta9-tetrahydrocannabinol exposure can be rescued by manipulating endocannabinoid signaling in adulthood with the anandamide-inactivating enzyme FAAH inhibitor, URB597.	Dronabinol	81-108	fatty-acid amide hydrolase-like	Rattus norvegicus	228-232
29126183-0	2018	Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of Tetrahydrocannabinol Immunoassay False Positives.	Dronabinol	85-105	ATPase H+/K+ transporting subunit alpha	Homo sapiens	47-58
29126183-2	2018	The drug package insert for pantoprazole mentions reports of false-positive urine screening tests for tetrahydrocannabinol in patients receiving proton pump inhibitors, but no method details or data are given, referenced, or found in literature searches.	Dronabinol	102-122	ATPase H+/K+ transporting subunit alpha	Homo sapiens	145-156
30232874-0	2018	Structural and Functional Interaction of Delta9-Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1).	Dronabinol	41-68	fatty acid binding protein 1, liver	Mus musculus	108-113
30232874-2	2018	A novel NBD-arachidonoylethanolamide (NBD-AEA) fluorescence displacement assay showed that liver fatty acid binding protein (FABP1), the major hepatic endocannabinoid (EC) binding protein, binds the first major metabolite of Delta9-THC (Delta9-THC-OH) as well as Delta9-THC itself.	Dronabinol	225-235	fatty acid binding protein 1, liver	Mus musculus	125-130
30232874-2	2018	A novel NBD-arachidonoylethanolamide (NBD-AEA) fluorescence displacement assay showed that liver fatty acid binding protein (FABP1), the major hepatic endocannabinoid (EC) binding protein, binds the first major metabolite of Delta9-THC (Delta9-THC-OH) as well as Delta9-THC itself.	Dronabinol	237-247	fatty acid binding protein 1, liver	Mus musculus	125-130
30232874-3	2018	Circular dichroism (CD) confirmed that not only Delta9-THC and Delta9-THC-OH but also downstream metabolites Delta9-THC-COOH and Delta9-THC-CO-glucuronide directly interact with FABP1.	Dronabinol	48-58	fatty acid binding protein 1, liver	Mus musculus	178-183
30232874-3	2018	Circular dichroism (CD) confirmed that not only Delta9-THC and Delta9-THC-OH but also downstream metabolites Delta9-THC-COOH and Delta9-THC-CO-glucuronide directly interact with FABP1.	Dronabinol	63-73	fatty acid binding protein 1, liver	Mus musculus	178-183
30232874-3	2018	Circular dichroism (CD) confirmed that not only Delta9-THC and Delta9-THC-OH but also downstream metabolites Delta9-THC-COOH and Delta9-THC-CO-glucuronide directly interact with FABP1.	Dronabinol	63-73	fatty acid binding protein 1, liver	Mus musculus	178-183
30232874-4	2018	Delta9-THC and metabolite interaction differentially altered the FABP1 secondary structure, increasing total alpha-helix (all), decreasing total beta-sheet (Delta9-THC-COOH, Delta9-THC-CO-glucuronide), increasing turns (Delta9-THC-OH, Delta9-THC-COOH, Delta9-THC-CO-glucuronide), and decreasing unordered structure (Delta9-THC, Delta9-THC-OH).	Dronabinol	0-10	fatty acid binding protein 1, liver	Mus musculus	65-70
30232874-6	2018	Fabp1 gene ablation (LKO) dramatically increased hepatocyte accumulation of Delta9-THC and even more so its primary metabolites Delta9-THC-OH and Delta9-THC-COOH.	Dronabinol	76-86	fatty acid binding protein 1, liver	Mus musculus	0-5
30232874-6	2018	Fabp1 gene ablation (LKO) dramatically increased hepatocyte accumulation of Delta9-THC and even more so its primary metabolites Delta9-THC-OH and Delta9-THC-COOH.	Dronabinol	128-138	fatty acid binding protein 1, liver	Mus musculus	0-5
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	diacylglycerol lipase, beta	Mus musculus	205-210
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	diacylglycerol lipase, alpha	Mus musculus	216-221
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	N-acylethanolamine acid amidase	Mus musculus	223-227
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	cannabinoid receptor 1 (brain)	Mus musculus	229-233
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	carnitine palmitoyltransferase 1a, liver	Mus musculus	247-252
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	fatty acid synthase	Mus musculus	258-262
30232874-7	2018	Concomitantly, rtPCR and Western blotting indicated that LKO significantly increased Delta9-THC"s ability to regulate downstream nuclear receptor transcription of genes important in both EC ( Napepld &gt; Daglb &gt; Dagla, Naaa, Cnr1) and lipid ( Cpt1A &gt; Fasn, FATP4) metabolism.	Dronabinol	92-95	solute carrier family 27 (fatty acid transporter), member 4	Mus musculus	264-269
30232874-8	2018	Taken together, the data indicated that FABP1 may play important roles in Delta9-THC uptake and elimination as well as Delta9-THC induction of genes regulating hepatic EC levels and downstream targets in lipid metabolism.	Dronabinol	81-84	fatty acid binding protein 1, liver	Mus musculus	40-45
30285892-13	2018	The discrepancy was explained by the observation that THC, one of the major ISL metabolite identified in lung cancer cells abrogated Src activity both in cells and cell-free system.	Dronabinol	54-57	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	133-136
30285892-16	2018	CONCLUSION: Our study suggests that ISL inhibits lung cancer cell migration and tumorigenesis by interfering with Src through its metabolite THC.	Dronabinol	141-144	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	114-117
30285892-17	2018	As licorice is safely used for culinary purposes, our study suggests that ISL or THC may be safely used as a Src inhibitor.	Dronabinol	81-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	109-112
30195587-1	2018	Delta9-tetrahydracannabinol (THC) is recognized as an effective treatment for nausea and vomiting via its action on the cannabinoid 1 (CB1) receptor.	Dronabinol	29-32	cannabinoid receptor 1	Rattus norvegicus	135-138
30195587-5	2018	We then investigated the ability of the CB1 receptor antagonist, rimonabant, to block the establishment of THC-induced conditioned gaping.	Dronabinol	107-110	cannabinoid receptor 1	Rattus norvegicus	40-43
30195587-8	2018	Pre-treatment with rimonabant reversed this effect, indicating that THC-induced conditioned gaping was CB1 receptor mediated.	Dronabinol	68-71	cannabinoid receptor 1	Rattus norvegicus	103-106
30195587-9	2018	The RT-PCR analysis revealed an upregulation of genes for the degrading enzyme, monoacylglycerol lipase (MAGL), of the endocannabinoid, 2-arachidolyl glycerol (2-AG), in the hypothalamus of rats treated with 10 mg/kg THC.	Dronabinol	217-220	monoglyceride lipase	Rattus norvegicus	80-103
30195587-9	2018	The RT-PCR analysis revealed an upregulation of genes for the degrading enzyme, monoacylglycerol lipase (MAGL), of the endocannabinoid, 2-arachidolyl glycerol (2-AG), in the hypothalamus of rats treated with 10 mg/kg THC.	Dronabinol	217-220	monoglyceride lipase	Rattus norvegicus	105-109
30170189-1	2018	Compounds extracted from the cannabis plant, including the psychoactive Delta9-tetrahydrocannabinol (THC) and related phytocannabinoids, evoke multiple diverse biological actions as ligands of the G protein-coupled cannabinoid receptors CB1 and CB2.	Dronabinol	72-99	cannabinoid receptor 1	Danio rerio	237-240
30170189-1	2018	Compounds extracted from the cannabis plant, including the psychoactive Delta9-tetrahydrocannabinol (THC) and related phytocannabinoids, evoke multiple diverse biological actions as ligands of the G protein-coupled cannabinoid receptors CB1 and CB2.	Dronabinol	72-99	flotillin 1b	Danio rerio	245-248
30170189-1	2018	Compounds extracted from the cannabis plant, including the psychoactive Delta9-tetrahydrocannabinol (THC) and related phytocannabinoids, evoke multiple diverse biological actions as ligands of the G protein-coupled cannabinoid receptors CB1 and CB2.	Dronabinol	101-104	cannabinoid receptor 1	Danio rerio	237-240
30170189-1	2018	Compounds extracted from the cannabis plant, including the psychoactive Delta9-tetrahydrocannabinol (THC) and related phytocannabinoids, evoke multiple diverse biological actions as ligands of the G protein-coupled cannabinoid receptors CB1 and CB2.	Dronabinol	101-104	flotillin 1b	Danio rerio	245-248
31453119-5	2019	Significant reductions in CD4 counts in THL and THC groups (p= 0.003 for both) were seen with no significant reductions in the CD4 counts in THI and THH groups (p=0.447 and 0.053 respectively).	Dronabinol	48-51	CD4 molecule	Homo sapiens	26-29
29928919-0	2018	The psychoactive substance of cannabis Delta9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells.	Dronabinol	39-66	CF transmembrane conductance regulator	Homo sapiens	94-98
29928919-0	2018	The psychoactive substance of cannabis Delta9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells.	Dronabinol	68-71	CF transmembrane conductance regulator	Homo sapiens	94-98
29928919-3	2018	The goal of this study was to assess the effect that exposure to Delta9-tetrahydrocannabinol (THC), the psychoactive substance present in marijuana, has on CFTR expression and function.	Dronabinol	65-92	CF transmembrane conductance regulator	Homo sapiens	156-160
29928919-3	2018	The goal of this study was to assess the effect that exposure to Delta9-tetrahydrocannabinol (THC), the psychoactive substance present in marijuana, has on CFTR expression and function.	Dronabinol	94-97	CF transmembrane conductance regulator	Homo sapiens	156-160
29928919-6	2018	We also used specific pharmacological inhibitors of EGFR and ERK to determine the role of this pathway in THC-induced regulation of CFTR.	Dronabinol	106-109	CF transmembrane conductance regulator	Homo sapiens	132-136
29928919-9	2018	THC also induced activation of the ERK MAPK pathway via activation of EGFR.	Dronabinol	0-3	mitogen-activated protein kinase 1	Homo sapiens	35-38
29928919-9	2018	THC also induced activation of the ERK MAPK pathway via activation of EGFR.	Dronabinol	0-3	epidermal growth factor receptor	Homo sapiens	70-74
29928919-10	2018	Inhibition of EGFR or MEK/ERK prevented THC-induced down regulation of CFTR protein expression.	Dronabinol	40-43	epidermal growth factor receptor	Homo sapiens	14-18
29928919-10	2018	Inhibition of EGFR or MEK/ERK prevented THC-induced down regulation of CFTR protein expression.	Dronabinol	40-43	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
29928919-10	2018	Inhibition of EGFR or MEK/ERK prevented THC-induced down regulation of CFTR protein expression.	Dronabinol	40-43	mitogen-activated protein kinase 1	Homo sapiens	26-29
29928919-10	2018	Inhibition of EGFR or MEK/ERK prevented THC-induced down regulation of CFTR protein expression.	Dronabinol	40-43	CF transmembrane conductance regulator	Homo sapiens	71-75
29928919-11	2018	CONCLUSIONS AND GENERAL SIGNIFICANCE: THC negatively regulates CFTR and this is mediated through the EGFR/ERK axis.	Dronabinol	38-41	CF transmembrane conductance regulator	Homo sapiens	63-67
29928919-11	2018	CONCLUSIONS AND GENERAL SIGNIFICANCE: THC negatively regulates CFTR and this is mediated through the EGFR/ERK axis.	Dronabinol	38-41	epidermal growth factor receptor	Homo sapiens	101-105
29928919-11	2018	CONCLUSIONS AND GENERAL SIGNIFICANCE: THC negatively regulates CFTR and this is mediated through the EGFR/ERK axis.	Dronabinol	38-41	mitogen-activated protein kinase 1	Homo sapiens	106-109
29928919-12	2018	This study provides the first evidence that THC present in marijuana reduces the expression and function of CFTR in airway epithelial cells.	Dronabinol	44-47	CF transmembrane conductance regulator	Homo sapiens	108-112
29748632-8	2018	In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT2AR signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC.	Dronabinol	193-196	AKT serine/threonine kinase 1	Homo sapiens	41-44
29748632-8	2018	In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT2AR signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC.	Dronabinol	193-196	mechanistic target of rapamycin kinase	Homo sapiens	45-49
29294249-1	2018	Cannabinoid CB1 receptors (CB1R) and serotonergic 2A receptors (5HT2AR) form heteromers in the brain of mice where they mediate the cognitive deficits produced by delta-9-tetrahydrocannabinol.	Dronabinol	163-191	cannabinoid receptor 1 (brain)	Mus musculus	12-15
29294249-1	2018	Cannabinoid CB1 receptors (CB1R) and serotonergic 2A receptors (5HT2AR) form heteromers in the brain of mice where they mediate the cognitive deficits produced by delta-9-tetrahydrocannabinol.	Dronabinol	163-191	cannabinoid receptor 1 (brain)	Mus musculus	27-31
29860612-1	2018	OBJECTIVE: Cannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Delta9-THC) enhance the antinociceptive potency of mu opioid receptor agonists such as morphine, indicating that opioid/cannabinoid mixtures might be effective for treating pain.	Dronabinol	49-77	opioid receptor mu 1	Macaca mulatta	130-148
29860612-1	2018	OBJECTIVE: Cannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Delta9-THC) enhance the antinociceptive potency of mu opioid receptor agonists such as morphine, indicating that opioid/cannabinoid mixtures might be effective for treating pain.	Dronabinol	79-89	opioid receptor mu 1	Macaca mulatta	130-148
30108473-8	2018	Moreover, augmentation of CB1R signaling with tetrahydrocannabinol also failed to restore normal fear extinction in DO34-treated mice.	Dronabinol	46-66	cannabinoid receptor 1 (brain)	Mus musculus	26-30
29902723-5	2018	The compounds were investigated in beta-arrestin recruitment assays as inhibitors of human GPR18 activation by tetrahydrocannabinol (THC).	Dronabinol	111-131	G protein-coupled receptor 18	Homo sapiens	91-96
29902723-5	2018	The compounds were investigated in beta-arrestin recruitment assays as inhibitors of human GPR18 activation by tetrahydrocannabinol (THC).	Dronabinol	133-136	G protein-coupled receptor 18	Homo sapiens	91-96
29902723-9	2018	Importantly, in contrast to 5, which showed only partial inhibition (60%), 23 led to a complete blockade of THC-induced GPR18 activation and is thus a superior tool for target validation.	Dronabinol	108-111	G protein-coupled receptor 18	Homo sapiens	120-125
29689453-8	2018	We have also determined that the phytocannabinoids are potent inhibitors of CYP2J2-mediated AEA metabolism, with Delta9-THC being the strongest inhibitor.	Dronabinol	113-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
29750976-1	2018	Mice with a mutation in the transmembrane domain of the schizophrenia risk gene, neuregulin 1 (Nrg1 TM HET), are more susceptible to the neuro-behavioural effects of Delta9-tetrahydrocannabinol (D9-THC), the principal psychoactive component in cannabis.	Dronabinol	166-193	neuregulin 1	Mus musculus	81-93
29750976-1	2018	Mice with a mutation in the transmembrane domain of the schizophrenia risk gene, neuregulin 1 (Nrg1 TM HET), are more susceptible to the neuro-behavioural effects of Delta9-tetrahydrocannabinol (D9-THC), the principal psychoactive component in cannabis.	Dronabinol	166-193	neuregulin 1	Mus musculus	95-99
29750976-1	2018	Mice with a mutation in the transmembrane domain of the schizophrenia risk gene, neuregulin 1 (Nrg1 TM HET), are more susceptible to the neuro-behavioural effects of Delta9-tetrahydrocannabinol (D9-THC), the principal psychoactive component in cannabis.	Dronabinol	195-201	neuregulin 1	Mus musculus	81-93
29750976-1	2018	Mice with a mutation in the transmembrane domain of the schizophrenia risk gene, neuregulin 1 (Nrg1 TM HET), are more susceptible to the neuro-behavioural effects of Delta9-tetrahydrocannabinol (D9-THC), the principal psychoactive component in cannabis.	Dronabinol	195-201	neuregulin 1	Mus musculus	95-99
29787777-2	2018	THC-induced impairments in decision making are thought to be the result of cannabinoid CB1 receptor activation, and although clinical literature suggests that chronic activation via THC contributes to perturbations in decision making, acute CB1 receptor modulation has yielded mixed results.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	87-90
29865166-8	2018	Although single THC affected ALP and AP levels more than single IRI, the levels of liver function markers measured after the administration of a combined treatment mostly did not significantly differ from control.	Dronabinol	16-19	PDZ and LIM domain 3	Rattus norvegicus	29-32
29580953-9	2018	Tetrahydrocannabinol (1-10 muM) and morphine (30-100 muM) significantly inhibited ChR2 currents while the cannabinoid receptor antagonist AM-251 had no effect.	Dronabinol	0-20	latexin	Homo sapiens	27-30
29805589-0	2018	9-tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer.	Dronabinol	0-22	matrix metallopeptidase 9	Homo sapiens	94-120
29805589-7	2018	Furthermore, THC inhibited EC cell viability and motility by inhibiting epithelial-mesenchymal transition (EMT) and downregulating matrix metalloproteinase-9 (MMP-9) gene expression in aggressive human EC cells.	Dronabinol	13-16	matrix metallopeptidase 9	Homo sapiens	131-157
29805589-7	2018	Furthermore, THC inhibited EC cell viability and motility by inhibiting epithelial-mesenchymal transition (EMT) and downregulating matrix metalloproteinase-9 (MMP-9) gene expression in aggressive human EC cells.	Dronabinol	13-16	matrix metallopeptidase 9	Homo sapiens	159-164
29805589-9	2018	The presnet findings suggest that THC may inhibit human EC cell migration through regulating EMT and MMP-9 pathways.	Dronabinol	34-37	matrix metallopeptidase 9	Homo sapiens	101-106
29549157-8	2018	This study demonstrates that novel structures being sold and used illicitly as substitutes for cannabis are retaining high affinity at the CB1 receptor, exhibiting greater efficacy than THC, and producing THC-like effects in models relevant to subjective effects in humans.	Dronabinol	205-208	cannabinoid receptor 1	Homo sapiens	139-142
29616245-8	2018	Furthermore, THC substantially induced the release of cytochrome C, caspase-3, caspase-9 and the cleavage of PARP to induce H22 cell apoptosis.	Dronabinol	13-16	caspase 3	Mus musculus	68-77
29616245-8	2018	Furthermore, THC substantially induced the release of cytochrome C, caspase-3, caspase-9 and the cleavage of PARP to induce H22 cell apoptosis.	Dronabinol	13-16	caspase 9	Mus musculus	79-88
29616245-8	2018	Furthermore, THC substantially induced the release of cytochrome C, caspase-3, caspase-9 and the cleavage of PARP to induce H22 cell apoptosis.	Dronabinol	13-16	poly (ADP-ribose) polymerase family, member 1	Mus musculus	109-113
29713172-4	2018	Preclinical studies show that genetic or pharmacological manipulation of the kappa opioid receptor/dynorphin system modulates the effects of delta 9-THC.	Dronabinol	141-152	opioid receptor kappa 1	Homo sapiens	77-98
29514950-8	2018	Because Delta-9-tetrahydrocannabinol exerted protective effects in the intestine in our previous studies, we successfully used it to reverse miR-130a- and miR-212-mediated reduction in transepithelial electrical resistance.	Dronabinol	8-36	microRNA 130a	Macaca mulatta	141-149
29514950-8	2018	Because Delta-9-tetrahydrocannabinol exerted protective effects in the intestine in our previous studies, we successfully used it to reverse miR-130a- and miR-212-mediated reduction in transepithelial electrical resistance.	Dronabinol	8-36	microRNA 212	Macaca mulatta	155-162
29514950-9	2018	Finally, ex vivo Delta-9-tetrahydrocannabinol treatment of colon tissue from chronically SIV-infected rhesus macaques significantly increased PPARgamma expression.	Dronabinol	17-45	peroxisome proliferator activated receptor gamma	Macaca mulatta	142-151
29414765-0	2018	Delta9-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by Fabp1 gene ablation.	Dronabinol	0-27	fatty acid binding protein 1, liver	Mus musculus	101-106
29414765-2	2018	The recent discovery that liver fatty acid binding protein-1 (FABP1) is the major cytosolic "chaperone" protein with high affinity for both Delta9-THC and ECs suggests that Delta9-THC may alter hepatic EC levels.	Dronabinol	140-150	fatty acid binding protein 1, liver	Mus musculus	32-60
29414765-2	2018	The recent discovery that liver fatty acid binding protein-1 (FABP1) is the major cytosolic "chaperone" protein with high affinity for both Delta9-THC and ECs suggests that Delta9-THC may alter hepatic EC levels.	Dronabinol	140-150	fatty acid binding protein 1, liver	Mus musculus	62-67
29414765-2	2018	The recent discovery that liver fatty acid binding protein-1 (FABP1) is the major cytosolic "chaperone" protein with high affinity for both Delta9-THC and ECs suggests that Delta9-THC may alter hepatic EC levels.	Dronabinol	173-183	fatty acid binding protein 1, liver	Mus musculus	32-60
29414765-2	2018	The recent discovery that liver fatty acid binding protein-1 (FABP1) is the major cytosolic "chaperone" protein with high affinity for both Delta9-THC and ECs suggests that Delta9-THC may alter hepatic EC levels.	Dronabinol	173-183	fatty acid binding protein 1, liver	Mus musculus	62-67
29414765-9	2018	This may arise from Delta9-THC competing with AEA and 2-AG binding to FABP1, thereby decreasing targeting of bound AEA and 2-AG to the degradative enzymes, fatty acid amide hydrolase and monoacylglyceride lipase, to decrease hydrolysis within hepatocytes.	Dronabinol	20-30	fatty acid binding protein 1, liver	Mus musculus	70-75
29414765-9	2018	This may arise from Delta9-THC competing with AEA and 2-AG binding to FABP1, thereby decreasing targeting of bound AEA and 2-AG to the degradative enzymes, fatty acid amide hydrolase and monoacylglyceride lipase, to decrease hydrolysis within hepatocytes.	Dronabinol	20-30	lipase, endothelial	Mus musculus	205-211
28816239-8	2018	Moreover, THC transiently enhanced the phosphorylation of the postsynaptic calmodulin-binding protein neurogranin in a PKC dependent manner.	Dronabinol	10-13	neurogranin	Homo sapiens	102-113
28816239-9	2018	These data demonstrate that THC alters short-term object-recognition memory through hippocampal PKC/neurogranin signaling.	Dronabinol	28-31	neurogranin	Homo sapiens	100-111
28917442-0	2018	ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users.	Dronabinol	45-65	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
28917442-2	2018	The objective of this study is to determine if ABCB1 C3435T (rs1045642) polymorphism may modulate Delta9-Tetrahydrocannabinol (THC) blood levels in a sample of heavy cannabis users.	Dronabinol	98-125	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
28917442-2	2018	The objective of this study is to determine if ABCB1 C3435T (rs1045642) polymorphism may modulate Delta9-Tetrahydrocannabinol (THC) blood levels in a sample of heavy cannabis users.	Dronabinol	127-130	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
28917442-7	2018	Our results show that ABCB1 C3435T polymorphism may modulate serum THC levels in chronic heavy cannabis users.	Dronabinol	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	22-27
29454037-8	2018	THC-induced reduction in sperm motility and kinematics were partly inhibited by cannabinoid receptor (CB) 1 or 2 blockade, but abolished by blockade of both CBs.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	80-107
29454037-11	2018	Conclusively, the spermatotoxic effect of THC is mediated by CBs 1 and 2 and is ameliorated by melatonin in-vitro.	Dronabinol	42-45	cannabinoid receptor 1	Rattus norvegicus	61-72
29307655-0	2018	RhoA/MLC signaling pathway is involved in Delta9-tetrahydrocannabinol-impaired placental angiogenesis.	Dronabinol	42-69	ras homolog family member A	Mus musculus	0-4
29307655-0	2018	RhoA/MLC signaling pathway is involved in Delta9-tetrahydrocannabinol-impaired placental angiogenesis.	Dronabinol	42-69	megalencephalic leukoencephalopathy with subcortical cysts 1 homolog (human)	Mus musculus	5-8
29307655-8	2018	Taken together, these findings identify THC plays a pivotal role in impairing placental angiogenesis potentially via RhoA/MLC signaling nexus.	Dronabinol	40-43	ras homolog family member A	Mus musculus	117-121
29307655-8	2018	Taken together, these findings identify THC plays a pivotal role in impairing placental angiogenesis potentially via RhoA/MLC signaling nexus.	Dronabinol	40-43	megalencephalic leukoencephalopathy with subcortical cysts 1 homolog (human)	Mus musculus	122-125
29607411-1	2018	Introduction: Memory impairment is one of the most commonly reported effects of cannabis use, especially among those who initiate use earlier, perhaps due to the effects of delta-9- tetrahydrocannabinol on cannabinoid (CB1) receptors in the brain.	Dronabinol	173-202	cannabinoid receptor 1	Homo sapiens	219-222
29286085-14	2018	Finally, the effects of SSd and E2 could be blocked by co-incubation with ICI-182780 or THC, but not MPP, thus indicating that ERbeta may be the potential target of SSd in HSC-T6 cells.	Dronabinol	88-91	estrogen receptor 2	Rattus norvegicus	127-133
29311110-9	2018	The effective reduction in CB1 receptor reserve was used to calculate the relative efficacy (tau values) of WIN 55,212, THC, and AM4054 in mice and of AM4054 monkeys, with results indicating that THC has a lower efficacy than WIN 55,212 or AM4054 in mice.	Dronabinol	196-199	cannabinoid receptor 1 (brain)	Mus musculus	27-30
29481316-7	2018	Adolescent THC exposure significantly increased Suv39H1 levels, which could account for the enhanced H3K9me3.	Dronabinol	11-14	SUV39H1 histone lysine methyltransferase	Rattus norvegicus	48-55
29481316-10	2018	CONCLUSION: Through a mechanism involving SUV39H1, THC modifies histone modifications and, thereby, expression of plasticity genes.	Dronabinol	51-54	SUV39H1 histone lysine methyltransferase	Rattus norvegicus	42-49
29106691-6	2018	At 96 hpf, c-fos, dazl, and vasa were differentially expressed following THC exposure, but only c-fos expression was significantly increased by CBD.	Dronabinol	73-76	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	11-16
29194121-4	2018	In-vitro experimentation using THC was performed on primary leukocytes isolated from HIV-MJ-, HIV+MJ- and HIV+MJ+ donors to determine if THC has an impact on CD16 monocyte and IP-10 levels.	Dronabinol	137-140	Fc gamma receptor IIIa	Homo sapiens	158-162
29194121-4	2018	In-vitro experimentation using THC was performed on primary leukocytes isolated from HIV-MJ-, HIV+MJ- and HIV+MJ+ donors to determine if THC has an impact on CD16 monocyte and IP-10 levels.	Dronabinol	137-140	C-X-C motif chemokine ligand 10	Homo sapiens	176-181
29194121-9	2018	Lastly, in-vitro THC treatment impaired CD16 monocyte transition to CD16 and monocyte-derived IP-10.	Dronabinol	17-20	Fc gamma receptor IIIa	Homo sapiens	40-44
29194121-9	2018	Lastly, in-vitro THC treatment impaired CD16 monocyte transition to CD16 and monocyte-derived IP-10.	Dronabinol	17-20	Fc gamma receptor IIIa	Homo sapiens	68-72
29194121-9	2018	Lastly, in-vitro THC treatment impaired CD16 monocyte transition to CD16 and monocyte-derived IP-10.	Dronabinol	17-20	C-X-C motif chemokine ligand 10	Homo sapiens	94-99
29191629-11	2018	High-dose of THC (30uM, but not 20 and 10uM) significantly inhibited (p&lt;0.01) human amniotic epithelial cell lines (WISH) proliferation.	Dronabinol	13-16	NCK interacting protein with SH3 domain	Homo sapiens	119-123
29191629-12	2018	Meanwhile, THC at both 10uM and 20uM (p&lt;0.05) significantly suppressed cells migration in both WISH and primary human amniotic epithelial cells.	Dronabinol	11-14	NCK interacting protein with SH3 domain	Homo sapiens	98-102
29191629-13	2018	The PCR array data and siRNA experiments demonstrated that MMP2/9 were tightly involved in the regulation of THC-inhibited cell migration in WISH cells.	Dronabinol	109-112	matrix metallopeptidase 2	Homo sapiens	59-65
29191629-13	2018	The PCR array data and siRNA experiments demonstrated that MMP2/9 were tightly involved in the regulation of THC-inhibited cell migration in WISH cells.	Dronabinol	109-112	NCK interacting protein with SH3 domain	Homo sapiens	141-145
29191629-14	2018	CONCLUSION: These results suggested that THC inhibited the migration of human amniotic epithelial cell through the regulation of MMP2 and MMP9, which in turn altered the development of the amnion during the gestation and partially resulted in preterm labor and other adverse pregnancy outcomes.	Dronabinol	41-44	matrix metallopeptidase 2	Homo sapiens	129-133
29191629-14	2018	CONCLUSION: These results suggested that THC inhibited the migration of human amniotic epithelial cell through the regulation of MMP2 and MMP9, which in turn altered the development of the amnion during the gestation and partially resulted in preterm labor and other adverse pregnancy outcomes.	Dronabinol	41-44	matrix metallopeptidase 9	Homo sapiens	138-142
29288688-8	2018	Human peroxisome proliferator-activated receptor gamma (PPARgamma) has been proposed to be a cannabinoid target, and PPARgamma has also been demonstrated to mediate some of the longer-term vascular effects of the plant cannabinoid,  9-tetrahydrocannabinol.	Dronabinol	233-255	peroxisome proliferator activated receptor gamma	Homo sapiens	117-126
29111112-8	2018	Administration of a CB1, but not a CB2, receptor antagonist attenuated the anti-migraine effect of THC.	Dronabinol	99-102	cannabinoid receptor 1	Rattus norvegicus	20-23
29111112-9	2018	These data suggest that: 1) THC reduces migraine-like pain when administered at the right dose (0.32mg/kg) and time (immediately after AITC); 2) THC"s anti-migraine effect is mediated by CB1 receptors; and 3) Wheel running is an effective method to assess migraine treatments because only treatments producing antinociception without disruptive side effects will restore normal activity.	Dronabinol	28-31	cannabinoid receptor 1	Rattus norvegicus	187-190
29111112-9	2018	These data suggest that: 1) THC reduces migraine-like pain when administered at the right dose (0.32mg/kg) and time (immediately after AITC); 2) THC"s anti-migraine effect is mediated by CB1 receptors; and 3) Wheel running is an effective method to assess migraine treatments because only treatments producing antinociception without disruptive side effects will restore normal activity.	Dronabinol	145-148	cannabinoid receptor 1	Rattus norvegicus	187-190
28641517-5	2018	Specifically, clinical trials testing the bronchodilator effects of THC in beta2 agonist resistant asthmatic patients would show whether THC could fill the role of rescue bronchodilator in cases of beta2 agonist resistance.	Dronabinol	68-71	G protein-coupled receptor 162	Homo sapiens	75-80
28371432-2	2018	Combined with a downscaled version of the classic liquid-liquid extraction, the proposed method allows for the quantification of Delta9-tetrahydrocannabinol, three of its major metabolites (the monohydroxylated, the dehydroxylated, and the carboxylated species) and four synthetic cannabinoid metabolites (from the JWH-series) at low ng L-1 levels.	Dronabinol	129-156	immunoglobulin kappa variable 1-16	Homo sapiens	337-340
29963207-5	2018	The most potent CB1 receptor agonist of the present series MDMB-FUBINACA (12) (Ki = 98.5 pM) was docked into the human CB1 receptor structure, and a plausible binding mode was identified showing high similarity with that of the co-crystallized THC derivatives.	Dronabinol	244-247	cannabinoid receptor 1	Homo sapiens	16-19
29963207-5	2018	The most potent CB1 receptor agonist of the present series MDMB-FUBINACA (12) (Ki = 98.5 pM) was docked into the human CB1 receptor structure, and a plausible binding mode was identified showing high similarity with that of the co-crystallized THC derivatives.	Dronabinol	244-247	cannabinoid receptor 1	Homo sapiens	119-122
28983686-1	2018	The  9-tetrahydrocannabinol (THC) metabolites 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use.	Dronabinol	5-27	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	46-51
28983686-1	2018	The  9-tetrahydrocannabinol (THC) metabolites 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use.	Dronabinol	5-27	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	68-73
28983686-1	2018	The  9-tetrahydrocannabinol (THC) metabolites 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use.	Dronabinol	29-32	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	46-51
28983686-1	2018	The  9-tetrahydrocannabinol (THC) metabolites 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC are mentioned in the literature as potential blood markers of recent cannabis use.	Dronabinol	29-32	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	68-73
28983686-9	2018	Hence, we were able to prove the in vivo metabolism from THC to both 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC in detectable concentrations.	Dronabinol	57-60	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	69-74
28983686-9	2018	Hence, we were able to prove the in vivo metabolism from THC to both 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC in detectable concentrations.	Dronabinol	57-60	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	91-96
28983686-10	2018	The quantitative comparison of 8beta-hydroxy-THC and 8beta,11-dihydroxy-THC with the main cannabinoids THC, 11-hydroxy-THC, and 11-nor-9-carboxy-THC revealed no further informative value for 8beta-hydroxy-THC regarding the last time of cannabis consumption.	Dronabinol	45-48	spectrin repeat containing nuclear envelope protein 1	Homo sapiens	31-36
28641496-1	2018	The cannabinoid-1 receptor (CB1R) agonist Delta9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.	Dronabinol	42-69	cannabinoid receptor 1	Homo sapiens	4-26
28641496-1	2018	The cannabinoid-1 receptor (CB1R) agonist Delta9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.	Dronabinol	42-69	cannabinoid receptor 1	Homo sapiens	28-32
28641496-1	2018	The cannabinoid-1 receptor (CB1R) agonist Delta9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.	Dronabinol	71-74	cannabinoid receptor 1	Homo sapiens	4-26
28641496-1	2018	The cannabinoid-1 receptor (CB1R) agonist Delta9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.	Dronabinol	71-74	cannabinoid receptor 1	Homo sapiens	28-32
29107185-4	2018	The single injection of THC increased the level of Sirtuin1, an enzyme that has been previously shown to be involved in neuroprotection and neuroplasticity, in the hippocampus and in the frontal cortex of old mice, for at least 7 weeks.	Dronabinol	24-27	sirtuin 1	Mus musculus	51-59
29121334-0	2018	Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.	Dronabinol	92-102	furin, paired basic amino acid cleaving enzyme	Homo sapiens	0-54
29121334-4	2018	Here, we present initial findings of the Phase II PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial, a fully blinded parallel groups, placebo-controlled randomized trial of dronabinol in people with moderate or severe OSA.	Dronabinol	191-201	furin, paired basic amino acid cleaving enzyme	Homo sapiens	50-54
29121334-4	2018	Here, we present initial findings of the Phase II PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial, a fully blinded parallel groups, placebo-controlled randomized trial of dronabinol in people with moderate or severe OSA.	Dronabinol	191-201	furin, paired basic amino acid cleaving enzyme	Homo sapiens	56-110
29161035-0	2017	Synthesis of Photoswitchable Delta9-Tetrahydrocannabinol Derivatives Enables Optical Control of Cannabinoid Receptor 1 Signaling.	Dronabinol	29-56	cannabinoid receptor 1	Homo sapiens	96-118
29057576-2	2017	Intraperitoneal injections of low dose of THC resulted in increased positive and negative BOLD signals compared to vehicle and high dose in areas rich in cannabinoid receptor 1, as well as throughout the pain and hippocampal neural systems.	Dronabinol	42-45	cannabinoid receptor 1	Rattus norvegicus	154-176
28947487-2	2017	Exogenous cannabinoid type 1 (CB1) receptor agonists such as Delta9-tetrahydrocannabinol are increasingly used for their medicinal actions; however, their utility is constrained by concern regarding abuse-related subjective effects.	Dronabinol	61-88	cannabinoid receptor 1	Homo sapiens	30-33
29107728-9	2017	Repeated THC administration also produced a protracted effected on CB1R protein expression.	Dronabinol	9-12	cannabinoid receptor 1 (brain)	Mus musculus	67-71
29107728-10	2017	Animals treated with THC in adolescence maintained increased levels of CB1R protein expression compared to their adult THC-treated counterparts at five weeks following the last injection.	Dronabinol	21-24	cannabinoid receptor 1 (brain)	Mus musculus	71-75
28905207-0	2017	Role of vasopressin V1a receptor in  9-tetrahydrocannabinol-induced cataleptic immobilization in mice.	Dronabinol	37-59	arginine vasopressin receptor 1A	Mus musculus	8-32
29285308-0	2017	Decisive role of P42/44 mitogen-activated protein kinase in Delta9-tetrahydrocannabinol-induced migration of human mesenchymal stem cells.	Dronabinol	60-87	cyclin dependent kinase 20	Homo sapiens	17-20
29285308-4	2017	Migration by THC was almost completely suppressed by the CB1 receptor antagonist AM-251 and to a lesser extent by the CB2 receptor antagonist AM-630.	Dronabinol	13-16	cannabinoid receptor 1	Homo sapiens	57-60
29285308-4	2017	Migration by THC was almost completely suppressed by the CB1 receptor antagonist AM-251 and to a lesser extent by the CB2 receptor antagonist AM-630.	Dronabinol	13-16	cannabinoid receptor 2	Homo sapiens	118-121
29285308-6	2017	Furthermore, increased migration by THC was fully suppressed by PD98059, an inhibitor of p42/44 mitogen-activated protein kinase (MAPK) activation, and was accompanied by a time-dependent activation of this pathway accordingly.	Dronabinol	36-39	cyclin dependent kinase 20	Homo sapiens	89-92
29285308-7	2017	In line with the migration data, additional inhibitor experiments pointed towards a decisive role of the CB1 receptor in conferring THC-induced activation of p42/44 MAPK.	Dronabinol	132-135	cannabinoid receptor 1	Homo sapiens	105-108
29285308-7	2017	In line with the migration data, additional inhibitor experiments pointed towards a decisive role of the CB1 receptor in conferring THC-induced activation of p42/44 MAPK.	Dronabinol	132-135	cyclin dependent kinase 20	Homo sapiens	158-161
29285308-8	2017	Collectively, this study demonstrates THC to exert a promigratory effect on MSCs via a CB1 receptor-dependent activation of p42/44 MAPK phosphorylation.	Dronabinol	38-41	cannabinoid receptor 1	Homo sapiens	87-90
29285308-8	2017	Collectively, this study demonstrates THC to exert a promigratory effect on MSCs via a CB1 receptor-dependent activation of p42/44 MAPK phosphorylation.	Dronabinol	38-41	cyclin dependent kinase 20	Homo sapiens	124-127
28736128-13	2017	The extra augmentation in the absorption of CBD and THC by incorporating piperine into PNL is attributed to the inhibition of Phase I and phase II metabolism by piperine in addition to the Phase I metabolism and P-gp inhibition by PNL.	Dronabinol	52-55	phosphoglycolate phosphatase	Rattus norvegicus	212-216
29101333-0	2017	Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors.	Dronabinol	40-68	cannabinoid receptor 1	Homo sapiens	105-108
28722246-9	2017	Co-administration of the CB1 antagonist AM251 blocked the effect of THC on masseter muscle mechanoreceptors while the CB2 antagonist AM630 had no effect.	Dronabinol	68-71	cannabinoid receptor 1	Rattus norvegicus	25-28
28722246-11	2017	Peripheral application of THC may counter this effect by activating the CB1 receptors on masseter muscle mechanoreceptors to provide analgesic relief without central side effects.	Dronabinol	26-29	cannabinoid receptor 1	Rattus norvegicus	72-75
28722246-12	2017	SIGNIFICANCE: Our results suggest THC could reduce masticatory muscle pain through activating peripheral CB1 receptors.	Dronabinol	34-37	cannabinoid receptor 1	Rattus norvegicus	105-108
29230395-2	2017	Here, we utilize excitatory neurons derived from human-induced pluripotent stem cells (hiPSCs), and report that in vitro THC exposure reduced expression of glutamate receptor subunit genes (GRIA1, GRIA2, GRIN2A, and GRIN2B).	Dronabinol	121-124	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	190-195
29230395-2	2017	Here, we utilize excitatory neurons derived from human-induced pluripotent stem cells (hiPSCs), and report that in vitro THC exposure reduced expression of glutamate receptor subunit genes (GRIA1, GRIA2, GRIN2A, and GRIN2B).	Dronabinol	121-124	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	197-202
29230395-2	2017	Here, we utilize excitatory neurons derived from human-induced pluripotent stem cells (hiPSCs), and report that in vitro THC exposure reduced expression of glutamate receptor subunit genes (GRIA1, GRIA2, GRIN2A, and GRIN2B).	Dronabinol	121-124	glutamate ionotropic receptor NMDA type subunit 2A	Homo sapiens	204-210
29230395-2	2017	Here, we utilize excitatory neurons derived from human-induced pluripotent stem cells (hiPSCs), and report that in vitro THC exposure reduced expression of glutamate receptor subunit genes (GRIA1, GRIA2, GRIN2A, and GRIN2B).	Dronabinol	121-124	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	216-222
29158718-0	2017	Effects of chronic Delta9-tetrahydrocannabinol treatment on Rho/Rho-kinase signalization pathway in mouse brain.	Dronabinol	19-46	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	64-74
29158718-4	2017	Thus, a study is planned to investigate rhoA and rho-kinase enzyme expressions and their activities in the brain of chronic Delta9-THC treated mice.	Dronabinol	131-134	ras homolog family member A	Mus musculus	40-44
29158718-4	2017	Thus, a study is planned to investigate rhoA and rho-kinase enzyme expressions and their activities in the brain of chronic Delta9-THC treated mice.	Dronabinol	131-134	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	49-59
29158718-8	2017	Chronic administration of Delta9-THC decreased the expression of rhoA while acute treatment has no meaningful effect on it.	Dronabinol	26-36	ras homolog family member A	Mus musculus	65-69
29158718-11	2017	This study showed that chronic Delta9-THC treatment down-regulated rhoA expression and did not change the expression level of rho-kinase which is downstream effector of rhoA.	Dronabinol	31-41	ras homolog family member A	Mus musculus	67-71
29158718-13	2017	Delta9-THC induced down-regulation of rhoA may cause elevation of cypin expression and may have benefit on cypin related diseases.	Dronabinol	0-10	ras homolog family member A	Mus musculus	38-42
29096499-2	2017	By exploiting the THC factorization, the formal scaling of MP2 and SOS-MP2 gradient calculations with respect to system size is reduced to quartic and cubic, respectively.	Dronabinol	18-21	tryptase pseudogene 1	Homo sapiens	59-62
29096499-4	2017	THC-MP2 has been applied to both geometry optimization and ab initio molecular dynamics (AIMD) simulations.	Dronabinol	0-3	tryptase pseudogene 1	Homo sapiens	4-7
29096499-5	2017	The resulting energy conservation in micro-canonical AIMD demonstrates that the implementation provides accurate nuclear gradients with respect to the THC-MP2 potential energy surfaces.	Dronabinol	151-154	tryptase pseudogene 1	Homo sapiens	155-158
28438413-5	2017	In contrast, acute 2-AG depletion increased anxiety-like behaviors, which was normalized by selective pharmacological augmentation of AEA signaling and via direct cannabinoid receptor 1 stimulation with Delta9-tetrahydrocannabinol.	Dronabinol	203-230	cannabinoid receptor 1 (brain)	Mus musculus	163-185
28272498-5	2017	As risperidone and its active metabolite are excellent substrates of the ABC transporter P-glycoprotein (P-gp), we hypothesized that THC might increase P-gp expression at the blood-brain barrier (BBB) and thus enhance efflux of risperidone and its metabolite from brain tissue.	Dronabinol	133-136	phosphoglycolate phosphatase	Mus musculus	105-109
28272498-5	2017	As risperidone and its active metabolite are excellent substrates of the ABC transporter P-glycoprotein (P-gp), we hypothesized that THC might increase P-gp expression at the blood-brain barrier (BBB) and thus enhance efflux of risperidone and its metabolite from brain tissue.	Dronabinol	133-136	phosphoglycolate phosphatase	Mus musculus	152-156
28272498-7	2017	Furthermore, we demonstrated that THC exposure increased P-gp expression in various brain regions important to risperidone"s antipsychotic action.	Dronabinol	34-37	phosphoglycolate phosphatase	Mus musculus	57-61
28673548-1	2017	Substantial challenges exist for investigating the cannabinoid receptor type 1 (CB1)-mediated discriminative stimulus effects of the endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide; AEA), compared with exogenous CB1 receptor agonists, such as Delta9-tetrahydrocannabinol (THC) and the synthetic cannabinoid CP55,940.	Dronabinol	286-313	cannabinoid receptor 1 (brain)	Mus musculus	51-83
28673548-1	2017	Substantial challenges exist for investigating the cannabinoid receptor type 1 (CB1)-mediated discriminative stimulus effects of the endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide; AEA), compared with exogenous CB1 receptor agonists, such as Delta9-tetrahydrocannabinol (THC) and the synthetic cannabinoid CP55,940.	Dronabinol	286-313	cannabinoid receptor 1 (brain)	Mus musculus	80-83
28673548-1	2017	Substantial challenges exist for investigating the cannabinoid receptor type 1 (CB1)-mediated discriminative stimulus effects of the endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide; AEA), compared with exogenous CB1 receptor agonists, such as Delta9-tetrahydrocannabinol (THC) and the synthetic cannabinoid CP55,940.	Dronabinol	315-318	cannabinoid receptor 1 (brain)	Mus musculus	51-83
28673548-1	2017	Substantial challenges exist for investigating the cannabinoid receptor type 1 (CB1)-mediated discriminative stimulus effects of the endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide; AEA), compared with exogenous CB1 receptor agonists, such as Delta9-tetrahydrocannabinol (THC) and the synthetic cannabinoid CP55,940.	Dronabinol	315-318	cannabinoid receptor 1 (brain)	Mus musculus	80-83
28803965-3	2017	Recently, pregnenolone was reported to act as an allosteric modulator of CB1, blocking THC"s effects in vitro and in vivo, highlighting the potential of CB1 allosteric modulators for treatment of cannabis intoxication.	Dronabinol	87-90	cannabinoid receptor 1 (brain)	Mus musculus	73-76
28803965-3	2017	Recently, pregnenolone was reported to act as an allosteric modulator of CB1, blocking THC"s effects in vitro and in vivo, highlighting the potential of CB1 allosteric modulators for treatment of cannabis intoxication.	Dronabinol	87-90	cannabinoid receptor 1 (brain)	Mus musculus	153-156
28951549-0	2017	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Delta9-Tetrahydrocannabinol (Delta9-THC)-Induced Aversive Effects in Mice.	Dronabinol	77-104	cannabinoid receptor 1 (brain)	Mus musculus	0-3
28951549-0	2017	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Delta9-Tetrahydrocannabinol (Delta9-THC)-Induced Aversive Effects in Mice.	Dronabinol	77-104	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6	Mus musculus	27-33
28951549-0	2017	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Delta9-Tetrahydrocannabinol (Delta9-THC)-Induced Aversive Effects in Mice.	Dronabinol	106-116	cannabinoid receptor 1 (brain)	Mus musculus	0-3
28951549-0	2017	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Delta9-Tetrahydrocannabinol (Delta9-THC)-Induced Aversive Effects in Mice.	Dronabinol	106-116	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6	Mus musculus	27-33
28951549-7	2017	In contrast, Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reduction in the above optical ICSS in VgluT2-cre control mice, but not in VgluT2-CB1 -/- mice.	Dronabinol	13-40	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6	Mus musculus	197-203
28951549-7	2017	In contrast, Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reduction in the above optical ICSS in VgluT2-cre control mice, but not in VgluT2-CB1 -/- mice.	Dronabinol	13-40	cannabinoid receptor 1 (brain)	Mus musculus	240-243
28951549-7	2017	In contrast, Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reduction in the above optical ICSS in VgluT2-cre control mice, but not in VgluT2-CB1 -/- mice.	Dronabinol	42-52	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6	Mus musculus	197-203
28951549-7	2017	In contrast, Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reduction in the above optical ICSS in VgluT2-cre control mice, but not in VgluT2-CB1 -/- mice.	Dronabinol	42-52	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6	Mus musculus	233-239
28951549-7	2017	In contrast, Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reduction in the above optical ICSS in VgluT2-cre control mice, but not in VgluT2-CB1 -/- mice.	Dronabinol	42-52	cannabinoid receptor 1 (brain)	Mus musculus	240-243
27126842-4	2017	We found similar reduced social recognition, increased motor stereotypies and increased anxiety with relevant c-fos response alterations in morphine, nicotine, THC and alcohol abstinent mice.	Dronabinol	160-163	FBJ osteosarcoma oncogene	Mus musculus	110-115
28967368-8	2017	The action of THC is mediated by two major G-protein coupled receptors, cannabinoid receptor type 1 (CB1) and CB2, and recent work has suggested that other targets may also exist.	Dronabinol	14-17	cannabinoid receptor 1	Homo sapiens	72-104
28967368-8	2017	The action of THC is mediated by two major G-protein coupled receptors, cannabinoid receptor type 1 (CB1) and CB2, and recent work has suggested that other targets may also exist.	Dronabinol	14-17	cannabinoid receptor 2	Homo sapiens	110-113
28653801-1	2017	GPR55, an orphan G-protein coupled receptor, is activated by lysophosphatidylinositol (LPI) and the endocannabinoid anandamide, as well as by other compounds including THC.	Dronabinol	168-171	G protein-coupled receptor 55	Mus musculus	0-5
28655644-12	2017	Delta9-Tetrahydrocannabinol (2x10-5M), which is a partial agonist of both CB1 and CB2 receptors, suppressed the glutamatergic and GABAergic synaptic transmission in the rat nucleus accumbens.	Dronabinol	0-27	cannabinoid receptor 1	Rattus norvegicus	74-77
28655644-12	2017	Delta9-Tetrahydrocannabinol (2x10-5M), which is a partial agonist of both CB1 and CB2 receptors, suppressed the glutamatergic and GABAergic synaptic transmission in the rat nucleus accumbens.	Dronabinol	0-27	cannabinoid receptor 2	Rattus norvegicus	82-85
28934522-2	2017	In anesthetized rats, dronabinol attenuates reflex apnea via activation of cannabinoid (CB) receptors located on vagal afferents; an effect blocked by cannabinoid type 1 (CB1) and/or type 2 (CB2) receptor antagonists.	Dronabinol	22-32	cannabinoid receptor 1	Rattus norvegicus	171-174
28934522-2	2017	In anesthetized rats, dronabinol attenuates reflex apnea via activation of cannabinoid (CB) receptors located on vagal afferents; an effect blocked by cannabinoid type 1 (CB1) and/or type 2 (CB2) receptor antagonists.	Dronabinol	22-32	cannabinoid receptor 2	Rattus norvegicus	191-194
28934522-9	2017	Dronabinol also decreased apneas during sleep, and this apnea suppression was reversed by CB1 or CB1/CB2 receptor antagonism.	Dronabinol	0-10	cannabinoid receptor 1	Rattus norvegicus	90-93
28934522-9	2017	Dronabinol also decreased apneas during sleep, and this apnea suppression was reversed by CB1 or CB1/CB2 receptor antagonism.	Dronabinol	0-10	cannabinoid receptor 1	Rattus norvegicus	97-100
28934522-9	2017	Dronabinol also decreased apneas during sleep, and this apnea suppression was reversed by CB1 or CB1/CB2 receptor antagonism.	Dronabinol	0-10	cannabinoid receptor 2	Rattus norvegicus	101-104
28934522-10	2017	Conclusions: Dronabinol"s effects on apneas were dependent on CB1 receptor activation, while dronabinol"s effects on REM sleep were CB receptor-independent.	Dronabinol	13-23	cannabinoid receptor 1	Rattus norvegicus	62-65
28692581-0	2017	Delta9-Tetrahydrocannabinol Suppresses Secretion of IFNalpha by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.	Dronabinol	0-27	interferon alpha 1	Homo sapiens	52-60
28692581-6	2017	Here, we report that THC suppressed secretion of IFNalpha by pDC from both healthy and HIV+ donors through a mechanism involving impaired phosphorylation of interferon regulatory factor 7.	Dronabinol	21-24	interferon alpha 1	Homo sapiens	49-57
28561272-6	2017	KEY RESULTS: Our data show that subchronic treatment with both the natural CB1 /CB2 receptor agonist Delta9 -tetrahydrocannabinol and the synthetic CB1 /CB2 receptor agonist CP-55,940 significantly reduced body weight loss and running wheel activity in ABA rats.	Dronabinol	101-129	cannabinoid receptor 1	Rattus norvegicus	75-78
28561272-6	2017	KEY RESULTS: Our data show that subchronic treatment with both the natural CB1 /CB2 receptor agonist Delta9 -tetrahydrocannabinol and the synthetic CB1 /CB2 receptor agonist CP-55,940 significantly reduced body weight loss and running wheel activity in ABA rats.	Dronabinol	101-129	cannabinoid receptor 2	Rattus norvegicus	80-83
28561272-6	2017	KEY RESULTS: Our data show that subchronic treatment with both the natural CB1 /CB2 receptor agonist Delta9 -tetrahydrocannabinol and the synthetic CB1 /CB2 receptor agonist CP-55,940 significantly reduced body weight loss and running wheel activity in ABA rats.	Dronabinol	101-129	cannabinoid receptor 2	Rattus norvegicus	80-92
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	20-48	cannabinoid receptor 1	Homo sapiens	114-127
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	20-48	cannabinoid receptor 1	Homo sapiens	129-132
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	20-48	cannabinoid receptor 1	Homo sapiens	155-158
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	50-53	cannabinoid receptor 1	Homo sapiens	114-127
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	50-53	cannabinoid receptor 1	Homo sapiens	129-132
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	50-53	cannabinoid receptor 1	Homo sapiens	155-158
29082317-1	2017	Background: Because delta-9-tetrahydrocannabinol (THC), the primary psychoactive ingredient in cannabis, binds to cannabinoid 1 (CB1) receptors, levels of CB1 protein could serve as a potential biomarker for response to THC.	Dronabinol	220-223	cannabinoid receptor 1	Homo sapiens	155-158
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	0-3	cyclin-dependent kinase 5	Mus musculus	87-112
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	0-3	cyclin-dependent kinase 5	Mus musculus	114-118
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	0-3	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	147-150
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	49-52	cyclin-dependent kinase 5	Mus musculus	87-112
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	49-52	cyclin-dependent kinase 5	Mus musculus	114-118
29082320-8	2017	THC injection in mice with a history of repeated THC treatment increased expression of cyclin-dependent kinase 5 (Cdk5) and its regulatory protein p35 only in the PFC.	Dronabinol	49-52	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	147-150
29082320-9	2017	This increase in Cdk5 and p35 expression in PFC was also found in mice that had only received repeated THC administration, suggesting that this effect might be due to induction of DeltaFosB.	Dronabinol	103-106	cyclin-dependent kinase 5	Mus musculus	17-21
29082320-9	2017	This increase in Cdk5 and p35 expression in PFC was also found in mice that had only received repeated THC administration, suggesting that this effect might be due to induction of DeltaFosB.	Dronabinol	103-106	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	26-29
29082320-10	2017	Extracellular signal-regulated kinase (ERK) phosphorylation was increased in PFC after THC injection in repeated THC-treated mice.	Dronabinol	87-90	mitogen-activated protein kinase 1	Mus musculus	0-37
29082320-10	2017	Extracellular signal-regulated kinase (ERK) phosphorylation was increased in PFC after THC injection in repeated THC-treated mice.	Dronabinol	87-90	mitogen-activated protein kinase 1	Mus musculus	39-42
29082320-10	2017	Extracellular signal-regulated kinase (ERK) phosphorylation was increased in PFC after THC injection in repeated THC-treated mice.	Dronabinol	113-116	mitogen-activated protein kinase 1	Mus musculus	0-37
29082320-10	2017	Extracellular signal-regulated kinase (ERK) phosphorylation was increased in PFC after THC injection in repeated THC-treated mice.	Dronabinol	113-116	mitogen-activated protein kinase 1	Mus musculus	39-42
29082320-11	2017	Phosphorylation of glycogen synthase kinase-3beta (GSK3beta), a Cdk5 target, was reduced in PFC after repeated THC treatment regardless of THC history, and phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the Cdk5-regulated threonine 75 site was unchanged.	Dronabinol	111-114	glycogen synthase kinase 3 beta	Mus musculus	19-49
29082320-11	2017	Phosphorylation of glycogen synthase kinase-3beta (GSK3beta), a Cdk5 target, was reduced in PFC after repeated THC treatment regardless of THC history, and phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the Cdk5-regulated threonine 75 site was unchanged.	Dronabinol	111-114	glycogen synthase kinase 3 beta	Mus musculus	51-59
29082320-11	2017	Phosphorylation of glycogen synthase kinase-3beta (GSK3beta), a Cdk5 target, was reduced in PFC after repeated THC treatment regardless of THC history, and phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the Cdk5-regulated threonine 75 site was unchanged.	Dronabinol	111-114	cyclin-dependent kinase 5	Mus musculus	64-68
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	61-64	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	219-222
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	61-64	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	255-259
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	87-90	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	219-222
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	87-90	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	255-259
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	87-90	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	219-222
29082320-12	2017	Conclusion: These results suggest that a history of repeated THC administration primes THC-mediated induction of DeltaFosB in the NAc and PFC, and that expression of both downstream targets of DeltaFosB (e.g., Cdk5 and p35) and upstream activators (e.g., pERK) in the PFC is dependent on THC history, which might have functional implications in addiction and neuropsychiatric disease.	Dronabinol	87-90	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	255-259
28648819-8	2017	Decreased cortical receptor expression of NMDA receptor 1 subunit (NR1) was observed in mice that received PCP and PCP+Delta9-THC, while mice that received Delta9-THC and PCP+Delta9-THC displayed decreases in CB1 receptor expression.	Dronabinol	119-129	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	67-70
28678776-1	2017	The cannabinoid receptor 1 (CB1) is the principal target of the psychoactive constituent of marijuana, the partial agonist Delta9-tetrahydrocannabinol (Delta9-THC).	Dronabinol	123-150	cannabinoid receptor 1	Homo sapiens	28-31
28678776-1	2017	The cannabinoid receptor 1 (CB1) is the principal target of the psychoactive constituent of marijuana, the partial agonist Delta9-tetrahydrocannabinol (Delta9-THC).	Dronabinol	152-162	cannabinoid receptor 1	Homo sapiens	28-31
28678776-2	2017	Here we report two agonist-bound crystal structures of human CB1 in complex with a tetrahydrocannabinol (AM11542) and a hexahydrocannabinol (AM841) at 2.80 A and 2.95 A resolution, respectively.	Dronabinol	83-103	cannabinoid receptor 1	Homo sapiens	61-64
28686594-7	2017	They revealed that THC served to functionally isolate CA1 from CA3 by reducing feedforward excitation and theta information flow.	Dronabinol	19-22	carbonic anhydrase 1	Rattus norvegicus	54-57
28686594-7	2017	They revealed that THC served to functionally isolate CA1 from CA3 by reducing feedforward excitation and theta information flow.	Dronabinol	19-22	carbonic anhydrase 3	Rattus norvegicus	63-66
28678398-2	2017	The tetrad is characterized by hypolocomotion, hypothermia, catalepsy, and analgesia, four phenotypes that are induced by acute administration of CB1 agonists exemplified by the prototypic cannabinoid delta-9-tetrahydrocannabinol (THC).	Dronabinol	201-229	cannabinoid receptor 1 (brain)	Mus musculus	146-149
28678398-2	2017	The tetrad is characterized by hypolocomotion, hypothermia, catalepsy, and analgesia, four phenotypes that are induced by acute administration of CB1 agonists exemplified by the prototypic cannabinoid delta-9-tetrahydrocannabinol (THC).	Dronabinol	231-234	cannabinoid receptor 1 (brain)	Mus musculus	146-149
28456476-6	2017	Administration of THC to mice did not cause significant change in plasma ammonia concentrations within the first 5min, but significantly reduced striatal glutamine-synthetase (GS) activity (P=0.046) and increased striatal ammonia concentration (P=0.016).	Dronabinol	18-21	glutamate-ammonia ligase (glutamine synthetase)	Mus musculus	154-174
28724152-4	2017	METHODS: In 2011 a collaboration to develop a community health center (CHC) academic medical partnership (CHAMP), was formed and created a THC as a training site for expansion of an existing family medicine residency program.	Dronabinol	139-142	chromosome alignment maintaining phosphoprotein 1	Homo sapiens	106-111
28402427-4	2017	Here, utilizing a unique mouse model based on host (DISC1) X environment (THC administration) interaction, we aimed at studying the pathobiological basis through which THC exposure elicits psychiatric manifestations.	Dronabinol	168-171	disrupted in schizophrenia 1	Mus musculus	52-57
28402427-8	2017	Our results indicate that THC exposure elicits deficits in exploratory activity and recognition memory, together with reduced short-term synaptic facilitation and loss of BDNF surge in the hippocampus of DN-DISC mice, but not in wild-type mice.	Dronabinol	26-29	brain derived neurotrophic factor	Mus musculus	171-175
28402427-9	2017	Over-expression of BDNF in the hippocampus of THC-treated DN-DISC1 mice prevented the impairment in recognition memory.	Dronabinol	46-49	brain derived neurotrophic factor	Mus musculus	19-23
28402427-9	2017	Over-expression of BDNF in the hippocampus of THC-treated DN-DISC1 mice prevented the impairment in recognition memory.	Dronabinol	46-49	disrupted in schizophrenia 1	Mus musculus	61-66
28402427-10	2017	The results of this study imply that induction of BDNF following adolescence THC exposure may serve as a homeostatic response geared to maintain proper cognitive function against exogenous insult.	Dronabinol	77-80	brain derived neurotrophic factor	Mus musculus	50-54
28402427-11	2017	The BDNF surge in response to THC is perturbed in the presence of mutant DISC1, suggesting DISC1 may be a useful probe to identify biological cascades involved in the neurochemical, electrophysiological, and behavioral effects of cannabis related psychiatric manifestations.	Dronabinol	30-33	brain derived neurotrophic factor	Mus musculus	4-8
28402427-11	2017	The BDNF surge in response to THC is perturbed in the presence of mutant DISC1, suggesting DISC1 may be a useful probe to identify biological cascades involved in the neurochemical, electrophysiological, and behavioral effects of cannabis related psychiatric manifestations.	Dronabinol	30-33	disrupted in schizophrenia 1	Mus musculus	73-78
28402427-11	2017	The BDNF surge in response to THC is perturbed in the presence of mutant DISC1, suggesting DISC1 may be a useful probe to identify biological cascades involved in the neurochemical, electrophysiological, and behavioral effects of cannabis related psychiatric manifestations.	Dronabinol	30-33	disrupted in schizophrenia 1	Mus musculus	91-96
28442584-0	2017	Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.	Dronabinol	70-73	cannabinoid receptor 1 (brain)	Mus musculus	9-12
28412574-6	2017	Air samples collected inside the cargo area of the storage trucks used during FCP raids indicated that THC can be volatilised when lush plants are compressed by other seized plants loaded on top of them in the truck over a period of several days, allowing composting of plants at the bottom of the load to commence.	Dronabinol	103-106	FCP1	Homo sapiens	78-81
28481360-8	2017	The transcriptional effects of THC were critically dependent on glutamatergic CB1 receptors and histone acetylation, as their inhibition blocked the beneficial effects of THC.	Dronabinol	31-34	cannabinoid receptor 1 (brain)	Mus musculus	78-81
28481360-8	2017	The transcriptional effects of THC were critically dependent on glutamatergic CB1 receptors and histone acetylation, as their inhibition blocked the beneficial effects of THC.	Dronabinol	171-174	cannabinoid receptor 1 (brain)	Mus musculus	78-81
28861508-5	2017	Binding affinity of THCA-A and THC at human (h) CB1 and hCB2 was measured in competition binding assays, using transfected HEK cells and [3H]CP55,940.	Dronabinol	20-23	cannabinoid receptor 1	Homo sapiens	48-51
28861508-5	2017	Binding affinity of THCA-A and THC at human (h) CB1 and hCB2 was measured in competition binding assays, using transfected HEK cells and [3H]CP55,940.	Dronabinol	20-23	cannabinoid receptor 2	Homo sapiens	56-60
28861508-9	2017	THC showed 62-fold greater affinity at hCB1 and 125-fold greater affinity at hCB2.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	39-43
28861508-9	2017	THC showed 62-fold greater affinity at hCB1 and 125-fold greater affinity at hCB2.	Dronabinol	0-3	cannabinoid receptor 2	Homo sapiens	77-81
27639448-3	2017	First, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as THC, and review studies demonstrating that THC-induced impairments in decision-making processes are mediated by actions at prefrontal CB1 receptors.	Dronabinol	225-228	cannabinoid receptor 1	Homo sapiens	316-319
28219717-10	2017	This glucose PET study showed that stimulation of CB1 receptors by THC affects the glucose uptake in the rat brain, whereby the effect of THC is regionally different and dependent on dose - an effect that may be of relevance in behavioural studies.	Dronabinol	67-70	cannabinoid receptor 1	Rattus norvegicus	50-53
28219717-10	2017	This glucose PET study showed that stimulation of CB1 receptors by THC affects the glucose uptake in the rat brain, whereby the effect of THC is regionally different and dependent on dose - an effect that may be of relevance in behavioural studies.	Dronabinol	138-141	cannabinoid receptor 1	Rattus norvegicus	50-53
28104530-7	2017	Perinatal exposure to Delta9-THC induced a significant reduction of CB1 receptor binding (Bmax) in the hippocampus of 90-day-old rats.	Dronabinol	22-32	cannabinoid receptor 1	Rattus norvegicus	68-71
27965084-7	2017	To test the influence of the zebrafish endocannabinoid system on fear acquisition learning, an experimental group of ten fish was pretreated with the CB1 receptor agonist THC (Delta9-tetrahydrocannabinol; 100nM for 1h).	Dronabinol	171-174	cannabinoid receptor 1	Danio rerio	150-153
27965084-11	2017	THC administration before fear conditioning significantly decreased c-Fos expression in these structures to a level similar to the control group without Schreckstoff experience, suggesting that Schreckstoff induced fear learning requires brain circuits restricted mainly to pallial regions of the dorsal telencephalon.	Dronabinol	0-3	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	68-73
28377876-1	2017	OBJECTIVES: Phytocannabinoids, such as THC and endocannabinoids, are well known to promote feeding behavior and to control energy metabolism through cannabinoid type 1 receptors (CB1R).	Dronabinol	39-42	cannabinoid receptor 1 (brain)	Mus musculus	149-177
28377876-1	2017	OBJECTIVES: Phytocannabinoids, such as THC and endocannabinoids, are well known to promote feeding behavior and to control energy metabolism through cannabinoid type 1 receptors (CB1R).	Dronabinol	39-42	cannabinoid receptor 1 (brain)	Mus musculus	179-183
28154257-4	2017	Here, we used in vitro affinity maturation to generate a single-chain Fv fragment (scFv) that recognizes with high affinity the psychoactive cannabinoid, Delta9-tetrahydrocannabinol (THC).	Dronabinol	154-181	immunglobulin heavy chain variable region	Homo sapiens	83-87
28154257-4	2017	Here, we used in vitro affinity maturation to generate a single-chain Fv fragment (scFv) that recognizes with high affinity the psychoactive cannabinoid, Delta9-tetrahydrocannabinol (THC).	Dronabinol	183-186	immunglobulin heavy chain variable region	Homo sapiens	83-87
28154257-5	2017	A mouse monoclonal antibody against THC, Ab-THC#33, with Ka 6.2x107 M-1 (as Fab fragment) was established by the hybridoma technique.	Dronabinol	36-39	FA complementation group B	Homo sapiens	76-79
28154257-5	2017	A mouse monoclonal antibody against THC, Ab-THC#33, with Ka 6.2x107 M-1 (as Fab fragment) was established by the hybridoma technique.	Dronabinol	44-47	FA complementation group B	Homo sapiens	76-79
28154257-8	2017	Repeated panning identified a mutant scFv (scFv#m1-36) with 10-fold enhanced affinity (Ka 1.1x108 M-1) for THC, in which only a single conservative substitution (Ser50Thr) was present at the N-terminus of the VH-complementarity-determining region 2 (CDR2) sequence.	Dronabinol	107-110	immunglobulin heavy chain variable region	Homo sapiens	37-41
28154257-8	2017	Repeated panning identified a mutant scFv (scFv#m1-36) with 10-fold enhanced affinity (Ka 1.1x108 M-1) for THC, in which only a single conservative substitution (Ser50Thr) was present at the N-terminus of the VH-complementarity-determining region 2 (CDR2) sequence.	Dronabinol	107-110	immunglobulin heavy chain variable region	Homo sapiens	43-53
28154257-9	2017	In competitive enzyme-linked immunosorbent assay (ELISA), the mutant scFv generated dose-response curves with midpoint 0.27 ng/assay THC, which was 3-fold lower than that of wt-scFv.	Dronabinol	133-136	immunglobulin heavy chain variable region	Homo sapiens	69-73
28154257-9	2017	In competitive enzyme-linked immunosorbent assay (ELISA), the mutant scFv generated dose-response curves with midpoint 0.27 ng/assay THC, which was 3-fold lower than that of wt-scFv.	Dronabinol	133-136	immunglobulin heavy chain variable region	Homo sapiens	177-181
28154257-10	2017	Even higher reactivity with a major THC metabolite, 11-nor-9-carboxy-Delta9-tetrahydrocannabinol, indicated that the mutant scFv will be useful for testing not only THC in confiscated materials, but also the metabolite in urine.	Dronabinol	36-39	immunglobulin heavy chain variable region	Homo sapiens	124-128
28154257-10	2017	Even higher reactivity with a major THC metabolite, 11-nor-9-carboxy-Delta9-tetrahydrocannabinol, indicated that the mutant scFv will be useful for testing not only THC in confiscated materials, but also the metabolite in urine.	Dronabinol	165-168	immunglobulin heavy chain variable region	Homo sapiens	124-128
28412920-7	2017	CONCLUSION: THC and CBD are metabolized mainly in the liver by cytochrome P-450 isoenzymes (mainly CYP2Cs and CYP3A4).	Dronabinol	12-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
28412920-8	2017	In vitro studies indicate that THC and CBD both inhibit CYP1A1, 1A2 and 1B1 enzymes, and recent studies have indicated that CBD is also a potent inhibitor of CYP2C19 and CYP3A4.	Dronabinol	31-34	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	56-62
26976041-3	2017	Maternal treatment with THC or the synthetic CB1R agonist WIN55,212-2 (WIN) produced a significant loss of CCK-INTs in the offspring.	Dronabinol	24-27	cannabinoid receptor 1 (brain)	Mus musculus	45-49
26976041-3	2017	Maternal treatment with THC or the synthetic CB1R agonist WIN55,212-2 (WIN) produced a significant loss of CCK-INTs in the offspring.	Dronabinol	24-27	cholecystokinin	Mus musculus	107-110
28049300-6	2016	The ground states of ThC, UC, and PuC have two doubly occupied pi orbitals resulting in short bond distances between 1.8 and 2.0 A, whereas the ground state of AmC has significant occupation of the antibonding orbitals, causing a bond distance of 2.15 A.	Dronabinol	21-24	Arthrogryposis multiplex congenital, neurogenic	Homo sapiens	160-163
27966915-2	2016	In order to identify the most probable ligand entrance pathway into the CB1 receptor, we performed several steered molecular dynamics (SMD) simulations of two CB1 agonists, THC and anandamide, pulling them from the receptor"s binding site with constant velocity.	Dronabinol	173-176	cannabinoid receptor 1	Homo sapiens	72-75
27966915-2	2016	In order to identify the most probable ligand entrance pathway into the CB1 receptor, we performed several steered molecular dynamics (SMD) simulations of two CB1 agonists, THC and anandamide, pulling them from the receptor"s binding site with constant velocity.	Dronabinol	173-176	cannabinoid receptor 1	Homo sapiens	159-162
27966915-5	2016	We also performed supervised molecular dynamics (SuMD) simulations for both anandamide and THC entering the CB1 receptor"s binding site and found the same pathway as in the pulling simulations.	Dronabinol	91-94	cannabinoid receptor 1	Homo sapiens	108-111
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	Dronabinol	222-249	cannabinoid receptor 1	Homo sapiens	58-61
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	Dronabinol	222-249	cannabinoid receptor 2	Homo sapiens	66-69
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	Dronabinol	251-254	cannabinoid receptor 1	Homo sapiens	58-61
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	Dronabinol	251-254	cannabinoid receptor 2	Homo sapiens	66-69
26750641-4	2016	RESULTS: At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at $3,836/patient (ICER: $10,891/quality-adjusted life year [QALY]).	Dronabinol	49-52	cAMP responsive element modulator	Homo sapiens	109-113
27654887-0	2016	THC (Delta9-Tetrahydrocannabinol) Exerts Neuroprotective Effect in Glutamate-affected Murine Primary Mesencephalic Cultures Through Restoring Mitochondrial Membrane Potential and Anti-apoptosis Involving CB1 Receptor-dependent Mechanism.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	204-207
27654887-0	2016	THC (Delta9-Tetrahydrocannabinol) Exerts Neuroprotective Effect in Glutamate-affected Murine Primary Mesencephalic Cultures Through Restoring Mitochondrial Membrane Potential and Anti-apoptosis Involving CB1 Receptor-dependent Mechanism.	Dronabinol	5-32	cannabinoid receptor 1 (brain)	Mus musculus	204-207
27798282-2	2016	Through RT-PCR and immunocytochemistry, this study confirms the presence of CB1 and CB2 cannabinoid receptors in bovine oocytes and shows how exposure to the exogenous cannabinoids HU-210 and THC during their in vitro maturation (IVM) activates the phosphorylation of AKT and ERK1/2 proteins associated with the resumption of meiosis.	Dronabinol	192-195	AKT serine/threonine kinase 1	Bos taurus	268-271
27798282-2	2016	Through RT-PCR and immunocytochemistry, this study confirms the presence of CB1 and CB2 cannabinoid receptors in bovine oocytes and shows how exposure to the exogenous cannabinoids HU-210 and THC during their in vitro maturation (IVM) activates the phosphorylation of AKT and ERK1/2 proteins associated with the resumption of meiosis.	Dronabinol	192-195	mitogen-activated protein kinase 3	Bos taurus	276-282
27916089-9	2016	THC blocked the effects of estrogen on the IL-1beta and estrogen treated cells, and the mRNA and protein levels of IL-6, IkappaBalpha and p-IkappaBalpha had no significant difference compared with IL-1beta treated cells.	Dronabinol	0-3	interleukin 1 beta	Homo sapiens	43-51
27641813-0	2016	Delta9-Tetrahydrocannabinol reverses TNFalpha-induced increase in airway epithelial cell permeability through CB2 receptors.	Dronabinol	0-27	tumor necrosis factor	Homo sapiens	37-45
27641813-0	2016	Delta9-Tetrahydrocannabinol reverses TNFalpha-induced increase in airway epithelial cell permeability through CB2 receptors.	Dronabinol	0-27	cannabinoid receptor 2	Homo sapiens	110-113
27641813-3	2016	The aim of this study was to investigate the effects of THC on bronchial epithelial cell permeability after exposure to the pro-inflammatory cytokine, TNFalpha.	Dronabinol	56-59	tumor necrosis factor	Homo sapiens	151-159
27641813-6	2016	Treatment with THC prevented the TNFalpha-induced decrease in TEER and increase in paracellular permeability.	Dronabinol	15-18	tumor necrosis factor	Homo sapiens	33-41
27641813-8	2016	Subsequent experiments revealed that pharmacological blockade of CB2, but not CB1 receptor inhibited the THC effect.	Dronabinol	105-108	cannabinoid receptor 2	Homo sapiens	65-68
27641813-9	2016	Selective stimulation of CB2 receptors displayed a similar effect to that of THC.	Dronabinol	77-80	cannabinoid receptor 2	Homo sapiens	25-28
27641813-10	2016	TNFalpha decreased expression of the tight junction proteins occludin and ZO-1, which was prevented by pre-incubation with THC.	Dronabinol	123-126	tumor necrosis factor	Homo sapiens	0-8
27641813-10	2016	TNFalpha decreased expression of the tight junction proteins occludin and ZO-1, which was prevented by pre-incubation with THC.	Dronabinol	123-126	tight junction protein 1	Homo sapiens	74-78
27641813-11	2016	These data indicate that THC prevents cytokine-induced increase in airway epithelial permeability through CB2 receptor activation.	Dronabinol	25-28	cannabinoid receptor 2	Homo sapiens	106-109
27681840-5	2016	Immunoprecipitation experiments showed that DMT1 is serine-phosphorylated under basal conditions, but that treatment with Delta9-THC reduced phosphorylation.	Dronabinol	122-132	solute carrier family 11 member 2	Homo sapiens	44-48
27535976-1	2016	Synthetic cannabinoids (SCs) are an emerging class of abused drugs that differ from each other and the phytocannabinoid  9-tetrahydrocannabinol (THC) in their safety and cannabinoid-1 receptor (CB1R) pharmacology.	Dronabinol	121-143	cannabinoid receptor 1 (brain)	Mus musculus	170-192
27826249-10	2016	Functionally, acute 100 nM or 200 nM THC treatment specifically decreased mitochondria coupled respiration between 12 and 15% in wild-type isolated mitochondria of myocardial muscles but no significant difference was noticed between THC treated and vehicle in mitochondria isolated from CB1 -KO heart.	Dronabinol	37-40	cannabinoid receptor 1 (brain)	Mus musculus	287-290
27768894-1	2016	Cannabinoid receptor 1 (CB1) is the principal target of Delta9-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.	Dronabinol	56-83	cannabinoid receptor 1	Homo sapiens	24-27
27768894-1	2016	Cannabinoid receptor 1 (CB1) is the principal target of Delta9-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.	Dronabinol	85-88	cannabinoid receptor 1	Homo sapiens	24-27
27768894-5	2016	In combination with functional studies and molecular modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.	Dronabinol	160-163	cannabinoid receptor 1	Homo sapiens	139-142
27639147-0	2016	Trace detection of tetrahydrocannabinol (THC) with a SERS-based capillary platform prepared by the in situ microwave synthesis of AgNPs.	Dronabinol	19-39	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	53-57
27639147-0	2016	Trace detection of tetrahydrocannabinol (THC) with a SERS-based capillary platform prepared by the in situ microwave synthesis of AgNPs.	Dronabinol	41-44	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	53-57
27639147-1	2016	In the present study, an ultra-sensitive and highly reproducible novel SERS-based capillary platform was developed and utilized for the trace detection of tetrahydrocannabinol (THC).	Dronabinol	155-175	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	71-75
27639147-1	2016	In the present study, an ultra-sensitive and highly reproducible novel SERS-based capillary platform was developed and utilized for the trace detection of tetrahydrocannabinol (THC).	Dronabinol	177-180	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	71-75
27567873-1	2016	Previous reports have demonstrated that the combination of Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AbetaPP/PS1 transgenic mice when chronically administered during the early symptomatic stage.	Dronabinol	59-86	presenilin 1	Mus musculus	262-265
27567873-1	2016	Previous reports have demonstrated that the combination of Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AbetaPP/PS1 transgenic mice when chronically administered during the early symptomatic stage.	Dronabinol	88-98	presenilin 1	Mus musculus	262-265
27567873-4	2016	The positive effects induced by Delta9-THC and CBD in aged AbetaPP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Ralpha1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.	Dronabinol	32-42	presenilin 1	Mus musculus	67-70
27567873-4	2016	The positive effects induced by Delta9-THC and CBD in aged AbetaPP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Ralpha1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.	Dronabinol	32-42	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	104-109
27567873-4	2016	The positive effects induced by Delta9-THC and CBD in aged AbetaPP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Ralpha1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.	Dronabinol	32-42	gamma-aminobutyric acid (GABA) A receptor, subunit alpha 1	Mus musculus	136-150
27784066-10	2016	Direct plasma membrane stretch triggered cation current activity that was blocked by tranilast and specific TRPV2 pore-blocking antibodies and mimicked by the TRPV2 activator, Delta9-tetrahydrocannabinol.	Dronabinol	176-203	transient receptor potential cation channel, subfamily V, member 2	Rattus norvegicus	159-164
27484193-3	2016	In ancient times, this depression-pain comorbidity was treated using extracts of the Cannabis sativa plant, known now as marijuana and the mode of action of Delta9-tetrahydrocannabinol, the active cannabinoid ingredient of marijuana, has only recently become known, with the identification of cannabinoid receptor type 1 (CB1) and CB2.	Dronabinol	157-184	cannabinoid receptor 1	Homo sapiens	322-325
27484193-3	2016	In ancient times, this depression-pain comorbidity was treated using extracts of the Cannabis sativa plant, known now as marijuana and the mode of action of Delta9-tetrahydrocannabinol, the active cannabinoid ingredient of marijuana, has only recently become known, with the identification of cannabinoid receptor type 1 (CB1) and CB2.	Dronabinol	157-184	cannabinoid receptor 2	Homo sapiens	331-334
27038180-6	2016	Interestingly, while DTH caused an overexpression of miR-21, which increases Th17 differentiation via SMAD7 inhibition, and downregulation of miR-29b, an IFN-gamma inhibitor, THC treatment reversed this microRNA (miR) dysregulation.	Dronabinol	175-178	microRNA 21a	Mus musculus	53-59
27038180-6	2016	Interestingly, while DTH caused an overexpression of miR-21, which increases Th17 differentiation via SMAD7 inhibition, and downregulation of miR-29b, an IFN-gamma inhibitor, THC treatment reversed this microRNA (miR) dysregulation.	Dronabinol	175-178	interferon gamma	Mus musculus	154-163
27038180-7	2016	Furthermore, when we transfected primary cells from DTH mice with miR-21 inhibitor or miR-29b mimic, as seen with THC treatment, the expression of target gene message was directly impacted increasing SMAD7 and decreasing IFN-gamma expression, respectively.	Dronabinol	114-117	microRNA 21a	Mus musculus	66-72
27038180-7	2016	Furthermore, when we transfected primary cells from DTH mice with miR-21 inhibitor or miR-29b mimic, as seen with THC treatment, the expression of target gene message was directly impacted increasing SMAD7 and decreasing IFN-gamma expression, respectively.	Dronabinol	114-117	SMAD family member 7	Mus musculus	200-205
27038180-7	2016	Furthermore, when we transfected primary cells from DTH mice with miR-21 inhibitor or miR-29b mimic, as seen with THC treatment, the expression of target gene message was directly impacted increasing SMAD7 and decreasing IFN-gamma expression, respectively.	Dronabinol	114-117	interferon gamma	Mus musculus	221-230
27422357-5	2016	At cellular level, the expression of the NMDA receptor subunit, GluN2B, as well as the levels of the AMPA subunits, GluA1 and GluA2, were significantly increased in hippocampal post-synaptic fractions from THC-exposed rats compared to controls.	Dronabinol	206-209	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	64-70
27422357-5	2016	At cellular level, the expression of the NMDA receptor subunit, GluN2B, as well as the levels of the AMPA subunits, GluA1 and GluA2, were significantly increased in hippocampal post-synaptic fractions from THC-exposed rats compared to controls.	Dronabinol	206-209	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	116-121
27422357-5	2016	At cellular level, the expression of the NMDA receptor subunit, GluN2B, as well as the levels of the AMPA subunits, GluA1 and GluA2, were significantly increased in hippocampal post-synaptic fractions from THC-exposed rats compared to controls.	Dronabinol	206-209	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	126-131
27422357-8	2016	Moreover, in the same brain region, adolescent THC treatment also resulted in a persistent neuroinflammatory state, characterized by increased expression of the astrocyte marker, GFAP, increased levels of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, as well as a concomitant reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	47-50	glial fibrillary acidic protein	Rattus norvegicus	179-183
27422357-8	2016	Moreover, in the same brain region, adolescent THC treatment also resulted in a persistent neuroinflammatory state, characterized by increased expression of the astrocyte marker, GFAP, increased levels of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, as well as a concomitant reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	47-50	tumor necrosis factor	Rattus norvegicus	235-244
27422357-8	2016	Moreover, in the same brain region, adolescent THC treatment also resulted in a persistent neuroinflammatory state, characterized by increased expression of the astrocyte marker, GFAP, increased levels of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, as well as a concomitant reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	47-50	nitric oxide synthase 2	Rattus norvegicus	246-250
27422357-8	2016	Moreover, in the same brain region, adolescent THC treatment also resulted in a persistent neuroinflammatory state, characterized by increased expression of the astrocyte marker, GFAP, increased levels of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, as well as a concomitant reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	47-50	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	255-260
27422357-8	2016	Moreover, in the same brain region, adolescent THC treatment also resulted in a persistent neuroinflammatory state, characterized by increased expression of the astrocyte marker, GFAP, increased levels of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, as well as a concomitant reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	47-50	interleukin 10	Rattus norvegicus	332-337
27501235-10	2016	While both THC and JZL195 significantly increased food intake two hours after injection, this increase was similar between the S426A/S430A mutant and wildtype control mice Our results indicate that S426A/S430A mutant mice expressing the desensitization-resistant form of CB1 do not exhibit differences in body weight, food intake, glucose homeostasis, or re-feeding following a fast.	Dronabinol	11-14	cannabinoid receptor 1 (brain)	Mus musculus	271-274
27184925-1	2016	Cannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Delta(9)-THC) enhance some (antinociceptive) but not other (positive reinforcing) effects of mu opioid receptor agonists, suggesting that cannabinoids might be combined with opioids to treat pain without increasing, and possibly decreasing, abuse.	Dronabinol	38-66	opioid receptor mu 1	Macaca mulatta	161-179
27184925-1	2016	Cannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Delta(9)-THC) enhance some (antinociceptive) but not other (positive reinforcing) effects of mu opioid receptor agonists, suggesting that cannabinoids might be combined with opioids to treat pain without increasing, and possibly decreasing, abuse.	Dronabinol	68-80	opioid receptor mu 1	Macaca mulatta	161-179
27385208-7	2016	Incomplete substitution of JZL184 was observed in THC-trained FAAH mice in the water-maze task, as contrasted with full substitution in a food-reinforced nose-poke procedure.	Dronabinol	50-53	fatty acid amide hydrolase	Mus musculus	62-66
27261878-1	2016	The CB1 cannabinoid receptor is targeted in the brain by endocannabinoids under physiological conditions as well as by delta9-tetrahydrocannabinol under cannabis use.	Dronabinol	119-146	cannabinoid receptor 1	Homo sapiens	4-7
27231154-11	2016	The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1).	Dronabinol	46-49	cannabinoid receptor 1 (brain)	Mus musculus	129-132
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	246-275	fatty acid amide hydrolase	Mus musculus	37-52
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	246-275	fatty acid amide hydrolase	Mus musculus	54-58
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	246-275	monoglyceride lipase	Mus musculus	63-86
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	246-275	monoglyceride lipase	Mus musculus	88-92
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	277-280	fatty acid amide hydrolase	Mus musculus	37-52
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	277-280	fatty acid amide hydrolase	Mus musculus	54-58
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	277-280	monoglyceride lipase	Mus musculus	63-86
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	277-280	monoglyceride lipase	Mus musculus	88-92
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	375-378	fatty acid amide hydrolase	Mus musculus	37-52
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	375-378	fatty acid amide hydrolase	Mus musculus	54-58
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	375-378	monoglyceride lipase	Mus musculus	63-86
27307500-1	2016	Whereas the inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the respective major hydrolytic enzymes of N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), elicits no or partial substitution for Delta(9)-tetrahydrocannabinol (THC) in drug-discrimination procedures, combined inhibition of both enzymes fully substitutes for THC, as well as produces a constellation of cannabimimetic effects.	Dronabinol	375-378	monoglyceride lipase	Mus musculus	88-92
27206280-6	2016	MDMA, THC, and cocaine demonstrated single nanogram sensitivity at 90% TPR and &lt;10% FPR, with improvements to both MDMA and cocaine in the elevated temperature/increased sampling mode.	Dronabinol	6-9	translocated promoter region, nuclear basket protein	Homo sapiens	71-74
27206280-6	2016	MDMA, THC, and cocaine demonstrated single nanogram sensitivity at 90% TPR and &lt;10% FPR, with improvements to both MDMA and cocaine in the elevated temperature/increased sampling mode.	Dronabinol	6-9	formyl peptide receptor 1	Homo sapiens	87-90
27366949-2	2016	The cannabinoid Delta9-tetrahydrocannabinol (Delta9-THC) may have PPARgamma dependent anti-oxidant properties.	Dronabinol	16-43	peroxisome proliferator activated receptor gamma	Homo sapiens	66-75
27366949-2	2016	The cannabinoid Delta9-tetrahydrocannabinol (Delta9-THC) may have PPARgamma dependent anti-oxidant properties.	Dronabinol	45-55	peroxisome proliferator activated receptor gamma	Homo sapiens	66-75
27366949-5	2016	We found that only Delta9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARgamma dependent manner by increasing expression of the PPARgamma co-activator 1alpha (PGC-1alpha), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content.	Dronabinol	19-29	peroxisome proliferator activated receptor gamma	Homo sapiens	107-116
27366949-5	2016	We found that only Delta9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARgamma dependent manner by increasing expression of the PPARgamma co-activator 1alpha (PGC-1alpha), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content.	Dronabinol	19-29	PPARG coactivator 1 alpha	Homo sapiens	166-195
27366949-5	2016	We found that only Delta9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARgamma dependent manner by increasing expression of the PPARgamma co-activator 1alpha (PGC-1alpha), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content.	Dronabinol	19-29	PPARG coactivator 1 alpha	Homo sapiens	197-207
27366949-5	2016	We found that only Delta9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARgamma dependent manner by increasing expression of the PPARgamma co-activator 1alpha (PGC-1alpha), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content.	Dronabinol	19-29	transcription factor A, mitochondrial	Homo sapiens	250-254
27366949-7	2016	Furthermore, using lentiviral knock down of the PPARgamma receptor we showed that, unlike pioglitazone, Delta9-THC resulted in a PPARgamma dependent reduction of MPP+ induced oxidative stress.	Dronabinol	104-114	peroxisome proliferator activated receptor gamma	Homo sapiens	48-57
27366949-7	2016	Furthermore, using lentiviral knock down of the PPARgamma receptor we showed that, unlike pioglitazone, Delta9-THC resulted in a PPARgamma dependent reduction of MPP+ induced oxidative stress.	Dronabinol	104-114	peroxisome proliferator activated receptor gamma	Homo sapiens	129-138
27366949-8	2016	We therefore suggest that, in contrast to pioglitazone, Delta9-THC mediates neuroprotection via PPARgamma-dependent restoration of mitochondrial content which may be beneficial for PD treatment.	Dronabinol	56-66	peroxisome proliferator activated receptor gamma	Homo sapiens	96-105
27058925-1	2016	Both Delta(9)-tetrahydrocannabinol (THC) and ibuprofen have analgesic properties by interacting with the cannabinoid receptor type 1 (CB1R) and the cyclooxygenase (COX) systems, respectively.	Dronabinol	5-34	cannabinoid receptor 1 (brain)	Mus musculus	105-132
27058925-1	2016	Both Delta(9)-tetrahydrocannabinol (THC) and ibuprofen have analgesic properties by interacting with the cannabinoid receptor type 1 (CB1R) and the cyclooxygenase (COX) systems, respectively.	Dronabinol	5-34	cannabinoid receptor 1 (brain)	Mus musculus	134-138
27058925-1	2016	Both Delta(9)-tetrahydrocannabinol (THC) and ibuprofen have analgesic properties by interacting with the cannabinoid receptor type 1 (CB1R) and the cyclooxygenase (COX) systems, respectively.	Dronabinol	36-39	cannabinoid receptor 1 (brain)	Mus musculus	105-132
27058925-1	2016	Both Delta(9)-tetrahydrocannabinol (THC) and ibuprofen have analgesic properties by interacting with the cannabinoid receptor type 1 (CB1R) and the cyclooxygenase (COX) systems, respectively.	Dronabinol	36-39	cannabinoid receptor 1 (brain)	Mus musculus	134-138
27234658-2	2016	This proof-of-concept study examined the potential efficacy of a CB1 receptor partial agonist, dronabinol, in relieving signs and symptoms of opioid withdrawal.	Dronabinol	95-105	cannabinoid receptor 1	Homo sapiens	65-68
27358460-9	2016	Moreover, we found that administration of CB1R agonists, including Delta(9)-tetrahydrocannabinol, caused substantial retraction of TCAs.	Dronabinol	67-96	cannabinoid receptor 1 (brain)	Mus musculus	42-46
27469923-6	2016	MVD(t=2.049,P=0.04) and THC(t=2.167,P=0.034) of HIF-1Alpha-positive group were significantly higher than those of HIF-1Alpha-negative group.	Dronabinol	24-27	hypoxia inducible factor 1 subunit alpha	Homo sapiens	48-58
27469923-7	2016	Conclusions HIF-1Alpha can promote tumor angiogenesis and thus increase the blood supply and THC.	Dronabinol	93-96	hypoxia inducible factor 1 subunit alpha	Homo sapiens	12-22
27333182-1	2016	PURPOSE: Cannabinoids, such as Delta9-THC, act through an endogenous signaling system in the vertebrate eye that reduces IOP via CB1 receptors.	Dronabinol	31-41	cannabinoid receptor 1 (brain)	Mus musculus	129-132
26984820-0	2016	Lack of hippocampal CB1 receptor desensitization by Delta(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.	Dronabinol	52-81	cannabinoid receptor 1 (brain)	Mus musculus	20-23
27155629-2	2016	We present a tensor hypercontracted (THC) scaled opposite spin second order Moller-Plesset perturbation theory (SOS-MP2) method.	Dronabinol	37-40	tryptase pseudogene 1	Homo sapiens	116-119
27155629-3	2016	By using THC, we reduce the formal scaling of SOS-MP2 with respect to molecular size from quartic to cubic.	Dronabinol	9-12	tryptase pseudogene 1	Homo sapiens	50-53
27028159-5	2016	The actions of such THC-MSN-ARA290 nanocomplexes depend on the enhanced permeability and retention of THC through nanosized carriers, and a redox-sensitive release of conjugated ARA290 peptide into the local inflammatory milieu.	Dronabinol	20-23	moesin	Mus musculus	24-27
27028159-5	2016	The actions of such THC-MSN-ARA290 nanocomplexes depend on the enhanced permeability and retention of THC through nanosized carriers, and a redox-sensitive release of conjugated ARA290 peptide into the local inflammatory milieu.	Dronabinol	102-105	moesin	Mus musculus	24-27
26514581-2	2016	However, the clinical use of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) has progressed with justified caution, which also owes to the incomplete mechanistic understanding of its analgesic effects, in particular its interference with the processing of sensory or affective components of pain.	Dronabinol	29-58	WASP actin nucleation promoting factor	Homo sapiens	69-72
26987641-7	2016	Research in animals tends to consistently suggest that Delta9-THC depresses glutamate synaptic transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after prolonged exposure.	Dronabinol	55-65	cannabinoid receptor 1	Homo sapiens	112-115
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	65-93	CD8a molecule	Homo sapiens	21-24
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	65-93	microRNA 150	Homo sapiens	133-140
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	65-93	interleukin 1 receptor associated kinase 1	Homo sapiens	160-165
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	95-107	CD8a molecule	Homo sapiens	21-24
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	95-107	microRNA 150	Homo sapiens	133-140
26937033-11	2016	Finally, blockade of CD8(+) T-cell activation/proliferation with delta-9 tetrahydrocannabinol (Delta(9)-THC) significantly prevented miR-150 downregulation and IRAK1 upregulation.	Dronabinol	95-107	interleukin 1 receptor associated kinase 1	Homo sapiens	160-165
26937033-13	2016	Finally, the ability of Delta(9)-THC to block the miR-150-IRAK1 regulatory cascade highlights the potential of cannabinoids to inhibit persistent inflammation/immune activation in HIV/SIV infection.	Dronabinol	24-36	microRNA 150	Homo sapiens	50-57
26937033-13	2016	Finally, the ability of Delta(9)-THC to block the miR-150-IRAK1 regulatory cascade highlights the potential of cannabinoids to inhibit persistent inflammation/immune activation in HIV/SIV infection.	Dronabinol	24-36	interleukin 1 receptor associated kinase 1	Homo sapiens	58-63
26937033-20	2016	Finally, Delta(9)-THC-mediated blockade of CD8(+) T-cell activation in vitro significantly inhibited miR-150 downregulation and IRAK1 upregulation, suggesting its potential for targeted immune modulation in HIV infection.	Dronabinol	9-21	CD8a molecule	Homo sapiens	43-46
26937033-20	2016	Finally, Delta(9)-THC-mediated blockade of CD8(+) T-cell activation in vitro significantly inhibited miR-150 downregulation and IRAK1 upregulation, suggesting its potential for targeted immune modulation in HIV infection.	Dronabinol	9-21	microRNA 150	Homo sapiens	101-108
26937033-20	2016	Finally, Delta(9)-THC-mediated blockade of CD8(+) T-cell activation in vitro significantly inhibited miR-150 downregulation and IRAK1 upregulation, suggesting its potential for targeted immune modulation in HIV infection.	Dronabinol	9-21	interleukin 1 receptor associated kinase 1	Homo sapiens	128-133
27071101-3	2016	OX-A is crucial for the control of wakefulness and energy homeostasis and promotes, in OX-1R-expressing cells, the biosynthesis of the endogenous counterpart of marijuana"s psychotropic and appetite-inducing component Delta(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachidonoylglycerol (2-AG), which acts at CB1R.	Dronabinol	218-247	hypocretin	Mus musculus	0-4
27071101-3	2016	OX-A is crucial for the control of wakefulness and energy homeostasis and promotes, in OX-1R-expressing cells, the biosynthesis of the endogenous counterpart of marijuana"s psychotropic and appetite-inducing component Delta(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachidonoylglycerol (2-AG), which acts at CB1R.	Dronabinol	218-247	hypocretin (orexin) receptor 1	Mus musculus	87-92
27071101-3	2016	OX-A is crucial for the control of wakefulness and energy homeostasis and promotes, in OX-1R-expressing cells, the biosynthesis of the endogenous counterpart of marijuana"s psychotropic and appetite-inducing component Delta(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachidonoylglycerol (2-AG), which acts at CB1R.	Dronabinol	218-247	cannabinoid receptor 1 (brain)	Mus musculus	320-324
26617196-4	2016	THC-induced effects on heart rate and the visual analogue scale of feeling high in healthy volunteers and inhibitive effects of CB1 antagonists on THC-induced effects were modelled in PD models linked to the PK models.	Dronabinol	147-150	cannabinoid receptor 1	Homo sapiens	128-131
26617196-11	2016	CONCLUSIONS: PK/PD modelling and simulation approach was suitable for describing and predicting heart rate and feeling high for CB1 antagonists in THC challenge tests.	Dronabinol	147-150	cannabinoid receptor 1	Homo sapiens	128-131
26799708-0	2016	Involvement of the orexin/hypocretin system in the pharmacological effects induced by Delta(9) -tetrahydrocannabinol.	Dronabinol	86-116	hypocretin	Mus musculus	19-25
26799708-6	2016	The expression of c-Fos after THC treatment was analysed in several brain areas in wild-type mice and in mice lacking the PPO gene.	Dronabinol	30-33	FBJ osteosarcoma oncogene	Mus musculus	18-23
26799708-7	2016	KEY RESULTS: The hypothermia, supraspinal antinociception and anxiolytic-like effects induced by THC were modulated by orexins through OX2 receptor signalling.	Dronabinol	97-100	CD200 antigen	Mus musculus	135-138
26799708-10	2016	THC-induced increase in c-Fos expression was reduced in the central amygdala, medial preoptic area and lateral septum in these mutant mice.	Dronabinol	0-3	FBJ osteosarcoma oncogene	Mus musculus	24-29
26824325-0	2016	Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.	Dronabinol	97-117	cannabinoid receptor 2 (macrophage)	Mus musculus	163-166
26824325-6	2016	In addition, we found that tetrahydrocannabinol (THC) activated CB2 receptor and ERK signaling, consequently enhancing the modulation of MSCs on inflammation-associated cytokine release from lipopolysaccharides-stimulated microglia.	Dronabinol	27-47	cannabinoid receptor 2 (macrophage)	Mus musculus	64-67
26824325-6	2016	In addition, we found that tetrahydrocannabinol (THC) activated CB2 receptor and ERK signaling, consequently enhancing the modulation of MSCs on inflammation-associated cytokine release from lipopolysaccharides-stimulated microglia.	Dronabinol	49-52	cannabinoid receptor 2 (macrophage)	Mus musculus	64-67
26815533-6	2016	The THC in the thyroid ranged from 131.9 muM to 144.8 muM, showing a 25-44% increase compared to the surrounding sternocleidomastoid muscle tissue.	Dronabinol	4-7	latexin	Homo sapiens	41-44
26815533-6	2016	The THC in the thyroid ranged from 131.9 muM to 144.8 muM, showing a 25-44% increase compared to the surrounding sternocleidomastoid muscle tissue.	Dronabinol	4-7	latexin	Homo sapiens	54-57
26377899-3	2016	The aim of this study was to investigate whether CBD modulated the functional effects and c-Fos expression induced by THC, using a 1:1 dose ratio that approximates therapeutic strains of cannabis and nabiximols.	Dronabinol	118-121	FBJ osteosarcoma oncogene	Mus musculus	90-95
26377899-8	2016	THC increased brain activation as measured by c-Fos expression in 11 of the 35 brain regions studied.	Dronabinol	0-3	FBJ osteosarcoma oncogene	Mus musculus	46-51
26377899-9	2016	CBD co-administration suppressed THC-induced c-Fos expression in six of these brain regions.	Dronabinol	33-36	FBJ osteosarcoma oncogene	Mus musculus	45-50
26462539-0	2016	Chronic Delta9-Tetrahydrocannabinol during Adolescence Differentially Modulates Striatal CB1 Receptor Expression and the Acute and Chronic Effects on Learning in Adult Rats.	Dronabinol	8-35	cannabinoid receptor 1	Rattus norvegicus	89-92
26898326-11	2016	Within the animals dosed from P29-38, THC increased cannabinoid receptor 1 (CB1R) mRNA expression and tended to decrease CP55,940 stimulated [35S]GTPgammaS binding in the central amygdala only of females.	Dronabinol	38-41	cannabinoid receptor 1	Rattus norvegicus	52-80
26499171-6	2015	Present data indicate that adolescent THC administration induces a persistent neuroinflammatory state specifically localized within the adult prefrontal cortex (PFC), characterized by increased expression of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, and reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	38-41	tumor necrosis factor	Rattus norvegicus	238-247
26499171-6	2015	Present data indicate that adolescent THC administration induces a persistent neuroinflammatory state specifically localized within the adult prefrontal cortex (PFC), characterized by increased expression of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, and reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	38-41	nitric oxide synthase 2	Rattus norvegicus	249-253
26499171-6	2015	Present data indicate that adolescent THC administration induces a persistent neuroinflammatory state specifically localized within the adult prefrontal cortex (PFC), characterized by increased expression of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, and reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	38-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	258-263
26499171-6	2015	Present data indicate that adolescent THC administration induces a persistent neuroinflammatory state specifically localized within the adult prefrontal cortex (PFC), characterized by increased expression of the pro-inflammatory markers, TNF-alpha, iNOS and COX-2, and reduction of the anti-inflammatory cytokine, IL-10.	Dronabinol	38-41	interleukin 10	Rattus norvegicus	314-319
26409163-8	2015	The in-vitro metabolism assay with the human CYP2C9 isoform led to the formation of THCOH and THCCOOH of Delta(8)-THC and Delta(9)-THC.	Dronabinol	122-134	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
26327678-2	2015	JWH-018 is a CB1 and CB2 agonist with a higher affinity than Delta9-THC.	Dronabinol	61-71	cannabinoid receptor 1	Rattus norvegicus	13-16
26361728-0	2015	Repeated administration of phytocannabinoid Delta(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.	Dronabinol	44-56	cannabinoid receptor 1 (brain)	Mus musculus	187-190
26460022-1	2015	The CB1 cannabinoid receptor, the main target of Delta(9)-tetrahydrocannabinol (THC), the most prominent psychoactive compound of marijuana, plays a crucial regulatory role in brain development as evidenced by the neurodevelopmental consequences of its manipulation in animal models.	Dronabinol	49-78	cannabinoid receptor 1 (brain)	Mus musculus	4-7
26460022-1	2015	The CB1 cannabinoid receptor, the main target of Delta(9)-tetrahydrocannabinol (THC), the most prominent psychoactive compound of marijuana, plays a crucial regulatory role in brain development as evidenced by the neurodevelopmental consequences of its manipulation in animal models.	Dronabinol	80-83	cannabinoid receptor 1 (brain)	Mus musculus	4-7
26460022-4	2015	As CB1 signaling is known to modulate long-range corticofugal connectivity, we analyzed the impact of THC exposure on cortical projection neuron development.	Dronabinol	102-105	cannabinoid receptor 1 (brain)	Mus musculus	3-6
26460022-6	2015	Consequences of THC exposure were reminiscent of those elicited by CB1 receptor genetic ablation, and CB1-null mice were resistant to THC-induced alterations.	Dronabinol	134-137	cannabinoid receptor 1 (brain)	Mus musculus	102-105
26460022-8	2015	Early and selective CB1 reexpression in dorsal telencephalic glutamatergic neurons but not forebrain GABAergic neurons rescued the deficits in corticospinal motor neuron development of CB1-null mice and restored susceptibility to THC-induced motor alterations.	Dronabinol	230-233	cannabinoid receptor 1 (brain)	Mus musculus	20-23
26460022-9	2015	In addition, THC administration induced an increase in seizure susceptibility that was mediated by its interference with CB1-dependent regulation of both glutamatergic and GABAergic neuron development.	Dronabinol	13-16	cannabinoid receptor 1 (brain)	Mus musculus	121-124
26460022-10	2015	These findings demonstrate that prenatal exposure to THC has long-lasting deleterious consequences in the adult offspring solely mediated by its ability to disrupt the neurodevelopmental role of CB1 signaling.	Dronabinol	53-56	cannabinoid receptor 1 (brain)	Mus musculus	195-198
26464454-0	2015	Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Delta9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.	Dronabinol	105-132	catechol-O-methyltransferase	Homo sapiens	47-75
26464454-0	2015	Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Delta9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.	Dronabinol	105-132	catechol-O-methyltransferase	Homo sapiens	77-81
26464454-0	2015	Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Delta9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.	Dronabinol	134-137	catechol-O-methyltransferase	Homo sapiens	47-75
26464454-0	2015	Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Delta9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.	Dronabinol	134-137	catechol-O-methyltransferase	Homo sapiens	77-81
26464454-2	2015	A functional polymorphism in the catechol-O-methyltransferase (COMT) gene (Val(158)Met) appears to influence the immediate cognitive and psychotic effects of cannabis, or  (9)-tetrahydrocannabinol (THC), its primary psychoactive ingredient.	Dronabinol	198-201	catechol-O-methyltransferase	Homo sapiens	33-61
26464454-2	2015	A functional polymorphism in the catechol-O-methyltransferase (COMT) gene (Val(158)Met) appears to influence the immediate cognitive and psychotic effects of cannabis, or  (9)-tetrahydrocannabinol (THC), its primary psychoactive ingredient.	Dronabinol	198-201	catechol-O-methyltransferase	Homo sapiens	63-67
26464454-3	2015	This study investigated the moderation of the impact of experimentally administered THC by COMT.	Dronabinol	84-87	catechol-O-methyltransferase	Homo sapiens	91-95
26464454-7	2015	Specifically, THC impaired performance in COMT Val/Val, but not Met, carriers.	Dronabinol	14-17	catechol-O-methyltransferase	Homo sapiens	42-46
26464454-9	2015	This study is the largest to date examining the impact of COMT genotype on response to experimentally administered THC, and the first using a purely non-clinical cohort.	Dronabinol	115-118	catechol-O-methyltransferase	Homo sapiens	58-62
26464454-10	2015	The data suggest that COMT genotype moderates the cognitive, but not the psychotic, effects of acutely administered THC.	Dronabinol	116-119	catechol-O-methyltransferase	Homo sapiens	22-26
26590655-0	2015	The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Delta9-tetrahydrocannabinol acting through CB1 receptors.	Dronabinol	162-189	cannabinoid receptor 1 (brain)	Mus musculus	205-208
26590655-8	2015	Next, we investigated the potential targets involved in the effects of Delta(9)-THC-BDS by selectively blocking CB(1) or PPAR-gamma receptors, and we found a complete reversion of neurological benefits and the reduction in cell aggregates only with rimonabant, a selective CB(1) receptor antagonist.	Dronabinol	71-83	peroxisome proliferator activated receptor gamma	Mus musculus	121-131
26511920-6	2015	RESULTS: Among the synthesized compounds, 1-(thiophen-2-yl) ethylidene] hydrazine carboxamides (THb) and 1-(thiophen-2-yl) ethylidene] hydrazine carbothioamide (THc) showed a broad-spectrum anticonvulsant activity since they were active in both maximal electroshock-induced seizure and 6Hz-Psychomotor induced seizure models with no neurotoxicity.	Dronabinol	161-164	lymphocyte antigen 6 complex, locus D	Mus musculus	96-99
26218440-5	2015	KEY RESULTS: Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Delta(9)-tetrahydrocannabinol on PLCbeta3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors.	Dronabinol	87-116	phospholipase C beta 3	Homo sapiens	120-128
26218440-5	2015	KEY RESULTS: Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Delta(9)-tetrahydrocannabinol on PLCbeta3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors.	Dronabinol	87-116	mitogen-activated protein kinase 3	Homo sapiens	134-140
26218440-5	2015	KEY RESULTS: Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Delta(9)-tetrahydrocannabinol on PLCbeta3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors.	Dronabinol	87-116	cannabinoid receptor 1	Homo sapiens	239-242
25914169-2	2015	Cannabinoids, including the active component of the Cannabis plant, tetrahydrocannabinol (THC), and the synthetic alkylindole (AI) compound, WIN55212-2 (WIN-2), activate two molecularly identified GPCRs: CB1 and CB2 .	Dronabinol	68-88	cannabinoid receptor 1 (brain)	Mus musculus	204-207
25914169-2	2015	Cannabinoids, including the active component of the Cannabis plant, tetrahydrocannabinol (THC), and the synthetic alkylindole (AI) compound, WIN55212-2 (WIN-2), activate two molecularly identified GPCRs: CB1 and CB2 .	Dronabinol	68-88	cannabinoid receptor 2 (macrophage)	Mus musculus	212-215
25914169-2	2015	Cannabinoids, including the active component of the Cannabis plant, tetrahydrocannabinol (THC), and the synthetic alkylindole (AI) compound, WIN55212-2 (WIN-2), activate two molecularly identified GPCRs: CB1 and CB2 .	Dronabinol	90-93	cannabinoid receptor 1 (brain)	Mus musculus	204-207
25914169-2	2015	Cannabinoids, including the active component of the Cannabis plant, tetrahydrocannabinol (THC), and the synthetic alkylindole (AI) compound, WIN55212-2 (WIN-2), activate two molecularly identified GPCRs: CB1 and CB2 .	Dronabinol	90-93	cannabinoid receptor 2 (macrophage)	Mus musculus	212-215
25921771-4	2015	MAIN METHODS: First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)).	Dronabinol	46-49	cannabinoid receptor 1 (brain)	Mus musculus	80-83
25921771-4	2015	MAIN METHODS: First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)).	Dronabinol	46-49	cannabinoid receptor 2 (macrophage)	Mus musculus	85-88
25921771-4	2015	MAIN METHODS: First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)).	Dronabinol	46-49	cannabinoid receptor 1 (brain)	Mus musculus	197-200
25921771-4	2015	MAIN METHODS: First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)).	Dronabinol	46-49	cannabinoid receptor 2 (macrophage)	Mus musculus	201-204
25921771-4	2015	MAIN METHODS: First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)).	Dronabinol	46-49	cannabinoid receptor 1 (brain)	Mus musculus	230-234
26093170-4	2015	Here we show for the first time that a perturbation in disrupted in schizophrenia 1 (DISC1) exacerbates the response to adolescent exposure to delta-9-tetrahydrocannabinol (Delta(9)-THC), a major psychoactive ingredient of cannabis, consistent with the concept that gene-environment interaction may contribute to the pathophysiology of psychiatric conditions.	Dronabinol	143-171	disrupted in schizophrenia 1	Mus musculus	85-90
26093170-4	2015	Here we show for the first time that a perturbation in disrupted in schizophrenia 1 (DISC1) exacerbates the response to adolescent exposure to delta-9-tetrahydrocannabinol (Delta(9)-THC), a major psychoactive ingredient of cannabis, consistent with the concept that gene-environment interaction may contribute to the pathophysiology of psychiatric conditions.	Dronabinol	173-185	disrupted in schizophrenia 1	Mus musculus	85-90
26093170-5	2015	We found that chronic adolescent treatment with Delta(9)-THC exacerbates deficits in fear-associated memory in adult mice that express a putative dominant-negative mutant of DISC1 (DN-DISC1).	Dronabinol	48-60	disrupted in schizophrenia 1	Mus musculus	174-179
26093170-5	2015	We found that chronic adolescent treatment with Delta(9)-THC exacerbates deficits in fear-associated memory in adult mice that express a putative dominant-negative mutant of DISC1 (DN-DISC1).	Dronabinol	48-60	disrupted in schizophrenia 1	Mus musculus	181-189
26093170-6	2015	Synaptic expression of cannabinoid receptor 1 (CB1R) is down-regulated in the prefrontal cortex, hippocampus, and amygdala, critical brain regions for fear-associated memory, by either expression of DN-DISC1 or adolescent Delta(9)-THC treatment.	Dronabinol	231-234	cannabinoid receptor 1 (brain)	Mus musculus	23-51
26093170-8	2015	We also found a synergistic reduction of c-Fos expression induced by cue-dependent fear memory retrieval in DN-DISC1 with adolescent Delta(9)-THC exposure.	Dronabinol	142-145	FBJ osteosarcoma oncogene	Mus musculus	41-46
26093170-8	2015	We also found a synergistic reduction of c-Fos expression induced by cue-dependent fear memory retrieval in DN-DISC1 with adolescent Delta(9)-THC exposure.	Dronabinol	142-145	disrupted in schizophrenia 1	Mus musculus	111-116
26034207-0	2015	Delta9-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	131-153
26034207-6	2015	THC treatment significantly reduced T cell proliferation and activation in draining LNs of the recipient mice and decreased early stage rejection-indicator cytokines, including IL-2 and IFN-gamma.	Dronabinol	0-3	interleukin 2	Mus musculus	177-181
26034207-6	2015	THC treatment significantly reduced T cell proliferation and activation in draining LNs of the recipient mice and decreased early stage rejection-indicator cytokines, including IL-2 and IFN-gamma.	Dronabinol	0-3	interferon gamma	Mus musculus	186-195
26034207-10	2015	Additionally, using pharmacological inhibitors of CB1 and CB2 receptors and CB1 and CB2 knockout mice, we found that THC was working preferentially through CB1.	Dronabinol	117-120	cannabinoid receptor 1 (brain)	Mus musculus	50-53
26034207-10	2015	Additionally, using pharmacological inhibitors of CB1 and CB2 receptors and CB1 and CB2 knockout mice, we found that THC was working preferentially through CB1.	Dronabinol	117-120	cannabinoid receptor 2 (macrophage)	Mus musculus	58-61
26034207-10	2015	Additionally, using pharmacological inhibitors of CB1 and CB2 receptors and CB1 and CB2 knockout mice, we found that THC was working preferentially through CB1.	Dronabinol	117-120	cannabinoid receptor 1 (brain)	Mus musculus	76-79
26034207-10	2015	Additionally, using pharmacological inhibitors of CB1 and CB2 receptors and CB1 and CB2 knockout mice, we found that THC was working preferentially through CB1.	Dronabinol	117-120	cannabinoid receptor 2 (macrophage)	Mus musculus	84-87
26034207-10	2015	Additionally, using pharmacological inhibitors of CB1 and CB2 receptors and CB1 and CB2 knockout mice, we found that THC was working preferentially through CB1.	Dronabinol	117-120	cannabinoid receptor 1 (brain)	Mus musculus	76-79
26099530-0	2015	Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Delta9-Tetrahydrocannabinol-Mediated Induction of DeltaFosB in the Mouse Forebrain.	Dronabinol	95-122	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	38-91
26099530-7	2015	THC was then acutely or repeatedly administered to wild-type (WT) and DARPP-32 knockout (KO) mice, and in vivo responses were measured.	Dronabinol	0-3	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	70-78
26099530-8	2015	DARPP-32 KO mice exhibited enhanced acute THC-mediated hypolocomotion and developed greater tolerance to this response relative to the WT mice.	Dronabinol	42-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
26099530-10	2015	These results indicate that D1Rs play a major role in THC-mediated DeltaFosB induction in the forebrain, whereas the role of DARPP-32 in THC-mediated DeltaFosB induction and modulation of motor activity appears to be more complex.	Dronabinol	137-140	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
26187180-1	2015	AIMS: We herein investigated the inducibility of cytochrome P450 1A1 (CYP1A1) by Delta(9)-tetrahydrocannabinol, cannabidiol (CBD), and cannabinol, three major phytocannabinoids, using human hepatoma HepG2 cells.	Dronabinol	81-110	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	49-68
26187180-1	2015	AIMS: We herein investigated the inducibility of cytochrome P450 1A1 (CYP1A1) by Delta(9)-tetrahydrocannabinol, cannabidiol (CBD), and cannabinol, three major phytocannabinoids, using human hepatoma HepG2 cells.	Dronabinol	81-110	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	70-76
26187180-3	2015	KEY FINDINGS: Delta(9)-Tetrahydrocannabinol and CBD concentration-dependently induced the expression of CYP1A1 mRNA, whereas cannabinol showed little or no induction.	Dronabinol	14-43	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	104-110
26118897-0	2015	Sex-specific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat.	Dronabinol	95-123	cannabinoid receptor 1	Rattus norvegicus	40-53
26118897-6	2015	In order to characterize CB1 receptor expression following chronic adolescent Delta-9-tetrahydrocannabinol (THC) exposure, we used [(3)H] CP55,940 binding to assess CB1 receptor expression in the dentate gyrus and areas CA1, CA2, and CA3 of the hippocampus in both male and female adolescent rats at both 24h and 2 weeks post chronic THC treatment.	Dronabinol	108-111	cannabinoid receptor 1	Rattus norvegicus	25-28
25820672-5	2015	Citrate synthase activity was decreased only by Delta(9)-tetrahydrocannabinol and AM251.	Dronabinol	48-77	citrate synthase	Sus scrofa	0-16
26124120-3	2015	However, the endogenous cannabinoids, as well as Delta(9)-tetrahydrocannabinol, the main plant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2.	Dronabinol	49-78	cannabinoid receptor 1 (brain)	Mus musculus	158-161
26124120-3	2015	However, the endogenous cannabinoids, as well as Delta(9)-tetrahydrocannabinol, the main plant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2.	Dronabinol	49-78	cannabinoid receptor 2 (macrophage)	Mus musculus	166-169
26158621-0	2015	Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors.	Dronabinol	32-59	cannabinoid receptor 1 (brain)	Mus musculus	106-109
26158621-1	2015	Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents.	Dronabinol	50-77	cannabinoid receptor 1 (brain)	Mus musculus	26-29
26158621-1	2015	Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents.	Dronabinol	50-77	cannabinoid receptor 1 (brain)	Mus musculus	41-45
26158621-1	2015	Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents.	Dronabinol	79-82	cannabinoid receptor 1 (brain)	Mus musculus	26-29
26158621-1	2015	Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents.	Dronabinol	79-82	cannabinoid receptor 1 (brain)	Mus musculus	41-45
26158621-7	2015	Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CB1R, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization in vivo, leading to a selective abrogation of memory impairments caused by exposure to THC.	Dronabinol	250-253	cannabinoid receptor 1 (brain)	Mus musculus	73-77
26158621-9	2015	CB1R-5-HT2AR heteromers are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial antinociceptive properties.	Dronabinol	94-97	cannabinoid receptor 1 (brain)	Mus musculus	0-4
26132518-3	2015	Although both Delta-tetrahydrocannabinol (THC) and SCBs stimulate the same receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), studies have shown that SCBs are associated with higher rates of toxicity and hospital admissions than is natural cannabis.	Dronabinol	42-45	cannabinoid receptor 1	Homo sapiens	110-113
26132518-3	2015	Although both Delta-tetrahydrocannabinol (THC) and SCBs stimulate the same receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), studies have shown that SCBs are associated with higher rates of toxicity and hospital admissions than is natural cannabis.	Dronabinol	42-45	cannabinoid receptor 2	Homo sapiens	119-141
26132518-3	2015	Although both Delta-tetrahydrocannabinol (THC) and SCBs stimulate the same receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), studies have shown that SCBs are associated with higher rates of toxicity and hospital admissions than is natural cannabis.	Dronabinol	42-45	cannabinoid receptor 2	Homo sapiens	143-146
26267945-4	2015	Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.	Dronabinol	69-89	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-26
26085816-0	2015	Delta(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.	Dronabinol	0-29	coagulation factor III, tissue factor	Homo sapiens	75-88
26085816-0	2015	Delta(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles.	Dronabinol	31-34	coagulation factor III, tissue factor	Homo sapiens	75-88
26085816-5	2015	After 24 h of LPS stimulation, TF activity declined in control-treated or untreated cells and microvesicles, but persisted with THC treatment.	Dronabinol	128-131	coagulation factor III, tissue factor	Homo sapiens	31-33
26085816-7	2015	Steady-state TF mRNA levels were similar up to 2 h in the presence of LPS with or without THC, while 10-fold greater TF mRNA levels persisted over 3-24 h with THC treatment.	Dronabinol	159-162	coagulation factor III, tissue factor	Homo sapiens	117-119
25674907-4	2015	Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.	Dronabinol	15-44	autophagy and beclin 1 regulator 1	Homo sapiens	224-230
25674907-4	2015	Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.	Dronabinol	46-49	autophagy related 7	Homo sapiens	198-202
25674907-4	2015	Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.	Dronabinol	46-49	beclin 1	Homo sapiens	212-220
25674907-4	2015	Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.	Dronabinol	46-49	autophagy and beclin 1 regulator 1	Homo sapiens	224-230
25674907-4	2015	Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of autophagy, loss of cell viability, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but not Beclin-1 or Ambra1, prevented THC-induced autophagy and cell death in vitro.	Dronabinol	242-245	autophagy related 7	Homo sapiens	198-202
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	115-142	cannabinoid receptor 1	Homo sapiens	52-55
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	115-142	cannabinoid receptor 2	Homo sapiens	64-67
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	115-142	cannabinoid receptor 2	Homo sapiens	230-233
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	144-147	cannabinoid receptor 1	Homo sapiens	52-55
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	144-147	cannabinoid receptor 2	Homo sapiens	64-67
25614186-2	2015	Monocytes express intracellular cannabinoid type 1 (CB1) and 2 (CB2) receptors and we demonstrate that exposure to Delta9-tetrahydrocannabinol (THC) inhibits the forskolin-induced generation of cyclic adenosine monophosphate in a CB2-specific manner.	Dronabinol	144-147	cannabinoid receptor 2	Homo sapiens	230-233
25614186-4	2015	The presence of THC (0.25-1.0 mug/ml) altered key features of DC differentiation, producing a concentration-dependent decrease in surface expression of CD11c, HLA-DR and costimulatory molecules (CD40 and CD86), less effective antigen uptake, and signs of functional skewing with decreased production of IL-12 but normal levels of IL-10.	Dronabinol	16-19	integrin subunit alpha X	Homo sapiens	152-157
25614186-4	2015	The presence of THC (0.25-1.0 mug/ml) altered key features of DC differentiation, producing a concentration-dependent decrease in surface expression of CD11c, HLA-DR and costimulatory molecules (CD40 and CD86), less effective antigen uptake, and signs of functional skewing with decreased production of IL-12 but normal levels of IL-10.	Dronabinol	16-19	CD40 molecule	Homo sapiens	195-199
25614186-4	2015	The presence of THC (0.25-1.0 mug/ml) altered key features of DC differentiation, producing a concentration-dependent decrease in surface expression of CD11c, HLA-DR and costimulatory molecules (CD40 and CD86), less effective antigen uptake, and signs of functional skewing with decreased production of IL-12 but normal levels of IL-10.	Dronabinol	16-19	CD86 molecule	Homo sapiens	204-208
25614186-4	2015	The presence of THC (0.25-1.0 mug/ml) altered key features of DC differentiation, producing a concentration-dependent decrease in surface expression of CD11c, HLA-DR and costimulatory molecules (CD40 and CD86), less effective antigen uptake, and signs of functional skewing with decreased production of IL-12 but normal levels of IL-10.	Dronabinol	16-19	interleukin 10	Homo sapiens	330-335
25875136-6	2015	Acute THC administration induced a similar reduction of macrophage proinflammatory cytokines and an IL-10 increase in adult and adolescent mice.	Dronabinol	6-9	interleukin 10	Mus musculus	100-105
25900076-8	2015	The IFNgamma response and cellular activation were enhanced by THC in C57Bl/6 wild type (WT) mice but suppressed or not affected by THC in cannabinoid receptor 1 (CB1) and 2 (CB2) knockout (CB1 (-/-)CB2 (-/-)) mice.	Dronabinol	63-66	interferon gamma	Mus musculus	4-12
25900076-10	2015	Collectively, our findings demonstrate that under certain conditions, THC enhances HIV antigen-specific immune responses, which occurs through CB1/CB2-dependent and -independent mechanisms.	Dronabinol	70-73	cannabinoid receptor 1 (brain)	Mus musculus	143-146
25900076-10	2015	Collectively, our findings demonstrate that under certain conditions, THC enhances HIV antigen-specific immune responses, which occurs through CB1/CB2-dependent and -independent mechanisms.	Dronabinol	70-73	cannabinoid receptor 2 (macrophage)	Mus musculus	147-150
25916739-1	2015	As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Delta(9)-tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes.	Dronabinol	142-171	cannabinoid receptor 1	Homo sapiens	224-227
25916739-1	2015	As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of Cannabis sativa (CS), Delta(9)-tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor subtypes.	Dronabinol	173-176	cannabinoid receptor 1	Homo sapiens	224-227
25916739-2	2015	Through the activation primarily of CB1 receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy.	Dronabinol	81-84	cannabinoid receptor 1	Homo sapiens	36-39
26054900-2	2015	The major psychoactive phytocannabinoid found in cannabis  (9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid receptors, termed CB1 and CB2.	Dronabinol	85-88	cannabinoid receptor 1	Homo sapiens	185-188
26054900-2	2015	The major psychoactive phytocannabinoid found in cannabis  (9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid receptors, termed CB1 and CB2.	Dronabinol	85-88	cannabinoid receptor 2	Homo sapiens	193-196
25698527-0	2015	Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.	Dronabinol	25-28	fatty acid amide hydrolase	Mus musculus	78-93
25698527-4	2015	Anandamide fully substituted for THC in FAAH knockout, but not wildtype, mice.	Dronabinol	33-36	fatty acid amide hydrolase	Mus musculus	40-44
25698527-6	2015	The CB1 receptor antagonist rimonabant dose-dependently attenuated THC generalization in both groups and anandamide substitution in FAAH knockouts.	Dronabinol	67-70	cannabinoid receptor 1 (brain)	Mus musculus	4-7
25698527-7	2015	Pharmacological inhibition of monoacylglycerol lipase (MAGL), the primary catabolic enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG), with JZL184 resulted in full substitution for THC in FAAH knockout mice and nearly full substitution in wildtypes.	Dronabinol	192-195	monoglyceride lipase	Mus musculus	30-53
25698527-7	2015	Pharmacological inhibition of monoacylglycerol lipase (MAGL), the primary catabolic enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG), with JZL184 resulted in full substitution for THC in FAAH knockout mice and nearly full substitution in wildtypes.	Dronabinol	192-195	monoglyceride lipase	Mus musculus	55-59
25698527-9	2015	Dual inhibition of FAAH and MAGL with JZL195 resulted in roughly equipotent increases in THC-appropriate responding in both groups.	Dronabinol	89-92	fatty acid amide hydrolase	Mus musculus	19-23
25698527-9	2015	Dual inhibition of FAAH and MAGL with JZL195 resulted in roughly equipotent increases in THC-appropriate responding in both groups.	Dronabinol	89-92	monoglyceride lipase	Mus musculus	28-32
25711338-0	2015	Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Delta9-tetrahydrocannabinol in mice.	Dronabinol	126-153	fatty acid amide hydrolase	Mus musculus	38-53
25711338-0	2015	Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Delta9-tetrahydrocannabinol in mice.	Dronabinol	126-153	monoglyceride lipase	Mus musculus	58-81
25711338-3	2015	Here, FAAH and MAGL inhibition was examined separately and together in a Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 5.6 mg/kg i.p.)	Dronabinol	73-102	fatty acid amide hydrolase	Mus musculus	6-10
25711338-3	2015	Here, FAAH and MAGL inhibition was examined separately and together in a Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 5.6 mg/kg i.p.)	Dronabinol	73-102	monoglyceride lipase	Mus musculus	15-19
25711338-3	2015	Here, FAAH and MAGL inhibition was examined separately and together in a Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 5.6 mg/kg i.p.)	Dronabinol	104-116	fatty acid amide hydrolase	Mus musculus	6-10
25711338-3	2015	Here, FAAH and MAGL inhibition was examined separately and together in a Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 5.6 mg/kg i.p.)	Dronabinol	104-116	monoglyceride lipase	Mus musculus	15-19
25395060-3	2015	OBJECTIVES: The potential of the exogenous CB1 ligand, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), to facilitate extinction of this CPA was tested.	Dronabinol	55-84	cannabinoid receptor 1	Rattus norvegicus	43-46
25395060-3	2015	OBJECTIVES: The potential of the exogenous CB1 ligand, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), to facilitate extinction of this CPA was tested.	Dronabinol	86-98	cannabinoid receptor 1	Rattus norvegicus	43-46
25086297-7	2015	The cannabinoid type-1 receptor (CB1R) partial agonist, tetrahydrocannabinol (THC), selectively reduced multifractal dynamics in FCT neurons compared to non-FCT neurons.	Dronabinol	56-76	cannabinoid receptor 1	Homo sapiens	4-31
25086297-7	2015	The cannabinoid type-1 receptor (CB1R) partial agonist, tetrahydrocannabinol (THC), selectively reduced multifractal dynamics in FCT neurons compared to non-FCT neurons.	Dronabinol	56-76	cannabinoid receptor 1	Homo sapiens	33-37
25086297-7	2015	The cannabinoid type-1 receptor (CB1R) partial agonist, tetrahydrocannabinol (THC), selectively reduced multifractal dynamics in FCT neurons compared to non-FCT neurons.	Dronabinol	78-81	cannabinoid receptor 1	Homo sapiens	4-31
25086297-7	2015	The cannabinoid type-1 receptor (CB1R) partial agonist, tetrahydrocannabinol (THC), selectively reduced multifractal dynamics in FCT neurons compared to non-FCT neurons.	Dronabinol	78-81	cannabinoid receptor 1	Homo sapiens	33-37
25790278-3	2015	Here, we develop a strategy to discover analgesic drugs via structure-based virtual screening based on the recently published NMR structure of the hGlyR-alpha1 transmembrane domain (PDB ID: 2M6I ) and the critical role of residue S296 in hGlyR-alpha1 potentiation by Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	267-296	glycine receptor alpha 1	Homo sapiens	147-159
25790278-3	2015	Here, we develop a strategy to discover analgesic drugs via structure-based virtual screening based on the recently published NMR structure of the hGlyR-alpha1 transmembrane domain (PDB ID: 2M6I ) and the critical role of residue S296 in hGlyR-alpha1 potentiation by Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	298-301	glycine receptor alpha 1	Homo sapiens	147-159
25753593-6	2015	RESULTS: In univariate analysis, THC was significantly correlated with the following prognostic factors: tumor size (P &lt; .001), histologic grade (P &lt; .001), ER (P &lt; .05), PR (P &lt; .001), and c-erbB-2 (P &lt; .05).	Dronabinol	33-36	estrogen receptor 1	Homo sapiens	163-165
25753593-6	2015	RESULTS: In univariate analysis, THC was significantly correlated with the following prognostic factors: tumor size (P &lt; .001), histologic grade (P &lt; .001), ER (P &lt; .05), PR (P &lt; .001), and c-erbB-2 (P &lt; .05).	Dronabinol	33-36	progesterone receptor	Homo sapiens	180-182
25753593-6	2015	RESULTS: In univariate analysis, THC was significantly correlated with the following prognostic factors: tumor size (P &lt; .001), histologic grade (P &lt; .001), ER (P &lt; .05), PR (P &lt; .001), and c-erbB-2 (P &lt; .05).	Dronabinol	33-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-210
25753593-8	2015	On the basis of a stepwise multiple regression analysis, THC of invasive ductal carcinoma was significantly correlated with tumor size (P &lt; .001), histologic grade (P &lt; .001), and PR (P &lt; .05).	Dronabinol	57-60	progesterone receptor	Homo sapiens	186-188
25425209-0	2015	Delta(9) Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.	Dronabinol	9-29	Mir17 host gene (non-protein coding)	Mus musculus	151-160
25713087-0	2015	Delta9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8.	Dronabinol	0-27	signal transducer and activator of transcription 3	Mus musculus	116-121
25713087-0	2015	Delta9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8.	Dronabinol	0-27	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	122-128
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	18-21	DNA methyltransferase 3A	Mus musculus	90-96
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	18-21	DNA methyltransferase 3B	Mus musculus	101-107
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	18-21	DNA methyltransferase 3A	Mus musculus	174-180
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	18-21	DNA methyltransferase 3B	Mus musculus	185-191
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	111-114	DNA methyltransferase 3A	Mus musculus	90-96
25713087-4	2015	Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b.	Dronabinol	111-114	DNA methyltransferase 3B	Mus musculus	101-107
25713087-5	2015	Furthermore, promoter region methylation was decreased at Arg1 and STAT3 in THC-induced MDSCs, and consequently, such MDSCs expressed higher levels of Arg1 and STAT3.	Dronabinol	76-79	arginase, liver	Mus musculus	58-62
25713087-5	2015	Furthermore, promoter region methylation was decreased at Arg1 and STAT3 in THC-induced MDSCs, and consequently, such MDSCs expressed higher levels of Arg1 and STAT3.	Dronabinol	76-79	signal transducer and activator of transcription 3	Mus musculus	67-72
25713087-5	2015	Furthermore, promoter region methylation was decreased at Arg1 and STAT3 in THC-induced MDSCs, and consequently, such MDSCs expressed higher levels of Arg1 and STAT3.	Dronabinol	76-79	arginase, liver	Mus musculus	151-155
25713087-5	2015	Furthermore, promoter region methylation was decreased at Arg1 and STAT3 in THC-induced MDSCs, and consequently, such MDSCs expressed higher levels of Arg1 and STAT3.	Dronabinol	76-79	signal transducer and activator of transcription 3	Mus musculus	160-165
25713087-6	2015	In addition, THC-induced MDSCs secreted elevated levels of S100A8, a calcium-binding protein associated with accumulation of MDSCs in cancer models.	Dronabinol	13-16	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	59-65
25713087-7	2015	Neutralization of S100A8 by use of anti-S100A8 (8H150) in vivo reduced the ability of THC to trigger MDSCs.	Dronabinol	86-89	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	18-24
25713087-7	2015	Neutralization of S100A8 by use of anti-S100A8 (8H150) in vivo reduced the ability of THC to trigger MDSCs.	Dronabinol	86-89	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	40-46
25655949-6	2015	Delta(9)-Tetrahydrocannabinol and CP55940 reduced TNF-alpha-enhanced nerve-evoked contractions in vitro to the magnitude of saline-incubated trachea.	Dronabinol	0-29	tumor necrosis factor	Cavia porcellus	50-59
25655949-10	2015	Only Delta(9)-tetrahydrocannabinol inhibited TNF-alpha-enhanced vagal-induced bronchoconstriction, neutrophil recruitment to the airways, and citric acid-induced cough responses.	Dronabinol	5-34	tumor necrosis factor	Cavia porcellus	45-54
25655949-12	2015	Delta(9)-Tetrahydrocannabinol and CP55940 inhibited the TNF-alpha-enhanced acetylcholine release, and hence contraction and bronchoconstriction, through activation of presynaptic CB(1) and CB(2) receptors.	Dronabinol	0-29	tumor necrosis factor	Cavia porcellus	56-65
25804389-1	2015	OBJECTIVE: In this study, we investigated the possible effect of Delta(9)-tetrahydrocannabinol (THC), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on metabolic control and vascular complications of diabetes in streptozotocin/nicotinamide (STZ/NIC) induced type 2 diabetes mellitus.	Dronabinol	65-94	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	104-152
25804389-1	2015	OBJECTIVE: In this study, we investigated the possible effect of Delta(9)-tetrahydrocannabinol (THC), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on metabolic control and vascular complications of diabetes in streptozotocin/nicotinamide (STZ/NIC) induced type 2 diabetes mellitus.	Dronabinol	65-94	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	154-163
25804389-1	2015	OBJECTIVE: In this study, we investigated the possible effect of Delta(9)-tetrahydrocannabinol (THC), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on metabolic control and vascular complications of diabetes in streptozotocin/nicotinamide (STZ/NIC) induced type 2 diabetes mellitus.	Dronabinol	96-99	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	104-152
24373053-1	2015	Delta(9) -Tetrahydrocannabinol, the main psychoactive component of cannabis, exerts its central effects through activation of the cerebral type 1 cannabinoid (CB1 ) receptor.	Dronabinol	0-30	cannabinoid receptor 1	Homo sapiens	159-162
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	78-107	cannabinoid receptor 1 (brain)	Mus musculus	18-46
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	78-107	cannabinoid receptor 1 (brain)	Mus musculus	48-51
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	78-107	cannabinoid receptor 2 (macrophage)	Mus musculus	56-59
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	78-107	cannabinoid receptor 1 (brain)	Mus musculus	180-183
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	109-121	cannabinoid receptor 1 (brain)	Mus musculus	18-46
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	109-121	cannabinoid receptor 1 (brain)	Mus musculus	48-51
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	109-121	cannabinoid receptor 2 (macrophage)	Mus musculus	56-59
24853387-1	2015	BACKGROUND: Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce tolerance, physical withdrawal, and unwanted CB1-mediated central nervous system side effects.	Dronabinol	109-121	cannabinoid receptor 1 (brain)	Mus musculus	180-183
25586398-2	2015	Cannabis containing high levels of the partial cannabinoid receptor subtype 1 (CB1) agonist tetrahydrocannabinol (THC) is associated with the induction of psychosis in susceptible subjects and with the development of schizophrenia, whereas the use of cannabis variants with relatively high levels of cannabidiol (CBD) is associated with fewer psychotic experiences.	Dronabinol	92-112	cannabinoid receptor 1	Homo sapiens	79-82
25586398-2	2015	Cannabis containing high levels of the partial cannabinoid receptor subtype 1 (CB1) agonist tetrahydrocannabinol (THC) is associated with the induction of psychosis in susceptible subjects and with the development of schizophrenia, whereas the use of cannabis variants with relatively high levels of cannabidiol (CBD) is associated with fewer psychotic experiences.	Dronabinol	114-117	cannabinoid receptor 1	Homo sapiens	79-82
25257544-3	2015	Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant.	Dronabinol	71-74	cannabinoid receptor 1	Homo sapiens	139-142
25257544-3	2015	Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant.	Dronabinol	71-74	cannabinoid receptor 1	Homo sapiens	190-193
25398241-3	2015	In this study, we investigated the impact of THC and inhibitors of the endocannabinoid hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) on operant responding for electrical stimulation of the medial forebrain bundle [intracranial self-stimulation (ICSS)], which is known to activate the mesolimbic dopamine system.	Dronabinol	45-48	fatty acid amide hydrolase	Mus musculus	134-138
25398241-3	2015	In this study, we investigated the impact of THC and inhibitors of the endocannabinoid hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) on operant responding for electrical stimulation of the medial forebrain bundle [intracranial self-stimulation (ICSS)], which is known to activate the mesolimbic dopamine system.	Dronabinol	45-48	monoglyceride lipase	Mus musculus	169-173
25378491-9	2015	Furthermore, compared to the VEH/SIV group, THC selectively upregulated the expression of miR-10a, miR-24, miR-99b, miR-145, miR-149, and miR-187, previously been shown to target proinflammatory molecules.	Dronabinol	44-47	microRNA 99b	Homo sapiens	107-114
25378491-11	2015	A significant increase in NOX4+ crypt epithelial cells was detected in VEH/SIV macaques compared to the THC/SIV group.	Dronabinol	104-107	NADPH oxidase 4	Homo sapiens	26-30
25378491-19	2015	Specifically, miR-99b was significantly upregulated in THC-treated SIV-infected macaques and confirmed to directly target NADPH oxidase 4 (NOX4), a reactive oxygen species generator known to damage intestinal epithelial cells.	Dronabinol	55-58	microRNA 99b	Homo sapiens	14-21
25378491-19	2015	Specifically, miR-99b was significantly upregulated in THC-treated SIV-infected macaques and confirmed to directly target NADPH oxidase 4 (NOX4), a reactive oxygen species generator known to damage intestinal epithelial cells.	Dronabinol	55-58	NADPH oxidase 4	Homo sapiens	139-143
25378491-20	2015	Elevated miR-99b expression was associated with a significantly decreased number of NOX4+ epithelial cells in the intestines of THC-treated SIV-infected macaques.	Dronabinol	128-131	microRNA 99b	Homo sapiens	9-16
25378491-20	2015	Elevated miR-99b expression was associated with a significantly decreased number of NOX4+ epithelial cells in the intestines of THC-treated SIV-infected macaques.	Dronabinol	128-131	NADPH oxidase 4	Homo sapiens	84-88
25588018-5	2015	Synthetic cannabinoids are another group of novel substances which all act as agonists at the cannabinoid CB1 receptor similar to THC but are chemically diverse.	Dronabinol	130-133	cannabinoid receptor 1	Homo sapiens	106-109
25573322-0	2015	CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Delta9-tetrahydrocannabinol.	Dronabinol	78-105	cannabinoid receptor 1 (brain)	Mus musculus	0-3
25573322-6	2015	We find that Delta(9) -tetrahydrocannabinol (THC) slows skeletal elongation of female WT and CB2-, but not CB1-, deficient mice, which is reflected in femoral and lumbar vertebral body length.	Dronabinol	13-43	cannabinoid receptor 2 (macrophage)	Mus musculus	93-96
25573322-6	2015	We find that Delta(9) -tetrahydrocannabinol (THC) slows skeletal elongation of female WT and CB2-, but not CB1-, deficient mice, which is reflected in femoral and lumbar vertebral body length.	Dronabinol	45-48	cannabinoid receptor 2 (macrophage)	Mus musculus	93-96
25573322-8	2015	THC inhibits EGC chondrocyte hypertrophy in ex vivo cultures and reduces the hypertrophic cell zone thickness of CB1-, but not CB2-, deficient mice.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	113-116
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	glutamic pyruvic transaminase, soluble	Mus musculus	153-156
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	161-164
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	cAMP responsive element binding protein 1	Mus musculus	238-242
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	tumor necrosis factor	Mus musculus	289-298
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	interleukin 1 alpha	Mus musculus	300-309
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	interleukin 10	Mus musculus	311-316
26202357-7	2015	RESULTS: THC administration 2h prior to the induction of hepatic I/R was associated with significant attenuated elevations of: serum liver transaminases ALT and AST, the hepatic oxidative stress (activation of the intracellular signaling CREB pathway), the acute proinflammatory response (TNF-alpha, IL-1alpha, IL-10 and c-FOS hepatic mRNA levels, and ERK signaling pathway activation).	Dronabinol	9-12	FBJ osteosarcoma oncogene	Mus musculus	321-326
25125475-2	2015	The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AbetaPP/PS1 transgenic mice when chronically administered during the early symptomatic stage.	Dronabinol	62-90	amyloid beta (A4) precursor protein	Mus musculus	288-295
25125475-2	2015	The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AbetaPP/PS1 transgenic mice when chronically administered during the early symptomatic stage.	Dronabinol	62-90	presenilin 1	Mus musculus	296-299
25125475-3	2015	Moreover, THC + CBD reduced learning impairment in AbetaPP/PS1 mice.	Dronabinol	10-13	amyloid beta (A4) precursor protein	Mus musculus	51-58
25125475-3	2015	Moreover, THC + CBD reduced learning impairment in AbetaPP/PS1 mice.	Dronabinol	10-13	presenilin 1	Mus musculus	59-62
25125475-4	2015	A significant decrease in soluble Abeta42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AbetaPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Abeta peptide.	Dronabinol	115-118	amyloid beta (A4) precursor protein	Mus musculus	133-140
25125475-4	2015	A significant decrease in soluble Abeta42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AbetaPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Abeta peptide.	Dronabinol	115-118	presenilin 1	Mus musculus	141-144
25125475-6	2015	Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AbetaPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD.	Dronabinol	161-164	amyloid beta (A4) precursor protein	Mus musculus	99-106
25125475-6	2015	Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AbetaPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD.	Dronabinol	161-164	presenilin 1	Mus musculus	107-110
25125475-6	2015	Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AbetaPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD.	Dronabinol	188-191	amyloid beta (A4) precursor protein	Mus musculus	99-106
25125475-6	2015	Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AbetaPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD.	Dronabinol	188-191	presenilin 1	Mus musculus	107-110
25125475-8	2015	Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model.	Dronabinol	123-126	thioredoxin 2	Mus musculus	43-56
25125475-8	2015	Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model.	Dronabinol	123-126	wingless-type MMTV integration site family, member 16	Mus musculus	83-88
25653478-0	2015	Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells.	Dronabinol	40-60	cannabinoid receptor 2	Homo sapiens	21-24
25653478-2	2015	Activation of cannabinoid receptor CB2 reduces inflammation; whether the activation CB2 is involved in THC-induced therapeutic action for OA is still unknown.	Dronabinol	103-106	cannabinoid receptor 2	Homo sapiens	84-87
25653478-5	2015	We hypothesized that the activation of CB2 is involved in THC-induced anti-inflammation in the MG-63 cells exposed to LPS, and the anti-inflammation is mediated by cofilin-1.	Dronabinol	58-61	cannabinoid receptor 2	Homo sapiens	39-42
25653478-6	2015	We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor alpha (TNF-alpha), interleukin- (IL-) 1beta, IL-6, and IL-8, decreased nuclear factor-kappaB (NF-kappaB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.	Dronabinol	14-17	tumor necrosis factor	Homo sapiens	79-106
25653478-6	2015	We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor alpha (TNF-alpha), interleukin- (IL-) 1beta, IL-6, and IL-8, decreased nuclear factor-kappaB (NF-kappaB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.	Dronabinol	14-17	tumor necrosis factor	Homo sapiens	108-117
25653478-6	2015	We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor alpha (TNF-alpha), interleukin- (IL-) 1beta, IL-6, and IL-8, decreased nuclear factor-kappaB (NF-kappaB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.	Dronabinol	14-17	interleukin 6	Homo sapiens	146-150
25653478-6	2015	We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor alpha (TNF-alpha), interleukin- (IL-) 1beta, IL-6, and IL-8, decreased nuclear factor-kappaB (NF-kappaB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.	Dronabinol	14-17	C-X-C motif chemokine ligand 8	Homo sapiens	156-160
25653478-6	2015	We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor alpha (TNF-alpha), interleukin- (IL-) 1beta, IL-6, and IL-8, decreased nuclear factor-kappaB (NF-kappaB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.	Dronabinol	14-17	cofilin 1	Homo sapiens	252-261
25653478-7	2015	However, administration of CB2 receptor antagonist or the CB2-siRNA, not CB1 antagonist AM251, partially abolished the THC-induced anti-inflammatory effects above.	Dronabinol	119-122	cannabinoid receptor 2	Homo sapiens	27-30
25653478-7	2015	However, administration of CB2 receptor antagonist or the CB2-siRNA, not CB1 antagonist AM251, partially abolished the THC-induced anti-inflammatory effects above.	Dronabinol	119-122	cannabinoid receptor 2	Homo sapiens	58-61
25653478-8	2015	In addition, overexpression of cofilin-1 significantly reversed the THC-induced anti-inflammatory effects in MG-63 cells.	Dronabinol	68-71	cofilin 1	Homo sapiens	31-40
25653478-9	2015	These results suggested that CB2 is involved in the THC-induced anti-inflammation in LPS-stimulated MG-63 cells, and the anti-inflammation may be mediated by cofilin-1.	Dronabinol	52-55	cannabinoid receptor 2	Homo sapiens	29-32
25485758-4	2015	Furthermore, chronic Delta(9)-tetrahydrocannabinol administration, which reduces cannabinoid efficacy on GABA release, evoked marked CB1 downregulation in a dose-dependent manner.	Dronabinol	21-50	cannabinoid receptor 1 (brain)	Mus musculus	133-136
25281318-5	2015	THC also altered the maturational fluctuations of NMDA subunits, leading to larger amounts of gluN2B at adulthood.	Dronabinol	0-3	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	94-100
25281318-6	2015	Adult animals exposed to THC during adolescence also showed increased AMPA gluA1 with no changes in gluA2 subunits.	Dronabinol	25-28	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	75-80
25454117-2	2014	This analysis explored the influence of personality on the differences in subjective effects in response to a standardized pharmacological challenge with the cannabinoid CB1/CB2 partial agonist Delta9-tetrahydrocannabinol (THC).	Dronabinol	194-221	cannabinoid receptor 1	Homo sapiens	170-173
25454117-2	2014	This analysis explored the influence of personality on the differences in subjective effects in response to a standardized pharmacological challenge with the cannabinoid CB1/CB2 partial agonist Delta9-tetrahydrocannabinol (THC).	Dronabinol	194-221	cannabinoid receptor 2	Homo sapiens	174-177
25200516-3	2014	Since cannabinoids can alter NCAM polysialylation, we hypothesized that delta-9-tetrahydrocannabinol (Delta9-THC) might act as environmental "second hit" regarding cognition of St8sia2(-/-) mice.	Dronabinol	72-100	neural cell adhesion molecule 1	Mus musculus	29-33
25200516-3	2014	Since cannabinoids can alter NCAM polysialylation, we hypothesized that delta-9-tetrahydrocannabinol (Delta9-THC) might act as environmental "second hit" regarding cognition of St8sia2(-/-) mice.	Dronabinol	72-100	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Mus musculus	177-184
25200516-3	2014	Since cannabinoids can alter NCAM polysialylation, we hypothesized that delta-9-tetrahydrocannabinol (Delta9-THC) might act as environmental "second hit" regarding cognition of St8sia2(-/-) mice.	Dronabinol	102-112	neural cell adhesion molecule 1	Mus musculus	29-33
25200516-3	2014	Since cannabinoids can alter NCAM polysialylation, we hypothesized that delta-9-tetrahydrocannabinol (Delta9-THC) might act as environmental "second hit" regarding cognition of St8sia2(-/-) mice.	Dronabinol	102-112	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Mus musculus	177-184
25200516-6	2014	St8sia2(-/-) mice, however, displayed a synergistic negative consequence of Delta9-THC on learning/memory, accompanied by polysialic acid-free NCAM-180 reduction in hippocampus and polysialic acid increase in dentate outer molecular layer.	Dronabinol	76-86	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Mus musculus	0-7
25446925-12	2014	The antinociceptive effect induced by the systemic administration of THC was mediated by CB1 receptors in the masseter muscle whereas in gastrocnemius both CB1 and CB2 receptors participated.	Dronabinol	69-72	cannabinoid receptor 1	Homo sapiens	89-92
25446925-13	2014	When THC was administered locally, only CB2 receptors were involved in the antinociceptive effect in both muscles.	Dronabinol	5-8	cannabinoid receptor 2	Homo sapiens	40-43
25291031-0	2014	Delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells.	Dronabinol	0-12	fatty acid 2-hydroxylase	Homo sapiens	27-51
25291031-0	2014	Delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells.	Dronabinol	0-12	fatty acid 2-hydroxylase	Homo sapiens	53-57
25291031-0	2014	Delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells.	Dronabinol	0-12	peroxisome proliferator activated receptor alpha	Homo sapiens	118-127
25291031-1	2014	We recently reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), significantly stimulated the expression of fatty acid 2-hydroxylase (FA2H) in human breast cancer MDA-MB-231 cells.	Dronabinol	26-55	fatty acid 2-hydroxylase	Homo sapiens	177-201
25291031-1	2014	We recently reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), significantly stimulated the expression of fatty acid 2-hydroxylase (FA2H) in human breast cancer MDA-MB-231 cells.	Dronabinol	26-55	fatty acid 2-hydroxylase	Homo sapiens	203-207
25291031-1	2014	We recently reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), significantly stimulated the expression of fatty acid 2-hydroxylase (FA2H) in human breast cancer MDA-MB-231 cells.	Dronabinol	57-69	fatty acid 2-hydroxylase	Homo sapiens	177-201
25291031-1	2014	We recently reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), significantly stimulated the expression of fatty acid 2-hydroxylase (FA2H) in human breast cancer MDA-MB-231 cells.	Dronabinol	57-69	fatty acid 2-hydroxylase	Homo sapiens	203-207
25291031-4	2014	We performed a DNA microarray analysis of Delta(9)-THC-treated samples and showed the selective up-regulation of the PPARalpha isoform coupled with the induction of FA2H over the other isoforms (beta and gamma).	Dronabinol	51-54	peroxisome proliferator activated receptor alpha	Homo sapiens	117-126
25291031-4	2014	We performed a DNA microarray analysis of Delta(9)-THC-treated samples and showed the selective up-regulation of the PPARalpha isoform coupled with the induction of FA2H over the other isoforms (beta and gamma).	Dronabinol	51-54	fatty acid 2-hydroxylase	Homo sapiens	165-169
25291031-7	2014	Taken together, these results support the concept that the induced levels of PPARalpha may be involved in the Delta(9)-THC up-regulation of FA2H in MDA-MB-231 cells.	Dronabinol	119-122	peroxisome proliferator activated receptor alpha	Homo sapiens	77-86
25291031-7	2014	Taken together, these results support the concept that the induced levels of PPARalpha may be involved in the Delta(9)-THC up-regulation of FA2H in MDA-MB-231 cells.	Dronabinol	119-122	fatty acid 2-hydroxylase	Homo sapiens	140-144
25282526-7	2014	There is strong evidence that THC acts via the cannabinoid receptor CB1.	Dronabinol	30-33	cannabinoid receptor 1	Homo sapiens	68-71
25042014-5	2014	The protective effect of THC was blocked by the cannabinoid (CB) 1 receptor antagonist SR14176A but not by the CB2 receptor antagonist SR141528 and was mimicked by the CB1 agonist ACEA but not by the CB2 agonist HU308.	Dronabinol	25-28	cannabinoid receptor 1 (brain)	Mus musculus	168-171
25042014-6	2014	The protective effect of THC was also blocked by pretreatment with GW9662, indicating the involvement of peroxisome proliferator-activated receptor-gamma.	Dronabinol	25-28	peroxisome proliferator activated receptor gamma	Mus musculus	105-153
25091807-5	2014	Pretreatment of rat mesangial cells with THC significantly attenuated LPS-induced PGE2 production and COX-2 expression.	Dronabinol	41-44	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	102-107
25091807-6	2014	THC also significantly suppressed LPS-induced expression of MCP-1 in LPS-activated septic kidney and rat mesangial cells.	Dronabinol	0-3	mast cell protease 1-like 1	Rattus norvegicus	60-65
25091807-7	2014	In addition, THC significantly attenuated LPS-induced degradation of IkappaB-alpha in LPS-induced rat mesangial cells.	Dronabinol	13-16	NFKB inhibitor alpha	Rattus norvegicus	69-82
25091807-8	2014	THC also increased the expression of heme oxygenase-1 (HO-1) in LPS-challenged septic kidney and mesangial cells.	Dronabinol	0-3	heme oxygenase 1	Rattus norvegicus	37-53
25091807-8	2014	THC also increased the expression of heme oxygenase-1 (HO-1) in LPS-challenged septic kidney and mesangial cells.	Dronabinol	0-3	heme oxygenase 1	Rattus norvegicus	55-59
25091807-9	2014	Multiple signaling pathways including p38 and AKT have been observed to be involved in the THC-induced activation of HO-1 expression.	Dronabinol	91-94	mitogen activated protein kinase 14	Rattus norvegicus	38-41
25091807-9	2014	Multiple signaling pathways including p38 and AKT have been observed to be involved in the THC-induced activation of HO-1 expression.	Dronabinol	91-94	AKT serine/threonine kinase 1	Rattus norvegicus	46-49
25091807-9	2014	Multiple signaling pathways including p38 and AKT have been observed to be involved in the THC-induced activation of HO-1 expression.	Dronabinol	91-94	heme oxygenase 1	Rattus norvegicus	117-121
25091807-10	2014	The present data clearly demonstrate that THC protects LPS-challenged septic kidney by decreasing macrophage infiltration and increasing HO-1 expression, suggesting that THC might be a valuable therapeutic agent for compromised kidney in sepsis.	Dronabinol	42-45	heme oxygenase 1	Rattus norvegicus	137-141
25091807-10	2014	The present data clearly demonstrate that THC protects LPS-challenged septic kidney by decreasing macrophage infiltration and increasing HO-1 expression, suggesting that THC might be a valuable therapeutic agent for compromised kidney in sepsis.	Dronabinol	170-173	heme oxygenase 1	Rattus norvegicus	137-141
25069049-6	2014	ICAM-1-dependent pro-killing effects were further confirmed for the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC) and R(+)-methanandamide (MA), a hydrolysis-stable endocannabinoid analogue.	Dronabinol	85-114	intercellular adhesion molecule 1	Homo sapiens	0-6
25069049-6	2014	ICAM-1-dependent pro-killing effects were further confirmed for the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC) and R(+)-methanandamide (MA), a hydrolysis-stable endocannabinoid analogue.	Dronabinol	116-119	intercellular adhesion molecule 1	Homo sapiens	0-6
25066892-1	2014	Cannabinoid Receptor 1 (CB1) has been initially described as the receptor for Delta-9-Tetrahydrocannabinol in the central nervous system (CNS), mediating retrograde synaptic signaling of the endocannabinoid system.	Dronabinol	78-106	cannabinoid receptor 1	Homo sapiens	0-27
25194020-1	2014	Cannabinoid receptor agonists, such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC), enhance the antinociceptive effects of mu-opioid receptor agonists, which suggests that combining cannabinoids with opioids would improve pain treatment.	Dronabinol	39-68	opioid receptor mu 1	Macaca mulatta	124-142
25194020-1	2014	Cannabinoid receptor agonists, such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC), enhance the antinociceptive effects of mu-opioid receptor agonists, which suggests that combining cannabinoids with opioids would improve pain treatment.	Dronabinol	70-82	opioid receptor mu 1	Macaca mulatta	124-142
25311884-4	2014	The resulting Ki values to CB1 range from 23.5 nM (THCA) to 14711 nM (CBDV), whereas Ki values to CB2 range from 8.5 nM (THC) to 574.2 nM (CBDV).	Dronabinol	51-54	cannabinoid receptor 1 (brain)	Mus musculus	27-30
25065544-7	2014	There was a direct relationship (r = -0.327, p = 0.045) between the behavioural effect of THC and its physiological effect in the inferior frontal gyrus, where AKT1 genotype modulated the effect of THC.	Dronabinol	90-93	AKT serine/threonine kinase 1	Homo sapiens	160-164
25065544-7	2014	There was a direct relationship (r = -0.327, p = 0.045) between the behavioural effect of THC and its physiological effect in the inferior frontal gyrus, where AKT1 genotype modulated the effect of THC.	Dronabinol	198-201	AKT serine/threonine kinase 1	Homo sapiens	160-164
25350456-4	2014	Injections of dronabinol, a non-selective CB1/CB2 receptor agonist, into the nodose ganglia reduced serotonin (5-HT)-induced reflex apneas.	Dronabinol	14-24	cannabinoid receptor 1	Rattus norvegicus	42-45
25350456-4	2014	Injections of dronabinol, a non-selective CB1/CB2 receptor agonist, into the nodose ganglia reduced serotonin (5-HT)-induced reflex apneas.	Dronabinol	14-24	cannabinoid receptor 2	Rattus norvegicus	46-49
25350456-6	2014	Here, to determine the independent and combined effects of activating CB1 and/or CB2 receptors on dronabinol"s attenuating effect, rats were pre-treated with CB1 (AM251) and/or CB2 (AM630) receptor antagonists.	Dronabinol	98-108	cannabinoid receptor 2	Rattus norvegicus	81-84
25093286-1	2014	Repeated Delta(9)-tetrahydrocannabinol (THC) administration produces cannabinoid type 1 receptor (CB1R) desensitization and downregulation, as well as tolerance to its in vivo pharmacological effects.	Dronabinol	9-38	cannabinoid receptor 1 (brain)	Mus musculus	69-96
25093286-1	2014	Repeated Delta(9)-tetrahydrocannabinol (THC) administration produces cannabinoid type 1 receptor (CB1R) desensitization and downregulation, as well as tolerance to its in vivo pharmacological effects.	Dronabinol	9-38	cannabinoid receptor 1 (brain)	Mus musculus	98-102
25093286-1	2014	Repeated Delta(9)-tetrahydrocannabinol (THC) administration produces cannabinoid type 1 receptor (CB1R) desensitization and downregulation, as well as tolerance to its in vivo pharmacological effects.	Dronabinol	40-43	cannabinoid receptor 1 (brain)	Mus musculus	69-96
25093286-1	2014	Repeated Delta(9)-tetrahydrocannabinol (THC) administration produces cannabinoid type 1 receptor (CB1R) desensitization and downregulation, as well as tolerance to its in vivo pharmacological effects.	Dronabinol	40-43	cannabinoid receptor 1 (brain)	Mus musculus	98-102
25093286-3	2014	A growing body of data indicates that regional differences in CB1R desensitization are produced, in part, by THC-mediated induction of the stable transcription factor, DeltaFosB, and subsequent regulation of CB1Rs.	Dronabinol	109-112	cannabinoid receptor 1 (brain)	Mus musculus	62-66
25093286-4	2014	The purpose of the present study was to determine whether THC-mediated induction of DeltaFosB in the striatum inhibits CB1R desensitization in the striatum and output nuclei.	Dronabinol	58-61	cannabinoid receptor 1 (brain)	Mus musculus	119-123
25187240-8	2014	Treatment with Delta(9)-THC significantly increased pancreas glutathione levels, enzyme activities of superoxide dismutase and catalase in diabetes compared with non-treatment diabetes group.	Dronabinol	15-27	catalase	Rattus norvegicus	127-135
24744434-4	2014	Immediately at the end of chronic Delta(9)-THC, a decrease of proinflammatory cytokines IL- 1beta and TNF-alpha and an increase of anti-inflammatory cytokine IL-10 production by macrophages were present as protein and mRNA in adolescent and adult mice.	Dronabinol	34-46	interleukin 1 beta	Mus musculus	88-97
24744434-4	2014	Immediately at the end of chronic Delta(9)-THC, a decrease of proinflammatory cytokines IL- 1beta and TNF-alpha and an increase of anti-inflammatory cytokine IL-10 production by macrophages were present as protein and mRNA in adolescent and adult mice.	Dronabinol	34-46	tumor necrosis factor	Mus musculus	102-111
24744434-4	2014	Immediately at the end of chronic Delta(9)-THC, a decrease of proinflammatory cytokines IL- 1beta and TNF-alpha and an increase of anti-inflammatory cytokine IL-10 production by macrophages were present as protein and mRNA in adolescent and adult mice.	Dronabinol	34-46	interleukin 10	Mus musculus	158-163
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	negative elongation factor complex member C/D, Th1l	Mus musculus	39-42
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	heart and neural crest derivatives expressed 2	Mus musculus	43-46
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	heart and neural crest derivatives expressed 2	Mus musculus	72-75
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	interferon gamma	Mus musculus	77-86
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	interleukin 4	Mus musculus	104-108
24744434-5	2014	In splenocytes, Delta(9)-THC modulated Th1/Th2 cytokines skewing toward Th2: IFN-gamma was reduced, and IL-4 and IL-10 increased.	Dronabinol	16-28	interleukin 10	Mus musculus	113-118
24639045-1	2014	RATIONALE: The present study examined the effect of acute administration of endocannabinoid receptor CB1 ligand  -9-tetrahydrocannabinol (THC) on intracellular signalling in the brain and retrieval from two different memory systems in the zebrafish (Danio rerio).	Dronabinol	114-136	cannabinoid receptor 1	Danio rerio	101-104
24639045-1	2014	RATIONALE: The present study examined the effect of acute administration of endocannabinoid receptor CB1 ligand  -9-tetrahydrocannabinol (THC) on intracellular signalling in the brain and retrieval from two different memory systems in the zebrafish (Danio rerio).	Dronabinol	138-141	cannabinoid receptor 1	Danio rerio	101-104
25037227-11	2014	THC and CP55,940 promoted CB1 internalization and decreased CB1 protein levels over an 18-h period.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	26-29
25037227-11	2014	THC and CP55,940 promoted CB1 internalization and decreased CB1 protein levels over an 18-h period.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	60-63
24949658-2	2014	In a first series of experiments, whole-body and BAT thermogenesis were investigated in rats infused in the third ventricle of the brain with the MC4R agonist melanotan II (MTII) and the CB1 agonist delta9-tetrahydrocannabinol (delta(9)-THC) or the CB1 antagonist AM251.	Dronabinol	199-226	cannabinoid receptor 1	Rattus norvegicus	187-190
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	PPARG coactivator 1 alpha	Rattus norvegicus	90-158
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	PPARG coactivator 1 alpha	Rattus norvegicus	160-169
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	iodothyronine deiodinase 2	Rattus norvegicus	172-204
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	iodothyronine deiodinase 2	Rattus norvegicus	206-210
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	carnitine palmitoyltransferase 1B	Rattus norvegicus	213-246
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	carnitine palmitoyltransferase 1B	Rattus norvegicus	248-253
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	uncoupling protein 1	Rattus norvegicus	260-280
24949658-6	2014	Additionally, delta(9)-THC attenuated the stimulating effect of MTII on the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (Pgc1alpha), type II iodothyronine deiodinase (Dio2), carnitine palmitoyltransferase 1B (Cpt1b), and uncoupling protein 1 (Ucp1).	Dronabinol	14-26	uncoupling protein 1	Rattus norvegicus	282-286
24949658-9	2014	delta(9)-THC also blocked the PVH effect of MTII on (14)C-bromopalmitate uptake as well as on Pgc1alpha and Dio2 expression in iBAT.	Dronabinol	0-12	PPARG coactivator 1 alpha	Rattus norvegicus	94-103
24857780-9	2014	These studies demonstrate that the SCBs JWH-018 and JWH-073 elicit dose-dependent, CB1 receptor-mediated Delta(9)-THC-like effects in mice when delivered via inhalation or via injection.	Dronabinol	105-117	cannabinoid receptor 1 (brain)	Mus musculus	83-86
24858366-7	2014	In mice trained at higher baseline response rates (Experiment 2), the FAAH inhibitor PF3845 (10mg/kg) enhanced anandamide substitution for THC without producing effects of its own.	Dronabinol	139-142	fatty acid amide hydrolase	Mus musculus	70-74
24858366-8	2014	The MAGL inhibitor JZL184 increased brain levels of 2-AG in vitro and in vivo, increased THC-like responding without co-administration of 2-AG.	Dronabinol	89-92	monoglyceride lipase	Mus musculus	4-8
24762058-6	2014	KEY RESULTS: Concentration-dependent increases in intracellular calcium and ERK1/2 phosphorylation were observed in the presence of NAGly, abnormal cannabidiol (AbnCBD), O-1602, O-1918 and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) in HEK293/GPR18 cells.	Dronabinol	189-218	mitogen-activated protein kinase 3	Homo sapiens	76-82
24762058-7	2014	The initial rise in intracellular calcium in the presence of NAGly, O1918 and THC was blocked by either Galpha(q) or Galpha(i/o) inhibition.	Dronabinol	78-81	G protein subunit alpha o1	Homo sapiens	117-127
25057822-9	2014	However, Delta9-THC significantly suppressed IL-12p70 and IL-12p40 as well as marginally suppressed IL-17 versus vehicle treated mice.	Dronabinol	9-19	interleukin 12b	Mus musculus	58-66
25057822-9	2014	However, Delta9-THC significantly suppressed IL-12p70 and IL-12p40 as well as marginally suppressed IL-17 versus vehicle treated mice.	Dronabinol	9-19	interleukin 17A	Mus musculus	100-105
24400995-4	2014	Duodenal tissue samples excised from chronic THC- (N=4) and vehicle (VEH)-treated (N=4) subjects at ~5 months postinoculation showed lower viral load, increased duodenal integrin beta 7(+)(beta7) CD4(+) and CD8(+) central memory T cells, and a significant preferential increase in Th2 cytokine expression.	Dronabinol	45-48	integrin subunit beta 7	Homo sapiens	170-185
26413452-6	2014	Importantly, the distinct structures of the SCBs also typically result in increased affinity for and efficacy at cannabinoid CB1 receptors, which are thought to be responsible for the psychoactive effects of Delta9-THC and its analogues.	Dronabinol	208-218	cannabinoid receptor 1	Homo sapiens	125-128
26413452-10	2014	In contrast, essentially all in vitro measures of drug efficacy confirm Delta9-THC as a relatively weak CB1 partial agonist, while the majority of the SCBs detected in commercial preparations are full agonists at the CB1 receptor.	Dronabinol	72-82	cannabinoid receptor 1	Homo sapiens	104-107
24562630-7	2014	Specific receptor agonists indicated that the THC effect during monocyte differentiation was mediated primarily through CB2.	Dronabinol	46-49	cannabinoid receptor 2	Homo sapiens	120-123
24562630-8	2014	THC reduced the number of p24 positive cells with little to no effect on virus production per infected cell, while quantitation of intracellular viral gag pinpointed the THC effect to an early event in the viral life cycle.	Dronabinol	0-3	transmembrane p24 trafficking protein 2	Homo sapiens	26-29
24562630-9	2014	Cells treated during differentiation with THC displayed reduced expression of CD14, CD16, and CD163 and donor dependent increases in mRNA expression of selected viral restriction factors, suggesting a fundamental alteration in phenotype.	Dronabinol	42-45	CD14 molecule	Homo sapiens	78-82
24562630-9	2014	Cells treated during differentiation with THC displayed reduced expression of CD14, CD16, and CD163 and donor dependent increases in mRNA expression of selected viral restriction factors, suggesting a fundamental alteration in phenotype.	Dronabinol	42-45	Fc gamma receptor IIIa	Homo sapiens	84-88
24562630-9	2014	Cells treated during differentiation with THC displayed reduced expression of CD14, CD16, and CD163 and donor dependent increases in mRNA expression of selected viral restriction factors, suggesting a fundamental alteration in phenotype.	Dronabinol	42-45	CD163 molecule	Homo sapiens	94-99
24424782-3	2014	In this first human study, we probed CB1R function in individuals vulnerable to alcoholism with the exogenous cannabinoid Delta(9)-tetrahydrocannabinol (Delta(9)-THC).	Dronabinol	122-151	cannabinoid receptor 1	Homo sapiens	37-41
24424782-3	2014	In this first human study, we probed CB1R function in individuals vulnerable to alcoholism with the exogenous cannabinoid Delta(9)-tetrahydrocannabinol (Delta(9)-THC).	Dronabinol	153-165	cannabinoid receptor 1	Homo sapiens	37-41
24424782-10	2014	CONCLUSIONS: Enhanced sensitivity to the rewarding effects of Delta(9)-THC in high-FH volunteers suggests that alterations in CB1R function might contribute to alcohol misuse vulnerability.	Dronabinol	62-74	cannabinoid receptor 1	Homo sapiens	126-130
24844285-5	2014	Here, we investigated the neuroprotective effect of Delta9-THC on METH-induced neurotoxicity by examining its ability to reduce astrocyte activation and nNOS overexpression in selected brain areas.	Dronabinol	52-62	nitric oxide synthase 1	Rattus norvegicus	153-157
24844285-10	2014	Our results indicate that Delta9-THC reduces METH-induced brain damage via inhibition of nNOS expression and astrocyte activation through CB1-dependent and independent mechanisms, respectively.	Dronabinol	26-36	nitric oxide synthase 1	Rattus norvegicus	89-93
24844285-10	2014	Our results indicate that Delta9-THC reduces METH-induced brain damage via inhibition of nNOS expression and astrocyte activation through CB1-dependent and independent mechanisms, respectively.	Dronabinol	26-36	cannabinoid receptor 1	Rattus norvegicus	138-141
24474616-3	2014	Pretreatment of RAW 264.7 cells with THC significantly attenuated LPS-induced NO, PGE2 production, and expression of iNOS and COX-2.	Dronabinol	37-40	toll-like receptor 4	Mus musculus	66-69
24474616-3	2014	Pretreatment of RAW 264.7 cells with THC significantly attenuated LPS-induced NO, PGE2 production, and expression of iNOS and COX-2.	Dronabinol	37-40	nitric oxide synthase 2, inducible	Mus musculus	117-121
24474616-3	2014	Pretreatment of RAW 264.7 cells with THC significantly attenuated LPS-induced NO, PGE2 production, and expression of iNOS and COX-2.	Dronabinol	37-40	cytochrome c oxidase II, mitochondrial	Mus musculus	126-131
24474616-4	2014	THC also significantly suppressed LPS-induced release of pro-inflammatory cytokines and degradation of IkappaB-alpha.	Dronabinol	0-3	toll-like receptor 4	Mus musculus	34-37
24474616-4	2014	THC also significantly suppressed LPS-induced release of pro-inflammatory cytokines and degradation of IkappaB-alpha.	Dronabinol	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	103-116
24474616-5	2014	Increased phosphorylation of Nrf2 and nuclear translocation of Nrf2 were observed with THC treatment with consequent expression of HO-1.	Dronabinol	87-90	nuclear factor, erythroid derived 2, like 2	Mus musculus	29-33
24474616-5	2014	Increased phosphorylation of Nrf2 and nuclear translocation of Nrf2 were observed with THC treatment with consequent expression of HO-1.	Dronabinol	87-90	nuclear factor, erythroid derived 2, like 2	Mus musculus	63-67
24474616-5	2014	Increased phosphorylation of Nrf2 and nuclear translocation of Nrf2 were observed with THC treatment with consequent expression of HO-1.	Dronabinol	87-90	heme oxygenase 1	Mus musculus	131-135
24474616-6	2014	The data demonstrated that multiple signaling pathways including Akt, p38, and PKC are involved in the THC-induced activation of Nrf2/HO-1 pathway.	Dronabinol	103-106	mitogen-activated protein kinase 14	Mus musculus	70-73
24474616-6	2014	The data demonstrated that multiple signaling pathways including Akt, p38, and PKC are involved in the THC-induced activation of Nrf2/HO-1 pathway.	Dronabinol	103-106	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-133
24474616-6	2014	The data demonstrated that multiple signaling pathways including Akt, p38, and PKC are involved in the THC-induced activation of Nrf2/HO-1 pathway.	Dronabinol	103-106	heme oxygenase 1	Mus musculus	134-138
24474616-7	2014	Treatment of THC resulted in significantly increased survival of LPS-induced septic mice.	Dronabinol	13-16	toll-like receptor 4	Mus musculus	65-68
24474616-8	2014	THC also significantly ameliorated LPS-induced septic features such as hypothermia and increased vascular leakage.	Dronabinol	0-3	toll-like receptor 4	Mus musculus	35-38
24474616-9	2014	In accordance with the data from cell culture model, THC exhibited increased expression of HO-1 in kidney and decreased serum level of pro-inflammatory mediators such as TNF-alpha, IL-1beta, and NO.	Dronabinol	53-56	heme oxygenase 1	Mus musculus	91-95
24474616-9	2014	In accordance with the data from cell culture model, THC exhibited increased expression of HO-1 in kidney and decreased serum level of pro-inflammatory mediators such as TNF-alpha, IL-1beta, and NO.	Dronabinol	53-56	tumor necrosis factor	Mus musculus	170-179
24474616-9	2014	In accordance with the data from cell culture model, THC exhibited increased expression of HO-1 in kidney and decreased serum level of pro-inflammatory mediators such as TNF-alpha, IL-1beta, and NO.	Dronabinol	53-56	interleukin 1 beta	Mus musculus	181-189
24474616-10	2014	Taken together, the present study for the first time demonstrates that THC inhibits inflammation in LPS-induced RAW264.7 cells by Nrf2 activation and improves survival of mice in LPS-induced endotoxemia model.	Dronabinol	71-74	toll-like receptor 4	Mus musculus	100-103
24474616-10	2014	Taken together, the present study for the first time demonstrates that THC inhibits inflammation in LPS-induced RAW264.7 cells by Nrf2 activation and improves survival of mice in LPS-induced endotoxemia model.	Dronabinol	71-74	nuclear factor, erythroid derived 2, like 2	Mus musculus	130-134
24719095-8	2014	CB1R desensitization in the periaqueductal gray and spinal cord following 7 d of treatment with Delta(9)-THC was absent in S426A/S430A mutants.	Dronabinol	96-108	cannabinoid receptor 1 (brain)	Mus musculus	0-4
24719095-9	2014	Delta(9)-THC-induced downregulation of CB1R in the spinal cord was also absent in S426A/S430A mutants.	Dronabinol	0-12	cannabinoid receptor 1 (brain)	Mus musculus	39-43
24469251-0	2014	Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.	Dronabinol	21-48	stathmin 2	Homo sapiens	94-99
24469251-0	2014	Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.	Dronabinol	21-48	stathmin 2	Homo sapiens	100-110
24469251-4	2014	Here, we show that repeated THC exposure disrupts endocannabinoid signaling, particularly the temporal dynamics of CB1 cannabinoid receptor, to rewire the fetal cortical circuitry.	Dronabinol	28-31	cannabinoid receptor 1	Homo sapiens	115-118
24469251-5	2014	By interrogating the THC-sensitive neuronal proteome we identify Superior Cervical Ganglion 10 (SCG10)/stathmin-2, a microtubule-binding protein in axons, as a substrate of altered neuronal connectivity.	Dronabinol	21-24	stathmin 2	Homo sapiens	65-94
24469251-5	2014	By interrogating the THC-sensitive neuronal proteome we identify Superior Cervical Ganglion 10 (SCG10)/stathmin-2, a microtubule-binding protein in axons, as a substrate of altered neuronal connectivity.	Dronabinol	21-24	stathmin 2	Homo sapiens	96-101
24469251-5	2014	By interrogating the THC-sensitive neuronal proteome we identify Superior Cervical Ganglion 10 (SCG10)/stathmin-2, a microtubule-binding protein in axons, as a substrate of altered neuronal connectivity.	Dronabinol	21-24	stathmin 2	Homo sapiens	103-113
24671907-2	2014	The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2), and thus, may modulate the effects of excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) neurotransmitters.	Dronabinol	27-30	cannabinoid receptor 1	Homo sapiens	90-93
24671907-2	2014	The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2), and thus, may modulate the effects of excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) neurotransmitters.	Dronabinol	27-30	cannabinoid receptor 2	Homo sapiens	98-101
23896204-11	2014	The enhancement in dopamine extracellular levels in the nucleus accumbens induced by Delta(9)-tetrahydrocannabinol was blocked in mice lacking the Hcrtr-1.	Dronabinol	85-114	hypocretin (orexin) receptor 1	Mus musculus	147-154
24236988-10	2014	THC also reduced immunostaining for CB1 receptors in females and this effect was aggravated by the combination with MDMA.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	36-39
24469020-2	2014	Tandem hydrolysis, i.e. enzymatic and basic, has been found optimal for the simultaneous analysis of the selected analytes in urine: basic hydrolysis is more effective for the cleavage of THC-COOH glucuronide while enzymatic hydrolysis allows the cleavage of the conjugated cannabinoids possessing ether bonds (THC, THC-OH, CBD).	Dronabinol	188-191	opsin 1, medium wave sensitive	Homo sapiens	324-327
24200867-6	2014	Biochemical analyses revealed that adolescent THC exposure results in reduced GAD67 and basal GABA levels within the adult PFC.	Dronabinol	46-49	glutamate decarboxylase 1	Rattus norvegicus	78-83
24200867-7	2014	GAD67 expression is reduced both in parvalbumin (PV)- and cholecystokinin (CCK)-containing interneurons; this alteration may be related to the altered emotional reactivity triggered by adolescent THC, as silencing PFC GAD67 expression through a siRNA-mediated approach is sufficient to impact rats" behavior in the forced swim test.	Dronabinol	196-199	glutamate decarboxylase 1	Rattus norvegicus	0-5
24200867-7	2014	GAD67 expression is reduced both in parvalbumin (PV)- and cholecystokinin (CCK)-containing interneurons; this alteration may be related to the altered emotional reactivity triggered by adolescent THC, as silencing PFC GAD67 expression through a siRNA-mediated approach is sufficient to impact rats" behavior in the forced swim test.	Dronabinol	196-199	cholecystokinin	Rattus norvegicus	75-78
24200867-7	2014	GAD67 expression is reduced both in parvalbumin (PV)- and cholecystokinin (CCK)-containing interneurons; this alteration may be related to the altered emotional reactivity triggered by adolescent THC, as silencing PFC GAD67 expression through a siRNA-mediated approach is sufficient to impact rats" behavior in the forced swim test.	Dronabinol	196-199	glutamate decarboxylase 1	Rattus norvegicus	218-223
24418217-6	2014	Using a conditioning-testing paradigm with paired auditory stimuli, the effects of clozapine and dronabinol (a pharmaceutical THC formulation) on inhibitory P20-N40 AEP processing were assessed from in vivo hippocampal CA3 recordings in anesthetized DBA/2 mice.	Dronabinol	97-107	demilune cell and parotid protein 1	Mus musculus	157-160
24418217-6	2014	Using a conditioning-testing paradigm with paired auditory stimuli, the effects of clozapine and dronabinol (a pharmaceutical THC formulation) on inhibitory P20-N40 AEP processing were assessed from in vivo hippocampal CA3 recordings in anesthetized DBA/2 mice.	Dronabinol	126-129	demilune cell and parotid protein 1	Mus musculus	157-160
23914904-9	2014	Delta9-THC significantly increased CB1 mRNA levels and lipid accumulation but decreased CPT1A and CPT1B mRNA levels.	Dronabinol	0-10	carnitine palmitoyltransferase 1A	Sus scrofa	88-93
23914904-9	2014	Delta9-THC significantly increased CB1 mRNA levels and lipid accumulation but decreased CPT1A and CPT1B mRNA levels.	Dronabinol	0-10	carnitine palmitoyltransferase 1B	Sus scrofa	98-103
24160757-4	2014	CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism.	Dronabinol	67-70	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-7
24160757-4	2014	CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism.	Dronabinol	190-193	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-7
24160757-5	2014	Clinical pharmacogenetic data further support CYP2C9 as a significant contributor to THC metabolism, and a pharmacokinetic interaction study using ketoconazole with oromucosal cannabis extract further supports CYP3A4 as a significant metabolic pathway for THC and CBD.	Dronabinol	85-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	46-52
24160757-5	2014	Clinical pharmacogenetic data further support CYP2C9 as a significant contributor to THC metabolism, and a pharmacokinetic interaction study using ketoconazole with oromucosal cannabis extract further supports CYP3A4 as a significant metabolic pathway for THC and CBD.	Dronabinol	256-259	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	210-216
24090766-0	2014	DeltaFosB induction correlates inversely with CB1 receptor desensitization in a brain region-dependent manner following repeated Delta9-THC administration.	Dronabinol	129-139	cannabinoid receptor 1 (brain)	Mus musculus	46-49
24090766-11	2014	THC-induced expression of DeltaFosB was absent in the striatum of CB1R knockout mice.	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	66-70
24427137-0	2014	Delta(9)-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18.	Dronabinol	0-12	G protein-coupled receptor 18	Homo sapiens	139-144
24427137-4	2014	N-arachidonoyl glycine (NAGly) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) signaling via GPR18 has been introduced as an important new target in microglial-neuronal communication.	Dronabinol	35-64	G protein-coupled receptor 18	Homo sapiens	94-99
24427137-4	2014	N-arachidonoyl glycine (NAGly) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) signaling via GPR18 has been introduced as an important new target in microglial-neuronal communication.	Dronabinol	66-78	G protein-coupled receptor 18	Homo sapiens	94-99
24427137-5	2014	Our hypothesis is that endogenous NAGly-GPR18 signaling regulates phenotypic shape and cytokine production in microglia, and is mimicked by Delta(9)-THC in the BV-2 microglia model system.	Dronabinol	140-152	G protein-coupled receptor 18	Homo sapiens	40-45
24427137-9	2014	Production of Axl, CD40, IGF-I, OPN, and Pro-MMP-9 were significantly altered by NAGly and Delta(9)-THC, and antagonized by CBD.	Dronabinol	91-103	AXL receptor tyrosine kinase	Homo sapiens	14-17
24427137-9	2014	Production of Axl, CD40, IGF-I, OPN, and Pro-MMP-9 were significantly altered by NAGly and Delta(9)-THC, and antagonized by CBD.	Dronabinol	91-103	secreted phosphoprotein 1	Homo sapiens	32-35
24424856-1	2014	The effects of tetrahydrocannabinol (THC) and endogenous cannabinoids (endocannabinoids, ECs) are both mediated by activation of the cannabinoid receptors CB1 and CB2.	Dronabinol	15-35	cannabinoid receptor 1	Homo sapiens	155-158
24424856-1	2014	The effects of tetrahydrocannabinol (THC) and endogenous cannabinoids (endocannabinoids, ECs) are both mediated by activation of the cannabinoid receptors CB1 and CB2.	Dronabinol	15-35	cannabinoid receptor 2	Homo sapiens	163-166
24424856-1	2014	The effects of tetrahydrocannabinol (THC) and endogenous cannabinoids (endocannabinoids, ECs) are both mediated by activation of the cannabinoid receptors CB1 and CB2.	Dronabinol	37-40	cannabinoid receptor 1	Homo sapiens	155-158
24424856-1	2014	The effects of tetrahydrocannabinol (THC) and endogenous cannabinoids (endocannabinoids, ECs) are both mediated by activation of the cannabinoid receptors CB1 and CB2.	Dronabinol	37-40	cannabinoid receptor 2	Homo sapiens	163-166
25024327-3	2014	THC was also tested for synergy with caffeine, in respect to the reduction of the Abeta level in N2a/AbetaPPswe cells.	Dronabinol	0-3	amyloid beta (A4) precursor protein	Mus musculus	82-87
25024327-6	2014	Thioflavin T assays and western blots were performed to test the direct anti-Abeta aggregation significance of THC.	Dronabinol	111-114	amyloid beta (A4) precursor protein	Mus musculus	77-82
25024327-7	2014	Lastly, THC was tested to determine its effects on glycogen synthase kinase-3beta (GSK-3beta) and related signaling pathways.	Dronabinol	8-11	glycogen synthase kinase 3 beta	Mus musculus	51-81
25024327-7	2014	Lastly, THC was tested to determine its effects on glycogen synthase kinase-3beta (GSK-3beta) and related signaling pathways.	Dronabinol	8-11	glycogen synthase kinase 3 beta	Mus musculus	83-92
25024327-8	2014	From the results, we have discovered THC to be effective at lowering Abeta levels in N2a/AbetaPPswe cells at extremely low concentrations in a dose-dependent manner.	Dronabinol	37-40	amyloid beta (A4) precursor protein	Mus musculus	69-74
25024327-10	2014	We did discover that THC directly interacts with Abeta peptide, thereby inhibiting aggregation.	Dronabinol	21-24	amyloid beta (A4) precursor protein	Mus musculus	49-54
25024327-11	2014	Furthermore, THC was effective at lowering both total GSK-3beta levels and phosphorylated GSK-3beta in a dose-dependent manner at low concentrations.	Dronabinol	13-16	glycogen synthase kinase 3 beta	Mus musculus	54-63
25024327-11	2014	Furthermore, THC was effective at lowering both total GSK-3beta levels and phosphorylated GSK-3beta in a dose-dependent manner at low concentrations.	Dronabinol	13-16	glycogen synthase kinase 3 beta	Mus musculus	90-99
24202177-0	2013	Distinct microRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by Delta9-tetrahydrocannabinol in vivo: regulation of CCAAT/enhancer-binding protein alpha by microRNA-690.	Dronabinol	128-155	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	179-215
24202177-0	2013	Distinct microRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by Delta9-tetrahydrocannabinol in vivo: regulation of CCAAT/enhancer-binding protein alpha by microRNA-690.	Dronabinol	128-155	microRNA 690	Mus musculus	219-231
24202177-4	2013	Expression of CD31 and Ki-67 confirmed that the THC-MDSCs were immature and proliferating.	Dronabinol	48-51	platelet/endothelial cell adhesion molecule 1	Mus musculus	14-18
24202177-4	2013	Expression of CD31 and Ki-67 confirmed that the THC-MDSCs were immature and proliferating.	Dronabinol	48-51	antigen identified by monoclonal antibody Ki 67	Mus musculus	23-28
24099963-8	2013	Direct-acting cannabinoid CB1 agonists Delta(9)-tetrahydrocannabinol (THC), WIN 55,212, AM7418 and AM4054, had biphasic effects on diuresis, with peak diuretic effects occurring at lower doses than peak antinociceptive effects.	Dronabinol	39-68	cannabinoid receptor 1 (brain)	Mus musculus	26-29
24099963-8	2013	Direct-acting cannabinoid CB1 agonists Delta(9)-tetrahydrocannabinol (THC), WIN 55,212, AM7418 and AM4054, had biphasic effects on diuresis, with peak diuretic effects occurring at lower doses than peak antinociceptive effects.	Dronabinol	70-73	cannabinoid receptor 1 (brain)	Mus musculus	26-29
24094141-11	2013	Of the agonists assayed for activity, only Delta(9)-tetrahydrocannabinol (THC) exhibited a difference between genotypes, in that it was less efficacious in beta-arrestin2-/- than +/+ mouse membranes.	Dronabinol	43-72	arrestin, beta 2	Mus musculus	156-170
24094141-11	2013	Of the agonists assayed for activity, only Delta(9)-tetrahydrocannabinol (THC) exhibited a difference between genotypes, in that it was less efficacious in beta-arrestin2-/- than +/+ mouse membranes.	Dronabinol	74-77	arrestin, beta 2	Mus musculus	156-170
29450159-8	2013	With full adjustment, Cox regression hazard ratios (95% confidence intervals) for CVD mortality and morbidity, using no calcification as reference, for THC-1, THC-2, and THC-3 were 2.21 (1.31-3.74), 2.59 (1.53-4.39) and 4.14 (2.30-7.47), respectively.	Dronabinol	152-155	cytochrome c oxidase subunit 8A	Homo sapiens	22-25
24267894-0	2013	Delta9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.	Dronabinol	0-10	cytochrome c oxidase subunit 2	Cannabis sativa	71-76
24267894-3	2013	Here, we show that synaptic and cognitive impairments following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid to prostanoids in the brain.	Dronabinol	85-114	cytochrome c oxidase subunit 2	Cannabis sativa	167-183
24267894-3	2013	Here, we show that synaptic and cognitive impairments following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid to prostanoids in the brain.	Dronabinol	85-114	cytochrome c oxidase subunit 2	Cannabis sativa	185-190
24267894-3	2013	Here, we show that synaptic and cognitive impairments following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid to prostanoids in the brain.	Dronabinol	116-128	cytochrome c oxidase subunit 2	Cannabis sativa	167-183
24267894-3	2013	Here, we show that synaptic and cognitive impairments following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid to prostanoids in the brain.	Dronabinol	116-128	cytochrome c oxidase subunit 2	Cannabis sativa	185-190
24267894-4	2013	COX-2 induction by Delta(9)-THC is mediated via CB1 receptor-coupled G protein betagamma subunits.	Dronabinol	19-31	cytochrome c oxidase subunit 2	Cannabis sativa	0-5
24267894-5	2013	Pharmacological or genetic inhibition of COX-2 blocks downregulation and internalization of glutamate receptor subunits and alterations of the dendritic spine density of hippocampal neurons induced by repeated Delta(9)-THC exposures.	Dronabinol	219-222	cytochrome c oxidase subunit 2	Cannabis sativa	41-46
24267894-6	2013	Ablation of COX-2 also eliminates Delta(9)-THC-impaired hippocampal long-term synaptic plasticity, working, and fear memories.	Dronabinol	34-46	cytochrome c oxidase subunit 2	Cannabis sativa	12-17
23865723-1	2013	The cannabinoid receptor type 2 (CB2) is a class A GPCR that was cloned in 1993 while looking for an alternative receptor that could explain the pharmacological properties of Delta(9)-tetrahydrocannabinol.	Dronabinol	175-204	cannabinoid receptor 2	Homo sapiens	33-36
23999542-0	2013	Impaired NFAT and NFkappaB activation are involved in suppression of CD40 ligand expression by Delta(9)-tetrahydrocannabinol in human CD4(+) T cells.	Dronabinol	95-124	nuclear factor kappa B subunit 1	Homo sapiens	18-26
23999542-0	2013	Impaired NFAT and NFkappaB activation are involved in suppression of CD40 ligand expression by Delta(9)-tetrahydrocannabinol in human CD4(+) T cells.	Dronabinol	95-124	CD40 ligand	Homo sapiens	69-80
23999542-0	2013	Impaired NFAT and NFkappaB activation are involved in suppression of CD40 ligand expression by Delta(9)-tetrahydrocannabinol in human CD4(+) T cells.	Dronabinol	95-124	CD4 molecule	Homo sapiens	69-72
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	33-62	CD40 ligand	Homo sapiens	138-149
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	33-62	CD40 ligand	Homo sapiens	151-156
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	33-62	CD4 antigen	Mus musculus	138-141
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	64-76	CD40 ligand	Homo sapiens	138-149
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	64-76	CD40 ligand	Homo sapiens	151-156
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	64-76	CD4 antigen	Mus musculus	138-141
23999542-3	2013	In the present study, we investigated the molecular mechanism of Delta(9)-THC-mediated suppression of CD40L expression using peripheral blood human T cells.	Dronabinol	74-77	CD40 ligand	Homo sapiens	102-107
23999542-4	2013	Pretreatment with Delta(9)-THC attenuated CD40L expression in human CD4(+) T cells activated by anti-CD3/CD28 at both the protein and mRNA level, as determined by flow cytometry and quantitative real-time PCR, respectively.	Dronabinol	18-30	CD40 ligand	Homo sapiens	42-47
23999542-4	2013	Pretreatment with Delta(9)-THC attenuated CD40L expression in human CD4(+) T cells activated by anti-CD3/CD28 at both the protein and mRNA level, as determined by flow cytometry and quantitative real-time PCR, respectively.	Dronabinol	18-30	CD4 antigen	Mus musculus	42-45
23999542-4	2013	Pretreatment with Delta(9)-THC attenuated CD40L expression in human CD4(+) T cells activated by anti-CD3/CD28 at both the protein and mRNA level, as determined by flow cytometry and quantitative real-time PCR, respectively.	Dronabinol	18-30	CD28 molecule	Homo sapiens	105-109
23999542-5	2013	Electrophoretic mobility shift assays revealed that Delta(9)-THC suppressed the DNA-binding activity of both NFAT and NFkappaB to their respective response elements within the CD40L promoter.	Dronabinol	52-64	nuclear factor kappa B subunit 1	Homo sapiens	118-126
23999542-5	2013	Electrophoretic mobility shift assays revealed that Delta(9)-THC suppressed the DNA-binding activity of both NFAT and NFkappaB to their respective response elements within the CD40L promoter.	Dronabinol	52-64	CD40 ligand	Homo sapiens	176-181
23999542-6	2013	An assessment of the effect of Delta(9)-THC on proximal T cell-receptor (TCR) signaling induced by anti-CD3/CD28 showed significant impairment in the rise of intracellular calcium, but no significant effect on the phosphorylation of ZAP70, PLCgamma1/2, Akt, and GSK3beta.	Dronabinol	31-43	CD28 molecule	Homo sapiens	108-112
23999542-7	2013	Collectively, these findings identify perturbation of the calcium-NFAT and NFkappaB signaling cascade as a key mechanistic event by which Delta(9)-THC suppresses human T cell function.	Dronabinol	138-150	nuclear factor kappa B subunit 1	Homo sapiens	75-83
24105081-0	2013	Female neuregulin 1 heterozygous mice require repeated exposure to Delta9-tetrahydrocannabinol to alter sensorimotor gating function.	Dronabinol	67-94	neuregulin 1	Mus musculus	7-19
24105081-3	2013	We aim to observe whether repeated administration of THC may overcome the acute insensitivity of female Nrg1 HET mice to THC exposure.	Dronabinol	53-56	neuregulin 1	Mus musculus	104-108
24105081-5	2013	RESULTS: Following repeated, but not acute THC exposure, female Nrg1 HET mice displayed THC-induced facilitation of PPI which was not observed in WT mice treated with THC.	Dronabinol	88-91	neuregulin 1	Mus musculus	64-68
24105081-5	2013	RESULTS: Following repeated, but not acute THC exposure, female Nrg1 HET mice displayed THC-induced facilitation of PPI which was not observed in WT mice treated with THC.	Dronabinol	88-91	neuregulin 1	Mus musculus	64-68
24105081-8	2013	DISCUSSION: These findings show that the acute insensitivity of female Nrg1 HET mice to THC-induced PPI facilitation may be overcome following repeated THC exposure.	Dronabinol	88-91	neuregulin 1	Mus musculus	71-75
24130809-10	2013	Whilst sedative doses of tetrahydrocannabinol could induce immunosuppression, this was associated with a CB1 receptor rather than a CB2 receptor-mediated effect.	Dronabinol	25-45	cannabinoid receptor 1 (brain)	Mus musculus	105-108
23987522-2	2013	Cytochrome-P450-mediated metabolism of each leads to the generation of pharmacologically active (omega)- and (omega-1)-monohydroxyl metabolites that retain high affinity for cannabinoid type-1 receptors, exhibit Delta(9)-THC-like effects in rodents, and are conjugated with glucuronic acid prior to excretion in human urine.	Dronabinol	212-224	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
23567453-3	2013	Here, we took advantage of the use of cells derived from Trib3-deficient mice to investigate the precise mechanisms by which TRIB3 regulates the anti-cancer action of THC.	Dronabinol	167-170	tribbles pseudokinase 3	Mus musculus	125-130
23567453-4	2013	Our data show that RasV(12)/E1A-transformed embryonic fibroblasts derived from Trib3-deficient mice are resistant to THC-induced cell death.	Dronabinol	117-120	tribbles pseudokinase 3	Mus musculus	79-84
23567453-5	2013	We also show that genetic inactivation of this protein abolishes the ability of THC to inhibit the phosphorylation of AKT and several of its downstream targets, including those involved in the regulation of the AKT/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	80-83	AKT serine/threonine kinase 1	Homo sapiens	118-121
23567453-5	2013	We also show that genetic inactivation of this protein abolishes the ability of THC to inhibit the phosphorylation of AKT and several of its downstream targets, including those involved in the regulation of the AKT/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	80-83	AKT serine/threonine kinase 1	Homo sapiens	211-214
23567453-5	2013	We also show that genetic inactivation of this protein abolishes the ability of THC to inhibit the phosphorylation of AKT and several of its downstream targets, including those involved in the regulation of the AKT/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	80-83	CREB regulated transcription coactivator 1	Mus musculus	256-262
23567453-6	2013	Our data support the idea that THC-induced TRIB3 up-regulation inhibits AKT phosphorylation by regulating the accessibility of AKT to its upstream activatory kinase (the mammalian target of rapamycin complex 2; mTORC2).	Dronabinol	31-34	tribbles pseudokinase 3	Homo sapiens	43-48
23567453-6	2013	Our data support the idea that THC-induced TRIB3 up-regulation inhibits AKT phosphorylation by regulating the accessibility of AKT to its upstream activatory kinase (the mammalian target of rapamycin complex 2; mTORC2).	Dronabinol	31-34	AKT serine/threonine kinase 1	Homo sapiens	72-75
23567453-6	2013	Our data support the idea that THC-induced TRIB3 up-regulation inhibits AKT phosphorylation by regulating the accessibility of AKT to its upstream activatory kinase (the mammalian target of rapamycin complex 2; mTORC2).	Dronabinol	31-34	AKT serine/threonine kinase 1	Homo sapiens	127-130
23567453-6	2013	Our data support the idea that THC-induced TRIB3 up-regulation inhibits AKT phosphorylation by regulating the accessibility of AKT to its upstream activatory kinase (the mammalian target of rapamycin complex 2; mTORC2).	Dronabinol	31-34	CREB regulated transcription coactivator 2	Mus musculus	211-217
23567453-7	2013	Finally, we found that tumors generated by inoculation of Trib3-deficient cells in nude mice are resistant to THC anticancer action.	Dronabinol	110-113	tribbles pseudokinase 3	Mus musculus	58-63
23567453-8	2013	Altogether, the observations presented here strongly support that TRIB3 plays a crucial role on THC anti-neoplastic activity.	Dronabinol	96-99	tribbles pseudokinase 3	Mus musculus	66-71
23902406-10	2013	The Delta(9) -tetrahydrocannabinol and Delta(9) -tetrahydrocannabivarin content of CBDV BDS accounted for its greater affinity for CB1 cannabinoid receptors than purified CBDV.	Dronabinol	4-34	cannabinoid receptor 1	Rattus norvegicus	131-134
23707295-12	2013	THC was blocked by the CB1 receptor-selective antagonist rimonabant in both sexes.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	23-26
23707295-20	2013	Furthermore, sex differences in THC"s peripheral effects against inflammatory pain may be a result of activation of both types of cannabinoid receptors in females, in contrast to predominantly CB1 receptors in males.	Dronabinol	32-35	cannabinoid receptor 1	Rattus norvegicus	193-196
23727458-0	2013	Suppression by Delta(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation.	Dronabinol	15-44	signal transducer and activator of transcription 3	Homo sapiens	148-153
23727458-4	2013	The attenuation of IgM secretion by Delta(9)-THC involved, at least in part, the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression.	Dronabinol	36-48	joining chain of multimeric IgA and IgM	Homo sapiens	154-182
23727458-4	2013	The attenuation of IgM secretion by Delta(9)-THC involved, at least in part, the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression.	Dronabinol	36-48	joining chain of multimeric IgA and IgM	Homo sapiens	184-187
23727458-6	2013	Interestingly, Delta(9)-THC selectively suppressed the surface expression of CD80, but not other measured B-cell activation markers (CD69, CD86, and ICAM1).	Dronabinol	15-27	CD80 molecule	Homo sapiens	77-81
23727458-7	2013	Furthermore, pretreatment with Delta(9)-THC was accompanied by a robust decrease of STAT3 phosphorylation, whereas the phosphorylation of the p65 NFkappaB subunit was not affected.	Dronabinol	31-43	signal transducer and activator of transcription 3	Homo sapiens	84-89
23889474-1	2013	BACKGROUND:  (9) -Tetrahydrocannabinol (THC), the active constituent of Cannabis sativa, exerts its biological effects in part through the G-protein-coupled CB1 and CB2 receptors, which were initially discovered in brain and spleen tissue, respectively.	Dronabinol	40-43	cannabinoid receptor 1 (brain)	Mus musculus	157-160
23889474-1	2013	BACKGROUND:  (9) -Tetrahydrocannabinol (THC), the active constituent of Cannabis sativa, exerts its biological effects in part through the G-protein-coupled CB1 and CB2 receptors, which were initially discovered in brain and spleen tissue, respectively.	Dronabinol	40-43	cannabinoid receptor 2 (macrophage)	Mus musculus	165-168
23889474-7	2013	RESULTS: Topical THC application effectively decreased contact allergic ear swelling and myeloid immune cell infiltration not only in wild-type but also in CB1/2 receptor-deficient mice.	Dronabinol	17-20	cannabinoid receptor 1 (brain)	Mus musculus	156-159
23889474-8	2013	We found that THC (1) inhibited the production of IFNgamma by T cells, (2) decreased the production of CCL2 and of IFNgamma-induced CCL8 and CXL10 by epidermal keratinocytes and (3) thereby limited the recruitment of myeloid immune cells in vitro in a CB1/2 receptor-independent manner.	Dronabinol	14-17	interferon gamma	Mus musculus	50-58
23889474-8	2013	We found that THC (1) inhibited the production of IFNgamma by T cells, (2) decreased the production of CCL2 and of IFNgamma-induced CCL8 and CXL10 by epidermal keratinocytes and (3) thereby limited the recruitment of myeloid immune cells in vitro in a CB1/2 receptor-independent manner.	Dronabinol	14-17	chemokine (C-C motif) ligand 2	Mus musculus	103-107
23889474-8	2013	We found that THC (1) inhibited the production of IFNgamma by T cells, (2) decreased the production of CCL2 and of IFNgamma-induced CCL8 and CXL10 by epidermal keratinocytes and (3) thereby limited the recruitment of myeloid immune cells in vitro in a CB1/2 receptor-independent manner.	Dronabinol	14-17	interferon gamma	Mus musculus	115-123
23889474-8	2013	We found that THC (1) inhibited the production of IFNgamma by T cells, (2) decreased the production of CCL2 and of IFNgamma-induced CCL8 and CXL10 by epidermal keratinocytes and (3) thereby limited the recruitment of myeloid immune cells in vitro in a CB1/2 receptor-independent manner.	Dronabinol	14-17	chemokine (C-C motif) ligand 8	Mus musculus	132-136
23889474-8	2013	We found that THC (1) inhibited the production of IFNgamma by T cells, (2) decreased the production of CCL2 and of IFNgamma-induced CCL8 and CXL10 by epidermal keratinocytes and (3) thereby limited the recruitment of myeloid immune cells in vitro in a CB1/2 receptor-independent manner.	Dronabinol	14-17	cannabinoid receptor 1 (brain)	Mus musculus	252-255
23889474-9	2013	CONCLUSIONS: Topically applied THC can effectively attenuate contact allergic inflammation by decreasing keratinocyte-derived pro-inflammatory mediators that orchestrate myeloid immune cell infiltration independent of CB1/2 receptors.	Dronabinol	31-34	cannabinoid receptor 1 (brain)	Mus musculus	218-223
23863631-4	2013	combined mouse genetics with classic mouse behavioral analysis to deepen our understanding of the physiological consequence of subchronic THC intake on eyeblink reflexes, a fundamental neuronal adaptive response, revealing that this regimen leads to downregulation of the cannabinoid CB1 receptor (referred to as CB1 in the Cutando et al.	Dronabinol	138-141	cannabinoid receptor 1 (brain)	Mus musculus	284-287
23863631-4	2013	combined mouse genetics with classic mouse behavioral analysis to deepen our understanding of the physiological consequence of subchronic THC intake on eyeblink reflexes, a fundamental neuronal adaptive response, revealing that this regimen leads to downregulation of the cannabinoid CB1 receptor (referred to as CB1 in the Cutando et al.	Dronabinol	138-141	cannabinoid receptor 1 (brain)	Mus musculus	313-316
23718638-0	2013	Delta(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor beta (ERbeta).	Dronabinol	0-29	estrogen receptor 2	Homo sapiens	83-105
23718638-0	2013	Delta(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor beta (ERbeta).	Dronabinol	0-29	estrogen receptor 2	Homo sapiens	107-113
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	79-91	estrogen receptor 2	Homo sapiens	105-111
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	79-91	estrogen receptor 1	Homo sapiens	128-135
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	79-91	estrogen receptor 1	Homo sapiens	169-176
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	79-91	estrogen receptor 2	Homo sapiens	258-264
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	79-91	cystatin 12, pseudogene	Homo sapiens	166-176
23718638-4	2013	Mechanistically, the data obtained from biochemical analyses revealed that (i) Delta(9)-THC up-regulates ERbeta, a repressor of ERalpha, inhibiting the expression of E2/ERalpha-regulated genes that promote cell growth and that (ii) Delta(9)-THC induction of ERbeta modulates E2/ERalpha signaling in the absence of direct interaction with the E2 ligand binding site.	Dronabinol	232-244	estrogen receptor 2	Homo sapiens	105-111
23718638-5	2013	Therefore, the data presented support the concept that Delta(9)-THC"s antiestrogenic activities are mediated by the ERbeta disruption of E2/ERalpha signaling.	Dronabinol	64-67	estrogen receptor 2	Homo sapiens	116-122
23718638-5	2013	Therefore, the data presented support the concept that Delta(9)-THC"s antiestrogenic activities are mediated by the ERbeta disruption of E2/ERalpha signaling.	Dronabinol	64-67	cystatin 12, pseudogene	Homo sapiens	137-147
23934130-2	2013	Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1beta.	Dronabinol	98-125	interleukin 1 beta	Mus musculus	233-241
23934130-2	2013	Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1beta.	Dronabinol	127-130	interleukin 1 beta	Mus musculus	233-241
23934130-6	2013	Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1beta receptor signaling prevented the deficits in cerebellar function in Cb1(-/-) and THC-withdrawn mice.	Dronabinol	174-177	interleukin 1 beta	Mus musculus	84-92
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	81-108	catechol-O-methyltransferase	Homo sapiens	167-195
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	81-108	catechol-O-methyltransferase	Homo sapiens	197-201
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	81-108	solute carrier family 6 member 4	Homo sapiens	239-245
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	110-113	catechol-O-methyltransferase	Homo sapiens	167-195
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	110-113	catechol-O-methyltransferase	Homo sapiens	197-201
23449176-2	2013	Two common genetic polymorphisms have been linked to the neuroadaptive impact of Delta9-tetrahydrocannabinol (THC) exposure and to executive functions in animals: the catechol-O-methyltransferase (COMT) gene val158met polymorphism and the SLC6A4 gene 5-HTTLPR polymorphism.	Dronabinol	110-113	solute carrier family 6 member 4	Homo sapiens	239-245
23537701-1	2013	UNLABELLED: Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.	Dronabinol	12-32	cannabinoid receptor 1 (brain)	Mus musculus	183-186
23537701-1	2013	UNLABELLED: Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.	Dronabinol	12-32	cannabinoid receptor 2 (macrophage)	Mus musculus	191-194
23537701-1	2013	UNLABELLED: Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.	Dronabinol	34-37	cannabinoid receptor 1 (brain)	Mus musculus	183-186
23537701-1	2013	UNLABELLED: Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.	Dronabinol	34-37	cannabinoid receptor 2 (macrophage)	Mus musculus	191-194
23537701-9	2013	ERK1/2 phosphorylation following infarct was also inhibited by pre-treatment with THC (p&lt;0.01).	Dronabinol	82-85	mitogen-activated protein kinase 3	Mus musculus	0-6
23072421-7	2013	The cannabinoid CB1/CB2 receptor agonist Delta9-tetrahydrocannabinol significantly increased margarine intake selectively in LR rats, while the fatty acid amide hydrolase inhibitor URB597 showed no effect.	Dronabinol	41-68	cannabinoid receptor 1	Rattus norvegicus	16-19
23072421-7	2013	The cannabinoid CB1/CB2 receptor agonist Delta9-tetrahydrocannabinol significantly increased margarine intake selectively in LR rats, while the fatty acid amide hydrolase inhibitor URB597 showed no effect.	Dronabinol	41-68	cannabinoid receptor 2	Rattus norvegicus	20-23
23280930-2	2013	Further, we determined if THC-002 could decrease expression of transient receptor potential melastatin 8 (TRPM8) channels associated with the cold responses.	Dronabinol	26-29	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	63-104
23280930-2	2013	Further, we determined if THC-002 could decrease expression of transient receptor potential melastatin 8 (TRPM8) channels associated with the cold responses.	Dronabinol	26-29	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	106-111
23280930-12	2013	THC-002 significantly reduced expression of TRPM8 channel protein and mRNA.	Dronabinol	0-3	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	44-49
23358238-0	2013	Dissociation of the pharmacological effects of THC by mTOR blockade.	Dronabinol	47-50	mechanistic target of rapamycin kinase	Mus musculus	54-58
23358238-2	2013	We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway.	Dronabinol	60-87	mechanistic target of rapamycin kinase	Homo sapiens	145-174
23358238-2	2013	We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway.	Dronabinol	60-87	mechanistic target of rapamycin kinase	Homo sapiens	176-180
23358238-2	2013	We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway.	Dronabinol	89-92	mechanistic target of rapamycin kinase	Homo sapiens	145-174
23358238-2	2013	We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway.	Dronabinol	89-92	mechanistic target of rapamycin kinase	Homo sapiens	176-180
23358238-3	2013	In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC.	Dronabinol	120-123	mechanistic target of rapamycin kinase	Mus musculus	53-57
23358238-4	2013	The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC.	Dronabinol	195-198	mechanistic target of rapamycin kinase	Mus musculus	59-63
23358238-9	2013	Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure.	Dronabinol	153-156	cannabinoid receptor 1 (brain)	Mus musculus	108-111
23561296-3	2013	Transcript levels for the recently discovered 2-AG metabolizing enzyme, alpha-beta-hydrolase domain 6 (ABHD6), were assessed using quantitative PCR in the prefrontal cortex of schizophrenia and healthy subjects (n=84) and antipsychotic- or tetrahydrocannabinol-exposed monkeys.	Dronabinol	240-260	abhydrolase domain containing 6, acylglycerol lipase	Homo sapiens	72-101
23561296-3	2013	Transcript levels for the recently discovered 2-AG metabolizing enzyme, alpha-beta-hydrolase domain 6 (ABHD6), were assessed using quantitative PCR in the prefrontal cortex of schizophrenia and healthy subjects (n=84) and antipsychotic- or tetrahydrocannabinol-exposed monkeys.	Dronabinol	240-260	abhydrolase domain containing 6, acylglycerol lipase	Homo sapiens	103-108
23750331-10	2013	Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19.	Dronabinol	25-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
23750331-11	2013	On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.	Dronabinol	132-135	peptidylprolyl isomerase G	Homo sapiens	96-99
23640460-2	2013	In this study, we examined whether the PPARgamma-activated pathway contributed to the antitumor effect of two cannabinoids, Delta9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells.	Dronabinol	124-151	peroxisome proliferator activated receptor gamma	Homo sapiens	39-48
23640460-2	2013	In this study, we examined whether the PPARgamma-activated pathway contributed to the antitumor effect of two cannabinoids, Delta9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells.	Dronabinol	153-156	peroxisome proliferator activated receptor gamma	Homo sapiens	39-48
23640460-8	2013	Taken together, we demonstrate for the first time that the antiproliferative action of the cannabinoids THC and JWH-015 on HCC, in vitro and in vivo, are modulated by upregulation of PPARgamma-dependent pathways.	Dronabinol	104-107	peroxisome proliferator activated receptor gamma	Homo sapiens	183-192
23095052-2	2013	Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC.	Dronabinol	128-131	cannabinoid receptor 1	Homo sapiens	111-114
23477308-2	2013	In this context, since the modulation of the endocannabinoid system with the non selective phytocannabinoid Delta9-THC produces analgesia and potentiates opioid analgesia in animal models, CB2 ligands studies aimed to explore the involvement of endocannabinoid system in management of pain were started.	Dronabinol	108-118	cannabinoid receptor 2	Homo sapiens	189-192
23111884-0	2013	Estimation of BDNF gene polymorphism and predisposition to dependence development for selected psychoactive compounds: genetic aspects of addiction with the selected drugs, amphetamine, tetrahydrocannabinol and opiates.	Dronabinol	186-206	brain derived neurotrophic factor	Homo sapiens	14-18
23447498-3	2013	Nrg1 HET mice also display idiosyncratic responses to the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	101-130	neuregulin 1	Mus musculus	0-4
23447498-3	2013	Nrg1 HET mice also display idiosyncratic responses to the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	132-135	neuregulin 1	Mus musculus	0-4
23447498-8	2013	Nrg1 HET mice treated with THC expressed a distinct protein expression signature compared to WT mice.	Dronabinol	27-30	neuregulin 1	Mus musculus	0-4
23447498-10	2013	We have previously observed that THC selectively increased hippocampal NMDA receptor binding of adolescent Nrg1 HET mice.	Dronabinol	33-36	neuregulin 1	Mus musculus	107-111
22226049-0	2013	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence.	Dronabinol	110-113	neuregulin 1	Mus musculus	21-25
22226049-7	2013	The hyperlocomotor phenotype typical of Nrg1 mutants emerged after drug withdrawal and was more pronounced in vehicle than THC-treated Nrg1 TM HET mice.	Dronabinol	123-126	neuregulin 1	Mus musculus	40-44
22226049-7	2013	The hyperlocomotor phenotype typical of Nrg1 mutants emerged after drug withdrawal and was more pronounced in vehicle than THC-treated Nrg1 TM HET mice.	Dronabinol	123-126	neuregulin 1	Mus musculus	135-139
23219038-8	2013	In univariate analysis, HER2 positivity, tumor size, and Ki-67 positivity showed significant correlations with maximum THC (p &lt; 0.05).	Dronabinol	119-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
23219038-9	2013	In multivariate analysis including tumor size, and ER, PR, HER2, and Ki-67 status, HER2 positivity correlated with maximum THC significantly (p = 0.007, parameter estimate 76.44).	Dronabinol	123-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
23219038-10	2013	Maximum THC correlated with HER2, Ki-67 and tumor size in this group of ductal breast carcinomas.	Dronabinol	8-11	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
24009860-6	2013	THC effectively suppressed the LPS-induced induction of pro-inflammatory mediators such as NO, TNF-alpha, and IL-1beta.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	95-104
24009860-6	2013	THC effectively suppressed the LPS-induced induction of pro-inflammatory mediators such as NO, TNF-alpha, and IL-1beta.	Dronabinol	0-3	interleukin 1 beta	Mus musculus	110-118
24009860-7	2013	THC also suppressed expression of MCP-1, which plays a key role in the migration of activated microglia.	Dronabinol	0-3	mast cell protease 1	Mus musculus	34-39
24009860-9	2013	THC resulted in increased phosphorylation of Nrf2 with consequent expression of HO-1 in a concentration-dependent manner.	Dronabinol	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	45-49
24009860-9	2013	THC resulted in increased phosphorylation of Nrf2 with consequent expression of HO-1 in a concentration-dependent manner.	Dronabinol	0-3	heme oxygenase 1	Mus musculus	80-84
24009860-10	2013	THC-induced phosphorylation of Nrf2 was blocked with SB203580, a p38 MAPK inhibitor, indicating that p38 MAPK is the responsible kinase for the phosphorylation of Nrf2.	Dronabinol	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
24009860-10	2013	THC-induced phosphorylation of Nrf2 was blocked with SB203580, a p38 MAPK inhibitor, indicating that p38 MAPK is the responsible kinase for the phosphorylation of Nrf2.	Dronabinol	0-3	mitogen-activated protein kinase 14	Mus musculus	65-73
24009860-10	2013	THC-induced phosphorylation of Nrf2 was blocked with SB203580, a p38 MAPK inhibitor, indicating that p38 MAPK is the responsible kinase for the phosphorylation of Nrf2.	Dronabinol	0-3	mitogen-activated protein kinase 14	Mus musculus	101-109
24009860-10	2013	THC-induced phosphorylation of Nrf2 was blocked with SB203580, a p38 MAPK inhibitor, indicating that p38 MAPK is the responsible kinase for the phosphorylation of Nrf2.	Dronabinol	0-3	nuclear factor, erythroid derived 2, like 2	Mus musculus	163-167
24009860-11	2013	Taken together, the present study for the first time demonstrates that THC exerts anti-inflammatory properties through the activation of Nrf2 in BV2 microglial cells, suggesting that THC might be a valuable therapeutic adjuvant for the treatment of inflammation-related disorders in the CNS.	Dronabinol	71-74	nuclear factor, erythroid derived 2, like 2	Mus musculus	137-141
24009860-11	2013	Taken together, the present study for the first time demonstrates that THC exerts anti-inflammatory properties through the activation of Nrf2 in BV2 microglial cells, suggesting that THC might be a valuable therapeutic adjuvant for the treatment of inflammation-related disorders in the CNS.	Dronabinol	183-186	nuclear factor, erythroid derived 2, like 2	Mus musculus	137-141
22948261-8	2013	CB1 receptor expression levels and methylation status appear to be altered in subjects with THC dependence.	Dronabinol	92-95	cannabinoid receptor 1	Homo sapiens	0-3
23535410-0	2013	Induction of the fatty acid 2-hydroxylase (FA2H) gene by Delta(9)-tetrahydrocannabinol in human breast cancer cells.	Dronabinol	57-86	fatty acid 2-hydroxylase	Homo sapiens	43-47
22796109-4	2013	Specifically, CB1 receptor agonists, such as Delta9-tetrahydrocannibinol (THC), can facilitate extinction recall by preventing recovery of extinguished fear in rats.	Dronabinol	45-72	cannabinoid receptor 1	Rattus norvegicus	14-17
22796109-4	2013	Specifically, CB1 receptor agonists, such as Delta9-tetrahydrocannibinol (THC), can facilitate extinction recall by preventing recovery of extinguished fear in rats.	Dronabinol	74-77	cannabinoid receptor 1	Rattus norvegicus	14-17
23075707-1	2012	Delta-Tetrahydrocannabinol (THC) has been characterized as a partial agonist at cannabinoid CB1 receptors in vitro; however, it often produces the same maximum effects in vivo as other cannabinoid agonists.	Dronabinol	28-31	cannabinoid receptor 1 (brain)	Mus musculus	92-95
22851303-0	2012	Differential modulation by delta9-tetrahydrocannabinol ( 9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.	Dronabinol	27-54	CD40 ligand	Mus musculus	68-79
22851303-0	2012	Differential modulation by delta9-tetrahydrocannabinol ( 9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.	Dronabinol	27-54	CD40 ligand	Mus musculus	81-86
22851303-0	2012	Differential modulation by delta9-tetrahydrocannabinol ( 9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.	Dronabinol	27-54	CD4 antigen	Mus musculus	68-71
21789506-5	2012	Furthermore, viability in CD4(+) and CD8(+) cells was reduced in a concentration-dependent manner with Delta(9)-THC, independent of CB(1) and CB(2), but no effect of Delta(9)-THC on proliferation was observed, suggesting that Delta(9)-THC decreases the number of T cells initially activated.	Dronabinol	103-115	CD4 antigen	Mus musculus	26-29
21789506-6	2012	Delta(9)-THC increased expression of the activation markers, CD69 in CD8(+) cells and CD25 in CD4(+) cells in a concentration-dependent manner in cells derived from WT and CB(1)                                   (-/-)CB(2)                                   (-/-) mice.	Dronabinol	0-12	CD69 antigen	Mus musculus	61-65
21789506-6	2012	Delta(9)-THC increased expression of the activation markers, CD69 in CD8(+) cells and CD25 in CD4(+) cells in a concentration-dependent manner in cells derived from WT and CB(1)                                   (-/-)CB(2)                                   (-/-) mice.	Dronabinol	0-12	CD4 antigen	Mus musculus	94-97
21789506-7	2012	Furthermore, Delta(9)-THC synergized with the calcium ionophore, ionomycin, to increase CD69 expression on both CD4(+) and CD8(+) cells.	Dronabinol	13-25	CD69 antigen	Mus musculus	88-92
21789506-7	2012	Furthermore, Delta(9)-THC synergized with the calcium ionophore, ionomycin, to increase CD69 expression on both CD4(+) and CD8(+) cells.	Dronabinol	13-25	CD4 antigen	Mus musculus	112-115
21789506-8	2012	In addition, without stimulation, Delta(9)-THC increased CD69 expression in CD8(+) cells from CB(1)                                   (-/-)CB(2)                                   (-/-) and WT mice.	Dronabinol	34-46	CD69 antigen	Mus musculus	57-61
22290123-0	2012	Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function.	Dronabinol	143-171	AKT serine/threonine kinase 1	Homo sapiens	95-99
22290123-0	2012	Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function.	Dronabinol	143-171	solute carrier family 6 member 3	Homo sapiens	104-108
22683090-7	2012	Selective viral-mediated knockdown of Penk in striatopallidal neurons attenuates heroin SA in adolescent THC-exposed rats, whereas Penk overexpression potentiates heroin SA in THC-naive rats.	Dronabinol	105-108	proenkephalin	Rattus norvegicus	38-42
22683090-8	2012	Furthermore, we report that adolescent THC exposure mediates Penk upregulation through reduction of histone H3 lysine 9 (H3K9) methylation in the NAcsh, thereby disrupting the normal developmental pattern of H3K9 methylation.	Dronabinol	39-42	proenkephalin	Rattus norvegicus	61-65
22683090-9	2012	CONCLUSIONS: These data establish a direct association between THC-induced NAcsh Penk upregulation and heroin SA and indicate that epigenetic dysregulation of Penk underlies the long-term effects of THC.	Dronabinol	63-66	proenkephalin	Rattus norvegicus	81-85
22683090-9	2012	CONCLUSIONS: These data establish a direct association between THC-induced NAcsh Penk upregulation and heroin SA and indicate that epigenetic dysregulation of Penk underlies the long-term effects of THC.	Dronabinol	63-66	proenkephalin	Rattus norvegicus	159-163
22683090-9	2012	CONCLUSIONS: These data establish a direct association between THC-induced NAcsh Penk upregulation and heroin SA and indicate that epigenetic dysregulation of Penk underlies the long-term effects of THC.	Dronabinol	199-202	proenkephalin	Rattus norvegicus	159-163
22899554-4	2012	THC, a marijuana-derived cannabinoid, suppressed or enhanced mouse CD8(+) T cell proliferation and the gp120-specific CTL response depending on the magnitude of the IFN-gamma response.	Dronabinol	0-3	interferon gamma	Mus musculus	165-174
22899554-6	2012	THC or CBD suppressed or enhanced IFN-gamma and IL-2 production by mouse splenocytes under optimal or suboptimal stimulation, respectively.	Dronabinol	0-3	interferon gamma	Mus musculus	34-43
22899554-6	2012	THC or CBD suppressed or enhanced IFN-gamma and IL-2 production by mouse splenocytes under optimal or suboptimal stimulation, respectively.	Dronabinol	0-3	interleukin 2	Mus musculus	48-52
22243563-2	2012	The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Delta9-tetrahydrocannabinol (THC), in healthy human subjects.	Dronabinol	183-210	opioid receptor mu 1	Homo sapiens	81-84
22243563-2	2012	The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Delta9-tetrahydrocannabinol (THC), in healthy human subjects.	Dronabinol	183-210	cannabinoid receptor 1	Homo sapiens	169-173
22243563-2	2012	The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist, Delta9-tetrahydrocannabinol (THC), in healthy human subjects.	Dronabinol	212-215	opioid receptor mu 1	Homo sapiens	81-84
22236282-10	2012	However, the peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist T0070907 dose-dependently blocked the neuroprotective, antioxidant and anti-apoptotic effects of Delta9-THC, while the PPARgamma agonist pioglitazone resulted in protection from MPP+-induced neurotoxicity.	Dronabinol	182-192	peroxisome proliferator activated receptor gamma	Homo sapiens	13-61
22236282-10	2012	However, the peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist T0070907 dose-dependently blocked the neuroprotective, antioxidant and anti-apoptotic effects of Delta9-THC, while the PPARgamma agonist pioglitazone resulted in protection from MPP+-induced neurotoxicity.	Dronabinol	182-192	peroxisome proliferator activated receptor gamma	Homo sapiens	63-72
22236282-11	2012	Furthermore, Delta9-THC increased PPARgamma expression in MPP+-treated SH-SY5Y cells, another indicator of PPARgamma activation.	Dronabinol	13-23	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
22236282-11	2012	Furthermore, Delta9-THC increased PPARgamma expression in MPP+-treated SH-SY5Y cells, another indicator of PPARgamma activation.	Dronabinol	13-23	peroxisome proliferator activated receptor gamma	Homo sapiens	107-116
22236282-12	2012	CONCLUSIONS: We have demonstrated up-regulation of the CB1 receptor in direct response to neuronal injury in a human PD cell culture model, and a direct neuronal protective effect of Delta9-THC that may be mediated through PPARgamma activation.	Dronabinol	183-193	peroxisome proliferator activated receptor gamma	Homo sapiens	223-232
22692568-1	2012	Delta9-tetrahydrocannabinol (THC), through its action on cannabinoid type-1 receptor (CB1R), is known to activate dopamine (DA) neurotransmission.	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	57-84
22692568-1	2012	Delta9-tetrahydrocannabinol (THC), through its action on cannabinoid type-1 receptor (CB1R), is known to activate dopamine (DA) neurotransmission.	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	86-90
22692568-1	2012	Delta9-tetrahydrocannabinol (THC), through its action on cannabinoid type-1 receptor (CB1R), is known to activate dopamine (DA) neurotransmission.	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	57-84
22692568-1	2012	Delta9-tetrahydrocannabinol (THC), through its action on cannabinoid type-1 receptor (CB1R), is known to activate dopamine (DA) neurotransmission.	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	86-90
22692568-2	2012	Functional evidence of a direct antagonistic interaction between CB1R and DA D2-receptors (D2R) suggests that D2R may be an important target for the modulation of DA neurotransmission by THC.	Dronabinol	187-190	cannabinoid receptor 1	Homo sapiens	65-69
22692568-2	2012	Functional evidence of a direct antagonistic interaction between CB1R and DA D2-receptors (D2R) suggests that D2R may be an important target for the modulation of DA neurotransmission by THC.	Dronabinol	187-190	dopamine receptor D2	Homo sapiens	91-94
22692568-2	2012	Functional evidence of a direct antagonistic interaction between CB1R and DA D2-receptors (D2R) suggests that D2R may be an important target for the modulation of DA neurotransmission by THC.	Dronabinol	187-190	dopamine receptor D2	Homo sapiens	110-113
22692568-3	2012	The current study evaluated, in rodents, the effects of chronic exposure to THC (1 mg/kg/day; 21 days) on D2R and D3R availabilities using the D2R-prefering antagonist and the D3R-preferring agonist radiotracers [18F]fallypride and [3H]-(+)-PHNO, respectively.	Dronabinol	76-79	dopamine receptor D2	Homo sapiens	106-109
22692568-4	2012	At 24 h after the last THC dose, D2R and D3R densities were significantly increased in midbrain.	Dronabinol	23-26	dopamine receptor D2	Homo sapiens	33-36
22692568-5	2012	In caudate/putamen (CPu), THC exposure was associated with increased densities of D2R with no change in D2R mRNA expression, whereas in nucleus accumbens (NAcc) both D3R binding and mRNA levels were upregulated.	Dronabinol	26-29	dopamine receptor D2	Homo sapiens	82-85
22492781-2	2012	Ajulemic acid (AjA) is a non-psychoactive synthetic analogue of tetrahydrocannabinol that can bind the peroxisome proliferator-activated receptor-gamma (PPAR-gamma).	Dronabinol	64-84	peroxisome proliferator activated receptor gamma	Homo sapiens	103-151
22492781-2	2012	Ajulemic acid (AjA) is a non-psychoactive synthetic analogue of tetrahydrocannabinol that can bind the peroxisome proliferator-activated receptor-gamma (PPAR-gamma).	Dronabinol	64-84	peroxisome proliferator activated receptor gamma	Homo sapiens	153-163
22772336-5	2012	The nonselective CB1 receptor agonists Delta9-THC, CP55,940 and Win 55,212-2 increased the number of licks for condensed milk, primarily by a significant increase in bout number.	Dronabinol	39-49	cannabinoid receptor 1 (brain)	Mus musculus	17-20
22821081-0	2012	Long-term behavioral and biochemical effects of an ultra-low dose of Delta9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling.	Dronabinol	69-96	mitogen-activated protein kinase 1	Mus musculus	124-127
22821081-0	2012	Long-term behavioral and biochemical effects of an ultra-low dose of Delta9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling.	Dronabinol	98-101	mitogen-activated protein kinase 1	Mus musculus	124-127
22821081-4	2012	The same ultra-low dose of THC (0.002 mg/kg, a dose that is 3-4 orders of magnitude lower than the doses that produce the known acute effects of the drug in mice) induced long-lasting (7 weeks) modifications of extracellular signal-regulated kinase (ERK) activity in the hippocampus, frontal cortex and cerebellum of the mice.	Dronabinol	27-30	mitogen-activated protein kinase 1	Mus musculus	211-248
22821081-4	2012	The same ultra-low dose of THC (0.002 mg/kg, a dose that is 3-4 orders of magnitude lower than the doses that produce the known acute effects of the drug in mice) induced long-lasting (7 weeks) modifications of extracellular signal-regulated kinase (ERK) activity in the hippocampus, frontal cortex and cerebellum of the mice.	Dronabinol	27-30	mitogen-activated protein kinase 1	Mus musculus	250-253
22821081-6	2012	Furthermore, a single treatment with the low dose of THC elevated the level of pCREB (phosphorylated cAMP response element-binding protein) in the hippocampus and the level of BDNF (brain-derived neurotrophic factor) in the frontal cortex.	Dronabinol	53-56	brain derived neurotrophic factor	Mus musculus	176-180
22821081-6	2012	Furthermore, a single treatment with the low dose of THC elevated the level of pCREB (phosphorylated cAMP response element-binding protein) in the hippocampus and the level of BDNF (brain-derived neurotrophic factor) in the frontal cortex.	Dronabinol	53-56	brain derived neurotrophic factor	Mus musculus	182-215
22552780-1	2012	Marijuana cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) have been shown in experimental systems to bias T helper immunity towards Th2 and away from Th1.	Dronabinol	31-60	heart and neural crest derivatives expressed 2	Mus musculus	141-144
22552780-1	2012	Marijuana cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) have been shown in experimental systems to bias T helper immunity towards Th2 and away from Th1.	Dronabinol	31-60	negative elongation factor complex member C/D, Th1l	Mus musculus	159-162
22552780-1	2012	Marijuana cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) have been shown in experimental systems to bias T helper immunity towards Th2 and away from Th1.	Dronabinol	62-65	heart and neural crest derivatives expressed 2	Mus musculus	141-144
22552780-1	2012	Marijuana cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) have been shown in experimental systems to bias T helper immunity towards Th2 and away from Th1.	Dronabinol	62-65	negative elongation factor complex member C/D, Th1l	Mus musculus	159-162
22552780-6	2012	Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a.	Dronabinol	24-27	cannabinoid receptor 2 (macrophage)	Mus musculus	141-163
22552780-6	2012	Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a.	Dronabinol	24-27	cannabinoid receptor 2 (macrophage)	Mus musculus	165-168
22552780-6	2012	Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a.	Dronabinol	24-27	cannabinoid receptor 1 (brain)	Mus musculus	174-196
22552780-6	2012	Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a.	Dronabinol	24-27	cannabinoid receptor 1 (brain)	Mus musculus	198-201
22552780-6	2012	Our results showed that THC injection enhanced total IgE serum levels in response to antigen immunization even under conditions of deficient cannabinoid receptor 2 (CB2) and cannabinoid receptor 1 (CB1) activity and furthermore the increase in IgE was accompanied by a decrease in serum IgG2a.	Dronabinol	24-27	immunoglobulin heavy variable V1-9	Mus musculus	287-292
22552780-8	2012	These results suggest that in this IgE induction model in mice, non-selective cannabinoids such as THC increase IgE through receptors other than CB1 and CB2 but that CB2 receptors do play a suppressive role in the control of serum IgE levels.	Dronabinol	99-102	cannabinoid receptor 2 (macrophage)	Mus musculus	153-156
22718500-4	2012	One potential explanation for atypical effects is CB1 receptor agonist efficacy, which is reportedly higher for JWH-018 and JWH-073 compared with Delta9-THC.	Dronabinol	146-156	cannabinoid receptor 1	Macaca mulatta	50-53
22718500-8	2012	(1R,3R,4R)-3-[2-Hydroxy-4-(1,1-dimethylheptyl) phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol (CP-55,940), a prototype high-efficacy CB1 receptor agonist, JWH-018, and JWH-073 substituted for the discriminative stimulus effects of Delta9-THC.	Dronabinol	227-237	cannabinoid receptor 1	Macaca mulatta	129-132
22718500-12	2012	The greater loss of sensitivity to Delta9-THC relative to CP-55,940 and JWH-018 suggests that differences in CB1 receptor agonist efficacy are important in vivo and might underlie differences in the dependence liability and adverse effects of synthetic CBs versus cannabis.	Dronabinol	35-45	cannabinoid receptor 1	Macaca mulatta	109-112
22705493-7	2012	In contrast to the hippocampus, chronic Delta9-THC selectively increased p-CREB in the OVX/saline group in the striatum.	Dronabinol	40-50	cAMP responsive element binding protein 1	Rattus norvegicus	75-79
22634064-8	2012	In intact animals, chronic THC increased brain derived neurotrophic factor (BDNF) expression levels in the hippocampus and frontal cortex but rimonabant had no effect.	Dronabinol	27-30	brain-derived neurotrophic factor	Rattus norvegicus	41-74
22634064-8	2012	In intact animals, chronic THC increased brain derived neurotrophic factor (BDNF) expression levels in the hippocampus and frontal cortex but rimonabant had no effect.	Dronabinol	27-30	brain-derived neurotrophic factor	Rattus norvegicus	76-80
22658658-5	2012	Under optimal conditions, limits of detection at low nanograms per liter were achieved (1.0 and 2.5 ng L-1 for THC and THCCOOH respectively).	Dronabinol	111-114	immunoglobulin kappa variable 1-16	Homo sapiens	103-106
22434221-0	2012	Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways.	Dronabinol	31-59	catechol-O-methyltransferase	Mus musculus	63-67
22434221-4	2012	Male mice with knockout of the COMT gene were treated chronically with delta-9-tetrahydrocannabinol (THC) during adolescence (postnatal day 32-52).	Dronabinol	71-99	catechol-O-methyltransferase	Mus musculus	31-35
22434221-7	2012	COMT genotype x THC treatment interactions were observed for: (1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC.	Dronabinol	16-19	catechol-O-methyltransferase	Mus musculus	0-4
22434221-7	2012	COMT genotype x THC treatment interactions were observed for: (1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC.	Dronabinol	16-19	cannabinoid receptor 1 (brain)	Mus musculus	105-109
22434221-7	2012	COMT genotype x THC treatment interactions were observed for: (1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC.	Dronabinol	16-19	parvalbumin	Mus musculus	149-160
22434221-9	2012	COMT genotype modulates the effects of chronic THC administration during adolescence on indices of neurotransmitter function in the brain.	Dronabinol	47-50	catechol-O-methyltransferase	Mus musculus	0-4
22894054-8	2012	The discriminative effects of synthetic cannabinoids may overlap with the delta 9-THC cue mediated by CB1 receptors.	Dronabinol	74-85	cannabinoid receptor 1 (brain)	Mus musculus	102-105
22623656-8	2012	The CB1 receptor agonist Delta9-tetrahydrocannabinol exerted a biphasic control of fear coping strategies, with lower and higher doses favoring active and passive responses, respectively.	Dronabinol	25-52	cannabinoid receptor 1 (brain)	Mus musculus	4-7
22860205-0	2012	Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.	Dronabinol	78-81	fatty acid amide hydrolase	Mus musculus	16-31
22860205-0	2012	Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.	Dronabinol	78-81	monoglyceride lipase	Mus musculus	36-59
22860205-4	2012	Previous research demonstrated that simultaneous, complete blockade of FAAH and MAGL produces full blown THC-like effects.	Dronabinol	105-108	fatty acid amide hydrolase	Mus musculus	71-75
22860205-4	2012	Previous research demonstrated that simultaneous, complete blockade of FAAH and MAGL produces full blown THC-like effects.	Dronabinol	105-108	monoglyceride lipase	Mus musculus	80-84
22264443-8	2012	betaarr2-KO mice exhibited enhanced acute THC-mediated antinociception and hypothermia, with no difference in catalepsy.	Dronabinol	42-45	arrestin, beta 2	Mus musculus	0-8
22264443-9	2012	After repeated THC administration, betaarr2-KO mice showed reduced CB(1)R desensitization and/or downregulation in cerebellum, caudal periaqueductal gray, and spinal cord and attenuated tolerance to THC-mediated antinociception.	Dronabinol	15-18	arrestin, beta 2	Mus musculus	35-43
22264443-9	2012	After repeated THC administration, betaarr2-KO mice showed reduced CB(1)R desensitization and/or downregulation in cerebellum, caudal periaqueductal gray, and spinal cord and attenuated tolerance to THC-mediated antinociception.	Dronabinol	15-18	cannabinoid receptor 1 (brain)	Mus musculus	67-73
22264443-9	2012	After repeated THC administration, betaarr2-KO mice showed reduced CB(1)R desensitization and/or downregulation in cerebellum, caudal periaqueductal gray, and spinal cord and attenuated tolerance to THC-mediated antinociception.	Dronabinol	199-202	arrestin, beta 2	Mus musculus	35-43
22264443-11	2012	Enhanced tolerance to THC-induced catalepsy was observed in betaarr2-KO mice.	Dronabinol	22-25	arrestin, beta 2	Mus musculus	60-68
22264443-12	2012	CONCLUSIONS: beta-arrestin2 regulation of CB(1)R signaling following acute and repeated THC administration was region-specific, and results suggest that multiple, overlapping mechanisms regulate CB(1)Rs.	Dronabinol	88-91	arrestin, beta 2	Mus musculus	13-27
22264443-12	2012	CONCLUSIONS: beta-arrestin2 regulation of CB(1)R signaling following acute and repeated THC administration was region-specific, and results suggest that multiple, overlapping mechanisms regulate CB(1)Rs.	Dronabinol	88-91	cannabinoid receptor 1 (brain)	Mus musculus	42-48
22264443-13	2012	The observations that betaarr2-KO mice display enhanced antinociceptive responses to acute THC and decreased tolerance to the antinociceptive effects of the drug, yet enhanced tolerance to catalepsy, suggest that development of cannabinoid drugs that minimize CB(1)R interactions with beta-arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression.	Dronabinol	91-94	arrestin, beta 2	Mus musculus	22-30
21506952-3	2012	Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Delta(9) -tetrahydrocannabinol (THC).	Dronabinol	179-209	fatty acid amide hydrolase	Mus musculus	33-59
21506952-3	2012	Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Delta(9) -tetrahydrocannabinol (THC).	Dronabinol	179-209	fatty acid amide hydrolase	Mus musculus	61-65
21506952-3	2012	Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Delta(9) -tetrahydrocannabinol (THC).	Dronabinol	211-214	fatty acid amide hydrolase	Mus musculus	33-59
21506952-3	2012	Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Delta(9) -tetrahydrocannabinol (THC).	Dronabinol	211-214	fatty acid amide hydrolase	Mus musculus	61-65
21595653-0	2012	Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.	Dronabinol	0-30	G protein-coupled receptor 18	Homo sapiens	78-83
21595653-0	2012	Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.	Dronabinol	0-30	NDC80 kinetochore complex component	Homo sapiens	136-141
21595653-9	2012	MAPK activation in HEK293-GPR18 cells revealed novel pharmacology for known CB(1) and CB(2) receptor ligands at GPR18 receptors, including Delta(9) -THC, which activates MAPK at nanomolar concentrations, whereas WIN 55212-2, CP55940, JWH-133 and JWH-015, and arachidonyl-1-hydroxy-2-propylamide (R1-methanandamide) had no effect.	Dronabinol	139-152	G protein-coupled receptor 18	Homo sapiens	26-31
21595653-9	2012	MAPK activation in HEK293-GPR18 cells revealed novel pharmacology for known CB(1) and CB(2) receptor ligands at GPR18 receptors, including Delta(9) -THC, which activates MAPK at nanomolar concentrations, whereas WIN 55212-2, CP55940, JWH-133 and JWH-015, and arachidonyl-1-hydroxy-2-propylamide (R1-methanandamide) had no effect.	Dronabinol	139-152	G protein-coupled receptor 18	Homo sapiens	112-117
22014238-1	2012	BACKGROUND AND PURPOSE: Cannabinoids such as Delta(9) - tetrahydrocannabinol, the major psychoactive component of marijuana and hashish, primarily act via cannabinoid CB(1) and CB(2) receptors to produce characteristic behavioural effects in humans.	Dronabinol	45-76	cannabinoid receptor 1	Homo sapiens	167-172
22006184-7	2012	The ERbeta-selective antagonist THC reversed these changes.	Dronabinol	32-35	estrogen receptor 2	Homo sapiens	4-10
22563255-3	2012	THC significantly suppressed LPS-induced excessive production of nitric oxide (NO) and expression of iNOS, which is responsible for the production of iNOS.	Dronabinol	0-3	nitric oxide synthase 2, inducible	Mus musculus	101-105
22563255-3	2012	THC significantly suppressed LPS-induced excessive production of nitric oxide (NO) and expression of iNOS, which is responsible for the production of iNOS.	Dronabinol	0-3	nitric oxide synthase 2, inducible	Mus musculus	150-154
22563255-4	2012	THC also suppressed LPS-induced overproduction of pro-inflammatory cytokines such as IL-1beta and TNF-alpha in BV2 microgilal cells.	Dronabinol	0-3	interleukin 1 beta	Mus musculus	85-93
22563255-4	2012	THC also suppressed LPS-induced overproduction of pro-inflammatory cytokines such as IL-1beta and TNF-alpha in BV2 microgilal cells.	Dronabinol	0-3	tumor necrosis factor	Mus musculus	98-107
22563255-5	2012	Furthermore, THC significantly suppressed LPS-induced degradation of IkappaB, which retains NF-kappaB in the cytoplasm.	Dronabinol	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-101
22563255-6	2012	Therefore, THC attenuated nuclear translocation of NF-kappaB, a major pro-inflammatory transcription factor.	Dronabinol	11-14	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	51-60
22563255-7	2012	Taken together, the present study for the first time demonstrates that THC exhibits anti-inflammatory activity through the suppression of NF-kappaB transcriptional activation in LPS-stimulated BV2 microglial cells.	Dronabinol	71-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-147
21726418-1	2012	AIM: Plant cannabinoids, like Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), activate/desensitize thermosensitive transient receptor potential (TRP) channels of vanilloid type-1 or -2 (TRPV1 or TRPV2).	Dronabinol	30-59	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	197-202
21726418-1	2012	AIM: Plant cannabinoids, like Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), activate/desensitize thermosensitive transient receptor potential (TRP) channels of vanilloid type-1 or -2 (TRPV1 or TRPV2).	Dronabinol	30-59	transient receptor potential cation channel, subfamily V, member 2	Mus musculus	206-211
21726418-1	2012	AIM: Plant cannabinoids, like Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), activate/desensitize thermosensitive transient receptor potential (TRP) channels of vanilloid type-1 or -2 (TRPV1 or TRPV2).	Dronabinol	61-64	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	197-202
21726418-1	2012	AIM: Plant cannabinoids, like Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), activate/desensitize thermosensitive transient receptor potential (TRP) channels of vanilloid type-1 or -2 (TRPV1 or TRPV2).	Dronabinol	61-64	transient receptor potential cation channel, subfamily V, member 2	Mus musculus	206-211
22189757-6	2012	We also showed that THC induced macrophage infiltration and increased expression of the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) in adipose tissue but did not induce apoptosis as measured by TUNEL staining.	Dronabinol	20-23	tumor necrosis factor	Rattus norvegicus	139-148
22189757-5	2012	However, THC promoted adipocyte hypertrophy that was accompanied by a significant increase in cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) expression, an enzyme important in packaging triglycerides.	Dronabinol	9-12	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	139-146
22189757-6	2012	We also showed that THC induced macrophage infiltration and increased expression of the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) in adipose tissue but did not induce apoptosis as measured by TUNEL staining.	Dronabinol	20-23	tumor necrosis factor	Rattus norvegicus	110-137
22076597-5	2012	Our study evaluated immunological and clinical data on a cohort of 28 Argentinean pediatric CVID patients and allowed the identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain.	Dronabinol	227-230	TNF receptor superfamily member 13B	Homo sapiens	163-172
21603976-4	2012	In this study, we used the neuroblastoma SH-SY5Y cell line to investigate the effect of delta-9-tetrahydrocannabinol ( (9)-THC) on nociceptin/NOP system.	Dronabinol	88-116	prepronociceptin	Homo sapiens	131-141
21603976-4	2012	In this study, we used the neuroblastoma SH-SY5Y cell line to investigate the effect of delta-9-tetrahydrocannabinol ( (9)-THC) on nociceptin/NOP system.	Dronabinol	88-116	prepronociceptin	Homo sapiens	142-145
22846875-10	2012	CONCLUSIONS: Orexin might be a possible target in THC as well as nicotine dependence, taking into account the effect of THC on energy homeostasis in the circuit of reward and motivation and its impact on appetite and body weight.	Dronabinol	50-53	hypocretin neuropeptide precursor	Homo sapiens	13-19
22846875-10	2012	CONCLUSIONS: Orexin might be a possible target in THC as well as nicotine dependence, taking into account the effect of THC on energy homeostasis in the circuit of reward and motivation and its impact on appetite and body weight.	Dronabinol	120-123	hypocretin neuropeptide precursor	Homo sapiens	13-19
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	51-80	latexin	Homo sapiens	100-103
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	51-80	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	51-80	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	82-94	latexin	Homo sapiens	100-103
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
22814029-5	2012	RESULTS: We showed that both cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (10 muM) transiently induced the MDR1 transcript in P-gp overexpressing cells at 4 but not 8 or 48 h incubation durations.	Dronabinol	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
22814029-6	2012	CBD and THC also concomitantly increased P-gp activity as measured by reduced accumulation of the P-gp substrate Rhodamine 123 in these cells with a maximal inhibitory effect observed at 4 h that slowly diminished by 48 h. CEM/VLB(100) cell lines were shown to express CB(2) and TRPV(1) receptors.	Dronabinol	8-11	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
22814029-6	2012	CBD and THC also concomitantly increased P-gp activity as measured by reduced accumulation of the P-gp substrate Rhodamine 123 in these cells with a maximal inhibitory effect observed at 4 h that slowly diminished by 48 h. CEM/VLB(100) cell lines were shown to express CB(2) and TRPV(1) receptors.	Dronabinol	8-11	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
22814029-6	2012	CBD and THC also concomitantly increased P-gp activity as measured by reduced accumulation of the P-gp substrate Rhodamine 123 in these cells with a maximal inhibitory effect observed at 4 h that slowly diminished by 48 h. CEM/VLB(100) cell lines were shown to express CB(2) and TRPV(1) receptors.	Dronabinol	8-11	transient receptor potential cation channel subfamily V member 1	Homo sapiens	279-286
22536451-0	2012	Enhanced brain disposition and effects of Delta9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.	Dronabinol	42-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-124
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	46-75	phosphoglycolate phosphatase	Mus musculus	99-103
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	46-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	77-80	phosphoglycolate phosphatase	Mus musculus	99-103
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	77-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Dronabinol	76-79	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-45
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Dronabinol	76-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
22536451-6	2012	Brain THC concentrations were higher in both Abcb1a/b (-/-) and Abcg2 (-/-) mice than WT mice.	Dronabinol	6-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	45-51
22536451-6	2012	Brain THC concentrations were higher in both Abcb1a/b (-/-) and Abcg2 (-/-) mice than WT mice.	Dronabinol	6-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
22536451-7	2012	ABC transporter knockout mice exhibited delayed elimination of THC from the brain with the effect being more prominent in Abcg2 (-/-) mice.	Dronabinol	63-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
22536451-9	2012	These results show P-gp and Bcrp prolong the brain disposition and hypothermic effects of THC and offer a novel mechanism for both genetic vulnerability to the psychoactive effects of cannabis and drug interactions between CNS therapies and cannabis.	Dronabinol	90-93	phosphoglycolate phosphatase	Mus musculus	19-23
22536451-9	2012	These results show P-gp and Bcrp prolong the brain disposition and hypothermic effects of THC and offer a novel mechanism for both genetic vulnerability to the psychoactive effects of cannabis and drug interactions between CNS therapies and cannabis.	Dronabinol	90-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-32
22509273-2	2012	We have previously shown that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol.	Dronabinol	183-212	neuregulin 1	Mus musculus	51-63
22509273-2	2012	We have previously shown that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol.	Dronabinol	183-212	neuregulin 1	Mus musculus	72-76
21484257-0	2011	Chronic Delta-9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques.	Dronabinol	8-36	C-X-C motif chemokine receptor 4	Macaca mulatta	73-78
21484257-2	2011	We have recently demonstrated that chronic Delta-9-tetrahydrocannabinol (THC; 0.32 mg/kg i.m., BID) decreased early mortality in rhesus macaques infected with simian immunodeficiency virus (SIV).	Dronabinol	43-71	BH3 interacting domain death agonist	Macaca mulatta	95-98
21484257-2	2011	We have recently demonstrated that chronic Delta-9-tetrahydrocannabinol (THC; 0.32 mg/kg i.m., BID) decreased early mortality in rhesus macaques infected with simian immunodeficiency virus (SIV).	Dronabinol	73-76	BH3 interacting domain death agonist	Macaca mulatta	95-98
21484257-7	2011	However, chronic THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes compared to control.	Dronabinol	17-20	C-X-C motif chemokine receptor 4	Macaca mulatta	44-49
21735070-6	2011	Using a mouse BV-2 microglial-like cell model, it was demonstrated that the exogenous cannabinoids Delta-9-tetrahydrocannabinol (THC) and CP55940 exerted a concentration-related reduction in the migration of BV-2 cells towards Tat.	Dronabinol	99-127	tyrosine aminotransferase	Mus musculus	227-230
21735070-6	2011	Using a mouse BV-2 microglial-like cell model, it was demonstrated that the exogenous cannabinoids Delta-9-tetrahydrocannabinol (THC) and CP55940 exerted a concentration-related reduction in the migration of BV-2 cells towards Tat.	Dronabinol	129-132	tyrosine aminotransferase	Mus musculus	227-230
21884703-2	2011	THC activates central cannabinoid-1 receptors (CB1) with subsequent psychoactive effects as well as peripheral cannabinoid-2 receptors (CB2).	Dronabinol	0-3	cannabinoid receptor 1 (brain)	Mus musculus	47-50
21884703-2	2011	THC activates central cannabinoid-1 receptors (CB1) with subsequent psychoactive effects as well as peripheral cannabinoid-2 receptors (CB2).	Dronabinol	0-3	cannabinoid receptor 2 (macrophage)	Mus musculus	136-139
21763331-8	2011	THC additionally attenuated MDMA -induced decreases in 5-HT levels and in SERT binding in the frontal cortex, parietal cortex, and striatum, but not in the hippocampus.	Dronabinol	0-3	solute carrier family 6 member 4	Rattus norvegicus	74-78
21803011-11	2011	Dronabinol affected fasting distal MI in patients, regardless of FAAH rs324420 variant (CA/AA vs CC) (P = .046); the greatest effects were observed among IBS with constipation patients with the FAAH CC variant (P = .045).	Dronabinol	0-10	fatty acid amide hydrolase	Homo sapiens	194-198
21803011-12	2011	Dronabinol affected fasting proximal MI in patients with IBS with diarrhea or alternating with the variant FAAH CA/AA (P = .013).	Dronabinol	0-10	fatty acid amide hydrolase	Homo sapiens	107-111
21831965-5	2011	These outcomes were reversed by CB1/CB2 antagonists, suggesting that THC-mediated these effects through cannabinoid receptors.	Dronabinol	69-72	cannabinoid receptor 1 (brain)	Mus musculus	32-35
21831965-5	2011	These outcomes were reversed by CB1/CB2 antagonists, suggesting that THC-mediated these effects through cannabinoid receptors.	Dronabinol	69-72	cannabinoid receptor 2 (macrophage)	Mus musculus	36-39
21820648-8	2011	Chromatin immunoprecipitation of the adult NAc revealed increased 2meH3K9 repressive mark and decreased 3meH3K4 and RNA polymerase II at the Drd2 gene locus in the THC-exposed offspring.	Dronabinol	164-167	dopamine receptor D2	Homo sapiens	141-145
21795705-1	2011	The classical cannabinoid agonist HU210, a structural analog of (-)-Delta(9)-tetrahydrocannabinol, binds to brain cannabinoid (CB1) receptors and activates signal transduction pathways.	Dronabinol	64-97	cannabinoid receptor 1	Homo sapiens	127-130
21674569-4	2011	The administration of Delta(9)-THC- and CBD-enriched botanical extracts combined in a ratio of 1:1 as in Sativex attenuated 3NP-induced GABA deficiency, loss of Nissl-stained neurons, down-regulation of CB(1) receptor and IGF-1 expression, and up-regulation of calpain expression, whereas it completely reversed the reduction in superoxide dismutase-1 expression.	Dronabinol	22-34	insulin-like growth factor 1	Rattus norvegicus	222-227
21674569-5	2011	Similar responses were generally found with other combinations of Delta(9)-THC- and CBD-enriched botanical extracts, suggesting that these effects are probably related to the antioxidant and CB(1) and CB(2) receptor-independent properties of both phytocannabinoids.	Dronabinol	75-78	cannabinoid receptor 1	Rattus norvegicus	191-196
21781118-0	2011	Delta9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use.	Dronabinol	0-10	activator of HSP90 ATPase activity 1	Homo sapiens	32-36
21781118-0	2011	Delta9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use.	Dronabinol	0-10	cannabinoid receptor 1	Rattus norvegicus	83-86
21781118-5	2011	AHA1 over-expression also enhanced cell surface levels of endogenous CB1R and the effects of Delta9-THC on the cAMP levels in Neuro-2A cells.	Dronabinol	93-103	activator of HSP90 ATPase activity 1	Homo sapiens	0-4
21781118-7	2011	Our data indicate that chronic Delta9-THC administration in adolescence altered the endogenous levels of specialized proteins in the cerebellum, such as AHA1, and that this protein can change CB1R cell surface levels and signaling.	Dronabinol	31-41	activator of HSP90 ATPase activity 1	Homo sapiens	153-157
21781118-7	2011	Our data indicate that chronic Delta9-THC administration in adolescence altered the endogenous levels of specialized proteins in the cerebellum, such as AHA1, and that this protein can change CB1R cell surface levels and signaling.	Dronabinol	31-41	cannabinoid receptor 1 (brain)	Mus musculus	192-196
21673072-7	2011	THC treatment reduced the expansion of donor-derived effector T cells and blocked the killing of host-derived immune cells while promoting Foxp3(+) regulatory T cells.	Dronabinol	0-3	forkhead box P3	Homo sapiens	139-144
21673072-9	2011	The ability of THC to reduce the clinical GVHD was reversed, at least in part, by administration of cannabinoid receptor (CB) 1 and CB2 antagonists, thereby demonstrating that THC-mediated amelioration of GVHD was cannabinoid receptor-dependent.	Dronabinol	15-18	cannabinoid receptor 1	Homo sapiens	100-127
21673072-9	2011	The ability of THC to reduce the clinical GVHD was reversed, at least in part, by administration of cannabinoid receptor (CB) 1 and CB2 antagonists, thereby demonstrating that THC-mediated amelioration of GVHD was cannabinoid receptor-dependent.	Dronabinol	15-18	cannabinoid receptor 2	Homo sapiens	132-135
21673072-9	2011	The ability of THC to reduce the clinical GVHD was reversed, at least in part, by administration of cannabinoid receptor (CB) 1 and CB2 antagonists, thereby demonstrating that THC-mediated amelioration of GVHD was cannabinoid receptor-dependent.	Dronabinol	176-179	cannabinoid receptor 1	Homo sapiens	100-127
21673072-9	2011	The ability of THC to reduce the clinical GVHD was reversed, at least in part, by administration of cannabinoid receptor (CB) 1 and CB2 antagonists, thereby demonstrating that THC-mediated amelioration of GVHD was cannabinoid receptor-dependent.	Dronabinol	176-179	cannabinoid receptor 2	Homo sapiens	132-135
21867498-12	2011	In contrast, a sub-chronic in vivo treatment with Delta9-THC once daily for 7 seven days had no effect on Cyp1b1 expression CONCLUSIONS: Our results show that TCDD and DEP strongly induced Cyp1b1 in rat brain microvessels, likely through AhR activation.	Dronabinol	50-60	cytochrome P450, family 1, subfamily b, polypeptide 1	Rattus norvegicus	189-195
21541653-6	2011	Selective ERalpha blockade with methyl piperidinopyrazole (MPP) led to a significant reduction in both proliferation and differentiation, while ERbeta blockade with R,R tetrahydrochrysene (THC) led to an increase in these parameters.	Dronabinol	189-192	estrogen receptor 2	Homo sapiens	144-150
21054689-4	2011	A low dose of the selective adenosine A(2A) receptor antagonist MSX-3 (1 mg/kg) caused downward shifts of THC and anandamide dose-response curves.	Dronabinol	106-109	msh homeobox 3	Rattus norvegicus	64-69
21054689-5	2011	In contrast, a higher dose of MSX-3 (3 mg/kg) shifted THC and anandamide dose-response curves to the left.	Dronabinol	54-57	msh homeobox 3	Rattus norvegicus	30-35
21054689-8	2011	Finally, using in vivo microdialysis in freely-moving rats, a behaviorally active dose of MSX-3 significantly counteracted THC-induced, but not cocaine-induced, increases in extracellular dopamine levels in the nucleus accumbens shell.	Dronabinol	123-126	msh homeobox 3	Rattus norvegicus	90-95
21475304-5	2011	We found that Delta(9)-tetrahydrocannabinol (Delta(9)-THC, the main active component of Cannabis sativa) and JWH-015 (a cannabinoid receptor 2 (CB(2)) cannabinoid receptor-selective agonist) reduced the viability of the human HCC cell lines HepG2 (human hepatocellular liver carcinoma cell line) and HuH-7 (hepatocellular carcinoma cells), an effect that relied on the stimulation of CB(2) receptor.	Dronabinol	14-43	MIR7-3 host gene	Homo sapiens	300-305
21475304-6	2011	We also found that Delta(9)-THC- and JWH-015-induced autophagy relies on tribbles homolog 3 (TRB3) upregulation, and subsequent inhibition of the serine-threonine kinase Akt/mammalian target of rapamycin C1 axis and adenosine monophosphate-activated kinase (AMPK) stimulation.	Dronabinol	19-31	tribbles pseudokinase 3	Homo sapiens	73-91
21475304-6	2011	We also found that Delta(9)-THC- and JWH-015-induced autophagy relies on tribbles homolog 3 (TRB3) upregulation, and subsequent inhibition of the serine-threonine kinase Akt/mammalian target of rapamycin C1 axis and adenosine monophosphate-activated kinase (AMPK) stimulation.	Dronabinol	19-31	tribbles pseudokinase 3	Homo sapiens	93-97
21475304-6	2011	We also found that Delta(9)-THC- and JWH-015-induced autophagy relies on tribbles homolog 3 (TRB3) upregulation, and subsequent inhibition of the serine-threonine kinase Akt/mammalian target of rapamycin C1 axis and adenosine monophosphate-activated kinase (AMPK) stimulation.	Dronabinol	19-31	AKT serine/threonine kinase 1	Homo sapiens	170-173
21475304-6	2011	We also found that Delta(9)-THC- and JWH-015-induced autophagy relies on tribbles homolog 3 (TRB3) upregulation, and subsequent inhibition of the serine-threonine kinase Akt/mammalian target of rapamycin C1 axis and adenosine monophosphate-activated kinase (AMPK) stimulation.	Dronabinol	19-31	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	216-256
21475304-6	2011	We also found that Delta(9)-THC- and JWH-015-induced autophagy relies on tribbles homolog 3 (TRB3) upregulation, and subsequent inhibition of the serine-threonine kinase Akt/mammalian target of rapamycin C1 axis and adenosine monophosphate-activated kinase (AMPK) stimulation.	Dronabinol	19-31	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	258-262
21315768-7	2011	Biochemical studies indicated a concomitant reduction in phosphorylated-ERK (extracellular signal-regulated kinase) in the cerebella of mice 7 weeks following the injection of THC.	Dronabinol	176-179	mitogen-activated protein kinase 1	Mus musculus	72-75
21477640-2	2011	While most THC-induced behavioral effects are thought to depend on endogenous cannabinoid 1 (CB1) receptors, the molecular targets for CBD remain unclear.	Dronabinol	11-14	cannabinoid receptor 1	Homo sapiens	93-96
21477640-3	2011	Here, we report that CBD and THC inhibited the function of human 5-HT(3A) receptors (h5-HT(3A)Rs) expressed in HEK 293 cells.	Dronabinol	29-32	5-hydroxytryptamine receptor 3A	Homo sapiens	65-72
21512341-9	2011	Rimonabant (CB1 antagonist; 3 mg/kg) reversed all Delta9-THC and URB-597 effects on auditory discriminations and olfactory discrimination reversals.	Dronabinol	50-60	cannabinoid receptor 1	Rattus norvegicus	12-15
21233844-6	2011	Furthermore, in vivo Mdk silencing or ALK pharmacological inhibition sensitizes cannabinod-resistant tumors to THC antitumoral action.	Dronabinol	111-114	midkine	Homo sapiens	21-24
21233844-6	2011	Furthermore, in vivo Mdk silencing or ALK pharmacological inhibition sensitizes cannabinod-resistant tumors to THC antitumoral action.	Dronabinol	111-114	ALK receptor tyrosine kinase	Homo sapiens	38-41
21233844-7	2011	Altogether, our findings identify Mdk as a pivotal factor involved in the resistance of glioma cells to THC pro-autophagic and antitumoral action, and suggest that selective targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas.	Dronabinol	104-107	midkine	Homo sapiens	34-37
21233844-7	2011	Altogether, our findings identify Mdk as a pivotal factor involved in the resistance of glioma cells to THC pro-autophagic and antitumoral action, and suggest that selective targeting of the Mdk/ALK axis could help to improve the efficacy of antitumoral therapies for gliomas.	Dronabinol	104-107	ALK receptor tyrosine kinase	Homo sapiens	195-198
21557446-0	2011	Binding of delta9-tetrahydrocannabinol and diazepam to human serum albumin.	Dronabinol	11-38	albumin	Homo sapiens	61-74
21513772-3	2011	As previously reported, both acute oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive constituent of cannabis, and standardized cannabis extract containing Delta(9)-THC and cannabidiol (CBD) revealed a significant reduction of P300 amplitudes in healthy subjects but did not show any differences among each other.	Dronabinol	40-69	E1A binding protein p300	Homo sapiens	249-253
21513772-4	2011	The aim of this study was to investigate whether the (AAT)n polymorphism differentially modulates the effects of Delta(9)-THC and cannabis extract on P300 generation in 20 healthy volunteers during an auditory choice reaction task.	Dronabinol	113-125	serpin family A member 1	Homo sapiens	54-57
21513772-4	2011	The aim of this study was to investigate whether the (AAT)n polymorphism differentially modulates the effects of Delta(9)-THC and cannabis extract on P300 generation in 20 healthy volunteers during an auditory choice reaction task.	Dronabinol	113-125	E1A binding protein p300	Homo sapiens	150-154
21513772-5	2011	For the &gt;10/&gt;10 genotype, there was a significant decrease of P300 amplitude as well as a significant prolongation of P300 latency under pure Delta(9)-THC but not under cannabis extract.	Dronabinol	148-160	E1A binding protein p300	Homo sapiens	124-128
20101600-1	2011	Both natural and synthetic cannabinoid receptor (e.g., CB1) agonists such as Delta(9)-THC, WIN 55,212-2 (WIN-2), and HU-210 disrupt spatial cognition presumably through the inhibition of synchrony of hippocampal ensemble firing to task-related events.	Dronabinol	77-89	cannabinoid receptor 1	Rattus norvegicus	55-58
21356216-5	2011	The IC(50) values of Delta(9)-THC and CBN for CYP3A4 and CYP3A5 were higher than 35 muM.	Dronabinol	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
21356216-5	2011	The IC(50) values of Delta(9)-THC and CBN for CYP3A4 and CYP3A5 were higher than 35 muM.	Dronabinol	21-33	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	57-63
21356216-5	2011	The IC(50) values of Delta(9)-THC and CBN for CYP3A4 and CYP3A5 were higher than 35 muM.	Dronabinol	21-33	latexin	Homo sapiens	84-87
21356216-6	2011	For CYP3A7, Delta(9)-THC, CBD, and CBN inhibited the activity to a similar extent (IC(50)=23-31 muM).	Dronabinol	12-24	latexin	Homo sapiens	96-99
21238476-1	2011	Delta9-THC is a component of Cannabis sativa that increases food intake in animals and humans, an effect prevented by selective CB1 receptor antagonists.	Dronabinol	0-10	cannabinoid receptor 1	Homo sapiens	128-131
21091643-5	2011	KEY RESULTS: Delta9-THC decreased responding for both food presentation and stimulus-shock termination; these effects were antagonized by the CB1 antagonist rimonabant.	Dronabinol	13-23	cannabinoid receptor 1	Macaca mulatta	142-145
21091643-11	2011	CONCLUSIONS AND IMPLICATIONS: In Delta9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB1 receptor agonists varied inversely with agonist efficacy, suggesting that CB1 agonist efficacy is an important determinant of behavioural effects.	Dronabinol	40-43	cannabinoid receptor 1	Macaca mulatta	117-120
21091643-11	2011	CONCLUSIONS AND IMPLICATIONS: In Delta9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB1 receptor agonists varied inversely with agonist efficacy, suggesting that CB1 agonist efficacy is an important determinant of behavioural effects.	Dronabinol	40-43	cannabinoid receptor 1	Macaca mulatta	195-198
21265548-5	2011	The PEPs for the reactions with C(2)H(6) effectively rationalize the observed reaction products, ThC(2)H(2)(2+) and UC(2)H(4)(2+).	Dronabinol	97-100	leucine aminopeptidase 3	Homo sapiens	4-8
21290620-10	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana, and it activates CB1 receptors (10).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	101-104
21290620-10	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana, and it activates CB1 receptors (10).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	101-104
20929960-6	2011	Moreover, pharmacological administration of the cannabinoid Delta(9)-tetrahydrocannabinol to mice expressing human mutant huntingtin exon 1 exerted a therapeutic effect and ameliorated those parameters.	Dronabinol	60-89	huntingtin	Homo sapiens	122-132
21863215-8	2011	In vitro, acetaldehyde, H2O2, as well as 2-AG and THC, alone or in combination with acetaldehyde, induced CB1 mRNA expression, whereas CB1 blockage with SR141716 dose-dependently inhibited HSC proliferation and downregulated mRNA expression of fibrosis-mediated genes PCalpha1(I), TIMP-1 and MMP-13.	Dronabinol	50-53	cannabinoid receptor 1	Homo sapiens	106-109
21863215-8	2011	In vitro, acetaldehyde, H2O2, as well as 2-AG and THC, alone or in combination with acetaldehyde, induced CB1 mRNA expression, whereas CB1 blockage with SR141716 dose-dependently inhibited HSC proliferation and downregulated mRNA expression of fibrosis-mediated genes PCalpha1(I), TIMP-1 and MMP-13.	Dronabinol	50-53	cannabinoid receptor 1	Homo sapiens	135-138
21863215-8	2011	In vitro, acetaldehyde, H2O2, as well as 2-AG and THC, alone or in combination with acetaldehyde, induced CB1 mRNA expression, whereas CB1 blockage with SR141716 dose-dependently inhibited HSC proliferation and downregulated mRNA expression of fibrosis-mediated genes PCalpha1(I), TIMP-1 and MMP-13.	Dronabinol	50-53	TIMP metallopeptidase inhibitor 1	Homo sapiens	281-287
21863215-8	2011	In vitro, acetaldehyde, H2O2, as well as 2-AG and THC, alone or in combination with acetaldehyde, induced CB1 mRNA expression, whereas CB1 blockage with SR141716 dose-dependently inhibited HSC proliferation and downregulated mRNA expression of fibrosis-mediated genes PCalpha1(I), TIMP-1 and MMP-13.	Dronabinol	50-53	matrix metallopeptidase 13	Homo sapiens	292-298
22016780-6	2011	Direct CB1 receptor activation by Delta9-Tetrahydrocannabinol (Delta9-THC) did, however, not affect inhibitory control.	Dronabinol	34-61	cannabinoid receptor 1	Homo sapiens	7-10
22016780-8	2011	Indeed, acute Delta9-THC was found to reduce impulsive choice in a CB1 receptor-dependent way.	Dronabinol	14-24	cannabinoid receptor 1	Homo sapiens	67-70
23471192-1	2011	The plant cannabinoid Delta(9)-tetrahydrocannabinol and the endocannabinoid anandamide increase the amount of sleep via a CB1 receptor mediated mechanism.	Dronabinol	22-51	cannabinoid receptor 1	Rattus norvegicus	122-125
21110319-2	2010	Here, we show that administration of THC in mice leads to rapid and massive expansion of CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSC) expressing functional arginase and exhibiting potent immunosuppressive properties both in vitro and in vivo.	Dronabinol	37-40	integrin alpha M	Mus musculus	89-94
21110319-3	2010	The induction of MDSC by THC was associated with a significant increase in granulocyte CSF.	Dronabinol	25-28	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	87-90
21110319-4	2010	Moreover, administration of anti-granulocyte CSF Ab inhibited the induction of MDSC by THC.	Dronabinol	87-90	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	45-48
21110319-5	2010	THC was able to induce MDSC in TLR4 mutant C3H and C57BL10/ScN mice and hence acted independently of TLR4.	Dronabinol	0-3	toll-like receptor 4	Mus musculus	31-35
20800662-4	2010	Pretreatment with actinomycin D, which inhibits transcription, decreased the mean 5-HT(3) receptor current density and increased the extent of THC inhibition on 5-HT(3) receptor-mediated currents.	Dronabinol	143-146	5-hydroxytryptamine receptor 3A	Rattus norvegicus	161-177
20617520-1	2010	OBJECTIVE: Cannabinoids are derivates of the marijuana component Delta(9) -tetrahydrocannabinol that exert their effects on mesenchymal cells and immune cells via CB1 and CB2 receptors.	Dronabinol	65-95	cannabinoid receptor 1 (brain)	Mus musculus	163-166
20668056-10	2010	CB1s in adolescent hippocampus are less functionally coupled to G proteins and desensitize more slowly in response to THC treatment than those of adults.	Dronabinol	118-121	cannabinoid receptor 1	Rattus norvegicus	0-3
20467421-8	2010	Cells treated with THC underwent adipogenesis shown by the expression of PPARgamma and had increased lipid accumulation.	Dronabinol	19-22	peroxisome proliferator activated receptor gamma	Mus musculus	73-82
20467421-11	2010	THC decreased NAPE-PLD in preadipocytes and increased adiponectin and TGFbeta transcription in adipocytes.	Dronabinol	0-3	N-acyl phosphatidylethanolamine phospholipase D	Mus musculus	14-22
20467421-11	2010	THC decreased NAPE-PLD in preadipocytes and increased adiponectin and TGFbeta transcription in adipocytes.	Dronabinol	0-3	adiponectin, C1Q and collagen domain containing	Mus musculus	54-65
20467421-11	2010	THC decreased NAPE-PLD in preadipocytes and increased adiponectin and TGFbeta transcription in adipocytes.	Dronabinol	0-3	transforming growth factor, beta 1	Mus musculus	70-77
21061493-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
21061493-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
21061494-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
21061494-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
20945557-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20945557-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
20945559-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20945559-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
20963941-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20963941-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
20963942-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20963942-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
20963943-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20963943-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
19941698-6	2010	Both high and low doses of Delta9-THC increased DARPP-32 phosphorylation in most brain regions studied in both phenotypes, an effect that was also observed following high-dose WIN55,212-2 administration only in the striatum.	Dronabinol	27-37	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	48-56
20463317-12	2010	The 17beta-E(2)-mediated cytoprotection was inhibited by ER antagonists ICI (ERalpha and ERbeta) and THC (ERbeta) but not by tamoxifen (ERalpha).	Dronabinol	101-104	estrogen receptor 2	Homo sapiens	106-112
20631688-0	2010	Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes.	Dronabinol	31-59	catechol-O-methyltransferase	Mus musculus	63-67
20631688-2	2010	A high-low activity catechol-O-methyltransferase (COMT) polymorphism may modulate the effects of adolescent Delta-9-tetrahydrocannabinol (THC) exposure on the risk for adult psychosis.	Dronabinol	108-136	catechol-O-methyltransferase	Mus musculus	20-48
20631688-2	2010	A high-low activity catechol-O-methyltransferase (COMT) polymorphism may modulate the effects of adolescent Delta-9-tetrahydrocannabinol (THC) exposure on the risk for adult psychosis.	Dronabinol	108-136	catechol-O-methyltransferase	Mus musculus	50-54
20631688-2	2010	A high-low activity catechol-O-methyltransferase (COMT) polymorphism may modulate the effects of adolescent Delta-9-tetrahydrocannabinol (THC) exposure on the risk for adult psychosis.	Dronabinol	138-141	catechol-O-methyltransferase	Mus musculus	20-48
20631688-2	2010	A high-low activity catechol-O-methyltransferase (COMT) polymorphism may modulate the effects of adolescent Delta-9-tetrahydrocannabinol (THC) exposure on the risk for adult psychosis.	Dronabinol	138-141	catechol-O-methyltransferase	Mus musculus	50-54
20631688-3	2010	Mice with knockout of the COMT gene were treated chronically with THC (4.0 and 8.0 mg/kg over 20 days) during either adolescence (postnatal days (PDs) 32-52) or adulthood (PDs 70-90).	Dronabinol	66-69	catechol-O-methyltransferase	Mus musculus	26-30
20631688-5	2010	Adolescent THC administration induced a larger increase in exploratory activity, greater impairment in spatial working memory, and a stronger anti-anxiety effect in COMT knockouts than in wild types, primarily among males.	Dronabinol	11-14	catechol-O-methyltransferase	Mus musculus	165-169
20631688-8	2010	The COMT genotype exerts specific modulation of responsivity to chronic THC administration during adolescence in terms of exploratory activity, spatial working memory, and anxiety.	Dronabinol	72-75	catechol-O-methyltransferase	Mus musculus	4-8
20806446-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	97-100
20806446-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	97-100
27713369-2	2010	Previously, we have demonstrated that the psychoactive D9-tetrahydrocannabinol (THC) and the non-psychotropic cannabidiol (CBD) modulate mitogen-induced Th1-type immune responses in peripheral blood mononuclear cells (PBMC).	Dronabinol	80-83	negative elongation factor complex member C/D	Homo sapiens	153-156
19833407-4	2010	The major endocannabinoids, anandamide and 2-arachidonoylglycerol, and ajulemic acid, a structural analogue of the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC), have anti-inflammatory properties mediated by PPARgamma.	Dronabinol	132-161	peroxisome proliferator activated receptor gamma	Homo sapiens	215-224
19785914-4	2010	Delta9-THC produced the classic cannabinoid CB1 receptor-mediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest hyperthermic effects.	Dronabinol	0-10	cannabinoid receptor 1 (brain)	Mus musculus	44-47
19887017-5	2010	Human P-gp was significantly inhibited in a concentration-dependent manner by norbuprenorphine&gt;buprenorphine&gt;methadone&gt;ibogaine and THC.	Dronabinol	141-144	ATP binding cassette subfamily B member 1	Homo sapiens	6-10
19887017-6	2010	Similarly, BCRP was inhibited by buprenorphine&gt;norbuprenorphine&gt;ibogaine and THC.	Dronabinol	83-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	11-15
20715479-3	2010	It has been suggested that regular use of cannabis might induce several adverse effects such as dependence syndrome, because delta-9-tetrahydrocannabinol(THC), a primary psychoactive component of cannabis, stimulates brain-reward areas through the activation of cannabinoid(CB1) receptor and induce drug-seeking behavior.	Dronabinol	125-153	cannabinoid receptor 1	Homo sapiens	274-277
20715479-3	2010	It has been suggested that regular use of cannabis might induce several adverse effects such as dependence syndrome, because delta-9-tetrahydrocannabinol(THC), a primary psychoactive component of cannabis, stimulates brain-reward areas through the activation of cannabinoid(CB1) receptor and induce drug-seeking behavior.	Dronabinol	154-157	cannabinoid receptor 1	Homo sapiens	274-277
20571781-2	2010	We showed previously that male heterozygous neuregulin 1 transmembrane domain (Nrg1 HET) mice are more sensitive to some effects of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	170-199	neuregulin 1	Mus musculus	79-83
20571781-2	2010	We showed previously that male heterozygous neuregulin 1 transmembrane domain (Nrg1 HET) mice are more sensitive to some effects of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	170-199	NADPH oxidase 3	Mus musculus	84-87
20571781-2	2010	We showed previously that male heterozygous neuregulin 1 transmembrane domain (Nrg1 HET) mice are more sensitive to some effects of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	201-204	neuregulin 1	Mus musculus	79-83
20571781-2	2010	We showed previously that male heterozygous neuregulin 1 transmembrane domain (Nrg1 HET) mice are more sensitive to some effects of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	201-204	NADPH oxidase 3	Mus musculus	84-87
20571781-3	2010	We report data from a follow-up study in female Nrg1 HET mice, investigating THC effects on behaviours with some relevance to schizophrenia.	Dronabinol	77-80	neuregulin 1	Mus musculus	48-52
20571781-11	2010	CONCLUSIONS: This study reports novel findings on the baseline PPI profile and resistance to THC-induced social withdrawal in female Nrg1 HET mice.	Dronabinol	93-96	neuregulin 1	Mus musculus	133-137
20571781-11	2010	CONCLUSIONS: This study reports novel findings on the baseline PPI profile and resistance to THC-induced social withdrawal in female Nrg1 HET mice.	Dronabinol	93-96	NADPH oxidase 3	Mus musculus	138-141
20357755-0	2010	FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.	Dronabinol	99-127	fatty acid amide hydrolase	Mus musculus	0-4
20357755-3	2010	FAAH(-/-) mice dosed subchronically with equi-active maximally effective doses of AEA or THC displayed greater rightward shifts in THC dose-effect curves for antinociception, catalepsy, and hypothermia than in AEA dose-effect curves.	Dronabinol	89-92	fatty acid amide hydrolase	Mus musculus	0-4
20357755-3	2010	FAAH(-/-) mice dosed subchronically with equi-active maximally effective doses of AEA or THC displayed greater rightward shifts in THC dose-effect curves for antinociception, catalepsy, and hypothermia than in AEA dose-effect curves.	Dronabinol	131-134	fatty acid amide hydrolase	Mus musculus	0-4
20417220-0	2010	Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	49-52
20417220-1	2010	Marijuana impairs learning and memory through actions of its psychoactive constituent, delta-9-tetrahydrocannabinol (Delta(9)-THC), in the hippocampus, through activation of cannabinoid CB1 receptors (CB1R).	Dronabinol	87-115	cannabinoid receptor 1 (brain)	Mus musculus	186-189
20417220-1	2010	Marijuana impairs learning and memory through actions of its psychoactive constituent, delta-9-tetrahydrocannabinol (Delta(9)-THC), in the hippocampus, through activation of cannabinoid CB1 receptors (CB1R).	Dronabinol	87-115	cannabinoid receptor 1 (brain)	Mus musculus	201-205
20417220-1	2010	Marijuana impairs learning and memory through actions of its psychoactive constituent, delta-9-tetrahydrocannabinol (Delta(9)-THC), in the hippocampus, through activation of cannabinoid CB1 receptors (CB1R).	Dronabinol	117-129	cannabinoid receptor 1 (brain)	Mus musculus	186-189
20417220-3	2010	Previous studies suggest that Delta(9)-THC is a partial agonist of CB1Rs on glutamate axon terminals in the hippocampus, whereas its effects on GABA terminals have not been described.	Dronabinol	30-42	cannabinoid receptor 1 (brain)	Mus musculus	67-70
20417220-8	2010	Concentration-response curves revealed that the maximal effects of Delta(9)-THC and WIN55,212-2 were similar, indicating that Delta(9)-THC is a full agonist at CB1Rs on GABA axon terminals.	Dronabinol	126-138	cannabinoid receptor 1 (brain)	Mus musculus	160-163
20417220-10	2010	Furthermore, full agonist effects of Delta(9)-THC on IPSCs likely result from a much higher expression of CB1Rs on GABA versus glutamate axon terminals in the hippocampus.	Dronabinol	37-49	cannabinoid receptor 1 (brain)	Mus musculus	106-109
20582876-0	2010	Acute effects of delta9-tetrahydrocannabinol on the auditory evoked mismatch negativity are modulated by the NRG1 gene.	Dronabinol	17-44	neuregulin 1	Homo sapiens	109-113
20534838-5	2010	Single injections with the main psychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), increased GluR2-lacking AMPA receptors and permitted LTD in only the PPN pathway, and these effects were prevented by in vivo pretreatment with the cannabinoid CB1 receptor antagonist AM251.	Dronabinol	101-113	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	126-131
20534838-6	2010	These results demonstrate that cocaine more globally increases GluR2-lacking AMPA receptors at all glutamate synapses on VTA dopamine neurons, whereas Delta(9)-THC selectively increased GluR2-lacking AMPA receptors at subcortical PPN synapses.	Dronabinol	151-163	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	186-191
20117100-1	2010	Inhibitory effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabidiol (CBD), and cannabinol (CBN), the three major constituents in marijuana, on catalytic activities of human cytochrome P450 (CYP) 1 enzymes were investigated.	Dronabinol	22-51	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	185-208
20117100-1	2010	Inhibitory effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabidiol (CBD), and cannabinol (CBN), the three major constituents in marijuana, on catalytic activities of human cytochrome P450 (CYP) 1 enzymes were investigated.	Dronabinol	53-65	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	185-208
20117100-5	2010	Delta(9)-THC less potently inhibited the CYP1 activity than CBD and CBN, and showed low selectivity against the CYP1 inhibition (K(i)=2.47-7.54microM).	Dronabinol	0-12	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	41-45
20117100-5	2010	Delta(9)-THC less potently inhibited the CYP1 activity than CBD and CBN, and showed low selectivity against the CYP1 inhibition (K(i)=2.47-7.54microM).	Dronabinol	0-12	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	112-116
20117100-7	2010	Similarly, the preincubation of Delta(9)-THC or CBN caused a time- and concentration-dependent inhibition of recombinant CYP1A1.	Dronabinol	32-44	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	121-127
20457524-5	2010	In this context, it is important to recognize the utility of cannabinoid receptor 1 (CB1R) agonists, natural as Delta(9)-tetrahydrocannabinol (THC) or synthetic as Nabilone as useful drugs to alleviate this kind of patients" suffering.	Dronabinol	112-141	cannabinoid receptor 1	Homo sapiens	61-89
20457524-5	2010	In this context, it is important to recognize the utility of cannabinoid receptor 1 (CB1R) agonists, natural as Delta(9)-tetrahydrocannabinol (THC) or synthetic as Nabilone as useful drugs to alleviate this kind of patients" suffering.	Dronabinol	143-146	cannabinoid receptor 1	Homo sapiens	61-89
20332000-7	2010	The antidepressant-like action of Delta(9)-THC and CBC was further confirmed in the TST.	Dronabinol	34-46	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	84-87
19941959-0	2010	Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Delta(9)-THC.	Dronabinol	191-203	solute carrier family 1 member 2	Rattus norvegicus	92-96
19941959-0	2010	Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Delta(9)-THC.	Dronabinol	191-203	solute carrier family 1 member 3	Rattus norvegicus	101-106
20228383-10	2010	CONCLUSION: Delta(9)-Tetrahydrocannabinol contributes to the regulation of gestational duration in LPS-induced preterm delivery probably by NO coupling through the CB1 receptor.	Dronabinol	12-41	cannabinoid receptor 1 (brain)	Mus musculus	164-167
19847654-1	2010	The molecular mechanism of action of Delta(9)-tetrahydrocannabinol (THC), the psychotropic constituent of Cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid CB1 and CB2 receptors.	Dronabinol	37-66	cannabinoid receptor 1	Homo sapiens	247-250
19847654-1	2010	The molecular mechanism of action of Delta(9)-tetrahydrocannabinol (THC), the psychotropic constituent of Cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid CB1 and CB2 receptors.	Dronabinol	37-66	cannabinoid receptor 2	Homo sapiens	255-258
19847654-1	2010	The molecular mechanism of action of Delta(9)-tetrahydrocannabinol (THC), the psychotropic constituent of Cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid CB1 and CB2 receptors.	Dronabinol	68-71	cannabinoid receptor 1	Homo sapiens	247-250
19847654-1	2010	The molecular mechanism of action of Delta(9)-tetrahydrocannabinol (THC), the psychotropic constituent of Cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid CB1 and CB2 receptors.	Dronabinol	68-71	cannabinoid receptor 2	Homo sapiens	255-258
18801827-0	2010	Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.	Dronabinol	14-17	cannabinoid receptor 1	Homo sapiens	90-93
18801827-2	2010	Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist.	Dronabinol	100-128	cannabinoid receptor 1	Homo sapiens	138-141
18801827-2	2010	Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist.	Dronabinol	100-128	cannabinoid receptor 2	Homo sapiens	142-145
18801827-2	2010	Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist.	Dronabinol	130-133	cannabinoid receptor 1	Homo sapiens	138-141
18801827-2	2010	Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist.	Dronabinol	130-133	cannabinoid receptor 2	Homo sapiens	142-145
19766676-4	2010	Similar ultra-low doses of THC (3-4 orders of magnitude lower than doses that are known to evoke the acute effects of THC) also induced sustained activation of extracellular-regulated kinase (ERK1/2) in the cerebellum, indicating that a single injection of such low doses of the cannabinoid drug can stimulate neuronal regulatory mechanisms.	Dronabinol	27-30	mitogen-activated protein kinase 3	Mus musculus	192-198
19910459-0	2010	Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.	Dronabinol	13-42	interferon beta 1, fibroblast	Mus musculus	129-144
19910459-9	2010	Following CBD treatment, but less so with THC, we observed a decreased level of mRNA for the Socs3 gene, a main negative regulator of STATs and particularly of STAT3.	Dronabinol	42-45	suppressor of cytokine signaling 3	Mus musculus	93-98
19910459-9	2010	Following CBD treatment, but less so with THC, we observed a decreased level of mRNA for the Socs3 gene, a main negative regulator of STATs and particularly of STAT3.	Dronabinol	42-45	signal transducer and activator of transcription 1	Mus musculus	134-139
19910459-10	2010	However, both CBD and THC decreased the activation of the LPS-induced STAT1 transcription factor, a key player in IFNbeta-dependent proinflammatory processes.	Dronabinol	22-25	signal transducer and activator of transcription 1	Mus musculus	70-75
19910459-10	2010	However, both CBD and THC decreased the activation of the LPS-induced STAT1 transcription factor, a key player in IFNbeta-dependent proinflammatory processes.	Dronabinol	22-25	interferon beta 1, fibroblast	Mus musculus	114-121
19910459-11	2010	In summary, our observations show that CBD and THC vary in their effects on the anti-inflammatory pathways, including the NF-kappaB and IFNbeta-dependent pathways.	Dronabinol	47-50	interferon beta 1, fibroblast	Mus musculus	136-143
20071517-8	2010	The CB1R-A1R interaction was observed with the agonists WIN55,212-2 and Delta(9)-THC and during endocannabinoid-mediated depolarization-induced suppression of excitation.	Dronabinol	72-84	cannabinoid receptor 1 (brain)	Mus musculus	4-8
20053780-1	2010	The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma.	Dronabinol	69-98	cannabinoid receptor 1	Homo sapiens	4-24
20053780-1	2010	The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma.	Dronabinol	100-103	cannabinoid receptor 1	Homo sapiens	4-24
20689343-2	2010	We therefore tested for panic and anxiety-related behaviour in rats coadministered with the selective serotonin reuptake inhibitor fluoxetine hydrochloride and the CB1 agonist delta9-tetrahydrocannabinol.	Dronabinol	176-203	cannabinoid receptor 1	Rattus norvegicus	164-167
19858202-3	2009	In human primary and Jurkat T lymphocytes, activation of CB1 by R(+)-methanandamide, CB2 by JWH015, and both by Delta9-tetrahydrocannabinol induced a short decrease in cyclic AMP lasting less than 1 h. However, this decrease was followed by a massive (up to 10-fold) and sustained (at least up to 48 h) increase in cyclic AMP.	Dronabinol	112-139	cannabinoid receptor 1	Homo sapiens	57-60
19733208-2	2009	In mouse models, following chronic treatment with delta9-tetrahydrocannabinol (THC), administration of the selective cannabinoid CB1 receptor antagonist SR141716 (rimonabant) elicited varying behavioral responses, depending on mouse strain and dosing regimen.	Dronabinol	79-82	cannabinoid receptor 1 (brain)	Mus musculus	129-132
19819240-0	2009	Delta(9)-tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brain.	Dronabinol	0-29	transformation related protein 53, pseudogene	Mus musculus	44-47
19819240-1	2009	The phytocannabinoid Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in cannabis, activates a number of signalling cascades including p53.	Dronabinol	21-50	transformation related protein 53, pseudogene	Mus musculus	166-169
19819240-1	2009	The phytocannabinoid Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in cannabis, activates a number of signalling cascades including p53.	Dronabinol	52-64	transformation related protein 53, pseudogene	Mus musculus	166-169
19819240-2	2009	This study examines the role of Delta(9)-THC in regulating the p53 post-translational modifier proteins, Murine double minute (Mdm2) and Small Ubquitin-like MOdifier protein 1 (SUMO-1) in cortical neurons.	Dronabinol	32-44	transformation related protein 53, pseudogene	Mus musculus	63-66
19819240-2	2009	This study examines the role of Delta(9)-THC in regulating the p53 post-translational modifier proteins, Murine double minute (Mdm2) and Small Ubquitin-like MOdifier protein 1 (SUMO-1) in cortical neurons.	Dronabinol	32-44	transformed mouse 3T3 cell double minute 2	Mus musculus	127-131
19819240-2	2009	This study examines the role of Delta(9)-THC in regulating the p53 post-translational modifier proteins, Murine double minute (Mdm2) and Small Ubquitin-like MOdifier protein 1 (SUMO-1) in cortical neurons.	Dronabinol	32-44	small ubiquitin-like modifier 1	Mus musculus	137-175
19819240-2	2009	This study examines the role of Delta(9)-THC in regulating the p53 post-translational modifier proteins, Murine double minute (Mdm2) and Small Ubquitin-like MOdifier protein 1 (SUMO-1) in cortical neurons.	Dronabinol	32-44	small ubiquitin-like modifier 1	Mus musculus	177-183
19819240-3	2009	Delta(9)-THC increased both Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid receptor type 1 (CB(1))-receptor dependent manner.	Dronabinol	0-12	transformed mouse 3T3 cell double minute 2	Mus musculus	28-32
19819240-3	2009	Delta(9)-THC increased both Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid receptor type 1 (CB(1))-receptor dependent manner.	Dronabinol	0-12	small ubiquitin-like modifier 1	Mus musculus	37-43
19819240-3	2009	Delta(9)-THC increased both Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid receptor type 1 (CB(1))-receptor dependent manner.	Dronabinol	0-12	transformation related protein 53, pseudogene	Mus musculus	96-99
19819240-3	2009	Delta(9)-THC increased both Mdm2 and SUMO-1 protein expression and induced the deSUMOylation of p53 in a cannabinoid receptor type 1 (CB(1))-receptor dependent manner.	Dronabinol	0-12	cannabinoid receptor 1 (brain)	Mus musculus	105-149
19345076-11	2009	Insulin-induced glucose uptake increased, while the rate of adipogenesis decreased with increasing THC concentration.	Dronabinol	99-102	insulin	Homo sapiens	0-7
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	cannabinoid receptor 1	Homo sapiens	14-38
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	cannabinoid receptor 1	Homo sapiens	40-44
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	mechanistic target of rapamycin kinase	Homo sapiens	83-112
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	mechanistic target of rapamycin kinase	Homo sapiens	114-118
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	245-272	ribosomal protein S6 kinase B1	Homo sapiens	120-126
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	cannabinoid receptor 1	Homo sapiens	14-38
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	cannabinoid receptor 1	Homo sapiens	40-44
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	mechanistic target of rapamycin kinase	Homo sapiens	83-112
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	mechanistic target of rapamycin kinase	Homo sapiens	114-118
19648913-2	2009	We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC).	Dronabinol	274-277	ribosomal protein S6 kinase B1	Homo sapiens	120-126
19648913-3	2009	In addition, non-amnesic doses of either the mTOR blocker rapamycin or the protein synthesis inhibitor anisomycin abrogated the amnesic-like effects of THC, pointing to a mechanism involving new protein synthesis.	Dronabinol	152-155	mechanistic target of rapamycin kinase	Mus musculus	45-49
19648913-4	2009	Moreover, using pharmacological and genetic tools, we found that THC long-term memory deficits were mediated by CB1Rs expressed on GABAergic interneurons through a glutamatergic mechanism, as both the amnesic-like effects and p70S6K phosphorylation were reduced in GABA-CB1R knockout mice and by NMDA blockade.	Dronabinol	65-68	cannabinoid receptor 1 (brain)	Mus musculus	112-115
19648913-4	2009	Moreover, using pharmacological and genetic tools, we found that THC long-term memory deficits were mediated by CB1Rs expressed on GABAergic interneurons through a glutamatergic mechanism, as both the amnesic-like effects and p70S6K phosphorylation were reduced in GABA-CB1R knockout mice and by NMDA blockade.	Dronabinol	65-68	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	226-232
19648913-4	2009	Moreover, using pharmacological and genetic tools, we found that THC long-term memory deficits were mediated by CB1Rs expressed on GABAergic interneurons through a glutamatergic mechanism, as both the amnesic-like effects and p70S6K phosphorylation were reduced in GABA-CB1R knockout mice and by NMDA blockade.	Dronabinol	65-68	cannabinoid receptor 1 (brain)	Mus musculus	112-116
19440186-6	2009	These results show that THC mediates heart rate increase independent of sympathetic (catecholaminergic) activity, probably through direct cannabinoid receptor type 1 (CB(1)) agonism in cardiac tissue.	Dronabinol	24-27	cannabinoid receptor 1	Homo sapiens	138-172
19016476-2	2009	The cannabinoid receptor 1 gene (CNR1) on chromosome 6q14-15 is an excellent candidate gene for cannabis dependence due to the important role of the G-protein coupled receptor encoded by this gene in the rewarding effects of Delta9-tetrahydrocannabinol.	Dronabinol	225-252	cannabinoid receptor 1	Homo sapiens	4-26
19016476-2	2009	The cannabinoid receptor 1 gene (CNR1) on chromosome 6q14-15 is an excellent candidate gene for cannabis dependence due to the important role of the G-protein coupled receptor encoded by this gene in the rewarding effects of Delta9-tetrahydrocannabinol.	Dronabinol	225-252	cannabinoid receptor 1	Homo sapiens	33-37
19339377-1	2009	Tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive ingredient in marijuana, is subject to cytochrome P450 oxidation and subsequent UDP-glucuronosyltransferase (UGT)-dependent glucuronidation.	Dronabinol	0-20	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	142-169
19339377-1	2009	Tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive ingredient in marijuana, is subject to cytochrome P450 oxidation and subsequent UDP-glucuronosyltransferase (UGT)-dependent glucuronidation.	Dronabinol	0-20	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	171-174
19339377-1	2009	Tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive ingredient in marijuana, is subject to cytochrome P450 oxidation and subsequent UDP-glucuronosyltransferase (UGT)-dependent glucuronidation.	Dronabinol	22-34	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	142-169
19339377-1	2009	Tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive ingredient in marijuana, is subject to cytochrome P450 oxidation and subsequent UDP-glucuronosyltransferase (UGT)-dependent glucuronidation.	Dronabinol	22-34	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	171-174
19339377-7	2009	These results may reflect the introduction of an aromatic ring to Delta(9)-THC, leading to favorable pi stacking with phenylalanines in the UGT active site.	Dronabinol	66-78	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	140-143
19339377-8	2009	Likewise, oxidation of Delta(9)-THC to THC-OH results in UGT1A9 and UGT1A10 activity toward the cannabinoid.	Dronabinol	23-35	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	57-63
19339377-8	2009	Likewise, oxidation of Delta(9)-THC to THC-OH results in UGT1A9 and UGT1A10 activity toward the cannabinoid.	Dronabinol	23-35	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	68-75
19339377-9	2009	Further oxidation to THC-COOH surprisingly leads to a loss in metabolism by UGT1A9 and UGT1A10, while creating a substrate recognized by UGT1A1 and UGT1A3.	Dronabinol	21-24	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	76-82
19339377-9	2009	Further oxidation to THC-COOH surprisingly leads to a loss in metabolism by UGT1A9 and UGT1A10, while creating a substrate recognized by UGT1A1 and UGT1A3.	Dronabinol	21-24	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	87-94
19339377-9	2009	Further oxidation to THC-COOH surprisingly leads to a loss in metabolism by UGT1A9 and UGT1A10, while creating a substrate recognized by UGT1A1 and UGT1A3.	Dronabinol	21-24	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	87-93
19339377-9	2009	Further oxidation to THC-COOH surprisingly leads to a loss in metabolism by UGT1A9 and UGT1A10, while creating a substrate recognized by UGT1A1 and UGT1A3.	Dronabinol	21-24	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	148-154
19285060-2	2009	Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma.	Dronabinol	41-68	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	81-129
19428940-0	2009	Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.	Dronabinol	14-41	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	104-113
19428940-6	2009	It was shown that Delta(9)-THC-induced MCF-7 cell growth was inhibited by COX-2 inhibitors and was stimulated by arachidonic acid (a COX substrate).	Dronabinol	18-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-79
19428940-7	2009	However, the growth of MCF-7 cells induced by Delta(9)-THC was not stimulated by PGE(2), and the expression of aromatase was not affected by COX-2 inhibitors, arachidonic acid, and PGE(2), suggesting that there is a disconnection between COX-2 (PGE(2)) and aromatase in Delta(9)-THC-mediated MCF-7 cell proliferation.	Dronabinol	270-282	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	111-120
19428940-8	2009	On the other hand, Delta(9)-THC-induced MCF-7 cell growth was elevated by two kinds of aromatase inhibitors.	Dronabinol	19-31	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	87-96
19425170-3	2009	Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3-dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	23-26	eukaryotic translation initiation factor 2A	Homo sapiens	61-108
19425170-3	2009	Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3-dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	23-26	eukaryotic translation initiation factor 2A	Homo sapiens	110-119
19425170-3	2009	Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3-dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	23-26	tribbles pseudokinase 3	Homo sapiens	239-243
19425170-3	2009	Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3-dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	23-26	AKT serine/threonine kinase 1	Homo sapiens	273-276
19425170-3	2009	Our data indicate that THC induced ceramide accumulation and eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and thereby activated an ER stress response that promoted autophagy via tribbles homolog 3-dependent (TRB3-dependent) inhibition of the Akt/mammalian target of rapamycin complex 1 (mTORC1) axis.	Dronabinol	23-26	CREB regulated transcription coactivator 1	Mus musculus	318-324
19384563-6	2009	A significant decrease in synaptophysin and PSD95 proteins was found in the prefrontal cortex of THC pre-treated rats, with no alterations in the hippocampus.	Dronabinol	97-100	synaptophysin	Rattus norvegicus	26-39
19384563-6	2009	A significant decrease in synaptophysin and PSD95 proteins was found in the prefrontal cortex of THC pre-treated rats, with no alterations in the hippocampus.	Dronabinol	97-100	discs large MAGUK scaffold protein 4	Rattus norvegicus	44-49
19367504-2	2009	The rewarding and positive reinforcing effects of the primary psychoactive component of smoked cannabis, delta-9-tetrahydrocannabinol (THC) are mediated by the cannabinoid CB1 receptor.	Dronabinol	105-133	cannabinoid receptor 1	Homo sapiens	172-175
19367504-2	2009	The rewarding and positive reinforcing effects of the primary psychoactive component of smoked cannabis, delta-9-tetrahydrocannabinol (THC) are mediated by the cannabinoid CB1 receptor.	Dronabinol	135-138	cannabinoid receptor 1	Homo sapiens	172-175
19023563-5	2009	Chronically, uptake was increased by caffeine and decreased by tetrahydrocannabinol and MDMA; reverse transcription quantitative real-time PCR analysis showed that these three compounds decreased the mRNA levels of MCT1.	Dronabinol	63-83	solute carrier family 16 member 1	Homo sapiens	215-219
19023563-10	2009	In conclusion, MCT1-mediated transport of (14)C-BT in Caco-2 cells is modulated by either acute or chronic exposure to some pharmacological agents and drugs of abuse (acetaldehyde, acetylsalicylic acid, indomethacin, caffeine, theophylline and the drugs of abuse tetrahydrocannabinol and MDMA).	Dronabinol	263-283	solute carrier family 16 member 1	Homo sapiens	15-19
19118122-1	2009	Delta(9)-tetrahydrocannabinol (THC), the principal psychoactive ingredient in marijuana, acts as a partial agonist on presynaptic cannabinoid type 1 (CB1) receptors to inhibit neurotransmitter release.	Dronabinol	0-29	cannabinoid receptor 1	Rattus norvegicus	150-153
19118122-1	2009	Delta(9)-tetrahydrocannabinol (THC), the principal psychoactive ingredient in marijuana, acts as a partial agonist on presynaptic cannabinoid type 1 (CB1) receptors to inhibit neurotransmitter release.	Dronabinol	31-34	cannabinoid receptor 1	Rattus norvegicus	150-153
18521574-4	2009	RESULTS: Dose-generalization curves of AM1346, Delta(9)-THC, and mAEA suggested the following order of potency: Delta(9)-THC &gt; AM1346 &gt; mAEA both for rats discriminating between 3 and 5.6 mg/kg AM1346 from vehicle.	Dronabinol	112-124	macrophage erythroblast attacher	Mus musculus	65-69
19184452-5	2009	FAAH-compromised animals reliably display antinociceptive and anti-inflammatory phenotypes with a similar efficacy as direct-acting cannabinoid receptor agonists, such as Delta(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa.	Dronabinol	202-205	fatty acid amide hydrolase	Homo sapiens	0-4
19005461-0	2009	Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.	Dronabinol	53-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	120-126
19005461-1	2009	The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers.	Dronabinol	85-107	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	18-24
19005461-3	2009	However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes.	Dronabinol	44-47	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	138-144
19005461-4	2009	CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC.	Dronabinol	92-95	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
19005461-5	2009	Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.	Dronabinol	90-93	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	15-21
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	Dronabinol	0-28	negative elongation factor complex member C/D, Th1l	Mus musculus	84-87
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	Dronabinol	0-28	heart and neural crest derivatives expressed 2	Mus musculus	91-94
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	Dronabinol	30-33	negative elongation factor complex member C/D, Th1l	Mus musculus	84-87
18792785-2	2009	Delta-9-tetrahydrocannabinol (THC) treatment prior to infection causes a shift from Th1 to Th2 immunity and here we demonstrate that CB(1) and CB(2) cannabinoid receptors mediate different aspects of the shift.	Dronabinol	30-33	heart and neural crest derivatives expressed 2	Mus musculus	91-94
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	Dronabinol	80-83	interferon gamma	Mus musculus	0-8
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	Dronabinol	80-83	cannabinoid receptor 1 (brain)	Mus musculus	227-230
18792785-4	2009	IFNgamma production is dependent upon signaling through IL-12Rbeta2 (beta2) and THC treatment suppressed splenic beta2 message; moreover, this effect was CB(1) but not CB(2)-dependent from studies with receptor antagonists and CB1(-/-) and CB2(-/-) mice.	Dronabinol	80-83	cannabinoid receptor 2 (macrophage)	Mus musculus	240-243
18792785-5	2009	Furthermore, observed increases in IL-4 induced by THC, were not involved in the drug effect on beta2 from studies with IL-4 deficient mice.	Dronabinol	51-54	interleukin 4	Mus musculus	35-39
18792785-7	2009	GATA-3 message levels were elevated in spleens of THC-treated and L. pneumophila-infected mice and the effect was shown to be CB(2) but not CB(1)-dependent.	Dronabinol	50-53	GATA binding protein 3	Mus musculus	0-6
18792785-8	2009	Furthermore, GATA-3 regulatory factors were modulated in that Notch ligand Delta4 mRNA was decreased and Jagged1 increased by THC also in a CB2-dependent manner and splenic NFkappaB p65 was increased.	Dronabinol	126-129	GATA binding protein 3	Mus musculus	13-19
18792785-8	2009	Furthermore, GATA-3 regulatory factors were modulated in that Notch ligand Delta4 mRNA was decreased and Jagged1 increased by THC also in a CB2-dependent manner and splenic NFkappaB p65 was increased.	Dronabinol	126-129	jagged 1	Mus musculus	105-112
18792785-8	2009	Furthermore, GATA-3 regulatory factors were modulated in that Notch ligand Delta4 mRNA was decreased and Jagged1 increased by THC also in a CB2-dependent manner and splenic NFkappaB p65 was increased.	Dronabinol	126-129	cannabinoid receptor 2 (macrophage)	Mus musculus	140-143
18792785-9	2009	Together, these results indicate that CB(1) and CB(2) mediate the THC-induced shift in T helper activity in L. pneumophila-infected mice, with CB(1) involved in suppressing IL-12Rbeta2 and CB(2) involved in enhancing GATA-3.	Dronabinol	66-69	GATA binding protein 3	Mus musculus	217-223
18807247-4	2009	Accordingly, we hypothesized that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the principal active component of cannabis, would alter BDNF levels in humans.	Dronabinol	34-63	brain derived neurotrophic factor	Homo sapiens	136-140
18807247-4	2009	Accordingly, we hypothesized that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the principal active component of cannabis, would alter BDNF levels in humans.	Dronabinol	65-77	brain derived neurotrophic factor	Homo sapiens	136-140
18807247-7	2009	RESULTS: Delta(9)-THC increased serum BDNF levels in healthy controls but not light users of cannabis.	Dronabinol	9-21	brain derived neurotrophic factor	Homo sapiens	38-42
19084905-0	2009	Nicotine and Delta(9)-tetrahydrocannabinol withdrawal induce Narp in the central nucleus of the amygdala.	Dronabinol	13-42	neuronal pentraxin 2	Homo sapiens	61-65
19084905-4	2009	We now report that Narp is also induced in the central nucleus following withdrawal from other drugs of abuse, nicotine and Delta(9)-tetrahydrocannabinol, indicating that Narp is a common component of the transcriptional response triggered by drug withdrawal.	Dronabinol	124-153	neuronal pentraxin 2	Homo sapiens	19-23
19084905-4	2009	We now report that Narp is also induced in the central nucleus following withdrawal from other drugs of abuse, nicotine and Delta(9)-tetrahydrocannabinol, indicating that Narp is a common component of the transcriptional response triggered by drug withdrawal.	Dronabinol	124-153	neuronal pentraxin 2	Homo sapiens	171-175
19167098-1	2009	Nanomolar concentrations of Delta9-tetrahydrocannabinol or cannabidiol are demonstrated to enhance mitogen-induced degradation of tryptophan in human peripheral blood mononuclear cells in dependence of CB1- or CB2-receptor activation.	Dronabinol	28-55	cannabinoid receptor 1	Homo sapiens	202-205
19179850-0	2009	Chronic treatment with Delta(9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain.	Dronabinol	23-52	early growth response 1	Mus musculus	88-94
19179850-6	2009	Zif268 immunoreactivity was reduced in the CA3 of the hippocampus and in the prefrontal cortex only in non-pretreated animals, indicating that although tolerance to the effects of THC on neuronal activity was evident, cannabinoid-induced memory impairment in these animals persisted even after 24 days of exposure.	Dronabinol	180-183	early growth response 1	Mus musculus	0-6
18584336-0	2009	Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol.	Dronabinol	141-169	RAS protein-specific guanine nucleotide-releasing factor 1	Mus musculus	81-88
18988696-0	2009	Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.	Dronabinol	43-70	inducible T cell co-stimulator	Mus musculus	35-39
18988696-4	2009	In light of an emerging role by ICOS in T cell-mediated immunity, the objective of this study was to investigate the effect of Delta(9)-THC on ICOS in activated mouse T cells.	Dronabinol	127-139	inducible T cell co-stimulator	Mus musculus	143-147
18988696-5	2009	Induction of ICOS mRNA levels by phorbol ester (PMA) plus ionomycin (Io) activation in mouse splenocytes was attenuated by Delta(9)-THC in a concentration-related manner.	Dronabinol	123-135	inducible T cell co-stimulator	Mus musculus	13-17
18988696-7	2009	Anti-CD3/CD28 induced ICOS expression on CD4(+) splenic T cells, which was suppressed by Delta(9)-THC in a time- and concentration-related manner.	Dronabinol	89-101	CD28 antigen	Mus musculus	9-13
18988696-7	2009	Anti-CD3/CD28 induced ICOS expression on CD4(+) splenic T cells, which was suppressed by Delta(9)-THC in a time- and concentration-related manner.	Dronabinol	89-101	inducible T cell co-stimulator	Mus musculus	22-26
18988696-9	2009	Moreover, transcriptional activation of the NFAT was also down-regulated by Delta(9)-THC as shown by a NFAT luciferase reporter assay, which is consistent with a putative role of NFAT in regulating ICOS expression.	Dronabinol	76-88	inducible T cell co-stimulator	Mus musculus	198-202
18988696-10	2009	Collectively, Delta(9)-THC suppresses ICOS expression in activated T cells, and this suppression may be related, in part, to its modulation of NFAT signaling.	Dronabinol	14-26	inducible T cell co-stimulator	Mus musculus	38-42
20641388-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
20641388-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
19634029-1	2009	The active component of marijuana, Delta(9)-tetrahydrocannabinol, activates the CB1 and CB2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids.	Dronabinol	35-64	cannabinoid receptor 2	Homo sapiens	88-91
18691603-2	2009	This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors.	Dronabinol	70-97	cannabinoid receptor 1	Homo sapiens	196-199
18691603-2	2009	This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors.	Dronabinol	70-97	cannabinoid receptor 2	Homo sapiens	213-216
18691603-2	2009	This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors.	Dronabinol	99-109	cannabinoid receptor 1	Homo sapiens	196-199
18691603-2	2009	This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors.	Dronabinol	99-109	cannabinoid receptor 2	Homo sapiens	213-216
19283865-0	2009	An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats.	Dronabinol	12-15	purinergic receptor P2X 3	Rattus norvegicus	85-89
19283865-0	2009	An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats.	Dronabinol	12-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	94-99
19283865-8	2009	RESULTS: Treatment with PSS caused and upregulation of tachykinins and P2X3 and TRPV1 receptors, which was prevented in the group treated with THC-002.	Dronabinol	143-146	purinergic receptor P2X 3	Rattus norvegicus	71-75
19283865-8	2009	RESULTS: Treatment with PSS caused and upregulation of tachykinins and P2X3 and TRPV1 receptors, which was prevented in the group treated with THC-002.	Dronabinol	143-146	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	80-85
19283865-11	2009	CONCLUSIONS: In SHRs, THC-002 reduced the bladder expression of tachykinins and P2X3 and TRPV1 receptors, and inhibited ATP-induced detrusor overactivity.	Dronabinol	22-25	purinergic receptor P2X 3	Rattus norvegicus	80-84
19283865-11	2009	CONCLUSIONS: In SHRs, THC-002 reduced the bladder expression of tachykinins and P2X3 and TRPV1 receptors, and inhibited ATP-induced detrusor overactivity.	Dronabinol	22-25	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	89-94
18791168-0	2008	Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.	Dronabinol	127-154	cannabinoid receptor 2 (macrophage)	Mus musculus	62-65
18791168-4	2008	Likewise, similar control responses and sensitivity to Delta9-THC were observed in mixed lymphocyte responses (MLR) and in IL-2 and IFN-gamma production in both genotypes.	Dronabinol	55-65	interleukin 2	Mus musculus	123-127
18791168-4	2008	Likewise, similar control responses and sensitivity to Delta9-THC were observed in mixed lymphocyte responses (MLR) and in IL-2 and IFN-gamma production in both genotypes.	Dronabinol	55-65	interferon gamma	Mus musculus	132-141
18791168-6	2008	Delta9-THC suppressed the in vivo T cell-dependent, anti-sheep RBC (anti-sRBC) IgM antibody-forming cell (AFC) response in wild-type but not in CB1(-/-)/CB2(-/-) mice, and the in vitro anti-sRBC IgM response in CB1(-/-)/CB2(-/-) splenocytes was too low to rigorously assess CB1/CB2 involvement in modulation by Delta9-THC.	Dronabinol	0-10	cannabinoid receptor 1 (brain)	Mus musculus	211-214
18791168-6	2008	Delta9-THC suppressed the in vivo T cell-dependent, anti-sheep RBC (anti-sRBC) IgM antibody-forming cell (AFC) response in wild-type but not in CB1(-/-)/CB2(-/-) mice, and the in vitro anti-sRBC IgM response in CB1(-/-)/CB2(-/-) splenocytes was too low to rigorously assess CB1/CB2 involvement in modulation by Delta9-THC.	Dronabinol	0-10	cannabinoid receptor 2 (macrophage)	Mus musculus	220-223
18791168-6	2008	Delta9-THC suppressed the in vivo T cell-dependent, anti-sheep RBC (anti-sRBC) IgM antibody-forming cell (AFC) response in wild-type but not in CB1(-/-)/CB2(-/-) mice, and the in vitro anti-sRBC IgM response in CB1(-/-)/CB2(-/-) splenocytes was too low to rigorously assess CB1/CB2 involvement in modulation by Delta9-THC.	Dronabinol	0-10	cannabinoid receptor 1 (brain)	Mus musculus	211-214
18791168-6	2008	Delta9-THC suppressed the in vivo T cell-dependent, anti-sheep RBC (anti-sRBC) IgM antibody-forming cell (AFC) response in wild-type but not in CB1(-/-)/CB2(-/-) mice, and the in vitro anti-sRBC IgM response in CB1(-/-)/CB2(-/-) splenocytes was too low to rigorously assess CB1/CB2 involvement in modulation by Delta9-THC.	Dronabinol	0-10	cannabinoid receptor 2 (macrophage)	Mus musculus	220-223
18791168-8	2008	Interestingly, LPS-induced IgM responses were refractory to suppression by Delta9-THC, regardless of genotype, and CD40L-induced IgM responses were only suppressed by Delta9-THC in wild-type but not in CB1(-/-)/CB2(-/-) B cells.	Dronabinol	167-177	CD40 ligand	Mus musculus	115-120
18789920-0	2008	Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration.	Dronabinol	0-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-63
18789920-3	2008	Western Blot and immunocytochemistry stereological analyses indicated that delta-9-tetrahydrocannabinol (0.5 mg/kg) increased striatal c-Fos immunoreactivity induced by haloperidol (0.1 mg/kg).	Dronabinol	75-103	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	135-140
18789920-5	2008	The present results indicate that the behavioral effects induced by delta-9-tetrahydrocannabinol in haloperidol- and clozapine-treated rats are associated with different striatal c-Fos expressions.	Dronabinol	68-96	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	179-184
18674887-9	2008	Other significant THC-induced effects were confined to the NAc - increased anandamide, decreased Met-enkephalin and decreased microORs.	Dronabinol	18-21	proenkephalin	Rattus norvegicus	101-111
18554250-2	2008	A recent study showed that phytocannabinoids like tetrahydrocannabinol reduce AANAT activity and attenuate NE-induced melatonin biosynthesis in rat pineal glands, raising the possibility that an endocannabinoid system is present in the pineal gland.	Dronabinol	50-70	aralkylamine N-acetyltransferase	Rattus norvegicus	78-83
18172430-5	2008	CB1 receptor level and CB1/G-protein coupling were significantly reduced by THC exposure in the amygdala (Amyg), ventral tegmental area (VTA) and nucleus accumbens (NAc) of female rats, whereas male rats had significant alterations only in the amygdala and hippocampal formation.	Dronabinol	76-79	cannabinoid receptor 1	Rattus norvegicus	0-3
18172430-5	2008	CB1 receptor level and CB1/G-protein coupling were significantly reduced by THC exposure in the amygdala (Amyg), ventral tegmental area (VTA) and nucleus accumbens (NAc) of female rats, whereas male rats had significant alterations only in the amygdala and hippocampal formation.	Dronabinol	76-79	cannabinoid receptor 1	Rattus norvegicus	23-26
18556036-0	2008	Clarifying CB2 receptor-dependent and independent effects of THC on human lung epithelial cells.	Dronabinol	61-64	cannabinoid receptor 2	Homo sapiens	11-14
18556036-19	2008	Serum exposure activated several signaling events of which phosphorylation of IkappaB-alpha and JNK was regulated in a CB2R- and THC-dependent manner.	Dronabinol	129-132	NFKB inhibitor alpha	Homo sapiens	78-91
18556036-19	2008	Serum exposure activated several signaling events of which phosphorylation of IkappaB-alpha and JNK was regulated in a CB2R- and THC-dependent manner.	Dronabinol	129-132	mitogen-activated protein kinase 8	Homo sapiens	96-99
18619955-3	2008	Indeed, the cannabinoids enhanced the intracellular accumulation of two ABCC1 substrates, Fluo3 and vincristine, in ovarian carcinoma cells over-expressing ABCC1 (2008/MRP1) with a rank order of potency: cannabidiol&gt;cannabinol&gt;Delta(9)-tetrahydrocannabinol.	Dronabinol	233-262	ATP binding cassette subfamily C member 1	Homo sapiens	156-161
18331373-3	2008	Being lipophilic, Delta(9) tetrahydrocannabinol (THC), the main cannabis component, could be a potential P-gp substrate.	Dronabinol	18-47	phosphoglycolate phosphatase	Mus musculus	105-109
18331373-3	2008	Being lipophilic, Delta(9) tetrahydrocannabinol (THC), the main cannabis component, could be a potential P-gp substrate.	Dronabinol	49-52	phosphoglycolate phosphatase	Mus musculus	105-109
18331373-4	2008	The aim of this project was to determine the contribution of the mdr1a gene product to THC disposition.	Dronabinol	87-90	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	65-70
18331373-7	2008	The application of Bailer"s method showed that THC total exposure measured by the area under the plasma concentration time curve was 2.17-fold higher in CF1 mice naturally deficient in P-gp than in wild type mice after oral administration of 25 mg/kg of THC, and 2.4-fold higher after oral administration of 33 microg/kg of digoxin.	Dronabinol	47-50	phosphoglycolate phosphatase	Mus musculus	185-189
18331373-7	2008	The application of Bailer"s method showed that THC total exposure measured by the area under the plasma concentration time curve was 2.17-fold higher in CF1 mice naturally deficient in P-gp than in wild type mice after oral administration of 25 mg/kg of THC, and 2.4-fold higher after oral administration of 33 microg/kg of digoxin.	Dronabinol	254-257	phosphoglycolate phosphatase	Mus musculus	185-189
18331373-9	2008	We concluded that P-gp limits THC oral uptake and mediates direct drug excretion from the systemic circulation into the intestinal lumen.	Dronabinol	30-33	phosphoglycolate phosphatase	Mus musculus	18-22
18608861-5	2008	Sensitisation appeared to be dependent upon the ability of THC to down regulate phosphorylated ERK, as cells dominantly expressive of MEK were not sensitised to the cytotoxic drugs by equi-molar amounts of THC.	Dronabinol	59-62	mitogen-activated protein kinase 1	Homo sapiens	95-98
18608861-5	2008	Sensitisation appeared to be dependent upon the ability of THC to down regulate phosphorylated ERK, as cells dominantly expressive of MEK were not sensitised to the cytotoxic drugs by equi-molar amounts of THC.	Dronabinol	59-62	mitogen-activated protein kinase kinase 7	Homo sapiens	134-137
18602444-5	2008	The existing information indicating the importance of beta-endorphin neurotransmission in mediating the reward pathways of nicotine and THC, is thus far circumstantial.	Dronabinol	136-139	pro-opiomelanocortin-alpha	Mus musculus	54-68
18454173-0	2008	JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.	Dronabinol	52-79	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-4
18454173-2	2008	Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family.	Dronabinol	33-62	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-158
18454173-2	2008	Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family.	Dronabinol	64-67	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-158
18454173-3	2008	THC activates JunD both by upregulating gene expression and by translocating the protein to the nuclear compartment, and these events are accompanied by a decrease in cell proliferation.	Dronabinol	0-3	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-18
18454173-6	2008	Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized fibroblasts, the antiproliferative effect exerted by THC was significantly diminished.	Dronabinol	151-154	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-18
18454173-6	2008	Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized fibroblasts, the antiproliferative effect exerted by THC was significantly diminished.	Dronabinol	151-154	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-62
18454173-8	2008	In addition, our data suggest that the stress-regulated protein p8 participates in THC antiproliferative action in a JunD-independent manner.	Dronabinol	83-86	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-121
18544469-0	2008	Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.	Dronabinol	22-49	E1A binding protein p300	Homo sapiens	100-104
18544469-6	2008	As expected, Delta9-THC revealed a significant reduction of P300 amplitude at midline frontal, central, and parietal electrodes.	Dronabinol	13-23	E1A binding protein p300	Homo sapiens	60-64
18924447-2	2008	delta9-tetrahydrocannabinol, the main psychotropic component of Cannabis, acts via at least two types of cannabinoid receptors, named CB1 and CB2 receptors.	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	134-137
18924447-2	2008	delta9-tetrahydrocannabinol, the main psychotropic component of Cannabis, acts via at least two types of cannabinoid receptors, named CB1 and CB2 receptors.	Dronabinol	0-27	cannabinoid receptor 2	Homo sapiens	142-145
18565508-15	2008	These findings suggest that the 5-HT(1A) receptors are involved in THC-induced enhancement of immobility.	Dronabinol	67-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-39
18515013-5	2008	In HeLa cells transiently expressing mouse TRPA1, activation of TRPA1 by THC was slow and weak from the extracellular side (cell-attached; K(1/2) &gt;20 microM), but was faster and more potent from the intracellular side (inside-out; K(1/2), approximately 0.7 microM), and this did not require the presence of a polyphosphate.	Dronabinol	73-76	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	43-48
18515013-5	2008	In HeLa cells transiently expressing mouse TRPA1, activation of TRPA1 by THC was slow and weak from the extracellular side (cell-attached; K(1/2) &gt;20 microM), but was faster and more potent from the intracellular side (inside-out; K(1/2), approximately 0.7 microM), and this did not require the presence of a polyphosphate.	Dronabinol	73-76	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	64-69
18515013-11	2008	THC can activate TRPA1 even in the absence of polyphosphates, whereas pungent chemicals and Ca(2+) require it for activation.	Dronabinol	0-3	transient receptor potential cation channel subfamily A member 1	Homo sapiens	17-22
18622177-0	2008	Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice.	Dronabinol	15-42	arrestin, beta 2	Mus musculus	70-84
18388242-9	2008	The modulatory effect of THC in ConA-induced hepatitis was reversed by both CB1 and CB2 antagonists.	Dronabinol	25-28	cannabinoid receptor 1 (brain)	Mus musculus	76-79
18388242-9	2008	The modulatory effect of THC in ConA-induced hepatitis was reversed by both CB1 and CB2 antagonists.	Dronabinol	25-28	cannabinoid receptor 2 (macrophage)	Mus musculus	84-87
18390906-2	2008	THC is the prototypic cannabinoid CB1 receptor agonist and is psychoactive and analgesic.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	34-37
18390906-6	2008	At moderately hyperpolarized potentials, THC and CBD inhibited peak Ca(V)3.1 and Ca(V)3.2 currents with IC(50) values of approximately 1 mum but were less potent on Ca(V)3.3 channels.	Dronabinol	41-44	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	68-76
18390906-6	2008	At moderately hyperpolarized potentials, THC and CBD inhibited peak Ca(V)3.1 and Ca(V)3.2 currents with IC(50) values of approximately 1 mum but were less potent on Ca(V)3.3 channels.	Dronabinol	41-44	caveolin 3	Homo sapiens	68-74
18390906-6	2008	At moderately hyperpolarized potentials, THC and CBD inhibited peak Ca(V)3.1 and Ca(V)3.2 currents with IC(50) values of approximately 1 mum but were less potent on Ca(V)3.3 channels.	Dronabinol	41-44	immunoglobulin lambda variable 7-46	Homo sapiens	165-173
18390906-8	2008	However, in recordings made from a holding potential of -70 mV, 100 nm THC or CBD inhibited more than 50% of the peak Ca(V)3.1 current.	Dronabinol	71-74	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	118-126
18390906-9	2008	THC and CBD produced a significant hyperpolarizing shift in the steady state inactivation potentials for each of the Ca(V)3 channels, which accounts for inhibition of channel currents.	Dronabinol	0-3	caveolin 3	Homo sapiens	117-123
18390906-10	2008	Additionally, THC caused a modest hyperpolarizing shift in the activation of Ca(V)3.1 and Ca(V)3.2.	Dronabinol	14-17	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	77-85
18390906-10	2008	Additionally, THC caused a modest hyperpolarizing shift in the activation of Ca(V)3.1 and Ca(V)3.2.	Dronabinol	14-17	immunoglobulin lambda variable 7-43	Homo sapiens	90-98
18390906-11	2008	THC but not CBD slowed Ca(V)3.1 and Ca(V)3.2 deactivation and inactivation kinetics.	Dronabinol	0-3	calcium voltage-gated channel subunit alpha1 G	Homo sapiens	23-31
18390906-11	2008	THC but not CBD slowed Ca(V)3.1 and Ca(V)3.2 deactivation and inactivation kinetics.	Dronabinol	0-3	immunoglobulin lambda variable 7-43	Homo sapiens	36-44
18390906-12	2008	Thus, THC and CBD inhibit Ca(V)3 channels at pharmacologically relevant concentrations.	Dronabinol	6-9	caveolin 3	Homo sapiens	26-32
18482430-1	2008	A major finding--that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis--prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB(1) and CB(2), and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications.	Dronabinol	22-61	cannabinoid receptor 1	Homo sapiens	294-299
18482430-1	2008	A major finding--that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis--prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB(1) and CB(2), and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications.	Dronabinol	22-61	cannabinoid receptor 2	Homo sapiens	304-309
18482430-1	2008	A major finding--that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis--prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB(1) and CB(2), and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications.	Dronabinol	63-75	cannabinoid receptor 1	Homo sapiens	294-299
18482430-1	2008	A major finding--that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis--prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB(1) and CB(2), and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications.	Dronabinol	63-75	cannabinoid receptor 2	Homo sapiens	304-309
18247131-0	2008	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.	Dronabinol	16-44	chemokine (C-C motif) ligand 5	Mus musculus	93-99
18247131-0	2008	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.	Dronabinol	16-44	chemokine (C-C motif) ligand 5	Mus musculus	100-104
18247131-0	2008	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.	Dronabinol	16-44	cannabinoid receptor 2 (macrophage)	Mus musculus	121-124
18247131-1	2008	The chemotactic response of murine peritoneal macrophages to RANTES/CCL5 was inhibited significantly following pretreatment with delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana.	Dronabinol	129-157	chemokine (C-C motif) ligand 5	Mus musculus	61-67
18247131-1	2008	The chemotactic response of murine peritoneal macrophages to RANTES/CCL5 was inhibited significantly following pretreatment with delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana.	Dronabinol	129-157	chemokine (C-C motif) ligand 5	Mus musculus	68-72
18247131-1	2008	The chemotactic response of murine peritoneal macrophages to RANTES/CCL5 was inhibited significantly following pretreatment with delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana.	Dronabinol	159-162	chemokine (C-C motif) ligand 5	Mus musculus	61-67
18247131-1	2008	The chemotactic response of murine peritoneal macrophages to RANTES/CCL5 was inhibited significantly following pretreatment with delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana.	Dronabinol	159-162	chemokine (C-C motif) ligand 5	Mus musculus	68-72
18247131-4	2008	The THC-mediated inhibition was reversed by the CB2 receptor-specific antagonist SR144528 but not by the CB1 receptor-specific antagonist SR141716A.	Dronabinol	4-7	cannabinoid receptor 2 (macrophage)	Mus musculus	48-51
18354058-1	2008	The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Delta(9)-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1), respectively.	Dronabinol	67-96	transient receptor potential cation channel subfamily V member 1	Homo sapiens	201-206
18354058-1	2008	The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Delta(9)-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1), respectively.	Dronabinol	67-96	transient receptor potential cation channel subfamily A member 1	Homo sapiens	228-233
18354058-1	2008	The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Delta(9)-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1), respectively.	Dronabinol	98-101	transient receptor potential cation channel subfamily V member 1	Homo sapiens	201-206
18354058-1	2008	The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Delta(9)-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1), respectively.	Dronabinol	98-101	transient receptor potential cation channel subfamily A member 1	Homo sapiens	228-233
18205240-3	2008	When delta-9-THC was derivatized by trifluoroacetic anhydride/hexafluoroisopropanol (TFAA/HFIPOH) and analyzed by GC-MS using full scan mode (50-550 amu), two peaks (P1 and P2) with an identical molecular mass of 410 amu were observed.	Dronabinol	5-16	crystallin gamma F, pseudogene	Homo sapiens	166-175
18248609-0	2008	A role for p53 in the regulation of lysosomal permeability by delta 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration.	Dronabinol	62-90	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	11-14
18248609-5	2008	Delta9-THC increased the localization of phospho-p53Ser15 at the lysosome and stimulated the release of the lysosomal cathepsin enzyme, cathepsin-D, into the cytosol.	Dronabinol	0-10	cathepsin D	Rattus norvegicus	136-147
18248609-6	2008	The p53 inhibitor, pifithrin-alpha and small interfering RNA-mediated knockdown of p53 prevented the Delta9-THC-mediated increase in lysosomal permeability.	Dronabinol	101-111	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	4-7
18248609-6	2008	The p53 inhibitor, pifithrin-alpha and small interfering RNA-mediated knockdown of p53 prevented the Delta9-THC-mediated increase in lysosomal permeability.	Dronabinol	101-111	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	83-86
18248609-7	2008	Furthermore, the Delta9-THC -mediated induction of apoptosis was abrogated by a cell-permeable cathepsin-D inhibitor (10 microM).	Dronabinol	17-27	cathepsin D	Rattus norvegicus	95-106
18248609-8	2008	Thus, the study demonstrates that Delta9-THC impacts on the lysosomal system, via p53, to evoke lysosomal instability as an early event in the apoptotic cascade.	Dronabinol	34-44	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	82-85
18248609-9	2008	This provides evidence for a novel link between the CB1 receptor and the lysosomal branch of the apoptotic pathway which is crucial in regulating neuronal viability following exposure to Delta9-THC.	Dronabinol	187-197	cannabinoid receptor 1	Rattus norvegicus	52-55
18083204-11	2008	The expression of the cytokine IL-6 was upregulated 48 h after the single treatment with 5 microM of THC or JWH 015, whereas the expression of TNF-alpha remained unchanged.	Dronabinol	101-104	interleukin 6	Rattus norvegicus	31-35
18083204-12	2008	These results suggest that the adverse effects of THC were related either to THC accumulation or to cannabinoid receptor activation and associated with IL-6 upregulation.	Dronabinol	50-53	interleukin 6	Rattus norvegicus	152-156
18339876-4	2008	Local administration of Delta(9)-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated MMP-2 expression in gliomas generated in mice, as determined by Western blot, immunofluorescence, and real-time quantitative PCR analyses.	Dronabinol	24-53	matrix metallopeptidase 2	Homo sapiens	117-122
18339876-4	2008	Local administration of Delta(9)-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated MMP-2 expression in gliomas generated in mice, as determined by Western blot, immunofluorescence, and real-time quantitative PCR analyses.	Dronabinol	55-58	matrix metallopeptidase 2	Homo sapiens	117-122
18339876-6	2008	THC inhibited MMP-2 expression and cell invasion in cultured glioma cells.	Dronabinol	0-3	matrix metallopeptidase 2	Homo sapiens	14-19
18339876-7	2008	Manipulation of MMP-2 expression by RNA interference and cDNA overexpression experiments proved that down-regulation of this MMP plays a critical role in THC-mediated inhibition of cell invasion.	Dronabinol	154-157	matrix metallopeptidase 2	Homo sapiens	16-21
18339876-7	2008	Manipulation of MMP-2 expression by RNA interference and cDNA overexpression experiments proved that down-regulation of this MMP plays a critical role in THC-mediated inhibition of cell invasion.	Dronabinol	154-157	matrix metallopeptidase 2	Homo sapiens	16-19
18249480-7	2008	Interestingly, Delta(9)-THC upregulated human epithelial growth factor receptor type 2 (HER2) expression, which is known to be a predictive factor of human breast cancer and is able to stimulate cancer cells as well as MCF-7 cells.	Dronabinol	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
18249480-9	2008	Taken together, these studies suggest that, in the absence of CB receptors, Delta(9)-THC can stimulate the proliferation of MCF-7 cells by modulating, at least in part, HER2 transcription.	Dronabinol	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
18323569-3	2008	Here we show that CB1 activation by WIN55,212-2 and Delta(9)-THC inhibits long-term depression (LTD) of basal synaptic transmission in the LA, induced by low-frequency stimulation (LFS; 900 pulses/1 Hz).	Dronabinol	52-64	cannabinoid receptor 1 (brain)	Mus musculus	18-21
18263732-4	2008	GPR55 is highly expressed in large dorsal root ganglion neurons and, upon activation by various cannabinoids (Delta(9)THC, the anandamide analog methanandamide, and JWH015) increases intracellular calcium in these neurons.	Dronabinol	110-121	G protein-coupled receptor 55	Homo sapiens	0-5
20641836-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
20641836-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
18041576-3	2008	Here, we review previous literatures that focus on the effects of exposure to cocaine, amphetamine, Delta(9)-tetrahydrocannabinol (THC), nicotine, morphine, and alcohol on ERK signaling in the mesocorticolimbic dopamine system; these alterations of ERK signaling have been thought to contribute to the drug"s rewarding effects and to the long-term maladaptation induced by drug abuse.	Dronabinol	100-129	mitogen-activated protein kinase 1	Homo sapiens	172-175
18041576-3	2008	Here, we review previous literatures that focus on the effects of exposure to cocaine, amphetamine, Delta(9)-tetrahydrocannabinol (THC), nicotine, morphine, and alcohol on ERK signaling in the mesocorticolimbic dopamine system; these alterations of ERK signaling have been thought to contribute to the drug"s rewarding effects and to the long-term maladaptation induced by drug abuse.	Dronabinol	100-129	mitogen-activated protein kinase 1	Homo sapiens	249-252
18041576-3	2008	Here, we review previous literatures that focus on the effects of exposure to cocaine, amphetamine, Delta(9)-tetrahydrocannabinol (THC), nicotine, morphine, and alcohol on ERK signaling in the mesocorticolimbic dopamine system; these alterations of ERK signaling have been thought to contribute to the drug"s rewarding effects and to the long-term maladaptation induced by drug abuse.	Dronabinol	131-134	mitogen-activated protein kinase 1	Homo sapiens	172-175
18041576-3	2008	Here, we review previous literatures that focus on the effects of exposure to cocaine, amphetamine, Delta(9)-tetrahydrocannabinol (THC), nicotine, morphine, and alcohol on ERK signaling in the mesocorticolimbic dopamine system; these alterations of ERK signaling have been thought to contribute to the drug"s rewarding effects and to the long-term maladaptation induced by drug abuse.	Dronabinol	131-134	mitogen-activated protein kinase 1	Homo sapiens	249-252
17986216-3	2008	The treatment of CB1 receptors with the low endocytotic agonist Delta9-THC induced a faster receptor desensitization and slower resensitization than the high endocytotic agonist WIN 55,212-2.	Dronabinol	64-74	cannabinoid receptor 1	Homo sapiens	17-20
17986216-7	2008	Moreover, in primary cultured neurons, the low endocytotic agonist Delta9-THC or anandamide exhibited a greater desensitization of endogenous CB1 receptors than the high endocytotic agonist WIN 55,212-2, CP 55940 or 2-arachidonoyl glycerol, indicating that cannabinoids with high endocytotic efficacy might cause reduced development of cannabinoid tolerance to some kind cannabinoid-mediated effects.	Dronabinol	67-77	cannabinoid receptor 1	Homo sapiens	142-145
20641952-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
20641952-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
17621270-2	2008	Little is known about the activity of cannabinoids like THC on epidermal growth factor receptor-overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy.	Dronabinol	56-59	epidermal growth factor receptor	Homo sapiens	63-95
17621270-5	2008	Moreover, signaling studies indicated that THC may act by inhibiting the EGF-induced phosphorylation of ERK1/2, JNK1/2 and AKT.	Dronabinol	43-46	mitogen-activated protein kinase 3	Homo sapiens	104-110
17621270-5	2008	Moreover, signaling studies indicated that THC may act by inhibiting the EGF-induced phosphorylation of ERK1/2, JNK1/2 and AKT.	Dronabinol	43-46	AKT serine/threonine kinase 1	Homo sapiens	112-126
18159069-7	2008	RESULTS: Without modifying migration, MA and THC caused a time- and concentration-dependent suppression of HeLa cell invasion through Matrigel that was accompanied by increased expression of TIMP-1.	Dronabinol	45-48	TIMP metallopeptidase inhibitor 1	Homo sapiens	191-197
17934890-0	2008	Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.	Dronabinol	0-28	E2F transcription factor 1 L homeolog	Xenopus laevis	82-86
17934890-9	2008	CONCLUSIONS: Delta(9)-THC is shown to significantly affect viability of GBM cells via a mechanism that appears to elicit G(1) arrest due to downregulation of E2F1 and Cyclin A.	Dronabinol	13-25	E2F transcription factor 1	Homo sapiens	158-162
17934890-9	2008	CONCLUSIONS: Delta(9)-THC is shown to significantly affect viability of GBM cells via a mechanism that appears to elicit G(1) arrest due to downregulation of E2F1 and Cyclin A.	Dronabinol	13-25	cyclin A2	Homo sapiens	167-175
17965744-4	2008	Delta-9-Tetrahydrocannabinol (THC)-mediated activation has been shown to inhibit atherosclerotic plaque progression in a CB2 dependent manner.	Dronabinol	0-28	cannabinoid receptor 2	Homo sapiens	121-124
17965744-4	2008	Delta-9-Tetrahydrocannabinol (THC)-mediated activation has been shown to inhibit atherosclerotic plaque progression in a CB2 dependent manner.	Dronabinol	30-33	cannabinoid receptor 2	Homo sapiens	121-124
17675107-4	2008	Local administration of Delta(9)-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated TIMP-1 expression in mice bearing subcutaneous gliomas, as determined by Western blot and immunofluorescence analyses.	Dronabinol	24-53	TIMP metallopeptidase inhibitor 1	Homo sapiens	117-123
17675107-4	2008	Local administration of Delta(9)-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated TIMP-1 expression in mice bearing subcutaneous gliomas, as determined by Western blot and immunofluorescence analyses.	Dronabinol	55-58	TIMP metallopeptidase inhibitor 1	Homo sapiens	117-123
17675107-6	2008	THC also depressed TIMP-1 expression in cultures of various human glioma cell lines as well as in primary tumor cells obtained from a glioblastoma multiforme patient.	Dronabinol	0-3	TIMP metallopeptidase inhibitor 1	Homo sapiens	19-25
17686497-0	2008	Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.	Dronabinol	42-69	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	14-22
17686497-3	2008	In this study, we have examined the effect produced by systemic administration of Delta(9)-tetrahydrocannabinol (THC), the major component of marihuana and hashish, on DARPP-32.	Dronabinol	82-111	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	168-176
17686497-3	2008	In this study, we have examined the effect produced by systemic administration of Delta(9)-tetrahydrocannabinol (THC), the major component of marihuana and hashish, on DARPP-32.	Dronabinol	113-116	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	168-176
17686497-4	2008	We show that THC increases DARPP-32 phosphorylation at Thr 34 both in dorsal striatum and nucleus accumbens.	Dronabinol	13-16	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	27-35
17686497-5	2008	Time-course and dose-response experiments indicate that DARPP-32 phosphorylation is maximal 30 min following administration of 10mg/kg of THC.	Dronabinol	138-141	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	56-64
17686497-6	2008	The THC-mediated increase in DARPP-32 phosphorylation is reduced by administration of the CB1 receptor antagonist, SR141716A (3mg/kg).	Dronabinol	4-7	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	29-37
17686497-6	2008	The THC-mediated increase in DARPP-32 phosphorylation is reduced by administration of the CB1 receptor antagonist, SR141716A (3mg/kg).	Dronabinol	4-7	cannabinoid receptor 1	Homo sapiens	90-93
17686497-7	2008	A similar attenuation of the effect of THC is also exerted by suppression of cAMP signaling achieved using the dopamine D1 receptor antagonist, SCH23390 (0.125 mg/kg), or the adenosine A2A receptor antagonist, KW6002 (3mg/kg).	Dronabinol	39-42	dopamine receptor D1	Homo sapiens	111-131
17686497-7	2008	A similar attenuation of the effect of THC is also exerted by suppression of cAMP signaling achieved using the dopamine D1 receptor antagonist, SCH23390 (0.125 mg/kg), or the adenosine A2A receptor antagonist, KW6002 (3mg/kg).	Dronabinol	39-42	adenosine A2a receptor	Homo sapiens	175-197
17686497-8	2008	These results indicate that, in the striatum, THC promotes PKA-dependent phosphorylation of DARPP-32 in striatal medium spiny neurons expressing dopamine D1 and adenosine A2A receptors.	Dronabinol	46-49	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	92-100
17692344-3	2008	We investigated the effect on rat anxiety behavior of local administration of THC in the prefrontal cortex, basolateral amygdala and ventral hippocampus, brain regions belonging to the emotional circuit and containing high levels of CB1 receptors.	Dronabinol	78-81	cannabinoid receptor 1	Rattus norvegicus	233-236
17692344-7	2008	Specifically, THC anxiolytic activity in the prefrontal cortex and ventral hippocampus was paralleled by an increase in CREB activation, whilst THC anxiogenic response in the basolateral amygdala was paralleled by a decrease in CREB activation.	Dronabinol	14-17	cAMP responsive element binding protein 1	Rattus norvegicus	120-124
17692344-7	2008	Specifically, THC anxiolytic activity in the prefrontal cortex and ventral hippocampus was paralleled by an increase in CREB activation, whilst THC anxiogenic response in the basolateral amygdala was paralleled by a decrease in CREB activation.	Dronabinol	14-17	cAMP responsive element binding protein 1	Rattus norvegicus	228-232
17888506-4	2008	In an attempt to find a biochemical correlate to these deleterious consequences of such a low dose of THC, we investigated its effect on the activation of extracellular signal-regulated kinase (ERK1/2) in the cerebellum and hippocampus of the mice, two brain regions that were shown to participate in spatial learning.	Dronabinol	102-105	mitogen-activated protein kinase 3	Mus musculus	194-200
17888506-5	2008	A significant increase in ERK1/2 phosphorylation was found in the cerebellum of mice 24 h following the injection of 0.001 mg/kg THC.	Dronabinol	129-132	mitogen-activated protein kinase 3	Mus musculus	26-32
17705665-6	2008	Curcuminoids and THC had dose-dependent inhibitory effects on ROS production and MPO release by activated neutrophils and on purified MPO activity.	Dronabinol	17-20	myeloperoxidase	Equus caballus	81-84
17705665-6	2008	Curcuminoids and THC had dose-dependent inhibitory effects on ROS production and MPO release by activated neutrophils and on purified MPO activity.	Dronabinol	17-20	myeloperoxidase	Equus caballus	134-137
17705665-7	2008	We suggest that the higher efficacy of curcuminoids versus THC could be explained, at least partially, by its chemical structure: the conjugated double bounds and the plane structure of curcuminoids made easier the neutralization of the radical species generated by activated neutrophils and the interaction of the drug with the active site of MPO.	Dronabinol	59-62	myeloperoxidase	Equus caballus	344-347
18772044-4	2008	Systemic or intra-amygdaloid application of the interfering peptide Tat-3L4F is able to disrupt PTEN coupling with 5-HT2cR in the rat VTA, resulting both in a suppression of the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana, and in a blockade of the conditioned place preference induced by THC and nicotine [Ji, S.P.	Dronabinol	239-267	phosphatase and tensin homolog	Rattus norvegicus	96-100
18772044-4	2008	Systemic or intra-amygdaloid application of the interfering peptide Tat-3L4F is able to disrupt PTEN coupling with 5-HT2cR in the rat VTA, resulting both in a suppression of the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana, and in a blockade of the conditioned place preference induced by THC and nicotine [Ji, S.P.	Dronabinol	269-272	phosphatase and tensin homolog	Rattus norvegicus	96-100
18772044-4	2008	Systemic or intra-amygdaloid application of the interfering peptide Tat-3L4F is able to disrupt PTEN coupling with 5-HT2cR in the rat VTA, resulting both in a suppression of the increased firing rate of VTA dopaminergic neurons induced by Delta 9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana, and in a blockade of the conditioned place preference induced by THC and nicotine [Ji, S.P.	Dronabinol	382-385	phosphatase and tensin homolog	Rattus norvegicus	96-100
17827022-4	2007	Hybrid 1 (O-2220) was found to have very high binding affinity to CB1 receptors (K(i)=8.5 nM), and it is interesting to note that the orientation of the side chain with respect to the oxygen in the phenol is the same as in THCs.	Dronabinol	223-227	cannabinoid receptor 1	Homo sapiens	66-69
17876300-5	2007	For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.	Dronabinol	116-143	cannabinoid receptor 1 (brain)	Mus musculus	17-20
17876300-5	2007	For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.	Dronabinol	116-143	G protein-coupled receptor 55	Mus musculus	59-64
17876300-5	2007	For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.	Dronabinol	116-143	G protein-coupled receptor 55	Mus musculus	175-180
17876300-5	2007	For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.	Dronabinol	116-143	cannabinoid receptor 1 (brain)	Mus musculus	189-192
17876300-5	2007	For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors.	Dronabinol	116-143	cannabinoid receptor 2 (macrophage)	Mus musculus	196-199
18057774-9	2007	Thus, on the basis of these results, it appears that 5-HT(2A)-receptor mechanisms might be responsible for the inhibitory effect of DOI on THC-induced catalepsy-like immobilization.	Dronabinol	139-142	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	53-70
17905522-0	2007	Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression.	Dronabinol	69-89	neuregulin 1	Mus musculus	13-25
17905522-0	2007	Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression.	Dronabinol	69-89	FBJ osteosarcoma oncogene	Mus musculus	98-103
17905522-3	2007	We have recently shown that Nrg1 HET mice are more sensitive to the behavioral effects of the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	137-166	neuregulin 1	Mus musculus	28-32
17905522-3	2007	We have recently shown that Nrg1 HET mice are more sensitive to the behavioral effects of the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	137-166	NADPH oxidase 3	Mus musculus	33-36
17905522-3	2007	We have recently shown that Nrg1 HET mice are more sensitive to the behavioral effects of the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	168-171	neuregulin 1	Mus musculus	28-32
17905522-3	2007	We have recently shown that Nrg1 HET mice are more sensitive to the behavioral effects of the main psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC).	Dronabinol	168-171	NADPH oxidase 3	Mus musculus	33-36
17905522-6	2007	In the lateral septum, THC selectively increased c-Fos expression in Nrg1 HET mice with no corresponding effect being observed in WT mice.	Dronabinol	23-26	FBJ osteosarcoma oncogene	Mus musculus	49-54
17905522-6	2007	In the lateral septum, THC selectively increased c-Fos expression in Nrg1 HET mice with no corresponding effect being observed in WT mice.	Dronabinol	23-26	neuregulin 1	Mus musculus	69-73
17905522-6	2007	In the lateral septum, THC selectively increased c-Fos expression in Nrg1 HET mice with no corresponding effect being observed in WT mice.	Dronabinol	23-26	NADPH oxidase 3	Mus musculus	74-77
17905522-7	2007	In addition, THC promoted a greater increase in c-Fos expression in Nrg1 HET mice than WT mice in the central nucleus of the amygdala, the bed nucleus of the stria terminalis and the paraventricular nucleus of the hypothalamus.	Dronabinol	13-16	FBJ osteosarcoma oncogene	Mus musculus	48-53
17905522-7	2007	In addition, THC promoted a greater increase in c-Fos expression in Nrg1 HET mice than WT mice in the central nucleus of the amygdala, the bed nucleus of the stria terminalis and the paraventricular nucleus of the hypothalamus.	Dronabinol	13-16	neuregulin 1	Mus musculus	68-72
17905522-7	2007	In addition, THC promoted a greater increase in c-Fos expression in Nrg1 HET mice than WT mice in the central nucleus of the amygdala, the bed nucleus of the stria terminalis and the paraventricular nucleus of the hypothalamus.	Dronabinol	13-16	NADPH oxidase 3	Mus musculus	73-76
17905522-9	2007	Interestingly, the effects of genotype on c-Fos expression, drug-free or following THC exposure, were only observed when animals experienced behavioral testing prior to perfusion.	Dronabinol	83-86	FBJ osteosarcoma oncogene	Mus musculus	42-47
17905522-11	2007	These data provide neurobiological correlates for the enhanced behavioral sensitivity of Nrg1 HET mice to THC and reinforce the existence of cannabinoid-neuregulin 1 interactions in the CNS.	Dronabinol	106-109	neuregulin 1	Mus musculus	89-93
17905522-11	2007	These data provide neurobiological correlates for the enhanced behavioral sensitivity of Nrg1 HET mice to THC and reinforce the existence of cannabinoid-neuregulin 1 interactions in the CNS.	Dronabinol	106-109	NADPH oxidase 3	Mus musculus	94-97
17583570-0	2007	The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.	Dronabinol	16-45	mitogen-activated protein kinase 1	Homo sapiens	59-63
17583570-0	2007	The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.	Dronabinol	16-45	AKT serine/threonine kinase 1	Homo sapiens	73-76
17583570-5	2007	Here, we report that CB1 and CB2 cannabinoid receptors are expressed in human colorectal adenoma and carcinoma cells, and show for the first time that THC induces apoptosis in colorectal cancer cells.	Dronabinol	151-154	cannabinoid receptor 1	Homo sapiens	21-24
17583570-5	2007	Here, we report that CB1 and CB2 cannabinoid receptors are expressed in human colorectal adenoma and carcinoma cells, and show for the first time that THC induces apoptosis in colorectal cancer cells.	Dronabinol	151-154	cannabinoid receptor 2	Homo sapiens	29-32
17583570-6	2007	THC-induced apoptosis was rescued by pharmacological blockade of the CB1, but not CB2, cannabinoid receptor.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	69-72
17583570-7	2007	Importantly, THC treatment resulted in CB1-mediated inhibition of both RAS-MAPK/ERK and PI3K-AKT survival signalling cascades; two key cell survival pathways frequently deregulated in colorectal tumours.	Dronabinol	13-16	cannabinoid receptor 1	Homo sapiens	39-42
17583570-7	2007	Importantly, THC treatment resulted in CB1-mediated inhibition of both RAS-MAPK/ERK and PI3K-AKT survival signalling cascades; two key cell survival pathways frequently deregulated in colorectal tumours.	Dronabinol	13-16	mitogen-activated protein kinase 1	Homo sapiens	75-79
17583570-7	2007	Importantly, THC treatment resulted in CB1-mediated inhibition of both RAS-MAPK/ERK and PI3K-AKT survival signalling cascades; two key cell survival pathways frequently deregulated in colorectal tumours.	Dronabinol	13-16	mitogen-activated protein kinase 1	Homo sapiens	80-83
17583570-7	2007	Importantly, THC treatment resulted in CB1-mediated inhibition of both RAS-MAPK/ERK and PI3K-AKT survival signalling cascades; two key cell survival pathways frequently deregulated in colorectal tumours.	Dronabinol	13-16	AKT serine/threonine kinase 1	Homo sapiens	93-96
17583570-8	2007	The inhibition of ERK and AKT activity by THC was accompanied by activation of the proapoptotic BCL-2 family member BAD.	Dronabinol	42-45	mitogen-activated protein kinase 1	Homo sapiens	18-21
17583570-8	2007	The inhibition of ERK and AKT activity by THC was accompanied by activation of the proapoptotic BCL-2 family member BAD.	Dronabinol	42-45	AKT serine/threonine kinase 1	Homo sapiens	26-29
17704824-8	2007	Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma.	Dronabinol	67-96	peroxisome proliferator activated receptor gamma	Homo sapiens	153-163
17704824-8	2007	Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma.	Dronabinol	98-101	peroxisome proliferator activated receptor gamma	Homo sapiens	153-163
17704824-9	2007	THC also activates PPAR gamma, leading to a time-dependent vasorelaxation in isolated arteries.	Dronabinol	0-3	peroxisome proliferator activated receptor gamma	Homo sapiens	19-29
17828286-0	2007	Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed.	Dronabinol	0-28	calcitonin-related polypeptide alpha	Rattus norvegicus	58-62
17828286-8	2007	THC inhibited the electrically-evoked release of CGRP and sensory neurogenic vasorelaxation.	Dronabinol	0-3	calcitonin-related polypeptide alpha	Rattus norvegicus	49-53
17828286-10	2007	CONCLUSIONS AND IMPLICATIONS: THC inhibits the EFS-induced release of CGRP (and subsequent vasorelaxation), from capsaicin-sensitive sensory nerves in the rat perfused mesentery.	Dronabinol	30-33	calcitonin-related polypeptide alpha	Rattus norvegicus	70-74
17828286-11	2007	The effect of THC was not mediated by CB1, CB2 or TRPV1 receptors, but was sensitive to ruthenium red, suggesting a possible involvement of TRP ion channels.	Dronabinol	14-17	cannabinoid receptor 1	Rattus norvegicus	38-41
17828286-11	2007	The effect of THC was not mediated by CB1, CB2 or TRPV1 receptors, but was sensitive to ruthenium red, suggesting a possible involvement of TRP ion channels.	Dronabinol	14-17	cannabinoid receptor 2	Rattus norvegicus	43-46
17906686-3	2007	Here we address the interaction of cannabinol (CBN), cannabidiol (CBD) and delta 9-tetrahydrocannabinol (THC) with the related multidrug transporter, ABCG2.	Dronabinol	75-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	150-155
17906686-3	2007	Here we address the interaction of cannabinol (CBN), cannabidiol (CBD) and delta 9-tetrahydrocannabinol (THC) with the related multidrug transporter, ABCG2.	Dronabinol	105-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	150-155
17906686-7	2007	KEY RESULTS: CBN, CBD and THC increased the intracellular accumulation of the Abcg2/ABCG2 substrate, mitoxantrone, in an over-expressing cell line.	Dronabinol	26-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-83
17906686-7	2007	KEY RESULTS: CBN, CBD and THC increased the intracellular accumulation of the Abcg2/ABCG2 substrate, mitoxantrone, in an over-expressing cell line.	Dronabinol	26-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-89
17884022-5	2007	In this study we report that Delta(9)-tetrahydrocannabinol (5-50 microM) activates the stress-activated protein kinase, c-jun N-terminal kinase, and the pro-apoptotic protease, caspase-3, in in vitro cerebral cortical slices obtained from the neonatal rat brain.	Dronabinol	29-58	caspase 3	Rattus norvegicus	177-186
17884022-7	2007	In vivo, subcutaneous administration of Delta(9)-tetrahydrocannabinol (1-30 mg/kg) activated c-jun N-terminal kinase, caspase-3 and cathepsin-D, and induced DNA fragmentation in the cerebral cortex of neonatal rats.	Dronabinol	40-69	caspase 3	Rattus norvegicus	118-127
17884022-7	2007	In vivo, subcutaneous administration of Delta(9)-tetrahydrocannabinol (1-30 mg/kg) activated c-jun N-terminal kinase, caspase-3 and cathepsin-D, and induced DNA fragmentation in the cerebral cortex of neonatal rats.	Dronabinol	40-69	cathepsin D	Rattus norvegicus	132-143
17603035-1	2007	Morphine and delta9-tetrahydrocannabinol (THC) produce antinociception via mu opioid and cannabinoid CB1 receptors, respectively, located in central nervous system (CNS) regions including periaqueductal gray and spinal cord.	Dronabinol	13-40	cannabinoid receptor 1	Rattus norvegicus	101-104
17603035-1	2007	Morphine and delta9-tetrahydrocannabinol (THC) produce antinociception via mu opioid and cannabinoid CB1 receptors, respectively, located in central nervous system (CNS) regions including periaqueductal gray and spinal cord.	Dronabinol	42-45	cannabinoid receptor 1	Rattus norvegicus	101-104
17603035-10	2007	Administration of THC attenuated cannabinoid CB1 receptor-stimulated G-protein activity in both periaqueductal gray and spinal cord, and administration of morphine decreased mu opioid receptor-stimulated [35S]GTPgammaS binding in spinal cord or periaqueductal gray, depending on route of administration.	Dronabinol	18-21	cannabinoid receptor 1	Rattus norvegicus	45-48
17927447-1	2007	Marijuana and its main psychotropic ingredient Delta(9)-tetrahydrocannabinol (THC) exert a plethora of psychoactive effects through the activation of the neuronal cannabinoid receptor type 1 (CB1), which is expressed by different neuronal subpopulations in the central nervous system.	Dronabinol	47-76	cannabinoid receptor 1 (brain)	Mus musculus	192-195
17927447-1	2007	Marijuana and its main psychotropic ingredient Delta(9)-tetrahydrocannabinol (THC) exert a plethora of psychoactive effects through the activation of the neuronal cannabinoid receptor type 1 (CB1), which is expressed by different neuronal subpopulations in the central nervous system.	Dronabinol	78-81	cannabinoid receptor 1 (brain)	Mus musculus	192-195
17927447-4	2007	Surprisingly, mice lacking CB1 in GABAergic neurons responded to THC similarly as wild-type littermates did, whereas deletion of the receptor in all principal neurons abolished or strongly reduced the behavioural and autonomic responses to the drug.	Dronabinol	65-68	cannabinoid receptor 1 (brain)	Mus musculus	27-30
18035205-2	2007	Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS.	Dronabinol	0-29	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	186-189
18035205-2	2007	Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS.	Dronabinol	43-46	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	186-189
18035205-3	2007	OBJECTIVE: The purpose of this extension was to establish long-term tolerability and effectiveness profiles for THC/CBD (Sativex (R), GW Pharmaceuticals plc, Salisbury, United Kingdom) oromucosal spray in CNP associated with MS. METHODS: This uncontrolled, open-label trial was an indefinite-duration extension of a previously reported 5-week randomized study in patients with MS and CNP.	Dronabinol	112-115	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	205-208
18035205-3	2007	OBJECTIVE: The purpose of this extension was to establish long-term tolerability and effectiveness profiles for THC/CBD (Sativex (R), GW Pharmaceuticals plc, Salisbury, United Kingdom) oromucosal spray in CNP associated with MS. METHODS: This uncontrolled, open-label trial was an indefinite-duration extension of a previously reported 5-week randomized study in patients with MS and CNP.	Dronabinol	112-115	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	384-387
18035205-24	2007	CONCLUSIONS: THC/CBD was effective, with no evidence of tolerance, in these select patients with CNP and MS who completed approximately 2 years of treatment (n = 28).	Dronabinol	13-16	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	97-100
17640739-0	2007	Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.	Dronabinol	15-42	cannabinoid receptor 2	Homo sapiens	91-94
17287821-4	2007	In order to elucidate the neuroanatomical substrates underlying the effect of the maximal effective dose of THC, we investigated cFos expression in anxiety-related brain regions (prefrontal cortex, nucleus accumbens, amygdala, and hippocampus) of rats exposed to the EPM.	Dronabinol	108-111	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-133
17287821-5	2007	THC significantly lowered the amount of cFos in prefrontal cortex and amygdala without affecting the other cerebral areas.	Dronabinol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	40-44
17287821-7	2007	Rats treated with THC showed a significant increase in CREB activation in the prefrontal cortex and hippocampus.	Dronabinol	18-21	cAMP responsive element binding protein 1	Rattus norvegicus	55-59
17484726-1	2007	Delta9-tetrahydrocannabinol (THC), the main psychoactive component in Cannabis sativa preparations, exerts its central effects mainly through the G-protein coupled receptor CB1, a component of the endocannabinoid system.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	173-176
17484726-1	2007	Delta9-tetrahydrocannabinol (THC), the main psychoactive component in Cannabis sativa preparations, exerts its central effects mainly through the G-protein coupled receptor CB1, a component of the endocannabinoid system.	Dronabinol	29-32	cannabinoid receptor 1 (brain)	Mus musculus	173-176
17484726-7	2007	Moreover, PI3K inhibition by wortmannin abrogated THC-induced phosphorylation of Akt, but blockade of extracellular signal-regulated protein kinases by SL327 did not modify this activation/phosphorylation of Akt.	Dronabinol	50-53	thymoma viral proto-oncogene 1	Mus musculus	81-84
17484726-9	2007	In addition, THC increased the phosphorylation of glycogen synthase kinase 3 beta.	Dronabinol	13-16	glycogen synthase kinase 3 beta	Mus musculus	50-81
17604617-7	2007	Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis.	Dronabinol	31-34	estrogen receptor 1 (alpha)	Mus musculus	36-43
17604617-7	2007	Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis.	Dronabinol	31-34	estrogen receptor 2 (beta)	Mus musculus	116-122
17604617-7	2007	Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis.	Dronabinol	31-34	erb-b2 receptor tyrosine kinase 2	Mus musculus	126-130
17604617-7	2007	Furthermore, experiments using THC (ERalpha-agonist and ERbeta-antagonist) clearly demonstrate the critical role of ERbeta in HER2/neu-mediated tumorigenesis.	Dronabinol	31-34	erb-b2 receptor tyrosine kinase 2	Mus musculus	131-134
17290447-4	2007	Consistent with our knowledge that the A/A genotype results in reduced FAAH expression and activity in humans, subjects with the A/A genotype were less likely to be THC dependent than subjects with either a C/C or C/A genotype (11% vs. 26%, P &lt; 0.05).	Dronabinol	165-168	fatty acid amide hydrolase	Homo sapiens	71-75
17563462-6	2007	Both anandamide and synthetic cannabinoid type 1 receptor agonists such as HU210 and the plant-derived cannabinoid tetrahydro-cannabinol also significantly inhibit tumor necrosis factor-alpha.	Dronabinol	115-136	tumor necrosis factor	Homo sapiens	164-191
17936984-3	2007	The S1 nuclease sensitivity of the duplex CC(GCC)3 x GG(CGG)3 was found to occur under the action of THC-ApoA-I complex.	Dronabinol	101-104	apolipoprotein A1	Homo sapiens	105-111
17936984-4	2007	The role of the interaction sites of eukaryotic DNA with steroid (THC, androsterone)-ApoA-I complexes in the initiation of the copy reaction in vitro was revealed.	Dronabinol	66-69	apolipoprotein A1	Homo sapiens	85-91
17455326-2	2007	By microarray analysis, Ywhah, CK1, Hsp60, Pdcd 4, and Pdcd 7 were identified as being strongly regulated by both NMDA toxicity and THC neuroprotection.	Dronabinol	132-135	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta	Rattus norvegicus	24-29
17455326-3	2007	The 14-3-3 eta (14-3-3eta; gene symbol Ywhah) and 14-3-3 zeta (14-3-3zeta; gene symbol Ywhaz) transcripts were deceased by NMDA treatment and increased by THC treatment prior to NMDA, as measured by cDNA microarray analysis and quantitative real-time RT-PCR.	Dronabinol	155-158	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta	Rattus norvegicus	39-44
17455326-3	2007	The 14-3-3 eta (14-3-3eta; gene symbol Ywhah) and 14-3-3 zeta (14-3-3zeta; gene symbol Ywhaz) transcripts were deceased by NMDA treatment and increased by THC treatment prior to NMDA, as measured by cDNA microarray analysis and quantitative real-time RT-PCR.	Dronabinol	155-158	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta	Rattus norvegicus	87-92
17917113-2	2007	Cannabinoid type 1 (CB1) receptor belongs to the G protein-coupled receptor superfamily and is activated by cannabinoids such as AEA and exogenous Delta-9-tetrahydrocannabinol (THC).	Dronabinol	147-175	cannabinoid receptor 1	Homo sapiens	20-23
17917113-2	2007	Cannabinoid type 1 (CB1) receptor belongs to the G protein-coupled receptor superfamily and is activated by cannabinoids such as AEA and exogenous Delta-9-tetrahydrocannabinol (THC).	Dronabinol	177-180	cannabinoid receptor 1	Homo sapiens	20-23
17333138-0	2007	Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.	Dronabinol	80-107	neuregulin 1	Mus musculus	13-25
17333138-3	2007	OBJECTIVES: The aim of this study was to investigate whether dysfunction in the Nrg1 gene modulates the behavioural effects of Delta(9)-tetrahydrocannabinol (THC), the major psychotropic component of cannabis.	Dronabinol	127-156	neuregulin 1	Mus musculus	80-84
17333138-3	2007	OBJECTIVES: The aim of this study was to investigate whether dysfunction in the Nrg1 gene modulates the behavioural effects of Delta(9)-tetrahydrocannabinol (THC), the major psychotropic component of cannabis.	Dronabinol	158-161	neuregulin 1	Mus musculus	80-84
17333138-8	2007	In addition, Nrg1 HET mice expressed a greater THC-induced enhancement in % PPI than WT mice.	Dronabinol	47-50	neuregulin 1	Mus musculus	13-17
17333138-9	2007	The effects of THC on anxiety-related behaviour were task-dependent, with Nrg1 HET mice being more susceptible than WT mice to the anxiogenic effects of THC in LD, but not in the EPM, SI and OF tests.	Dronabinol	153-156	neuregulin 1	Mus musculus	74-78
17333138-10	2007	CONCLUSIONS: Nrg1 HET mice were more sensitive to the acute effects of THC in an array of different behaviours including those that model symptoms of schizophrenia.	Dronabinol	71-74	neuregulin 1	Mus musculus	13-17
17395593-6	2007	Human TRPV2 protein was expressed at levels comparable with those of rat TRPV2, exhibited similar surface localization and responded to a novelly identified TRPV2 agonist, Delta(9)-tetrahydrocannabinol, indicating that human TRPV2 is functionally expressed on the cell surface.	Dronabinol	172-201	transient receptor potential cation channel subfamily V member 2	Homo sapiens	6-11
17284670-13	2007	However, in vivo, THC causes a CB1 receptor-mediated pressor effect with hindquarters vasodilatation.	Dronabinol	18-21	cannabinoid receptor 1	Rattus norvegicus	31-34
17210800-7	2007	Cyclohexyl carbamic acid 3"-carbamoyl-biphenyl-3-yl ester (URB-597), an inhibitor of fatty acid amide hydrolase (FAAH), the main enzyme responsible for metabolic inactivation of anandamide, produced no THC-like discriminative effects alone but dramatically potentiated discriminative effects of anandamide, with 3 mg/kg anandamide completely substituting for the THC training dose.	Dronabinol	202-205	fatty-acid amide hydrolase-like	Rattus norvegicus	113-117
17210800-7	2007	Cyclohexyl carbamic acid 3"-carbamoyl-biphenyl-3-yl ester (URB-597), an inhibitor of fatty acid amide hydrolase (FAAH), the main enzyme responsible for metabolic inactivation of anandamide, produced no THC-like discriminative effects alone but dramatically potentiated discriminative effects of anandamide, with 3 mg/kg anandamide completely substituting for the THC training dose.	Dronabinol	363-366	fatty-acid amide hydrolase-like	Rattus norvegicus	113-117
17210800-9	2007	The THC-like discriminative-stimulus effects of anandamide after URB-597 and methanandamide were blocked by the CB1 receptor antagonist rimonabant, but not the vanilloid VR1 receptor antagonist capsazepine.	Dronabinol	4-7	cannabinoid receptor 1	Rattus norvegicus	112-115
17210800-11	2007	Thus, anandamide has THC-like discriminative and neurochemical effects that are enhanced after treatment with a FAAH inhibitor but not after treatment with transport inhibitors, suggesting brain area specificity for FAAH versus transport/FAAH inactivation of anandamide.	Dronabinol	21-24	fatty-acid amide hydrolase-like	Rattus norvegicus	112-116
17303175-0	2007	Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.	Dronabinol	54-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
17303175-4	2007	Human CYP2C9-Arg expressed in the microsomes of human B lymphoblastoid cells efficiently catalyzed the 11-hydroxylation of Delta(8)-THC (7.60 nmol/min/nmol CYP), Delta(9)-THC (19.2 nmol/min/nmol CYP) and CBN (6.62 nmol/min/nmol CYP).	Dronabinol	162-174	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	6-12
17303175-4	2007	Human CYP2C9-Arg expressed in the microsomes of human B lymphoblastoid cells efficiently catalyzed the 11-hydroxylation of Delta(8)-THC (7.60 nmol/min/nmol CYP), Delta(9)-THC (19.2 nmol/min/nmol CYP) and CBN (6.62 nmol/min/nmol CYP).	Dronabinol	162-174	peptidylprolyl isomerase G	Homo sapiens	6-9
17303175-7	2007	In addition, CYP3A4 is a major enzyme responsible for the 7alpha- and 7beta-hydroxylation of Delta(8)-THC, and the 9alpha,10alpha-epoxidation of Delta(9)-THC.	Dronabinol	145-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
20641838-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
20641838-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
20641257-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	0-27	cannabinoid receptor 1	Homo sapiens	105-108
20641257-7	2004	Delta9-Tetrahydrocannabinol (THC) is a major active cannabinoid that is found in marijuana and activates CB1 receptors (7).	Dronabinol	29-32	cannabinoid receptor 1	Homo sapiens	105-108
16876136-5	2007	THC exposure reduced preproenkephalin (PENK) mRNA expression in the nucleus accumbens during early development, but was elevated in adulthood; no adult striatal changes on preprodynorphin mRNA or PENK in caudate-putamen.	Dronabinol	0-3	proenkephalin	Rattus norvegicus	21-37
16876136-5	2007	THC exposure reduced preproenkephalin (PENK) mRNA expression in the nucleus accumbens during early development, but was elevated in adulthood; no adult striatal changes on preprodynorphin mRNA or PENK in caudate-putamen.	Dronabinol	0-3	proenkephalin	Rattus norvegicus	39-43
16876136-6	2007	PENK mRNA was also increased in the central and medial amygdala in adult THC-exposed animals.	Dronabinol	73-76	proenkephalin	Rattus norvegicus	0-4
16876136-8	2007	CONCLUSIONS: This study demonstrates enduring effects of prenatal THC exposure into adulthood that is evident on heroin-seeking behavior during extinction and allostatic changes in mesocorticolimbic PENK systems relevant to drug motivation/reward and stress response.	Dronabinol	66-69	proenkephalin	Rattus norvegicus	199-203
17006433-7	2007	These results suggest that THC mediates specific motivational processes and the processing of reinforcement cues during risky choice, perhaps reflecting altered CB1 receptor or catecholamine activity within corticolimbic pathways.	Dronabinol	27-30	cannabinoid receptor 1	Homo sapiens	161-164
17116299-0	2007	5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats.	Dronabinol	58-85	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
19166390-2	2007	THC is an exogenous agonist of the central cannabinoid receptor (CB1), one of the most abundant G-coupled receptors in the mammalian brain.	Dronabinol	0-3	cannabinoid receptor 1	Homo sapiens	65-68
17041005-3	2007	Transcription of the CB1 gene was strongly induced in response to Delta9-tetrahydrocannabinol (THC), whereas the CB2 gene was not regulated.	Dronabinol	66-93	cannabinoid receptor 1	Homo sapiens	21-24
17041005-3	2007	Transcription of the CB1 gene was strongly induced in response to Delta9-tetrahydrocannabinol (THC), whereas the CB2 gene was not regulated.	Dronabinol	95-98	cannabinoid receptor 1	Homo sapiens	21-24
17041005-4	2007	The induction of CB1 gene expression is mediated by CB2 receptors only, as demonstrated by using the CB1 and CB2 agonists R(+)-methanandamide and JWH 015, respectively, and combinations of THC plus CB1- and CB2-specific antagonists.	Dronabinol	189-192	cannabinoid receptor 1	Homo sapiens	17-20
17369778-8	2007	Drugs acting as agonists of CB1 receptors (Dronabinol, Dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer"s and Parkinson"s diseases), epilepsy, anxiety, and stroke.	Dronabinol	43-53	cannabinoid receptor 1	Homo sapiens	28-31
16936704-0	2006	An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition.	Dronabinol	78-106	catechol-O-methyltransferase	Homo sapiens	25-53
16936704-8	2006	Experimental effects of Delta-9-THC on cognition and psychosis are moderated by COMT Val(158)Met genotype, but the effects may in part be conditional on the additional presence of pre-existing psychosis liability.	Dronabinol	24-35	catechol-O-methyltransferase	Homo sapiens	80-84
17083384-8	2006	RESULTS: Patients with thrombocytosis and patients with elevated CRP levels had significantly higher pathological T stage, clinical stage, tumor size, histological grade, and percentage of microvascular invasion than did patients without THC and patients with CRP levels &lt;1.0 mg/dL, respectively.	Dronabinol	238-241	C-reactive protein	Homo sapiens	65-68
16960500-3	2006	In the apolipoprotein E knockout mouse model of atherosclerosis, Delta9-tetrahydrocannabinol was shown to inhibit disease progression through pleiotropic effects on inflammatory cells.	Dronabinol	65-92	apolipoprotein E	Mus musculus	7-23
16953389-0	2006	Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.	Dronabinol	111-138	cannabinoid receptor 1	Macaca mulatta	51-54
16760363-7	2006	The mechanism of CB1 binding site down-regulation was investigated after long-term Delta9-THC treatment.	Dronabinol	83-93	cannabinoid receptor 1 (brain)	Mus musculus	17-20
16969427-3	2006	GW Pharmaceuticals have developed Sativex (GW- 1,000-02), a combined cannabinoid medicine that delivers and maintains therapeutic levels of two principal cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), via an oromucosal pump spray, that aims to minimize psychotropic side effects.	Dronabinol	168-196	trinucleotide repeat containing adaptor 6A	Homo sapiens	43-55
16969427-3	2006	GW Pharmaceuticals have developed Sativex (GW- 1,000-02), a combined cannabinoid medicine that delivers and maintains therapeutic levels of two principal cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), via an oromucosal pump spray, that aims to minimize psychotropic side effects.	Dronabinol	198-201	trinucleotide repeat containing adaptor 6A	Homo sapiens	43-55
16886056-4	2006	Adverse effects of elevated levels of anandamide on these processes resulting from FAAH inactivation are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive constituent of marijuana), due to enhanced signaling via CB1.	Dronabinol	135-166	fatty acid amide hydrolase	Mus musculus	83-87
16886056-4	2006	Adverse effects of elevated levels of anandamide on these processes resulting from FAAH inactivation are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive constituent of marijuana), due to enhanced signaling via CB1.	Dronabinol	135-166	cannabinoid receptor 1 (brain)	Mus musculus	253-256
16886056-4	2006	Adverse effects of elevated levels of anandamide on these processes resulting from FAAH inactivation are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive constituent of marijuana), due to enhanced signaling via CB1.	Dronabinol	168-171	fatty acid amide hydrolase	Mus musculus	83-87
16886056-4	2006	Adverse effects of elevated levels of anandamide on these processes resulting from FAAH inactivation are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive constituent of marijuana), due to enhanced signaling via CB1.	Dronabinol	168-171	cannabinoid receptor 1 (brain)	Mus musculus	253-256
16886060-4	2006	FAAH inactivation yielding higher anandamide or experimentally induced higher cannabinoid [(-)-Delta9-tetrahydrocannabinol] levels constrain preimplantation embryo development with aberrant expression of Cdx2, Nanog, and Oct3/4, genes known to direct lineage specification.	Dronabinol	91-122	fatty acid amide hydrolase	Homo sapiens	0-4
16886060-4	2006	FAAH inactivation yielding higher anandamide or experimentally induced higher cannabinoid [(-)-Delta9-tetrahydrocannabinol] levels constrain preimplantation embryo development with aberrant expression of Cdx2, Nanog, and Oct3/4, genes known to direct lineage specification.	Dronabinol	91-122	caudal type homeobox 2	Homo sapiens	204-208
16908594-2	2006	In the current study, we investigated the effect of THC on the upstream and downstream events that modulate the extracellular signal-regulated kinase (ERK) module of mitogen-activated protein kinase pathways primarily in human Jurkat leukemia T cells.	Dronabinol	52-55	mitogen-activated protein kinase 1	Homo sapiens	112-149
16908594-2	2006	In the current study, we investigated the effect of THC on the upstream and downstream events that modulate the extracellular signal-regulated kinase (ERK) module of mitogen-activated protein kinase pathways primarily in human Jurkat leukemia T cells.	Dronabinol	52-55	mitogen-activated protein kinase 1	Homo sapiens	151-154
16908594-3	2006	The data showed that THC down-regulated Raf-1/mitogen-activated protein kinase/ERK kinase (MEK)/ERK/RSK pathway leading to translocation of Bad to mitochondria.	Dronabinol	21-24	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	40-45
16908594-3	2006	The data showed that THC down-regulated Raf-1/mitogen-activated protein kinase/ERK kinase (MEK)/ERK/RSK pathway leading to translocation of Bad to mitochondria.	Dronabinol	21-24	mitogen-activated protein kinase 1	Homo sapiens	79-82
16908594-3	2006	The data showed that THC down-regulated Raf-1/mitogen-activated protein kinase/ERK kinase (MEK)/ERK/RSK pathway leading to translocation of Bad to mitochondria.	Dronabinol	21-24	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
16908594-3	2006	The data showed that THC down-regulated Raf-1/mitogen-activated protein kinase/ERK kinase (MEK)/ERK/RSK pathway leading to translocation of Bad to mitochondria.	Dronabinol	21-24	mitogen-activated protein kinase 1	Homo sapiens	96-99
16908594-3	2006	The data showed that THC down-regulated Raf-1/mitogen-activated protein kinase/ERK kinase (MEK)/ERK/RSK pathway leading to translocation of Bad to mitochondria.	Dronabinol	21-24	ribosomal protein S6 kinase A2	Homo sapiens	100-103
16908594-4	2006	THC also decreased the phosphorylation of Akt.	Dronabinol	0-3	AKT serine/threonine kinase 1	Homo sapiens	42-45
16908594-7	2006	Jurkat cells expressing a constitutively active MEK construct were found to be resistant to THC-mediated apoptosis and failed to exhibit decreased phospho-Bad on Ser(112) as well as Bad translocation to mitochondria.	Dronabinol	92-95	mitogen-activated protein kinase kinase 7	Homo sapiens	48-51
16908594-9	2006	Together, these data suggested that Raf-1/MEK/ERK/RSK-mediated Bad translocation played a critical role in THC-induced apoptosis in Jurkat cells.	Dronabinol	107-110	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	36-41
16908594-9	2006	Together, these data suggested that Raf-1/MEK/ERK/RSK-mediated Bad translocation played a critical role in THC-induced apoptosis in Jurkat cells.	Dronabinol	107-110	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
16908594-9	2006	Together, these data suggested that Raf-1/MEK/ERK/RSK-mediated Bad translocation played a critical role in THC-induced apoptosis in Jurkat cells.	Dronabinol	107-110	mitogen-activated protein kinase 1	Homo sapiens	46-49
16908594-9	2006	Together, these data suggested that Raf-1/MEK/ERK/RSK-mediated Bad translocation played a critical role in THC-induced apoptosis in Jurkat cells.	Dronabinol	107-110	ribosomal protein S6 kinase A2	Homo sapiens	50-53
16818634-0	2006	Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.	Dronabinol	0-27	cyclin dependent kinase 1	Homo sapiens	97-101
16818634-5	2006	In particular, THC arrests cells in G(2)-M via down-regulation of Cdc2, as suggested by the decreased sensitivity to THC acquired by Cdc2-overexpressing cells.	Dronabinol	15-18	cyclin dependent kinase 1	Homo sapiens	66-70
16818634-5	2006	In particular, THC arrests cells in G(2)-M via down-regulation of Cdc2, as suggested by the decreased sensitivity to THC acquired by Cdc2-overexpressing cells.	Dronabinol	15-18	cyclin dependent kinase 1	Homo sapiens	133-137
16818634-5	2006	In particular, THC arrests cells in G(2)-M via down-regulation of Cdc2, as suggested by the decreased sensitivity to THC acquired by Cdc2-overexpressing cells.	Dronabinol	117-120	cyclin dependent kinase 1	Homo sapiens	133-137
16818650-6	2006	Knockdown experiments using selective small interfering RNAs showed the involvement of p8 via its downstream endoplasmic reticulum stress-related targets activating transcription factor 4 (ATF-4) and TRB3 in Delta(9)-tetrahydrocannabinol-induced apoptosis.	Dronabinol	217-237	activating transcription factor 4	Homo sapiens	154-187
16818650-6	2006	Knockdown experiments using selective small interfering RNAs showed the involvement of p8 via its downstream endoplasmic reticulum stress-related targets activating transcription factor 4 (ATF-4) and TRB3 in Delta(9)-tetrahydrocannabinol-induced apoptosis.	Dronabinol	217-237	activating transcription factor 4	Homo sapiens	189-194
16818650-6	2006	Knockdown experiments using selective small interfering RNAs showed the involvement of p8 via its downstream endoplasmic reticulum stress-related targets activating transcription factor 4 (ATF-4) and TRB3 in Delta(9)-tetrahydrocannabinol-induced apoptosis.	Dronabinol	217-237	taste 2 receptor member 13	Homo sapiens	200-204
16624285-1	2006	Delta9-tetrahydrocannabinol and other cannabinoids exert pro-apoptotic actions in tumor cells via the CB2 cannabinoid receptor.	Dronabinol	0-27	cannabinoid receptor 2	Homo sapiens	102-105
16624285-4	2006	Our results show that incubation with the selective CB2 antagonist SR144528 abrogated the pro-apoptotic effect of Delta9-tetrahydrocannabinol.	Dronabinol	114-141	cannabinoid receptor 2	Homo sapiens	52-55
16624285-5	2006	Cannabinoid treatment led to a CB2 receptor-dependent stimulation of ceramide biosynthesis and inhibition of this pathway prevented Delta9-tetrahydrocannabinol-induced mitochondrial hypopolarization and cytochrome c release, indicating that ceramide acts at a pre-mitochondrial level.	Dronabinol	132-159	cannabinoid receptor 2	Homo sapiens	31-34
16624285-5	2006	Cannabinoid treatment led to a CB2 receptor-dependent stimulation of ceramide biosynthesis and inhibition of this pathway prevented Delta9-tetrahydrocannabinol-induced mitochondrial hypopolarization and cytochrome c release, indicating that ceramide acts at a pre-mitochondrial level.	Dronabinol	132-159	cytochrome c, somatic	Homo sapiens	203-215
16805813-4	2006	We demonstrated that treatment of cultured rat pineals with 9-carboxy-11-nor-delta-9-tetrahydrocannabinol (THC), cannabidiol or cannabinol significantly reduced norepinephrine-induced arylalkylamine N-acetyltransferase (AANAT) activity and melatonin biosynthesis.	Dronabinol	107-110	aralkylamine N-acetyltransferase	Rattus norvegicus	184-218
16805813-4	2006	We demonstrated that treatment of cultured rat pineals with 9-carboxy-11-nor-delta-9-tetrahydrocannabinol (THC), cannabidiol or cannabinol significantly reduced norepinephrine-induced arylalkylamine N-acetyltransferase (AANAT) activity and melatonin biosynthesis.	Dronabinol	107-110	aralkylamine N-acetyltransferase	Rattus norvegicus	220-225
16500063-3	2006	THC was eluted using a mobile phase composed of methanol, acetonitrile and tetrabutylammonium perchlorate solution (0.005 M, pH 3.2), through a C18 Nucleosil column and detected at a wavelength of 215 nm.	Dronabinol	0-3	Bardet-Biedl syndrome 9	Homo sapiens	144-147
16808676-21	2006	The IOP-lowering effect of LTHC was blocked by the CB1R-selective antagonist, SR141716A, suggesting that CB1Rs contribute to the ocular hypotensive effect of Delta9-tetrahydrocannabinol.	Dronabinol	158-185	cannabinoid receptor 1	Rattus norvegicus	51-54
16954596-2	2006	In wild-type mice, chronic Delta9-tetrahydrocannabinol (THC) exposure significantly activated specific GRK and beta- arrestin subunits in all the considered brain areas (striatum, cerebellum, hippocampus, and prefrontal cortex), suggesting their involvement in the adaptive processes underlying CB1 receptor downregulation and desensitization.	Dronabinol	27-54	G protein-coupled receptor kinase 4	Mus musculus	103-106
16954596-2	2006	In wild-type mice, chronic Delta9-tetrahydrocannabinol (THC) exposure significantly activated specific GRK and beta- arrestin subunits in all the considered brain areas (striatum, cerebellum, hippocampus, and prefrontal cortex), suggesting their involvement in the adaptive processes underlying CB1 receptor downregulation and desensitization.	Dronabinol	27-54	cannabinoid receptor 1 (brain)	Mus musculus	295-298
16954596-2	2006	In wild-type mice, chronic Delta9-tetrahydrocannabinol (THC) exposure significantly activated specific GRK and beta- arrestin subunits in all the considered brain areas (striatum, cerebellum, hippocampus, and prefrontal cortex), suggesting their involvement in the adaptive processes underlying CB1 receptor downregulation and desensitization.	Dronabinol	56-59	G protein-coupled receptor kinase 4	Mus musculus	103-106
16954596-2	2006	In wild-type mice, chronic Delta9-tetrahydrocannabinol (THC) exposure significantly activated specific GRK and beta- arrestin subunits in all the considered brain areas (striatum, cerebellum, hippocampus, and prefrontal cortex), suggesting their involvement in the adaptive processes underlying CB1 receptor downregulation and desensitization.	Dronabinol	56-59	cannabinoid receptor 1 (brain)	Mus musculus	295-298
16954596-4	2006	In the latter areas, ERK activation after chronic THC increased the transcription factors cyclic adenosine monophosphate response element-binding protein and Fos B as well as a downstream protein known as brainderived neurotrophic factor.	Dronabinol	50-53	mitogen-activated protein kinase 1	Mus musculus	21-24
16954596-4	2006	In the latter areas, ERK activation after chronic THC increased the transcription factors cyclic adenosine monophosphate response element-binding protein and Fos B as well as a downstream protein known as brainderived neurotrophic factor.	Dronabinol	50-53	FBJ osteosarcoma oncogene B	Mus musculus	158-163
16954596-5	2006	As a whole, our data suggest that in the striatum and cerebellum, THC-induced ERK activation could represent a key signaling event to initiate homologous desensitization of CB1 receptor, accounting for the development of tolerance to THC-induced hypolocomotion.	Dronabinol	66-69	mitogen-activated protein kinase 1	Mus musculus	78-81
16954596-5	2006	As a whole, our data suggest that in the striatum and cerebellum, THC-induced ERK activation could represent a key signaling event to initiate homologous desensitization of CB1 receptor, accounting for the development of tolerance to THC-induced hypolocomotion.	Dronabinol	66-69	cannabinoid receptor 1 (brain)	Mus musculus	173-176
16954596-5	2006	As a whole, our data suggest that in the striatum and cerebellum, THC-induced ERK activation could represent a key signaling event to initiate homologous desensitization of CB1 receptor, accounting for the development of tolerance to THC-induced hypolocomotion.	Dronabinol	234-237	mitogen-activated protein kinase 1	Mus musculus	78-81
16954596-6	2006	In the prefrontal cortex and hippocampus, THC-induced alteration in GRKs and beta-arrestins primarily depends on other kinases, whereas ERK activation could be part of the molecular adaptations that underlie the complex behavioral phenotype that defines the addicted state.	Dronabinol	42-45	mitogen-activated protein kinase 1	Mus musculus	136-139
16443242-5	2006	Nandrolone pre-exposure blocked THC- and food-induced conditioned place preference and increased the somatic manifestations of THC withdrawal precipitated by the CB1 cannabinoid antagonist rimonabant (SR141617A).	Dronabinol	127-130	cannabinoid receptor 1 (brain)	Mus musculus	162-165
16723539-0	2006	ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure.	Dronabinol	73-100	mitogen-activated protein kinase 1	Mus musculus	0-3
16723539-7	2006	Additionally, after repeated THC exposures, presynaptic PF-PC long-term potentiation was blocked by A1R (adenosine receptor-1) activation.	Dronabinol	29-32	adenosine A1 receptor	Mus musculus	100-125
16723539-9	2006	In summary, we provide evidence for ERK-dependent modulatory mechanisms at PF-PC synapses after chronic THC administration.	Dronabinol	104-107	mitogen-activated protein kinase 1	Mus musculus	36-39
16672367-1	2006	The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly.	Dronabinol	31-58	cannabinoid receptor 2 (macrophage)	Mus musculus	173-176
16672367-1	2006	The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly.	Dronabinol	31-58	cannabinoid receptor 2 (macrophage)	Mus musculus	187-190
16672367-1	2006	The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly.	Dronabinol	60-63	cannabinoid receptor 2 (macrophage)	Mus musculus	173-176
16436496-8	2006	Taken together, the present results demonstrate that classic tricyclic cannabinoids with structural similarity to Delta(9)-THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.	Dronabinol	114-126	cannabinoid receptor 1 (brain)	Mus musculus	311-314
16436496-8	2006	Taken together, the present results demonstrate that classic tricyclic cannabinoids with structural similarity to Delta(9)-THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.	Dronabinol	114-126	cannabinoid receptor 2 (macrophage)	Mus musculus	319-322
16439618-2	2006	The purpose of this study was to investigate the possible interaction of P-gp with each of four major marijuana constituents: Delta(9)-tetrahydrocannabinol (THC), 11-nor-Delta(9)-tetrahydrocannabinol-carboxylic acid (THC-COOH), cannabinol (CBN), and cannabidiol (CBD).	Dronabinol	126-155	phosphoglycolate phosphatase	Homo sapiens	73-77
16439618-2	2006	The purpose of this study was to investigate the possible interaction of P-gp with each of four major marijuana constituents: Delta(9)-tetrahydrocannabinol (THC), 11-nor-Delta(9)-tetrahydrocannabinol-carboxylic acid (THC-COOH), cannabinol (CBN), and cannabidiol (CBD).	Dronabinol	157-160	phosphoglycolate phosphatase	Homo sapiens	73-77
16439618-2	2006	The purpose of this study was to investigate the possible interaction of P-gp with each of four major marijuana constituents: Delta(9)-tetrahydrocannabinol (THC), 11-nor-Delta(9)-tetrahydrocannabinol-carboxylic acid (THC-COOH), cannabinol (CBN), and cannabidiol (CBD).	Dronabinol	217-220	phosphoglycolate phosphatase	Homo sapiens	73-77
16439618-3	2006	The results of a P-gp ATPase activity screen showed that THC-COOH, CBN, THC, and CBD all stimulated P-gp ATPase activity with a Michaelis-Menten parameter (V(max)/K(m)) value of 1.3, 0.7, 0.1, and 0.05, respectively.	Dronabinol	57-60	phosphoglycolate phosphatase	Homo sapiens	17-21
16439618-3	2006	The results of a P-gp ATPase activity screen showed that THC-COOH, CBN, THC, and CBD all stimulated P-gp ATPase activity with a Michaelis-Menten parameter (V(max)/K(m)) value of 1.3, 0.7, 0.1, and 0.05, respectively.	Dronabinol	57-60	phosphoglycolate phosphatase	Homo sapiens	100-104
16439618-3	2006	The results of a P-gp ATPase activity screen showed that THC-COOH, CBN, THC, and CBD all stimulated P-gp ATPase activity with a Michaelis-Menten parameter (V(max)/K(m)) value of 1.3, 0.7, 0.1, and 0.05, respectively.	Dronabinol	72-75	phosphoglycolate phosphatase	Homo sapiens	17-21
16439618-3	2006	The results of a P-gp ATPase activity screen showed that THC-COOH, CBN, THC, and CBD all stimulated P-gp ATPase activity with a Michaelis-Menten parameter (V(max)/K(m)) value of 1.3, 0.7, 0.1, and 0.05, respectively.	Dronabinol	72-75	phosphoglycolate phosphatase	Homo sapiens	100-104
16597638-6	2006	The expression of transcription factors, such as thyroid hormone receptor-beta1 (TRbeta1), and transcriptional co-repressors, such as histone deactylase 3 (HDAC3), was affected by Delta9-THC in a dose-dependent manner, whereby 15 microM Delta9-THC caused a 2.8-fold inhibition of TRbeta1 expression, but a 3.5-fold increase in HDAC3 expression.	Dronabinol	180-190	histone deacetylase 3	Homo sapiens	134-154
16597638-6	2006	The expression of transcription factors, such as thyroid hormone receptor-beta1 (TRbeta1), and transcriptional co-repressors, such as histone deactylase 3 (HDAC3), was affected by Delta9-THC in a dose-dependent manner, whereby 15 microM Delta9-THC caused a 2.8-fold inhibition of TRbeta1 expression, but a 3.5-fold increase in HDAC3 expression.	Dronabinol	180-190	histone deacetylase 3	Homo sapiens	156-161
16597638-6	2006	The expression of transcription factors, such as thyroid hormone receptor-beta1 (TRbeta1), and transcriptional co-repressors, such as histone deactylase 3 (HDAC3), was affected by Delta9-THC in a dose-dependent manner, whereby 15 microM Delta9-THC caused a 2.8-fold inhibition of TRbeta1 expression, but a 3.5-fold increase in HDAC3 expression.	Dronabinol	180-190	histone deacetylase 3	Homo sapiens	327-332
16597638-6	2006	The expression of transcription factors, such as thyroid hormone receptor-beta1 (TRbeta1), and transcriptional co-repressors, such as histone deactylase 3 (HDAC3), was affected by Delta9-THC in a dose-dependent manner, whereby 15 microM Delta9-THC caused a 2.8-fold inhibition of TRbeta1 expression, but a 3.5-fold increase in HDAC3 expression.	Dronabinol	237-247	histone deacetylase 3	Homo sapiens	134-154
16597638-6	2006	The expression of transcription factors, such as thyroid hormone receptor-beta1 (TRbeta1), and transcriptional co-repressors, such as histone deactylase 3 (HDAC3), was affected by Delta9-THC in a dose-dependent manner, whereby 15 microM Delta9-THC caused a 2.8-fold inhibition of TRbeta1 expression, but a 3.5-fold increase in HDAC3 expression.	Dronabinol	237-247	histone deacetylase 3	Homo sapiens	156-161
16458258-7	2006	However, in CEM/VLB(100) cells, prolonged 72 h exposure to the cannabinoids, THC and CBD, decreased P-gp expression to a similar extent as the flavonoid, curcumin (turmeric).	Dronabinol	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
16570100-2	2006	CB1 receptors also mediate most of the psychotropic effects of Delta9-tetrahydrocannabinol (Delta9THC), the principal psychoactive component of cannabis.	Dronabinol	63-90	cannabinoid receptor 1	Homo sapiens	0-3
16570100-2	2006	CB1 receptors also mediate most of the psychotropic effects of Delta9-tetrahydrocannabinol (Delta9THC), the principal psychoactive component of cannabis.	Dronabinol	92-101	cannabinoid receptor 1	Homo sapiens	0-3
16352700-1	2006	We have previously shown that over time (2 h), the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), produces peroxisome proliferator-activated receptor (PPAR) gamma-mediated vasorelaxation of conduit arteries.	Dronabinol	82-111	peroxisome proliferator activated receptor alpha	Rattus norvegicus	128-170
16352700-1	2006	We have previously shown that over time (2 h), the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), produces peroxisome proliferator-activated receptor (PPAR) gamma-mediated vasorelaxation of conduit arteries.	Dronabinol	82-111	peroxisome proliferator activated receptor alpha	Rattus norvegicus	172-176
16352700-1	2006	We have previously shown that over time (2 h), the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), produces peroxisome proliferator-activated receptor (PPAR) gamma-mediated vasorelaxation of conduit arteries.	Dronabinol	113-116	peroxisome proliferator activated receptor alpha	Rattus norvegicus	128-170
16352700-1	2006	We have previously shown that over time (2 h), the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), produces peroxisome proliferator-activated receptor (PPAR) gamma-mediated vasorelaxation of conduit arteries.	Dronabinol	113-116	peroxisome proliferator activated receptor alpha	Rattus norvegicus	172-176
16352700-5	2006	This effect of THC was abolished in the presence of the enzyme catalase, which breaks down H(2)O(2), and was reduced in the presence of the superoxide dismutase inhibitor diethyldithiocarbamate (DETCA), but it was not PPARgamma-mediated.	Dronabinol	15-18	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	218-227
16504646-2	2006	In human studies, activation of CB1 receptors by cannabis or its active ingredient, Delta9-tetrahydrocannabinol (THC), has modest and inconsistent effects on BP.	Dronabinol	84-111	cannabinoid receptor 1	Homo sapiens	32-35
16504646-2	2006	In human studies, activation of CB1 receptors by cannabis or its active ingredient, Delta9-tetrahydrocannabinol (THC), has modest and inconsistent effects on BP.	Dronabinol	113-116	cannabinoid receptor 1	Homo sapiens	32-35
16618028-2	2006	However, it is only recently that one has identified two subtypes of G-protein-coupled receptors, namely CB1 and CB2-receptors, which mediate the numerous effects of delta9-tetrahydrocannabinol and other cannabinoids.	Dronabinol	166-193	cannabinoid receptor 1	Rattus norvegicus	105-108
16618028-2	2006	However, it is only recently that one has identified two subtypes of G-protein-coupled receptors, namely CB1 and CB2-receptors, which mediate the numerous effects of delta9-tetrahydrocannabinol and other cannabinoids.	Dronabinol	166-193	cannabinoid receptor 2	Rattus norvegicus	113-116
16330497-9	2006	Two other COX-2-inducing cannabinoids, anandamide and Delta9-tetrahydrocannabinol, caused the same pattern of MMP and TIMP expression as R(+)-MA both in the absence and presence of NS-398.	Dronabinol	54-81	prostaglandin-endoperoxide synthase 2	Homo sapiens	10-15
16330497-9	2006	Two other COX-2-inducing cannabinoids, anandamide and Delta9-tetrahydrocannabinol, caused the same pattern of MMP and TIMP expression as R(+)-MA both in the absence and presence of NS-398.	Dronabinol	54-81	TIMP metallopeptidase inhibitor 1	Homo sapiens	118-122
16332990-3	2006	Here, we report that THC and AEA, in a CB1 receptor-independent manner, cause a significant potentiation of the amplitudes of glycine-activated currents (I(Gly)) in acutely isolated neurons from rat ventral tegmental area (VTA) and in Xenopus laevis oocytes expressing human homomeric (alpha1) and heteromeric (alpha1beta1) subunits of glycine receptors (GlyRs).	Dronabinol	21-24	cannabinoid receptor 1	Rattus norvegicus	39-42
16332990-3	2006	Here, we report that THC and AEA, in a CB1 receptor-independent manner, cause a significant potentiation of the amplitudes of glycine-activated currents (I(Gly)) in acutely isolated neurons from rat ventral tegmental area (VTA) and in Xenopus laevis oocytes expressing human homomeric (alpha1) and heteromeric (alpha1beta1) subunits of glycine receptors (GlyRs).	Dronabinol	21-24	adrenoceptor alpha 1D	Homo sapiens	286-292
16332990-4	2006	The potentiation of I(Gly) by THC and AEA is concentration-dependent, with respective EC50 values of 86 +/- 9 and 319 +/- 31 nM for alpha1 homomeric receptors, 73 +/- 8 and 318 +/- 24 nM for alpha1beta1 heteromeric receptors, and 115 +/- 13 and 230 +/- 29 nM for native GlyRs in VTA neurons.	Dronabinol	30-33	adrenoceptor alpha 1D	Homo sapiens	132-138
16637271-2	2006	By a method of small-angle X-ray scattering it is shown, that appreciable interaction with eukariotic DNA is marked only in case of use of a complex THC-apoA-I, thus there is local fusion of DNA.	Dronabinol	149-152	apolipoprotein A1	Homo sapiens	153-159
16637271-5	2006	It is shown, that at his interaction with complex THC-apoA-I there is a formation of more difficult complex, which breaks up with formation of complementary chains of oligonucleotides.	Dronabinol	50-53	apolipoprotein A1	Homo sapiens	54-60
16637271-6	2006	The last also enter interaction with complex THC-apoA-I.	Dronabinol	45-48	apolipoprotein A1	Homo sapiens	49-55
17687403-1	2006	Objective Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a multifunctional protein that has thc capacity to modify cellular activities and to modulate matrix turnover.	Dronabinol	97-100	TIMP metallopeptidase inhibitor 1	Homo sapiens	10-49
17687403-1	2006	Objective Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a multifunctional protein that has thc capacity to modify cellular activities and to modulate matrix turnover.	Dronabinol	97-100	TIMP metallopeptidase inhibitor 1	Homo sapiens	51-57
16443217-0	2006	Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.	Dronabinol	33-61	interleukin 12b	Mus musculus	77-85
16443217-7	2006	These results suggest that THC-induced suppression of serum IL-12 is partly due to a suppression of IL-12 production by dendritic cells and that G(i) signaling and cannabinoid receptors, but not TRPV1, are involved in this suppressive effect.	Dronabinol	27-30	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	195-200
16244107-0	2006	Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels.	Dronabinol	48-75	transient receptor potential cation channel subfamily C member 1	Homo sapiens	96-101
16244107-7	2006	Finally, small interference RNA knockdown of TRPC1 attenuated the Delta9-THC-mediated elevation of [Ca2+]i.	Dronabinol	66-76	transient receptor potential cation channel subfamily C member 1	Homo sapiens	45-50
16244107-8	2006	Collectively, these results suggest that Delta9-THC-induced elevation in [Ca2+]i is attributable entirely to extracellular calcium influx, which is independent of [Ca2+]i store depletion, and is mediated, at least partially, through the DAG-sensitive TRPC1 channels.	Dronabinol	41-51	transient receptor potential cation channel subfamily C member 1	Homo sapiens	251-256
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	5-32	cannabinoid receptor 1	Homo sapiens	238-241
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	5-32	cannabinoid receptor 1	Homo sapiens	238-241
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	5-32	cannabinoid receptor 2	Homo sapiens	291-294
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	34-44	cannabinoid receptor 1	Homo sapiens	238-241
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	34-44	cannabinoid receptor 1	Homo sapiens	238-241
16506408-3	2006	Both delta9-tetrahydrocannibinol (delta9-THC) and well-studied representatives of other classes of exogenous cannabinoid CB1/CB2 receptor agonists inhibit gastrointestinal motility, peristalsis, defecation, and secretions via cannabinoid CB1 receptors since the CB1 (SR141716A)- and not the CB2 (SR144528)-receptor antagonist reverses these effects in a dose-dependent manner.	Dronabinol	34-44	cannabinoid receptor 2	Homo sapiens	291-294
15920503-0	2006	Perinatal exposure to delta(9)-tetrahydrocannabinol alters heroin-induced place conditioning and fos-immunoreactivity.	Dronabinol	22-51	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	97-100
15920503-9	2006	Perinatal THC exposure significantly increased heroin-induced Fos-IR in the dorsomedial CPu.	Dronabinol	10-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	62-65
15920503-10	2006	Conversely, perinatal THC exposure reduced heroin-induced Fos-IR in the NAC (shell), BNST, CEA, dorsolateral and lateral PAG, VTA, and EW.	Dronabinol	22-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-61
15920503-10	2006	Conversely, perinatal THC exposure reduced heroin-induced Fos-IR in the NAC (shell), BNST, CEA, dorsolateral and lateral PAG, VTA, and EW.	Dronabinol	22-25	carcinoembryonic antigen gene family 4	Rattus norvegicus	91-94
16307294-11	2006	CONCLUSION: Data support that the discriminative stimulus effects of (R)-methanandamide and its overlap with the Delta(9)-THC cue are, indeed, CB1 receptor mediated events as revealed in antagonism tests with the selective central CB1 receptor antagonists SR-141716 and AM-251.	Dronabinol	113-125	cannabinoid receptor 1	Rattus norvegicus	143-146
16307294-11	2006	CONCLUSION: Data support that the discriminative stimulus effects of (R)-methanandamide and its overlap with the Delta(9)-THC cue are, indeed, CB1 receptor mediated events as revealed in antagonism tests with the selective central CB1 receptor antagonists SR-141716 and AM-251.	Dronabinol	113-125	cannabinoid receptor 1	Rattus norvegicus	231-234
16352709-2	2005	The active constituent of cannabis, delta9-tetrahydrocannabinol, acts by binding to brain CB1 cannabinoid receptors, but an alternative approach might be to develop agents that amplify the actions of endogenous cannabinoids by blocking their deactivation.	Dronabinol	36-63	cannabinoid receptor 1	Rattus norvegicus	90-93
16354920-4	2005	Using biochemical and electrophysiological approaches, we now report that 1 week of repeated in vivo THC treatment reduces the coupling efficiency of cannabinoid CB1 receptors (CB1Rs) to G(i/o) transduction proteins, as well as CB1R-mediated inhibition of excitatory synaptic transmission at the excitatory synapses between the prefrontal cortex and the nucleus accumbens (NAc).	Dronabinol	101-104	cannabinoid receptor 1 (brain)	Mus musculus	162-165
16354920-4	2005	Using biochemical and electrophysiological approaches, we now report that 1 week of repeated in vivo THC treatment reduces the coupling efficiency of cannabinoid CB1 receptors (CB1Rs) to G(i/o) transduction proteins, as well as CB1R-mediated inhibition of excitatory synaptic transmission at the excitatory synapses between the prefrontal cortex and the nucleus accumbens (NAc).	Dronabinol	101-104	cannabinoid receptor 1 (brain)	Mus musculus	177-181
16354920-6	2005	The present data show that, in THC-treated mice, long-term depression is expressed because a presynaptic mGluR2/3 (metabotropic glutamate receptor 2/3)-dependent mechanism replaces the impaired endocannabinoid system.	Dronabinol	31-34	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	105-111
16354920-6	2005	The present data show that, in THC-treated mice, long-term depression is expressed because a presynaptic mGluR2/3 (metabotropic glutamate receptor 2/3)-dependent mechanism replaces the impaired endocannabinoid system.	Dronabinol	31-34	glutamate receptor, metabotropic 2	Mus musculus	115-150
16339038-2	2005	Extracellular signal-regulated kinase (ERK) is critical for the expression of immediate-early genes in the striatum in response to cocaine and Delta9-tetrahydrocannabinol and for the rewarding properties of these drugs.	Dronabinol	143-170	mitogen-activated protein kinase 1	Mus musculus	0-37
16339038-2	2005	Extracellular signal-regulated kinase (ERK) is critical for the expression of immediate-early genes in the striatum in response to cocaine and Delta9-tetrahydrocannabinol and for the rewarding properties of these drugs.	Dronabinol	143-170	mitogen-activated protein kinase 1	Mus musculus	39-42
16339038-2	2005	Extracellular signal-regulated kinase (ERK) is critical for the expression of immediate-early genes in the striatum in response to cocaine and Delta9-tetrahydrocannabinol and for the rewarding properties of these drugs.	Dronabinol	143-170	jun proto-oncogene	Mus musculus	78-93
16098661-0	2005	Reactive oxygen species and p38 phosphorylation regulate the protective effect of Delta9-tetrahydrocannabinol in the apoptotic response to NMDA.	Dronabinol	82-109	mitogen activated protein kinase 14	Rattus norvegicus	28-31
16098661-7	2005	The present data suggest that THC protects against NMDA-induced apoptosis in AF5 cells by blocking ROS generation and inhibiting the activation of p38-MAPK.	Dronabinol	30-33	mitogen activated protein kinase 14	Rattus norvegicus	147-155
16179366-7	2005	Delta9-Tetrahydrocannabinol (delta9-THC) fails to inhibit EPSCs, yet readily occludes both DSE and EPSC inhibition by a synthetic CB1 agonist, WIN 55212-2.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	130-133
16179366-7	2005	Delta9-Tetrahydrocannabinol (delta9-THC) fails to inhibit EPSCs, yet readily occludes both DSE and EPSC inhibition by a synthetic CB1 agonist, WIN 55212-2.	Dronabinol	29-39	cannabinoid receptor 1 (brain)	Mus musculus	130-133
16179366-8	2005	With long-term exposure (approximately 18 h), delta9-THC also desensitizes CB1 receptors.	Dronabinol	46-56	cannabinoid receptor 1 (brain)	Mus musculus	75-78
16137723-0	2005	Repeated exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity.	Dronabinol	21-50	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	101-104
16137723-12	2005	Pre-exposure to THC significantly increased heroin-induced Fos-IR in the dorsomedial CPu and the NAC (core).	Dronabinol	16-19	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	59-62
16137723-13	2005	Conversely, THC pre-exposure reduced heroin-induced Fos-IR in the BNST, CEA, and the PAG (dorsolateral and lateral).	Dronabinol	12-15	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	52-55
16137723-13	2005	Conversely, THC pre-exposure reduced heroin-induced Fos-IR in the BNST, CEA, and the PAG (dorsolateral and lateral).	Dronabinol	12-15	carcinoembryonic antigen gene family 4	Rattus norvegicus	72-75
16213464-0	2005	Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma.	Dronabinol	41-68	peroxisome proliferator activated receptor gamma	Homo sapiens	81-129
16213464-3	2005	Here we show for the first time that THC also causes slowly developing vasorelaxation through activation of peroxisome proliferator-activated receptors gamma (PPARgamma).	Dronabinol	37-40	peroxisome proliferator activated receptor gamma	Homo sapiens	159-168
16213464-5	2005	Time-dependent vasorelaxation to THC was similar to that produced by the PPARgamma agonist rosiglitazone and was inhibited by the PPARgamma antagonist GW9662 (1 microM), but not the cannabinoid CB1 receptor antagonist AM251 (1 microM).	Dronabinol	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	73-82
16213464-5	2005	Time-dependent vasorelaxation to THC was similar to that produced by the PPARgamma agonist rosiglitazone and was inhibited by the PPARgamma antagonist GW9662 (1 microM), but not the cannabinoid CB1 receptor antagonist AM251 (1 microM).	Dronabinol	33-36	peroxisome proliferator activated receptor gamma	Homo sapiens	130-139
16213464-5	2005	Time-dependent vasorelaxation to THC was similar to that produced by the PPARgamma agonist rosiglitazone and was inhibited by the PPARgamma antagonist GW9662 (1 microM), but not the cannabinoid CB1 receptor antagonist AM251 (1 microM).	Dronabinol	33-36	cannabinoid receptor 1	Homo sapiens	194-197
16213464-7	2005	In transactivation assays in cultured HEK293 cells, THC-activated PPARgamma, transiently expressed in combination with retinoid X receptor alpha and a luciferase reporter gene, in a concentration-dependent manner (100 nM-10 microM).	Dronabinol	52-55	peroxisome proliferator activated receptor gamma	Homo sapiens	66-75
16213464-7	2005	In transactivation assays in cultured HEK293 cells, THC-activated PPARgamma, transiently expressed in combination with retinoid X receptor alpha and a luciferase reporter gene, in a concentration-dependent manner (100 nM-10 microM).	Dronabinol	52-55	retinoid X receptor alpha	Homo sapiens	119-144
16213464-8	2005	In vitro incubation with THC (1 or 10 microM, 8 days) stimulated adipocyte differentiation in cultured 3T3L1 cells, a well-accepted property of PPARgamma ligands.	Dronabinol	25-28	peroxisome proliferator activated receptor gamma	Mus musculus	144-153
16213464-9	2005	The present results provide strong evidence that THC is a PPARgamma ligand, stimulation of which causes time-dependent vasorelaxation, implying some of the pleiotropic effects of cannabis may be mediated by nuclear receptors.	Dronabinol	49-52	peroxisome proliferator activated receptor gamma	Homo sapiens	58-67
16185725-5	2005	In Experiment 2, the CB1 antagonist, SR141716, reversed the enhanced sucrose palatability produced by THC.	Dronabinol	102-105	cannabinoid receptor 1	Rattus norvegicus	21-24
16185725-6	2005	These results suggest that the increased intake of palatable food 2 h, but not earlier, following administration of a low dose of THC may be the result of enhanced palatability and that this effect is the result of action of THC at the CB1 receptor.	Dronabinol	130-133	cannabinoid receptor 1	Rattus norvegicus	236-239
16185725-6	2005	These results suggest that the increased intake of palatable food 2 h, but not earlier, following administration of a low dose of THC may be the result of enhanced palatability and that this effect is the result of action of THC at the CB1 receptor.	Dronabinol	225-228	cannabinoid receptor 1	Rattus norvegicus	236-239
16358735-3	2005	Earlier we have shown, that blocks of THC dynamically bind telomeric protein TRF1 in Chinese hamster cells.	Dronabinol	38-41	TTAGGG repeat-binding factor 1	Cricetulus griseus	77-81
15812567-10	2005	Effects of THC were blocked by rimonabant and effects of morphine were blocked by naloxone, demonstrating that THC"s effects depended on cannabinoid CB1 receptor activation and morphine"s effects depended on opioid-receptor activation.	Dronabinol	111-114	cannabinoid receptor 1	Rattus norvegicus	149-152
15812567-11	2005	Furthermore, THC"s effects were blocked by naloxone and morphine"s effects were blocked by rimonabant, demonstrating that mu-opioid receptors were involved in the effects of THC and cannabinoid CB1 receptors were involved in the effects of morphine on food-reinforced behavior.	Dronabinol	13-16	cannabinoid receptor 1	Rattus norvegicus	194-197
15870833-3	2005	The natural cannnabinoid CB1 receptor agonist delta-9-tetrahydrocannabinol (THC, 0.3-3 mg/kg i.p.)	Dronabinol	46-74	cannabinoid receptor 1	Rattus norvegicus	25-28
16386537-7	2005	The vWF was significantly correlated with tHC (P &lt; .05) and was higher in the HHC patients (P &lt; .05).	Dronabinol	42-45	von Willebrand factor	Homo sapiens	4-7
16112652-0	2005	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.	Dronabinol	16-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-5
16112652-4	2005	The present study was designed to address the kinetics and pharmacogenetics of CYP2C-mediated metabolism of (delta9)-THC by studying its metabolism in human liver microsomes and expressed enzymes.	Dronabinol	108-120	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	79-84
16112652-5	2005	Expressed CYP2C9.1 exhibited high affinity for the hydroxylation of delta9-THC (apparent Km, 2 microM), similar to that observed in human liver microsomes (apparent Km 0.8 microM).	Dronabinol	68-78	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	10-16
16112652-7	2005	Given the high affinity of CYP2C9 for the hydroxylation of delta9-THC, we evaluated the potential for an interaction between delta9-THC, 11-hydroxy-delta9-THC, or 11-nor-9-carboxy-delta9-THC and the CYP2C9 substrate, phenytoin.	Dronabinol	59-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	27-33
16112652-8	2005	Surprisingly, delta9-THC increased the rate of phenytoin hydroxylation in human liver microsomes and expressed CYP2C9 enzyme.	Dronabinol	14-24	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	111-117
16341592-7	2005	When investigating survival of hippocampal neurons in culture, we found significant protection against hypoxia-induced cell death with CB1-analogs (noladin, (9-tetrahydrocannabinol) only in ETB-deficient neurons.	Dronabinol	158-180	cannabinoid receptor 1	Rattus norvegicus	135-138
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	172-199	cannabinoid receptor 1	Macaca mulatta	27-30
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	172-199	cannabinoid receptor 1	Macaca mulatta	103-106
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	201-211	cannabinoid receptor 1	Macaca mulatta	27-30
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	201-211	cannabinoid receptor 1	Macaca mulatta	103-106
16148447-2	2005	Perinatal activation of cannabinoid CB1 receptors by chronic administration of delta9-tetrahydrocannabinol at different doses (0.1, 0.5, 2 mg/kg, p.o.)	Dronabinol	79-106	cannabinoid receptor 1	Rattus norvegicus	36-39
15964028-3	2005	Administration of THC alone, in the absence of HIV, decreased CD4 counts and the CD4:CD8 ratio.	Dronabinol	18-21	CD4 antigen	Mus musculus	62-65
15964028-3	2005	Administration of THC alone, in the absence of HIV, decreased CD4 counts and the CD4:CD8 ratio.	Dronabinol	18-21	CD4 antigen	Mus musculus	81-84
15964028-7	2005	Administration of THC for 5 days increased the percentage of PBL expressing CCR5 and, to a lesser extent, CXCR4.	Dronabinol	18-21	chemokine (C-C motif) receptor 5	Mus musculus	76-80
15964028-7	2005	Administration of THC for 5 days increased the percentage of PBL expressing CCR5 and, to a lesser extent, CXCR4.	Dronabinol	18-21	chemokine (C-X-C motif) receptor 4	Mus musculus	106-111
15978631-1	2005	CB1 cannabinoid receptors mediate the psychoactive effects of Delta(9)THC and actions of the endogenous cannabinoids [Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G., 2002. International Union of Pharmacology: XXVII.	Dronabinol	62-73	cannabinoid receptor 1	Homo sapiens	0-3
15978942-6	2005	Furthermore, overexpression of Bcl-2 rendered the cells resistant to THC at early time points but not upon prolonged exposure.	Dronabinol	69-72	BCL2 apoptosis regulator	Homo sapiens	31-36
15978942-7	2005	THC treatment led to loss of Deltapsi(m), in both wild-type and FADD-deficient Jurkat cells thereby suggesting that THC-induced intrinsic pathway was independent of FADD.	Dronabinol	0-3	Fas associated via death domain	Homo sapiens	64-68
15978942-7	2005	THC treatment led to loss of Deltapsi(m), in both wild-type and FADD-deficient Jurkat cells thereby suggesting that THC-induced intrinsic pathway was independent of FADD.	Dronabinol	116-119	Fas associated via death domain	Homo sapiens	64-68
15978942-8	2005	THC treatment of wild-type Jurkat cells caused cytochrome c release, and cleavage of caspase-8, -9, -2, -10, and Bid.	Dronabinol	0-3	cytochrome c, somatic	Homo sapiens	47-59
15978942-8	2005	THC treatment of wild-type Jurkat cells caused cytochrome c release, and cleavage of caspase-8, -9, -2, -10, and Bid.	Dronabinol	0-3	caspase 8	Homo sapiens	85-94
15978942-8	2005	THC treatment of wild-type Jurkat cells caused cytochrome c release, and cleavage of caspase-8, -9, -2, -10, and Bid.	Dronabinol	0-3	BH3 interacting domain death agonist	Homo sapiens	113-116
15978942-9	2005	Caspase-2 inhibitor blocked THC-induced caspase-3 in wild-type Jurkat cells but not loss of Deltapsi(m).	Dronabinol	28-31	caspase 2	Homo sapiens	0-9
15978942-9	2005	Caspase-2 inhibitor blocked THC-induced caspase-3 in wild-type Jurkat cells but not loss of Deltapsi(m).	Dronabinol	28-31	caspase 3	Homo sapiens	40-49
15831444-2	2005	The present experiments assessed the cannabinoid activity of marijuana smoke exposure in mice and tested the hypothesis that delta9-THC mediates these effects through a CB1 receptor mechanism of action.	Dronabinol	125-135	cannabinoid receptor 1 (brain)	Mus musculus	169-172
15831444-8	2005	Both marijuana and delta9-THC produced comparable levels of antinociception, hypothermia, and catalepsy regardless of the route of administration, and these effects were blocked by pretreatment with the CB1 antagonist SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl].	Dronabinol	19-29	cannabinoid receptor 1 (brain)	Mus musculus	203-206
15936883-1	2005	CT-3 (ajulemic acid) is a synthetic analogue of a metabolite of Delta9-tetrahydrocannabinol that has reported analgesic efficacy in neuropathic pain states in man.	Dronabinol	64-91	cancer antigen 1	Homo sapiens	0-4
15913574-0	2005	Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study.	Dronabinol	10-37	cAMP responsive element binding protein 1	Rattus norvegicus	56-60
15913574-4	2005	This immunohistochemical study examines the effect of delta9-tetrahydrocannabinol (delta9-THC), the principal psychoactive component of marijuana, on the levels of phosphorylated CREB (p-CREB) in the rat cerebellum.	Dronabinol	54-81	cAMP responsive element binding protein 1	Rattus norvegicus	179-183
15913574-4	2005	This immunohistochemical study examines the effect of delta9-tetrahydrocannabinol (delta9-THC), the principal psychoactive component of marijuana, on the levels of phosphorylated CREB (p-CREB) in the rat cerebellum.	Dronabinol	54-81	cAMP responsive element binding protein 1	Rattus norvegicus	187-191
15913574-4	2005	This immunohistochemical study examines the effect of delta9-tetrahydrocannabinol (delta9-THC), the principal psychoactive component of marijuana, on the levels of phosphorylated CREB (p-CREB) in the rat cerebellum.	Dronabinol	83-93	cAMP responsive element binding protein 1	Rattus norvegicus	179-183
15913574-4	2005	This immunohistochemical study examines the effect of delta9-tetrahydrocannabinol (delta9-THC), the principal psychoactive component of marijuana, on the levels of phosphorylated CREB (p-CREB) in the rat cerebellum.	Dronabinol	83-93	cAMP responsive element binding protein 1	Rattus norvegicus	187-191
15913574-5	2005	Acute treatments with delta9-THC at doses of 5 or 10 mg/kg induced a significant increase of p-CREB in the granule cell layer of the cerebellum, an effect blocked by the CB1 receptor antagonist SR 141716A.	Dronabinol	22-32	cAMP responsive element binding protein 1	Rattus norvegicus	95-99
15913574-5	2005	Acute treatments with delta9-THC at doses of 5 or 10 mg/kg induced a significant increase of p-CREB in the granule cell layer of the cerebellum, an effect blocked by the CB1 receptor antagonist SR 141716A.	Dronabinol	22-32	cannabinoid receptor 1	Rattus norvegicus	170-173
15913574-6	2005	Following chronic delta9-THC administration (10 mg/kg/day for 4 weeks), the density of p-CREB was markedly attenuated compared to controls, and this attenuation persisted 3 weeks after withdrawal from delta9-THC.	Dronabinol	18-28	cAMP responsive element binding protein 1	Rattus norvegicus	89-93
15882845-4	2005	Despite this increase, the motor inhibition caused by the acute administration of the cannabinoid agonist Delta(9)-tetrahydrocannabinol to Park-2 knockout female mice was markedly of lesser magnitude compared with the response found in wild-type animals.	Dronabinol	106-135	parkin RBR E3 ubiquitin protein ligase	Mus musculus	139-145
15821751-2	2005	2 In G3, vasorelaxation to THC was inhibited by pertussis toxin, but was unaffected by the CB1 receptor antagonist, AM251 (1 microM), incubation with the TRPV1 receptor agonist capsaicin (10 microM, 1 h), the TRPV1 receptor antagonist capsazepine (10 microM) or de-endothelialisation.	Dronabinol	27-30	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	154-159
15821751-8	2005	7 These data show that THC causes vasorelaxation through activation of K+ channels and inhibition of Ca2+ channels, and this involves non-CB1, non-TRPV1 but G-protein-coupled receptors.	Dronabinol	23-26	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	147-152
15910887-1	2005	Delta-9 tetrahydrocannabinol (Delta(9)-THC) and (-)-cannabidiol ((-)-CBD) are major constituents of the Cannabis sativa plant with different pharmacological profiles: (Delta(9)-THC activates cannabinoid CB(1) and CB(2) receptors and induces psychoactive and peripheral effects.	Dronabinol	0-28	cannabinoid receptor 1 (brain)	Mus musculus	203-208
15910887-1	2005	Delta-9 tetrahydrocannabinol (Delta(9)-THC) and (-)-cannabidiol ((-)-CBD) are major constituents of the Cannabis sativa plant with different pharmacological profiles: (Delta(9)-THC activates cannabinoid CB(1) and CB(2) receptors and induces psychoactive and peripheral effects.	Dronabinol	30-42	cannabinoid receptor 1 (brain)	Mus musculus	203-208
15857384-2	2005	Here we show that chronic administration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active psychotropic agent in marijuana and hashish, at 1.5 mg per kg per day intraperitoneally for 7 days, increases the expression, at both mRNA and protein levels, of brain-derived neurotrophic factor (BDNF), in specific rat brain areas, notably in those involved in reward and addiction.	Dronabinol	44-73	brain-derived neurotrophic factor	Rattus norvegicus	263-296
15857384-2	2005	Here we show that chronic administration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active psychotropic agent in marijuana and hashish, at 1.5 mg per kg per day intraperitoneally for 7 days, increases the expression, at both mRNA and protein levels, of brain-derived neurotrophic factor (BDNF), in specific rat brain areas, notably in those involved in reward and addiction.	Dronabinol	44-73	brain-derived neurotrophic factor	Rattus norvegicus	298-302
15857384-2	2005	Here we show that chronic administration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active psychotropic agent in marijuana and hashish, at 1.5 mg per kg per day intraperitoneally for 7 days, increases the expression, at both mRNA and protein levels, of brain-derived neurotrophic factor (BDNF), in specific rat brain areas, notably in those involved in reward and addiction.	Dronabinol	75-87	brain-derived neurotrophic factor	Rattus norvegicus	263-296
15857384-2	2005	Here we show that chronic administration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active psychotropic agent in marijuana and hashish, at 1.5 mg per kg per day intraperitoneally for 7 days, increases the expression, at both mRNA and protein levels, of brain-derived neurotrophic factor (BDNF), in specific rat brain areas, notably in those involved in reward and addiction.	Dronabinol	75-87	brain-derived neurotrophic factor	Rattus norvegicus	298-302
15857384-3	2005	Real-time PCR revealed a 10-fold up-regulation of BDNF mRNA in the nucleus accumbens (NAc) upon chronic Delta(9)-THC treatment, but there was no change at 3 or 24 h after a single injection.	Dronabinol	113-116	brain-derived neurotrophic factor	Rattus norvegicus	50-54
15857384-6	2005	Altogether, our study indicates that chronic exposure to Delta(9)-THC up-regulates BDNF in specific brain areas involved with reward, and provides evidence for different BDNF expression in the anterior and posterior VTA.	Dronabinol	57-69	brain-derived neurotrophic factor	Rattus norvegicus	83-87
15857384-6	2005	Altogether, our study indicates that chronic exposure to Delta(9)-THC up-regulates BDNF in specific brain areas involved with reward, and provides evidence for different BDNF expression in the anterior and posterior VTA.	Dronabinol	57-69	brain-derived neurotrophic factor	Rattus norvegicus	170-174
15857384-8	2005	We suggest that Delta(9)-THC up-regulation of BDNF expression has an important role in inducing the neuroadaptive processes taking place upon exposure to cannabinoids.	Dronabinol	16-28	brain-derived neurotrophic factor	Rattus norvegicus	46-50
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	116-145	mitogen-activated protein kinase 1	Mus musculus	32-66
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	116-145	mitogen-activated protein kinase 1	Mus musculus	68-71
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	116-145	RAS protein-specific guanine nucleotide-releasing factor 1	Mus musculus	267-275
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	147-150	mitogen-activated protein kinase 1	Mus musculus	32-66
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	147-150	mitogen-activated protein kinase 1	Mus musculus	68-71
15857401-1	2005	We investigated the role of the Ras/extracellular-regulated kinase (ERK) pathway in the development of tolerance to Delta(9)-tetrahydrocannabinol (THC)-induced reduction in spontaneous locomotor activity by a genetic (Ras-specific guanine nucleotide exchange factor (Ras-GRF1) knock-out mice) and pharmacological approach.	Dronabinol	147-150	RAS protein-specific guanine nucleotide-releasing factor 1	Mus musculus	267-275
15857401-3	2005	), a specific inhibitor of mitogen-activated protein kinase kinase (MEK), the upstream kinase of ERK, fully prevented the development of tolerance to THC-induced hypolocomotion.	Dronabinol	150-153	midkine	Mus musculus	27-66
15857401-3	2005	), a specific inhibitor of mitogen-activated protein kinase kinase (MEK), the upstream kinase of ERK, fully prevented the development of tolerance to THC-induced hypolocomotion.	Dronabinol	150-153	midkine	Mus musculus	68-71
15857401-3	2005	), a specific inhibitor of mitogen-activated protein kinase kinase (MEK), the upstream kinase of ERK, fully prevented the development of tolerance to THC-induced hypolocomotion.	Dronabinol	150-153	mitogen-activated protein kinase 1	Mus musculus	97-100
15857401-7	2005	These findings suggest that at least in the caudate putamen and cerebellum, the Ras/ERK pathway is essential for triggering the alteration in CB1 receptor function responsible for tolerance to THC-induced hypomotility.	Dronabinol	193-196	mitogen-activated protein kinase 1	Mus musculus	84-87
15857401-7	2005	These findings suggest that at least in the caudate putamen and cerebellum, the Ras/ERK pathway is essential for triggering the alteration in CB1 receptor function responsible for tolerance to THC-induced hypomotility.	Dronabinol	193-196	cannabinoid receptor 1 (brain)	Mus musculus	142-145
15894066-2	2005	The present study explored whether a single acute stimulation of CB1 cannabinoid receptors with (-)-Delta9-tetrahydrocannabinol (THC, 5 mg kg(-1) i.p.)	Dronabinol	96-127	cannabinoid receptor 1	Homo sapiens	65-68
15894066-2	2005	The present study explored whether a single acute stimulation of CB1 cannabinoid receptors with (-)-Delta9-tetrahydrocannabinol (THC, 5 mg kg(-1) i.p.)	Dronabinol	129-132	cannabinoid receptor 1	Homo sapiens	65-68
15894066-5	2005	The data indicated that THC induced a desensitization of cannabinoid receptors, as revealed by a reduction in CB1 receptor-agonist induced GTP-gamma-S incorporation in striatal membranes.	Dronabinol	24-27	cannabinoid receptor 1	Homo sapiens	110-113
15815632-7	2005	Lymphoid cells isolated from THC-treated mice showed diminished proliferation capacity and decreased interferon-gamma secretion.	Dronabinol	29-32	interferon gamma	Mus musculus	101-117
15815632-10	2005	Our data demonstrate that oral treatment with a low dose of THC inhibits atherosclerosis progression in the apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells.	Dronabinol	60-63	apolipoprotein E	Mus musculus	108-124
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	25-35	interleukin 4	Mus musculus	67-71
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	25-35	interleukin 10	Mus musculus	76-81
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	25-35	negative elongation factor complex member C/D, Th1l	Mus musculus	163-166
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	99-109	interleukin 4	Mus musculus	67-71
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	99-109	interleukin 10	Mus musculus	76-81
15749859-5	2005	Furthermore, exposure to Delta9-THC led to increased production of IL-4 and IL-10, suggesting that Delta9-THC exposure may specifically suppress the cell-mediated Th1 response by enhancing Th2-associated cytokines.	Dronabinol	99-109	negative elongation factor complex member C/D, Th1l	Mus musculus	163-166
15749859-7	2005	Finally, injection of anti-IL-4 and anti-IL-10 mAbs led to a partial reversal of the Delta9-THC-induced suppression of the immune response to 4T1.	Dronabinol	85-95	interleukin 4	Mus musculus	27-31
15749859-7	2005	Finally, injection of anti-IL-4 and anti-IL-10 mAbs led to a partial reversal of the Delta9-THC-induced suppression of the immune response to 4T1.	Dronabinol	85-95	interleukin 10	Mus musculus	41-46
15740725-8	2005	Although the basis for this unique pharmacology has not as yet been determined, it is possible that regional specificity of cannabinoid CB1 receptor downregulation and endocannabinoid release induced by repeated dosing with Delta9-tetrahydrocannabinol may play a role.	Dronabinol	224-251	cannabinoid receptor 1 (brain)	Mus musculus	136-139
15322725-0	2005	Delta(9)-THC-induced cognitive deficits in mice are reversed by the GABA(A) antagonist bicuculline.	Dronabinol	0-12	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	68-75
15608059-5	2005	Activation of ERK by d-amphetamine or by widely abused drugs, including cocaine, nicotine, morphine, and Delta(9)-tetrahydrocannabinol was absent in mice lacking dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32).	Dronabinol	105-134	mitogen-activated protein kinase 1	Mus musculus	14-17
15659311-6	2005	The vasorelaxant effects of the cannabinoids were not inhibited by cannabinoid CB1 receptor antagonism; however, vasorelaxation to both CP55,940 and THC was inhibited by cannabinoid CB2 receptor antagonism.	Dronabinol	149-152	cannabinoid receptor 2	Rattus norvegicus	182-185
15659311-9	2005	The vasoconstrictor effects of THC were inhibited by in vivo pre-treatment with pertussis toxin or CP55,940, acute exposure to CP55,940, cannabinoid CB1 receptor antagonism and cyclooxygenase inhibition.	Dronabinol	31-34	cannabinoid receptor 1	Rattus norvegicus	149-152
15572271-2	2005	The cannabinoid CB1 receptors have recently been implicated in rewarding aspects of not only the cannabinoid drug Delta9-tetrahydrocannabinol (Delta9-THC), but also of other drugs of abuse, including cocaine.	Dronabinol	114-141	cannabinoid receptor 1	Homo sapiens	16-19
15572271-2	2005	The cannabinoid CB1 receptors have recently been implicated in rewarding aspects of not only the cannabinoid drug Delta9-tetrahydrocannabinol (Delta9-THC), but also of other drugs of abuse, including cocaine.	Dronabinol	143-153	cannabinoid receptor 1	Homo sapiens	16-19
16596779-1	2005	CB1 cannabinoid receptors appear to mediate most, if not all of the psychoactive effects of delta-9-tetrahydrocannabinol and related compounds.	Dronabinol	92-120	cannabinoid receptor 1	Homo sapiens	0-3
15975726-2	2005	However, the activation of the CB1 receptor in cultured C6 glioma cells by (-)delta9-tetrahydrocannabinol in the presence of reagents generating reactive oxygen species leads to amplification of the cellular damage from oxidative stress.	Dronabinol	78-105	cannabinoid receptor 1	Homo sapiens	31-34
15588739-1	2004	Delta9-Tetrahydrocannabinol (Delta9-THC) and (-)-cannabidiol are major constituents of the Cannabis sativa plant with different pharmacological profiles: (-)-Delta9-tetrahydrocannabinol, but not (-)-cannabidiol, activates cannabinoid CB1 and CB2 receptors and induces psychoactive and peripheral effects.	Dronabinol	0-27	cannabinoid receptor 1 (brain)	Mus musculus	234-237
15588739-1	2004	Delta9-Tetrahydrocannabinol (Delta9-THC) and (-)-cannabidiol are major constituents of the Cannabis sativa plant with different pharmacological profiles: (-)-Delta9-tetrahydrocannabinol, but not (-)-cannabidiol, activates cannabinoid CB1 and CB2 receptors and induces psychoactive and peripheral effects.	Dronabinol	0-27	cannabinoid receptor 2 (macrophage)	Mus musculus	242-245
15588739-1	2004	Delta9-Tetrahydrocannabinol (Delta9-THC) and (-)-cannabidiol are major constituents of the Cannabis sativa plant with different pharmacological profiles: (-)-Delta9-tetrahydrocannabinol, but not (-)-cannabidiol, activates cannabinoid CB1 and CB2 receptors and induces psychoactive and peripheral effects.	Dronabinol	29-39	cannabinoid receptor 1 (brain)	Mus musculus	234-237
15588739-1	2004	Delta9-Tetrahydrocannabinol (Delta9-THC) and (-)-cannabidiol are major constituents of the Cannabis sativa plant with different pharmacological profiles: (-)-Delta9-tetrahydrocannabinol, but not (-)-cannabidiol, activates cannabinoid CB1 and CB2 receptors and induces psychoactive and peripheral effects.	Dronabinol	29-39	cannabinoid receptor 2 (macrophage)	Mus musculus	242-245
15599103-8	2004	Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Delta9-THC-induced impairment of spatial memory, and the therapeutic effect of Delta9-THC on EAE, and a Delta9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.	Dronabinol	157-167	cannabinoid receptor 1	Rattus norvegicus	103-106
15599103-8	2004	Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Delta9-THC-induced impairment of spatial memory, and the therapeutic effect of Delta9-THC on EAE, and a Delta9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.	Dronabinol	236-246	cannabinoid receptor 1	Rattus norvegicus	103-106
15599103-8	2004	Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Delta9-THC-induced impairment of spatial memory, and the therapeutic effect of Delta9-THC on EAE, and a Delta9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.	Dronabinol	163-167	cannabinoid receptor 1	Rattus norvegicus	103-106
15548217-6	2004	We also evaluated the consequences of Delta9-THC administration on c-Fos expression in several brain structures after chronic nicotine administration and withdrawal.	Dronabinol	38-48	FBJ osteosarcoma oncogene	Mus musculus	67-72
15286206-0	2004	Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.	Dronabinol	28-55	cannabinoid receptor 1 (brain)	Mus musculus	69-72
15640760-3	2004	The neuroprotective effects of Delta(9)-tetrahydrocannabinol but not cannabidiol were inhibited by SR141716, a cannabinoid CB1 receptor antagonist, and were abolished by warming of the animals to the levels observed in the controls.	Dronabinol	31-60	cannabinoid receptor 1 (brain)	Mus musculus	123-126
15640760-5	2004	These results surely show that the neuroprotective effect of Delta(9)-tetrahydrocannabinol are via a CB1 receptor and temperature-dependent mechanisms whereas the neuroprotective effects of cannabidiol are independent of CB1 blockade and of hypothermia.	Dronabinol	61-90	cannabinoid receptor 1 (brain)	Mus musculus	101-104
15385362-7	2004	THC increased the expression of glycoprotein IIb-IIIa and P selectin on human platelets in a concentration-dependent manner.	Dronabinol	0-3	selectin P	Homo sapiens	32-68
15258190-0	2004	The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.	Dronabinol	4-7	negative elongation factor complex member C/D, Th1l	Mus musculus	31-34
15369590-11	2004	THC was shown to selectively inhibit the immediate early ORF 50 gene promoter of KSHV and MHV 68.	Dronabinol	0-3	ORF50	Human gammaherpesvirus 8	57-63
15369590-13	2004	The immediate early gene ORF 50 promoter activity was specifically inhibited by THC.	Dronabinol	80-83	ORF50	Human gammaherpesvirus 8	25-31
15312802-1	2004	A large body of evidence supports the notion that Delta9-tetrahydrocannabinol (THC) stimulates food intake by its actions on CB1 cannabinoid receptors.	Dronabinol	50-77	cannabinoid receptor 1	Rattus norvegicus	125-128
15312802-1	2004	A large body of evidence supports the notion that Delta9-tetrahydrocannabinol (THC) stimulates food intake by its actions on CB1 cannabinoid receptors.	Dronabinol	79-82	cannabinoid receptor 1	Rattus norvegicus	125-128
15138755-11	2004	CONCLUSIONS: These results are the first to show that both delta9-THC, which acts on both CB 1 and CB2 receptors, and CBD, which does not bind to CB1 or CB2 receptors, potentiate the extinction of conditioned incentive learning.	Dronabinol	66-69	cannabinoid receptor 1	Rattus norvegicus	90-94
15138755-11	2004	CONCLUSIONS: These results are the first to show that both delta9-THC, which acts on both CB 1 and CB2 receptors, and CBD, which does not bind to CB1 or CB2 receptors, potentiate the extinction of conditioned incentive learning.	Dronabinol	66-69	cannabinoid receptor 2	Rattus norvegicus	99-102
15294950-5	2004	Treatment with THC induced caspase-2, -8, and -9 activation, cleavage of Bid, decreased mitochondrial membrane potential, and cytochrome c release, suggesting involvement of death-receptor and mitochondrial pathways.	Dronabinol	15-18	caspase 2	Mus musculus	27-48
15294950-5	2004	Treatment with THC induced caspase-2, -8, and -9 activation, cleavage of Bid, decreased mitochondrial membrane potential, and cytochrome c release, suggesting involvement of death-receptor and mitochondrial pathways.	Dronabinol	15-18	BH3 interacting domain death agonist	Mus musculus	73-76
15294950-6	2004	DCs from Bid-knockout mice were sensitive to THC-induced apoptosis thereby suggesting that Bid was dispensable.	Dronabinol	45-48	BH3 interacting domain death agonist	Mus musculus	9-12
15294950-8	2004	However, THC treatment induced phosphorylation of IkappaB-alpha, and enhanced the transcription of several apoptotic genes regulated by NF-kappaB.	Dronabinol	9-12	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	50-63
15294950-8	2004	However, THC treatment induced phosphorylation of IkappaB-alpha, and enhanced the transcription of several apoptotic genes regulated by NF-kappaB.	Dronabinol	9-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	136-145
15294950-9	2004	Moreover, inhibition of NF-kappaB was able to block THC-induced apoptosis in DCs.	Dronabinol	52-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	24-33
15313899-7	2004	Moreover, intratumoral administration of the cannabinoid Delta9-tetrahydrocannabinol to two patients with glioblastoma multiforme (grade IV astrocytoma) decreased VEGF levels and VEGFR-2 activation in the tumors.	Dronabinol	57-84	vascular endothelial growth factor A	Homo sapiens	163-167
15313899-7	2004	Moreover, intratumoral administration of the cannabinoid Delta9-tetrahydrocannabinol to two patients with glioblastoma multiforme (grade IV astrocytoma) decreased VEGF levels and VEGFR-2 activation in the tumors.	Dronabinol	57-84	kinase insert domain receptor	Homo sapiens	179-186
15280536-1	2004	Because Delta-9-tetrahydrocannabinol (THC) inhibited luteinizing hormone-releasing hormone (LHRH) in male rats, we hypothesized that the endocannabinoid, anandamide (AEA), would act similarly.	Dronabinol	8-36	gonadotropin releasing hormone 1	Rattus norvegicus	53-90
15280536-1	2004	Because Delta-9-tetrahydrocannabinol (THC) inhibited luteinizing hormone-releasing hormone (LHRH) in male rats, we hypothesized that the endocannabinoid, anandamide (AEA), would act similarly.	Dronabinol	8-36	gonadotropin releasing hormone 1	Rattus norvegicus	92-96
15280536-1	2004	Because Delta-9-tetrahydrocannabinol (THC) inhibited luteinizing hormone-releasing hormone (LHRH) in male rats, we hypothesized that the endocannabinoid, anandamide (AEA), would act similarly.	Dronabinol	38-41	gonadotropin releasing hormone 1	Rattus norvegicus	53-90
15280536-1	2004	Because Delta-9-tetrahydrocannabinol (THC) inhibited luteinizing hormone-releasing hormone (LHRH) in male rats, we hypothesized that the endocannabinoid, anandamide (AEA), would act similarly.	Dronabinol	38-41	gonadotropin releasing hormone 1	Rattus norvegicus	92-96
15288581-6	2004	Src tyrosine kinase inhibition reversed tolerance to only the hypoactive effects of THC.	Dronabinol	84-87	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
15182311-0	2004	DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine.	Dronabinol	34-37	Kv channel interacting protein 3, calsenilin	Mus musculus	0-5
15182311-3	2004	The aversive effects of THC were potentiated in dream(-/-) mice in a kappa-opioid receptor-dependent fashion, whereas morphine reward and the aversive effects of morphine withdrawal remained intact.	Dronabinol	24-27	Kv channel interacting protein 3, calsenilin	Mus musculus	48-53
15182311-5	2004	Moreover, the aversive properties of lithium chloride and naloxone were unaffected by the absence of DREAM, indicating that the effect of DREAM on THC-induced dysphoria is not due to a general involvement in the behavioral response to aversive stimuli.	Dronabinol	147-150	Kv channel interacting protein 3, calsenilin	Mus musculus	138-143
15182311-7	2004	Finally, whereas the absence of DREAM reduced the analgesic efficacy of THC, morphine analgesia was unaffected in dream(-/-) mice.	Dronabinol	72-75	Kv channel interacting protein 3, calsenilin	Mus musculus	32-37
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	12-40	mitogen-activated protein kinase 1	Mus musculus	56-93
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	12-40	mitogen-activated protein kinase 1	Mus musculus	95-98
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	12-40	mitogen-activated protein kinase 1	Mus musculus	136-139
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	42-45	mitogen-activated protein kinase 1	Mus musculus	56-93
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	42-45	mitogen-activated protein kinase 1	Mus musculus	95-98
15078556-2	2004	Cocaine and delta-9-tetrahydrocannabinol (THC) activate extracellular signal-regulated kinase (ERK) in the striatum and blockade of the ERK pathway prevents establishment of conditioned place preference to these drugs.	Dronabinol	42-45	mitogen-activated protein kinase 1	Mus musculus	136-139
15078556-4	2004	We studied the appearance of phospho-ERK immunoreactive neurons in CD-1 mouse brain following acute administration of drugs commonly abused by humans, cocaine, morphine, nicotine and THC, or of other psychoactive compounds including caffeine, scopolamine, antidepressants and antipsychotics.	Dronabinol	183-186	mitogen-activated protein kinase 1	Mus musculus	37-40
14718593-0	2004	Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.	Dronabinol	24-51	cannabinoid receptor 1 (brain)	Mus musculus	74-77
14718593-5	2004	Delta(9)-Tetrahydrocannabinol (Delta(9)-THC) decreased lever press responding in CB1+/+ mice only, whereas methanandamide, a metabolically stable endocannabinoid analog, produced similar response rate decreases in both genotypic groups.	Dronabinol	0-29	cannabinoid receptor 1 (brain)	Mus musculus	81-84
14718593-5	2004	Delta(9)-Tetrahydrocannabinol (Delta(9)-THC) decreased lever press responding in CB1+/+ mice only, whereas methanandamide, a metabolically stable endocannabinoid analog, produced similar response rate decreases in both genotypic groups.	Dronabinol	31-43	cannabinoid receptor 1 (brain)	Mus musculus	81-84
14718593-7	2004	The CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A) blocked the effects of Delta(9)-THC, but not those of methanandamide.	Dronabinol	172-184	cannabinoid receptor 1 (brain)	Mus musculus	4-7
15026328-4	2004	Treatment of the glioblastoma cell line U373-MG and the lung carcinoma cell line NCI-H292 with nanomolar concentrations of THC led to accelerated cell proliferation that was completely dependent on metalloprotease and epidermal growth factor receptor (EGFR) activity.	Dronabinol	123-126	epidermal growth factor receptor	Homo sapiens	218-250
15026328-4	2004	Treatment of the glioblastoma cell line U373-MG and the lung carcinoma cell line NCI-H292 with nanomolar concentrations of THC led to accelerated cell proliferation that was completely dependent on metalloprotease and epidermal growth factor receptor (EGFR) activity.	Dronabinol	123-126	epidermal growth factor receptor	Homo sapiens	252-256
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	6-35	mitogen-activated protein kinase 1	Mus musculus	62-65
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	6-35	mitogen-activated protein kinase 1	Mus musculus	75-78
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	6-35	FBJ osteosarcoma oncogene	Mus musculus	91-96
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	37-40	mitogen-activated protein kinase 1	Mus musculus	62-65
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	37-40	mitogen-activated protein kinase 1	Mus musculus	75-78
15033164-1	2004	Acute Delta(9)-tetrahydrocannabinol (THC) injection increased ERK pathway (ERK, pCREB, and c-fos) mostly in the caudate putamen and cerebellum.	Dronabinol	37-40	FBJ osteosarcoma oncogene	Mus musculus	91-96
15033164-3	2004	Moreover, chronic THC exposure induced increases in the ERK cascade (ERK, pCREB, and Fos B) in the prefrontal cortex and hippocampus, suggesting that different neuronal circuits seem to be involved in the early phase and late phase of exposure.	Dronabinol	18-21	mitogen-activated protein kinase 1	Mus musculus	56-59
15033164-3	2004	Moreover, chronic THC exposure induced increases in the ERK cascade (ERK, pCREB, and Fos B) in the prefrontal cortex and hippocampus, suggesting that different neuronal circuits seem to be involved in the early phase and late phase of exposure.	Dronabinol	18-21	mitogen-activated protein kinase 1	Mus musculus	69-72
15033164-3	2004	Moreover, chronic THC exposure induced increases in the ERK cascade (ERK, pCREB, and Fos B) in the prefrontal cortex and hippocampus, suggesting that different neuronal circuits seem to be involved in the early phase and late phase of exposure.	Dronabinol	18-21	FBJ osteosarcoma oncogene B	Mus musculus	85-90
14996418-2	2004	THC"s impact on peritoneal macrophages to deliver costimulatory signals to a helper T cell hybridoma was investigated by T cell interleukin-2 production stimulated with immobilized anti-CD3 antibody.	Dronabinol	0-3	interleukin 2	Mus musculus	128-141
14996418-2	2004	THC"s impact on peritoneal macrophages to deliver costimulatory signals to a helper T cell hybridoma was investigated by T cell interleukin-2 production stimulated with immobilized anti-CD3 antibody.	Dronabinol	0-3	CD3 antigen, epsilon polypeptide	Mus musculus	186-189
14996418-9	2004	CB1-selective antagonist SR141716A completely reversed, and CB2-selective antagonist SR144528 partially blocked THC"s inhibition.	Dronabinol	112-115	cannabinoid receptor 2 (macrophage)	Mus musculus	60-63
14741443-5	2004	Furthermore, THC administration resulted in decreased levels of mRNA for the pro-inflammatory cytokines interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor alpha for neonatal rat microglia co-cultured with Acanthamoeba.	Dronabinol	13-16	interleukin 1 alpha	Rattus norvegicus	104-123
14741443-5	2004	Furthermore, THC administration resulted in decreased levels of mRNA for the pro-inflammatory cytokines interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor alpha for neonatal rat microglia co-cultured with Acanthamoeba.	Dronabinol	13-16	interleukin 1 beta	Rattus norvegicus	125-143
14741443-5	2004	Furthermore, THC administration resulted in decreased levels of mRNA for the pro-inflammatory cytokines interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor alpha for neonatal rat microglia co-cultured with Acanthamoeba.	Dronabinol	13-16	tumor necrosis factor	Rattus norvegicus	149-176
15159677-1	2004	Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 subtype of cannabinoid receptors.	Dronabinol	0-10	cannabinoid receptor 1	Homo sapiens	151-154
15159677-1	2004	Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 subtype of cannabinoid receptors.	Dronabinol	0-10	cannabinoid receptor 2	Homo sapiens	163-166
15159677-1	2004	Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 subtype of cannabinoid receptors.	Dronabinol	41-44	cannabinoid receptor 1	Homo sapiens	151-154
15159677-1	2004	Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 subtype of cannabinoid receptors.	Dronabinol	41-44	cannabinoid receptor 2	Homo sapiens	163-166
14586538-1	2004	RATIONALE: Recently, Delta(9)-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, and synthetic cannabinoid receptor agonists reportedly reduced the head-twitches induced by the 5-HT(2A/2C) receptor agonist 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane (DOI) in mice, which is mediated via the activation of 5-HT(2A) receptor.	Dronabinol	21-50	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	332-349
14586538-1	2004	RATIONALE: Recently, Delta(9)-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, and synthetic cannabinoid receptor agonists reportedly reduced the head-twitches induced by the 5-HT(2A/2C) receptor agonist 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane (DOI) in mice, which is mediated via the activation of 5-HT(2A) receptor.	Dronabinol	52-55	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	332-349
15233572-0	2004	Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure.	Dronabinol	125-152	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	56-61
15233572-0	2004	Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure.	Dronabinol	125-152	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	66-71
15233572-1	2004	This paper reports the effects of pre- and perinatal exposure to delta9-tetrahydrocannabinol (THC) on expression levels of specific AMPA glutamate receptor subunits (GluR1 and GluR2/3) in the cerebellum of male and female rats.	Dronabinol	65-92	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	166-171
15233572-1	2004	This paper reports the effects of pre- and perinatal exposure to delta9-tetrahydrocannabinol (THC) on expression levels of specific AMPA glutamate receptor subunits (GluR1 and GluR2/3) in the cerebellum of male and female rats.	Dronabinol	65-92	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	176-181
15233572-1	2004	This paper reports the effects of pre- and perinatal exposure to delta9-tetrahydrocannabinol (THC) on expression levels of specific AMPA glutamate receptor subunits (GluR1 and GluR2/3) in the cerebellum of male and female rats.	Dronabinol	94-97	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	166-171
15233572-1	2004	This paper reports the effects of pre- and perinatal exposure to delta9-tetrahydrocannabinol (THC) on expression levels of specific AMPA glutamate receptor subunits (GluR1 and GluR2/3) in the cerebellum of male and female rats.	Dronabinol	94-97	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	176-181
15233572-3	2004	Expression of the GluR1 and GluR2/3 subunits of AMPA glutamate receptors was analyzed by immunohistochemistry in THC-exposed rats at three postnatal ages: PD20 (still exposed to THC) to study the direct effect of drug exposure, and PD30 and PD70 (10 and 50 days following THC withdrawal) to analyze the long-term effects of prenatal exposure.	Dronabinol	113-116	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	18-23
15233572-3	2004	Expression of the GluR1 and GluR2/3 subunits of AMPA glutamate receptors was analyzed by immunohistochemistry in THC-exposed rats at three postnatal ages: PD20 (still exposed to THC) to study the direct effect of drug exposure, and PD30 and PD70 (10 and 50 days following THC withdrawal) to analyze the long-term effects of prenatal exposure.	Dronabinol	113-116	glutamate ionotropic receptor AMPA type subunit 3	Rattus norvegicus	28-35
15233572-4	2004	Compared to controls, pre- and perinatal THC exposure decreased the immunoreactivity levels of the GluR1 subunit in Bergmann glial cells, as well as levels of the GluR2/3 subunit in Purkinje neurons at PD20.	Dronabinol	41-44	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	99-104
15233572-4	2004	Compared to controls, pre- and perinatal THC exposure decreased the immunoreactivity levels of the GluR1 subunit in Bergmann glial cells, as well as levels of the GluR2/3 subunit in Purkinje neurons at PD20.	Dronabinol	41-44	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	163-170
15509898-6	2004	The expression of the glutamate transporter GLAST in astroglial cells and EAAC1 in Purkinje neurons decreased in THC-exposed offspring compared to controls.	Dronabinol	113-116	solute carrier family 1 member 3	Rattus norvegicus	22-43
15509898-6	2004	The expression of the glutamate transporter GLAST in astroglial cells and EAAC1 in Purkinje neurons decreased in THC-exposed offspring compared to controls.	Dronabinol	113-116	solute carrier family 1 member 3	Rattus norvegicus	44-49
15509898-6	2004	The expression of the glutamate transporter GLAST in astroglial cells and EAAC1 in Purkinje neurons decreased in THC-exposed offspring compared to controls.	Dronabinol	113-116	solute carrier family 1 member 1	Rattus norvegicus	74-79
15509898-8	2004	Moreover, the glial glutamate transporter level in THC-exposed rats (quantified by Western blot) was lower than in control rats.	Dronabinol	51-54	solute carrier family 1 member 3	Rattus norvegicus	14-41
14675158-2	2004	In the present study, we investigated the participation of the prostanoid EP3 receptor, the target of PGE2 in the brain, in behavioral suppression induced by Delta8-tetrahydrocannabinol (Delta8-THC), an isomer of the naturally occurring Delta9-THC, using a one-lever operant task in rats.	Dronabinol	237-247	prostaglandin E receptor 3	Rattus norvegicus	63-86
14770363-1	2004	The major psychoactive component of cannabis derivatives, delta9-THC, activates two G-protein coupled receptors: CB1 and CB2.	Dronabinol	58-68	cannabinoid receptor 1	Homo sapiens	113-116
14770363-1	2004	The major psychoactive component of cannabis derivatives, delta9-THC, activates two G-protein coupled receptors: CB1 and CB2.	Dronabinol	58-68	cannabinoid receptor 2	Homo sapiens	121-124
14665975-1	2003	Cannabinoid CB1 receptor agonists, including delta-9-tetrahydrocannabinol (Delta 9-THC) (the main psychoactive ingredient in marijuana) have been shown to increase feeding in rats and humans.	Dronabinol	45-73	cannabinoid receptor 1	Rattus norvegicus	12-15
14665975-1	2003	Cannabinoid CB1 receptor agonists, including delta-9-tetrahydrocannabinol (Delta 9-THC) (the main psychoactive ingredient in marijuana) have been shown to increase feeding in rats and humans.	Dronabinol	75-86	cannabinoid receptor 1	Rattus norvegicus	12-15
14683467-7	2003	In some of these researches the effect of Delta9-THC was antagonized by the CB1 receptor antagonist SR 141716A, showing the involvement of this subtype of cannabinoid receptor in its effect.	Dronabinol	42-52	cannabinoid receptor 1 (brain)	Mus musculus	76-79
14578199-9	2003	The effect of THC was in part mediated by the cannabinoid receptor CB1.	Dronabinol	14-17	cannabinoid receptor 1	Rattus norvegicus	67-70
12970091-7	2003	CLOZ and the 5-HT2A/2C antagonists ritanserin, RS102221 and SB242084 were more effective in antagonizing HP than HP+Delta9-THC-induced catalepsy.7 HP and CLOZ failed to inhibit in vitro [3H]CP-55,940 binding, while Delta9-THC and SR141716A did not show an appreciable affinity for the D2 receptor.	Dronabinol	122-126	5-hydroxytryptamine receptor 2A	Rattus norvegicus	13-19
12970091-7	2003	CLOZ and the 5-HT2A/2C antagonists ritanserin, RS102221 and SB242084 were more effective in antagonizing HP than HP+Delta9-THC-induced catalepsy.7 HP and CLOZ failed to inhibit in vitro [3H]CP-55,940 binding, while Delta9-THC and SR141716A did not show an appreciable affinity for the D2 receptor.	Dronabinol	116-126	5-hydroxytryptamine receptor 2A	Rattus norvegicus	13-19
14522843-0	2003	Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons.	Dronabinol	0-20	cannabinoid receptor 1	Rattus norvegicus	54-57
14522843-0	2003	Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons.	Dronabinol	0-20	mitogen-activated protein kinase 8	Rattus norvegicus	76-99
14522843-2	2003	THC exerts its apoptotic effects in cortical neurons by binding to the CB1 cannabinoid receptor.	Dronabinol	0-3	cannabinoid receptor 1	Rattus norvegicus	71-74
14522843-4	2003	However, the involvement of specific JNK isoforms in the neurotoxic properties of THC remains to be established.	Dronabinol	82-85	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
14522843-7	2003	Here we report that THC induces the activation of JNK via the CB1 receptor and its associated G-protein, Gi/o.	Dronabinol	20-23	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
14522843-7	2003	Here we report that THC induces the activation of JNK via the CB1 receptor and its associated G-protein, Gi/o.	Dronabinol	20-23	cannabinoid receptor 1	Rattus norvegicus	62-65
12791597-6	2003	The site of action of THC in the brain stem was further assessed using Fos immunohistochemistry.	Dronabinol	22-25	proto-oncogene c-Fos	Mustela putorius furo	71-74
12791597-7	2003	Fos expression induced by cisplatin in the dorsal motor nucleus of the vagus (DMNX) and the medial subnucleus of the nucleus of the solitary tract (NTS), but not other subnuclei of the NTS, was significantly reduced by THC rostral to obex.	Dronabinol	219-222	proto-oncogene c-Fos	Mustela putorius furo	0-3
12791597-7	2003	Fos expression induced by cisplatin in the dorsal motor nucleus of the vagus (DMNX) and the medial subnucleus of the nucleus of the solitary tract (NTS), but not other subnuclei of the NTS, was significantly reduced by THC rostral to obex.	Dronabinol	219-222	neurotensin/neuromedin N	Mustela putorius furo	148-151
12791597-8	2003	At the level of the obex, THC reduced Fos expression in the area postrema and the dorsal subnucleus of the NTS.	Dronabinol	26-29	proto-oncogene c-Fos	Mustela putorius furo	38-41
12791597-8	2003	At the level of the obex, THC reduced Fos expression in the area postrema and the dorsal subnucleus of the NTS.	Dronabinol	26-29	neurotensin/neuromedin N	Mustela putorius furo	107-110
14501260-1	2003	The present study estimated the apparent intrinsic activity of the cannabinoid CB1 receptor ligands CP 55,940, Delta9-tetrahydrocannabinol (Delta9-THC) and SR 141716A in a highly sensitive in vivo assay.	Dronabinol	111-138	cannabinoid receptor 1	Rattus norvegicus	79-82
14501260-1	2003	The present study estimated the apparent intrinsic activity of the cannabinoid CB1 receptor ligands CP 55,940, Delta9-tetrahydrocannabinol (Delta9-THC) and SR 141716A in a highly sensitive in vivo assay.	Dronabinol	140-150	cannabinoid receptor 1	Rattus norvegicus	79-82
12834810-11	2003	THC and MET induced translocation of Raf-1 to the membrane and phosphorylation of p44/42 Erk kinase, which was reversed by cannabinoid receptor antagonists and PI3K inhibitor.	Dronabinol	0-3	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	37-42
12834810-11	2003	THC and MET induced translocation of Raf-1 to the membrane and phosphorylation of p44/42 Erk kinase, which was reversed by cannabinoid receptor antagonists and PI3K inhibitor.	Dronabinol	0-3	mitogen-activated protein kinase 1	Homo sapiens	89-92
12821175-4	2003	As expected, a significant induction of the immediate early gene Fos was observed after acute administration of morphine, cocaine, 3, 4-methylenedioxymethamphetamine and Delta(9)-Tetrahydrocannabinol.	Dronabinol	170-199	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	65-68
12660305-3	2003	A Delta9-tetrahydrocannabinol (THC) drug-discrimination procedure was first used to determine effective CB1 antagonist doses of SR-141716A and optimal pretreatment times for self-administration studies.	Dronabinol	2-29	cannabinoid receptor 1	Rattus norvegicus	104-107
12660305-3	2003	A Delta9-tetrahydrocannabinol (THC) drug-discrimination procedure was first used to determine effective CB1 antagonist doses of SR-141716A and optimal pretreatment times for self-administration studies.	Dronabinol	31-34	cannabinoid receptor 1	Rattus norvegicus	104-107
12813001-12	2003	5 Specific CB2 receptor ligands could be useful anti-inflammatory agents, while avoiding the neurotoxic and psychoactive effects of CB1 receptor ligands such as Delta(9)-THC.	Dronabinol	161-173	cannabinoid receptor 2	Homo sapiens	11-14
12813001-12	2003	5 Specific CB2 receptor ligands could be useful anti-inflammatory agents, while avoiding the neurotoxic and psychoactive effects of CB1 receptor ligands such as Delta(9)-THC.	Dronabinol	161-173	cannabinoid receptor 1	Homo sapiens	132-135
12606657-11	2003	PP1, the Src family tyrosine kinase inhibitor, and KT5720, the PKA inhibitor, reversed THC-induced tolerance.	Dronabinol	87-90	protein phosphatase 1 catalytic subunit gamma	Mus musculus	0-3
12686391-0	2003	Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice.	Dronabinol	129-158	cannabinoid receptor 1 (brain)	Mus musculus	98-120
12877905-8	2003	Compounds bearing ethyl substituents (DES and THC derivatives) inhibited thrombin-induced release of calcium from the endoplasmic reticulum.	Dronabinol	46-49	coagulation factor II, thrombin	Homo sapiens	73-81
12679236-8	2003	CONCLUSIONS: Our data suggests that DAT is decreased in the caudate from THC(-) subjects with schizophrenia, a change that may be reversed by ingesting THC from cannabis.	Dronabinol	73-76	solute carrier family 6 member 3	Homo sapiens	36-39
12679236-8	2003	CONCLUSIONS: Our data suggests that DAT is decreased in the caudate from THC(-) subjects with schizophrenia, a change that may be reversed by ingesting THC from cannabis.	Dronabinol	152-155	solute carrier family 6 member 3	Homo sapiens	36-39
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	interleukin 2	Mus musculus	212-216
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	interleukin 4	Mus musculus	218-222
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	interleukin 5	Mus musculus	224-228
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	interleukin 13	Mus musculus	234-239
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	20-49	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	281-284
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	interleukin 2	Mus musculus	212-216
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	interleukin 4	Mus musculus	218-222
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	interleukin 5	Mus musculus	224-228
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	interleukin 13	Mus musculus	234-239
12668119-6	2003	Cannabinol (CBN) or Delta(9)-tetrahydrocannabinol (Delta(9)-THC; 50 mg/kg, ip), administered daily for 3 consecutive days before sensitization and then before challenge, significantly attenuated the elevation of IL-2, IL-4, IL-5, and IL-13 steady-state mRNA expression elicited by Ova challenge in the lungs.	Dronabinol	51-63	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	281-284
12668119-7	2003	In addition, the elevation of serum IgE and the mucus overproduction induced by Ova challenge was also markedly attenuated by CBN or Delta(9)-THC administration in Ova-sensitized mice.	Dronabinol	133-145	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	80-83
12668119-7	2003	In addition, the elevation of serum IgE and the mucus overproduction induced by Ova challenge was also markedly attenuated by CBN or Delta(9)-THC administration in Ova-sensitized mice.	Dronabinol	133-145	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	164-167
12657697-3	2003	We show that anandamide, 2-arachidonoyl-glycerol, and Delta9-tetrahydrocannabinol (THC) activated extracellular signal-regulated kinase (ERK) in hippocampal slices.	Dronabinol	54-81	mitogen-activated protein kinase 1	Mus musculus	98-135
12657697-3	2003	We show that anandamide, 2-arachidonoyl-glycerol, and Delta9-tetrahydrocannabinol (THC) activated extracellular signal-regulated kinase (ERK) in hippocampal slices.	Dronabinol	54-81	mitogen-activated protein kinase 1	Mus musculus	137-140
12657697-3	2003	We show that anandamide, 2-arachidonoyl-glycerol, and Delta9-tetrahydrocannabinol (THC) activated extracellular signal-regulated kinase (ERK) in hippocampal slices.	Dronabinol	83-86	mitogen-activated protein kinase 1	Mus musculus	98-135
12657697-3	2003	We show that anandamide, 2-arachidonoyl-glycerol, and Delta9-tetrahydrocannabinol (THC) activated extracellular signal-regulated kinase (ERK) in hippocampal slices.	Dronabinol	83-86	mitogen-activated protein kinase 1	Mus musculus	137-140
12657697-4	2003	In living mice, THC activated ERK in hippocampal neurons and induced its accumulation in the nuclei of pyramidal cells in CA1 and CA3.	Dronabinol	16-19	mitogen-activated protein kinase 1	Mus musculus	30-33
12657697-4	2003	In living mice, THC activated ERK in hippocampal neurons and induced its accumulation in the nuclei of pyramidal cells in CA1 and CA3.	Dronabinol	16-19	carbonic anhydrase 1	Mus musculus	122-125
12657697-4	2003	In living mice, THC activated ERK in hippocampal neurons and induced its accumulation in the nuclei of pyramidal cells in CA1 and CA3.	Dronabinol	16-19	carbonic anhydrase 3	Mus musculus	130-133
12657697-9	2003	In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK.	Dronabinol	8-11	jun proto-oncogene	Mus musculus	38-53
12657697-9	2003	In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK.	Dronabinol	8-11	FBJ osteosarcoma oncogene	Mus musculus	70-75
12657697-9	2003	In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK.	Dronabinol	8-11	early growth response 1	Mus musculus	85-91
12657697-9	2003	In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK.	Dronabinol	8-11	brain derived neurotrophic factor	Mus musculus	97-101
12657697-9	2003	In vivo THC induced the expression of immediate-early genes products (c-Fos protein, Zif268, and BDNF mRNAs), and this induction was prevented by an inhibitor of MEK.	Dronabinol	8-11	mitogen-activated protein kinase kinase 2	Mus musculus	162-165
12657697-10	2003	The strong potential of cannabinoids for inducing long-term alterations in hippocampal neurons through the activation of the ERK pathway may be important for the physiological control of synaptic plasticity and for the general effects of THC in the context of drug abuse.	Dronabinol	238-241	mitogen-activated protein kinase 1	Mus musculus	125-128
12532414-6	2003	Both Delta(9)-THC and CBN reversibly inhibited GJIC at noncytotoxic doses (15 microM) in a normal diploid WB rat liver epithelial oval cell line within 20 min and activated ERK1 and ERK2 within 5 min.	Dronabinol	5-17	mitogen activated protein kinase 3	Rattus norvegicus	173-177
12532414-6	2003	Both Delta(9)-THC and CBN reversibly inhibited GJIC at noncytotoxic doses (15 microM) in a normal diploid WB rat liver epithelial oval cell line within 20 min and activated ERK1 and ERK2 within 5 min.	Dronabinol	5-17	mitogen activated protein kinase 1	Rattus norvegicus	182-186
12566162-2	2003	In the spinal superperfusion model, Delta(9) tetrahydrocannabinol inhibited capsaicin induced CGRP release in a concentration dependent manner.	Dronabinol	36-65	calcitonin-related polypeptide alpha	Rattus norvegicus	94-98
12578974-1	2003	Recent research has revealed that endogenous cannabinoid receptors (CB1 and CB2) react with the active ingredient of marijuana, Delta(9)-tetrahydrocannabinol.	Dronabinol	128-157	cannabinoid receptor 1	Rattus norvegicus	68-71
12578974-5	2003	Because Delta(9)-tetrahydrocannabinol inhibited prolactin (Prl) secretion following its intraventricular injection into male rats, we hypothesized that AEA would have a similar effect.	Dronabinol	8-37	prolactin	Rattus norvegicus	48-57
12578974-5	2003	Because Delta(9)-tetrahydrocannabinol inhibited prolactin (Prl) secretion following its intraventricular injection into male rats, we hypothesized that AEA would have a similar effect.	Dronabinol	8-37	prolactin	Rattus norvegicus	59-62
12623225-0	2003	Regional differences in naloxone modulation of Delta(9)-THC induced Fos expression in rat brain.	Dronabinol	56-59	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	68-71
12623225-7	2003	Results showed that naloxone inhibited THC-induced Fos immunoreactivity in several key brain regions including the ventral tegmental area, ventromedial and dorsomedial hypothalamus, central caudate-putamen and ventrolateral periaqueductal grey.	Dronabinol	39-42	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-54
12623225-8	2003	Conversely, naloxone and THC had an additive effect on Fos immunoreactivity in the central nucleus of the amygdala, the bed nucleus of the stria terminalis (lateral division), the insular cortex, and the paraventricular nucleus of the thalamus.	Dronabinol	25-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-58
12623225-10	2003	The inhibitory effects of naloxone on THC-induced ventral tegmentum, hypothalamic and periaqueductal grey Fos expression point to these structures as key sites involved in cannabinoid-opioid interactions.	Dronabinol	38-41	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	106-109
12527200-1	2003	The G-protein coupled cannabinoid receptors CB(1) and CB(2) are activated by Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of cannabis, and mediate physiological effects of endogenous cannabinoids ("endocannabinoids").	Dronabinol	77-106	cannabinoid receptor 1	Homo sapiens	44-49
12527200-1	2003	The G-protein coupled cannabinoid receptors CB(1) and CB(2) are activated by Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of cannabis, and mediate physiological effects of endogenous cannabinoids ("endocannabinoids").	Dronabinol	77-106	cannabinoid receptor 2	Homo sapiens	54-59
12534979-7	2003	Interestingly, the somatic manifestations of THC withdrawal were also significantly attenuated in mutant mice, suggesting that a cooperative action of MOR and DOR is required for the entire expression of THC dependence.	Dronabinol	45-48	opioid receptor, mu 1	Mus musculus	151-154
12534979-7	2003	Interestingly, the somatic manifestations of THC withdrawal were also significantly attenuated in mutant mice, suggesting that a cooperative action of MOR and DOR is required for the entire expression of THC dependence.	Dronabinol	45-48	opioid receptor, delta 1	Mus musculus	159-162
12534979-7	2003	Interestingly, the somatic manifestations of THC withdrawal were also significantly attenuated in mutant mice, suggesting that a cooperative action of MOR and DOR is required for the entire expression of THC dependence.	Dronabinol	204-207	opioid receptor, mu 1	Mus musculus	151-154
12534979-7	2003	Interestingly, the somatic manifestations of THC withdrawal were also significantly attenuated in mutant mice, suggesting that a cooperative action of MOR and DOR is required for the entire expression of THC dependence.	Dronabinol	204-207	opioid receptor, delta 1	Mus musculus	159-162
12461523-1	2003	The psychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion.	Dronabinol	42-71	cannabinoid receptor 1	Homo sapiens	125-128
12477601-1	2002	While several studies are available on the immediate effects of marijuana and its active ingredient tetrahydrocannabinol (THC) on regional cerebral blood flow (rCBF), we examined the effects of intravenous infusion of THC on rCBF and behavior over a 120-min.	Dronabinol	100-120	CCAAT/enhancer binding protein zeta	Rattus norvegicus	160-164
12477601-1	2002	While several studies are available on the immediate effects of marijuana and its active ingredient tetrahydrocannabinol (THC) on regional cerebral blood flow (rCBF), we examined the effects of intravenous infusion of THC on rCBF and behavior over a 120-min.	Dronabinol	122-125	CCAAT/enhancer binding protein zeta	Rattus norvegicus	160-164
12477601-1	2002	While several studies are available on the immediate effects of marijuana and its active ingredient tetrahydrocannabinol (THC) on regional cerebral blood flow (rCBF), we examined the effects of intravenous infusion of THC on rCBF and behavior over a 120-min.	Dronabinol	218-221	CCAAT/enhancer binding protein zeta	Rattus norvegicus	225-229
12477601-16	2002	THC had significant effects on global CBF and rCBF, and feeling intoxicated accounted for changes in rCBF better than plasma level of THC.	Dronabinol	0-3	CCAAT/enhancer binding protein zeta	Rattus norvegicus	38-41
12477601-16	2002	THC had significant effects on global CBF and rCBF, and feeling intoxicated accounted for changes in rCBF better than plasma level of THC.	Dronabinol	0-3	CCAAT/enhancer binding protein zeta	Rattus norvegicus	46-50
12505703-3	2002	Exposure of human T-cells to THC suppresses their proliferation, inhibits the release of interferon-gamma, and skews the balance of T-helper cytokines towards a type 2 response.	Dronabinol	29-32	interferon gamma	Homo sapiens	89-105
12443781-2	2002	The results support the hypothesis for a subsite within CB1 and CB2 binding domain at the level of the benzylic side chain carbon in the tetrahydrocannabinol and cannabidiol series.	Dronabinol	137-157	cannabinoid receptor 1	Homo sapiens	56-59
12443781-2	2002	The results support the hypothesis for a subsite within CB1 and CB2 binding domain at the level of the benzylic side chain carbon in the tetrahydrocannabinol and cannabidiol series.	Dronabinol	137-157	cannabinoid receptor 2	Homo sapiens	64-67
12446015-0	2002	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells.	Dronabinol	0-28	negative elongation factor complex member C/D	Homo sapiens	39-42
12446015-3	2002	THC suppressed T cell proliferation, inhibited the production of interferon-gamma and shifted the balance of T helper 1 (Th1)/T helper 2 (Th2) cytokines.	Dronabinol	0-3	interferon gamma	Homo sapiens	65-81
12446015-3	2002	THC suppressed T cell proliferation, inhibited the production of interferon-gamma and shifted the balance of T helper 1 (Th1)/T helper 2 (Th2) cytokines.	Dronabinol	0-3	negative elongation factor complex member C/D	Homo sapiens	121-124
12446015-4	2002	Intracellular cytokine staining demonstrated that THC reduced both the percentage and mean fluorescence intensity of activated T cells capable of producing interferon-gamma, with variable effects on the number of T cells capable of producing interleukin-4.	Dronabinol	50-53	interferon gamma	Homo sapiens	156-172
12446015-5	2002	Exposure to THC also decreased steady-state levels of mRNA encoding for Th1 cytokines, while increasing mRNA levels for Th2 cytokines.	Dronabinol	12-15	negative elongation factor complex member C/D	Homo sapiens	72-75
12503826-0	2002	Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat.	Dronabinol	64-91	proenkephalin	Rattus norvegicus	22-35
12503826-1	2002	Chronic exposure to delta9-tetrahydrocannabinol (delta9-THC) produces an activation of preproenkephalin (PENK) gene expression in the rat hypothalamus.	Dronabinol	20-47	proenkephalin	Rattus norvegicus	87-103
12503826-1	2002	Chronic exposure to delta9-tetrahydrocannabinol (delta9-THC) produces an activation of preproenkephalin (PENK) gene expression in the rat hypothalamus.	Dronabinol	20-47	proenkephalin	Rattus norvegicus	105-109
12503826-1	2002	Chronic exposure to delta9-tetrahydrocannabinol (delta9-THC) produces an activation of preproenkephalin (PENK) gene expression in the rat hypothalamus.	Dronabinol	49-59	proenkephalin	Rattus norvegicus	87-103
12503826-1	2002	Chronic exposure to delta9-tetrahydrocannabinol (delta9-THC) produces an activation of preproenkephalin (PENK) gene expression in the rat hypothalamus.	Dronabinol	49-59	proenkephalin	Rattus norvegicus	105-109
12503826-3	2002	However, whether gonadal steroids regulate delta9-THC effects on PENK gene expression in the hypothalamus of male and female rats remains unknown.	Dronabinol	43-53	proenkephalin	Rattus norvegicus	65-69
12503826-7	2002	In males, delta9-THC administration to intact animals induced PENK mRNA in the paraventricular nucleus (PVN) and ventromedial nucleus (VMN) of the hypothalamus.	Dronabinol	10-20	proenkephalin	Rattus norvegicus	62-66
12503826-9	2002	However, delta9-THC treatment induced PENK gene expression to the same extent in both hypothalamic nuclei of intact, castrated and DHT-replaced males.	Dronabinol	9-19	proenkephalin	Rattus norvegicus	38-42
12503826-11	2002	delta9-THC administration increased PENK gene expression in castrated females, but had no effect in the oestradiol-replaced group.	Dronabinol	0-10	proenkephalin	Rattus norvegicus	36-40
12213538-0	2002	Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.	Dronabinol	46-57	cannabinoid receptor 1	Rattus norvegicus	25-28
12243867-1	2002	Binding of the endocannabinoid anandamide or of Delta(9)-tetrahydrocannabinol to the agonist site of the cannabinoid receptor (CB1) is commonly assayed with [3H]CP 55,940.	Dronabinol	48-77	cannabinoid receptor 1 (brain)	Mus musculus	127-130
12130702-6	2002	Treatment with CB2 antagonist inhibited THC-induced apoptosis in thymocytes and activated splenocytes.	Dronabinol	40-43	cannabinoid receptor 2 (macrophage)	Mus musculus	15-18
12091357-2	2002	Exposure of murine tumors EL-4, LSA, and P815 to delta-9-tetrahydrocannabinol (THC) in vitro led to a significant reduction in cell viability and an increase in apoptosis.	Dronabinol	49-77	epilepsy 4	Mus musculus	26-30
12091357-2	2002	Exposure of murine tumors EL-4, LSA, and P815 to delta-9-tetrahydrocannabinol (THC) in vitro led to a significant reduction in cell viability and an increase in apoptosis.	Dronabinol	79-82	epilepsy 4	Mus musculus	26-30
12091357-4	2002	Treatment of EL-4 tumor-bearing mice with THC in vivo led to a significant reduction in tumor load, increase in tumor-cell apoptosis, and increase in survival of tumor-bearing mice.	Dronabinol	42-45	epilepsy 4	Mus musculus	13-17
12091357-7	2002	This effect was mediated at least in part through the CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed the THC-induced apoptosis.	Dronabinol	145-148	cannabinoid receptor 2 (macrophage)	Mus musculus	54-57
12091357-7	2002	This effect was mediated at least in part through the CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed the THC-induced apoptosis.	Dronabinol	145-148	cannabinoid receptor 2 (macrophage)	Mus musculus	98-101
12086980-5	2002	In cultured endothelial cells, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the cannabinoid receptor agonist HU210, increased the phosphorylation of extracellular regulated kinases 1/2 (ERK1/2) and inhibited gap junctional communication, as determined by Lucifer Yellow dye transfer and electrical capacity measurements.	Dronabinol	31-60	mitogen-activated protein kinase 3	Homo sapiens	190-196
12086980-5	2002	In cultured endothelial cells, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the cannabinoid receptor agonist HU210, increased the phosphorylation of extracellular regulated kinases 1/2 (ERK1/2) and inhibited gap junctional communication, as determined by Lucifer Yellow dye transfer and electrical capacity measurements.	Dronabinol	62-74	mitogen-activated protein kinase 3	Homo sapiens	190-196
12086980-7	2002	Delta(9)-THC elicited a pronounced increase in the phosphorylation of connexin 43, which was sensitive to PD98059 and U0126, two inhibitors of ERK1/2 activation.	Dronabinol	0-12	gap junction protein alpha 1	Homo sapiens	70-81
12086980-7	2002	Delta(9)-THC elicited a pronounced increase in the phosphorylation of connexin 43, which was sensitive to PD98059 and U0126, two inhibitors of ERK1/2 activation.	Dronabinol	0-12	mitogen-activated protein kinase 3	Homo sapiens	143-149
12086980-8	2002	Inhibition of ERK1/2 also prevented the Delta(9)-THC-induced inhibition of gap junctional communication.	Dronabinol	40-52	mitogen-activated protein kinase 3	Homo sapiens	14-20
12086980-10	2002	Delta(9)-THC prevented both the bradykinin-induced hyperpolarization and the nitric oxide and prostacyclin-independent relaxation of pre-contracted rings of porcine coronary artery.	Dronabinol	0-12	kininogen 1	Homo sapiens	32-42
12086980-16	2002	These results indicate that the cannabinoid-induced activation of ERK1/2, which leads to the phosphorylation of connexin 43 and inhibition of gap junctional communication, may partially account for the Delta(9)-THC-induced inhibition of EDHF-mediated relaxation.	Dronabinol	202-214	mitogen-activated protein kinase 3	Homo sapiens	66-72
12086980-16	2002	These results indicate that the cannabinoid-induced activation of ERK1/2, which leads to the phosphorylation of connexin 43 and inhibition of gap junctional communication, may partially account for the Delta(9)-THC-induced inhibition of EDHF-mediated relaxation.	Dronabinol	202-214	gap junction protein alpha 1	Homo sapiens	112-123
12137404-8	2002	Furthermore, delta9-THC, as a broad-spectrum cannabinoid receptor agonist, will activate both CB1 and CB2 receptors.	Dronabinol	13-23	cannabinoid receptor 1	Homo sapiens	94-97
12137404-8	2002	Furthermore, delta9-THC, as a broad-spectrum cannabinoid receptor agonist, will activate both CB1 and CB2 receptors.	Dronabinol	13-23	cannabinoid receptor 2	Homo sapiens	102-105
12040079-0	2002	Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism.	Dronabinol	0-28	cannabinoid receptor 1 (brain)	Mus musculus	94-97
12040079-0	2002	Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism.	Dronabinol	0-28	cannabinoid receptor 2 (macrophage)	Mus musculus	102-105
12040079-6	2002	However, the effect of THC on sensory nerves is intact in vanilloid receptor subtype 1 gene knock-out mice.	Dronabinol	23-26	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	58-86
11953755-1	2002	The R,R enantiomer of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC) exerts opposite effects on the transcriptional activity of the two estrogen receptor (ER) subtypes, ER alpha and ER beta.	Dronabinol	78-81	estrogen receptor 1	Homo sapiens	150-167
11953755-1	2002	The R,R enantiomer of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC) exerts opposite effects on the transcriptional activity of the two estrogen receptor (ER) subtypes, ER alpha and ER beta.	Dronabinol	78-81	estrogen receptor 1	Homo sapiens	169-171
11953755-1	2002	The R,R enantiomer of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC) exerts opposite effects on the transcriptional activity of the two estrogen receptor (ER) subtypes, ER alpha and ER beta.	Dronabinol	78-81	estrogen receptor 1	Homo sapiens	183-191
11953755-1	2002	The R,R enantiomer of 5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (THC) exerts opposite effects on the transcriptional activity of the two estrogen receptor (ER) subtypes, ER alpha and ER beta.	Dronabinol	78-81	estrogen receptor 2	Homo sapiens	196-203
11953755-2	2002	THC acts as an ER alpha agonist and as an ER beta antagonist.	Dronabinol	0-3	estrogen receptor 1	Homo sapiens	15-23
11953755-2	2002	THC acts as an ER alpha agonist and as an ER beta antagonist.	Dronabinol	0-3	estrogen receptor 2	Homo sapiens	42-49
11953755-3	2002	We have determined the crystal structures of the ER alpha ligand binding domain (LBD) bound to both THC and a fragment of the transcriptional coactivator GRIP1, and the ER beta LBD bound to THC.	Dronabinol	100-103	estrogen receptor 1	Homo sapiens	49-57
11953755-3	2002	We have determined the crystal structures of the ER alpha ligand binding domain (LBD) bound to both THC and a fragment of the transcriptional coactivator GRIP1, and the ER beta LBD bound to THC.	Dronabinol	190-193	estrogen receptor 2	Homo sapiens	169-176
11953755-4	2002	THC stabilizes a conformation of the ER alpha LBD that permits coactivator association and a conformation of the ER beta LBD that prevents coactivator association.	Dronabinol	0-3	estrogen receptor 1	Homo sapiens	37-45
11953755-6	2002	Instead, THC antagonizes ER beta through a novel mechanism we term "passive antagonism".	Dronabinol	9-12	estrogen receptor 2	Homo sapiens	25-32
12829401-0	2002	Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Delta(9)-tetrahydrocannabinol.	Dronabinol	111-140	proopiomelanocortin	Rattus norvegicus	28-32
12829401-3	2002	Prenatal Delta(9)-THC exposure altered POMC and prodynorphin mRNA levels in most of the brain areas studied at different fetal ages, but the effects were sex-dependent.	Dronabinol	9-21	proopiomelanocortin	Rattus norvegicus	39-43
12829401-4	2002	Thus, POMC mRNA levels increased in Delta(9)-THC-exposed females, but decreased in Delta(9)-THC-exposed males at GD21 in the arcuate nucleus, cerebral cortex and habenular nuclei.	Dronabinol	45-48	proopiomelanocortin	Rattus norvegicus	6-10
12829401-4	2002	Thus, POMC mRNA levels increased in Delta(9)-THC-exposed females, but decreased in Delta(9)-THC-exposed males at GD21 in the arcuate nucleus, cerebral cortex and habenular nuclei.	Dronabinol	92-95	proopiomelanocortin	Rattus norvegicus	6-10
12829401-5	2002	POMC mRNA levels also increased in the arcuate nucleus and cerebral cortex of Delta(9)-THC-exposed fetuses at GD18.	Dronabinol	87-90	proopiomelanocortin	Rattus norvegicus	0-4
12829401-8	2002	In summary, Delta(9)-THC exposure altered the prenatal development of POMC and prodynorphin mRNA levels in several brain structures.	Dronabinol	21-24	proopiomelanocortin	Rattus norvegicus	70-74
11976437-1	2002	The primary psychoactive ingredient in cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), affects the brain mainly by activating a specific receptor (CB1).	Dronabinol	49-76	cannabinoid receptor 1	Homo sapiens	151-154
11976437-1	2002	The primary psychoactive ingredient in cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), affects the brain mainly by activating a specific receptor (CB1).	Dronabinol	78-88	cannabinoid receptor 1	Homo sapiens	151-154
11903061-4	2002	The activity of serine palmitoyltransferase (SPT), which catalyses the rate-limiting step of ceramide synthesis de novo, was remarkably enhanced by THC in C6.9 cells, but not in C6.4 cells.	Dronabinol	148-151	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	16-43
11903061-4	2002	The activity of serine palmitoyltransferase (SPT), which catalyses the rate-limiting step of ceramide synthesis de novo, was remarkably enhanced by THC in C6.9 cells, but not in C6.4 cells.	Dronabinol	148-151	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	45-48
11918216-10	2002	An ER-beta-selective antagonist R, R-tetrahydrochrysene (THC) abolished the induction of PR mRNA in hFOB/ER-beta but not in hFOB/ER-a cells, verifying that the response in the former cell line was ER-beta-mediated.	Dronabinol	57-60	estrogen receptor 2	Homo sapiens	3-10
11918216-10	2002	An ER-beta-selective antagonist R, R-tetrahydrochrysene (THC) abolished the induction of PR mRNA in hFOB/ER-beta but not in hFOB/ER-a cells, verifying that the response in the former cell line was ER-beta-mediated.	Dronabinol	57-60	RB transcriptional corepressor 1	Homo sapiens	89-91
11918216-10	2002	An ER-beta-selective antagonist R, R-tetrahydrochrysene (THC) abolished the induction of PR mRNA in hFOB/ER-beta but not in hFOB/ER-a cells, verifying that the response in the former cell line was ER-beta-mediated.	Dronabinol	57-60	estrogen receptor 2	Homo sapiens	105-112
11918216-10	2002	An ER-beta-selective antagonist R, R-tetrahydrochrysene (THC) abolished the induction of PR mRNA in hFOB/ER-beta but not in hFOB/ER-a cells, verifying that the response in the former cell line was ER-beta-mediated.	Dronabinol	57-60	estrogen receptor 2	Homo sapiens	105-112
11890697-2	2002	We have carried out [(35)S]GTPgammaS binding experiments in striata, hippocampi, and cerebella of CB1-/- and CB1(+/+) mice with Delta(9)-THC, WIN55,212-2, HU-210, SR141716A, and SR144528.	Dronabinol	137-140	cannabinoid receptor 1 (brain)	Mus musculus	109-112
11809870-7	2002	Enhancement of IL-2 was also demonstrated with CP55940, Delta(9)-tetrahydrocannabinol, and cannabidiol, thus suggesting that the phenomenon is not unique to CBN.	Dronabinol	56-85	interleukin 2	Mus musculus	15-19
12052043-3	2002	The identification of a G-protein-coupled receptor, namely, the cannabinoid receptor (CB1 receptor) that was activated by Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive component of marijuana, led to the discovery of endogenous cannabinoid agonists.	Dronabinol	122-151	cannabinoid receptor 1 (brain)	Mus musculus	86-89
12052043-3	2002	The identification of a G-protein-coupled receptor, namely, the cannabinoid receptor (CB1 receptor) that was activated by Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive component of marijuana, led to the discovery of endogenous cannabinoid agonists.	Dronabinol	153-165	cannabinoid receptor 1 (brain)	Mus musculus	86-89
11806710-7	2002	However, computation of accurate interaction scores indicates preferred binding to the steroid binding site over the second binding site of both ER alpha and ER beta for all THC derivatives.	Dronabinol	174-177	estrogen receptor 1	Homo sapiens	145-153
11806710-7	2002	However, computation of accurate interaction scores indicates preferred binding to the steroid binding site over the second binding site of both ER alpha and ER beta for all THC derivatives.	Dronabinol	174-177	estrogen receptor 2	Homo sapiens	158-165
11779138-3	2002	The ability of THC to stimulate TGF-beta production was blocked by the CB2 receptor specific antagonist SR144528 but not by the CB1 specific antagonist AM251.	Dronabinol	15-18	transforming growth factor beta 1	Homo sapiens	32-40
11779138-2	2002	We report that THC induces the immunosuppressive cytokine TGF-beta by human peripheral blood lymphocytes (PBL).	Dronabinol	15-18	transforming growth factor beta 1	Homo sapiens	58-66
11779138-3	2002	The ability of THC to stimulate TGF-beta production was blocked by the CB2 receptor specific antagonist SR144528 but not by the CB1 specific antagonist AM251.	Dronabinol	15-18	cannabinoid receptor 2	Homo sapiens	71-74
11779138-6	2002	We conclude that one mechanism by which THC contributes to immune suppression is by stimulating an enhanced production of lymphocyte TGF-beta.	Dronabinol	40-43	transforming growth factor beta 1	Homo sapiens	133-141
11815392-7	2002	THC and nicotine administration induced c-Fos expression in several brain structures.	Dronabinol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	40-45
12457068-0	2002	Reduced glial fibrillary acidic protein and glutamine synthetase expression in astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-tetrahydrocannabinol administration during development.	Dronabinol	147-176	glutamate-ammonia ligase	Rattus norvegicus	44-64
12457068-6	2002	Our data suggest that pre- and perinatal THC exposure directly interferes with astroglial maturation by disrupting normal cytoskeletal formation, as indicated by the irregular disposition of GFAP and the lower GFAP expression observed at all the ages studied.	Dronabinol	41-44	glial fibrillary acidic protein	Rattus norvegicus	191-195
12457068-6	2002	Our data suggest that pre- and perinatal THC exposure directly interferes with astroglial maturation by disrupting normal cytoskeletal formation, as indicated by the irregular disposition of GFAP and the lower GFAP expression observed at all the ages studied.	Dronabinol	41-44	glial fibrillary acidic protein	Rattus norvegicus	210-214
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	67-96	hesitator	Mus musculus	191-194
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	67-96	esterase 5 regulator	Mus musculus	199-202
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	67-96	hesitator	Mus musculus	329-332
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	67-96	esterase 5 regulator	Mus musculus	337-340
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	98-110	hesitator	Mus musculus	191-194
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	98-110	esterase 5 regulator	Mus musculus	199-202
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	98-110	hesitator	Mus musculus	329-332
11812518-3	2002	The purposes of the present study were: (1) to investigate whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other cannabinoids HU-210 and WIN 55, 212-2 can prevent SR 141716A-induced HTR and ESR and (2) to evaluate any correlation between the ID(50) potency order of the cited cannabinoids in blocking SR 141716A-induced HTR and ESR and their ED(50) order of potency in reducing spontaneous locomotor activity and rearing behavior.	Dronabinol	98-110	esterase 5 regulator	Mus musculus	337-340
11812541-5	2002	These data confirm mediation of Delta(9)-THC hyperphagia by central-type CB1 receptors, and support a functional relationship between cannabinoid and opioid systems in relation to appetite regulation.	Dronabinol	32-44	cannabinoid receptor 1	Rattus norvegicus	73-76
11602526-2	2001	The COS-7 cells transfected with the CYP3A11 expression vector formed 7-oxo-Delta(8)-tetrahydrocannabinol (7-oxo-Delta(8)-THC) from 7alpha- and 7beta-hydroxy-Delta(8)-THC.	Dronabinol	122-125	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	37-44
11713615-15	2001	The effect of the challenge with Delta(9)-THC was prevented by the administration of the CB1 antagonist SR141716A (1 mg/kg i.p.	Dronabinol	33-45	cannabinoid receptor 1	Rattus norvegicus	89-92
11468287-4	2001	Anandamide and 2-arachidonoylglycerol, two endocannabinoids, and Delta9-tetrahydrocannabinol, stimulated tyrosine phosphorylation of FAK+6,7, a neuronal splice isoform of FAK, on several residues including Tyr-397.	Dronabinol	65-92	PTK2 protein tyrosine kinase 2	Mus musculus	133-136
11468287-4	2001	Anandamide and 2-arachidonoylglycerol, two endocannabinoids, and Delta9-tetrahydrocannabinol, stimulated tyrosine phosphorylation of FAK+6,7, a neuronal splice isoform of FAK, on several residues including Tyr-397.	Dronabinol	65-92	PTK2 protein tyrosine kinase 2	Mus musculus	171-174